data_1x50_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1x50 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 2.3 t . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.836 0.35 . . . . 0.0 111.147 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -129.61 120.78 25.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . 0.48 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 12.4 m120 61.78 52.18 2.19 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.616 0.722 . . . . 0.0 110.907 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.48 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.2 Cg_endo -69.81 138.67 38.23 Favored 'Trans proline' 0 N--CA 1.466 -0.13 0 C-N-CA 122.705 2.27 . . . . 0.0 112.328 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 178.7 4.3 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.633 2.222 . . . . 0.0 112.357 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.528 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 95.4 t -138.09 138.24 22.83 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.658 0.742 . . . . 0.0 111.115 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.528 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.7 Cg_endo -69.7 143.61 74.22 Favored 'Cis proline' 0 C--N 1.342 0.193 0 C-N-CA 122.741 -1.774 . . . . 0.0 112.345 -0.083 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 2.2 t80 -95.82 116.68 29.27 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.886 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 72.3 m-85 -100.15 105.31 16.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.844 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -118.21 103.33 1.03 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.507 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.422 ' HD2' ' C ' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -72.44 135.4 45.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.84 0.352 . . . . 0.0 110.876 -179.837 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 4.9 mt -82.73 119.12 23.92 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.928 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 25.2 mt-30 -74.09 94.97 2.48 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.887 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 124.31 -55.81 0.7 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.483 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 120.37 176.3 15.69 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.51 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . 0.431 ' CD1' ' HB ' ' A' ' 142' ' ' VAL . 82.5 mt -62.6 101.37 0.24 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.936 0.398 . . . . 0.0 110.896 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.502 ' O ' ' N ' ' A' ' 41' ' ' ARG . 44.9 p -120.77 137.89 54.29 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.202 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -41.97 -23.39 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.119 179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.444 ' N ' ' O ' ' A' ' 38' ' ' THR . 20.9 mmt180 -104.62 34.13 3.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.866 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.502 ' N ' ' O ' ' A' ' 38' ' ' THR . 4.6 ttt85 -121.05 139.86 52.74 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.931 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 85.9 m -137.66 117.55 13.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.154 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.1 mp -90.68 133.98 30.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.146 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 94.7 mt -127.55 134.33 65.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.123 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 48.5 mt -135.57 107.63 7.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.142 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.5 mtmt -109.35 108.19 18.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.917 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.52 -145.72 4.68 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.49 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 0.545 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.7 OUTLIER -167.55 129.13 1.53 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.9 0.381 . . . . 0.0 110.912 -179.803 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 13.7 t -77.34 115.5 49.72 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.619 0.723 . . . . 0.0 111.116 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 155.54 65.7 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.681 2.254 . . . . 0.0 112.354 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -15.69 37.11 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.683 2.255 . . . . 0.0 112.344 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 52.8 p -109.65 14.2 23.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.13 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -111.22 122.82 6.25 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.523 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 17.5 mtpt -63.96 -60.21 3.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.798 0.332 . . . . 0.0 110.867 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.5 p -174.21 158.75 3.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.89 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.537 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 2.4 p90 -112.57 -173.72 2.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.851 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.469 ' CB ' ' OD1' ' A' ' 73' ' ' ASN . . . -155.56 135.57 12.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.157 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.6 mp -115.85 103.7 15.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.132 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.3 m-80 -104.41 143.13 33.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.904 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.519 ' CE2' HD13 ' A' ' 145' ' ' LEU . 6.7 m-85 -115.66 101.36 8.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.875 -179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.406 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 30.3 ttmt -95.33 169.08 10.32 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.89 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.478 ' CG2' HG21 ' A' ' 142' ' ' VAL . 35.0 t -100.24 123.73 53.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.136 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -60.59 -34.25 85.27 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.498 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.9 t -68.5 -71.54 0.21 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.926 0.393 . . . . 0.0 110.87 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 3.3 t -83.7 -71.34 0.51 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.856 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 131.6 40.82 0.22 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.5 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . 0.412 ' OD1' ' OD1' ' A' ' 88' ' ' ASN . 1.9 m-20 -110.87 143.11 41.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.776 0.322 . . . . 0.0 110.853 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 39.2 mt -88.9 119.2 35.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.113 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.425 ' CB ' HG23 ' A' ' 142' ' ' VAL . . . -91.57 -33.12 15.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.109 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.56 HD22 ' CD2' ' A' ' 132' ' ' PHE . 52.5 tp -138.46 130.0 27.66 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.939 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.489 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.2 OUTLIER -134.82 92.71 2.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.844 179.891 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 29.0 mt -96.25 134.98 31.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.146 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.503 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -140.33 107.76 6.7 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.596 0.712 . . . . 0.0 110.863 179.946 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.537 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.8 Cg_endo -69.79 154.87 67.1 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.665 2.243 . . . . 0.0 112.338 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 45.3 mtp85 -130.4 98.0 4.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.909 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' MET . . . . . 0.48 ' HE1' ' CE1' ' A' ' 56' ' ' PHE . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.878 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 32.4 p . . . . . 0 C--O 1.232 0.168 0 CA-C-O 120.802 0.334 . . . . 0.0 111.122 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 36.0 t -91.44 108.54 20.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.136 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 48.7 t -79.93 146.69 7.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.11 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -128.87 130.21 46.57 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.845 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.489 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.9 OUTLIER -142.45 179.62 6.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.928 -179.971 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 89.5 p -157.99 107.25 2.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.901 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.561 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 27.6 tp -76.98 117.86 18.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.926 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.505 ' N ' ' O ' ' A' ' 90' ' ' SER . 82.7 mt -95.1 162.3 13.77 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.927 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.422 ' C ' ' H ' ' A' ' 90' ' ' SER . 11.7 m-80 -41.1 102.14 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.855 179.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.89 -1.49 3.37 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.51 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.505 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -125.63 172.49 9.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.839 0.352 . . . . 0.0 110.84 -179.722 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.561 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 25.0 m95 -129.4 160.67 32.37 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.932 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -90.34 -104.18 1.21 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.507 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 39.2 m -165.56 171.92 12.6 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.834 0.35 . . . . 0.0 110.852 -179.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -95.54 120.8 36.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.92 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 60.3 mt-10 -120.07 122.21 40.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.845 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 7.6 mtmp? -126.29 122.23 34.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.873 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 10.4 tptp -171.89 105.87 0.2 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.895 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 2.0 tt -146.59 149.9 15.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.129 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 9.2 t -91.65 -41.39 10.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.149 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 2.6 p-80 -144.06 131.64 21.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.834 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 24.7 t30 -109.21 96.52 21.89 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.632 0.73 . . . . 0.0 110.881 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.44 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.8 Cg_endo -69.78 -41.27 4.39 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.648 2.232 . . . . 0.0 112.305 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.44 ' C ' ' O ' ' A' ' 102' ' ' PRO . 6.2 m-85 -35.33 108.65 0.07 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.898 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -137.14 138.77 10.02 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.48 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 103.12 1.11 Allowed 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.689 2.26 . . . . 0.0 112.38 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 119.95 -2.32 13.24 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.541 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.3 pt20 -134.03 147.62 50.97 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.857 0.361 . . . . 0.0 110.902 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' PHE . . . . . 0.545 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 29.6 m-85 -67.21 172.82 4.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.877 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.422 ' O ' ' CG ' ' A' ' 109' ' ' PHE . 14.4 p90 -161.33 124.25 3.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.867 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -99.08 105.09 17.16 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.837 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.445 ' CD1' HD13 ' A' ' 113' ' ' ILE . 0.7 OUTLIER -105.18 136.89 43.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.92 -179.98 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 3.4 m -144.8 113.63 6.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.847 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.445 HD13 ' CD1' ' A' ' 111' ' ' LEU . 4.7 mp -96.68 135.43 30.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.147 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 40.0 mtt180 -108.51 126.26 52.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.886 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . 0.524 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 11.7 t -93.06 120.42 33.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.902 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -122.31 -159.8 10.73 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.511 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.437 ' O ' ' CD2' ' A' ' 134' ' ' HIS . 7.8 mt -101.83 -42.3 6.2 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.838 0.351 . . . . 0.0 110.943 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -82.19 -37.1 26.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.883 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.1 ptt180 -173.5 -178.2 1.61 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.889 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.524 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.2 m-30 -102.48 158.52 16.16 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.892 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 24.2 mtpt -132.13 104.86 7.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.921 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 60.6 t -90.98 133.58 32.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.125 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 74.7 m-85 -121.69 146.96 46.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.938 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -133.27 107.98 8.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.133 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 55.04 39.5 31.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.885 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.12 36.73 34.43 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.451 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 22.6 mt-30 -143.93 123.65 13.36 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.848 0.356 . . . . 0.0 110.898 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 32.6 t-80 -57.79 95.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.863 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 9.4 tp -60.88 -68.75 0.28 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.929 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.473 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 4.5 p90 -164.96 175.87 9.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.903 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -116.32 155.74 27.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.894 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.56 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.2 OUTLIER -122.38 104.58 9.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.847 -179.874 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.531 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -60.6 134.8 57.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.077 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' HIS . . . . . 0.437 ' CD2' ' O ' ' A' ' 117' ' ' LEU . 18.4 m-70 -62.4 98.8 0.12 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.894 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 17.6 mtt-85 -81.47 -47.59 12.97 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.842 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 7.8 tp -98.72 107.8 20.33 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.924 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 15.0 m -49.35 -33.19 12.9 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.839 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . 0.449 ' HB2' ' CD ' ' A' ' 141' ' ' ARG . . . -83.3 27.67 0.57 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.122 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.44 ' CG ' ' N ' ' A' ' 140' ' ' GLN . 17.6 p90 -47.21 -44.29 22.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.892 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' GLN . . . . . 0.44 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 9.2 pt20 -46.24 -40.63 11.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.931 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.449 ' CD ' ' HB2' ' A' ' 138' ' ' ALA . 16.1 mtp180 -54.33 -41.71 69.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.875 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.478 HG21 ' CG2' ' A' ' 62' ' ' VAL . 88.7 t -50.3 104.72 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.167 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -127.38 28.83 5.64 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.877 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.3 m -137.67 131.96 32.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.168 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.519 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.4 tp -128.47 109.09 11.09 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.944 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 -112.3 152.31 28.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.901 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 19.8 mt -137.47 113.54 11.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.135 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -123.06 174.19 7.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.954 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.4 -144.5 15.99 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.512 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -114.71 92.1 3.84 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.871 0.367 . . . . 0.0 110.845 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.438 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 5.1 p -151.04 142.77 16.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.134 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 25.8 m -102.37 93.25 5.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.163 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.448 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 95.9 mt -74.31 136.73 42.58 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.899 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 5.1 m -117.18 -39.36 3.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.871 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . 0.426 ' C ' ' CD1' ' A' ' 155' ' ' TYR . 7.4 t80 -147.35 130.93 16.81 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.917 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 65.8 t -140.77 124.48 17.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.138 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 12.8 tt0 -148.85 132.95 17.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.908 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 5.1 mp . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.152 179.941 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.468 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.6 m . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.857 0.36 . . . . 0.0 111.119 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.468 ' CD1' ' O ' ' A' ' 22' ' ' THR . 9.8 m-85 -150.71 137.15 18.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.887 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . 0.601 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 52.8 m-80 51.37 44.48 2.16 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.663 0.744 . . . . 0.0 110.919 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.601 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.78 133.82 26.45 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.632 2.221 . . . . 0.0 112.316 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.85 179.36 3.8 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.673 2.249 . . . . 0.0 112.361 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.532 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 86.6 t -138.79 137.68 20.27 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.606 0.717 . . . . 0.0 111.134 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.532 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.2 Cg_endo -69.77 144.21 76.03 Favored 'Cis proline' 0 C--O 1.231 0.161 0 C-N-CA 122.668 -1.805 . . . . 0.0 112.338 -0.074 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 2.9 t80 -94.13 120.15 33.98 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.927 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -105.12 102.14 11.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.899 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -109.7 109.43 2.71 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.471 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 6.4 mmt85 -73.38 108.93 6.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.875 0.369 . . . . 0.0 110.873 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.41 ' HB3' ' NH1' ' A' ' 41' ' ' ARG . 5.3 mt -70.58 92.76 0.86 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.918 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 14.9 mm-40 -64.73 105.36 0.97 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.896 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 130.59 -46.89 1.05 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.477 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 98.67 161.36 29.98 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.51 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 95.9 mt -54.81 107.14 0.26 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.903 0.383 . . . . 0.0 110.872 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 73.0 p -118.71 149.04 42.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.128 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -49.8 -23.62 1.95 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.085 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.413 ' HB3' ' NH1' ' A' ' 40' ' ' ARG . 0.0 OUTLIER -108.81 34.19 3.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.882 -179.921 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.41 ' NH1' ' HB3' ' A' ' 33' ' ' LEU . 13.1 ttm180 -113.81 139.28 49.27 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.859 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 74.2 m -137.52 119.83 15.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.134 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.419 HG22 ' N ' ' A' ' 44' ' ' ILE . 5.3 mp -91.92 136.27 24.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.109 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.419 ' N ' HG22 ' A' ' 43' ' ' ILE . 97.0 mt -131.25 133.55 62.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.107 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 34.5 mt -136.53 111.52 10.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.143 179.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 16.1 mtmt -112.68 109.0 18.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.923 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -138.1 -142.95 4.42 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.44 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 0.435 ' CD1' ' O ' ' A' ' 48' ' ' TYR . 0.5 OUTLIER -170.2 117.04 0.54 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.914 0.388 . . . . 0.0 110.939 -179.769 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.462 HG23 ' CE1' ' A' ' 109' ' ' PHE . 15.2 t -70.19 115.8 38.05 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.644 0.735 . . . . 0.0 111.139 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 157.52 60.12 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.678 2.252 . . . . 0.0 112.356 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -15.42 37.17 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.664 2.243 . . . . 0.0 112.34 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 21.5 p -109.71 17.11 21.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.18 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -110.69 118.99 5.13 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.511 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.3 mtpt -61.31 -60.63 3.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.778 0.323 . . . . 0.0 110.912 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 13.2 p -173.64 158.44 3.35 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.869 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.579 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 6.1 p90 -115.88 -174.68 2.58 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.864 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.46 ' CB ' ' OD1' ' A' ' 73' ' ' ASN . . . -154.81 145.3 22.17 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.126 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.2 mp -123.52 98.77 5.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.115 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.7 m-80 -98.86 141.98 30.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.914 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.551 ' CE2' HD13 ' A' ' 145' ' ' LEU . 10.5 m-85 -117.16 99.03 6.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.893 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.427 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 31.3 ttmt -96.62 169.24 10.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.878 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.427 ' N ' ' HG2' ' A' ' 61' ' ' LYS . 38.7 t -101.44 119.59 49.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.129 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -55.22 -36.79 62.82 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.502 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.5 m -66.47 -72.86 0.15 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.889 0.376 . . . . 0.0 110.904 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 19.7 m -79.34 -74.68 0.28 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.868 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 132.92 38.58 0.23 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.523 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -111.36 143.61 41.89 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.795 0.331 . . . . 0.0 110.846 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 47.4 mt -89.77 117.71 33.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.123 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -89.25 -31.07 18.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.122 179.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.536 HD23 ' CD2' ' A' ' 132' ' ' PHE . 53.2 tp -140.84 130.25 23.83 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.927 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.452 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.3 OUTLIER -134.91 92.55 2.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.884 179.82 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 26.3 mt -96.36 133.81 36.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.149 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.498 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -141.24 106.78 6.13 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.619 0.723 . . . . 0.0 110.853 179.978 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.579 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.8 Cg_endo -69.78 155.28 66.3 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.647 2.231 . . . . 0.0 112.364 179.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 68.3 mtp180 -130.55 99.35 4.95 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.899 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 16.9 p . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.795 0.331 . . . . 0.0 111.133 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.3 t -99.67 111.72 30.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.123 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 92.5 t -79.36 142.06 14.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.176 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . 0.557 ' NH1' ' CD2' ' A' ' 130' ' ' PHE . 0.3 OUTLIER -126.19 125.52 42.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.885 -179.948 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.452 ' O ' ' N ' ' A' ' 71' ' ' HIS . 2.3 m120 -137.39 177.82 7.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.883 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 28.9 t -158.92 105.08 1.76 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.814 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.57 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 25.6 tp -77.36 119.58 21.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.918 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.513 ' N ' ' O ' ' A' ' 90' ' ' SER . 77.7 mt -96.98 161.47 13.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.893 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.529 HD21 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.28 101.67 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.868 179.938 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.76 -7.12 0.73 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.488 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.519 ' H ' ' C ' ' A' ' 88' ' ' ASN . 0.3 OUTLIER -118.13 170.74 8.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.885 0.374 . . . . 0.0 110.855 -179.719 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.57 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 21.4 m95 -128.31 160.89 30.75 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.959 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -94.16 -116.85 2.78 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.454 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 33.8 m -152.14 178.61 9.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.79 0.329 . . . . 0.0 110.898 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.418 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 11.9 mt-10 -103.73 126.05 50.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.891 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -123.36 105.37 9.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.893 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 18.2 mtmm -111.69 122.46 47.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.919 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -171.54 105.95 0.22 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.905 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.416 ' CG1' ' N ' ' A' ' 99' ' ' THR . 3.0 tt -145.13 152.85 14.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.125 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.416 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 9.5 t -96.39 -41.9 8.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.141 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 4.4 p-80 -142.89 128.57 19.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.852 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 -103.29 95.55 7.09 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.652 0.739 . . . . 0.0 110.882 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.75 -40.41 5.38 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.702 2.268 . . . . 0.0 112.318 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -41.01 108.41 0.09 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.867 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -131.49 139.64 11.11 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.491 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 100.62 0.84 Allowed 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.714 2.276 . . . . 0.0 112.328 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 117.89 6.63 12.45 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.472 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 4.7 pt20 -137.17 143.92 42.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.78 0.324 . . . . 0.0 110.926 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -66.14 168.76 7.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.915 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.462 ' CE1' HG23 ' A' ' 49' ' ' VAL . 30.1 p90 -161.28 144.74 12.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.85 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -118.31 101.73 8.41 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.87 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.401 ' CD1' ' CD1' ' A' ' 113' ' ' ILE . 1.1 tm? -99.24 137.18 38.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.923 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 6.2 m -144.98 111.27 5.61 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.864 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.401 ' CD1' ' CD1' ' A' ' 111' ' ' LEU . 4.8 mp -94.73 135.57 28.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.081 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -109.61 130.59 55.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.846 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . 0.572 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 11.9 t -101.19 116.02 31.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.876 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -115.26 -143.9 8.17 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.517 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.7 mt -116.02 -37.47 3.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.829 0.347 . . . . 0.0 110.88 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -87.66 -37.5 16.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.873 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.9 ptt180 -173.85 170.38 3.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.874 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.572 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.1 m-30 -90.71 158.23 17.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.85 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 30.5 mtpt -132.33 99.39 4.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.886 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 97.6 t -86.73 139.18 17.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.095 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 84.3 m-85 -129.4 148.96 51.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.947 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -137.12 109.77 7.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.096 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 57.97 34.66 24.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.849 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.9 40.5 21.23 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.494 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -144.84 134.86 23.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.81 0.338 . . . . 0.0 110.875 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 32.2 t-80 -68.06 101.31 1.12 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.865 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 8.0 tp -71.7 -67.39 0.53 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.898 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.557 ' CD2' ' NH1' ' A' ' 83' ' ' ARG . 5.1 p90 -166.89 173.44 9.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.886 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -116.12 155.69 27.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.574 ' CE1' ' O ' ' A' ' 133' ' ' ALA . 0.1 OUTLIER -120.15 104.47 10.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.896 -179.883 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.574 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -59.62 136.64 58.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.101 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 55.4 m-70 -63.52 106.16 0.89 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.879 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 23.6 mtt-85 -91.73 -50.2 5.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.861 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 6.1 tp -95.43 109.02 21.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.923 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 41.3 t -51.67 -33.4 33.7 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.812 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . 0.463 ' HB3' ' CD ' ' A' ' 141' ' ' ARG . . . -82.67 23.83 0.77 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.097 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 32.0 p90 -45.57 -37.87 5.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.854 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -52.73 -46.97 67.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.918 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.463 ' CD ' ' HB3' ' A' ' 138' ' ' ALA . 70.6 mtp85 -48.63 -43.38 36.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.87 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 85.5 t -41.24 106.93 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.171 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -131.86 31.68 4.18 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.861 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 18.9 m -142.03 114.94 8.66 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.134 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.551 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.9 tp -111.89 108.46 17.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.917 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' GLU . . . . . 0.414 ' C ' HG13 ' A' ' 147' ' ' ILE . 3.6 pt-20 -111.77 155.29 23.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.91 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . 0.414 HG13 ' C ' ' A' ' 146' ' ' GLU . 35.2 mt -143.45 116.4 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.105 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -124.79 170.27 11.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.94 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.79 -153.47 16.8 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.496 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -104.17 93.28 4.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.808 0.337 . . . . 0.0 110.879 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.475 HG21 ' N ' ' A' ' 152' ' ' THR . 8.8 p -151.3 143.59 16.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.126 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' THR . . . . . 0.475 ' N ' HG21 ' A' ' 151' ' ' VAL . 12.0 m -105.19 94.39 5.21 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.107 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 58.0 mt -78.51 134.4 37.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.88 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 58.6 m -119.25 -39.85 2.87 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.851 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 39.7 t80 -144.6 131.14 19.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.92 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 93.4 t -140.54 106.57 2.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.132 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 15.2 tt0 -118.42 138.97 52.1 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.922 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 18.4 mt . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.113 179.982 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.453 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.5 m . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.858 0.361 . . . . 0.0 111.145 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.424 ' C ' ' HD3' ' A' ' 25' ' ' PRO . 5.6 m-85 -142.95 133.63 25.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.893 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . 0.585 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.6 m120 48.42 45.6 2.94 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.591 0.71 . . . . 0.0 110.867 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.585 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.3 Cg_endo -69.79 137.33 35.11 Favored 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 122.702 2.268 . . . . 0.0 112.34 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 -176.93 1.63 Allowed 'Trans proline' 0 N--CA 1.465 -0.164 0 C-N-CA 122.732 2.288 . . . . 0.0 112.357 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.526 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 88.1 t -142.28 137.64 15.84 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.616 0.722 . . . . 0.0 111.125 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.526 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.3 Cg_endo -69.81 143.88 75.21 Favored 'Cis proline' 0 C--N 1.341 0.179 0 C-N-CA 122.671 -1.804 . . . . 0.0 112.318 0.005 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.9 t80 -95.61 120.72 36.35 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.904 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -102.94 104.01 14.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.866 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -115.92 109.55 2.04 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.524 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 3.2 mmt85 -74.08 118.47 17.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.856 0.36 . . . . 0.0 110.84 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.428 HD22 ' CD1' ' A' ' 158' ' ' ILE . 8.0 mt -76.8 92.13 3.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.935 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 23.0 mm-40 -65.4 102.86 0.73 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.961 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.23 -37.96 1.89 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.453 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 88.28 156.19 30.44 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.469 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 86.8 mt -52.43 100.0 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.905 0.383 . . . . 0.0 110.895 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 29.7 p -116.73 153.84 31.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.176 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.448 ' HB3' ' CD2' ' A' ' 117' ' ' LEU . . . -51.34 -31.51 22.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.127 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.429 ' HA ' ' NE ' ' A' ' 40' ' ' ARG . 10.8 mmp_? -100.14 33.7 2.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.852 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 28.2 ttm-85 -118.73 137.99 52.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.867 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 96.6 m -139.37 118.22 12.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.135 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 4.6 mp -91.58 136.28 24.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.099 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.426 HG23 ' N ' ' A' ' 45' ' ' ILE . 89.0 mt -128.87 133.8 65.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.138 179.843 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.426 ' N ' HG23 ' A' ' 44' ' ' ILE . 37.8 mt -134.26 107.61 9.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.113 179.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.3 mtmt -108.24 103.9 13.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -134.21 -148.35 5.78 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.517 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -169.17 127.56 1.0 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.98 0.419 . . . . 0.0 110.894 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 16.0 t -75.91 117.65 65.37 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.635 0.731 . . . . 0.0 111.158 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 154.01 68.35 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.687 2.258 . . . . 0.0 112.359 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -20.71 34.37 Favored 'Trans proline' 0 C--O 1.231 0.175 0 C-N-CA 122.674 2.249 . . . . 0.0 112.343 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 41.1 p -99.63 9.41 43.18 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.153 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -99.08 -172.16 31.28 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.491 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 4.1 mmmm -133.75 -64.56 0.7 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.787 0.327 . . . . 0.0 110.895 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 2.6 p -165.75 147.07 7.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.816 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.571 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 13.0 p90 -110.53 -175.35 2.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.898 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -154.98 143.58 20.59 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.123 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.2 mp -121.85 102.14 11.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.107 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.2 m-80 -102.06 143.57 31.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.888 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.566 ' CE2' HD13 ' A' ' 145' ' ' LEU . 5.4 m-85 -118.76 98.56 6.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.937 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.433 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 32.8 ttmt -96.93 169.25 9.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.892 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.433 ' N ' ' HG2' ' A' ' 61' ' ' LYS . 19.4 t -100.64 122.4 52.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.131 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.461 ' N ' ' HG1' ' A' ' 144' ' ' THR . . . -60.04 -34.24 82.75 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.509 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 10.1 t -67.15 -71.81 0.19 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.872 0.368 . . . . 0.0 110.89 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.4 t -81.86 -69.19 0.63 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.836 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 128.97 36.53 0.43 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.519 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -110.22 140.99 43.78 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.853 0.359 . . . . 0.0 110.856 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 58.9 mt -85.86 122.0 37.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.133 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.437 ' CB ' HG22 ' A' ' 142' ' ' VAL . . . -93.13 -30.01 15.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.098 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.512 HD21 ' CD2' ' A' ' 132' ' ' PHE . 46.3 tp -144.2 130.1 19.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.946 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.472 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.3 OUTLIER -134.93 92.58 2.9 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.862 179.899 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.401 ' CG2' HG11 ' A' ' 81' ' ' VAL . 41.4 mt -94.55 134.69 31.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.173 179.962 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.514 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -139.02 106.24 7.36 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.612 0.72 . . . . 0.0 110.879 179.959 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.571 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.7 Cg_endo -69.73 155.25 66.52 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.683 2.255 . . . . 0.0 112.329 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 42.1 mtp180 -131.56 99.41 4.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.865 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.858 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 16.9 p . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.887 0.375 . . . . 0.0 111.108 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.401 HG11 ' CG2' ' A' ' 72' ' ' ILE . 39.5 t -101.76 107.24 21.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.125 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.449 ' CG2' ' HD3' ' A' ' 96' ' ' LYS . 24.6 t -78.29 138.52 20.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.171 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . 0.615 HH12 ' N ' ' A' ' 97' ' ' LYS . 2.8 mpp_? -126.94 125.72 42.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.885 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.472 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.3 m120 -132.86 -176.23 4.04 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.854 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 30.3 t -159.31 105.18 1.68 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.864 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.566 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 25.8 tp -77.06 117.43 18.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.861 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 90' ' ' SER . 80.7 mt -95.28 161.63 14.01 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.913 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.538 HD21 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.42 101.59 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.863 179.98 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.83 -6.49 0.91 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.504 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.511 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -119.21 172.47 7.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.913 0.387 . . . . 0.0 110.833 -179.773 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.566 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 22.4 m95 -129.49 160.69 32.39 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.908 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -89.59 -92.5 1.17 Allowed Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.457 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 2.3 m -174.74 173.78 2.74 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.905 0.383 . . . . 0.0 110.838 -179.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.443 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 3.8 mt-10 -104.97 117.64 34.53 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.89 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 50.7 mm-40 -122.49 133.88 54.58 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.895 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.449 ' HD3' ' CG2' ' A' ' 82' ' ' VAL . 43.8 mtmt -131.1 128.13 39.54 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.91 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.615 ' N ' HH12 ' A' ' 83' ' ' ARG . 12.7 tmtt? -175.79 108.37 0.09 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.946 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.459 ' CD1' ' O ' ' A' ' 100' ' ' HIS . 4.1 tt -147.67 144.04 19.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.109 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.6 t -79.19 -39.58 32.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.141 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . 0.459 ' O ' ' CD1' ' A' ' 98' ' ' ILE . 3.1 p-80 -154.35 136.91 15.1 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.883 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . 0.432 ' CG ' HD11 ' A' ' 98' ' ' ILE . 8.1 m120 -105.11 95.78 9.98 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.573 0.702 . . . . 0.0 110.893 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.72 -35.04 13.49 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.674 2.249 . . . . 0.0 112.397 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -45.84 113.69 0.65 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.898 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -144.91 142.19 10.64 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.484 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.75 109.56 2.34 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.723 2.282 . . . . 0.0 112.334 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 118.88 -8.55 12.73 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.5 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -133.29 150.63 51.89 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.851 0.358 . . . . 0.0 110.883 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 2.3 p90 -77.86 160.02 28.57 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.919 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.511 ' CD1' ' O ' ' A' ' 109' ' ' PHE . 29.6 p90 -145.3 122.36 11.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.874 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -92.89 101.94 14.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.911 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.454 HD12 ' N ' ' A' ' 112' ' ' SER . 1.0 OUTLIER -101.84 138.37 38.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.875 -179.911 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.454 ' N ' HD12 ' A' ' 111' ' ' LEU . 4.3 m -144.67 114.41 7.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.871 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.3 mp -99.16 122.22 50.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.157 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 7.7 mtp180 -97.16 132.72 42.66 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.842 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . 0.441 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 7.0 t -98.61 123.07 42.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.867 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.93 -141.23 7.46 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.494 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.448 ' CD2' ' HB3' ' A' ' 39' ' ' ALA . 7.9 mt -118.57 -33.4 4.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.792 0.329 . . . . 0.0 110.931 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . 0.598 ' O ' ' CD2' ' A' ' 134' ' ' HIS . 16.1 m-20 -97.6 -45.26 6.46 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.908 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.414 ' HG3' ' C ' ' A' ' 118' ' ' ASP . 47.7 mtt180 -152.36 -175.85 5.44 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.91 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.441 ' CE2' ' HB2' ' A' ' 115' ' ' CYS . 12.1 m-85 -107.66 158.59 17.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.905 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 19.1 mtpt -130.83 105.23 7.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.903 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 47.7 t -94.37 134.83 30.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.121 179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -123.32 147.82 46.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.91 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -132.65 107.5 8.45 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.104 179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 59.34 34.17 22.75 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.86 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.55 28.99 41.25 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.468 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 13.0 mm100 -136.38 119.61 16.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.8 0.333 . . . . 0.0 110.921 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 26.5 t-80 -51.58 101.53 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.831 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 10.5 tp -65.57 -69.16 0.31 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.933 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.462 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 4.5 p90 -164.66 175.54 9.66 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.884 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 41.0 m-20 -113.75 157.42 22.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.893 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.561 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 0.1 OUTLIER -130.81 106.29 8.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.942 -179.911 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.545 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -64.54 131.77 47.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.075 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' HIS . . . . . 0.598 ' CD2' ' O ' ' A' ' 118' ' ' ASP . 16.7 m-70 -56.65 117.49 3.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.85 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 71.9 mtt-85 -97.61 -49.48 4.85 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.84 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 12.2 tp -95.37 109.08 21.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.941 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 79.3 p -48.74 -33.17 9.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.836 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . 0.443 ' HB3' ' CD ' ' A' ' 141' ' ' ARG . . . -83.36 28.24 0.55 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.096 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -51.47 -34.56 35.99 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.838 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' GLN . . . . . 0.426 ' HG2' ' N ' ' A' ' 141' ' ' ARG . 19.7 pm0 -60.58 -27.19 67.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.945 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.443 ' CD ' ' HB3' ' A' ' 138' ' ' ALA . 33.1 mtp180 -69.27 -37.58 77.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.908 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.437 HG22 ' CB ' ' A' ' 69' ' ' ALA . 89.4 t -46.52 104.35 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.096 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -127.84 29.24 5.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.875 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' THR . . . . . 0.461 ' HG1' ' N ' ' A' ' 63' ' ' GLY . 10.5 m -139.2 110.94 7.16 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.085 -179.867 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.566 HD13 ' CE2' ' A' ' 60' ' ' PHE . 6.2 tp -109.55 105.71 15.13 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.952 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -110.11 152.49 25.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.856 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 29.4 mt -139.92 118.67 11.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.131 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -126.77 171.43 11.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.927 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 109.36 -152.28 17.12 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.518 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -106.52 92.04 3.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.802 0.334 . . . . 0.0 110.89 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.44 HG23 ' N ' ' A' ' 152' ' ' THR . 8.7 p -150.37 149.27 14.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.114 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' THR . . . . . 0.44 ' N ' HG23 ' A' ' 151' ' ' VAL . 29.7 m -109.71 94.9 5.27 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.114 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.416 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 77.6 mt -76.93 132.22 38.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.917 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 3.0 m -117.37 -33.7 4.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.879 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 19.5 t80 -153.1 131.9 12.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.93 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 60.8 t -139.53 112.2 5.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.171 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 17.9 tt0 -124.92 136.56 53.88 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' ILE . . . . . 0.428 ' CD1' HD22 ' A' ' 33' ' ' LEU . 15.3 mt . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.129 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.525 ' CG2' ' N ' ' A' ' 23' ' ' PHE . 1.6 m . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.786 0.327 . . . . 0.0 111.132 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.525 ' N ' ' CG2' ' A' ' 22' ' ' THR . 8.6 m-85 -154.32 137.72 15.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.88 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . 0.549 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 12.5 m120 44.27 47.99 4.03 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.648 0.737 . . . . 0.0 110.909 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.549 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.6 Cg_endo -69.79 140.09 41.73 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.688 2.259 . . . . 0.0 112.327 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 178.61 4.38 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.718 2.279 . . . . 0.0 112.357 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.534 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 96.4 t -139.36 138.31 20.36 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.605 0.717 . . . . 0.0 111.136 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.534 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.74 144.3 76.2 Favored 'Cis proline' 0 C--O 1.231 0.158 0 C-N-CA 122.72 -1.783 . . . . 0.0 112.334 -0.082 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -95.37 114.07 25.8 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.923 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -97.65 105.34 17.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.896 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -119.34 106.32 1.24 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.487 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.482 ' O ' ' NE2' ' A' ' 34' ' ' GLN . 0.0 OUTLIER -77.98 128.19 33.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.904 0.383 . . . . 0.0 110.848 -179.855 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 5.5 mt -71.8 122.02 19.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.89 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . 0.482 ' NE2' ' O ' ' A' ' 32' ' ' ARG . 24.5 mp0 -77.15 79.6 3.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.899 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 139.01 -47.51 0.91 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.525 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.461 ' O ' ' CG2' ' A' ' 38' ' ' THR . . . 108.47 164.98 20.98 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.467 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 68.7 mt -50.85 106.48 0.13 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.92 0.39 . . . . 0.0 110.898 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.461 ' CG2' ' O ' ' A' ' 36' ' ' GLY . 10.2 p -124.61 141.19 52.28 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.146 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -42.86 -27.78 0.21 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.15 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 14.4 mmt85 -105.03 43.61 1.09 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.919 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.407 ' NH2' ' O ' ' A' ' 34' ' ' GLN . 6.6 ttt85 -130.43 139.93 50.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.838 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 98.0 m -139.73 121.6 15.52 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.09 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 4.7 mp -91.39 132.76 35.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.137 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.41 ' CG2' ' HE2' ' A' ' 46' ' ' LYS . 83.8 mt -125.16 117.01 48.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.113 179.893 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 46.6 mt -118.12 107.63 22.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.092 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.41 ' HE2' ' CG2' ' A' ' 44' ' ' ILE . 25.1 mtmt -111.06 112.12 23.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.907 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -145.04 -143.43 3.99 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.487 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -168.99 126.42 0.97 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.924 0.392 . . . . 0.0 110.957 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 21.6 t -75.99 116.89 59.75 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.642 0.734 . . . . 0.0 111.138 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.82 157.52 60.0 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.631 2.221 . . . . 0.0 112.302 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -16.88 37.63 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.685 2.257 . . . . 0.0 112.307 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 76.8 p -110.91 19.73 18.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.138 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -111.68 116.53 4.2 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.506 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 21.7 mtpp -59.24 -60.66 3.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.761 0.315 . . . . 0.0 110.904 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 21.7 p -174.06 157.43 2.89 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.888 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.569 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 5.7 p90 -112.52 -173.18 2.19 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.9 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.18 145.49 21.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.095 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 2.7 mp -125.52 100.01 6.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.087 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . 0.443 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 19.4 m-80 -101.9 144.76 30.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.882 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.54 ' CE2' HD13 ' A' ' 145' ' ' LEU . 32.7 m-85 -117.93 99.95 7.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.873 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.409 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 34.5 ttmt -95.65 168.16 10.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.945 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.475 ' CG2' HG22 ' A' ' 142' ' ' VAL . 22.6 t -99.72 122.86 52.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.147 179.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -58.23 -34.23 73.14 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.481 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 26.1 m -70.22 -75.26 0.12 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.865 0.364 . . . . 0.0 110.813 -179.695 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 26.9 t -77.64 -71.93 0.39 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.866 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 129.3 43.4 0.21 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.469 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . 0.408 ' OD1' ' OD1' ' A' ' 88' ' ' ASN . 1.1 m-20 -113.69 142.1 46.43 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.784 0.326 . . . . 0.0 110.866 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 44.9 mt -87.05 118.78 33.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.119 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.425 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -91.95 -30.09 16.29 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.089 179.835 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.566 HD22 ' CD2' ' A' ' 132' ' ' PHE . 58.2 tp -142.18 129.62 21.26 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.899 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.496 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.2 t60 -134.81 92.8 2.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.842 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.404 ' CG2' HG11 ' A' ' 81' ' ' VAL . 28.3 mt -94.78 130.88 42.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.102 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.499 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -136.04 104.79 9.62 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.643 0.735 . . . . 0.0 110.902 179.9 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.569 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.4 Cg_endo -69.78 155.66 65.3 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.644 2.229 . . . . 0.0 112.309 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 28.6 mtt-85 -130.77 101.92 5.87 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.859 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.879 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 7.0 p . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.827 0.346 . . . . 0.0 111.123 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.404 HG11 ' CG2' ' A' ' 72' ' ' ILE . 41.8 t -101.46 114.65 41.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.166 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 57.4 t -83.54 144.18 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.135 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -126.26 124.91 41.43 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.845 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.496 ' O ' ' N ' ' A' ' 71' ' ' HIS . 2.6 m120 -135.17 176.3 8.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.867 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 40.4 t -157.72 105.01 1.99 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.892 -179.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.564 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 34.5 tp -77.14 117.73 18.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.919 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 90' ' ' SER . 85.0 mt -95.48 162.36 13.68 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.951 179.893 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.429 ' C ' ' H ' ' A' ' 90' ' ' SER . 10.6 m-80 -41.08 102.23 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.866 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.19 -1.15 3.0 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.49 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.511 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -125.71 171.64 10.46 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.849 0.357 . . . . 0.0 110.853 -179.715 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.564 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 22.2 m95 -128.93 160.63 32.08 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.921 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.57 -115.21 2.23 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.491 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' SER . . . . . 0.416 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 58.3 m -151.42 173.67 14.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.82 0.343 . . . . 0.0 110.852 -179.768 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.407 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 14.4 mt-10 -102.59 123.95 47.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.875 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -123.08 125.86 45.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.904 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 45.6 mtmt -129.52 118.99 22.96 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.886 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 1.3 tppp? -170.58 106.52 0.29 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.851 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 7.4 tt -144.22 150.53 16.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.114 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.8 t -87.26 -46.12 10.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.154 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . 0.448 ' O ' ' CG ' ' A' ' 100' ' ' HIS . 4.6 p-80 -147.37 125.78 12.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.886 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . 0.44 ' OD1' ' C ' ' A' ' 101' ' ' ASN . 27.1 t-20 -99.41 100.73 11.13 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.628 0.727 . . . . 0.0 110.906 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.401 ' HD2' ' HA ' ' A' ' 101' ' ' ASN . 54.1 Cg_endo -69.72 -36.44 10.89 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.751 2.301 . . . . 0.0 112.335 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -41.51 109.72 0.13 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.872 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -137.96 138.56 9.68 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.481 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 103.06 1.11 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.646 2.231 . . . . 0.0 112.363 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 121.44 -2.12 11.31 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.485 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -137.05 146.04 44.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.871 0.367 . . . . 0.0 110.874 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 2.3 p90 -70.93 172.76 8.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.861 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 30.0 p90 -160.25 137.5 9.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.884 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.59 107.8 18.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.863 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -109.12 136.99 47.71 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.926 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 6.0 m -145.08 113.56 6.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.809 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.3 mp -93.92 137.42 22.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.129 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . 0.462 ' O ' ' CD2' ' A' ' 120' ' ' PHE . 14.5 mtp180 -109.56 133.93 52.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.855 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 9.0 t -101.45 115.29 30.18 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.86 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -110.94 -141.66 8.8 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.487 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 5.5 mt -118.58 -34.81 3.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.827 0.346 . . . . 0.0 110.948 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . 0.605 ' O ' ' CD2' ' A' ' 134' ' ' HIS . 2.0 m-20 -95.05 -45.83 7.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.856 179.858 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.433 ' HG3' ' C ' ' A' ' 118' ' ' ASP . 25.5 mtt180 -154.98 -179.72 8.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.462 ' CD2' ' O ' ' A' ' 114' ' ' ARG . 20.5 m-85 -103.41 157.59 16.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.919 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 32.9 mtpt -129.52 100.08 5.41 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.938 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 45.6 t -89.2 128.94 40.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.091 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -115.07 151.21 34.68 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.917 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -136.35 106.71 6.43 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.069 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 55.92 34.67 24.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.856 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 80.71 31.36 36.53 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.506 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 12.3 mm100 -138.32 123.78 19.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.844 0.354 . . . . 0.0 110.938 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 39.6 t-80 -55.46 101.43 0.05 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.874 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 11.6 tp -69.85 -69.62 0.34 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.952 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.452 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 6.7 p90 -165.13 169.84 15.67 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -111.22 159.93 17.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.895 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.566 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -130.52 104.39 7.2 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.897 -179.883 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.507 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -62.5 134.96 57.14 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.108 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' HIS . . . . . 0.605 ' CD2' ' O ' ' A' ' 118' ' ' ASP . 20.1 m-70 -58.72 104.62 0.24 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.875 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.416 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 8.8 mtt-85 -83.92 -53.65 5.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.867 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.7 tp -91.85 107.77 19.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.956 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 12.7 t -45.74 -36.14 4.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.893 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -82.72 29.97 0.44 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.09 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.466 ' CG ' ' N ' ' A' ' 140' ' ' GLN . 21.7 p90 -48.49 -45.82 37.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.886 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' GLN . . . . . 0.466 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 8.3 pt20 -47.8 -41.34 23.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.908 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.425 ' C ' HG13 ' A' ' 62' ' ' VAL . 30.7 mtp180 -54.21 -41.64 68.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.851 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.475 HG22 ' CG2' ' A' ' 62' ' ' VAL . 97.2 t -49.23 102.92 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.177 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -124.74 28.34 6.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.865 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 32' ' ' ARG . 0.6 OUTLIER -135.29 125.44 26.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.138 -179.927 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.54 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.2 tp -123.97 106.79 10.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.922 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -110.37 153.44 24.94 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.911 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 17.2 mt -138.47 115.28 11.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.104 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -125.52 174.92 7.89 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.917 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.04 -143.78 15.84 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.502 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -114.81 92.39 3.93 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.888 0.375 . . . . 0.0 110.86 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.458 HG23 ' N ' ' A' ' 152' ' ' THR . 6.3 p -151.31 145.74 16.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.171 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' THR . . . . . 0.458 ' N ' HG23 ' A' ' 151' ' ' VAL . 21.5 m -105.37 93.8 4.87 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.126 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.443 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 95.0 mt -75.76 131.43 39.81 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.869 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 7.5 m -113.62 -41.6 3.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.86 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . 0.413 ' CD1' ' C ' ' A' ' 155' ' ' TYR . 8.4 t80 -145.06 132.98 21.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.919 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 94.4 t -140.69 116.96 7.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.112 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 9.7 tt0 -134.18 125.13 27.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.941 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 24.0 mt . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.139 179.988 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 10.8 t . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.816 0.341 . . . . 0.0 111.151 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 7.8 m-85 -139.43 115.61 10.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.914 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . 0.489 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 5.3 t-20 66.95 51.63 0.65 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.568 0.699 . . . . 0.0 110.845 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.489 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.75 132.65 23.79 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.679 2.253 . . . . 0.0 112.343 179.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -178.43 2.34 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.68 2.253 . . . . 0.0 112.326 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.525 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 94.4 t -139.87 137.87 18.98 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.661 0.743 . . . . 0.0 111.146 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.525 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.8 Cg_endo -69.78 144.51 76.89 Favored 'Cis proline' 0 C--N 1.341 0.181 0 C-N-CA 122.731 -1.779 . . . . 0.0 112.292 0.009 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 14.4 t80 -94.87 118.2 31.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.973 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -102.33 100.76 10.95 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.905 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -107.54 109.58 3.01 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.464 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 10.2 mmt85 -75.35 117.65 17.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.85 0.357 . . . . 0.0 110.855 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 3.5 mt -78.17 93.22 4.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.897 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.8 mm-40 -64.83 99.74 0.36 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.899 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.23 -41.55 1.45 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.54 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.417 ' O ' ' NE ' ' A' ' 41' ' ' ARG . . . 95.21 164.59 34.97 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.499 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 87.5 mt -58.48 110.68 1.02 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.872 0.368 . . . . 0.0 110.903 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 44.4 p -124.12 146.23 48.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.134 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -47.27 -22.69 0.44 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.088 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.02 35.22 3.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.861 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.417 ' NE ' ' O ' ' A' ' 36' ' ' GLY . 20.3 ttm-85 -114.59 138.81 50.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.872 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 88.2 m -136.31 114.55 11.59 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.143 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.43 HG23 ' N ' ' A' ' 44' ' ' ILE . 4.8 mp -90.78 135.07 27.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.13 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.43 ' N ' HG23 ' A' ' 43' ' ' ILE . 80.1 mt -130.26 132.61 64.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.127 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 55.8 mt -133.56 107.09 10.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.103 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 10.7 mttm -102.46 108.42 19.73 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.927 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.03 -156.06 6.78 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.454 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -161.98 127.87 3.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.941 0.4 . . . . 0.0 110.867 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 21.9 t -76.05 114.53 38.28 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.675 0.75 . . . . 0.0 111.13 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 158.5 56.7 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.662 2.241 . . . . 0.0 112.317 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -13.65 34.93 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.681 2.254 . . . . 0.0 112.341 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 40.7 p -114.08 19.0 16.8 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.146 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -114.12 116.6 3.89 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.517 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 19.0 mtpp -61.64 -57.5 11.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.801 0.334 . . . . 0.0 110.895 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 16.6 p -174.88 160.7 2.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.857 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.575 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 17.6 p90 -115.44 -174.41 2.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.85 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.48 ' CB ' ' OD1' ' A' ' 73' ' ' ASN . . . -156.5 130.3 8.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.113 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.409 HD11 ' CE2' ' A' ' 56' ' ' PHE . 5.3 mp -114.55 103.56 15.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.11 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.4 m-80 -101.44 146.22 27.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.865 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.573 ' CE2' HD11 ' A' ' 145' ' ' LEU . 3.4 m-85 -118.38 99.72 7.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.887 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.44 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 32.8 ttmt -97.47 169.23 9.88 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.884 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.44 ' N ' ' HG2' ' A' ' 61' ' ' LYS . 39.8 t -101.23 120.4 50.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.133 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -56.54 -39.61 85.23 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.523 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 35.1 m -62.26 -72.33 0.13 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.875 0.369 . . . . 0.0 110.859 -179.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 40.6 p -80.17 -70.21 0.54 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.87 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 127.26 44.25 0.23 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.491 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . 0.404 ' OD1' ' OD1' ' A' ' 88' ' ' ASN . 0.6 OUTLIER -117.37 142.63 46.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.834 0.349 . . . . 0.0 110.87 179.977 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 41.0 mt -86.11 111.2 20.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.128 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.451 ' HB2' ' CG2' ' A' ' 142' ' ' VAL . . . -82.23 -31.25 30.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.075 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.55 HD21 ' CD2' ' A' ' 132' ' ' PHE . 32.4 tp -142.37 132.46 24.59 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.93 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.441 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.8 OUTLIER -134.78 98.79 4.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.88 179.838 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 17.9 mt -101.74 133.57 44.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.102 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.495 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -141.08 106.82 6.2 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.658 0.742 . . . . 0.0 110.878 179.918 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.575 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.2 Cg_endo -69.76 155.32 66.26 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.718 2.278 . . . . 0.0 112.332 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 38.4 mtp180 -132.37 96.56 3.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.875 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.862 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.3 p . . . . . 0 N--CA 1.457 -0.112 0 CA-C-O 120.828 0.346 . . . . 0.0 111.139 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.7 t -100.93 112.85 35.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.128 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 30.2 t -82.3 144.85 9.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.137 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -129.46 126.59 39.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.89 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.441 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.6 OUTLIER -137.07 -177.09 4.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.908 -179.943 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 40.1 t -158.65 105.32 1.82 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.855 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.572 ' HB2' ' CH2' ' A' ' 91' ' ' TRP . 35.9 tp -76.83 115.86 16.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.902 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.519 ' N ' ' O ' ' A' ' 90' ' ' SER . 83.2 mt -93.72 162.45 13.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.946 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.42 ' C ' ' H ' ' A' ' 90' ' ' SER . 8.2 m-80 -41.26 102.17 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.907 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.37 -0.49 3.74 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.51 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.519 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -126.45 171.16 11.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.919 0.39 . . . . 0.0 110.826 -179.713 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.572 ' CH2' ' HB2' ' A' ' 86' ' ' LEU . 26.6 m95 -128.25 160.72 31.24 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.899 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.85 -109.76 1.89 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.496 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' SER . . . . . 0.422 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 47.5 m -155.5 174.52 15.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.791 0.329 . . . . 0.0 110.905 -179.749 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -100.01 125.17 46.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.884 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -120.17 121.22 38.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.854 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 6.4 mtmp? -127.57 118.56 24.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.932 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 20.9 tttt -170.85 107.49 0.29 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.937 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.434 ' CG1' ' N ' ' A' ' 99' ' ' THR . 2.3 tt -145.53 153.38 13.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.147 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.434 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 8.9 t -97.52 -36.2 10.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.128 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . 0.4 ' O ' ' CG ' ' A' ' 100' ' ' HIS . 2.3 p-80 -148.88 128.16 12.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.848 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -102.87 96.66 8.07 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.619 0.723 . . . . 0.0 110.874 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.406 ' O ' ' C ' ' A' ' 103' ' ' PHE . 54.2 Cg_endo -69.74 -42.98 2.95 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.693 2.262 . . . . 0.0 112.374 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.434 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 8.6 m-85 -37.84 105.13 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.868 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -133.21 139.22 10.75 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.481 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 104.21 1.29 Allowed 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.63 2.22 . . . . 0.0 112.352 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 124.41 -7.88 8.45 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.529 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.485 ' NE2' ' O ' ' A' ' 108' ' ' PHE . 2.1 pp0? -131.37 168.7 17.13 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.83 0.348 . . . . 0.0 110.922 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' PHE . . . . . 0.485 ' O ' ' NE2' ' A' ' 107' ' ' GLN . 1.4 p90 -90.89 172.56 8.52 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.856 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 31.9 p90 -158.36 129.2 6.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.881 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -98.86 102.18 13.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.888 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.449 ' CD1' HD12 ' A' ' 113' ' ' ILE . 0.9 OUTLIER -99.85 137.51 38.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.876 -179.918 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.405 ' N ' ' CD1' ' A' ' 111' ' ' LEU . 2.4 m -145.14 111.71 5.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.9 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.449 HD12 ' CD1' ' A' ' 111' ' ' LEU . 3.9 mp -94.71 121.04 44.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.162 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . 0.566 ' HD3' ' CD1' ' A' ' 123' ' ' TYR . 0.2 OUTLIER -99.54 123.92 44.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.864 179.984 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . 0.574 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 7.9 t -90.11 126.66 35.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.907 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -123.35 -150.32 8.0 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.489 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 9.2 mt -111.8 -39.72 4.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.863 0.363 . . . . 0.0 110.946 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . 0.423 ' C ' ' CD2' ' A' ' 134' ' ' HIS . 29.0 t0 -88.78 -34.66 17.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.831 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.5 ptt180 -172.73 167.87 5.22 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.888 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.574 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.4 m-30 -93.18 158.68 15.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.865 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.409 ' HB3' ' CE1' ' A' ' 123' ' ' TYR . 17.9 mtpp -130.62 104.72 7.37 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.897 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . 0.423 HG22 ' CE1' ' A' ' 130' ' ' PHE . 92.5 t -93.4 108.47 20.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.116 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' TYR . . . . . 0.566 ' CD1' ' HD3' ' A' ' 114' ' ' ARG . 32.9 m-85 -96.43 147.86 23.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.904 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . 0.414 ' CB ' HD12 ' A' ' 129' ' ' LEU . . . -127.5 102.14 6.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.074 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 57.19 37.62 28.48 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.875 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.38 33.39 28.59 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.504 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -142.89 120.67 11.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.85 0.357 . . . . 0.0 110.895 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . 0.488 ' CE1' ' OD2' ' A' ' 131' ' ' ASP . 33.6 t-80 -53.22 99.86 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.884 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . 0.414 HD12 ' CB ' ' A' ' 124' ' ' ALA . 10.5 tp -70.01 -67.41 0.49 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.883 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.429 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 8.2 p90 -162.41 175.48 11.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.886 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.488 ' OD2' ' CE1' ' A' ' 128' ' ' HIS . 15.7 m-20 -120.21 150.17 41.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.864 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.558 ' CE1' ' O ' ' A' ' 133' ' ' ALA . 0.1 OUTLIER -115.86 107.81 15.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.848 -179.886 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.558 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -63.22 131.87 49.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.11 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' HIS . . . . . 0.423 ' CD2' ' C ' ' A' ' 118' ' ' ASP . 44.0 m-70 -62.35 102.39 0.31 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.893 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.422 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 68.9 mtt-85 -89.34 -45.98 9.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.872 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 4.5 tp -99.7 108.16 20.44 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.907 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 58.2 p -50.88 -33.17 22.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.853 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . 0.446 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.23 31.17 0.39 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.095 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 40.0 p90 -52.37 -42.31 63.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.883 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 8.2 pt20 -48.68 -42.31 34.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.916 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.446 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 72.2 mtp180 -54.36 -40.96 68.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.895 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.451 ' CG2' ' HB2' ' A' ' 69' ' ' ALA . 69.8 t -44.99 105.43 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.148 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -129.92 34.32 4.28 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.898 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 11.6 m -143.04 116.68 9.21 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.126 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.573 HD11 ' CE2' ' A' ' 60' ' ' PHE . 7.1 tp -116.45 107.8 15.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.959 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' GLU . . . . . 0.404 ' C ' HG13 ' A' ' 147' ' ' ILE . 8.0 pt-20 -111.79 153.02 27.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.852 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . 0.404 HG13 ' C ' ' A' ' 146' ' ' GLU . 16.8 mt -139.95 109.8 3.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.172 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -118.54 173.64 6.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.911 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.46 -145.45 16.09 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.503 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -112.18 93.05 4.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.868 0.366 . . . . 0.0 110.879 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 5.6 p -151.12 149.13 14.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.138 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 40.0 m -110.23 95.06 5.34 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.132 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.454 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 84.6 mt -76.53 136.09 39.3 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.901 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 6.0 m -120.08 -36.54 3.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.897 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 53.5 t80 -150.64 130.94 13.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.909 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 44.8 t -139.72 105.0 2.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.123 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 12.2 tt0 -120.37 135.42 55.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.879 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 16.9 mt . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.135 179.964 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.473 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.9 m . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.785 0.326 . . . . 0.0 111.131 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.473 ' CD1' ' O ' ' A' ' 22' ' ' THR . 6.7 m-85 -147.37 124.59 11.5 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.891 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . 0.575 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 4.6 t-20 58.93 46.23 1.48 Allowed Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.621 0.724 . . . . 0.0 110.883 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.575 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.77 134.47 28.04 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.679 2.252 . . . . 0.0 112.337 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.409 ' C ' HG22 ' A' ' 27' ' ' VAL . 53.6 Cg_endo -69.75 -177.77 2.03 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.714 2.276 . . . . 0.0 112.301 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.534 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 96.0 t -142.25 138.72 16.9 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-O 121.634 0.731 . . . . 0.0 111.14 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.534 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 54.2 Cg_endo -69.72 144.39 76.44 Favored 'Cis proline' 0 C--N 1.341 0.17 0 C-N-CA 122.685 -1.798 . . . . 0.0 112.381 -0.11 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -98.37 115.68 28.98 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.925 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.467 ' CD2' ' HB3' ' A' ' 146' ' ' GLU . 63.7 m-85 -103.27 102.65 12.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.851 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -115.75 103.97 1.25 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.479 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.486 ' NH1' ' NE2' ' A' ' 34' ' ' GLN . 0.0 OUTLIER -72.34 132.03 43.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.836 0.35 . . . . 0.0 110.862 -179.848 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 143' ' ' ASP . 9.5 mt -76.87 142.57 40.13 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.942 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . 0.486 ' NE2' ' NH1' ' A' ' 32' ' ' ARG . 23.0 mm-40 -100.39 91.49 4.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.926 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 133.23 -50.02 0.89 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.53 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.462 ' O ' ' CG2' ' A' ' 38' ' ' THR . . . 108.56 161.56 20.34 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.504 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 99.4 mt -50.31 105.32 0.09 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.881 0.372 . . . . 0.0 110.933 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.462 ' CG2' ' O ' ' A' ' 36' ' ' GLY . 12.1 p -123.12 146.27 47.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.11 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -44.59 -31.98 1.31 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.173 179.856 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -103.45 41.05 1.31 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.895 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.413 ' NH2' ' O ' ' A' ' 34' ' ' GLN . 45.5 ttm-85 -124.31 136.03 53.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.861 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 39.3 m -135.91 126.33 26.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.14 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 mp -98.94 132.48 44.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.101 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 95.3 mt -123.58 134.68 65.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.137 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 59.5 mt -135.95 107.88 7.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.144 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.4 mtmm -110.34 111.07 22.12 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.925 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.66 -143.45 4.31 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.51 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 1.6 t80 -170.16 126.78 0.82 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.851 0.357 . . . . 0.0 110.944 -179.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 11.2 t -77.36 116.13 55.11 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.616 0.722 . . . . 0.0 111.124 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 158.68 56.15 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.699 2.266 . . . . 0.0 112.331 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -19.36 36.38 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.733 2.288 . . . . 0.0 112.327 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 69.2 p -109.7 21.27 17.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.142 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -115.02 120.04 4.84 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.486 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 20.6 mtpp -61.27 -60.19 4.13 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.797 0.332 . . . . 0.0 110.897 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.7 p -175.29 157.59 2.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.886 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.508 ' O ' ' ND2' ' A' ' 73' ' ' ASN . 4.0 p90 -108.47 -172.5 2.07 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.857 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -154.82 141.41 18.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.082 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.446 HG21 ' CE1' ' A' ' 60' ' ' PHE . 2.6 mp -123.0 98.7 5.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.166 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.0 m-80 -101.07 144.84 29.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.908 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.446 ' CE1' HG21 ' A' ' 58' ' ' ILE . 29.6 m-85 -117.24 101.45 8.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.912 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.411 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 32.8 ttmt -95.83 168.39 10.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.863 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.482 ' CG2' HG21 ' A' ' 142' ' ' VAL . 61.4 t -100.41 122.27 52.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.171 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -57.08 -41.13 92.42 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.515 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 44.2 t -65.15 -73.04 0.13 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.888 0.375 . . . . 0.0 110.856 -179.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 39.0 t -77.99 -75.94 0.2 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.918 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 132.42 40.28 0.21 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.485 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -111.88 142.01 44.81 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.761 0.315 . . . . 0.0 110.892 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 50.0 mt -86.41 120.11 35.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.152 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.458 ' CB ' HG23 ' A' ' 142' ' ' VAL . . . -92.24 -33.55 14.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.08 179.829 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.514 HD13 ' CD1' ' A' ' 132' ' ' PHE . 59.8 tp -138.85 130.61 27.65 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.907 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.492 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.5 OUTLIER -134.96 92.63 2.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.913 179.843 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 30.5 mt -94.99 128.37 46.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.117 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.508 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -134.58 105.4 10.89 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.611 0.719 . . . . 0.0 110.897 179.929 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.476 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.2 Cg_endo -69.71 154.51 67.85 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.701 2.267 . . . . 0.0 112.354 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 36.1 mtp180 -130.32 96.94 4.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.876 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' MET . . . . . 0.476 ' HE2' ' CE1' ' A' ' 56' ' ' PHE . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.845 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 34.8 p . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.838 0.352 . . . . 0.0 111.17 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 13.1 t -89.29 108.73 19.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.097 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 91.6 t -80.93 145.97 8.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.088 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -127.34 124.81 39.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.892 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.492 ' O ' ' N ' ' A' ' 71' ' ' HIS . 2.7 m120 -135.22 179.3 6.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.901 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 46.1 t -160.78 105.63 1.4 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.861 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.574 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 27.0 tp -77.96 119.34 21.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.92 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.503 ' N ' ' O ' ' A' ' 90' ' ' SER . 87.0 mt -97.08 161.35 13.86 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.919 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.532 HD21 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.23 101.61 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.931 179.898 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.45 -6.41 0.82 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.501 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.512 ' H ' ' C ' ' A' ' 88' ' ' ASN . 0.3 OUTLIER -118.96 172.06 7.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.834 0.349 . . . . 0.0 110.844 -179.725 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.574 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 22.0 m95 -129.43 161.07 31.21 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.929 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.09 -106.01 1.55 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.476 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 2.9 m -165.76 174.92 9.2 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.812 0.339 . . . . 0.0 110.835 -179.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.416 ' HG2' ' ND2' ' A' ' 84' ' ' ASN . 7.6 mt-10 -104.66 117.62 34.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.88 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -123.05 108.78 13.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.876 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 35.8 mtmt -105.57 131.32 53.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.864 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.463 ' HE3' ' N ' ' A' ' 98' ' ' ILE . 0.0 OUTLIER -174.31 105.23 0.11 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.903 179.889 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.463 ' N ' ' HE3' ' A' ' 97' ' ' LYS . 5.1 tt -148.09 154.25 10.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.12 179.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.416 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 9.0 t -95.29 -44.62 7.51 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.143 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . 0.426 ' O ' ' CD1' ' A' ' 98' ' ' ILE . 4.9 p-80 -139.1 133.3 31.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.856 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 44.2 t-20 -110.92 95.99 27.07 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.628 0.728 . . . . 0.0 110.892 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.434 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.4 Cg_endo -69.78 -42.6 3.24 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.646 2.231 . . . . 0.0 112.34 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.434 ' C ' ' O ' ' A' ' 102' ' ' PRO . 5.2 m-85 -35.88 104.84 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.861 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -135.88 138.44 9.92 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.455 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 99.95 0.78 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.722 2.281 . . . . 0.0 112.319 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 130.45 -9.59 5.87 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.461 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.1 pt20 -131.49 159.22 38.76 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.806 0.336 . . . . 0.0 110.941 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -76.45 174.09 10.7 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.849 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.468 ' O ' ' CD2' ' A' ' 109' ' ' PHE . 23.4 p90 -161.55 117.87 2.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.887 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -94.76 102.08 13.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.878 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.449 ' CD1' HD13 ' A' ' 113' ' ' ILE . 0.9 OUTLIER -101.23 137.33 39.73 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.921 -179.943 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 5.2 m -144.2 114.16 7.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.859 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.449 HD13 ' CD1' ' A' ' 111' ' ' LEU . 5.1 mp -96.47 140.71 16.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.147 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 24.6 mtt180 -115.57 124.93 52.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.879 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . 0.552 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 6.5 t -92.89 118.45 31.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.85 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.99 -144.82 8.51 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.434 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 13.6 mt -116.85 -36.95 3.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.838 0.351 . . . . 0.0 110.933 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -92.23 -34.69 14.17 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.833 179.861 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 17.8 ptp180 -171.77 172.83 4.75 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.885 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.552 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.6 m-30 -96.28 158.17 15.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.845 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 27.4 mtpt -129.82 100.34 5.44 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.917 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 88.0 t -86.18 137.07 21.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.133 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -126.54 152.72 46.16 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.884 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -140.83 111.17 6.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.069 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 56.78 29.71 16.45 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.9 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 83.37 32.12 26.11 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.503 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 8.5 mm100 -139.01 125.77 20.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.872 0.368 . . . . 0.0 110.875 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . 0.445 ' CE1' ' OD1' ' A' ' 131' ' ' ASP . 31.3 t-80 -56.6 109.22 0.58 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.839 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 10.7 tp -77.8 -68.38 0.63 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.939 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.437 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 7.6 p90 -165.18 171.48 13.66 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.883 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.445 ' OD1' ' CE1' ' A' ' 128' ' ' HIS . 1.4 m-20 -113.97 151.64 32.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.865 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.514 ' CD1' HD13 ' A' ' 70' ' ' LEU . 0.3 OUTLIER -116.8 108.58 16.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.929 -179.933 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.513 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -63.49 134.42 55.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.065 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 15.8 m-70 -62.82 103.0 0.4 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.849 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 47.2 mtt-85 -87.1 -52.82 5.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.906 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 9.5 tp -91.54 108.34 19.83 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.934 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 99.2 p -50.5 -32.48 18.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.867 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . 0.457 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.93 25.54 0.67 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.06 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.436 ' CG ' ' N ' ' A' ' 140' ' ' GLN . 12.5 p90 -45.44 -42.81 10.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.869 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' GLN . . . . . 0.436 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 10.7 pt20 -48.93 -40.06 28.65 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.894 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.457 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 41.0 mtp85 -55.9 -39.71 71.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.9 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.482 HG21 ' CG2' ' A' ' 62' ' ' VAL . 53.1 t -51.7 103.24 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.511 ' O ' ' N ' ' A' ' 33' ' ' LEU . 3.1 p30 -125.47 25.94 6.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.849 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 2.2 m -132.99 140.19 47.65 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.137 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.427 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.7 tp -134.64 108.32 7.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.947 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' GLU . . . . . 0.467 ' HB3' ' CD2' ' A' ' 30' ' ' PHE . 5.8 pt-20 -111.51 148.85 32.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.896 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 9.9 mt -136.65 111.46 10.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.11 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 1.1 pm0 -124.26 176.68 6.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.956 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 109.97 -139.48 15.41 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.495 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -120.47 90.82 3.4 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.848 0.356 . . . . 0.0 110.898 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.446 HG22 ' N ' ' A' ' 152' ' ' THR . 2.8 p -151.15 155.33 7.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.13 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' THR . . . . . 0.446 ' N ' HG22 ' A' ' 151' ' ' VAL . 38.0 m -113.32 93.7 4.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.156 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.459 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 68.2 mt -77.27 137.33 38.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.939 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 6.9 t -121.42 -39.55 2.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.888 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 19.3 t80 -143.49 129.17 19.26 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.929 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 76.3 t -141.05 105.42 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.128 179.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 14.6 tt0 -118.39 134.39 55.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.927 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 21.3 mt . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.158 179.947 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.538 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.6 m . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.867 0.365 . . . . 0.0 111.118 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.538 ' CD1' ' O ' ' A' ' 22' ' ' THR . 8.3 m-85 -150.84 127.4 10.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.887 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . 0.59 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 3.4 m120 54.48 45.46 2.27 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.607 0.718 . . . . 0.0 110.893 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.59 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.6 Cg_endo -69.76 132.56 23.59 Favored 'Trans proline' 0 C--O 1.231 0.175 0 C-N-CA 122.655 2.236 . . . . 0.0 112.299 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.81 -175.11 1.06 Allowed 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.669 2.246 . . . . 0.0 112.394 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.529 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 86.9 t -143.17 137.63 14.95 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.616 0.722 . . . . 0.0 111.14 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.529 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.6 Cg_endo -69.79 144.63 77.27 Favored 'Cis proline' 0 C--N 1.341 0.184 0 C-N-CA 122.702 -1.791 . . . . 0.0 112.319 -0.017 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 6.4 t80 -98.31 121.99 40.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.938 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -102.17 101.95 12.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.842 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -100.82 108.77 3.52 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.455 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 6.8 mmt85 -73.28 123.29 23.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.856 0.36 . . . . 0.0 110.902 -179.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.453 HD12 ' N ' ' A' ' 144' ' ' THR . 7.8 mt -87.05 113.73 23.05 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.929 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 5.7 mm100 -84.62 80.53 9.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.888 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 143.54 -36.83 1.51 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.501 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.469 ' CA ' ' OD1' ' A' ' 143' ' ' ASP . . . 93.72 -177.93 37.59 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.48 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 89.0 mt -68.47 98.05 0.82 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.899 0.38 . . . . 0.0 110.885 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 34.6 p -107.77 161.85 14.52 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.1 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -62.18 -27.47 68.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.112 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 8.8 mpt_? -105.61 33.06 3.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.918 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.466 ' NH1' ' CG2' ' A' ' 158' ' ' ILE . 4.5 ttt85 -109.74 137.98 46.77 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 87.4 m -138.96 120.82 15.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.136 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.4 mp -93.74 137.78 21.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.159 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 76.2 mt -128.96 118.65 47.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.084 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 71.9 mt -118.1 107.37 21.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.104 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 21.9 mtmt -113.69 109.49 18.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.928 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -143.2 -143.61 4.15 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.528 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -168.03 128.6 1.35 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.941 0.4 . . . . 0.0 110.944 -179.845 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 15.4 t -79.11 119.6 77.75 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.646 0.736 . . . . 0.0 111.17 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 158.91 55.29 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.683 2.255 . . . . 0.0 112.313 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -17.96 37.03 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.712 2.274 . . . . 0.0 112.304 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 30.2 p -109.52 18.77 20.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.126 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -115.74 121.18 5.17 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.477 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 20.2 mtpp -63.91 -58.78 5.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.78 0.324 . . . . 0.0 110.906 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.0 m -173.12 167.77 4.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.833 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.461 ' CD1' ' N ' ' A' ' 56' ' ' PHE . 1.9 p90 -119.07 -172.2 2.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.86 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.485 ' CB ' ' OD1' ' A' ' 73' ' ' ASN . . . -154.67 133.82 12.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.106 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.6 mp -115.77 98.18 6.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.151 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . 0.415 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 6.0 m-80 -100.25 143.33 30.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.939 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.571 ' CE2' HD13 ' A' ' 145' ' ' LEU . 28.5 m-85 -115.32 98.38 6.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.904 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.417 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 33.7 ttmt -95.68 168.31 10.75 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.934 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.417 ' N ' ' HG2' ' A' ' 61' ' ' LYS . 53.4 t -100.24 125.08 54.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.147 179.85 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.593 ' N ' ' HG1' ' A' ' 144' ' ' THR . . . -60.44 -36.88 92.25 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.509 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 69.7 m -65.95 -73.34 0.13 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.871 0.367 . . . . 0.0 110.897 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 58.0 m -81.18 -73.36 0.38 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.853 -179.874 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 133.62 39.8 0.19 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.491 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . 0.435 ' OD2' ' ND2' ' A' ' 88' ' ' ASN . 1.2 m-20 -108.92 142.88 38.9 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.789 0.328 . . . . 0.0 110.886 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 35.8 mt -92.35 114.01 28.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.127 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.427 ' HB3' ' CG2' ' A' ' 142' ' ' VAL . . . -83.63 -31.49 26.19 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.112 179.817 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.557 HD21 ' CD2' ' A' ' 132' ' ' PHE . 56.0 tp -141.28 130.91 24.04 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.889 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.476 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.2 t60 -134.49 92.94 2.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.845 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 18.2 mt -97.31 132.97 40.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.112 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.485 ' OD1' ' CB ' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -140.27 106.49 6.65 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.63 0.728 . . . . 0.0 110.899 179.941 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.584 ' HB3' ' CD2' ' A' ' 103' ' ' PHE . 54.0 Cg_endo -69.74 154.98 67.16 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.652 2.235 . . . . 0.0 112.335 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 57.8 mtp180 -131.49 100.57 5.19 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.887 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' MET . . . . . 0.409 ' N ' ' SD ' ' A' ' 76' ' ' MET . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.891 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.2 p . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.797 0.332 . . . . 0.0 111.167 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 15.2 t -102.54 114.26 41.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.13 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 37.1 t -84.53 143.34 11.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.127 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -125.4 124.88 42.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.853 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.476 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.7 OUTLIER -136.23 176.29 8.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.906 -179.975 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 47.7 t -156.15 105.07 2.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.891 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.561 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 39.0 tp -77.18 114.33 15.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.904 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.518 ' N ' ' O ' ' A' ' 90' ' ' SER . 79.7 mt -92.44 161.93 14.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.929 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.435 ' ND2' ' OD2' ' A' ' 67' ' ' ASP . 13.5 m-80 -41.17 101.83 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.938 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.15 -1.55 3.61 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.485 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.518 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -125.31 170.59 11.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.828 0.347 . . . . 0.0 110.898 -179.815 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.561 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 23.1 m95 -128.12 160.57 31.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.903 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -91.97 -102.04 1.38 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.461 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 9.9 m -167.82 174.41 7.56 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.868 0.366 . . . . 0.0 110.823 -179.752 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -96.71 123.64 40.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.881 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 17.8 mm-40 -121.37 116.12 24.2 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.9 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 6.7 mtmp? -120.72 122.16 39.82 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.888 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -175.17 105.54 0.09 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.855 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.432 ' CD1' ' O ' ' A' ' 100' ' ' HIS . 6.4 tt -147.64 146.58 18.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.137 179.842 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 10.2 t -81.34 -44.79 17.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . 0.432 ' O ' ' CD1' ' A' ' 98' ' ' ILE . 5.1 p-80 -148.5 141.26 24.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.9 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . 0.443 ' OD1' ' C ' ' A' ' 101' ' ' ASN . 4.9 t-20 -101.63 102.13 20.97 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.605 0.717 . . . . 0.0 110.899 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.469 ' CD ' HD11 ' A' ' 129' ' ' LEU . 53.8 Cg_endo -69.78 -29.6 23.53 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.691 2.26 . . . . 0.0 112.33 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.584 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 19.6 m-85 -58.6 115.02 2.77 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.866 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -140.06 139.83 10.18 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.516 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 111.0 2.7 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.716 2.277 . . . . 0.0 112.305 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 107.18 0.9 35.64 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.487 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -137.85 142.09 40.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.849 0.356 . . . . 0.0 110.903 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.4 p90 -68.57 174.51 4.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.844 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.4 ' CD1' ' HE1' ' A' ' 103' ' ' PHE . 29.1 p90 -161.25 132.21 5.32 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.922 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -103.34 106.38 16.88 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.859 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.435 ' CD1' HG11 ' A' ' 122' ' ' VAL . 0.4 OUTLIER -109.16 138.39 45.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.912 -179.955 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 2.6 m -145.44 113.67 6.59 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.867 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.0 mp -93.55 136.82 24.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.108 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 50.1 mtt-85 -110.22 120.9 43.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.851 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . 0.444 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 26.3 t -92.06 122.21 34.35 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.918 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -123.62 -149.44 7.77 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.484 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 36.3 mt -109.37 -40.88 4.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.86 0.362 . . . . 0.0 110.904 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -80.72 -39.54 26.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.83 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -174.11 179.91 1.8 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.898 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.444 ' CE2' ' HB2' ' A' ' 115' ' ' CYS . 18.9 m-85 -97.95 155.04 17.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.877 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 15.5 mtpp -130.48 100.55 5.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.921 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . 0.435 HG11 ' CD1' ' A' ' 111' ' ' LEU . 21.3 t -88.16 128.61 40.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.116 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -120.59 149.79 41.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.909 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . 0.441 ' CB ' ' HG3' ' A' ' 102' ' ' PRO . . . -134.17 110.1 9.34 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.093 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 58.13 31.58 20.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.911 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.31 38.2 15.64 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.484 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 8.7 mm100 -143.77 128.88 18.66 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.868 0.366 . . . . 0.0 110.914 -179.854 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 35.6 t-80 -59.21 107.19 0.52 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.845 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . 0.469 HD11 ' CD ' ' A' ' 102' ' ' PRO . 8.5 tp -78.41 -66.12 0.89 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.899 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.472 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 5.3 p90 -166.42 169.53 13.86 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.861 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -115.21 149.71 37.28 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.917 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.579 ' CE1' ' O ' ' A' ' 133' ' ' ALA . 0.1 OUTLIER -117.73 108.02 14.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.899 -179.92 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.579 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -63.33 134.97 56.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.066 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 42.3 m-70 -63.34 107.3 1.06 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.884 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 67.6 mtt-85 -89.71 -48.85 7.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.849 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 12.2 tp -93.51 109.33 20.93 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.943 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 12.1 t -50.64 -33.37 22.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.868 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -87.19 33.55 0.68 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.107 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 8.2 p90 -50.74 -31.61 17.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.868 -179.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 6.1 pt20 -56.14 -46.46 79.22 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.885 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.433 ' O ' ' CG ' ' A' ' 143' ' ' ASP . 27.6 mtt-85 -47.5 -44.22 25.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.866 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.427 ' CG2' ' HB3' ' A' ' 69' ' ' ALA . 92.3 t -43.3 103.45 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.153 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.469 ' OD1' ' CA ' ' A' ' 36' ' ' GLY . 17.1 m-20 -128.19 31.48 5.05 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.841 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' THR . . . . . 0.593 ' HG1' ' N ' ' A' ' 63' ' ' GLY . 18.1 m -142.44 123.19 14.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.122 -179.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.571 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.6 tp -120.15 107.69 13.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.933 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -110.75 152.31 26.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.919 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 25.1 mt -139.58 112.77 6.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.177 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -123.57 171.29 9.64 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.928 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 113.03 -148.07 18.54 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.522 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 28.8 m-20 -111.56 89.1 2.96 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.859 0.361 . . . . 0.0 110.881 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.454 HG21 ' N ' ' A' ' 152' ' ' THR . 7.2 p -148.85 155.33 8.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.129 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' THR . . . . . 0.454 ' N ' HG21 ' A' ' 151' ' ' VAL . 16.9 m -116.21 94.51 4.68 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.16 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.457 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 78.6 mt -75.92 139.95 41.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.886 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 68.6 m -127.8 -35.57 2.09 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.858 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 39.6 t80 -146.93 125.08 12.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.942 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 79.4 t -138.97 106.33 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.118 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 13.9 tt0 -119.69 141.16 49.63 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.931 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' ILE . . . . . 0.466 ' CG2' ' NH1' ' A' ' 41' ' ' ARG . 15.6 mt . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.121 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 1.2 t . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.828 0.347 . . . . 0.0 111.129 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -138.92 127.83 23.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.92 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . 0.567 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 8.8 m-80 61.55 47.0 1.08 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.578 0.704 . . . . 0.0 110.901 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.567 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 54.0 Cg_endo -69.75 136.03 31.99 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.65 2.234 . . . . 0.0 112.312 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 -177.72 2.02 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.68 2.253 . . . . 0.0 112.331 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.524 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 97.0 t -141.72 138.09 16.87 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.685 0.755 . . . . 0.0 111.107 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.524 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.3 Cg_endo -69.77 144.33 76.38 Favored 'Cis proline' 0 C--N 1.342 0.198 0 C-N-CA 122.65 -1.812 . . . . 0.0 112.325 -0.027 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 8.2 t80 -97.47 117.15 31.09 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.933 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -100.66 102.3 13.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.884 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -97.77 109.4 3.81 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.456 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 9.7 mmt180 -72.91 102.99 3.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.854 0.359 . . . . 0.0 110.876 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.432 HD13 ' N ' ' A' ' 144' ' ' THR . 5.6 mt -71.1 114.7 9.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.939 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 5.6 mm-40 -86.32 94.49 9.36 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.911 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 131.33 -32.75 2.9 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.453 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.405 ' CA ' ' OD1' ' A' ' 143' ' ' ASP . . . 88.69 173.45 46.87 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.51 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . 0.406 HD22 ' NH2' ' A' ' 41' ' ' ARG . 88.0 mt -57.18 104.97 0.19 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.854 0.359 . . . . 0.0 110.938 -179.9 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.402 ' O ' ' SG ' ' A' ' 115' ' ' CYS . 29.0 p -117.07 149.94 39.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.116 -180.0 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -59.71 -21.27 60.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.122 179.83 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 25.5 mmm-85 -104.42 26.46 8.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.884 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.406 ' NH2' HD22 ' A' ' 37' ' ' LEU . 23.4 ttt180 -116.97 142.86 46.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.863 -179.892 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 91.2 m -137.16 121.21 17.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.123 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 mp -90.86 132.46 35.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.156 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.433 ' CG2' ' HE2' ' A' ' 46' ' ' LYS . 70.1 mt -128.57 117.24 44.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.154 179.792 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 34.9 mt -116.15 107.59 22.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.168 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.433 ' HE2' ' CG2' ' A' ' 44' ' ' ILE . 22.3 mtmt -111.65 111.18 21.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.904 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -143.67 -143.62 4.12 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.484 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 0.405 ' O ' ' CD1' ' A' ' 48' ' ' TYR . 1.1 t80 -167.59 118.27 0.85 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.944 0.402 . . . . 0.0 110.896 -179.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 15.1 t -69.96 115.45 34.0 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.638 0.732 . . . . 0.0 111.135 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 159.02 54.96 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.714 2.276 . . . . 0.0 112.359 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -25.16 29.01 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.683 2.256 . . . . 0.0 112.328 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 67.1 p -100.74 15.41 28.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.134 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -109.89 119.4 5.4 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.489 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.418 ' O ' ' SD ' ' A' ' 76' ' ' MET . 24.8 mtpt -62.47 -58.91 5.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.816 0.341 . . . . 0.0 110.89 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 37.0 p -175.58 162.37 2.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.827 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.572 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 3.5 p90 -116.14 -174.98 2.65 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.87 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.482 ' CB ' ' OD1' ' A' ' 73' ' ' ASN . . . -156.91 137.38 13.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.119 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.459 HG21 ' CE1' ' A' ' 60' ' ' PHE . 4.6 mp -118.14 100.78 10.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.152 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -99.85 144.04 29.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.911 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.561 ' CE2' HD11 ' A' ' 145' ' ' LEU . 50.1 m-85 -115.04 97.69 6.37 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.881 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.456 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 35.5 ttmt -96.13 167.68 11.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.899 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.456 ' N ' ' HG2' ' A' ' 61' ' ' LYS . 43.6 t -100.61 122.52 52.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.102 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -58.58 -40.21 94.28 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.515 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.0 t -64.43 -70.74 0.21 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.941 0.4 . . . . 0.0 110.902 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 48.5 t -79.75 -75.06 0.27 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.875 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 131.43 41.37 0.21 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.487 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -114.71 141.47 47.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.833 0.349 . . . . 0.0 110.879 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 43.0 mt -88.05 119.55 35.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.111 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -90.25 -33.57 16.1 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.059 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.561 HD23 ' CD2' ' A' ' 132' ' ' PHE . 62.7 tp -138.44 131.2 29.43 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.898 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.497 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.3 OUTLIER -135.01 93.91 3.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.866 179.877 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 17.1 mt -98.09 133.16 41.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.096 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.482 ' OD1' ' CB ' ' A' ' 57' ' ' ALA . 0.2 OUTLIER -140.8 106.87 6.36 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.597 0.713 . . . . 0.0 110.871 179.937 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.579 ' HB3' ' CD2' ' A' ' 103' ' ' PHE . 53.8 Cg_endo -69.75 154.63 67.56 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.702 2.268 . . . . 0.0 112.383 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 46.0 mtp85 -132.96 94.58 3.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.892 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' MET . . . . . 0.418 ' SD ' ' O ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.885 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 28.8 p . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.85 0.357 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.2 t -99.35 110.46 26.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.149 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 67.6 t -82.71 145.45 8.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.113 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -125.84 124.15 40.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.895 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.497 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.4 m120 -135.49 177.12 8.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.889 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 87.1 p -160.67 105.13 1.4 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.826 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.566 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 22.9 tp -77.74 119.34 21.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.943 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 90' ' ' SER . 93.0 mt -96.71 161.48 13.86 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.915 179.876 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.539 HD21 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -37.91 101.67 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.864 179.895 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.51 -7.05 0.68 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.477 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.522 ' H ' ' C ' ' A' ' 88' ' ' ASN . 0.3 OUTLIER -117.54 170.03 9.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.856 0.36 . . . . 0.0 110.871 -179.748 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.566 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 20.7 m95 -128.58 161.1 30.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.927 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -93.14 -110.26 1.98 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.465 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 72.0 m -159.91 178.12 10.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.855 0.359 . . . . 0.0 110.87 -179.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.435 ' C ' ' OE2' ' A' ' 95' ' ' GLU . 30.2 mt-10 -103.07 123.62 47.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.887 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . 0.435 ' OE2' ' C ' ' A' ' 94' ' ' GLU . 3.5 mp0 -122.88 116.96 24.5 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.89 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 9.4 mtmp? -118.79 120.55 37.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.891 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -171.84 108.0 0.23 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.966 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.438 HG12 ' N ' ' A' ' 99' ' ' THR . 4.1 tt -147.66 152.3 12.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.119 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.438 ' N ' HG12 ' A' ' 98' ' ' ILE . 8.9 t -85.42 -47.18 10.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.162 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 1.7 p-80 -147.06 133.49 19.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.87 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -103.67 98.17 12.34 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.674 0.749 . . . . 0.0 110.856 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.5 Cg_endo -69.75 -42.5 3.36 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.687 2.258 . . . . 0.0 112.331 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.579 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 11.7 m-85 -34.01 110.58 0.09 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.858 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -133.09 136.66 8.84 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.515 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 97.78 0.65 Allowed 'Trans proline' 0 N--CA 1.465 -0.151 0 C-N-CA 122.715 2.277 . . . . 0.0 112.371 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 119.97 1.92 12.8 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.473 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 9.4 pt20 -134.59 149.09 50.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.846 0.355 . . . . 0.0 110.911 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -66.52 168.39 9.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.901 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.41 ' O ' ' CG ' ' A' ' 109' ' ' PHE . 14.9 p90 -160.71 125.51 3.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.906 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -101.75 108.28 19.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.883 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.421 ' CD1' HD11 ' A' ' 113' ' ' ILE . 0.7 OUTLIER -111.81 139.01 47.65 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.932 -179.96 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.5 m -144.9 115.51 7.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.834 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.421 HD11 ' CD1' ' A' ' 111' ' ' LEU . 4.9 mp -97.28 132.03 42.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.135 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . 0.535 ' O ' ' CD2' ' A' ' 120' ' ' PHE . 6.1 mtp-105 -104.53 133.39 49.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.879 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . 0.557 ' HA ' ' CE2' ' A' ' 120' ' ' PHE . 5.7 t -98.08 121.72 40.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.895 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -122.97 -163.04 11.69 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.521 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 7.6 mt -104.82 -28.75 10.96 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.784 0.326 . . . . 0.0 110.892 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . 0.4 ' C ' ' OD1' ' A' ' 118' ' ' ASP . 7.2 t0 -97.43 -39.91 8.94 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.886 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 29.4 ptt-85 -170.34 163.89 8.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.557 ' CE2' ' HA ' ' A' ' 115' ' ' CYS . 14.8 m-85 -88.23 154.78 20.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.86 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 13.6 mtpp -126.94 100.17 6.04 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.908 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . 0.436 HG23 ' CE1' ' A' ' 130' ' ' PHE . 39.3 t -87.44 132.28 33.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.128 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -123.79 146.59 48.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.919 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -134.74 111.89 10.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.111 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 55.64 35.18 24.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.865 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.57 39.57 21.25 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.492 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 9.8 mt-30 -145.99 129.11 16.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.837 0.351 . . . . 0.0 110.937 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 33.0 t-80 -60.76 99.29 0.08 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.889 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 9.8 tp -66.71 -69.62 0.3 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.93 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.482 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 4.9 p90 -163.29 171.38 16.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.913 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -116.49 148.09 41.12 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.86 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.561 ' CD2' HD23 ' A' ' 70' ' ' LEU . 0.3 OUTLIER -116.99 107.66 14.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.859 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.463 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -64.89 133.27 51.49 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.092 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 34.3 m-70 -60.68 109.09 0.95 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.846 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 32.0 mtt-85 -91.54 -51.38 5.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.891 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.0 tp -93.18 109.3 20.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.913 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 81.6 p -49.72 -35.22 21.26 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.83 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -82.22 39.44 0.58 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.115 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 7.5 p90 -60.68 -37.62 82.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.942 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -55.5 -32.68 63.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.915 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.421 ' C ' HG12 ' A' ' 62' ' ' VAL . 34.6 mtp85 -62.2 -37.72 86.39 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.879 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 93.5 t -49.08 104.12 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.087 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.405 ' OD1' ' CA ' ' A' ' 36' ' ' GLY . 0.9 OUTLIER -127.56 34.55 4.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.905 179.892 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' THR . . . . . 0.432 ' N ' HD13 ' A' ' 33' ' ' LEU . 18.7 m -146.89 112.93 5.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.144 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.561 HD11 ' CE2' ' A' ' 60' ' ' PHE . 5.3 tp -112.18 107.14 15.93 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.902 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -109.21 153.97 23.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.903 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 20.2 mt -140.03 107.23 2.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.146 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -115.69 171.5 7.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.932 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 110.64 -146.72 17.5 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.502 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -114.6 93.44 4.33 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.801 0.334 . . . . 0.0 110.896 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.475 HG22 ' N ' ' A' ' 152' ' ' THR . 4.0 p -151.2 142.09 16.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.144 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' THR . . . . . 0.475 ' N ' HG22 ' A' ' 151' ' ' VAL . 9.9 m -101.94 94.78 5.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.161 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.443 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 83.8 mt -77.33 138.1 39.15 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.89 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 16.6 m -122.35 -39.75 2.54 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.87 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 23.8 t80 -146.0 129.01 16.5 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.914 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 70.1 t -140.3 106.33 2.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.138 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 8.9 tt0 -120.8 132.89 55.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.928 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 14.1 mt . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.165 179.945 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.432 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.4 m . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.851 0.358 . . . . 0.0 111.129 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -137.48 125.54 22.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . 0.501 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.2 t-20 52.15 50.69 8.59 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.583 0.706 . . . . 0.0 110.862 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.501 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.77 140.36 42.46 Favored 'Trans proline' 0 N--CA 1.465 -0.176 0 C-N-CA 122.678 2.252 . . . . 0.0 112.379 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 -178.4 2.3 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.709 2.273 . . . . 0.0 112.371 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.522 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 97.8 t -140.35 137.58 17.95 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.658 0.742 . . . . 0.0 111.085 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.522 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.8 Cg_endo -69.72 144.68 77.24 Favored 'Cis proline' 0 C--N 1.342 0.187 0 C-N-CA 122.658 -1.809 . . . . 0.0 112.338 -0.067 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 6.2 t80 -97.88 120.72 38.78 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.925 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -103.07 101.02 10.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.887 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -106.62 109.69 3.15 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.477 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.412 ' NH1' ' HA3' ' A' ' 63' ' ' GLY . 8.3 mmt180 -74.04 109.34 7.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.841 0.353 . . . . 0.0 110.876 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.441 ' CD2' HG12 ' A' ' 158' ' ' ILE . 6.9 mt -67.54 101.08 0.94 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.88 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 24.3 mt-30 -73.36 100.35 3.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.867 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 132.81 -40.18 1.64 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.498 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.492 ' N ' ' OD2' ' A' ' 143' ' ' ASP . . . 89.84 161.45 37.48 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.466 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 91.3 mt -55.42 99.07 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.891 0.376 . . . . 0.0 110.893 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.405 ' O ' ' N ' ' A' ' 41' ' ' ARG . 26.9 p -117.94 145.95 44.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.167 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -41.7 -33.76 0.53 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.113 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 19.0 mmt180 -101.9 41.63 1.2 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.885 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.491 ' NE ' ' O ' ' A' ' 36' ' ' GLY . 29.7 ttm-85 -122.66 138.6 54.55 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 52.7 m -139.54 120.34 14.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.15 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.406 HD12 ' N ' ' A' ' 43' ' ' ILE . 4.8 mp -93.32 136.47 25.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.099 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 96.6 mt -128.46 137.0 58.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.125 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 55.0 mt -136.97 107.49 5.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.202 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 24.2 mtmt -110.64 108.69 18.69 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.877 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -139.84 -139.69 3.8 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.498 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -171.39 136.72 1.03 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.948 0.404 . . . . 0.0 110.913 -179.853 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 21.5 t -86.73 116.34 65.61 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.64 0.733 . . . . 0.0 111.121 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 158.97 55.13 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.687 2.258 . . . . 0.0 112.324 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 -14.88 36.6 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.642 2.228 . . . . 0.0 112.368 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 38.0 p -113.91 20.13 16.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.154 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -113.03 113.45 3.18 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.501 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 25.1 mtpt -58.89 -58.91 6.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.809 0.337 . . . . 0.0 110.89 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 40.5 p -174.22 162.45 3.68 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.862 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.574 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 6.0 p90 -119.37 -173.57 2.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.874 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.45 137.37 13.49 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.147 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.426 HD12 ' CE2' ' A' ' 56' ' ' PHE . 3.9 mp -114.24 104.26 16.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.11 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . 0.497 ' ND2' ' ND1' ' A' ' 71' ' ' HIS . 22.0 m120 -98.48 141.4 31.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.875 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.57 ' CE2' HD12 ' A' ' 145' ' ' LEU . 5.6 m-85 -115.88 97.16 5.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.881 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.428 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 35.2 ttmt -96.02 168.37 10.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.874 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.428 ' N ' ' HG2' ' A' ' 61' ' ' LYS . 49.0 t -99.78 124.33 53.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.086 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.412 ' HA3' ' NH1' ' A' ' 32' ' ' ARG . . . -62.25 -30.46 76.03 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.467 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 9.7 t -71.24 -71.63 0.25 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.846 0.355 . . . . 0.0 110.821 -179.703 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 22.8 t -83.87 -70.98 0.53 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 132.14 42.82 0.17 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.501 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . 0.4 ' OD1' ' OD1' ' A' ' 88' ' ' ASN . 0.8 OUTLIER -114.02 141.74 47.05 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.808 0.337 . . . . 0.0 110.88 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 80.7 mt -86.6 120.2 35.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.14 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -90.09 -37.57 14.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.076 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.518 HD12 ' CD1' ' A' ' 132' ' ' PHE . 21.8 tp -139.26 133.48 31.33 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.902 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.518 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.2 OUTLIER -134.46 92.78 2.96 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.856 179.878 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 20.4 mt -93.52 135.66 27.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.126 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.5 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 1.1 t-20 -140.91 107.13 6.31 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.626 0.727 . . . . 0.0 110.881 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.574 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.8 Cg_endo -69.77 154.73 67.33 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.669 2.246 . . . . 0.0 112.373 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 45.4 mtp85 -131.67 98.46 4.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.919 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.883 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 16.9 p . . . . . 0 N--CA 1.457 -0.113 0 CA-C-O 120.807 0.337 . . . . 0.0 111.194 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 20.3 t -84.07 109.03 17.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.116 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 57.5 t -78.1 146.09 8.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.117 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -129.81 129.66 44.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.834 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.518 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.8 m120 -141.62 178.45 7.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.847 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 93.1 p -160.83 105.02 1.37 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.873 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.592 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 25.1 tp -77.77 118.79 20.46 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.899 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.521 ' N ' ' O ' ' A' ' 90' ' ' SER . 92.7 mt -95.88 162.22 13.67 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.905 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.439 ' C ' ' H ' ' A' ' 90' ' ' SER . 8.8 m-80 -40.76 101.87 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.878 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.03 -3.94 2.8 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.477 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.521 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -123.73 172.65 8.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.828 0.347 . . . . 0.0 110.885 -179.739 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.592 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 18.8 m95 -129.04 160.93 31.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.917 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -91.46 -106.65 1.47 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.52 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' SER . . . . . 0.419 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 3.5 m -163.06 174.83 11.75 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.787 0.327 . . . . 0.0 110.902 -179.759 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.462 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 24.7 mt-10 -99.53 121.74 41.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.844 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 25.0 mm-40 -120.97 109.55 15.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.895 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 39.6 mtmt -115.51 117.65 30.95 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.933 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 2.8 tppp? -168.59 107.1 0.47 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.887 179.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.435 HD12 ' CD1' ' A' ' 129' ' ' LEU . 8.7 tt -144.39 146.1 20.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.139 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.4 t -83.72 -38.34 21.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.109 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 5.2 p-80 -153.71 134.27 13.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.847 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . 0.441 ' OD1' ' C ' ' A' ' 101' ' ' ASN . 27.1 t-20 -107.86 96.92 18.67 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.604 0.716 . . . . 0.0 110.879 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -36.08 11.59 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.674 2.249 . . . . 0.0 112.36 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.463 ' CE2' ' HB3' ' A' ' 74' ' ' PRO . 5.7 m-85 -40.29 110.23 0.14 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.823 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -136.63 139.8 10.93 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.52 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 106.39 1.64 Allowed 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.694 2.263 . . . . 0.0 112.362 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 124.86 -11.47 7.82 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.51 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.9 pt20 -130.14 165.22 22.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.803 0.335 . . . . 0.0 110.925 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.3 p90 -87.48 169.26 12.37 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.889 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.48 ' CZ ' ' CZ ' ' A' ' 56' ' ' PHE . 30.0 p90 -153.63 124.75 7.41 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.898 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -94.34 103.38 15.38 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.843 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.471 ' CD1' ' N ' ' A' ' 112' ' ' SER . 0.5 OUTLIER -101.61 136.77 40.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.946 -179.965 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.471 ' N ' ' CD1' ' A' ' 111' ' ' LEU . 6.1 m -144.01 111.59 6.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.84 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.452 HD12 ' CD1' ' A' ' 111' ' ' LEU . 4.2 mp -93.53 141.72 14.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.103 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . 0.427 ' O ' ' CG ' ' A' ' 120' ' ' PHE . 19.6 mtp180 -112.52 142.07 45.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.917 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . 0.577 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 3.1 t -114.0 109.41 18.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.892 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -107.53 -138.76 8.86 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.515 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.5 mt -118.69 -40.56 2.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.811 0.339 . . . . 0.0 110.903 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . 0.427 ' OD1' ' N ' ' A' ' 119' ' ' ARG . 19.8 p-10 -87.73 -34.09 18.49 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.831 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.427 ' N ' ' OD1' ' A' ' 118' ' ' ASP . 10.6 ptp85 -172.57 176.07 3.33 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.922 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.577 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.7 m-30 -98.98 166.08 11.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.893 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 26.2 mtpt -137.73 105.92 5.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.916 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 42.8 t -90.84 132.52 35.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.096 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 53.9 m-85 -122.2 155.97 34.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.916 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . 0.499 ' O ' ' ND2' ' A' ' 125' ' ' ASN . . . -141.15 118.96 11.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.104 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.499 ' ND2' ' O ' ' A' ' 124' ' ' ALA . 10.2 p30 50.87 30.75 5.42 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.894 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 82.88 30.96 30.46 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.475 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 33.3 mm-40 -135.6 139.51 43.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.797 0.332 . . . . 0.0 110.905 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 31.2 t-80 -67.7 112.54 4.86 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.857 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . 0.435 ' CD1' HD12 ' A' ' 98' ' ' ILE . 8.3 tp -84.23 -66.97 0.83 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.894 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.4 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 12.1 p90 -168.63 170.76 9.27 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.906 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -114.01 149.11 35.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.806 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.518 ' CD1' HD12 ' A' ' 70' ' ' LEU . 0.4 OUTLIER -111.6 105.09 13.54 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.906 -179.931 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.487 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -60.45 137.15 58.19 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.105 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 8.2 m-70 -66.35 110.41 3.07 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.861 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.419 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 71.6 mtt-85 -96.72 -46.6 6.22 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.859 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.4 tp -98.54 108.06 20.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.852 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 29.4 t -50.23 -33.64 20.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.858 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . 0.433 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.79 29.28 0.46 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.083 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.416 ' CG ' ' N ' ' A' ' 140' ' ' GLN . 33.8 p90 -49.66 -44.35 47.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.869 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' GLN . . . . . 0.416 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 7.8 pt20 -47.81 -39.13 17.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.913 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.433 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 67.3 mtp180 -56.45 -40.83 75.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.85 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 58.7 t -45.68 101.82 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.11 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.492 ' OD2' ' N ' ' A' ' 36' ' ' GLY . 0.7 OUTLIER -127.04 34.28 4.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.851 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 24.6 m -147.02 115.55 6.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.148 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.57 HD12 ' CE2' ' A' ' 60' ' ' PHE . 4.1 tp -114.69 114.55 25.79 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.908 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' GLU . . . . . 0.413 ' C ' HG13 ' A' ' 147' ' ' ILE . 4.1 pt-20 -114.38 158.12 21.94 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.868 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . 0.413 HG13 ' C ' ' A' ' 146' ' ' GLU . 30.7 mt -142.9 123.14 10.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.119 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -132.21 175.65 9.07 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.912 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 102.49 -151.64 18.24 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.475 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -103.66 92.5 4.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.87 0.367 . . . . 0.0 110.85 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.4 p -150.95 150.15 13.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.165 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 26.7 m -113.57 93.7 4.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.131 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.429 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 66.5 mt -75.5 138.27 41.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.925 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 36.7 m -122.43 -34.91 3.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.878 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 17.3 t80 -150.59 130.69 13.5 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.96 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 94.8 t -140.56 111.89 4.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.123 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 11.9 tt0 -134.05 129.21 35.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.944 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' ILE . . . . . 0.441 HG12 ' CD2' ' A' ' 33' ' ' LEU . 4.6 mp . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.17 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.512 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.6 m . . . . . 0 C--O 1.232 0.149 0 CA-C-O 120.861 0.363 . . . . 0.0 111.158 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.512 ' CD1' ' O ' ' A' ' 22' ' ' THR . 10.2 m-85 -150.06 132.53 15.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.924 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . 0.565 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 22.1 m-80 50.74 46.58 3.83 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.607 0.718 . . . . 0.0 110.835 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.565 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.78 137.04 34.47 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.668 2.245 . . . . 0.0 112.378 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 179.88 3.38 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.674 2.249 . . . . 0.0 112.351 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.529 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 95.2 t -140.21 138.18 18.9 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.643 0.735 . . . . 0.0 111.11 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.529 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 54.1 Cg_endo -69.72 144.96 78.02 Favored 'Cis proline' 0 C--N 1.341 0.161 0 C-N-CA 122.658 -1.809 . . . . 0.0 112.353 -0.145 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 8.9 t80 -97.45 121.39 39.3 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.891 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 70.6 m-85 -108.02 101.65 10.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.86 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -116.33 104.61 1.27 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.487 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.54 130.48 40.73 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.848 0.356 . . . . 0.0 110.9 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.45 ' N ' ' O ' ' A' ' 143' ' ' ASP . 5.0 mt -74.2 147.47 42.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.905 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 55.8 mt-30 -107.81 89.59 3.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.903 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.78 -47.43 0.99 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.503 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 104.94 159.03 23.47 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.484 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 79.3 mt -53.32 110.73 0.58 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.88 0.372 . . . . 0.0 110.934 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.433 ' OG1' ' N ' ' A' ' 39' ' ' ALA . 0.0 OUTLIER -133.8 170.37 15.69 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.112 179.967 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.451 ' HB1' ' CD2' ' A' ' 117' ' ' LEU . . . -59.29 -41.93 90.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.085 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 6.5 mpt_? -94.5 51.07 1.4 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.862 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.41 ' NH1' ' CG2' ' A' ' 158' ' ' ILE . 20.4 ttm-85 -138.94 136.6 35.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 91.8 m -139.52 125.16 19.38 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.173 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.4 mp -96.31 138.79 20.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.152 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.475 HG23 ' N ' ' A' ' 45' ' ' ILE . 90.5 mt -131.57 138.38 53.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.143 179.83 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.475 ' N ' HG23 ' A' ' 44' ' ' ILE . 69.7 mt -135.42 107.56 7.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.152 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 8.7 mtmm -108.1 111.64 23.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -144.61 -144.92 4.25 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.495 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 0.568 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 1.3 t80 -170.65 123.87 0.66 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.853 0.359 . . . . 0.0 110.957 -179.82 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 13.1 t -73.58 115.28 40.07 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.584 0.707 . . . . 0.0 111.152 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 155.48 65.86 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.663 2.242 . . . . 0.0 112.337 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.85 -13.58 34.64 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.679 2.253 . . . . 0.0 112.305 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 32.9 p -111.71 14.51 21.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.114 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -111.02 122.07 6.03 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.51 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.4 mtpt -63.71 -59.81 4.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.809 0.338 . . . . 0.0 110.93 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 14.4 p -172.8 158.33 3.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.826 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.564 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 17.9 p90 -113.76 -172.62 2.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.846 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.463 ' CB ' ' OD1' ' A' ' 73' ' ' ASN . . . -155.68 140.98 17.62 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.098 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.441 HG21 ' CE1' ' A' ' 60' ' ' PHE . 7.2 mt -127.17 101.18 7.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.122 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . 0.415 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 5.4 m-80 -103.14 154.05 19.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.907 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.491 ' CE2' HD11 ' A' ' 145' ' ' LEU . 6.1 m-85 -122.4 102.01 7.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.857 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.8 ttmt -95.68 168.2 10.82 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.864 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 83.2 t -100.06 120.55 49.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.127 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -57.54 -30.25 61.85 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.479 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.1 m -72.84 -75.3 0.14 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.863 0.363 . . . . 0.0 110.882 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.3 t -79.33 -70.85 0.48 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.867 -179.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 131.18 40.51 0.23 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.486 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . 0.402 ' OD1' ' OD1' ' A' ' 88' ' ' ASN . 0.5 OUTLIER -109.38 147.95 31.91 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.758 0.314 . . . . 0.0 110.854 -179.981 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 53.4 mt -94.35 113.7 29.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.153 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.47 ' HB2' ' CG2' ' A' ' 142' ' ' VAL . . . -86.02 -32.15 21.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.117 179.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.564 HD22 ' CD2' ' A' ' 132' ' ' PHE . 43.3 tp -138.83 131.09 28.4 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.487 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.8 OUTLIER -134.42 95.38 3.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.867 179.855 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 32.1 mt -100.05 131.53 47.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.133 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.491 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -141.17 107.58 6.21 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.644 0.735 . . . . 0.0 110.874 179.933 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.564 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.9 Cg_endo -69.78 155.23 66.38 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.651 2.234 . . . . 0.0 112.333 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 80.0 mtp180 -132.15 100.01 4.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.87 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' MET . . . . . 0.503 ' HE3' ' CE1' ' A' ' 56' ' ' PHE . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.905 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 18.7 p . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.823 0.344 . . . . 0.0 111.135 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 18.4 t -94.39 109.72 22.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.184 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 41.5 t -81.88 145.25 8.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.137 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -126.45 123.92 38.96 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.888 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.487 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.7 OUTLIER -135.97 178.82 6.75 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.882 -179.935 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 50.7 p -160.07 106.29 1.58 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.855 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.559 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 24.4 tp -77.38 115.78 17.43 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.904 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.49 ' N ' ' O ' ' A' ' 90' ' ' SER . 24.0 mt -91.55 161.09 15.09 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.886 179.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.409 ' C ' ' H ' ' A' ' 90' ' ' SER . 12.3 m-80 -41.58 101.56 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.913 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 67.43 -3.56 4.53 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.46 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.49 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -124.26 172.25 9.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.836 0.351 . . . . 0.0 110.851 -179.709 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.559 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 21.0 m95 -129.43 158.63 38.66 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.908 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -89.22 -106.59 1.12 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.445 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 3.7 m -163.6 176.29 9.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.791 0.329 . . . . 0.0 110.887 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.449 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 16.1 mt-10 -99.04 119.65 38.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.908 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -119.23 116.4 26.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.883 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 39.8 mtmt -121.89 119.28 31.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.902 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 27.7 tttp -167.26 108.03 0.62 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.889 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 7.2 tt -149.4 147.21 16.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.165 179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 12.6 t -89.32 -47.47 8.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.134 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . 0.428 ' O ' ' CG ' ' A' ' 100' ' ' HIS . 4.2 p-80 -138.41 125.24 21.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.845 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -103.3 95.91 7.62 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.613 0.72 . . . . 0.0 110.898 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.82 -34.38 14.49 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.672 2.248 . . . . 0.0 112.303 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 -39.33 99.6 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.857 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -129.81 136.3 8.86 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.498 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 99.84 0.78 Allowed 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.658 2.239 . . . . 0.0 112.348 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 130.33 -8.38 5.95 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.48 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 -131.37 162.11 30.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.882 0.372 . . . . 0.0 110.896 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' PHE . . . . . 0.568 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 17.2 m-85 -80.27 172.1 14.2 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.858 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.483 ' CD1' ' O ' ' A' ' 109' ' ' PHE . 19.8 p90 -161.17 119.62 2.45 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.9 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -93.86 101.74 13.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.843 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.481 ' CD1' ' N ' ' A' ' 112' ' ' SER . 0.5 OUTLIER -101.2 136.75 40.53 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.909 -179.942 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.481 ' N ' ' CD1' ' A' ' 111' ' ' LEU . 10.4 m -141.6 112.88 7.5 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.882 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.433 HD11 ' CD1' ' A' ' 111' ' ' LEU . 4.1 mp -96.91 115.91 37.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.171 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 21.2 mtp85 -89.75 141.32 28.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.896 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . 0.578 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 13.6 t -113.41 115.25 27.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -111.76 -141.83 8.59 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.473 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.451 ' CD2' ' HB1' ' A' ' 39' ' ' ALA . 7.4 mt -115.2 -33.38 5.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.804 0.335 . . . . 0.0 110.922 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . 0.582 ' O ' ' CD2' ' A' ' 134' ' ' HIS . 6.3 m-20 -89.53 -42.27 11.54 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.904 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -166.22 -176.34 3.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.893 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.578 ' CE2' ' HB2' ' A' ' 115' ' ' CYS . 12.0 m-85 -102.44 156.2 17.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.897 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 23.2 mtpt -130.1 105.92 8.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.865 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . 0.429 HG22 ' CE1' ' A' ' 130' ' ' PHE . 46.8 t -91.3 131.73 37.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.109 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 79.5 m-85 -122.26 149.98 42.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.933 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -134.59 108.28 7.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.094 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 56.93 35.27 26.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.871 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.09 38.31 15.79 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.483 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 7.3 mt-30 -146.18 126.63 14.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.81 0.338 . . . . 0.0 110.924 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 -60.27 102.25 0.16 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.874 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 7.2 tp -70.19 -66.5 0.59 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.932 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.44 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 7.0 p90 -162.16 172.13 16.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.864 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 21.0 p-10 -118.1 145.79 44.6 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.847 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.587 ' CE1' ' O ' ' A' ' 133' ' ' ALA . 0.1 OUTLIER -112.92 107.02 15.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.833 -179.893 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.587 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -62.97 134.31 55.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.087 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' HIS . . . . . 0.582 ' CD2' ' O ' ' A' ' 118' ' ' ASP . 10.0 m-70 -60.54 101.68 0.15 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.883 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 12.3 mtt-85 -88.11 -45.97 9.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.875 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 10.0 tp -98.4 108.08 20.69 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.937 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 28.6 p -51.8 -31.23 26.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.858 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -82.71 29.08 0.46 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.08 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -49.59 -35.19 19.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.899 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' GLN . . . . . 0.454 ' HG2' ' N ' ' A' ' 141' ' ' ARG . 18.4 pm0 -60.17 -28.92 68.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.964 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.454 ' N ' ' HG2' ' A' ' 140' ' ' GLN . 52.9 mtp85 -65.27 -38.86 91.57 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.887 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.47 ' CG2' ' HB2' ' A' ' 69' ' ' ALA . 52.4 t -55.15 108.97 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.113 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.45 ' O ' ' N ' ' A' ' 33' ' ' LEU . 3.4 p30 -129.52 27.91 5.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.839 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -135.82 135.57 39.95 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.174 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.491 HD11 ' CE2' ' A' ' 60' ' ' PHE . 7.5 tp -131.13 103.9 6.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.9 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' GLU . . . . . 0.408 ' C ' HG13 ' A' ' 147' ' ' ILE . 2.6 pt-20 -106.51 151.22 25.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.874 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . 0.408 HG13 ' C ' ' A' ' 146' ' ' GLU . 15.7 mt -140.17 109.57 3.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.116 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -120.41 170.93 8.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.916 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 109.85 -150.68 17.42 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.517 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -107.5 91.36 3.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.886 0.374 . . . . 0.0 110.902 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.465 HG22 ' N ' ' A' ' 152' ' ' THR . 3.3 p -150.91 137.62 12.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.123 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' THR . . . . . 0.465 ' N ' HG22 ' A' ' 151' ' ' VAL . 24.7 m -96.96 93.65 6.74 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.119 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.463 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 61.3 mt -77.98 132.76 37.98 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.898 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 53.5 m -119.13 -40.86 2.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.894 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 36.4 t80 -141.74 129.53 21.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.948 -179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 75.3 t -140.77 105.65 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.159 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 19.3 tt0 -120.26 132.03 55.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.92 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' ILE . . . . . 0.41 ' CG2' ' NH1' ' A' ' 41' ' ' ARG . 12.8 mt . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.161 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.55 ' CG2' ' N ' ' A' ' 23' ' ' PHE . 1.8 m . . . . . 0 N--CA 1.457 -0.11 0 CA-C-O 120.804 0.335 . . . . 0.0 111.126 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.55 ' N ' ' CG2' ' A' ' 22' ' ' THR . 14.3 m-85 -154.52 136.18 14.37 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . 0.514 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 10.4 m-20 41.21 49.76 3.74 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.61 0.719 . . . . 0.0 110.858 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.514 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.8 Cg_endo -69.74 140.9 43.87 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.678 2.252 . . . . 0.0 112.341 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 178.4 4.61 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.663 2.242 . . . . 0.0 112.375 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.531 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 89.5 t -140.18 137.82 18.49 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.657 0.741 . . . . 0.0 111.123 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.531 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.4 Cg_endo -69.74 144.34 76.35 Favored 'Cis proline' 0 C--O 1.231 0.173 0 C-N-CA 122.7 -1.792 . . . . 0.0 112.345 -0.055 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 9.2 t80 -96.75 118.9 34.21 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.931 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 65.3 m-85 -104.8 101.12 10.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.888 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -112.83 102.05 1.26 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.456 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.437 ' O ' ' HG3' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -72.63 121.6 20.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.852 0.358 . . . . 0.0 110.923 -179.897 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.482 ' N ' ' O ' ' A' ' 143' ' ' ASP . 13.9 mt -65.71 149.62 49.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.914 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 10.4 mm-40 -110.68 82.06 1.53 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.919 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.447 ' C ' ' OD2' ' A' ' 143' ' ' ASP . . . 140.49 -46.87 0.9 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.504 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.42 ' CA ' ' OD1' ' A' ' 143' ' ' ASP . . . 109.54 166.55 20.14 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.505 -179.882 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . 0.43 ' CD1' ' HB ' ' A' ' 142' ' ' VAL . 49.8 mt -57.3 105.16 0.21 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.96 0.41 . . . . 0.0 110.891 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 2.1 p -116.76 151.81 35.67 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.148 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -58.07 -18.21 23.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.117 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 7.3 mpt_? -109.93 27.53 9.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.899 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.423 ' NH2' HD13 ' A' ' 33' ' ' LEU . 20.8 ttp85 -113.66 141.5 47.15 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.857 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 97.9 m -139.56 121.35 15.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.111 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.417 ' CD1' ' NH2' ' A' ' 41' ' ' ARG . 5.0 mp -90.95 143.64 10.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.125 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 89.3 mt -136.22 129.21 46.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.149 179.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 60.6 mt -130.05 107.74 15.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.152 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.492 ' HE3' ' CD1' ' A' ' 155' ' ' TYR . 18.5 mtmt -110.36 111.8 23.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.904 179.856 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -147.14 -145.54 4.21 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.505 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -166.81 126.14 1.47 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.884 0.374 . . . . 0.0 110.913 -179.815 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 24.6 t -74.82 117.02 59.3 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.643 0.735 . . . . 0.0 111.114 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 156.23 63.82 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.698 2.266 . . . . 0.0 112.331 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -15.44 37.1 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.657 2.238 . . . . 0.0 112.359 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 26.4 p -110.36 14.64 22.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.154 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -109.25 120.44 5.81 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.493 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 30.1 mtpt -61.65 -60.97 2.88 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.775 0.321 . . . . 0.0 110.914 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 9.2 p -174.19 156.51 2.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.823 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.589 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 11.1 p90 -111.0 -174.46 2.48 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.83 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.473 ' CB ' ' OD1' ' A' ' 73' ' ' ASN . . . -155.42 141.15 18.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.096 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.6 mp -121.24 100.08 8.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.136 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -102.56 148.08 25.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.887 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.555 ' CE2' HD12 ' A' ' 145' ' ' LEU . 34.7 m-85 -119.99 102.9 8.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.894 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 33.6 ttmt -95.62 166.95 11.59 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.91 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 91.4 t -98.2 125.54 51.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.166 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.463 ' N ' ' HG1' ' A' ' 144' ' ' THR . . . -61.26 -35.7 91.31 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.511 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.9 m -67.68 -73.27 0.14 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.896 0.379 . . . . 0.0 110.817 -179.708 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 32.3 t -80.37 -71.49 0.46 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.867 -179.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 130.7 41.69 0.22 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.464 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -112.58 146.37 38.69 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.782 0.325 . . . . 0.0 110.848 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 50.7 mt -91.65 121.23 41.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.135 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.471 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -91.3 -36.97 13.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.114 179.828 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.543 HD21 ' CD2' ' A' ' 132' ' ' PHE . 32.1 tp -134.87 130.4 35.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.919 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.487 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.3 OUTLIER -134.76 92.97 2.96 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.84 179.855 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.475 ' CG2' HG11 ' A' ' 81' ' ' VAL . 20.6 mt -96.69 134.08 35.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.17 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.508 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -140.93 107.42 6.32 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.591 0.71 . . . . 0.0 110.885 179.969 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.589 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.6 Cg_endo -69.76 155.05 66.93 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.679 2.253 . . . . 0.0 112.337 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 66.4 mtp85 -129.24 99.31 5.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.876 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.893 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 32.9 p . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.799 0.333 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.475 HG11 ' CG2' ' A' ' 72' ' ' ILE . 20.6 t -106.42 106.03 19.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.126 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 39.2 t -76.38 134.29 29.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.133 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . 0.415 ' NH1' ' O ' ' A' ' 95' ' ' GLU . 0.0 OUTLIER -120.57 123.52 43.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.881 -179.955 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.487 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.2 OUTLIER -134.25 -179.11 5.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.898 -179.934 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 93.5 p -160.57 105.54 1.44 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.839 -179.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.567 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 26.1 tp -77.26 117.04 18.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.921 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.501 ' N ' ' O ' ' A' ' 90' ' ' SER . 68.5 mt -93.97 160.9 14.52 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.887 179.897 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.533 HD21 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.72 101.35 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.87 179.913 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.93 -6.97 1.27 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.492 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.501 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -119.14 172.22 7.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.877 0.37 . . . . 0.0 110.832 -179.726 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.567 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 24.1 m95 -129.05 160.89 31.34 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.908 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -90.84 -93.94 1.26 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.513 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 2.4 m -174.49 169.46 3.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.841 0.353 . . . . 0.0 110.883 -179.727 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.41 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 27.3 mt-10 -100.84 118.4 36.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.895 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . 0.415 ' O ' ' NH1' ' A' ' 83' ' ' ARG . 5.3 mm-40 -123.19 134.81 54.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.881 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 40.9 mtmt -132.19 116.95 17.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.905 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 17.9 ttpp -164.48 110.4 1.01 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.934 179.862 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.408 HD11 ' C ' ' A' ' 100' ' ' HIS . 4.4 tt -148.72 153.04 11.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.134 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.448 HG23 ' N ' ' A' ' 100' ' ' HIS . 9.0 t -89.64 -48.52 7.23 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.118 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . 0.448 ' N ' HG23 ' A' ' 99' ' ' THR . 6.1 p-80 -141.24 125.41 17.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.858 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -104.46 96.83 10.79 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.633 0.73 . . . . 0.0 110.882 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 -30.46 22.07 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.725 2.283 . . . . 0.0 112.303 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.413 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 21.8 m-85 -43.94 104.64 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.887 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -132.65 135.86 8.38 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.489 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 97.79 0.66 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.69 2.26 . . . . 0.0 112.322 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 129.94 -3.67 6.03 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.524 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.2 pm0 -135.9 155.92 49.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.839 0.352 . . . . 0.0 110.908 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -77.85 171.16 15.4 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.887 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 29.8 p90 -160.03 133.21 6.81 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.897 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -103.1 103.79 13.89 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.874 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.476 ' CD1' ' N ' ' A' ' 112' ' ' SER . 0.6 OUTLIER -104.3 137.7 41.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.887 -179.919 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.476 ' N ' ' CD1' ' A' ' 111' ' ' LEU . 3.6 m -145.16 111.87 5.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.842 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.444 HD12 ' CD1' ' A' ' 111' ' ' LEU . 4.0 mp -92.99 140.38 16.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.165 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 18.9 mtp180 -113.24 137.67 51.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.86 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . 0.559 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 3.4 t -108.87 117.29 33.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -119.35 -140.97 6.35 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.464 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.5 mt -118.66 -36.09 3.56 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.844 0.354 . . . . 0.0 110.916 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 17.4 m-20 -87.2 -38.39 16.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.862 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 16.2 ptp180 -175.31 169.28 3.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.838 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.559 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.6 m-30 -92.02 147.71 22.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 24.9 mtpp -120.75 102.19 8.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.921 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 55.7 t -88.82 132.22 34.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.106 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 62.3 m-85 -118.9 156.66 29.13 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.947 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -142.21 109.45 5.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.097 179.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 56.3 28.78 13.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.888 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 85.67 30.52 23.8 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.466 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . 0.4 ' HB2' ' CE1' ' A' ' 100' ' ' HIS . 56.1 mm-40 -137.91 121.51 17.36 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.791 0.329 . . . . 0.0 110.949 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 29.1 t-80 -50.69 105.14 0.09 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.849 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 10.8 tp -72.84 -69.1 0.43 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.482 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 4.2 p90 -165.62 170.76 13.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.874 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 61.9 m-20 -114.96 148.76 38.32 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.876 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.574 ' CE1' ' O ' ' A' ' 133' ' ' ALA . 0.1 OUTLIER -115.01 107.88 15.95 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.88 -179.868 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.574 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -64.0 131.1 46.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.117 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 46.2 m-70 -56.62 100.58 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.847 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 17.6 mtt-85 -83.9 -51.45 7.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.865 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 14.2 tp -93.27 108.01 19.72 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.908 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 4.3 p -51.4 -30.26 18.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.829 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -87.28 24.23 1.66 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.114 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.426 ' CG ' ' N ' ' A' ' 140' ' ' GLN . 26.8 p90 -43.58 -44.67 6.31 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.911 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' GLN . . . . . 0.426 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 5.3 pt20 -44.7 -42.23 7.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.905 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . . . . . . . . . 21.5 mtt180 -52.07 -42.4 63.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.895 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.471 HG21 ' CB ' ' A' ' 69' ' ' ALA . 99.4 t -46.96 108.89 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.12 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.482 ' O ' ' N ' ' A' ' 33' ' ' LEU . 1.0 OUTLIER -129.8 20.43 5.52 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.902 179.903 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' THR . . . . . 0.463 ' HG1' ' N ' ' A' ' 63' ' ' GLY . 2.1 m -133.06 138.1 46.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.141 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.555 HD12 ' CE2' ' A' ' 60' ' ' PHE . 7.2 tp -132.41 116.08 16.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.949 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -118.59 151.8 37.23 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.838 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 24.8 mt -138.66 110.34 5.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.08 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 1.1 pm0 -120.17 171.99 8.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.888 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 111.28 -147.51 17.86 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.544 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -112.96 92.72 4.11 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.851 0.357 . . . . 0.0 110.858 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.453 HG23 ' N ' ' A' ' 152' ' ' THR . 4.3 p -151.02 141.9 16.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.145 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' THR . . . . . 0.453 ' N ' HG23 ' A' ' 151' ' ' VAL . 17.1 m -101.31 92.91 5.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.175 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.441 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 80.5 mt -76.03 139.85 41.66 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.913 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 58.1 m -125.01 -33.76 2.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.836 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . 0.492 ' CD1' ' HE3' ' A' ' 46' ' ' LYS . 36.3 t80 -150.46 130.97 13.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.917 -179.855 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 56.0 t -138.92 105.41 2.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.149 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 13.2 tt0 -114.17 120.67 41.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.92 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 83.1 mt . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.159 179.943 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.485 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.5 m . . . . . 0 C--O 1.232 0.151 0 CA-C-O 120.778 0.323 . . . . 0.0 111.174 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.485 ' CD1' ' O ' ' A' ' 22' ' ' THR . 9.3 m-85 -149.83 135.68 18.6 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.896 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . 0.558 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 4.1 t-20 46.1 47.25 3.95 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.625 0.726 . . . . 0.0 110.886 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.558 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.5 Cg_endo -69.78 138.69 38.35 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.669 2.246 . . . . 0.0 112.332 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -174.65 0.95 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.664 2.243 . . . . 0.0 112.344 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.528 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 93.5 t -142.45 138.25 16.24 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.62 0.724 . . . . 0.0 111.102 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.528 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.79 144.76 77.63 Favored 'Cis proline' 0 C--N 1.342 0.197 0 C-N-CA 122.642 -1.816 . . . . 0.0 112.354 -0.078 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -97.55 120.69 38.38 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.918 -179.886 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 86.3 m-85 -102.42 104.94 15.44 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.901 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -104.24 107.52 2.97 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.463 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 6.6 mmt180 -73.71 115.86 13.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.833 0.349 . . . . 0.0 110.903 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.422 HD23 ' NH1' ' A' ' 41' ' ' ARG . 5.0 mt -82.0 111.51 18.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.902 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 37.6 mt-30 -78.71 97.14 5.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.88 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 131.1 -51.22 0.86 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.515 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 107.96 168.39 21.51 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.496 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 68.4 mt -55.1 110.88 0.74 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.886 0.374 . . . . 0.0 110.902 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 81.6 p -128.69 146.37 50.9 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.181 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -51.67 -18.33 1.16 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.085 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 2.8 mpt_? -107.73 30.53 6.23 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.868 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.438 ' NH2' HD11 ' A' ' 43' ' ' ILE . 6.9 ttp85 -115.85 142.2 47.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.904 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 29.5 m -138.64 120.72 15.66 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.151 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.438 HD11 ' NH2' ' A' ' 41' ' ' ARG . 5.3 mp -94.39 134.21 32.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.135 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 76.7 mt -129.8 119.59 47.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.098 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 31.6 mt -119.11 107.36 21.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.159 179.822 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.418 ' HE3' ' CD1' ' A' ' 155' ' ' TYR . 16.5 mtmt -108.89 110.18 21.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.9 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -144.86 -147.94 4.74 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.473 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 0.559 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.7 OUTLIER -163.57 127.88 2.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.934 0.397 . . . . 0.0 110.955 -179.789 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 13.4 t -77.6 117.38 65.21 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 121.585 0.707 . . . . 0.0 111.14 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 154.91 67.1 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.7 2.266 . . . . 0.0 112.348 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -13.92 35.36 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.648 2.232 . . . . 0.0 112.353 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 70.6 p -112.64 16.78 19.58 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.163 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -110.09 123.24 6.63 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.497 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.402 ' O ' ' SD ' ' A' ' 76' ' ' MET . 19.2 mtpt -64.75 -61.72 2.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.801 0.334 . . . . 0.0 110.896 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 14.8 p -172.97 156.57 3.35 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.849 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.573 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 20.4 p90 -111.05 -174.57 2.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.874 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.82 135.37 11.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.126 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.403 HD12 ' CE2' ' A' ' 56' ' ' PHE . 5.3 mp -117.59 98.16 6.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.114 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -96.85 143.72 27.48 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.894 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.552 ' CE2' HD13 ' A' ' 145' ' ' LEU . 47.0 m-85 -115.24 97.62 6.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.906 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.417 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 31.3 ttmt -96.08 168.94 10.31 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.894 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.457 ' CG2' HG21 ' A' ' 142' ' ' VAL . 23.4 t -100.27 123.7 53.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.094 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.524 ' N ' ' HG1' ' A' ' 144' ' ' THR . . . -59.64 -29.17 66.46 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.506 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 11.5 t -75.18 -73.71 0.24 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.849 0.357 . . . . 0.0 110.854 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 5.3 t -77.53 -71.47 0.41 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.811 -179.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 128.65 39.7 0.32 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.492 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -112.81 139.15 48.67 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.801 0.334 . . . . 0.0 110.879 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 60.3 mt -84.7 120.65 35.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.145 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -90.16 -30.66 17.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.129 179.795 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.567 HD21 ' CD2' ' A' ' 132' ' ' PHE . 41.3 tp -143.11 132.34 23.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.921 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.494 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.7 OUTLIER -134.93 92.61 2.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.919 179.838 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 53.2 mt -94.85 132.7 38.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.107 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.503 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -139.12 105.66 7.29 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.661 0.743 . . . . 0.0 110.908 179.929 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.573 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.7 Cg_endo -69.74 154.84 67.34 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.72 2.28 . . . . 0.0 112.372 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 73.9 mtp85 -129.27 94.26 3.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.865 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' MET . . . . . 0.402 ' SD ' ' O ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.887 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 21.1 p . . . . . 0 N--CA 1.456 -0.132 0 CA-C-O 120.845 0.355 . . . . 0.0 111.161 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.4 t -102.79 107.29 21.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.128 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 99.9 t -76.15 144.36 11.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.087 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -126.19 124.65 40.94 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.887 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.494 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.8 OUTLIER -135.71 178.56 6.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.951 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 19.1 t -160.38 105.05 1.46 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 -179.837 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.566 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 25.4 tp -76.97 118.01 19.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.935 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.513 ' N ' ' O ' ' A' ' 90' ' ' SER . 69.9 mt -95.62 161.6 13.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.884 179.92 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.533 HD21 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.34 101.42 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.907 179.849 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.79 -6.58 0.87 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.441 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.513 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -118.42 170.57 8.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.874 0.369 . . . . 0.0 110.832 -179.727 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.566 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 23.7 m95 -128.82 161.05 30.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.929 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.31 -106.45 1.61 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.471 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 67.5 m -164.09 176.05 9.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.809 0.338 . . . . 0.0 110.915 -179.754 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -98.63 123.11 42.63 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.909 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 7.6 mm-40 -122.54 118.11 27.48 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.854 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -121.23 123.05 41.28 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.903 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 15.0 tptm -172.76 105.04 0.15 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.889 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 7.5 tt -147.66 151.32 13.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.152 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.42 ' CG2' ' N ' ' A' ' 100' ' ' HIS . 8.8 t -86.49 -50.54 6.79 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.149 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . 0.42 ' N ' ' CG2' ' A' ' 99' ' ' THR . 5.3 p-80 -141.75 135.67 29.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.843 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . 0.407 ' OD1' ' C ' ' A' ' 101' ' ' ASN . 6.9 t-20 -104.73 95.97 9.72 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.647 0.737 . . . . 0.0 110.918 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -31.18 21.12 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.692 2.261 . . . . 0.0 112.39 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -47.12 113.93 0.76 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.874 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -140.59 138.11 8.75 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.489 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.73 102.69 1.05 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.653 2.235 . . . . 0.0 112.336 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 122.86 -6.49 9.56 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.488 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -130.67 147.11 52.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.857 0.361 . . . . 0.0 110.855 -179.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' PHE . . . . . 0.559 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 54.5 m-85 -66.5 172.03 4.46 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.888 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 22.5 p90 -160.65 128.38 4.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.856 -179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -103.45 105.39 15.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.421 ' CD1' HD13 ' A' ' 113' ' ' ILE . 0.9 OUTLIER -107.32 137.97 44.38 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.946 -179.962 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 2.9 m -145.09 112.93 6.35 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.87 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.421 HD13 ' CD1' ' A' ' 111' ' ' LEU . 4.2 mp -94.29 134.64 31.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.113 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 57.1 mtt180 -109.14 123.19 48.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.853 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . 0.567 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 33.8 t -90.53 123.22 34.02 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -124.72 -153.76 8.65 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.501 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 7.8 mt -109.81 -37.96 5.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.804 0.335 . . . . 0.0 110.913 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -86.1 -37.73 18.52 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.853 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 22.8 ptt180 -174.75 168.56 3.64 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.894 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.567 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 2.9 m-30 -91.81 153.28 19.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.913 -179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 18.9 mtmt -127.29 106.41 9.21 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.897 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 45.9 t -90.41 137.69 21.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.166 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 40.4 m-85 -121.37 147.28 45.91 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.913 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -137.68 105.52 5.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.126 179.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 62.09 34.08 16.63 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.84 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . 0.416 ' C ' ' HG2' ' A' ' 127' ' ' GLN . . . 79.62 38.94 19.23 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.467 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . 0.416 ' HG2' ' C ' ' A' ' 126' ' ' GLY . 15.4 mm-40 -148.32 132.25 17.14 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.807 0.337 . . . . 0.0 110.892 -179.865 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 26.9 t-80 -61.58 101.05 0.16 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.828 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 9.8 tp -66.31 -69.85 0.28 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.877 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.434 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 7.3 p90 -161.87 174.66 12.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.874 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -114.96 150.73 35.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.868 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.581 ' CE1' ' O ' ' A' ' 133' ' ' ALA . 0.1 OUTLIER -117.53 104.62 11.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.896 -179.912 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.581 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -59.91 134.68 57.27 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.106 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 63.1 m-70 -61.99 112.89 2.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.889 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 83.1 mtt-85 -96.36 -52.48 3.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.834 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 9.4 tp -93.57 108.22 19.96 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.921 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 94.3 p -50.69 -32.25 18.81 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.896 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . 0.442 ' HB2' ' CD ' ' A' ' 141' ' ' ARG . . . -83.79 23.56 0.98 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.135 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 14.2 p90 -47.06 -38.99 12.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.883 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 10.0 pt20 -53.52 -34.01 56.62 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.938 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.442 ' CD ' ' HB2' ' A' ' 138' ' ' ALA . 51.9 mtp85 -63.47 -37.69 88.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.849 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.457 HG21 ' CG2' ' A' ' 62' ' ' VAL . 92.7 t -46.9 109.36 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.156 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -132.3 31.39 4.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.86 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' THR . . . . . 0.524 ' HG1' ' N ' ' A' ' 63' ' ' GLY . 8.6 m -141.45 111.98 7.02 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.118 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.552 HD13 ' CE2' ' A' ' 60' ' ' PHE . 3.9 tp -110.51 109.79 20.27 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.945 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' GLU . . . . . 0.413 ' C ' HG13 ' A' ' 147' ' ' ILE . 3.3 pt-20 -112.8 153.81 27.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.843 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . 0.413 HG13 ' C ' ' A' ' 146' ' ' GLU . 20.2 mt -140.72 110.63 3.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.096 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -119.6 174.37 6.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.943 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.17 -142.87 16.03 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.533 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -116.54 94.0 4.44 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.837 0.351 . . . . 0.0 110.913 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.6 p -151.08 151.15 12.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.173 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 10.4 m -110.98 94.5 5.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.13 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.456 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 37.6 mt -77.7 137.84 38.72 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.888 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 3.3 t -122.2 -37.43 2.82 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.869 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . 0.418 ' CD1' ' HE3' ' A' ' 46' ' ' LYS . 19.4 t80 -149.75 130.6 14.21 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.921 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 98.8 t -140.61 105.18 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.096 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 10.9 tt0 -112.13 145.3 40.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.89 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' ILE . . . . . 0.428 HG23 ' NH1' ' A' ' 41' ' ' ARG . 30.1 mt . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.109 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.4 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 7.6 t . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.803 0.335 . . . . 0.0 111.187 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.4 ' CD1' ' O ' ' A' ' 22' ' ' THR . 7.0 m-85 -142.07 117.28 10.1 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.908 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . 0.516 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 9.0 m120 66.92 49.97 0.56 Allowed Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.633 0.73 . . . . 0.0 110.927 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.516 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.7 Cg_endo -69.73 131.35 21.09 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.662 2.241 . . . . 0.0 112.335 179.919 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 -174.03 0.84 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.643 2.229 . . . . 0.0 112.319 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.531 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 97.5 t -144.03 138.33 14.91 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.593 0.711 . . . . 0.0 111.129 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.531 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.78 144.72 77.48 Favored 'Cis proline' 0 C--O 1.232 0.177 0 C-N-CA 122.73 -1.779 . . . . 0.0 112.321 -0.025 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.6 t80 -98.04 119.12 36.11 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.942 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 75.7 m-85 -105.66 108.26 19.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.844 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -119.89 103.39 0.95 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.454 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.417 ' O ' ' HG3' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -73.45 128.28 35.05 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.813 0.34 . . . . 0.0 110.899 -179.886 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 6.1 mt -73.07 151.83 41.51 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.902 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 20.0 mt-30 -88.29 -63.36 1.31 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.934 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.447 ' O ' ' C ' ' A' ' 36' ' ' GLY . . . -96.94 43.56 2.02 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.54 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.483 ' N ' ' OD2' ' A' ' 143' ' ' ASP . . . 34.39 -152.68 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.499 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 52.4 mt -87.64 113.16 23.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.854 0.359 . . . . 0.0 110.934 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.411 HG23 ' NH1' ' A' ' 41' ' ' ARG . 24.7 p -121.01 153.16 37.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.113 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -59.75 -25.77 65.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.12 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 13.2 mmt180 -105.43 35.62 2.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.869 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.44 ' HB2' ' NH1' ' A' ' 41' ' ' ARG . 9.4 ttm105 -125.02 140.78 52.6 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.915 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 90.7 m -139.68 121.7 15.67 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.14 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 mp -90.99 134.25 30.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.128 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 77.6 mt -123.45 133.41 69.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.139 179.817 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 75.0 mt -131.41 107.8 13.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.153 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.1 mtmt -109.31 107.74 18.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.9 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.26 -146.25 4.79 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.536 179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 0.559 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.7 OUTLIER -167.91 129.29 1.44 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.904 0.383 . . . . 0.0 110.934 -179.798 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.437 HG22 ' CD1' ' A' ' 109' ' ' PHE . 11.8 t -77.88 116.74 60.96 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.6 0.714 . . . . 0.0 111.14 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 158.52 56.63 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.627 2.218 . . . . 0.0 112.346 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -14.54 36.26 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.654 2.236 . . . . 0.0 112.394 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 66.7 p -113.16 19.22 17.33 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.151 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -113.37 118.34 4.49 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.419 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 15.7 mtpp -62.96 -58.85 5.95 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.755 0.312 . . . . 0.0 110.877 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 25.3 p -173.04 159.73 4.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.877 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.572 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 10.9 p90 -114.84 -173.19 2.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.873 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.481 ' CB ' ' OD1' ' A' ' 73' ' ' ASN . . . -156.65 141.79 17.28 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.067 179.911 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.473 HG23 ' CE1' ' A' ' 60' ' ' PHE . 9.1 mt -127.59 98.38 4.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.12 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . 0.471 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 2.2 m-80 -100.47 150.48 22.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.917 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.536 ' CE2' HD13 ' A' ' 145' ' ' LEU . 4.3 m-85 -118.1 101.17 8.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.912 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.402 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 28.3 ttmt -95.58 169.85 9.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.901 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.402 ' N ' ' HG2' ' A' ' 61' ' ' LYS . 67.8 t -101.17 124.14 54.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.105 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -59.08 -39.87 94.89 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.507 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 15.0 m -66.19 -73.5 0.13 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.837 0.351 . . . . 0.0 110.858 -179.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 68.5 m -76.72 -75.38 0.2 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.833 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 133.31 35.13 0.3 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.475 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -106.61 143.94 34.0 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.823 0.344 . . . . 0.0 110.861 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 58.7 mt -88.24 122.56 39.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.154 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.481 ' CB ' HG22 ' A' ' 142' ' ' VAL . . . -92.8 -33.33 14.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.114 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.519 HD21 ' CD2' ' A' ' 132' ' ' PHE . 42.4 tp -139.15 131.61 28.62 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.913 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.505 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.0 OUTLIER -134.66 92.95 2.97 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.838 179.863 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.435 ' CG2' HG13 ' A' ' 81' ' ' VAL . 40.3 mt -98.64 130.96 46.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.152 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.481 ' OD1' ' CB ' ' A' ' 57' ' ' ALA . 0.2 OUTLIER -140.67 107.74 6.5 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.64 0.733 . . . . 0.0 110.914 179.934 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.572 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.4 Cg_endo -69.74 155.13 66.82 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.704 2.269 . . . . 0.0 112.349 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 71.3 mtp180 -130.61 96.36 4.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.858 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' MET . . . . . 0.472 ' HE1' ' CE1' ' A' ' 56' ' ' PHE . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.901 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 7.6 p . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.788 0.327 . . . . 0.0 111.128 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.435 HG13 ' CG2' ' A' ' 72' ' ' ILE . 7.9 t -100.61 112.83 34.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.153 179.908 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 61.5 t -80.67 142.31 14.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.172 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -122.4 124.09 42.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.862 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.505 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.1 m120 -138.49 176.56 8.59 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.839 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 45.2 t -160.35 105.08 1.47 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.866 -179.854 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.587 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 24.8 tp -77.55 119.02 20.54 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.951 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.513 ' N ' ' O ' ' A' ' 90' ' ' SER . 76.0 mt -95.88 161.35 14.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.916 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.51 HD21 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.89 101.43 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.902 179.933 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.98 -5.83 1.14 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.493 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.513 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -120.0 171.36 8.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.827 0.346 . . . . 0.0 110.866 -179.763 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.587 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 23.8 m95 -129.12 159.82 34.81 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.925 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -93.31 -114.71 2.36 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.53 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' SER . . . . . 0.434 ' HB2' ' CZ ' ' A' ' 135' ' ' ARG . 3.6 m -151.96 169.36 22.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.825 0.345 . . . . 0.0 110.878 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.428 ' HG2' ' ND2' ' A' ' 84' ' ' ASN . 7.0 mt-10 -97.7 121.75 39.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.937 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -117.33 116.26 26.87 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.845 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 38.2 mtmt -122.32 117.21 25.54 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.896 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -169.37 108.96 0.44 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.896 179.843 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.431 ' CG1' ' N ' ' A' ' 99' ' ' THR . 3.5 tt -145.4 153.79 13.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.073 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.431 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 8.7 t -97.44 -38.74 9.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.169 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . 0.443 ' O ' ' CG ' ' A' ' 100' ' ' HIS . 3.3 p-80 -146.67 125.07 12.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.862 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 31.0 t-20 -102.56 96.82 7.93 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.633 0.73 . . . . 0.0 110.864 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.436 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.7 Cg_endo -69.83 -40.55 5.09 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.631 2.22 . . . . 0.0 112.357 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.436 ' C ' ' O ' ' A' ' 102' ' ' PRO . 32.0 m-85 -35.7 106.74 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.883 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -134.53 136.66 8.72 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.506 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 100.11 0.8 Allowed 'Trans proline' 0 C--N 1.34 0.124 0 C-N-CA 122.672 2.248 . . . . 0.0 112.299 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 124.9 -6.58 8.31 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.466 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 9.2 pt20 -131.01 147.29 52.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.852 0.358 . . . . 0.0 110.886 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' PHE . . . . . 0.559 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 66.0 m-85 -64.24 172.16 2.63 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.889 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.461 ' CG ' ' O ' ' A' ' 109' ' ' PHE . 21.8 p90 -160.73 117.97 2.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.882 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -93.64 106.8 18.74 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.848 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.438 ' CD1' ' N ' ' A' ' 112' ' ' SER . 0.5 OUTLIER -108.64 138.68 44.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.921 -179.961 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.438 ' N ' ' CD1' ' A' ' 111' ' ' LEU . 5.4 m -145.36 113.42 6.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.829 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.5 mp -93.66 137.5 22.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.125 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . 0.596 ' O ' ' CD2' ' A' ' 120' ' ' PHE . 16.9 mtp180 -109.88 135.05 51.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.87 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . 0.547 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 20.7 t -103.74 116.19 31.87 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.903 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -115.34 -149.2 9.54 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.504 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.414 ' O ' ' CD2' ' A' ' 134' ' ' HIS . 8.6 mt -111.83 -39.04 4.67 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.794 0.331 . . . . 0.0 110.899 -179.921 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . 0.553 ' C ' ' CD2' ' A' ' 134' ' ' HIS . 8.1 m-20 -89.41 -35.45 16.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.86 179.833 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 13.4 ptt180 -171.3 175.04 4.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 -179.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.596 ' CD2' ' O ' ' A' ' 114' ' ' ARG . 9.2 m-85 -98.9 162.51 13.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.887 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 36.6 mtpt -133.37 104.46 6.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.911 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 41.5 t -91.04 125.02 43.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.105 179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 48.6 m-85 -115.52 146.32 41.82 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.885 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -131.57 108.62 9.67 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.061 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 58.62 35.54 24.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.835 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.46 40.61 22.79 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.487 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 13.9 mt-30 -146.39 130.22 17.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.83 0.348 . . . . 0.0 110.922 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 33.2 t-80 -60.08 99.47 0.07 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.849 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 8.7 tp -70.17 -69.64 0.34 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.946 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.469 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 5.4 p90 -163.44 169.63 18.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.879 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -113.66 151.08 32.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.872 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.533 ' CE1' ' O ' ' A' ' 133' ' ' ALA . 0.2 OUTLIER -115.7 105.83 13.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.89 -179.942 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.533 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -61.71 134.01 56.25 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.132 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' HIS . . . . . 0.553 ' CD2' ' C ' ' A' ' 118' ' ' ASP . 14.3 m-70 -62.64 94.53 0.06 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.827 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.434 ' CZ ' ' HB2' ' A' ' 93' ' ' SER . 61.3 mtt-85 -78.78 -41.48 30.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.87 -179.935 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 12.3 tp -100.55 108.32 20.22 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.884 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 59.8 p -51.86 -30.78 25.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.887 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . 0.435 ' CB ' ' HD2' ' A' ' 141' ' ' ARG . . . -89.72 30.61 1.02 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.078 179.915 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.577 ' CE1' ' HG3' ' A' ' 140' ' ' GLN . 2.9 p90 -41.39 -40.14 1.64 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.91 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' GLN . . . . . 0.577 ' HG3' ' CE1' ' A' ' 139' ' ' PHE . 0.0 OUTLIER -48.05 -52.52 19.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.943 -179.952 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.435 ' HD2' ' CB ' ' A' ' 138' ' ' ALA . 47.9 mtt180 -42.4 -39.41 2.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.89 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.481 HG22 ' CB ' ' A' ' 69' ' ' ALA . 66.6 t -52.7 105.12 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.17 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.483 ' OD2' ' N ' ' A' ' 36' ' ' GLY . 0.9 OUTLIER -130.27 31.08 4.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.877 179.93 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -140.43 129.84 23.94 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.149 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.536 HD13 ' CE2' ' A' ' 60' ' ' PHE . 6.0 tp -125.59 108.91 12.04 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.869 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' GLU . . . . . 0.403 ' C ' HG13 ' A' ' 147' ' ' ILE . 3.0 pt-20 -111.12 148.85 31.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.907 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . 0.403 HG13 ' C ' ' A' ' 146' ' ' GLU . 8.8 mt -138.69 105.32 2.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.138 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -117.87 176.69 5.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.907 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.96 -145.94 16.57 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.477 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -114.6 91.63 3.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.868 0.366 . . . . 0.0 110.896 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 4.7 p -150.76 151.21 12.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.109 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 28.7 m -109.67 93.17 4.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.134 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.465 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 66.8 mt -76.52 138.34 40.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.957 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 74.0 m -122.82 -37.97 2.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.85 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 26.9 t80 -145.96 129.42 16.9 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.922 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 55.0 t -140.71 105.37 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.093 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 13.0 tt0 -121.58 120.4 34.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.907 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 27.1 mt . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.123 179.967 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.406 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 6.5 t . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.793 0.33 . . . . 0.0 111.171 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.406 ' CD1' ' O ' ' A' ' 22' ' ' THR . 7.4 m-85 -142.68 116.86 9.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.92 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . 0.474 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 11.8 m120 61.68 52.23 2.25 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.671 0.748 . . . . 0.0 110.914 -179.889 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.474 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 54.2 Cg_endo -69.76 133.41 25.5 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.665 2.243 . . . . 0.0 112.387 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.42 ' C ' HG22 ' A' ' 27' ' ' VAL . 54.2 Cg_endo -69.75 -174.22 0.86 Allowed 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.707 2.272 . . . . 0.0 112.33 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.53 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 84.7 t -144.04 138.77 15.28 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.621 0.724 . . . . 0.0 111.113 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.53 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.79 145.27 79.01 Favored 'Cis proline' 0 C--N 1.342 0.186 0 C-N-CA 122.659 -1.809 . . . . 0.0 112.303 -0.048 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.0 t80 -100.96 117.1 34.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.931 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.493 ' CD2' ' HB3' ' A' ' 146' ' ' GLU . 58.2 m-85 -104.61 105.98 16.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.896 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -116.34 103.44 1.15 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.496 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.513 ' CD ' ' O ' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -72.61 114.08 10.36 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.799 0.333 . . . . 0.0 110.856 -179.873 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 3.9 mt -59.1 151.32 22.78 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.932 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 3.0 mp0 -104.26 101.22 10.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.906 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.64 -58.62 0.52 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.493 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.492 ' N ' ' OD1' ' A' ' 143' ' ' ASP . . . 123.73 171.83 13.62 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.48 -179.872 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 93.7 mt -58.74 103.74 0.18 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.879 0.371 . . . . 0.0 110.949 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 22.0 p -118.98 150.16 40.4 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.098 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -54.83 -28.16 47.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.107 179.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 3.9 tpt180 -102.97 37.47 1.95 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.899 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 11.7 ttm180 -129.16 139.51 51.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.871 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 91.8 m -137.4 124.75 21.9 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.128 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 4.9 mp -92.67 134.05 31.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.161 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 89.7 mt -122.93 135.89 61.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.087 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 56.1 mt -133.98 107.92 10.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.132 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.3 mtmt -113.82 113.78 25.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.836 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.416 ' CA ' ' O ' ' A' ' 152' ' ' THR . . . -146.56 -140.6 3.47 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.519 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -170.55 137.45 1.38 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.916 0.389 . . . . 0.0 110.927 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 14.2 t -86.62 114.87 60.07 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.604 0.716 . . . . 0.0 111.124 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.83 155.71 65.0 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.685 2.256 . . . . 0.0 112.358 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 -13.9 35.46 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.701 2.267 . . . . 0.0 112.356 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 57.8 p -112.28 16.19 20.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.112 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -112.72 120.23 5.18 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.468 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 12.1 mtpt -61.62 -60.46 3.64 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.767 0.318 . . . . 0.0 110.857 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 25.8 p -173.16 158.4 3.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.85 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.555 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 8.2 p90 -112.01 -172.8 2.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.88 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.48 141.8 18.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.12 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.419 HD13 ' CE2' ' A' ' 56' ' ' PHE . 2.9 mp -123.01 102.23 11.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.105 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.5 m-80 -103.22 146.09 28.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.846 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.547 ' CE2' HD12 ' A' ' 145' ' ' LEU . 40.7 m-85 -117.63 101.16 8.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.905 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.412 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 33.1 ttmt -96.33 168.57 10.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.854 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.416 ' CG2' HG21 ' A' ' 142' ' ' VAL . 38.4 t -99.57 122.83 51.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.137 179.846 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.424 ' N ' ' OG1' ' A' ' 144' ' ' THR . . . -59.55 -28.69 65.46 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.482 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 t -77.53 -71.09 0.43 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.839 0.352 . . . . 0.0 110.856 -179.706 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.6 t -79.33 -75.51 0.24 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.818 -179.786 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 132.18 41.31 0.2 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.467 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -115.45 139.62 49.87 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.763 0.316 . . . . 0.0 110.855 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 37.6 mt -86.43 114.8 26.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.079 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.22 -34.69 21.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.092 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.539 HD13 ' CD1' ' A' ' 132' ' ' PHE . 32.1 tp -138.01 131.75 31.2 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.939 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.475 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.1 t60 -134.95 98.38 4.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.848 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.448 ' CG2' HG12 ' A' ' 81' ' ' VAL . 22.4 mt -96.42 129.27 46.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.129 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.503 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.2 OUTLIER -134.36 104.15 11.3 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.588 0.708 . . . . 0.0 110.927 179.966 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.555 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.6 Cg_endo -69.77 155.48 65.78 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.688 2.259 . . . . 0.0 112.341 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 81.6 mtt-85 -133.25 97.99 4.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.892 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.914 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 13.8 p . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.845 0.355 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.448 HG12 ' CG2' ' A' ' 72' ' ' ILE . 16.2 t -99.46 109.65 24.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.132 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.402 HG12 ' N ' ' A' ' 83' ' ' ARG . 82.5 t -79.24 140.19 17.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.123 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . 0.647 ' NH1' ' CD2' ' A' ' 130' ' ' PHE . 1.4 mpp_? -121.37 115.02 22.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.875 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.475 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.4 t-20 -125.98 179.75 5.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.896 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 94.7 p -160.95 110.07 1.64 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.869 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.574 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 24.5 tp -82.73 118.99 23.76 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.909 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.495 ' N ' ' O ' ' A' ' 90' ' ' SER . 96.8 mt -96.12 161.07 14.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.931 179.85 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.51 HD21 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.5 101.64 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.85 179.932 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.62 -7.0 1.11 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.481 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.502 ' H ' ' C ' ' A' ' 88' ' ' ASN . 0.3 OUTLIER -118.85 172.11 7.76 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.879 0.371 . . . . 0.0 110.85 -179.752 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.574 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 23.8 m95 -129.12 160.66 32.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.924 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.59 -114.7 2.19 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.454 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' SER . . . . . 0.424 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 4.5 m -152.78 167.56 28.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.806 0.336 . . . . 0.0 110.88 -179.728 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -97.66 120.46 38.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 20.8 mm-40 -119.63 128.22 53.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.875 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 47.4 mtmt -130.11 117.68 20.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.922 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 25.0 tptt -171.73 105.7 0.21 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.922 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.447 HG12 ' N ' ' A' ' 99' ' ' THR . 2.1 tt -145.23 151.09 15.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.101 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.447 ' N ' HG12 ' A' ' 98' ' ' ILE . 9.7 t -85.83 -50.35 7.19 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.168 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . 0.432 ' O ' ' CD1' ' A' ' 98' ' ' ILE . 9.7 p-80 -137.33 132.55 33.77 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.847 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . 0.41 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 43.2 t-20 -112.82 99.62 48.61 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.608 0.718 . . . . 0.0 110.907 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.442 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.6 Cg_endo -69.8 -41.1 4.51 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.705 2.27 . . . . 0.0 112.35 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.442 ' C ' ' O ' ' A' ' 102' ' ' PRO . 7.5 m-85 -35.32 101.91 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.866 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -131.5 136.5 8.83 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.522 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 97.9 0.66 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.675 2.25 . . . . 0.0 112.318 -179.87 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 133.56 -10.45 4.95 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.48 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -133.3 161.77 33.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.837 0.351 . . . . 0.0 110.879 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -82.23 175.08 10.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.864 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 23.0 p90 -161.81 127.26 3.54 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.866 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -98.39 104.49 16.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.85 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.479 ' CD1' ' N ' ' A' ' 112' ' ' SER . 0.6 OUTLIER -104.85 139.47 39.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.92 -179.945 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.479 ' N ' ' CD1' ' A' ' 111' ' ' LEU . 4.7 m -144.8 113.41 6.69 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.854 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.454 HD13 ' CD1' ' A' ' 111' ' ' LEU . 4.7 mp -93.36 136.16 25.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.175 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 42.7 mtt180 -111.68 120.22 41.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.901 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . 0.567 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 2.3 t -90.42 116.7 28.56 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.913 -179.929 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -113.03 -148.85 10.39 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.467 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 19.1 mt -112.76 -35.24 5.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.826 0.346 . . . . 0.0 110.903 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 52.4 m-20 -91.2 -33.14 15.51 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.893 179.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.2 ptp180 -174.77 176.2 2.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.867 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.567 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.9 m-30 -99.22 158.15 15.89 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 -179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.9 mtpt -130.75 100.82 5.42 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.9 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . 0.539 HG23 ' CZ ' ' A' ' 130' ' ' PHE . 25.1 t -87.83 126.67 41.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.136 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 85.2 m-85 -118.37 150.49 39.43 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.946 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . 0.403 ' C ' ' ND2' ' A' ' 125' ' ' ASN . . . -134.86 110.14 8.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.097 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.403 ' ND2' ' C ' ' A' ' 124' ' ' ALA . 0.6 OUTLIER 60.68 39.24 17.82 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.907 -179.889 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . 0.402 ' C ' ' HG2' ' A' ' 127' ' ' GLN . . . 72.92 41.59 48.32 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.495 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . 0.402 ' HG2' ' C ' ' A' ' 126' ' ' GLY . 20.3 mm-40 -148.41 136.84 21.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.79 0.329 . . . . 0.0 110.917 -179.851 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 46.5 t-80 -63.1 107.39 1.02 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.856 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 11.8 tp -78.35 -64.24 1.21 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.914 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.647 ' CD2' ' NH1' ' A' ' 83' ' ' ARG . 24.7 p90 -166.84 -178.68 4.38 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.889 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -125.37 144.86 50.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.861 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.539 ' CD1' HD13 ' A' ' 70' ' ' LEU . 0.4 OUTLIER -113.06 106.42 14.65 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.905 -179.915 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.491 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -61.74 137.98 58.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.106 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 17.8 m-70 -66.31 100.74 0.66 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.8 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.424 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 60.5 mtt-85 -83.97 -55.1 4.41 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.855 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 4.9 tp -88.67 107.91 19.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.913 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 19.9 p -48.79 -34.4 12.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.858 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . 0.472 ' HB2' ' CD ' ' A' ' 141' ' ' ARG . . . -82.67 28.99 0.46 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.107 179.912 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.416 ' CG ' ' N ' ' A' ' 140' ' ' GLN . 27.0 p90 -50.94 -42.54 59.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.899 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' GLN . . . . . 0.416 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 7.3 pt20 -48.83 -37.25 18.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.907 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.472 ' CD ' ' HB2' ' A' ' 138' ' ' ALA . 45.4 mtp85 -58.17 -40.91 82.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.861 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.416 HG21 ' CG2' ' A' ' 62' ' ' VAL . 60.0 t -48.17 102.3 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.133 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.492 ' OD1' ' N ' ' A' ' 36' ' ' GLY . 22.6 t0 -124.26 24.91 7.93 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.869 179.868 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' THR . . . . . 0.424 ' OG1' ' N ' ' A' ' 63' ' ' GLY . 1.5 m -132.59 140.63 48.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.127 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.547 HD12 ' CE2' ' A' ' 60' ' ' PHE . 4.5 tp -135.91 113.81 11.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.875 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' GLU . . . . . 0.493 ' HB3' ' CD2' ' A' ' 30' ' ' PHE . 5.9 pt-20 -117.82 151.85 36.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.932 179.903 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 18.0 mt -139.19 118.35 13.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.117 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 1.1 pm0 -128.19 177.9 6.61 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.868 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 106.32 -137.5 13.88 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.474 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -122.54 92.48 3.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.816 0.341 . . . . 0.0 110.905 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.45 HG22 ' N ' ' A' ' 152' ' ' THR . 2.1 p -151.17 150.6 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.103 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' THR . . . . . 0.45 ' N ' HG22 ' A' ' 151' ' ' VAL . 23.7 m -107.48 93.52 4.59 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.114 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.466 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 67.8 mt -77.24 128.97 35.29 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.938 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 3.8 m -111.96 -41.66 3.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.901 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 35.2 t80 -143.87 130.62 20.26 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.942 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 72.9 t -140.7 105.29 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.122 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -120.66 129.62 53.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.879 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 16.6 mt . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.103 179.979 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.411 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.4 m . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.844 0.354 . . . . 0.0 111.149 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.404 ' CD1' ' O ' ' A' ' 22' ' ' THR . 7.2 m-85 -142.52 134.47 27.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.854 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . 0.51 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.5 t-20 42.68 49.9 4.95 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.554 0.692 . . . . 0.0 110.878 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.51 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.8 Cg_endo -69.8 143.87 52.04 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.634 2.223 . . . . 0.0 112.378 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -178.74 2.49 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.701 2.267 . . . . 0.0 112.315 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.527 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 98.8 t -143.71 137.93 14.81 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.636 0.731 . . . . 0.0 111.106 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.527 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.77 144.65 77.25 Favored 'Cis proline' 0 C--O 1.231 0.171 0 C-N-CA 122.698 -1.792 . . . . 0.0 112.357 -0.066 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -98.8 118.12 34.83 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.954 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.417 ' CD1' ' HB3' ' A' ' 146' ' ' GLU . 63.8 m-85 -104.7 103.01 12.57 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.872 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -113.77 104.32 1.46 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.503 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.469 ' O ' ' HG3' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -73.44 121.89 21.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.876 0.37 . . . . 0.0 110.874 -179.868 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 5.4 mt -68.77 147.12 52.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.922 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 29.1 mt-30 -106.0 83.63 1.94 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.917 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 138.13 -49.0 0.86 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.49 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 109.35 166.98 20.33 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.454 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 87.5 mt -55.0 110.27 0.64 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.895 0.378 . . . . 0.0 110.901 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 61.7 p -129.93 145.4 51.62 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.178 179.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -47.37 -31.1 3.7 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.098 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 8.9 tpt180 -97.32 31.66 2.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.881 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 12.3 ttm180 -124.13 141.56 51.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.879 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 94.0 m -138.33 124.85 20.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.147 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.1 mp -96.85 130.15 45.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.112 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.417 HG21 ' N ' ' A' ' 45' ' ' ILE . 86.5 mt -123.49 134.04 67.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.132 179.812 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.417 ' N ' HG21 ' A' ' 44' ' ' ILE . 72.1 mt -133.32 107.39 11.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.156 179.903 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 25.9 mtmt -112.01 109.93 19.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.898 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.501 ' CA ' ' O ' ' A' ' 152' ' ' THR . . . -138.09 -139.89 3.93 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.492 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -173.63 119.4 0.29 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.947 0.404 . . . . 0.0 110.884 -179.777 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 21.9 t -70.77 113.52 19.37 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.615 0.721 . . . . 0.0 111.124 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 156.88 62.35 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.671 2.248 . . . . 0.0 112.344 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -14.48 36.18 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.669 2.246 . . . . 0.0 112.366 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 72.6 p -111.7 18.46 18.96 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.181 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -116.12 123.47 5.89 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.509 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 33.8 mtpt -65.39 -59.43 4.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.823 0.344 . . . . 0.0 110.891 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 34.9 p -174.03 160.74 3.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.833 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.58 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 3.4 p90 -114.19 -174.37 2.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.869 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.37 128.19 7.31 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.076 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 5.3 mp -112.22 102.28 13.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.155 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.3 m-80 -100.84 149.69 23.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.938 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 56.6 m-85 -118.65 101.08 7.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.872 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.409 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 34.9 ttmt -95.69 168.92 10.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.904 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.409 ' N ' ' HG2' ' A' ' 61' ' ' LYS . 55.2 t -100.48 124.83 54.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.124 179.856 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -60.48 -33.76 82.76 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.506 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 70.1 m -70.84 -71.05 0.27 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.837 0.351 . . . . 0.0 110.864 -179.738 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 82.6 p -82.07 -75.1 0.31 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.875 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 133.37 44.31 0.13 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.46 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . 0.411 ' OD1' ' OD1' ' A' ' 88' ' ' ASN . 1.2 m-20 -113.65 144.83 42.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.798 0.332 . . . . 0.0 110.889 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 40.9 mt -90.22 113.85 26.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.124 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.408 ' HB2' ' CG2' ' A' ' 142' ' ' VAL . . . -87.17 -32.3 19.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.126 179.799 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.5 HD21 ' CD2' ' A' ' 132' ' ' PHE . 41.4 tp -136.83 129.73 30.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.9 -179.936 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.482 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.0 OUTLIER -134.61 94.42 3.19 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.869 179.836 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 44.7 mt -99.59 134.74 37.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.148 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.504 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -141.38 106.9 6.07 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.594 0.711 . . . . 0.0 110.859 179.955 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.58 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.0 Cg_endo -69.81 155.14 66.54 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.708 2.272 . . . . 0.0 112.362 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . 0.42 ' NH1' HG21 ' A' ' 82' ' ' VAL . 34.6 mtt85 -128.97 97.49 4.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.877 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 24.7 p . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.777 0.322 . . . . 0.0 111.164 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 13.8 t -97.79 113.58 32.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.131 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.42 HG21 ' NH1' ' A' ' 75' ' ' ARG . 58.2 t -83.12 144.81 9.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.111 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -123.89 125.46 44.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.873 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.482 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.7 OUTLIER -139.29 177.96 7.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.935 -179.955 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 92.4 p -160.67 107.68 1.53 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.868 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.564 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 24.6 tp -76.98 117.41 18.54 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.935 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.486 ' N ' ' O ' ' A' ' 90' ' ' SER . 25.9 mt -93.44 161.19 14.48 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.908 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.413 ' C ' ' H ' ' A' ' 90' ' ' SER . 10.6 m-80 -41.31 101.48 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.866 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.94 -3.25 4.11 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.471 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.486 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.4 OUTLIER -124.5 173.41 8.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.87 0.367 . . . . 0.0 110.831 -179.716 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.564 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 23.8 m95 -130.21 159.58 36.44 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.948 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -90.8 -109.3 1.47 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.478 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 3.4 m -159.92 176.03 12.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.839 0.352 . . . . 0.0 110.832 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.42 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 4.6 mt-10 -104.05 122.96 46.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.866 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -121.75 113.25 19.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.892 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 40.4 mtmt -114.34 118.41 33.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.868 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 12.1 tptm -172.13 105.27 0.18 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.879 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 2.4 tt -144.23 143.58 23.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.155 179.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.45 ' CG2' ' N ' ' A' ' 100' ' ' HIS . 10.3 t -77.25 -51.58 10.67 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.154 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . 0.45 ' N ' ' CG2' ' A' ' 99' ' ' THR . 21.3 p80 -140.55 134.21 30.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.85 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . 0.404 ' OD1' ' C ' ' A' ' 101' ' ' ASN . 4.9 t-20 -101.65 99.13 10.88 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.608 0.718 . . . . 0.0 110.931 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.435 ' CD ' HD13 ' A' ' 129' ' ' LEU . 53.6 Cg_endo -69.76 -40.81 4.89 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.693 2.262 . . . . 0.0 112.328 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -41.02 111.86 0.25 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.885 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -134.08 133.85 7.1 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.511 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 96.5 0.6 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.632 2.222 . . . . 0.0 112.333 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 127.25 0.23 6.92 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.49 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -138.78 154.48 48.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.85 0.357 . . . . 0.0 110.952 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 -71.9 171.96 10.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.87 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 27.4 p90 -160.52 136.33 8.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.909 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.67 105.8 14.82 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.854 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.452 ' CD1' HD13 ' A' ' 113' ' ' ILE . 0.6 OUTLIER -107.14 139.72 41.11 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.9 -179.931 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.409 ' N ' ' CD1' ' A' ' 111' ' ' LEU . 3.6 m -144.88 114.88 7.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.839 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.452 HD13 ' CD1' ' A' ' 111' ' ' LEU . 4.6 mp -98.23 127.42 50.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.142 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 9.9 mtp180 -100.25 133.48 44.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.875 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 14.1 t -98.49 100.41 11.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.894 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -91.04 -140.51 8.87 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.469 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.3 mt -122.8 -38.55 2.62 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.845 0.355 . . . . 0.0 110.933 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.4 t0 -94.39 -21.43 18.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.867 179.848 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.402 ' CD ' ' C ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -175.18 -175.12 0.81 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.834 -179.902 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.404 ' CE1' ' HE1' ' A' ' 134' ' ' HIS . 20.4 m-85 -108.42 148.91 29.46 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.871 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 2.1 mmmm -120.17 101.95 8.18 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.866 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . 0.481 HG23 ' CE1' ' A' ' 130' ' ' PHE . 65.8 t -89.31 129.74 39.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.141 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 54.6 m-85 -116.16 160.7 20.01 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.925 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . 0.421 ' O ' ' N ' ' A' ' 127' ' ' GLN . . . -139.92 114.34 9.21 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.111 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 41.41 38.68 0.88 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.852 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 83.71 27.63 37.9 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.458 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . 0.421 ' N ' ' O ' ' A' ' 124' ' ' ALA . 9.4 mm100 -138.88 115.88 10.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.855 0.359 . . . . 0.0 110.897 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 34.4 t-80 -47.93 103.19 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.876 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . 0.435 HD13 ' CD ' ' A' ' 102' ' ' PRO . 13.5 tp -69.65 -68.48 0.41 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.894 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.481 ' CE1' HG23 ' A' ' 122' ' ' VAL . 9.4 p90 -164.2 175.8 9.81 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.912 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.48 ' OD1' ' N ' ' A' ' 132' ' ' PHE . 0.4 OUTLIER -117.06 156.73 27.05 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 179.967 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.605 ' CE1' ' O ' ' A' ' 133' ' ' ALA . 0.1 OUTLIER -128.31 106.12 8.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.889 -179.864 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.605 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -63.35 136.66 57.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.137 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' HIS . . . . . 0.404 ' HE1' ' CE1' ' A' ' 120' ' ' PHE . 15.8 m-70 -61.37 115.65 4.02 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.883 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 8.1 mtt-85 -95.9 -47.65 6.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.861 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 9.9 tp -96.56 108.19 20.74 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.905 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 78.9 p -47.73 -34.22 8.07 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.847 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -83.62 31.09 0.47 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.084 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -50.36 -34.89 25.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.871 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' GLN . . . . . 0.466 ' HG2' ' N ' ' A' ' 141' ' ' ARG . 18.1 pm0 -59.7 -29.41 68.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.923 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.466 ' N ' ' HG2' ' A' ' 140' ' ' GLN . 36.3 mtp85 -65.29 -39.64 92.81 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.408 ' CG2' ' HB2' ' A' ' 69' ' ' ALA . 84.3 t -50.62 103.94 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.151 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 9.3 p-10 -125.27 31.85 5.49 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.886 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.7 m -140.72 135.04 31.18 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.14 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . . . . . . . . . 6.4 tp -129.88 115.88 17.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.932 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' GLU . . . . . 0.417 ' HB3' ' CD1' ' A' ' 30' ' ' PHE . 5.1 pt-20 -120.0 150.95 39.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.885 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . 0.409 HG13 ' C ' ' A' ' 146' ' ' GLU . 15.0 mt -139.36 112.85 6.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.152 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -122.58 175.59 6.4 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.902 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 105.11 -146.36 16.06 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.498 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -111.69 92.51 4.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.886 0.374 . . . . 0.0 110.865 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.472 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 4.7 p -151.22 140.59 15.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.107 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' THR . . . . . 0.501 ' O ' ' CA ' ' A' ' 47' ' ' GLY . 14.1 m -100.52 94.15 5.99 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.16 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.446 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 80.4 mt -78.59 132.99 37.34 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.92 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 64.9 m -118.29 -34.38 4.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.889 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 13.8 t80 -149.98 130.36 13.79 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.941 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 86.3 t -140.77 106.14 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.152 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 16.0 tt0 -114.57 135.85 53.68 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.919 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 42.1 mt . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.166 179.967 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.51 ' CG2' ' N ' ' A' ' 23' ' ' PHE . 1.3 m . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.853 0.358 . . . . 0.0 111.115 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.51 ' N ' ' CG2' ' A' ' 22' ' ' THR . 8.4 m-85 -147.73 141.65 25.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.873 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . 0.485 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 15.8 m120 35.12 51.95 1.37 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.63 0.729 . . . . 0.0 110.88 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.485 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.6 Cg_endo -69.82 145.78 57.85 Favored 'Trans proline' 0 C--O 1.232 0.192 0 C-N-CA 122.693 2.262 . . . . 0.0 112.309 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.79 -178.25 2.27 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.663 2.242 . . . . 0.0 112.32 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.518 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 95.2 t -142.85 138.0 15.58 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.688 0.756 . . . . 0.0 111.081 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.518 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.9 Cg_endo -69.77 144.54 76.95 Favored 'Cis proline' 0 C--N 1.342 0.195 0 C-N-CA 122.656 -1.81 . . . . 0.0 112.347 -0.028 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 1.9 t80 -96.22 117.64 31.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.95 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -100.53 104.09 15.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.888 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -109.03 109.19 2.74 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.48 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 6.8 mmt85 -72.97 116.55 13.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.829 0.347 . . . . 0.0 110.887 -179.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 6.1 mt -75.69 94.61 3.27 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.913 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 22.2 mm-40 -67.22 92.55 0.27 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.886 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 138.21 -37.63 1.79 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.476 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.505 ' N ' ' OD2' ' A' ' 143' ' ' ASP . . . 88.92 157.48 32.85 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.493 -179.884 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 66.4 mt -51.08 95.77 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.914 0.388 . . . . 0.0 110.907 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 44.4 p -116.24 148.59 40.3 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.092 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -50.6 -21.27 1.48 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.106 179.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.453 ' HA ' ' NE ' ' A' ' 40' ' ' ARG . 3.8 mmp_? -106.88 34.28 3.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.859 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 14.7 ttt85 -125.9 140.06 52.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.904 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 99.9 m -139.36 119.81 13.95 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.168 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 4.9 mp -90.59 142.19 13.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.15 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.4 ' CG2' ' HZ1' ' A' ' 46' ' ' LYS . 82.4 mt -133.76 115.66 22.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.111 179.87 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 54.3 mt -114.92 107.59 23.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.123 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.4 ' HZ1' ' CG2' ' A' ' 44' ' ' ILE . 9.0 mtmm -110.18 109.3 19.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.885 179.877 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.59 -147.53 4.98 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.507 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 0.57 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.5 OUTLIER -168.14 127.13 1.22 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.892 0.377 . . . . 0.0 110.97 -179.806 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 11.3 t -75.97 115.38 46.06 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.627 0.727 . . . . 0.0 111.141 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 155.42 66.15 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.661 2.241 . . . . 0.0 112.423 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -14.83 36.61 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.657 2.238 . . . . 0.0 112.326 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 49.7 p -111.62 17.94 19.49 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.162 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -113.36 124.14 6.44 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.48 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 14.8 mttp -64.89 -62.6 1.46 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.802 0.334 . . . . 0.0 110.897 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 17.5 p -171.76 157.51 4.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.875 -179.869 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.576 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 9.1 p90 -113.1 -172.27 2.03 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.931 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.19 139.12 16.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.081 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.522 HG22 ' CE1' ' A' ' 60' ' ' PHE . 2.7 mp -118.95 99.03 7.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.139 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . 0.512 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 33.0 m-80 -101.22 141.67 33.77 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.897 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.522 ' CE1' HG22 ' A' ' 58' ' ' ILE . 26.8 m-85 -115.49 97.92 6.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.861 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.9 ttmt -95.59 169.91 9.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.94 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.426 HG12 ' C ' ' A' ' 141' ' ' ARG . 16.7 t -99.33 123.35 51.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.131 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -61.08 -22.87 61.05 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.497 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 30.7 t -81.73 -72.78 0.42 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.928 0.394 . . . . 0.0 110.855 -179.72 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 36.0 t -80.61 -72.79 0.4 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.839 -179.82 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 133.69 40.65 0.18 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.487 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . 0.488 ' OD2' ' ND2' ' A' ' 88' ' ' ASN . 1.1 m-20 -110.29 137.54 47.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.796 0.331 . . . . 0.0 110.847 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 57.0 mt -85.84 112.46 22.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.155 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.43 ' CB ' HG23 ' A' ' 142' ' ' VAL . . . -80.7 -34.66 34.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.114 179.829 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.558 HD12 ' CD1' ' A' ' 132' ' ' PHE . 53.4 tp -140.69 132.16 26.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.951 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.512 ' CG ' ' OD1' ' A' ' 59' ' ' ASN . 3.3 t60 -134.92 92.3 2.86 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.857 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.459 ' CG2' HG13 ' A' ' 81' ' ' VAL . 20.3 mt -96.17 134.78 32.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.163 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.501 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -140.06 105.88 6.75 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.643 0.735 . . . . 0.0 110.904 179.968 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.576 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.2 Cg_endo -69.75 155.01 67.1 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.67 2.247 . . . . 0.0 112.364 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 36.7 mtp180 -131.85 94.72 3.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.854 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.877 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 13.7 p . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.807 0.337 . . . . 0.0 111.187 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.459 HG13 ' CG2' ' A' ' 72' ' ' ILE . 29.4 t -104.43 109.47 27.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.119 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.448 HG21 ' CE ' ' A' ' 96' ' ' LYS . 58.2 t -80.01 135.53 25.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.107 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . 0.492 ' N ' ' HD3' ' A' ' 83' ' ' ARG . 0.7 OUTLIER -121.06 115.18 22.63 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.884 -179.989 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.434 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.2 t-20 -124.81 -176.82 3.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.911 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.406 ' CB ' ' HD2' ' A' ' 135' ' ' ARG . 47.5 t -161.17 106.45 1.36 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.883 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.562 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 28.9 tp -78.9 115.35 18.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.923 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.519 ' N ' ' O ' ' A' ' 90' ' ' SER . 73.2 mt -92.96 162.18 14.16 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.882 179.901 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.488 ' ND2' ' OD2' ' A' ' 67' ' ' ASP . 10.6 m-80 -40.66 101.64 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.891 179.902 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.77 -3.59 2.79 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.466 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.519 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -123.15 170.97 9.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.901 0.382 . . . . 0.0 110.833 -179.73 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.562 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 24.7 m95 -128.41 160.62 31.69 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.926 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -91.24 -108.26 1.5 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.483 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 2.9 m -163.07 169.5 19.38 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.851 0.358 . . . . 0.0 110.873 -179.73 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 71.6 mt-10 -93.58 119.19 32.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.901 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 -122.87 124.95 44.42 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.92 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.448 ' CE ' HG21 ' A' ' 82' ' ' VAL . 17.4 mttp -126.52 122.74 36.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.896 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.406 ' HB3' ' NH2' ' A' ' 83' ' ' ARG . 4.6 ttpm? -169.5 105.81 0.37 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.91 179.827 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 1.3 tt -147.75 150.2 14.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.144 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 11.5 t -86.52 -43.48 12.7 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.145 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 2.9 p-80 -149.64 127.2 11.58 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.898 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . 0.405 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 51.7 t-20 -99.51 101.01 11.91 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.604 0.716 . . . . 0.0 110.867 -179.89 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.405 ' HD2' ' HA ' ' A' ' 101' ' ' ASN . 53.8 Cg_endo -69.78 -31.81 19.72 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.738 2.292 . . . . 0.0 112.341 179.918 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.562 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 17.9 m-85 -44.2 102.48 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.837 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -132.06 135.18 8.02 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.482 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 98.26 0.67 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.672 2.248 . . . . 0.0 112.351 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 130.75 -5.87 5.82 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.44 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 -135.47 159.83 40.37 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.849 0.356 . . . . 0.0 110.91 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' PHE . . . . . 0.57 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 16.2 m-85 -77.64 174.56 10.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.876 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.544 ' CD1' ' O ' ' A' ' 109' ' ' PHE . 33.5 p90 -161.49 118.08 2.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.881 -179.872 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -92.5 106.93 18.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.892 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.468 HD13 ' N ' ' A' ' 112' ' ' SER . 0.3 OUTLIER -106.75 138.38 43.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.91 -179.948 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' SER . . . . . 0.468 ' N ' HD13 ' A' ' 111' ' ' LEU . 7.4 m -145.37 112.04 5.87 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.841 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.8 mp -94.55 134.12 33.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.116 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 70.7 mtt180 -111.79 123.35 50.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.844 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . 0.57 ' HB2' ' CZ ' ' A' ' 120' ' ' PHE . 3.5 t -93.91 100.87 12.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.89 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -93.11 -126.96 4.34 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.476 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.4 mt -132.74 -43.19 0.91 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.842 0.353 . . . . 0.0 110.885 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -86.04 -29.34 23.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.9 179.82 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 10.6 ptp85 -175.16 162.37 2.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.838 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.57 ' CZ ' ' HB2' ' A' ' 115' ' ' CYS . 3.0 m-30 -85.45 141.43 29.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.902 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 12.0 mmmt -113.67 105.01 12.8 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.941 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 48.8 t -95.18 133.2 36.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.12 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 11.0 m-85 -120.16 159.24 25.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.874 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -141.4 116.25 9.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.059 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 45.07 35.94 1.82 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.896 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 84.33 29.36 30.67 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.458 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 10.5 mm100 -140.96 116.11 9.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.789 0.328 . . . . 0.0 110.911 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 42.1 t-80 -51.27 105.02 0.09 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.831 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . 0.483 HD23 ' CE2' ' A' ' 130' ' ' PHE . 6.4 tp -72.13 -67.52 0.53 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.941 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.483 ' CE2' HD23 ' A' ' 129' ' ' LEU . 6.7 p90 -166.35 179.82 5.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.898 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -126.27 158.9 34.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.845 -179.979 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.595 ' CE1' ' O ' ' A' ' 133' ' ' ALA . 0.2 OUTLIER -115.4 110.24 19.05 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.89 -179.914 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.595 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -54.52 138.69 40.0 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.071 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 18.4 m-70 -78.15 69.22 4.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.83 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.406 ' HD2' ' CB ' ' A' ' 85' ' ' SER . 0.0 OUTLIER -66.33 -37.89 86.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.872 -179.948 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.8 tp -98.23 107.89 20.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.916 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 78.8 p -58.1 -25.12 60.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.859 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -91.06 39.71 1.0 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.114 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 28.9 p90 -65.47 -30.88 71.71 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.909 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 4.9 pt20 -59.32 -31.16 68.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.889 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.426 ' C ' HG12 ' A' ' 62' ' ' VAL . 27.4 mtt180 -64.26 -40.16 95.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.889 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.43 HG23 ' CB ' ' A' ' 69' ' ' ALA . 92.0 t -48.91 106.01 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.139 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.505 ' OD2' ' N ' ' A' ' 36' ' ' GLY . 0.7 OUTLIER -130.84 33.41 4.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.892 179.922 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 9.1 m -143.74 113.5 7.12 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.175 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.453 HD11 ' CE2' ' A' ' 60' ' ' PHE . 5.7 tp -111.19 106.99 16.17 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.905 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -108.59 153.91 22.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.901 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 21.3 mt -140.78 116.49 7.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.081 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -126.19 171.76 10.62 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.926 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 104.74 -157.07 16.84 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.459 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 64.6 m-20 -98.6 94.32 6.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.868 0.366 . . . . 0.0 110.844 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.466 HG23 ' N ' ' A' ' 152' ' ' THR . 10.4 p -151.07 141.5 16.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.142 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' THR . . . . . 0.466 ' N ' HG23 ' A' ' 151' ' ' VAL . 33.7 m -105.5 92.71 4.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.176 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.473 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 94.6 mt -71.75 133.65 45.71 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.895 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 3.6 m -114.61 -35.66 4.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.886 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . 0.462 ' C ' ' CD1' ' A' ' 155' ' ' TYR . 4.2 t80 -157.16 132.43 9.06 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.941 -179.885 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 85.0 t -140.47 133.79 33.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.113 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 8.0 tt0 -156.57 138.45 14.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.891 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 4.7 mp . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.141 179.938 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 3.7 t . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.839 0.352 . . . . 0.0 111.127 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -129.05 122.67 30.47 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.875 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . 0.555 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 6.3 t-20 74.11 47.76 0.21 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.589 0.709 . . . . 0.0 110.899 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.555 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.78 123.29 9.95 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.646 2.231 . . . . 0.0 112.375 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.78 -179.28 2.81 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.674 2.25 . . . . 0.0 112.363 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.532 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 90.8 t -140.97 138.5 18.11 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.592 0.711 . . . . 0.0 111.096 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.532 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.6 Cg_endo -69.76 144.22 76.05 Favored 'Cis proline' 0 C--O 1.231 0.174 0 C-N-CA 122.69 -1.796 . . . . 0.0 112.311 -0.056 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.6 t80 -97.29 114.32 26.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.942 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.411 ' CD1' ' HB3' ' A' ' 146' ' ' GLU . 66.6 m-85 -99.55 107.25 19.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.875 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -115.29 100.44 0.97 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.513 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . 0.483 ' O ' ' CG ' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -72.78 117.11 14.08 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.84 0.353 . . . . 0.0 110.895 -179.848 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 11.6 mt -63.45 150.11 44.47 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.937 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . 0.455 ' OE1' ' NH1' ' A' ' 32' ' ' ARG . 7.3 mm100 -98.01 -46.44 5.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.943 179.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.41 ' O ' ' O ' ' A' ' 36' ' ' GLY . . . -103.47 33.22 6.76 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.486 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.41 ' O ' ' O ' ' A' ' 35' ' ' GLY . . . 37.21 -157.5 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.443 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 51.3 mt -88.43 106.7 18.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.832 0.348 . . . . 0.0 110.92 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 34.4 p -122.12 170.57 9.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.109 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.13 -11.81 59.99 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.074 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 12.2 mmm180 -110.64 22.39 15.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.841 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.529 ' NH2' ' CG1' ' A' ' 43' ' ' ILE . 27.8 ttt-85 -117.94 143.22 46.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.873 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 51.9 m -138.14 129.1 27.07 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.129 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.529 ' CG1' ' NH2' ' A' ' 41' ' ' ARG . 4.8 mp -94.64 145.73 7.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.133 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 76.6 mt -142.73 114.33 3.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.125 179.852 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 48.3 mt -115.93 107.71 23.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.143 179.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.5 mtmm -109.89 112.92 25.24 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.919 179.827 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.411 ' CA ' ' O ' ' A' ' 152' ' ' THR . . . -146.85 -142.89 3.78 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.534 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -167.58 130.64 1.67 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.874 0.368 . . . . 0.0 110.92 -179.827 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 16.0 t -78.98 115.74 54.69 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.661 0.743 . . . . 0.0 111.099 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 155.42 65.81 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.676 2.251 . . . . 0.0 112.326 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 -19.27 36.47 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.723 2.282 . . . . 0.0 112.319 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 69.5 p -106.15 16.84 24.39 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.167 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -114.66 125.91 7.01 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.489 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 15.7 mttp -66.25 -61.84 1.8 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.785 0.326 . . . . 0.0 110.895 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.0 p -172.56 158.2 4.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.883 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.571 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 8.1 p90 -108.88 -173.85 2.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.845 -179.928 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.32 140.79 16.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.092 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.1 mp -122.38 107.84 20.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.098 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -111.74 143.52 42.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.852 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.509 ' CE2' HD11 ' A' ' 145' ' ' LEU . 13.6 m-85 -113.67 102.04 9.88 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.91 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 31.9 ttmt -95.1 168.07 10.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.888 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.426 HG11 ' C ' ' A' ' 141' ' ' ARG . 25.5 t -98.94 122.37 50.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.106 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -60.22 -26.62 64.05 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.479 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 66.4 m -75.47 -70.88 0.4 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.869 0.366 . . . . 0.0 110.855 -179.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.8 m -85.23 -73.54 0.43 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.825 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 137.58 35.87 0.17 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.447 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . 0.455 ' OD2' ' ND2' ' A' ' 88' ' ' ASN . 0.3 OUTLIER -104.11 146.87 28.11 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.766 0.317 . . . . 0.0 110.879 -179.972 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 60.4 mt -94.79 115.89 34.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.203 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.465 ' HB2' ' CG2' ' A' ' 142' ' ' VAL . . . -83.19 -39.11 21.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.075 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.526 HD22 ' CD2' ' A' ' 132' ' ' PHE . 38.8 tp -135.06 133.01 38.89 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.952 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.474 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.9 OUTLIER -134.34 93.09 3.01 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.827 179.885 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 59.3 mt -97.21 130.84 45.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.094 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.514 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -136.11 106.5 9.53 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.629 0.728 . . . . 0.0 110.942 179.87 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.571 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.1 Cg_endo -69.75 155.12 66.78 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.664 2.243 . . . . 0.0 112.399 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 25.9 mtp180 -132.35 101.48 5.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.822 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.855 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 25.1 p . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.823 0.344 . . . . 0.0 111.123 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 17.3 t -87.84 104.64 14.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.126 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.42 ' CG2' ' HD3' ' A' ' 96' ' ' LYS . 58.7 t -76.25 145.52 10.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.125 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -125.78 131.28 52.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.861 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.474 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.2 m120 -143.81 179.52 7.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.892 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.405 ' CB ' ' O ' ' A' ' 69' ' ' ALA . 96.6 p -160.7 107.29 1.49 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.816 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.57 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 28.5 tp -77.38 116.92 18.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.935 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.517 ' N ' ' O ' ' A' ' 90' ' ' SER . 66.7 mt -93.33 161.58 14.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.933 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.455 ' ND2' ' OD2' ' A' ' 67' ' ' ASP . 14.0 m-80 -41.63 101.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.869 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.86 -3.38 3.94 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.516 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.517 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -124.83 171.58 10.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.838 0.351 . . . . 0.0 110.868 -179.72 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.57 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 23.0 m95 -128.08 159.85 33.8 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.968 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -89.37 -105.82 1.12 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.478 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' SER . . . . . 0.416 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 25.2 m -165.91 166.15 17.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.86 0.362 . . . . 0.0 110.82 -179.76 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.407 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 5.6 mt-10 -88.32 119.99 29.26 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.867 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -120.03 116.44 25.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.85 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.42 ' HD3' ' CG2' ' A' ' 82' ' ' VAL . 46.5 mtmt -122.25 124.79 44.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.873 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 26.9 ttpt -172.53 107.95 0.19 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.919 179.882 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.482 ' CG1' ' N ' ' A' ' 99' ' ' THR . 7.1 tt -147.35 159.58 8.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.125 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.482 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 9.8 t -102.75 -34.23 9.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.13 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . 0.42 ' O ' ' ND1' ' A' ' 100' ' ' HIS . 1.7 p-80 -155.66 130.25 9.06 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.847 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . 0.411 ' CG ' HD13 ' A' ' 98' ' ' ILE . 11.6 m120 -101.71 97.72 8.41 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.61 0.719 . . . . 0.0 110.937 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.7 -31.06 21.54 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.698 2.265 . . . . 0.0 112.339 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -52.77 107.97 0.27 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.86 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -133.52 139.66 11.11 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.507 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 105.21 1.43 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.727 2.285 . . . . 0.0 112.38 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 122.97 -8.04 9.24 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.497 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.3 pt20 -132.97 153.85 51.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.83 0.348 . . . . 0.0 110.887 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -77.15 172.94 12.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.865 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 32.4 p90 -160.16 139.89 11.25 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.899 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -109.55 104.91 14.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.898 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.457 ' CD1' HD13 ' A' ' 113' ' ' ILE . 1.0 OUTLIER -105.51 138.17 42.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.919 -179.955 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 2.6 m -144.64 113.98 7.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.857 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.457 HD13 ' CD1' ' A' ' 111' ' ' LEU . 4.9 mp -95.32 131.62 41.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.116 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 15.7 mtp180 -106.38 128.01 53.71 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.842 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . 0.472 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 35.6 t -98.99 121.37 40.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.908 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -116.38 -138.13 6.22 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.477 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 9.7 mt -123.03 -31.38 3.63 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.806 0.336 . . . . 0.0 110.932 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . 0.423 ' C ' ' CD2' ' A' ' 134' ' ' HIS . 0.9 OUTLIER -96.66 -34.21 11.47 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.871 179.891 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 20.8 ptt-85 -172.91 171.48 4.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.472 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 4.1 m-30 -94.8 157.62 15.85 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.887 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 19.8 mtpp -130.49 99.77 5.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.891 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 42.2 t -84.46 133.97 28.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.131 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 81.5 m-85 -122.46 153.84 38.59 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.886 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . 0.435 ' O ' ' CG ' ' A' ' 125' ' ' ASN . . . -139.72 121.34 15.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.123 179.815 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.435 ' CG ' ' O ' ' A' ' 124' ' ' ALA . 10.7 p30 48.49 33.66 4.2 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.895 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.78 26.5 49.75 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.438 179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 37.0 mm-40 -129.76 168.02 17.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.842 0.353 . . . . 0.0 110.909 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 33.9 t-80 -91.16 116.09 28.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.829 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 9.0 tp -87.93 -68.32 0.77 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.957 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.49 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 3.9 p90 -168.68 172.21 8.15 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.862 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -115.43 156.73 25.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.853 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.526 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.2 OUTLIER -122.49 104.4 9.35 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.893 -179.94 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.514 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -60.08 134.13 56.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.13 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' HIS . . . . . 0.423 ' CD2' ' C ' ' A' ' 118' ' ' ASP . 25.7 m-70 -61.77 99.56 0.12 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.836 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.416 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 11.7 mtt-85 -82.12 -46.36 13.95 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 13.9 tp -97.55 113.67 25.42 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.906 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 90.8 p -56.05 -32.78 64.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.843 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . 0.412 ' CB ' ' HD2' ' A' ' 141' ' ' ARG . . . -85.69 37.88 0.72 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.061 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 4.7 p90 -56.13 -27.93 55.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.867 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' GLN . . . . . 0.465 ' HG2' ' N ' ' A' ' 141' ' ' ARG . 17.9 pm0 -63.48 -30.41 71.54 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.942 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.465 ' N ' ' HG2' ' A' ' 140' ' ' GLN . 22.5 mtt180 -65.38 -36.11 82.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.824 -179.866 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.465 ' CG2' ' HB2' ' A' ' 69' ' ' ALA . 90.5 t -56.55 105.0 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.119 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -126.01 35.7 4.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.879 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -144.58 137.98 27.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.138 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.509 HD11 ' CE2' ' A' ' 60' ' ' PHE . 5.0 tp -134.7 106.43 6.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.904 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' GLU . . . . . 0.411 ' HB3' ' CD1' ' A' ' 30' ' ' PHE . 4.9 pt-20 -109.22 149.16 29.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.934 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 12.7 mt -137.49 106.82 4.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.154 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -118.58 174.5 6.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.908 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 110.02 -140.81 15.99 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.482 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -117.86 91.92 3.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.811 0.338 . . . . 0.0 110.839 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.452 HG22 ' N ' ' A' ' 152' ' ' THR . 2.9 p -151.37 135.68 9.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.116 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' THR . . . . . 0.452 ' N ' HG22 ' A' ' 151' ' ' VAL . 17.7 m -95.93 92.82 6.68 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.171 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.475 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 93.3 mt -76.31 136.38 39.59 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.965 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 19.5 m -123.1 -39.27 2.5 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.858 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 37.3 t80 -141.81 127.07 18.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.905 -179.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 75.9 t -140.43 105.24 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.096 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -121.34 119.82 33.29 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.916 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 56.1 mt . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.107 -179.993 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.433 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.5 m . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.835 0.35 . . . . 0.0 111.127 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -137.35 120.18 16.35 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.907 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . 0.53 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 8.8 m120 60.27 49.03 1.94 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.57 0.7 . . . . 0.0 110.899 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.53 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.2 Cg_endo -69.82 141.75 45.8 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.646 2.23 . . . . 0.0 112.296 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -178.02 2.14 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.63 2.22 . . . . 0.0 112.387 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.531 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 96.6 t -142.35 137.89 16.01 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.651 0.739 . . . . 0.0 111.088 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.531 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.8 Cg_endo -69.78 145.23 78.87 Favored 'Cis proline' 0 C--O 1.232 0.192 0 C-N-CA 122.65 -1.812 . . . . 0.0 112.394 -0.057 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -97.52 123.03 41.24 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.885 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -107.74 102.79 11.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.853 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -108.5 110.66 3.12 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.508 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 9.0 mmt180 -73.14 113.36 10.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.87 0.366 . . . . 0.0 110.887 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 5.9 mt -73.25 97.9 2.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.909 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 20.6 mt-30 -66.79 94.76 0.32 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.885 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 135.69 -42.94 1.29 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.481 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.484 ' O ' ' NE ' ' A' ' 41' ' ' ARG . . . 96.23 170.13 34.85 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.423 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 96.1 mt -60.26 105.09 0.38 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.914 0.388 . . . . 0.0 110.913 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 38.2 p -117.31 158.76 23.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.119 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -64.32 -16.12 61.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.106 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -114.96 23.92 12.16 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.821 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.504 ' NH1' ' CG2' ' A' ' 158' ' ' ILE . 44.4 ttm-85 -112.6 135.35 53.42 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.869 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 92.3 m -133.16 126.1 30.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.166 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.447 HG22 ' N ' ' A' ' 44' ' ' ILE . 4.6 mp -95.44 138.86 20.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.166 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.447 ' N ' HG22 ' A' ' 43' ' ' ILE . 88.7 mt -128.91 126.67 65.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.13 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 58.5 mt -126.08 107.59 17.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.117 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 23.2 mtmt -112.05 112.43 24.06 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.883 179.849 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -143.69 -141.91 3.87 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.436 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 0.572 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.6 OUTLIER -169.28 124.03 0.84 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.931 0.396 . . . . 0.0 110.928 -179.775 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.453 HG22 ' CE2' ' A' ' 109' ' ' PHE . 14.1 t -75.35 116.39 54.17 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.651 0.738 . . . . 0.0 111.113 179.923 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 158.94 55.28 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.671 2.247 . . . . 0.0 112.355 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 -21.93 32.93 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.711 2.274 . . . . 0.0 112.393 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 24.4 p -105.88 18.88 21.44 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.142 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -110.2 117.71 4.81 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.44 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 29.2 mtpt -61.58 -60.04 4.3 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.797 0.332 . . . . 0.0 110.891 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 10.5 p -174.59 154.87 2.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.882 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.56 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 5.2 p90 -109.54 -173.48 2.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.881 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.24 143.9 20.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.123 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.515 HG22 ' CE1' ' A' ' 60' ' ' PHE . 2.8 mp -123.91 99.0 5.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.142 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.7 m-80 -99.0 143.71 28.98 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.934 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.577 ' CE2' HD12 ' A' ' 145' ' ' LEU . 15.8 m-85 -118.24 97.26 5.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.864 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.422 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 31.5 ttmt -96.66 169.77 9.65 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.906 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.426 HG13 ' C ' ' A' ' 141' ' ' ARG . 28.4 t -101.42 124.75 55.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.097 179.871 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -59.72 -36.21 88.95 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.51 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 23.1 t -67.21 -73.57 0.13 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.86 0.362 . . . . 0.0 110.857 -179.75 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 10.6 t -78.17 -72.48 0.37 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 -179.795 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 129.51 42.33 0.23 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.459 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -115.12 140.89 48.69 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.817 0.341 . . . . 0.0 110.84 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 55.2 mt -86.08 122.17 38.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.113 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -92.93 -31.8 14.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.087 179.831 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.565 HD22 ' CD2' ' A' ' 132' ' ' PHE . 40.0 tp -140.44 131.1 25.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.903 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.488 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.5 OUTLIER -134.1 92.31 2.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.863 179.862 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 55.7 mt -95.84 130.53 44.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.142 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.505 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -137.79 106.0 8.23 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.632 0.729 . . . . 0.0 110.905 179.924 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.56 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.3 Cg_endo -69.71 155.45 66.06 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.698 2.265 . . . . 0.0 112.394 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 39.3 mtp180 -130.67 96.11 4.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.868 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' MET . . . . . 0.436 ' HE3' ' CE1' ' A' ' 56' ' ' PHE . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.85 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.9 p . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.83 0.348 . . . . 0.0 111.112 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 20.6 t -99.67 108.38 22.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.169 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 47.3 t -76.95 143.1 13.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.133 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . 0.437 ' NH1' ' CD2' ' A' ' 130' ' ' PHE . 0.2 OUTLIER -126.93 129.87 49.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.873 -179.977 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.488 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.4 OUTLIER -140.6 179.65 6.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.905 -179.922 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 28.8 t -160.06 105.01 1.52 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.891 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.567 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 24.9 tp -76.92 118.29 19.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.93 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.51 ' N ' ' O ' ' A' ' 90' ' ' SER . 86.5 mt -95.8 161.63 13.94 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.901 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.512 ' C ' ' H ' ' A' ' 90' ' ' SER . 0.2 OUTLIER -38.64 101.81 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.911 179.931 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.33 -6.09 0.86 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.493 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.512 ' H ' ' C ' ' A' ' 88' ' ' ASN . 0.3 OUTLIER -118.47 169.24 9.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.879 0.371 . . . . 0.0 110.84 -179.705 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.567 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 20.5 m95 -128.39 161.29 29.81 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.939 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -93.96 -111.71 2.26 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.467 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' SER . . . . . 0.422 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 39.3 m -158.0 170.97 21.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.839 0.352 . . . . 0.0 110.844 -179.717 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -94.87 123.32 38.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.913 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -120.99 120.52 35.65 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.888 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 9.4 mtmp? -123.41 120.02 31.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.913 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -170.75 109.67 0.34 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.903 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.445 ' CG1' ' N ' ' A' ' 99' ' ' THR . 2.8 tt -148.84 154.2 10.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.127 179.86 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.445 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 9.0 t -93.95 -40.91 9.87 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.176 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 2.4 p-80 -147.18 128.44 14.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.865 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -103.32 95.62 7.23 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.652 0.739 . . . . 0.0 110.865 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.45 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.7 Cg_endo -69.79 -40.24 5.51 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.715 2.277 . . . . 0.0 112.324 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.458 ' CE2' ' HB3' ' A' ' 74' ' ' PRO . 8.1 m-85 -34.46 112.01 0.13 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.811 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -138.34 134.67 6.99 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.494 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 98.05 0.66 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.685 2.256 . . . . 0.0 112.337 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 126.01 -3.59 7.9 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.493 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.3 pt20 -132.46 149.39 52.34 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.806 0.336 . . . . 0.0 110.926 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' PHE . . . . . 0.572 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 79.8 m-85 -67.04 169.91 7.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.883 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.504 ' CD1' ' O ' ' A' ' 109' ' ' PHE . 19.6 p90 -161.1 120.02 2.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.847 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -96.6 107.13 19.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.895 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.416 ' CD1' HG12 ' A' ' 122' ' ' VAL . 0.6 OUTLIER -108.95 138.56 45.1 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.926 -179.921 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 3.7 m -145.27 115.4 7.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.854 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.1 mp -95.12 138.89 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.105 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 45.6 mtt-85 -113.19 123.74 50.92 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.874 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . 0.566 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 11.2 t -92.75 117.53 30.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.872 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.87 -142.41 7.83 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.468 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 17.4 mt -121.43 -35.99 3.16 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.788 0.328 . . . . 0.0 110.884 -179.9 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -92.32 -33.36 14.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.856 179.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -174.07 164.62 4.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.871 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.566 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 2.8 m-30 -90.52 156.8 17.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.921 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 23.2 mtpp -128.9 103.23 6.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.927 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . 0.416 HG12 ' CD1' ' A' ' 111' ' ' LEU . 46.3 t -92.7 127.95 44.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.121 179.92 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 14.7 m-85 -117.9 153.05 34.23 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.878 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -135.89 110.4 8.55 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.128 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 57.38 33.43 23.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.857 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 82.35 29.52 36.52 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.498 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 37.2 mm-40 -138.27 121.52 16.97 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.845 0.355 . . . . 0.0 110.907 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 26.4 t-80 -54.41 110.71 0.66 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.86 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 8.6 tp -76.81 -66.45 0.82 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.906 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.437 ' CD2' ' NH1' ' A' ' 83' ' ' ARG . 5.3 p90 -166.24 171.26 12.38 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.882 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -111.4 147.07 36.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.887 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.565 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -113.01 107.46 15.99 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.872 -179.872 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.557 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -64.0 130.95 46.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.132 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 33.7 m-70 -58.5 111.81 1.37 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.838 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.422 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 44.9 mtt-85 -96.08 -44.18 7.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.915 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 4.4 tp -100.96 109.35 21.26 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 97.4 p -49.37 -34.39 15.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . 0.464 ' HB3' ' CD ' ' A' ' 141' ' ' ARG . . . -83.27 31.53 0.45 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.086 179.893 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 3.9 p90 -50.44 -40.09 49.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.846 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 10.4 pt20 -52.87 -43.21 65.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.904 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.464 ' CD ' ' HB3' ' A' ' 138' ' ' ALA . 56.9 mtp85 -50.95 -42.76 60.04 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.874 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 97.1 t -44.35 106.12 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.121 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -130.43 29.44 4.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.838 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 25.4 m -139.92 112.65 7.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.124 -179.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.577 HD12 ' CE2' ' A' ' 60' ' ' PHE . 5.0 tp -110.54 108.03 17.86 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.929 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -111.67 153.59 26.18 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.858 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 16.9 mt -139.39 112.05 5.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.135 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -121.14 172.35 8.04 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.928 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 110.6 -142.47 16.71 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.452 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -117.49 93.57 4.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.88 0.371 . . . . 0.0 110.847 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.4 p -151.23 152.24 11.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.182 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 27.8 m -113.55 93.59 4.46 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.141 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.459 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 79.2 mt -73.03 141.4 47.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.94 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 50.1 m -125.83 -28.54 3.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.857 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 31.3 t80 -157.56 129.97 7.3 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 90.2 t -140.53 105.52 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.108 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 18.8 tt0 -121.13 140.56 51.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.855 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 158' ' ' ILE . . . . . 0.504 ' CG2' ' NH1' ' A' ' 41' ' ' ARG . 14.9 mt . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.092 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.421 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.9 m . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.83 0.347 . . . . 0.0 111.15 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -143.18 137.32 28.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.824 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . 0.549 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 9.0 m120 45.44 47.94 4.51 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.61 0.719 . . . . 0.0 110.93 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.549 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 54.1 Cg_endo -69.71 139.26 39.96 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.641 2.227 . . . . 0.0 112.375 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -177.62 1.95 Allowed 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.693 2.262 . . . . 0.0 112.304 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.52 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 84.2 t -143.7 136.73 13.82 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.592 0.711 . . . . 0.0 111.124 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.52 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.4 Cg_endo -69.71 145.37 79.12 Favored 'Cis proline' 0 C--N 1.341 0.153 0 C-N-CA 122.681 -1.799 . . . . 0.0 112.373 -0.091 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 4.9 t80 -98.34 115.26 28.07 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.937 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -99.44 103.1 14.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.901 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -118.09 102.16 0.95 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.488 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -73.45 128.47 35.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.843 0.354 . . . . 0.0 110.867 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.455 ' N ' ' O ' ' A' ' 143' ' ' ASP . 3.3 mt -74.0 150.25 40.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.885 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 10.6 mm100 -105.24 99.67 9.27 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.913 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 124.46 -55.92 0.7 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.488 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 119.47 169.65 14.3 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.515 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 87.5 mt -61.04 97.91 0.07 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.87 0.367 . . . . 0.0 110.953 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 48.4 p -109.5 160.73 15.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.159 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -58.1 -28.6 64.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.084 179.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 3.1 mpt_? -105.96 39.1 1.85 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.863 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 29.5 ttm-85 -117.76 137.62 52.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.872 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 93.6 m -138.41 120.84 16.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.155 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 4.7 mp -94.35 134.99 29.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.148 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 93.3 mt -125.24 138.41 54.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.116 179.839 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 42.9 mt -138.92 107.65 3.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.103 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 8.6 mtmm -110.04 111.32 22.62 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.924 179.823 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -142.23 -143.14 4.16 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.478 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 0.559 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 1.1 t80 -170.0 128.66 0.91 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.949 0.404 . . . . 0.0 110.91 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 4.4 t -80.41 115.96 58.55 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.624 0.726 . . . . 0.0 111.143 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.74 155.81 65.04 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.672 2.248 . . . . 0.0 112.369 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 -14.07 35.44 Favored 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.689 2.259 . . . . 0.0 112.33 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 46.8 p -112.24 15.91 20.25 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.107 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -112.06 118.88 4.85 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.491 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 14.1 mtpp -58.09 -62.78 1.57 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.77 0.319 . . . . 0.0 110.859 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 70.1 p -173.71 164.45 4.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.872 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.574 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 5.2 p90 -119.02 -173.27 2.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.879 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.56 138.73 15.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.105 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.7 mp -117.61 104.61 16.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.121 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 2.8 m-80 -105.24 147.94 27.51 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.883 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.521 ' CE2' HD12 ' A' ' 145' ' ' LEU . 2.4 m-85 -120.89 101.22 7.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.885 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.417 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 34.5 ttmt -95.78 167.26 11.37 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.901 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.466 HG22 ' N ' ' A' ' 142' ' ' VAL . 94.2 t -100.27 121.09 50.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.097 179.889 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -57.0 -41.2 92.27 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.481 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 10.8 t -62.18 -72.2 0.13 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.885 0.374 . . . . 0.0 110.89 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.4 t -80.56 -71.04 0.48 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.878 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 128.26 42.48 0.25 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.507 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . 0.406 ' OD1' ' OD1' ' A' ' 88' ' ' ASN . 1.5 m-20 -115.02 144.14 44.08 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.824 0.345 . . . . 0.0 110.856 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 42.8 mt -88.74 122.59 40.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.145 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.461 ' HB3' ' CG2' ' A' ' 142' ' ' VAL . . . -92.82 -34.77 13.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.134 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.56 HD22 ' CD2' ' A' ' 132' ' ' PHE . 30.3 tp -139.17 130.4 26.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.928 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.473 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.2 OUTLIER -134.81 92.14 2.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.83 179.914 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.438 ' CG2' HG11 ' A' ' 81' ' ' VAL . 16.0 mt -94.25 137.61 22.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.111 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.5 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 1.0 OUTLIER -141.86 106.17 5.81 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.619 0.723 . . . . 0.0 110.923 179.949 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.574 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.8 Cg_endo -69.75 154.87 67.26 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.677 2.251 . . . . 0.0 112.302 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 63.7 mtt-85 -129.78 100.76 5.6 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.854 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.92 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 20.7 p . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.803 0.335 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.438 HG11 ' CG2' ' A' ' 72' ' ' ILE . 18.5 t -86.59 111.01 20.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.121 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 61.4 t -82.84 139.81 17.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.097 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -126.94 124.46 39.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.865 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.473 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.5 OUTLIER -135.11 -178.15 4.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.885 -179.909 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 47.5 t -160.16 105.02 1.5 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.867 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.552 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 38.1 tp -77.09 116.71 17.98 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.932 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.518 ' N ' ' O ' ' A' ' 90' ' ' SER . 86.4 mt -94.84 162.07 13.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.9 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.428 ' C ' ' H ' ' A' ' 90' ' ' SER . 9.7 m-80 -40.88 102.0 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.86 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.49 -1.39 3.11 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.516 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.518 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -125.62 171.59 10.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.886 0.374 . . . . 0.0 110.841 -179.74 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.552 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 22.1 m95 -128.74 158.64 38.06 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.877 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -88.75 -96.3 1.02 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.427 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 2.0 m -174.68 164.76 3.66 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.894 0.378 . . . . 0.0 110.841 -179.711 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 14.2 mp0 -88.63 118.5 28.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.878 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 72.4 mm-40 -116.09 121.03 40.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.897 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 7.0 mtmp? -125.58 118.67 26.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.86 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -169.66 108.16 0.4 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.873 179.835 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.413 HD12 ' CD1' ' A' ' 129' ' ' LEU . 10.5 tt -147.89 151.19 13.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.132 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.9 t -91.64 -43.92 9.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.168 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . 0.413 ' O ' ' ND1' ' A' ' 100' ' ' HIS . 2.0 p-80 -145.0 127.58 16.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.896 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 38.6 t-20 -104.74 98.49 15.21 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.633 0.73 . . . . 0.0 110.835 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.404 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.8 Cg_endo -69.81 -37.14 9.45 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.674 2.25 . . . . 0.0 112.331 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.515 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 20.9 m-85 -37.96 112.83 0.24 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.892 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -137.92 137.98 9.26 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.468 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 100.21 0.81 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.69 2.26 . . . . 0.0 112.303 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 120.85 0.9 11.84 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.457 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -135.22 148.6 49.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.815 0.34 . . . . 0.0 110.93 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' PHE . . . . . 0.559 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 76.8 m-85 -68.23 171.08 7.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.822 -179.892 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 28.1 p90 -161.26 124.79 3.29 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.903 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -99.45 104.5 16.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.871 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.449 ' CD1' HD11 ' A' ' 113' ' ' ILE . 0.6 OUTLIER -104.68 136.83 43.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.903 -179.945 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 3.6 m -145.03 113.64 6.72 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.828 -179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.449 HD11 ' CD1' ' A' ' 111' ' ' LEU . 4.4 mp -96.56 137.22 24.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.111 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . 0.497 ' O ' ' CD2' ' A' ' 120' ' ' PHE . 18.2 mtp180 -110.11 138.12 46.92 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.852 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . 0.471 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 17.7 t -105.13 120.11 40.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.917 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -115.02 -140.55 7.23 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.447 -179.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.5 mt -117.53 -38.08 3.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.785 0.326 . . . . 0.0 110.895 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . 0.58 ' O ' ' CD2' ' A' ' 134' ' ' HIS . 20.3 t70 -89.79 -45.69 9.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.895 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.431 ' HG3' ' C ' ' A' ' 118' ' ' ASP . 32.3 mtp180 -157.56 -177.07 6.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.879 -179.903 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.497 ' CD2' ' O ' ' A' ' 114' ' ' ARG . 12.4 m-85 -103.32 162.09 13.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.876 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 21.4 mtpp -134.26 105.15 6.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.906 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 57.8 t -90.44 136.48 23.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.1 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -124.85 143.57 50.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.955 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -131.13 106.93 8.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.039 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 59.1 35.83 23.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.918 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.69 40.55 17.76 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.448 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 18.9 mt-30 -146.84 135.64 22.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.868 0.366 . . . . 0.0 110.919 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 40.8 t-80 -66.77 100.75 0.73 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.89 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . 0.413 ' CD1' HD12 ' A' ' 98' ' ' ILE . 10.2 tp -69.1 -68.58 0.39 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.875 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.482 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 4.4 p90 -164.02 171.3 15.4 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.845 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 24.1 p-10 -110.65 158.79 18.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.906 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.56 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -129.86 104.49 7.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.85 -179.883 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.555 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -62.99 135.71 57.44 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.04 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' HIS . . . . . 0.58 ' CD2' ' O ' ' A' ' 118' ' ' ASP . 29.9 m-70 -62.82 108.22 1.14 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.859 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 4.9 mtp-105 -88.37 -48.71 7.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.891 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 8.5 tp -94.06 108.1 19.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.913 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 14.7 t -47.31 -36.0 8.71 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -83.47 33.32 0.46 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.101 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 28.5 p90 -50.05 -36.12 27.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.872 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 6.1 pt20 -53.45 -46.4 69.86 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.904 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.41 ' C ' HG13 ' A' ' 62' ' ' VAL . 31.5 mtt180 -49.7 -41.78 44.22 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.859 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.466 ' N ' HG22 ' A' ' 62' ' ' VAL . 61.9 t -48.71 100.3 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.138 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.455 ' O ' ' N ' ' A' ' 33' ' ' LEU . 3.9 p30 -124.95 26.24 7.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.906 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -132.1 131.72 42.62 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.142 -179.848 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.521 HD12 ' CE2' ' A' ' 60' ' ' PHE . 4.8 tp -128.82 104.85 7.86 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.922 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -108.88 151.57 26.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.904 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 15.5 mt -136.82 118.23 18.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.127 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -128.65 173.43 10.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.891 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.41 -151.34 16.91 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.519 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -107.23 92.75 4.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.855 0.36 . . . . 0.0 110.845 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.414 HG22 ' N ' ' A' ' 152' ' ' THR . 7.7 p -151.19 154.88 7.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.094 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' THR . . . . . 0.414 ' N ' HG22 ' A' ' 151' ' ' VAL . 23.3 m -114.83 93.91 4.53 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.151 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 50.1 mt -79.25 132.83 36.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.911 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 14.7 m -117.42 -40.88 3.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.851 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 59.7 t80 -140.37 130.13 24.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.947 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 89.8 t -140.53 105.15 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.092 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 13.8 tt0 -120.81 121.93 39.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.958 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 14.9 mt . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.169 179.957 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.558 ' CG2' ' N ' ' A' ' 23' ' ' PHE . 1.9 m . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.786 0.327 . . . . 0.0 111.163 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.558 ' N ' ' CG2' ' A' ' 22' ' ' THR . 11.9 m-85 -156.01 135.95 12.75 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.908 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ASN . . . . . 0.544 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 72.3 m-20 42.9 48.42 3.7 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.645 0.736 . . . . 0.0 110.927 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.544 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.6 Cg_endo -69.74 137.96 36.75 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.709 2.273 . . . . 0.0 112.301 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -176.11 1.38 Allowed 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.646 2.231 . . . . 0.0 112.334 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.522 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 98.4 t -142.97 137.87 15.33 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.668 0.747 . . . . 0.0 111.109 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.522 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 54.0 Cg_endo -69.75 145.58 79.8 Favored 'Cis proline' 0 C--O 1.232 0.179 0 C-N-CA 122.71 -1.787 . . . . 0.0 112.342 -0.02 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 13.3 t80 -96.87 121.17 38.44 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.946 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -101.79 101.46 11.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.865 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -98.96 109.94 3.89 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.526 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 4.1 mmm180 -72.87 99.51 2.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.866 0.365 . . . . 0.0 110.877 -179.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 27.6 mt -66.94 93.05 0.25 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.905 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 18.7 mp0 -67.99 93.69 0.44 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.938 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.75 -37.77 1.9 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.501 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 91.19 175.07 43.71 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.454 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . 0.462 ' CD1' ' HB ' ' A' ' 142' ' ' VAL . 78.4 mt -65.4 93.43 0.15 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.859 0.361 . . . . 0.0 110.911 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 44.0 p -105.33 154.56 20.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.136 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -49.84 -30.61 10.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.061 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 2.6 mpt_? -105.13 34.93 2.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.875 -179.873 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 5.0 tpm_? -108.03 135.15 49.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 -179.878 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 85.3 m -136.87 116.35 12.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.193 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.0 mp -91.69 135.81 26.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.176 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.416 HG22 ' N ' ' A' ' 45' ' ' ILE . 96.8 mt -127.38 132.95 68.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.116 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.416 ' N ' HG22 ' A' ' 44' ' ' ILE . 50.7 mt -134.9 107.57 8.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.092 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 16.0 mtmt -111.2 111.4 22.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.864 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -142.88 -140.7 3.75 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.544 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 0.557 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.4 OUTLIER -172.08 119.95 0.43 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.937 0.399 . . . . 0.0 110.941 -179.8 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 40.5 t -69.16 117.09 48.7 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.638 0.732 . . . . 0.0 111.15 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 154.98 67.25 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.69 2.26 . . . . 0.0 112.333 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.72 -16.11 37.55 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.693 2.262 . . . . 0.0 112.358 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 70.6 p -110.41 18.6 19.66 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.122 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -113.54 123.23 6.06 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.465 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.403 ' O ' ' SD ' ' A' ' 76' ' ' MET . 22.2 mttt -63.03 -61.67 2.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.778 0.323 . . . . 0.0 110.859 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.8 p -174.03 157.9 3.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.886 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.574 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 12.3 p90 -111.16 -174.64 2.51 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.864 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -157.05 130.5 8.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.12 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 5.3 mp -112.91 101.78 12.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.11 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -101.2 143.59 31.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.913 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.553 ' CE2' HD12 ' A' ' 145' ' ' LEU . 16.0 m-85 -115.26 97.99 6.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.869 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.445 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 35.8 ttmt -96.79 167.88 10.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.886 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.448 ' CG2' HG22 ' A' ' 142' ' ' VAL . 59.1 t -100.94 123.88 54.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.089 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -59.79 -39.74 95.75 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.455 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 7.6 t -62.93 -70.67 0.19 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.868 0.366 . . . . 0.0 110.867 -179.728 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 60.0 m -82.33 -71.43 0.49 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.863 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 128.32 42.68 0.24 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.451 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . 0.425 ' OD2' ' ND2' ' A' ' 88' ' ' ASN . 3.9 m-20 -112.78 143.7 43.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.81 0.338 . . . . 0.0 110.847 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 66.6 mt -89.1 113.35 25.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.135 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.433 ' O ' ' CB ' ' A' ' 85' ' ' SER . . . -81.75 -39.3 24.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.105 179.836 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.559 HD12 ' CD1' ' A' ' 132' ' ' PHE . 48.1 tp -136.82 134.53 37.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.964 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.495 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.4 OUTLIER -134.89 97.03 3.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.894 179.877 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 27.0 mt -101.26 133.56 44.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.134 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.503 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -140.53 106.51 6.5 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.674 0.749 . . . . 0.0 110.905 179.961 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.574 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.0 Cg_endo -69.67 154.7 67.76 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.713 2.275 . . . . 0.0 112.347 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 36.7 mtp180 -130.6 94.99 3.76 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.932 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' MET . . . . . 0.407 ' HE2' ' CE1' ' A' ' 56' ' ' PHE . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.846 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 49.2 p . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.828 0.347 . . . . 0.0 111.142 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 14.1 t -99.8 110.45 26.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.132 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.405 HG13 ' N ' ' A' ' 83' ' ' ARG . 32.7 t -82.52 144.78 9.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.13 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . 0.405 ' N ' HG13 ' A' ' 82' ' ' VAL . 0.0 OUTLIER -126.86 124.17 38.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.864 -179.986 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.495 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.3 m120 -136.32 178.59 6.94 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.914 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.433 ' CB ' ' O ' ' A' ' 69' ' ' ALA . 78.1 p -158.69 105.55 1.83 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.864 -179.84 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.581 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 28.3 tp -78.06 117.34 19.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.917 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.532 ' N ' ' O ' ' A' ' 90' ' ' SER . 86.0 mt -95.38 162.54 13.62 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.936 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.426 ' C ' ' H ' ' A' ' 90' ' ' SER . 11.0 m-80 -40.97 102.14 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.878 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.35 -2.47 3.14 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.492 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.532 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -124.63 170.54 10.85 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.81 0.338 . . . . 0.0 110.85 -179.72 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.581 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 21.8 m95 -128.1 160.73 31.08 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.936 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -89.53 -100.31 1.06 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.487 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 16.4 m -172.4 167.97 5.57 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.819 0.343 . . . . 0.0 110.849 -179.753 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -89.99 121.85 32.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.904 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -122.22 115.33 22.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.88 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 9.9 mtmp? -119.68 119.79 34.73 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.904 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' LYS . . . . . 0.46 ' HE3' ' N ' ' A' ' 98' ' ' ILE . 0.0 OUTLIER -173.9 105.11 0.12 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.866 179.846 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . 0.46 ' N ' ' HE3' ' A' ' 97' ' ' LYS . 1.9 tt -141.76 149.86 19.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.172 179.862 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.425 HG23 ' N ' ' A' ' 100' ' ' HIS . 4.7 t -84.45 -41.06 16.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.084 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . 0.425 ' N ' HG23 ' A' ' 99' ' ' THR . 28.9 p80 -153.09 133.62 13.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.835 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' ASN . . . . . 0.407 ' OD1' ' C ' ' A' ' 101' ' ' ASN . 7.2 t-20 -103.47 95.84 7.74 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.597 0.713 . . . . 0.0 110.888 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.447 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.7 Cg_endo -69.77 -41.3 4.38 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.675 2.25 . . . . 0.0 112.368 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . 0.534 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 10.2 m-85 -34.17 104.66 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.881 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -127.85 137.16 9.61 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.695 -0.765 . . . . 0.0 112.451 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 97.25 0.62 Allowed 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.715 2.277 . . . . 0.0 112.325 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 118.39 3.53 14.58 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.513 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 17.5 pt20 -133.73 137.82 45.44 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.819 0.343 . . . . 0.0 110.906 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' PHE . . . . . 0.557 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 79.7 m-85 -61.34 166.35 3.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.882 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 17.9 p90 -158.45 130.58 6.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.886 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -103.68 104.62 14.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.877 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' LEU . . . . . 0.468 ' CD1' HD12 ' A' ' 113' ' ' ILE . 0.7 OUTLIER -105.09 136.5 44.46 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.948 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 3.8 m -145.15 113.49 6.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.864 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.468 HD12 ' CD1' ' A' ' 111' ' ' LEU . 4.0 mp -95.47 140.05 17.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.142 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 15.6 mtp85 -112.78 137.63 50.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.899 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . 0.575 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 2.9 t -110.03 114.47 28.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.874 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -113.77 -136.03 6.29 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.496 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 12.2 mt -121.52 -39.06 2.69 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.829 0.347 . . . . 0.0 110.924 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 23.2 p-10 -85.63 -37.26 19.69 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.88 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.8 ptp180 -173.66 172.62 3.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.875 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.575 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.7 m-30 -93.32 155.06 17.63 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.887 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 26.6 mtpt -128.99 102.12 6.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.898 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 51.5 t -89.27 136.77 22.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.105 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 57.9 m-85 -120.29 152.95 37.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.958 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -136.55 107.12 6.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.097 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 53.56 35.61 21.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.929 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 84.09 29.26 31.67 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.477 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 20.0 mm-40 -140.77 119.53 12.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.819 0.342 . . . . 0.0 110.931 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 35.5 t-80 -52.06 103.85 0.07 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.846 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 10.6 tp -67.12 -67.71 0.43 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.923 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.441 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 6.0 p90 -163.67 177.02 9.06 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.86 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 41.1 p30 -118.02 149.92 40.16 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.851 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.559 ' CD1' HD12 ' A' ' 70' ' ' LEU . 0.2 OUTLIER -117.17 107.02 13.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.872 -179.937 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . 0.525 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -62.41 133.56 55.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.099 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 29.7 m-70 -60.03 110.84 1.29 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.811 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.4 ' CD ' ' OG ' ' A' ' 85' ' ' SER . 10.0 mtt-85 -93.93 -51.5 4.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.878 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 6.8 tp -96.06 108.39 20.8 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.906 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 27.1 t -49.44 -33.33 13.87 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.862 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . 0.438 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.45 25.76 0.6 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.073 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.406 ' CG ' ' N ' ' A' ' 140' ' ' GLN . 19.3 p90 -45.49 -41.78 9.96 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.895 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' GLN . . . . . 0.406 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 5.7 pt20 -49.75 -41.0 42.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.885 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.438 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 57.0 mtp180 -55.48 -39.74 70.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.874 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.462 ' HB ' ' CD1' ' A' ' 37' ' ' LEU . 85.6 t -48.11 106.8 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.14 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -131.81 34.08 3.91 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.867 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 16.2 m -141.38 115.32 9.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.167 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.553 HD12 ' CE2' ' A' ' 60' ' ' PHE . 5.2 tp -113.66 107.96 16.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.91 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 -113.0 150.7 31.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.896 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 17.0 mt -138.29 106.94 3.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.115 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -115.42 173.33 6.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.915 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.57 -146.37 16.22 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.469 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 46.7 m-20 -112.27 92.56 4.07 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.852 0.358 . . . . 0.0 110.843 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.461 HG23 ' N ' ' A' ' 152' ' ' THR . 5.8 p -151.28 138.06 12.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.124 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' THR . . . . . 0.461 ' N ' HG23 ' A' ' 151' ' ' VAL . 33.7 m -99.62 93.92 6.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.134 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.443 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 68.8 mt -74.88 137.85 42.06 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.903 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 20.5 m -119.76 -39.28 2.86 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.878 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . 0.472 ' CE1' ' HB2' ' A' ' 157' ' ' GLN . 43.6 t80 -148.07 135.45 20.55 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.938 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 70.8 t -140.18 109.42 3.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.141 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . 0.472 ' HB2' ' CE1' ' A' ' 155' ' ' TYR . 14.7 tt0 -121.47 136.57 54.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.902 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 18.6 mt . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.065 -179.955 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 112.471 -0.252 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.2 m -158.13 138.23 12.42 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.85 0.357 . . . . 0.0 110.883 -179.74 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 39.2 m -129.96 161.94 29.79 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.855 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 91.76 140.09 9.02 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.48 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.3 m -160.43 137.53 9.22 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.832 0.349 . . . . 0.0 110.865 -179.708 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 44.2 t -66.24 -52.56 46.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.84 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 47.84 95.55 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.518 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 34.1 p-80 -132.49 101.13 5.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.763 0.316 . . . . 0.0 110.88 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -49.44 -41.05 38.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.89 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 27.1 mt-30 -150.83 122.21 7.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.957 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 5.2 mp -50.67 124.54 11.12 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.928 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.8 m120 -144.8 176.13 9.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.926 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 60.9 p -108.67 143.7 37.41 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.876 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 3.4 pp -59.76 154.68 45.6 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.615 0.721 . . . . 0.0 110.9 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.72 -176.57 1.52 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.686 2.257 . . . . 0.0 112.337 179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 7.0 t -63.87 159.95 18.59 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.132 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' MET . . . . . 0.47 ' HE3' ' N ' ' A' ' 32' ' ' ARG . 17.7 mtm -98.76 43.53 1.06 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.872 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -79.91 -179.06 6.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.913 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 84.84 -156.78 31.71 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.474 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 169.49 18.82 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.653 2.235 . . . . 0.0 112.363 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.457 ' HB2' ' CE2' ' A' ' 155' ' ' TYR . 54.0 Cg_endo -69.8 160.68 48.81 Favored 'Trans proline' 0 C--O 1.232 0.213 0 C-N-CA 122.68 2.253 . . . . 0.0 112.334 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 2.3 t -78.77 148.29 33.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.147 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -129.61 120.78 25.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . 0.48 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 12.4 m120 61.78 52.18 2.19 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.616 0.722 . . . . 0.0 110.907 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.48 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.2 Cg_endo -69.81 138.67 38.23 Favored 'Trans proline' 0 N--CA 1.466 -0.13 0 C-N-CA 122.705 2.27 . . . . 0.0 112.328 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 178.7 4.3 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.633 2.222 . . . . 0.0 112.357 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.528 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 95.4 t -138.09 138.24 22.83 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.658 0.742 . . . . 0.0 111.115 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.528 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.7 Cg_endo -69.7 143.61 74.22 Favored 'Cis proline' 0 C--N 1.342 0.193 0 C-N-CA 122.741 -1.774 . . . . 0.0 112.345 -0.083 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 2.2 t80 -95.82 116.68 29.27 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.886 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 72.3 m-85 -100.15 105.31 16.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.844 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -118.21 103.33 1.03 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.507 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.47 ' N ' ' HE3' ' A' ' 17' ' ' MET . 0.0 OUTLIER -72.44 135.4 45.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.84 0.352 . . . . 0.0 110.876 -179.837 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 4.9 mt -82.73 119.12 23.92 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.928 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 25.2 mt-30 -74.09 94.97 2.48 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.887 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 124.31 -55.81 0.7 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.483 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 120.37 176.3 15.69 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.51 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . 0.431 ' CD1' ' HB ' ' A' ' 142' ' ' VAL . 82.5 mt -62.6 101.37 0.24 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.936 0.398 . . . . 0.0 110.896 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.502 ' O ' ' N ' ' A' ' 41' ' ' ARG . 44.9 p -120.77 137.89 54.29 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.202 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -41.97 -23.39 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.119 179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.444 ' N ' ' O ' ' A' ' 38' ' ' THR . 20.9 mmt180 -104.62 34.13 3.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.866 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.502 ' N ' ' O ' ' A' ' 38' ' ' THR . 4.6 ttt85 -121.05 139.86 52.74 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.931 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 85.9 m -137.66 117.55 13.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.154 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.1 mp -90.68 133.98 30.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.146 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 94.7 mt -127.55 134.33 65.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.123 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 48.5 mt -135.57 107.63 7.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.142 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.5 mtmt -109.35 108.19 18.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.917 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.52 -145.72 4.68 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.49 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 0.545 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.7 OUTLIER -167.55 129.13 1.53 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.9 0.381 . . . . 0.0 110.912 -179.803 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 13.7 t -77.34 115.5 49.72 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.619 0.723 . . . . 0.0 111.116 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 155.54 65.7 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.681 2.254 . . . . 0.0 112.354 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -15.69 37.11 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.683 2.255 . . . . 0.0 112.344 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 52.8 p -109.65 14.2 23.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.13 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -111.22 122.82 6.25 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.523 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 17.5 mtpt -63.96 -60.21 3.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.798 0.332 . . . . 0.0 110.867 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.5 p -174.21 158.75 3.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.89 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.537 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 2.4 p90 -112.57 -173.72 2.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.851 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.469 ' CB ' ' OD1' ' A' ' 73' ' ' ASN . . . -155.56 135.57 12.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.157 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.6 mp -115.85 103.7 15.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.132 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.3 m-80 -104.41 143.13 33.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.904 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.519 ' CE2' HD13 ' A' ' 145' ' ' LEU . 6.7 m-85 -115.66 101.36 8.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.875 -179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.406 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 30.3 ttmt -95.33 169.08 10.32 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.89 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.478 ' CG2' HG21 ' A' ' 142' ' ' VAL . 35.0 t -100.24 123.73 53.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.136 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -60.59 -34.25 85.27 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.498 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.9 t -68.5 -71.54 0.21 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.926 0.393 . . . . 0.0 110.87 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 3.3 t -83.7 -71.34 0.51 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.856 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 131.6 40.82 0.22 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.5 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.412 ' OD1' ' OD1' ' A' ' 88' ' ' ASN . 1.9 m-20 -110.87 143.11 41.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.776 0.322 . . . . 0.0 110.853 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 39.2 mt -88.9 119.2 35.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.113 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.425 ' CB ' HG23 ' A' ' 142' ' ' VAL . . . -91.57 -33.12 15.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.109 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.56 HD22 ' CD2' ' A' ' 132' ' ' PHE . 52.5 tp -138.46 130.0 27.66 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.939 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.489 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.2 OUTLIER -134.82 92.71 2.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.844 179.891 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 29.0 mt -96.25 134.98 31.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.146 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.503 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -140.33 107.76 6.7 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.596 0.712 . . . . 0.0 110.863 179.946 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.537 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.8 Cg_endo -69.79 154.87 67.1 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.665 2.243 . . . . 0.0 112.338 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 45.3 mtp85 -130.4 98.0 4.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.909 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' MET . . . . . 0.48 ' HE1' ' CE1' ' A' ' 56' ' ' PHE . 0.0 OUTLIER -61.28 -39.99 92.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.878 179.967 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -60.63 -91.27 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.493 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 56.6 t30 -50.28 -56.41 11.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.933 0.397 . . . . 0.0 110.896 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 112.53 37.79 1.4 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.53 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 32.4 p -137.64 122.23 18.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.802 0.334 . . . . 0.0 111.122 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 36.0 t -91.44 108.54 20.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.136 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 48.7 t -79.93 146.69 7.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.11 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -128.87 130.21 46.57 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.845 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.489 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.9 OUTLIER -142.45 179.62 6.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.928 -179.971 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 89.5 p -157.99 107.25 2.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.901 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.561 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 27.6 tp -76.98 117.86 18.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.926 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.505 ' N ' ' O ' ' A' ' 90' ' ' SER . 82.7 mt -95.1 162.3 13.77 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.927 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.422 ' C ' ' H ' ' A' ' 90' ' ' SER . 11.7 m-80 -41.1 102.14 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.855 179.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.89 -1.49 3.37 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.51 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.505 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -125.63 172.49 9.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.839 0.352 . . . . 0.0 110.84 -179.722 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.561 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 25.0 m95 -129.4 160.67 32.37 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.932 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -90.34 -104.18 1.21 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.507 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 39.2 m -165.56 171.92 12.6 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.834 0.35 . . . . 0.0 110.852 -179.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -95.54 120.8 36.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.92 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 60.3 mt-10 -120.07 122.21 40.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.845 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 7.6 mtmp? -126.29 122.23 34.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.873 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 10.4 tptp -171.89 105.87 0.2 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.895 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 2.0 tt -146.59 149.9 15.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.129 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 9.2 t -91.65 -41.39 10.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.149 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 2.6 p-80 -144.06 131.64 21.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.834 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 24.7 t30 -109.21 96.52 21.89 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.632 0.73 . . . . 0.0 110.881 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.44 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.8 Cg_endo -69.78 -41.27 4.39 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.648 2.232 . . . . 0.0 112.305 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.44 ' C ' ' O ' ' A' ' 102' ' ' PRO . 6.2 m-85 -35.33 108.65 0.07 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.898 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -137.14 138.77 10.02 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.48 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 103.12 1.11 Allowed 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.689 2.26 . . . . 0.0 112.38 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 119.95 -2.32 13.24 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.541 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.3 pt20 -134.03 147.62 50.97 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.857 0.361 . . . . 0.0 110.902 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' PHE . . . . . 0.545 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 29.6 m-85 -67.21 172.82 4.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.877 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.422 ' O ' ' CG ' ' A' ' 109' ' ' PHE . 14.4 p90 -161.33 124.25 3.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.867 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -99.08 105.09 17.16 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.837 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.445 ' CD1' HD13 ' A' ' 113' ' ' ILE . 0.7 OUTLIER -105.18 136.89 43.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.92 -179.98 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 3.4 m -144.8 113.63 6.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.847 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.445 HD13 ' CD1' ' A' ' 111' ' ' LEU . 4.7 mp -96.68 135.43 30.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.147 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 40.0 mtt180 -108.51 126.26 52.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.886 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . 0.524 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 11.7 t -93.06 120.42 33.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.902 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -122.31 -159.8 10.73 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.511 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.437 ' O ' ' CD2' ' A' ' 134' ' ' HIS . 7.8 mt -101.83 -42.3 6.2 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.838 0.351 . . . . 0.0 110.943 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -82.19 -37.1 26.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.883 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.1 ptt180 -173.5 -178.2 1.61 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.889 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.524 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.2 m-30 -102.48 158.52 16.16 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.892 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 24.2 mtpt -132.13 104.86 7.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.921 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 60.6 t -90.98 133.58 32.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.125 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 74.7 m-85 -121.69 146.96 46.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.938 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -133.27 107.98 8.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.133 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 55.04 39.5 31.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.885 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.12 36.73 34.43 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.451 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 22.6 mt-30 -143.93 123.65 13.36 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.848 0.356 . . . . 0.0 110.898 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 32.6 t-80 -57.79 95.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.863 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 9.4 tp -60.88 -68.75 0.28 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.929 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.473 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 4.5 p90 -164.96 175.87 9.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.903 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -116.32 155.74 27.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.894 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.56 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.2 OUTLIER -122.38 104.58 9.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.847 -179.874 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.531 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -60.6 134.8 57.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.077 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' HIS . . . . . 0.437 ' CD2' ' O ' ' A' ' 117' ' ' LEU . 18.4 m-70 -62.4 98.8 0.12 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.894 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 17.6 mtt-85 -81.47 -47.59 12.97 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.842 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 7.8 tp -98.72 107.8 20.33 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.924 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 15.0 m -49.35 -33.19 12.9 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.839 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . 0.449 ' HB2' ' CD ' ' A' ' 141' ' ' ARG . . . -83.3 27.67 0.57 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.122 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.44 ' CG ' ' N ' ' A' ' 140' ' ' GLN . 17.6 p90 -47.21 -44.29 22.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.892 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' GLN . . . . . 0.44 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 9.2 pt20 -46.24 -40.63 11.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.931 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.449 ' CD ' ' HB2' ' A' ' 138' ' ' ALA . 16.1 mtp180 -54.33 -41.71 69.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.875 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.478 HG21 ' CG2' ' A' ' 62' ' ' VAL . 88.7 t -50.3 104.72 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.167 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -127.38 28.83 5.64 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.877 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.3 m -137.67 131.96 32.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.168 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.519 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.4 tp -128.47 109.09 11.09 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.944 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 -112.3 152.31 28.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.901 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 19.8 mt -137.47 113.54 11.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.135 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -123.06 174.19 7.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.954 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.4 -144.5 15.99 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.512 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -114.71 92.1 3.84 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.871 0.367 . . . . 0.0 110.845 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.438 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 5.1 p -151.04 142.77 16.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.134 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 25.8 m -102.37 93.25 5.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.163 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.448 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 95.9 mt -74.31 136.73 42.58 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.899 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 5.1 m -117.18 -39.36 3.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.871 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . 0.457 ' CE2' ' HB2' ' A' ' 21' ' ' PRO . 7.4 t80 -147.35 130.93 16.81 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.917 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 65.8 t -140.77 124.48 17.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.138 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 12.8 tt0 -148.85 132.95 17.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.908 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 5.1 mp -92.82 88.61 2.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.152 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 20.2 m -55.66 131.04 45.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.81 -179.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -129.03 -157.57 9.3 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.449 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -1.38 8.38 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.694 2.263 . . . . 0.0 112.328 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 29.9 t -44.73 -63.74 0.85 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.844 -179.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 28.8 t -59.77 115.76 3.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.871 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.487 -179.992 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 63.2 p -153.94 156.16 36.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.874 0.368 . . . . 0.0 110.845 -179.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.7 t -109.72 125.71 52.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.875 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -157.8 173.83 35.13 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.49 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.1 t -157.22 155.1 30.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.907 0.384 . . . . 0.0 110.86 -179.764 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 30.9 t -137.95 148.42 45.23 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.813 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.61 -140.53 4.86 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.461 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 30.3 m170 -115.13 145.21 42.58 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.762 0.315 . . . . 0.0 110.868 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 50.8 mt-30 -146.52 143.87 29.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.917 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -54.25 155.08 3.95 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.916 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -101.94 -37.05 8.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.92 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -56.87 -45.58 82.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.882 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 42.2 p -164.63 128.09 2.44 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.848 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 4.2 pp -68.62 153.42 95.83 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.568 0.699 . . . . 0.0 110.93 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -164.91 0.14 Allowed 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.657 2.238 . . . . 0.0 112.338 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -88.57 151.54 22.43 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.16 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 25.4 mtp -85.25 89.9 7.77 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.916 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -125.73 160.51 29.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.886 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.22 -136.45 12.92 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.468 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.71 168.64 20.92 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.689 2.26 . . . . 0.0 112.361 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.74 -175.37 1.13 Allowed 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.695 2.263 . . . . 0.0 112.354 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.468 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.6 m -95.53 151.41 19.34 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.119 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.468 ' CD1' ' O ' ' A' ' 22' ' ' THR . 9.8 m-85 -150.71 137.15 18.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.887 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . 0.601 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 52.8 m-80 51.37 44.48 2.16 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.663 0.744 . . . . 0.0 110.919 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.601 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.78 133.82 26.45 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.632 2.221 . . . . 0.0 112.316 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.85 179.36 3.8 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.673 2.249 . . . . 0.0 112.361 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.532 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 86.6 t -138.79 137.68 20.27 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.606 0.717 . . . . 0.0 111.134 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.532 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.2 Cg_endo -69.77 144.21 76.03 Favored 'Cis proline' 0 C--O 1.231 0.161 0 C-N-CA 122.668 -1.805 . . . . 0.0 112.338 -0.074 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 2.9 t80 -94.13 120.15 33.98 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.927 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -105.12 102.14 11.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.899 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -109.7 109.43 2.71 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.471 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 6.4 mmt85 -73.38 108.93 6.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.875 0.369 . . . . 0.0 110.873 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.41 ' HB3' ' NH1' ' A' ' 41' ' ' ARG . 5.3 mt -70.58 92.76 0.86 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.918 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 14.9 mm-40 -64.73 105.36 0.97 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.896 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 130.59 -46.89 1.05 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.477 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 98.67 161.36 29.98 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.51 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 95.9 mt -54.81 107.14 0.26 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.903 0.383 . . . . 0.0 110.872 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 73.0 p -118.71 149.04 42.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.128 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -49.8 -23.62 1.95 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.085 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.413 ' HB3' ' NH1' ' A' ' 40' ' ' ARG . 0.0 OUTLIER -108.81 34.19 3.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.882 -179.921 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.41 ' NH1' ' HB3' ' A' ' 33' ' ' LEU . 13.1 ttm180 -113.81 139.28 49.27 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.859 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 74.2 m -137.52 119.83 15.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.134 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.419 HG22 ' N ' ' A' ' 44' ' ' ILE . 5.3 mp -91.92 136.27 24.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.109 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.419 ' N ' HG22 ' A' ' 43' ' ' ILE . 97.0 mt -131.25 133.55 62.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.107 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 34.5 mt -136.53 111.52 10.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.143 179.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 16.1 mtmt -112.68 109.0 18.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.923 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -138.1 -142.95 4.42 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.44 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 0.435 ' CD1' ' O ' ' A' ' 48' ' ' TYR . 0.5 OUTLIER -170.2 117.04 0.54 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.914 0.388 . . . . 0.0 110.939 -179.769 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.462 HG23 ' CE1' ' A' ' 109' ' ' PHE . 15.2 t -70.19 115.8 38.05 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.644 0.735 . . . . 0.0 111.139 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 157.52 60.12 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.678 2.252 . . . . 0.0 112.356 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -15.42 37.17 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.664 2.243 . . . . 0.0 112.34 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 21.5 p -109.71 17.11 21.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.18 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -110.69 118.99 5.13 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.511 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.3 mtpt -61.31 -60.63 3.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.778 0.323 . . . . 0.0 110.912 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 13.2 p -173.64 158.44 3.35 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.869 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.579 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 6.1 p90 -115.88 -174.68 2.58 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.864 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.46 ' CB ' ' OD1' ' A' ' 73' ' ' ASN . . . -154.81 145.3 22.17 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.126 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.2 mp -123.52 98.77 5.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.115 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.7 m-80 -98.86 141.98 30.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.914 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.551 ' CE2' HD13 ' A' ' 145' ' ' LEU . 10.5 m-85 -117.16 99.03 6.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.893 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.427 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 31.3 ttmt -96.62 169.24 10.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.878 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.427 ' N ' ' HG2' ' A' ' 61' ' ' LYS . 38.7 t -101.44 119.59 49.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.129 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -55.22 -36.79 62.82 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.502 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.5 m -66.47 -72.86 0.15 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.889 0.376 . . . . 0.0 110.904 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 19.7 m -79.34 -74.68 0.28 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.868 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 132.92 38.58 0.23 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.523 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -111.36 143.61 41.89 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.795 0.331 . . . . 0.0 110.846 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 47.4 mt -89.77 117.71 33.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.123 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -89.25 -31.07 18.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.122 179.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.536 HD23 ' CD2' ' A' ' 132' ' ' PHE . 53.2 tp -140.84 130.25 23.83 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.927 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.452 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.3 OUTLIER -134.91 92.55 2.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.884 179.82 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 26.3 mt -96.36 133.81 36.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.149 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.498 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -141.24 106.78 6.13 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.619 0.723 . . . . 0.0 110.853 179.978 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.579 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.8 Cg_endo -69.78 155.28 66.3 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.647 2.231 . . . . 0.0 112.364 179.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 68.3 mtp180 -130.55 99.35 4.95 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -57.49 148.64 23.11 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.899 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 87.16 -89.89 1.65 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.495 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 15.1 t30 -42.78 -56.0 3.39 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.908 0.385 . . . . 0.0 110.873 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 98.57 54.59 1.14 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.467 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 16.9 p -147.7 118.19 7.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.795 0.331 . . . . 0.0 111.133 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.3 t -99.67 111.72 30.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.123 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 92.5 t -79.36 142.06 14.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.176 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . 0.557 ' NH1' ' CD2' ' A' ' 130' ' ' PHE . 0.3 OUTLIER -126.19 125.52 42.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.885 -179.948 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.452 ' O ' ' N ' ' A' ' 71' ' ' HIS . 2.3 m120 -137.39 177.82 7.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.883 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 28.9 t -158.92 105.08 1.76 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.814 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.57 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 25.6 tp -77.36 119.58 21.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.918 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.513 ' N ' ' O ' ' A' ' 90' ' ' SER . 77.7 mt -96.98 161.47 13.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.893 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.529 HD21 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.28 101.67 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.868 179.938 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.76 -7.12 0.73 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.488 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.519 ' H ' ' C ' ' A' ' 88' ' ' ASN . 0.3 OUTLIER -118.13 170.74 8.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.885 0.374 . . . . 0.0 110.855 -179.719 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.57 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 21.4 m95 -128.31 160.89 30.75 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.959 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -94.16 -116.85 2.78 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.454 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 33.8 m -152.14 178.61 9.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.79 0.329 . . . . 0.0 110.898 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.418 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 11.9 mt-10 -103.73 126.05 50.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.891 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -123.36 105.37 9.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.893 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 18.2 mtmm -111.69 122.46 47.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.919 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -171.54 105.95 0.22 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.905 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.416 ' CG1' ' N ' ' A' ' 99' ' ' THR . 3.0 tt -145.13 152.85 14.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.125 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.416 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 9.5 t -96.39 -41.9 8.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.141 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 4.4 p-80 -142.89 128.57 19.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.852 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 -103.29 95.55 7.09 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.652 0.739 . . . . 0.0 110.882 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.75 -40.41 5.38 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.702 2.268 . . . . 0.0 112.318 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -41.01 108.41 0.09 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.867 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -131.49 139.64 11.11 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.491 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 100.62 0.84 Allowed 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.714 2.276 . . . . 0.0 112.328 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 117.89 6.63 12.45 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.472 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 4.7 pt20 -137.17 143.92 42.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.78 0.324 . . . . 0.0 110.926 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -66.14 168.76 7.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.915 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.462 ' CE1' HG23 ' A' ' 49' ' ' VAL . 30.1 p90 -161.28 144.74 12.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.85 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -118.31 101.73 8.41 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.87 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.401 ' CD1' ' CD1' ' A' ' 113' ' ' ILE . 1.1 tm? -99.24 137.18 38.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.923 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 6.2 m -144.98 111.27 5.61 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.864 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.401 ' CD1' ' CD1' ' A' ' 111' ' ' LEU . 4.8 mp -94.73 135.57 28.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.081 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -109.61 130.59 55.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.846 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . 0.572 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 11.9 t -101.19 116.02 31.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.876 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -115.26 -143.9 8.17 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.517 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.7 mt -116.02 -37.47 3.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.829 0.347 . . . . 0.0 110.88 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -87.66 -37.5 16.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.873 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.9 ptt180 -173.85 170.38 3.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.874 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.572 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.1 m-30 -90.71 158.23 17.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.85 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 30.5 mtpt -132.33 99.39 4.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.886 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 97.6 t -86.73 139.18 17.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.095 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 84.3 m-85 -129.4 148.96 51.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.947 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -137.12 109.77 7.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.096 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 57.97 34.66 24.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.849 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.9 40.5 21.23 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.494 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -144.84 134.86 23.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.81 0.338 . . . . 0.0 110.875 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 32.2 t-80 -68.06 101.31 1.12 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.865 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 8.0 tp -71.7 -67.39 0.53 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.898 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.557 ' CD2' ' NH1' ' A' ' 83' ' ' ARG . 5.1 p90 -166.89 173.44 9.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.886 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -116.12 155.69 27.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.574 ' CE1' ' O ' ' A' ' 133' ' ' ALA . 0.1 OUTLIER -120.15 104.47 10.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.896 -179.883 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.574 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -59.62 136.64 58.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.101 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 55.4 m-70 -63.52 106.16 0.89 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.879 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 23.6 mtt-85 -91.73 -50.2 5.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.861 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 6.1 tp -95.43 109.02 21.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.923 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 41.3 t -51.67 -33.4 33.7 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.812 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . 0.463 ' HB3' ' CD ' ' A' ' 141' ' ' ARG . . . -82.67 23.83 0.77 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.097 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 32.0 p90 -45.57 -37.87 5.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.854 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -52.73 -46.97 67.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.918 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.463 ' CD ' ' HB3' ' A' ' 138' ' ' ALA . 70.6 mtp85 -48.63 -43.38 36.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.87 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 85.5 t -41.24 106.93 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.171 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -131.86 31.68 4.18 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.861 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 18.9 m -142.03 114.94 8.66 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.134 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.551 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.9 tp -111.89 108.46 17.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.917 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' GLU . . . . . 0.414 ' C ' HG13 ' A' ' 147' ' ' ILE . 3.6 pt-20 -111.77 155.29 23.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.91 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . 0.414 HG13 ' C ' ' A' ' 146' ' ' GLU . 35.2 mt -143.45 116.4 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.105 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -124.79 170.27 11.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.94 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.79 -153.47 16.8 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.496 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -104.17 93.28 4.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.808 0.337 . . . . 0.0 110.879 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.475 HG21 ' N ' ' A' ' 152' ' ' THR . 8.8 p -151.3 143.59 16.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.126 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' THR . . . . . 0.475 ' N ' HG21 ' A' ' 151' ' ' VAL . 12.0 m -105.19 94.39 5.21 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.107 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 58.0 mt -78.51 134.4 37.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.88 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 58.6 m -119.25 -39.85 2.87 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.851 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 39.7 t80 -144.6 131.14 19.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.92 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 93.4 t -140.54 106.57 2.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.132 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 15.2 tt0 -118.42 138.97 52.1 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.922 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 18.4 mt -106.73 93.51 2.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.113 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 46.1 t -61.7 149.12 40.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.882 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 135.45 -166.15 24.56 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.479 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 100.67 0.83 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.682 2.255 . . . . 0.0 112.361 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 31.2 t -81.54 153.92 26.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.858 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 87.5 p -104.27 152.72 21.87 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.868 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.544 179.983 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.27 0 N-CA-C 112.498 -0.241 . . . . 0.0 112.498 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.1 m -85.58 105.34 16.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.912 0.387 . . . . 0.0 110.838 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 4.0 t -174.16 107.08 0.12 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.868 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 166.62 107.12 0.2 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.527 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 5.2 m -147.68 155.65 41.97 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.812 0.339 . . . . 0.0 110.859 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.1 m -68.76 174.94 3.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.874 -179.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.442 ' O ' ' N ' ' A' ' 9' ' ' GLN . . . -139.36 -38.59 0.1 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.528 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 39.7 m80 -59.51 81.55 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.698 0.285 . . . . 0.0 110.825 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.442 ' N ' ' O ' ' A' ' 7' ' ' GLY . 38.9 mt-30 -136.82 157.56 46.48 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.919 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 10.2 pt20 -96.92 65.72 2.12 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.93 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 18.4 mt -145.04 176.93 9.14 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.937 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 20.2 m-80 -105.75 140.59 38.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.858 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 59.6 p -151.6 157.48 42.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.866 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 2.1 pp -121.97 156.22 59.85 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.682 0.753 . . . . 0.0 110.886 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 157.28 60.96 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.726 2.284 . . . . 0.0 112.339 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 8.8 t -48.86 146.35 3.3 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.166 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 45.7 mtm -96.86 31.05 2.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.832 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -59.65 163.52 4.24 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.887 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 101.15 -149.4 18.37 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.474 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 168.59 21.1 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.67 2.247 . . . . 0.0 112.383 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.82 174.74 9.12 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.654 2.236 . . . . 0.0 112.293 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.453 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.5 m -84.68 144.99 28.2 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.145 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.424 ' C ' ' HD3' ' A' ' 25' ' ' PRO . 5.6 m-85 -142.95 133.63 25.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.893 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . 0.585 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.6 m120 48.42 45.6 2.94 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.591 0.71 . . . . 0.0 110.867 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.585 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.3 Cg_endo -69.79 137.33 35.11 Favored 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 122.702 2.268 . . . . 0.0 112.34 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 -176.93 1.63 Allowed 'Trans proline' 0 N--CA 1.465 -0.164 0 C-N-CA 122.732 2.288 . . . . 0.0 112.357 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.526 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 88.1 t -142.28 137.64 15.84 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.616 0.722 . . . . 0.0 111.125 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.526 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.3 Cg_endo -69.81 143.88 75.21 Favored 'Cis proline' 0 C--N 1.341 0.179 0 C-N-CA 122.671 -1.804 . . . . 0.0 112.318 0.005 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.9 t80 -95.61 120.72 36.35 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.904 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -102.94 104.01 14.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.866 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -115.92 109.55 2.04 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.524 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 3.2 mmt85 -74.08 118.47 17.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.856 0.36 . . . . 0.0 110.84 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.428 HD22 ' CD1' ' A' ' 158' ' ' ILE . 8.0 mt -76.8 92.13 3.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.935 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 23.0 mm-40 -65.4 102.86 0.73 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.961 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.23 -37.96 1.89 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.453 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 88.28 156.19 30.44 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.469 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 86.8 mt -52.43 100.0 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.905 0.383 . . . . 0.0 110.895 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 29.7 p -116.73 153.84 31.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.176 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.448 ' HB3' ' CD2' ' A' ' 117' ' ' LEU . . . -51.34 -31.51 22.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.127 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.429 ' HA ' ' NE ' ' A' ' 40' ' ' ARG . 10.8 mmp_? -100.14 33.7 2.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.852 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 28.2 ttm-85 -118.73 137.99 52.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.867 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 96.6 m -139.37 118.22 12.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.135 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 4.6 mp -91.58 136.28 24.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.099 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.426 HG23 ' N ' ' A' ' 45' ' ' ILE . 89.0 mt -128.87 133.8 65.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.138 179.843 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.426 ' N ' HG23 ' A' ' 44' ' ' ILE . 37.8 mt -134.26 107.61 9.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.113 179.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.3 mtmt -108.24 103.9 13.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -134.21 -148.35 5.78 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.517 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -169.17 127.56 1.0 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.98 0.419 . . . . 0.0 110.894 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 16.0 t -75.91 117.65 65.37 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.635 0.731 . . . . 0.0 111.158 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 154.01 68.35 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.687 2.258 . . . . 0.0 112.359 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -20.71 34.37 Favored 'Trans proline' 0 C--O 1.231 0.175 0 C-N-CA 122.674 2.249 . . . . 0.0 112.343 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 41.1 p -99.63 9.41 43.18 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.153 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -99.08 -172.16 31.28 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.491 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 4.1 mmmm -133.75 -64.56 0.7 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.787 0.327 . . . . 0.0 110.895 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 2.6 p -165.75 147.07 7.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.816 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.571 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 13.0 p90 -110.53 -175.35 2.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.898 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -154.98 143.58 20.59 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.123 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.2 mp -121.85 102.14 11.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.107 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.2 m-80 -102.06 143.57 31.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.888 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.566 ' CE2' HD13 ' A' ' 145' ' ' LEU . 5.4 m-85 -118.76 98.56 6.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.937 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.433 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 32.8 ttmt -96.93 169.25 9.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.892 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.433 ' N ' ' HG2' ' A' ' 61' ' ' LYS . 19.4 t -100.64 122.4 52.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.131 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.461 ' N ' ' HG1' ' A' ' 144' ' ' THR . . . -60.04 -34.24 82.75 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.509 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 10.1 t -67.15 -71.81 0.19 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.872 0.368 . . . . 0.0 110.89 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.4 t -81.86 -69.19 0.63 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.836 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 128.97 36.53 0.43 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.519 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -110.22 140.99 43.78 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.853 0.359 . . . . 0.0 110.856 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 58.9 mt -85.86 122.0 37.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.133 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.437 ' CB ' HG22 ' A' ' 142' ' ' VAL . . . -93.13 -30.01 15.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.098 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.512 HD21 ' CD2' ' A' ' 132' ' ' PHE . 46.3 tp -144.2 130.1 19.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.946 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.472 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.3 OUTLIER -134.93 92.58 2.9 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.862 179.899 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.401 ' CG2' HG11 ' A' ' 81' ' ' VAL . 41.4 mt -94.55 134.69 31.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.173 179.962 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.514 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -139.02 106.24 7.36 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.612 0.72 . . . . 0.0 110.879 179.959 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.571 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.7 Cg_endo -69.73 155.25 66.52 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.683 2.255 . . . . 0.0 112.329 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 42.1 mtp180 -131.56 99.41 4.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.865 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -59.34 148.4 32.47 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.858 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 88.83 -81.98 1.51 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.464 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 28.9 t-20 -49.62 -67.57 0.25 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.877 0.37 . . . . 0.0 110.869 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.417 ' HA2' ' CG ' ' A' ' 101' ' ' ASN . . . 113.58 41.86 0.92 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.508 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 16.9 p -137.29 117.92 13.94 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.887 0.375 . . . . 0.0 111.108 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.401 HG11 ' CG2' ' A' ' 72' ' ' ILE . 39.5 t -101.76 107.24 21.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.125 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.449 ' CG2' ' HD3' ' A' ' 96' ' ' LYS . 24.6 t -78.29 138.52 20.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.171 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . 0.615 HH12 ' N ' ' A' ' 97' ' ' LYS . 2.8 mpp_? -126.94 125.72 42.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.885 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.472 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.3 m120 -132.86 -176.23 4.04 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.854 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 30.3 t -159.31 105.18 1.68 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.864 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.566 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 25.8 tp -77.06 117.43 18.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.861 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 90' ' ' SER . 80.7 mt -95.28 161.63 14.01 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.913 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.538 HD21 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.42 101.59 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.863 179.98 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.83 -6.49 0.91 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.504 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.511 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -119.21 172.47 7.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.913 0.387 . . . . 0.0 110.833 -179.773 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.566 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 22.4 m95 -129.49 160.69 32.39 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.908 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -89.59 -92.5 1.17 Allowed Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.457 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 2.3 m -174.74 173.78 2.74 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.905 0.383 . . . . 0.0 110.838 -179.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.443 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 3.8 mt-10 -104.97 117.64 34.53 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.89 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 50.7 mm-40 -122.49 133.88 54.58 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.895 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.449 ' HD3' ' CG2' ' A' ' 82' ' ' VAL . 43.8 mtmt -131.1 128.13 39.54 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.91 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.615 ' N ' HH12 ' A' ' 83' ' ' ARG . 12.7 tmtt? -175.79 108.37 0.09 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.946 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.459 ' CD1' ' O ' ' A' ' 100' ' ' HIS . 4.1 tt -147.67 144.04 19.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.109 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.6 t -79.19 -39.58 32.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.141 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . 0.459 ' O ' ' CD1' ' A' ' 98' ' ' ILE . 3.1 p-80 -154.35 136.91 15.1 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.883 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . 0.432 ' CG ' HD11 ' A' ' 98' ' ' ILE . 8.1 m120 -105.11 95.78 9.98 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.573 0.702 . . . . 0.0 110.893 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.72 -35.04 13.49 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.674 2.249 . . . . 0.0 112.397 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -45.84 113.69 0.65 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.898 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -144.91 142.19 10.64 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.484 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.75 109.56 2.34 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.723 2.282 . . . . 0.0 112.334 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 118.88 -8.55 12.73 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.5 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -133.29 150.63 51.89 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.851 0.358 . . . . 0.0 110.883 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 2.3 p90 -77.86 160.02 28.57 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.919 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.511 ' CD1' ' O ' ' A' ' 109' ' ' PHE . 29.6 p90 -145.3 122.36 11.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.874 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -92.89 101.94 14.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.911 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.454 HD12 ' N ' ' A' ' 112' ' ' SER . 1.0 OUTLIER -101.84 138.37 38.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.875 -179.911 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.454 ' N ' HD12 ' A' ' 111' ' ' LEU . 4.3 m -144.67 114.41 7.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.871 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.3 mp -99.16 122.22 50.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.157 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 7.7 mtp180 -97.16 132.72 42.66 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.842 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . 0.441 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 7.0 t -98.61 123.07 42.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.867 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.93 -141.23 7.46 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.494 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.448 ' CD2' ' HB3' ' A' ' 39' ' ' ALA . 7.9 mt -118.57 -33.4 4.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.792 0.329 . . . . 0.0 110.931 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . 0.598 ' O ' ' CD2' ' A' ' 134' ' ' HIS . 16.1 m-20 -97.6 -45.26 6.46 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.908 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.414 ' HG3' ' C ' ' A' ' 118' ' ' ASP . 47.7 mtt180 -152.36 -175.85 5.44 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.91 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.441 ' CE2' ' HB2' ' A' ' 115' ' ' CYS . 12.1 m-85 -107.66 158.59 17.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.905 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 19.1 mtpt -130.83 105.23 7.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.903 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 47.7 t -94.37 134.83 30.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.121 179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -123.32 147.82 46.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.91 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -132.65 107.5 8.45 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.104 179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 59.34 34.17 22.75 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.86 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.55 28.99 41.25 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.468 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 13.0 mm100 -136.38 119.61 16.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.8 0.333 . . . . 0.0 110.921 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 26.5 t-80 -51.58 101.53 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.831 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 10.5 tp -65.57 -69.16 0.31 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.933 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.462 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 4.5 p90 -164.66 175.54 9.66 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.884 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 41.0 m-20 -113.75 157.42 22.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.893 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.561 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 0.1 OUTLIER -130.81 106.29 8.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.942 -179.911 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.545 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -64.54 131.77 47.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.075 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' HIS . . . . . 0.598 ' CD2' ' O ' ' A' ' 118' ' ' ASP . 16.7 m-70 -56.65 117.49 3.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.85 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 71.9 mtt-85 -97.61 -49.48 4.85 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.84 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 12.2 tp -95.37 109.08 21.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.941 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 79.3 p -48.74 -33.17 9.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.836 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . 0.443 ' HB3' ' CD ' ' A' ' 141' ' ' ARG . . . -83.36 28.24 0.55 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.096 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -51.47 -34.56 35.99 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.838 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' GLN . . . . . 0.426 ' HG2' ' N ' ' A' ' 141' ' ' ARG . 19.7 pm0 -60.58 -27.19 67.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.945 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.443 ' CD ' ' HB3' ' A' ' 138' ' ' ALA . 33.1 mtp180 -69.27 -37.58 77.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.908 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.437 HG22 ' CB ' ' A' ' 69' ' ' ALA . 89.4 t -46.52 104.35 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.096 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -127.84 29.24 5.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.875 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' THR . . . . . 0.461 ' HG1' ' N ' ' A' ' 63' ' ' GLY . 10.5 m -139.2 110.94 7.16 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.085 -179.867 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.566 HD13 ' CE2' ' A' ' 60' ' ' PHE . 6.2 tp -109.55 105.71 15.13 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.952 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -110.11 152.49 25.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.856 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 29.4 mt -139.92 118.67 11.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.131 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -126.77 171.43 11.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.927 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 109.36 -152.28 17.12 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.518 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -106.52 92.04 3.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.802 0.334 . . . . 0.0 110.89 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.44 HG23 ' N ' ' A' ' 152' ' ' THR . 8.7 p -150.37 149.27 14.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.114 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' THR . . . . . 0.44 ' N ' HG23 ' A' ' 151' ' ' VAL . 29.7 m -109.71 94.9 5.27 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.114 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.416 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 77.6 mt -76.93 132.22 38.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.917 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 3.0 m -117.37 -33.7 4.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.879 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 19.5 t80 -153.1 131.9 12.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.93 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 60.8 t -139.53 112.2 5.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.171 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 17.9 tt0 -124.92 136.56 53.88 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' ILE . . . . . 0.428 ' CD1' HD22 ' A' ' 33' ' ' LEU . 15.3 mt -107.17 90.69 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.129 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 23.3 t -43.03 135.51 3.11 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.89 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 172.64 156.38 12.56 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.498 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 138.87 38.88 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.685 2.257 . . . . 0.0 112.306 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 58.2 m -81.67 164.33 21.88 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.829 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 6.9 m 58.98 41.81 20.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.871 -179.852 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.362 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.512 -179.927 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 N-CA-C 112.506 -0.238 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 16.1 m 53.83 42.11 31.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.912 0.387 . . . . 0.0 110.893 -179.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 42.6 t -148.19 155.62 41.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.865 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 171.03 100.11 0.13 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.454 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 68.2 m -156.08 135.09 12.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.88 0.371 . . . . 0.0 110.871 -179.749 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 98.4 p -123.05 109.35 13.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.9 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 179.63 73.35 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.47 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 29.1 m-70 -116.85 81.81 1.7 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.722 0.296 . . . . 0.0 110.825 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 61.6 tt0 -47.82 -48.12 30.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.963 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 64.8 mm-40 -138.1 131.0 29.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.922 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 11.7 mt -102.93 120.27 40.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.95 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.7 p-10 -108.59 -64.28 1.25 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.845 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 32.5 p -161.27 152.43 18.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.836 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.415 HD12 ' O ' ' A' ' 15' ' ' PRO . 2.4 pp -56.53 154.82 15.62 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.59 0.709 . . . . 0.0 110.92 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.415 ' O ' HD12 ' A' ' 14' ' ' LEU . 53.6 Cg_endo -69.78 -163.67 0.11 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.7 2.267 . . . . 0.0 112.323 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.4 m -85.6 149.02 25.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.154 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 42.8 mtm -89.03 88.26 7.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.883 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -112.86 167.09 10.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.884 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 87.57 -143.89 18.72 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.469 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 169.72 18.22 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.69 2.26 . . . . 0.0 112.353 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 -179.62 3.06 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.67 2.247 . . . . 0.0 112.336 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.525 ' CG2' ' N ' ' A' ' 23' ' ' PHE . 1.6 m -90.81 158.74 16.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.132 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.525 ' N ' ' CG2' ' A' ' 22' ' ' THR . 8.6 m-85 -154.32 137.72 15.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.88 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . 0.549 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 12.5 m120 44.27 47.99 4.03 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.648 0.737 . . . . 0.0 110.909 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.549 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.6 Cg_endo -69.79 140.09 41.73 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.688 2.259 . . . . 0.0 112.327 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 178.61 4.38 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.718 2.279 . . . . 0.0 112.357 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.534 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 96.4 t -139.36 138.31 20.36 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.605 0.717 . . . . 0.0 111.136 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.534 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.74 144.3 76.2 Favored 'Cis proline' 0 C--O 1.231 0.158 0 C-N-CA 122.72 -1.783 . . . . 0.0 112.334 -0.082 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -95.37 114.07 25.8 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.923 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -97.65 105.34 17.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.896 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -119.34 106.32 1.24 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.487 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.482 ' O ' ' NE2' ' A' ' 34' ' ' GLN . 0.0 OUTLIER -77.98 128.19 33.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.904 0.383 . . . . 0.0 110.848 -179.855 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 5.5 mt -71.8 122.02 19.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.89 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.482 ' NE2' ' O ' ' A' ' 32' ' ' ARG . 24.5 mp0 -77.15 79.6 3.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.899 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 139.01 -47.51 0.91 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.525 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.461 ' O ' ' CG2' ' A' ' 38' ' ' THR . . . 108.47 164.98 20.98 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.467 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 68.7 mt -50.85 106.48 0.13 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.92 0.39 . . . . 0.0 110.898 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.461 ' CG2' ' O ' ' A' ' 36' ' ' GLY . 10.2 p -124.61 141.19 52.28 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.146 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -42.86 -27.78 0.21 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.15 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 14.4 mmt85 -105.03 43.61 1.09 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.919 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.407 ' NH2' ' O ' ' A' ' 34' ' ' GLN . 6.6 ttt85 -130.43 139.93 50.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.838 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 98.0 m -139.73 121.6 15.52 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.09 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 4.7 mp -91.39 132.76 35.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.137 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.41 ' CG2' ' HE2' ' A' ' 46' ' ' LYS . 83.8 mt -125.16 117.01 48.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.113 179.893 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 46.6 mt -118.12 107.63 22.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.092 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.41 ' HE2' ' CG2' ' A' ' 44' ' ' ILE . 25.1 mtmt -111.06 112.12 23.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.907 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -145.04 -143.43 3.99 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.487 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -168.99 126.42 0.97 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.924 0.392 . . . . 0.0 110.957 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 21.6 t -75.99 116.89 59.75 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.642 0.734 . . . . 0.0 111.138 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.82 157.52 60.0 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.631 2.221 . . . . 0.0 112.302 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -16.88 37.63 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.685 2.257 . . . . 0.0 112.307 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 76.8 p -110.91 19.73 18.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.138 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -111.68 116.53 4.2 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.506 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 21.7 mtpp -59.24 -60.66 3.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.761 0.315 . . . . 0.0 110.904 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 21.7 p -174.06 157.43 2.89 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.888 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.569 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 5.7 p90 -112.52 -173.18 2.19 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.9 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.18 145.49 21.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.095 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 2.7 mp -125.52 100.01 6.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.087 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . 0.443 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 19.4 m-80 -101.9 144.76 30.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.882 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.54 ' CE2' HD13 ' A' ' 145' ' ' LEU . 32.7 m-85 -117.93 99.95 7.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.873 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.409 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 34.5 ttmt -95.65 168.16 10.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.945 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.475 ' CG2' HG22 ' A' ' 142' ' ' VAL . 22.6 t -99.72 122.86 52.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.147 179.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -58.23 -34.23 73.14 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.481 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 26.1 m -70.22 -75.26 0.12 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.865 0.364 . . . . 0.0 110.813 -179.695 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 26.9 t -77.64 -71.93 0.39 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.866 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 129.3 43.4 0.21 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.469 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.408 ' OD1' ' OD1' ' A' ' 88' ' ' ASN . 1.1 m-20 -113.69 142.1 46.43 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.784 0.326 . . . . 0.0 110.866 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 44.9 mt -87.05 118.78 33.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.119 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.425 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -91.95 -30.09 16.29 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.089 179.835 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.566 HD22 ' CD2' ' A' ' 132' ' ' PHE . 58.2 tp -142.18 129.62 21.26 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.899 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.496 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.2 t60 -134.81 92.8 2.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.842 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.404 ' CG2' HG11 ' A' ' 81' ' ' VAL . 28.3 mt -94.78 130.88 42.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.102 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.499 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -136.04 104.79 9.62 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.643 0.735 . . . . 0.0 110.902 179.9 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.569 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.4 Cg_endo -69.78 155.66 65.3 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.644 2.229 . . . . 0.0 112.309 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 28.6 mtt-85 -130.77 101.92 5.87 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.859 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -59.68 150.04 28.84 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.879 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 87.49 -87.88 1.55 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.497 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 12.7 t30 -47.34 -54.31 11.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.907 0.384 . . . . 0.0 110.9 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 97.87 52.85 1.35 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.498 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 7.0 p -143.15 118.01 9.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.827 0.346 . . . . 0.0 111.123 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.404 HG11 ' CG2' ' A' ' 72' ' ' ILE . 41.8 t -101.46 114.65 41.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.166 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 57.4 t -83.54 144.18 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.135 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -126.26 124.91 41.43 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.845 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.496 ' O ' ' N ' ' A' ' 71' ' ' HIS . 2.6 m120 -135.17 176.3 8.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.867 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 40.4 t -157.72 105.01 1.99 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.892 -179.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.564 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 34.5 tp -77.14 117.73 18.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.919 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 90' ' ' SER . 85.0 mt -95.48 162.36 13.68 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.951 179.893 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.429 ' C ' ' H ' ' A' ' 90' ' ' SER . 10.6 m-80 -41.08 102.23 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.866 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.19 -1.15 3.0 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.49 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.511 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -125.71 171.64 10.46 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.849 0.357 . . . . 0.0 110.853 -179.715 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.564 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 22.2 m95 -128.93 160.63 32.08 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.921 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.57 -115.21 2.23 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.491 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' SER . . . . . 0.416 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 58.3 m -151.42 173.67 14.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.82 0.343 . . . . 0.0 110.852 -179.768 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.407 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 14.4 mt-10 -102.59 123.95 47.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.875 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -123.08 125.86 45.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.904 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 45.6 mtmt -129.52 118.99 22.96 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.886 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 1.3 tppp? -170.58 106.52 0.29 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.851 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 7.4 tt -144.22 150.53 16.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.114 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.8 t -87.26 -46.12 10.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.154 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . 0.448 ' O ' ' CG ' ' A' ' 100' ' ' HIS . 4.6 p-80 -147.37 125.78 12.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.886 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . 0.44 ' OD1' ' C ' ' A' ' 101' ' ' ASN . 27.1 t-20 -99.41 100.73 11.13 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.628 0.727 . . . . 0.0 110.906 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.401 ' HD2' ' HA ' ' A' ' 101' ' ' ASN . 54.1 Cg_endo -69.72 -36.44 10.89 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.751 2.301 . . . . 0.0 112.335 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -41.51 109.72 0.13 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.872 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -137.96 138.56 9.68 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.481 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 103.06 1.11 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.646 2.231 . . . . 0.0 112.363 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 121.44 -2.12 11.31 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.485 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -137.05 146.04 44.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.871 0.367 . . . . 0.0 110.874 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 2.3 p90 -70.93 172.76 8.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.861 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 30.0 p90 -160.25 137.5 9.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.884 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.59 107.8 18.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.863 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -109.12 136.99 47.71 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.926 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 6.0 m -145.08 113.56 6.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.809 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.3 mp -93.92 137.42 22.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.129 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.462 ' O ' ' CD2' ' A' ' 120' ' ' PHE . 14.5 mtp180 -109.56 133.93 52.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.855 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 9.0 t -101.45 115.29 30.18 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.86 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -110.94 -141.66 8.8 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.487 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 5.5 mt -118.58 -34.81 3.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.827 0.346 . . . . 0.0 110.948 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . 0.605 ' O ' ' CD2' ' A' ' 134' ' ' HIS . 2.0 m-20 -95.05 -45.83 7.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.856 179.858 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.433 ' HG3' ' C ' ' A' ' 118' ' ' ASP . 25.5 mtt180 -154.98 -179.72 8.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.462 ' CD2' ' O ' ' A' ' 114' ' ' ARG . 20.5 m-85 -103.41 157.59 16.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.919 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 32.9 mtpt -129.52 100.08 5.41 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.938 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 45.6 t -89.2 128.94 40.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.091 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -115.07 151.21 34.68 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.917 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -136.35 106.71 6.43 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.069 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 55.92 34.67 24.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.856 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 80.71 31.36 36.53 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.506 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 12.3 mm100 -138.32 123.78 19.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.844 0.354 . . . . 0.0 110.938 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 39.6 t-80 -55.46 101.43 0.05 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.874 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 11.6 tp -69.85 -69.62 0.34 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.952 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.452 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 6.7 p90 -165.13 169.84 15.67 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -111.22 159.93 17.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.895 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.566 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -130.52 104.39 7.2 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.897 -179.883 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.507 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -62.5 134.96 57.14 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.108 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' HIS . . . . . 0.605 ' CD2' ' O ' ' A' ' 118' ' ' ASP . 20.1 m-70 -58.72 104.62 0.24 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.875 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.416 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 8.8 mtt-85 -83.92 -53.65 5.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.867 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.7 tp -91.85 107.77 19.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.956 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 12.7 t -45.74 -36.14 4.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.893 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -82.72 29.97 0.44 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.09 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.466 ' CG ' ' N ' ' A' ' 140' ' ' GLN . 21.7 p90 -48.49 -45.82 37.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.886 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' GLN . . . . . 0.466 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 8.3 pt20 -47.8 -41.34 23.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.908 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.425 ' C ' HG13 ' A' ' 62' ' ' VAL . 30.7 mtp180 -54.21 -41.64 68.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.851 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.475 HG22 ' CG2' ' A' ' 62' ' ' VAL . 97.2 t -49.23 102.92 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.177 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -124.74 28.34 6.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.865 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 32' ' ' ARG . 0.6 OUTLIER -135.29 125.44 26.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.138 -179.927 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.54 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.2 tp -123.97 106.79 10.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.922 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -110.37 153.44 24.94 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.911 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 17.2 mt -138.47 115.28 11.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.104 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -125.52 174.92 7.89 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.917 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.04 -143.78 15.84 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.502 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -114.81 92.39 3.93 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.888 0.375 . . . . 0.0 110.86 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.458 HG23 ' N ' ' A' ' 152' ' ' THR . 6.3 p -151.31 145.74 16.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.171 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' THR . . . . . 0.458 ' N ' HG23 ' A' ' 151' ' ' VAL . 21.5 m -105.37 93.8 4.87 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.126 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.443 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 95.0 mt -75.76 131.43 39.81 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.869 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 7.5 m -113.62 -41.6 3.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.86 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . 0.413 ' CD1' ' C ' ' A' ' 155' ' ' TYR . 8.4 t80 -145.06 132.98 21.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.919 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 94.4 t -140.69 116.96 7.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.112 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 9.7 tt0 -134.18 125.13 27.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.941 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 24.0 mt -96.95 88.92 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.139 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 53.3 p -69.65 136.65 51.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.821 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -139.08 -173.63 13.11 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.504 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 126.93 13.91 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.698 2.265 . . . . 0.0 112.359 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 3.8 m -154.56 120.84 5.33 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.855 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 22.6 t -110.25 133.87 52.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.865 -179.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.276 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.457 -179.999 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.484 -0.246 . . . . 0.0 112.484 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.8 t 59.53 42.16 17.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.912 0.387 . . . . 0.0 110.855 -179.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 36.4 m -88.92 119.51 29.5 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.837 -179.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 116.47 77.31 0.65 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.496 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.0 t -100.93 166.01 11.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.949 0.404 . . . . 0.0 110.814 -179.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.0 m -159.86 158.72 31.45 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.852 -179.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 85.18 -168.75 43.06 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.443 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 13.9 t-80 46.88 43.03 12.97 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.75 0.309 . . . . 0.0 110.858 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 42.7 tt0 -88.21 139.83 30.09 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.929 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 48.4 mt-30 -146.39 149.98 34.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.885 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -70.27 105.25 2.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.88 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 5.0 m120 -130.57 168.62 16.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.904 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 6.0 m -70.89 158.18 36.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.879 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 1.7 pp -38.54 155.95 0.12 Allowed Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.611 0.72 . . . . 0.0 110.926 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -170.7 0.41 Allowed 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.701 2.267 . . . . 0.0 112.334 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.2 m -86.64 150.47 24.18 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.128 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' MET . . . . . 0.446 ' CG ' ' O ' ' A' ' 17' ' ' MET . 5.9 ptt? -99.91 79.61 2.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.835 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -104.17 148.09 26.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.819 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.403 ' HA3' ' HD2' ' A' ' 20' ' ' PRO . . . 115.86 -137.03 13.43 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.442 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.403 ' HD2' ' HA3' ' A' ' 19' ' ' GLY . 53.8 Cg_endo -69.73 169.94 17.72 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.673 2.249 . . . . 0.0 112.365 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.545 ' HB2' ' CE2' ' A' ' 155' ' ' TYR . 53.5 Cg_endo -69.72 176.86 6.18 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.709 2.272 . . . . 0.0 112.324 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 10.8 t -93.74 157.32 16.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.151 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 7.8 m-85 -139.43 115.61 10.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.914 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . 0.489 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 5.3 t-20 66.95 51.63 0.65 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.568 0.699 . . . . 0.0 110.845 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.489 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.75 132.65 23.79 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.679 2.253 . . . . 0.0 112.343 179.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -178.43 2.34 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.68 2.253 . . . . 0.0 112.326 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.525 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 94.4 t -139.87 137.87 18.98 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.661 0.743 . . . . 0.0 111.146 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.525 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.8 Cg_endo -69.78 144.51 76.89 Favored 'Cis proline' 0 C--N 1.341 0.181 0 C-N-CA 122.731 -1.779 . . . . 0.0 112.292 0.009 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 14.4 t80 -94.87 118.2 31.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.973 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -102.33 100.76 10.95 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.905 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.432 ' CA ' ' HE2' ' A' ' 17' ' ' MET . . . -107.54 109.58 3.01 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.464 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 10.2 mmt85 -75.35 117.65 17.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.85 0.357 . . . . 0.0 110.855 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 3.5 mt -78.17 93.22 4.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.897 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.8 mm-40 -64.83 99.74 0.36 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.899 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.23 -41.55 1.45 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.54 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.417 ' O ' ' NE ' ' A' ' 41' ' ' ARG . . . 95.21 164.59 34.97 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.499 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 87.5 mt -58.48 110.68 1.02 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.872 0.368 . . . . 0.0 110.903 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 44.4 p -124.12 146.23 48.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.134 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -47.27 -22.69 0.44 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.088 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.02 35.22 3.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.861 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.417 ' NE ' ' O ' ' A' ' 36' ' ' GLY . 20.3 ttm-85 -114.59 138.81 50.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.872 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 88.2 m -136.31 114.55 11.59 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.143 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.43 HG23 ' N ' ' A' ' 44' ' ' ILE . 4.8 mp -90.78 135.07 27.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.13 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.43 ' N ' HG23 ' A' ' 43' ' ' ILE . 80.1 mt -130.26 132.61 64.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.127 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 55.8 mt -133.56 107.09 10.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.103 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 10.7 mttm -102.46 108.42 19.73 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.927 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.03 -156.06 6.78 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.454 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -161.98 127.87 3.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.941 0.4 . . . . 0.0 110.867 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 21.9 t -76.05 114.53 38.28 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.675 0.75 . . . . 0.0 111.13 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 158.5 56.7 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.662 2.241 . . . . 0.0 112.317 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -13.65 34.93 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.681 2.254 . . . . 0.0 112.341 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 40.7 p -114.08 19.0 16.8 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.146 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -114.12 116.6 3.89 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.517 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 19.0 mtpp -61.64 -57.5 11.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.801 0.334 . . . . 0.0 110.895 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 16.6 p -174.88 160.7 2.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.857 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.575 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 17.6 p90 -115.44 -174.41 2.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.85 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.48 ' CB ' ' OD1' ' A' ' 73' ' ' ASN . . . -156.5 130.3 8.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.113 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.409 HD11 ' CE2' ' A' ' 56' ' ' PHE . 5.3 mp -114.55 103.56 15.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.11 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.4 m-80 -101.44 146.22 27.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.865 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.573 ' CE2' HD11 ' A' ' 145' ' ' LEU . 3.4 m-85 -118.38 99.72 7.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.887 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.44 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 32.8 ttmt -97.47 169.23 9.88 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.884 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.44 ' N ' ' HG2' ' A' ' 61' ' ' LYS . 39.8 t -101.23 120.4 50.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.133 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -56.54 -39.61 85.23 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.523 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 35.1 m -62.26 -72.33 0.13 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.875 0.369 . . . . 0.0 110.859 -179.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 40.6 p -80.17 -70.21 0.54 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.87 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 127.26 44.25 0.23 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.491 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.404 ' OD1' ' OD1' ' A' ' 88' ' ' ASN . 0.6 OUTLIER -117.37 142.63 46.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.834 0.349 . . . . 0.0 110.87 179.977 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 41.0 mt -86.11 111.2 20.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.128 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.451 ' HB2' ' CG2' ' A' ' 142' ' ' VAL . . . -82.23 -31.25 30.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.075 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.55 HD21 ' CD2' ' A' ' 132' ' ' PHE . 32.4 tp -142.37 132.46 24.59 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.93 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.441 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.8 OUTLIER -134.78 98.79 4.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.88 179.838 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 17.9 mt -101.74 133.57 44.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.102 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.495 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -141.08 106.82 6.2 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.658 0.742 . . . . 0.0 110.878 179.918 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.575 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.2 Cg_endo -69.76 155.32 66.26 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.718 2.278 . . . . 0.0 112.332 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 38.4 mtp180 -132.37 96.56 3.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.875 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -55.4 168.08 0.41 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.862 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 70.86 -73.29 0.66 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.507 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 35.1 t30 -58.85 -63.54 1.26 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.833 0.349 . . . . 0.0 110.86 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 106.76 39.85 1.96 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.533 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.3 p -134.76 118.18 16.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.828 0.346 . . . . 0.0 111.139 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.7 t -100.93 112.85 35.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.128 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 30.2 t -82.3 144.85 9.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.137 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -129.46 126.59 39.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.89 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.441 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.6 OUTLIER -137.07 -177.09 4.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.908 -179.943 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 40.1 t -158.65 105.32 1.82 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.855 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.572 ' HB2' ' CH2' ' A' ' 91' ' ' TRP . 35.9 tp -76.83 115.86 16.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.902 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.519 ' N ' ' O ' ' A' ' 90' ' ' SER . 83.2 mt -93.72 162.45 13.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.946 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.42 ' C ' ' H ' ' A' ' 90' ' ' SER . 8.2 m-80 -41.26 102.17 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.907 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.37 -0.49 3.74 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.51 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.519 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -126.45 171.16 11.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.919 0.39 . . . . 0.0 110.826 -179.713 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.572 ' CH2' ' HB2' ' A' ' 86' ' ' LEU . 26.6 m95 -128.25 160.72 31.24 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.899 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.85 -109.76 1.89 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.496 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' SER . . . . . 0.422 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 47.5 m -155.5 174.52 15.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.791 0.329 . . . . 0.0 110.905 -179.749 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -100.01 125.17 46.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.884 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -120.17 121.22 38.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.854 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 6.4 mtmp? -127.57 118.56 24.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.932 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 20.9 tttt -170.85 107.49 0.29 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.937 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.434 ' CG1' ' N ' ' A' ' 99' ' ' THR . 2.3 tt -145.53 153.38 13.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.147 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.434 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 8.9 t -97.52 -36.2 10.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.128 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . 0.4 ' O ' ' CG ' ' A' ' 100' ' ' HIS . 2.3 p-80 -148.88 128.16 12.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.848 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -102.87 96.66 8.07 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.619 0.723 . . . . 0.0 110.874 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.406 ' O ' ' C ' ' A' ' 103' ' ' PHE . 54.2 Cg_endo -69.74 -42.98 2.95 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.693 2.262 . . . . 0.0 112.374 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.434 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 8.6 m-85 -37.84 105.13 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.868 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -133.21 139.22 10.75 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.481 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 104.21 1.29 Allowed 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.63 2.22 . . . . 0.0 112.352 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 124.41 -7.88 8.45 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.529 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.485 ' NE2' ' O ' ' A' ' 108' ' ' PHE . 2.1 pp0? -131.37 168.7 17.13 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.83 0.348 . . . . 0.0 110.922 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' PHE . . . . . 0.485 ' O ' ' NE2' ' A' ' 107' ' ' GLN . 1.4 p90 -90.89 172.56 8.52 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.856 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 31.9 p90 -158.36 129.2 6.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.881 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -98.86 102.18 13.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.888 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.449 ' CD1' HD12 ' A' ' 113' ' ' ILE . 0.9 OUTLIER -99.85 137.51 38.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.876 -179.918 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.405 ' N ' ' CD1' ' A' ' 111' ' ' LEU . 2.4 m -145.14 111.71 5.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.9 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.449 HD12 ' CD1' ' A' ' 111' ' ' LEU . 3.9 mp -94.71 121.04 44.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.162 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.566 ' HD3' ' CD1' ' A' ' 123' ' ' TYR . 0.2 OUTLIER -99.54 123.92 44.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.864 179.984 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . 0.574 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 7.9 t -90.11 126.66 35.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.907 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -123.35 -150.32 8.0 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.489 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 9.2 mt -111.8 -39.72 4.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.863 0.363 . . . . 0.0 110.946 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . 0.423 ' C ' ' CD2' ' A' ' 134' ' ' HIS . 29.0 t0 -88.78 -34.66 17.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.831 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.5 ptt180 -172.73 167.87 5.22 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.888 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.574 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.4 m-30 -93.18 158.68 15.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.865 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.409 ' HB3' ' CE1' ' A' ' 123' ' ' TYR . 17.9 mtpp -130.62 104.72 7.37 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.897 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . 0.423 HG22 ' CE1' ' A' ' 130' ' ' PHE . 92.5 t -93.4 108.47 20.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.116 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' TYR . . . . . 0.566 ' CD1' ' HD3' ' A' ' 114' ' ' ARG . 32.9 m-85 -96.43 147.86 23.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.904 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . 0.414 ' CB ' HD12 ' A' ' 129' ' ' LEU . . . -127.5 102.14 6.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.074 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 57.19 37.62 28.48 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.875 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.38 33.39 28.59 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.504 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -142.89 120.67 11.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.85 0.357 . . . . 0.0 110.895 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . 0.488 ' CE1' ' OD2' ' A' ' 131' ' ' ASP . 33.6 t-80 -53.22 99.86 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.884 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . 0.414 HD12 ' CB ' ' A' ' 124' ' ' ALA . 10.5 tp -70.01 -67.41 0.49 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.883 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.429 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 8.2 p90 -162.41 175.48 11.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.886 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.488 ' OD2' ' CE1' ' A' ' 128' ' ' HIS . 15.7 m-20 -120.21 150.17 41.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.864 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.558 ' CE1' ' O ' ' A' ' 133' ' ' ALA . 0.1 OUTLIER -115.86 107.81 15.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.848 -179.886 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.558 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -63.22 131.87 49.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.11 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' HIS . . . . . 0.423 ' CD2' ' C ' ' A' ' 118' ' ' ASP . 44.0 m-70 -62.35 102.39 0.31 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.893 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.422 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 68.9 mtt-85 -89.34 -45.98 9.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.872 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 4.5 tp -99.7 108.16 20.44 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.907 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 58.2 p -50.88 -33.17 22.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.853 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . 0.446 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.23 31.17 0.39 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.095 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 40.0 p90 -52.37 -42.31 63.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.883 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 8.2 pt20 -48.68 -42.31 34.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.916 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.446 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 72.2 mtp180 -54.36 -40.96 68.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.895 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.451 ' CG2' ' HB2' ' A' ' 69' ' ' ALA . 69.8 t -44.99 105.43 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.148 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -129.92 34.32 4.28 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.898 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 11.6 m -143.04 116.68 9.21 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.126 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.573 HD11 ' CE2' ' A' ' 60' ' ' PHE . 7.1 tp -116.45 107.8 15.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.959 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' GLU . . . . . 0.404 ' C ' HG13 ' A' ' 147' ' ' ILE . 8.0 pt-20 -111.79 153.02 27.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.852 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . 0.404 HG13 ' C ' ' A' ' 146' ' ' GLU . 16.8 mt -139.95 109.8 3.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.172 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -118.54 173.64 6.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.911 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.46 -145.45 16.09 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.503 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -112.18 93.05 4.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.868 0.366 . . . . 0.0 110.879 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 5.6 p -151.12 149.13 14.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.138 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 40.0 m -110.23 95.06 5.34 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.132 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.454 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 84.6 mt -76.53 136.09 39.3 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.901 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 6.0 m -120.08 -36.54 3.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.897 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . 0.545 ' CE2' ' HB2' ' A' ' 21' ' ' PRO . 53.5 t80 -150.64 130.94 13.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.909 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 44.8 t -139.72 105.0 2.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.123 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 12.2 tt0 -120.37 135.42 55.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.879 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' ILE . . . . . 0.43 HD12 ' CE ' ' A' ' 17' ' ' MET . 16.9 mt -104.38 94.36 3.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.135 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 36.9 t -56.99 152.06 13.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.882 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 171.36 -174.4 44.96 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.523 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 152.42 69.22 Favored 'Trans proline' 0 C--O 1.231 0.139 0 C-N-CA 122.671 2.247 . . . . 0.0 112.334 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 19.9 m -61.47 -48.84 79.28 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.875 -179.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 38.6 m -125.8 177.4 6.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.849 -179.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.3 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.505 -179.975 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.517 -0.233 . . . . 0.0 112.517 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.3 t 47.93 42.84 16.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.918 0.389 . . . . 0.0 110.871 -179.758 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 97.8 p -117.85 135.29 54.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.865 -179.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.15 169.77 28.12 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.515 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 71.0 m -106.08 123.1 47.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.862 0.363 . . . . 0.0 110.878 -179.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 28.7 t -89.63 98.73 11.93 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.875 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 162.29 137.86 2.29 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.489 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 22.2 p80 -160.51 163.08 33.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.766 0.317 . . . . 0.0 110.89 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 21.1 mm-40 -110.53 130.37 55.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.88 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -85.77 15.46 4.78 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.884 -179.909 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 8.2 mp -88.59 162.37 16.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.96 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . 0.444 ' O ' ' C ' ' A' ' 13' ' ' SER . 8.5 m-80 -40.68 -47.38 2.78 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.848 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.444 ' C ' ' O ' ' A' ' 12' ' ' ASN . 34.3 m -34.49 147.46 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.856 -179.838 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 4.6 pp -99.99 153.81 37.57 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.62 0.724 . . . . 0.0 110.901 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 -165.64 0.16 Allowed 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.649 2.233 . . . . 0.0 112.391 179.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.471 ' HG1' ' NE2' ' A' ' 34' ' ' GLN . 1.5 m -82.9 152.67 25.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.162 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' MET . . . . . 0.432 ' N ' ' CG2' ' A' ' 16' ' ' THR . 20.1 mtm -106.72 74.84 1.02 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.841 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -109.22 -176.84 3.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.878 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 87.49 -144.46 19.08 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.53 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 165.47 30.88 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.664 2.243 . . . . 0.0 112.33 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 174.91 8.82 Favored 'Trans proline' 0 C--O 1.232 0.213 0 C-N-CA 122.683 2.255 . . . . 0.0 112.398 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.473 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.9 m -84.95 147.02 26.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.131 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.473 ' CD1' ' O ' ' A' ' 22' ' ' THR . 6.7 m-85 -147.37 124.59 11.5 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.891 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . 0.575 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 4.6 t-20 58.93 46.23 1.48 Allowed Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.621 0.724 . . . . 0.0 110.883 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.575 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.77 134.47 28.04 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.679 2.252 . . . . 0.0 112.337 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.409 ' C ' HG22 ' A' ' 27' ' ' VAL . 53.6 Cg_endo -69.75 -177.77 2.03 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.714 2.276 . . . . 0.0 112.301 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.534 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 96.0 t -142.25 138.72 16.9 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-O 121.634 0.731 . . . . 0.0 111.14 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.534 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 54.2 Cg_endo -69.72 144.39 76.44 Favored 'Cis proline' 0 C--N 1.341 0.17 0 C-N-CA 122.685 -1.798 . . . . 0.0 112.381 -0.11 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -98.37 115.68 28.98 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.925 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.467 ' CD2' ' HB3' ' A' ' 146' ' ' GLU . 63.7 m-85 -103.27 102.65 12.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.851 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.43 ' C ' ' HE1' ' A' ' 17' ' ' MET . . . -115.75 103.97 1.25 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.479 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.486 ' NH1' ' NE2' ' A' ' 34' ' ' GLN . 0.0 OUTLIER -72.34 132.03 43.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.836 0.35 . . . . 0.0 110.862 -179.848 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 143' ' ' ASP . 9.5 mt -76.87 142.57 40.13 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.942 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.486 ' NE2' ' NH1' ' A' ' 32' ' ' ARG . 23.0 mm-40 -100.39 91.49 4.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.926 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 133.23 -50.02 0.89 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.53 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.462 ' O ' ' CG2' ' A' ' 38' ' ' THR . . . 108.56 161.56 20.34 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.504 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 99.4 mt -50.31 105.32 0.09 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.881 0.372 . . . . 0.0 110.933 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.462 ' CG2' ' O ' ' A' ' 36' ' ' GLY . 12.1 p -123.12 146.27 47.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.11 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -44.59 -31.98 1.31 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.173 179.856 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -103.45 41.05 1.31 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.895 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.413 ' NH2' ' O ' ' A' ' 34' ' ' GLN . 45.5 ttm-85 -124.31 136.03 53.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.861 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 39.3 m -135.91 126.33 26.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.14 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 mp -98.94 132.48 44.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.101 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 95.3 mt -123.58 134.68 65.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.137 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 59.5 mt -135.95 107.88 7.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.144 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.4 mtmm -110.34 111.07 22.12 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.925 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.66 -143.45 4.31 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.51 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 1.6 t80 -170.16 126.78 0.82 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.851 0.357 . . . . 0.0 110.944 -179.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 11.2 t -77.36 116.13 55.11 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.616 0.722 . . . . 0.0 111.124 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 158.68 56.15 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.699 2.266 . . . . 0.0 112.331 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -19.36 36.38 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.733 2.288 . . . . 0.0 112.327 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 69.2 p -109.7 21.27 17.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.142 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -115.02 120.04 4.84 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.486 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 20.6 mtpp -61.27 -60.19 4.13 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.797 0.332 . . . . 0.0 110.897 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.7 p -175.29 157.59 2.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.886 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.508 ' O ' ' ND2' ' A' ' 73' ' ' ASN . 4.0 p90 -108.47 -172.5 2.07 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.857 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -154.82 141.41 18.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.082 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.446 HG21 ' CE1' ' A' ' 60' ' ' PHE . 2.6 mp -123.0 98.7 5.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.166 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.0 m-80 -101.07 144.84 29.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.908 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.446 ' CE1' HG21 ' A' ' 58' ' ' ILE . 29.6 m-85 -117.24 101.45 8.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.912 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.411 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 32.8 ttmt -95.83 168.39 10.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.863 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.482 ' CG2' HG21 ' A' ' 142' ' ' VAL . 61.4 t -100.41 122.27 52.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.171 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -57.08 -41.13 92.42 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.515 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 44.2 t -65.15 -73.04 0.13 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.888 0.375 . . . . 0.0 110.856 -179.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 39.0 t -77.99 -75.94 0.2 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.918 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 132.42 40.28 0.21 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.485 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -111.88 142.01 44.81 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.761 0.315 . . . . 0.0 110.892 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 50.0 mt -86.41 120.11 35.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.152 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.458 ' CB ' HG23 ' A' ' 142' ' ' VAL . . . -92.24 -33.55 14.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.08 179.829 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.514 HD13 ' CD1' ' A' ' 132' ' ' PHE . 59.8 tp -138.85 130.61 27.65 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.907 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.492 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.5 OUTLIER -134.96 92.63 2.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.913 179.843 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 30.5 mt -94.99 128.37 46.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.117 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.508 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -134.58 105.4 10.89 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.611 0.719 . . . . 0.0 110.897 179.929 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.476 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.2 Cg_endo -69.71 154.51 67.85 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.701 2.267 . . . . 0.0 112.354 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 36.1 mtp180 -130.32 96.94 4.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.876 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' MET . . . . . 0.476 ' HE2' ' CE1' ' A' ' 56' ' ' PHE . 0.0 OUTLIER -61.42 -43.14 99.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.845 -179.984 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -55.2 -86.42 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.461 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 30.3 t30 -55.1 -60.09 3.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.884 0.374 . . . . 0.0 110.92 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 116.38 50.44 0.42 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.447 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 34.8 p -151.21 122.92 8.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.838 0.352 . . . . 0.0 111.17 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 13.1 t -89.29 108.73 19.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.097 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 91.6 t -80.93 145.97 8.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.088 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -127.34 124.81 39.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.892 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.492 ' O ' ' N ' ' A' ' 71' ' ' HIS . 2.7 m120 -135.22 179.3 6.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.901 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 46.1 t -160.78 105.63 1.4 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.861 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.574 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 27.0 tp -77.96 119.34 21.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.92 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.503 ' N ' ' O ' ' A' ' 90' ' ' SER . 87.0 mt -97.08 161.35 13.86 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.919 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.532 HD21 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.23 101.61 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.931 179.898 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.45 -6.41 0.82 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.501 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.512 ' H ' ' C ' ' A' ' 88' ' ' ASN . 0.3 OUTLIER -118.96 172.06 7.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.834 0.349 . . . . 0.0 110.844 -179.725 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.574 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 22.0 m95 -129.43 161.07 31.21 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.929 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.09 -106.01 1.55 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.476 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 2.9 m -165.76 174.92 9.2 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.812 0.339 . . . . 0.0 110.835 -179.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.416 ' HG2' ' ND2' ' A' ' 84' ' ' ASN . 7.6 mt-10 -104.66 117.62 34.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.88 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -123.05 108.78 13.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.876 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 35.8 mtmt -105.57 131.32 53.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.864 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.463 ' HE3' ' N ' ' A' ' 98' ' ' ILE . 0.0 OUTLIER -174.31 105.23 0.11 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.903 179.889 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.463 ' N ' ' HE3' ' A' ' 97' ' ' LYS . 5.1 tt -148.09 154.25 10.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.12 179.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.416 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 9.0 t -95.29 -44.62 7.51 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.143 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . 0.426 ' O ' ' CD1' ' A' ' 98' ' ' ILE . 4.9 p-80 -139.1 133.3 31.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.856 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 44.2 t-20 -110.92 95.99 27.07 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.628 0.728 . . . . 0.0 110.892 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.434 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.4 Cg_endo -69.78 -42.6 3.24 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.646 2.231 . . . . 0.0 112.34 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.434 ' C ' ' O ' ' A' ' 102' ' ' PRO . 5.2 m-85 -35.88 104.84 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.861 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -135.88 138.44 9.92 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.455 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 99.95 0.78 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.722 2.281 . . . . 0.0 112.319 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 130.45 -9.59 5.87 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.461 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.1 pt20 -131.49 159.22 38.76 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.806 0.336 . . . . 0.0 110.941 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -76.45 174.09 10.7 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.849 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.468 ' O ' ' CD2' ' A' ' 109' ' ' PHE . 23.4 p90 -161.55 117.87 2.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.887 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -94.76 102.08 13.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.878 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.449 ' CD1' HD13 ' A' ' 113' ' ' ILE . 0.9 OUTLIER -101.23 137.33 39.73 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.921 -179.943 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 5.2 m -144.2 114.16 7.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.859 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.449 HD13 ' CD1' ' A' ' 111' ' ' LEU . 5.1 mp -96.47 140.71 16.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.147 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 24.6 mtt180 -115.57 124.93 52.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.879 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . 0.552 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 6.5 t -92.89 118.45 31.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.85 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.99 -144.82 8.51 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.434 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 13.6 mt -116.85 -36.95 3.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.838 0.351 . . . . 0.0 110.933 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -92.23 -34.69 14.17 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.833 179.861 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 17.8 ptp180 -171.77 172.83 4.75 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.885 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.552 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.6 m-30 -96.28 158.17 15.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.845 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 27.4 mtpt -129.82 100.34 5.44 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.917 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 88.0 t -86.18 137.07 21.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.133 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -126.54 152.72 46.16 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.884 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -140.83 111.17 6.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.069 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 56.78 29.71 16.45 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.9 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 83.37 32.12 26.11 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.503 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 8.5 mm100 -139.01 125.77 20.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.872 0.368 . . . . 0.0 110.875 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . 0.445 ' CE1' ' OD1' ' A' ' 131' ' ' ASP . 31.3 t-80 -56.6 109.22 0.58 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.839 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 10.7 tp -77.8 -68.38 0.63 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.939 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.437 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 7.6 p90 -165.18 171.48 13.66 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.883 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.445 ' OD1' ' CE1' ' A' ' 128' ' ' HIS . 1.4 m-20 -113.97 151.64 32.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.865 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.514 ' CD1' HD13 ' A' ' 70' ' ' LEU . 0.3 OUTLIER -116.8 108.58 16.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.929 -179.933 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.513 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -63.49 134.42 55.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.065 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 15.8 m-70 -62.82 103.0 0.4 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.849 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 47.2 mtt-85 -87.1 -52.82 5.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.906 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 9.5 tp -91.54 108.34 19.83 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.934 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 99.2 p -50.5 -32.48 18.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.867 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . 0.457 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.93 25.54 0.67 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.06 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.436 ' CG ' ' N ' ' A' ' 140' ' ' GLN . 12.5 p90 -45.44 -42.81 10.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.869 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' GLN . . . . . 0.436 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 10.7 pt20 -48.93 -40.06 28.65 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.894 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.457 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 41.0 mtp85 -55.9 -39.71 71.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.9 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.482 HG21 ' CG2' ' A' ' 62' ' ' VAL . 53.1 t -51.7 103.24 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.511 ' O ' ' N ' ' A' ' 33' ' ' LEU . 3.1 p30 -125.47 25.94 6.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.849 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 2.2 m -132.99 140.19 47.65 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.137 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.427 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.7 tp -134.64 108.32 7.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.947 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' GLU . . . . . 0.467 ' HB3' ' CD2' ' A' ' 30' ' ' PHE . 5.8 pt-20 -111.51 148.85 32.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.896 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 9.9 mt -136.65 111.46 10.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.11 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 1.1 pm0 -124.26 176.68 6.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.956 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 109.97 -139.48 15.41 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.495 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -120.47 90.82 3.4 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.848 0.356 . . . . 0.0 110.898 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.446 HG22 ' N ' ' A' ' 152' ' ' THR . 2.8 p -151.15 155.33 7.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.13 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' THR . . . . . 0.446 ' N ' HG22 ' A' ' 151' ' ' VAL . 38.0 m -113.32 93.7 4.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.156 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.459 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 68.2 mt -77.27 137.33 38.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.939 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 6.9 t -121.42 -39.55 2.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.888 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 19.3 t80 -143.49 129.17 19.26 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.929 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 76.3 t -141.05 105.42 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.128 179.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 14.6 tt0 -118.39 134.39 55.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.927 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 21.3 mt -105.22 90.44 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.158 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 27.4 p -60.39 176.14 0.38 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.872 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 151.36 -156.74 26.84 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.503 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 178.68 4.32 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.701 2.267 . . . . 0.0 112.335 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 4.3 t -110.94 113.01 25.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.898 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 97.0 p -101.68 41.4 1.21 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.836 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.275 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.5 -179.997 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.305 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 25.4 t -129.25 81.05 2.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.877 0.37 . . . . 0.0 110.882 -179.751 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 23.2 t -43.76 102.12 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.839 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -142.03 90.37 0.18 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.492 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.8 m -109.02 86.23 2.24 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.919 0.39 . . . . 0.0 110.873 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.2 t -93.56 129.48 39.78 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.887 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -125.86 157.46 19.86 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.468 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 25.3 p80 -38.83 152.24 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.74 0.305 . . . . 0.0 110.894 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -84.66 163.84 18.99 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.89 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 50.9 mt-30 -72.58 105.17 4.12 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.963 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -65.53 -28.77 69.41 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.92 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 4.6 m120 -113.75 119.41 37.29 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.902 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 17.5 m -125.06 171.81 9.96 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.838 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 2.8 pp -119.56 155.23 54.55 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.653 0.739 . . . . 0.0 110.917 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.71 175.73 7.67 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.685 2.257 . . . . 0.0 112.366 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 9.2 t -70.24 148.37 48.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.108 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 4.0 ptt? -99.08 40.3 1.22 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.89 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -77.54 -176.64 4.36 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.841 -179.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.65 -131.08 10.52 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.476 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 166.52 27.26 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.701 2.267 . . . . 0.0 112.332 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -175.5 1.18 Allowed 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.684 2.256 . . . . 0.0 112.354 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.538 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.6 m -96.09 151.95 18.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.118 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.538 ' CD1' ' O ' ' A' ' 22' ' ' THR . 8.3 m-85 -150.84 127.4 10.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.887 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . 0.59 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 3.4 m120 54.48 45.46 2.27 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.607 0.718 . . . . 0.0 110.893 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.59 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.6 Cg_endo -69.76 132.56 23.59 Favored 'Trans proline' 0 C--O 1.231 0.175 0 C-N-CA 122.655 2.236 . . . . 0.0 112.299 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.81 -175.11 1.06 Allowed 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.669 2.246 . . . . 0.0 112.394 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.529 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 86.9 t -143.17 137.63 14.95 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.616 0.722 . . . . 0.0 111.14 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.529 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.6 Cg_endo -69.79 144.63 77.27 Favored 'Cis proline' 0 C--N 1.341 0.184 0 C-N-CA 122.702 -1.791 . . . . 0.0 112.319 -0.017 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 6.4 t80 -98.31 121.99 40.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.938 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -102.17 101.95 12.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.842 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -100.82 108.77 3.52 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.455 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 6.8 mmt85 -73.28 123.29 23.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.856 0.36 . . . . 0.0 110.902 -179.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.453 HD12 ' N ' ' A' ' 144' ' ' THR . 7.8 mt -87.05 113.73 23.05 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.929 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 5.7 mm100 -84.62 80.53 9.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.888 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 143.54 -36.83 1.51 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.501 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.469 ' CA ' ' OD1' ' A' ' 143' ' ' ASP . . . 93.72 -177.93 37.59 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.48 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 89.0 mt -68.47 98.05 0.82 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.899 0.38 . . . . 0.0 110.885 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 34.6 p -107.77 161.85 14.52 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.1 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -62.18 -27.47 68.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.112 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 8.8 mpt_? -105.61 33.06 3.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.918 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.466 ' NH1' ' CG2' ' A' ' 158' ' ' ILE . 4.5 ttt85 -109.74 137.98 46.77 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 87.4 m -138.96 120.82 15.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.136 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.4 mp -93.74 137.78 21.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.159 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 76.2 mt -128.96 118.65 47.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.084 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 71.9 mt -118.1 107.37 21.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.104 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 21.9 mtmt -113.69 109.49 18.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.928 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -143.2 -143.61 4.15 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.528 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -168.03 128.6 1.35 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.941 0.4 . . . . 0.0 110.944 -179.845 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 15.4 t -79.11 119.6 77.75 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.646 0.736 . . . . 0.0 111.17 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 158.91 55.29 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.683 2.255 . . . . 0.0 112.313 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -17.96 37.03 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.712 2.274 . . . . 0.0 112.304 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 30.2 p -109.52 18.77 20.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.126 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -115.74 121.18 5.17 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.477 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 20.2 mtpp -63.91 -58.78 5.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.78 0.324 . . . . 0.0 110.906 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.0 m -173.12 167.77 4.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.833 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.461 ' CD1' ' N ' ' A' ' 56' ' ' PHE . 1.9 p90 -119.07 -172.2 2.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.86 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.485 ' CB ' ' OD1' ' A' ' 73' ' ' ASN . . . -154.67 133.82 12.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.106 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.6 mp -115.77 98.18 6.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.151 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . 0.415 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 6.0 m-80 -100.25 143.33 30.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.939 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.571 ' CE2' HD13 ' A' ' 145' ' ' LEU . 28.5 m-85 -115.32 98.38 6.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.904 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.417 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 33.7 ttmt -95.68 168.31 10.75 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.934 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.417 ' N ' ' HG2' ' A' ' 61' ' ' LYS . 53.4 t -100.24 125.08 54.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.147 179.85 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.593 ' N ' ' HG1' ' A' ' 144' ' ' THR . . . -60.44 -36.88 92.25 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.509 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 69.7 m -65.95 -73.34 0.13 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.871 0.367 . . . . 0.0 110.897 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 58.0 m -81.18 -73.36 0.38 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.853 -179.874 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 133.62 39.8 0.19 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.491 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.435 ' OD2' ' ND2' ' A' ' 88' ' ' ASN . 1.2 m-20 -108.92 142.88 38.9 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.789 0.328 . . . . 0.0 110.886 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 35.8 mt -92.35 114.01 28.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.127 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.427 ' HB3' ' CG2' ' A' ' 142' ' ' VAL . . . -83.63 -31.49 26.19 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.112 179.817 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.557 HD21 ' CD2' ' A' ' 132' ' ' PHE . 56.0 tp -141.28 130.91 24.04 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.889 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.476 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.2 t60 -134.49 92.94 2.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.845 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 18.2 mt -97.31 132.97 40.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.112 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.485 ' OD1' ' CB ' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -140.27 106.49 6.65 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.63 0.728 . . . . 0.0 110.899 179.941 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.584 ' HB3' ' CD2' ' A' ' 103' ' ' PHE . 54.0 Cg_endo -69.74 154.98 67.16 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.652 2.235 . . . . 0.0 112.335 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 57.8 mtp180 -131.49 100.57 5.19 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.887 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' MET . . . . . 0.409 ' N ' ' SD ' ' A' ' 76' ' ' MET . 0.0 OUTLIER -63.63 161.62 14.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.891 179.952 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 85.28 -67.8 3.57 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.457 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -75.43 -57.83 3.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.848 0.356 . . . . 0.0 110.887 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 105.73 48.89 0.99 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.513 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.2 p -136.95 118.15 14.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.797 0.332 . . . . 0.0 111.167 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 15.2 t -102.54 114.26 41.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.13 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 37.1 t -84.53 143.34 11.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.127 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -125.4 124.88 42.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.853 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.476 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.7 OUTLIER -136.23 176.29 8.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.906 -179.975 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 47.7 t -156.15 105.07 2.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.891 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.561 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 39.0 tp -77.18 114.33 15.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.904 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.518 ' N ' ' O ' ' A' ' 90' ' ' SER . 79.7 mt -92.44 161.93 14.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.929 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.435 ' ND2' ' OD2' ' A' ' 67' ' ' ASP . 13.5 m-80 -41.17 101.83 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.938 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.15 -1.55 3.61 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.485 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.518 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -125.31 170.59 11.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.828 0.347 . . . . 0.0 110.898 -179.815 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.561 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 23.1 m95 -128.12 160.57 31.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.903 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -91.97 -102.04 1.38 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.461 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 9.9 m -167.82 174.41 7.56 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.868 0.366 . . . . 0.0 110.823 -179.752 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -96.71 123.64 40.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.881 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 17.8 mm-40 -121.37 116.12 24.2 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.9 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 6.7 mtmp? -120.72 122.16 39.82 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.888 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -175.17 105.54 0.09 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.855 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.432 ' CD1' ' O ' ' A' ' 100' ' ' HIS . 6.4 tt -147.64 146.58 18.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.137 179.842 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 10.2 t -81.34 -44.79 17.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . 0.432 ' O ' ' CD1' ' A' ' 98' ' ' ILE . 5.1 p-80 -148.5 141.26 24.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.9 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . 0.443 ' OD1' ' C ' ' A' ' 101' ' ' ASN . 4.9 t-20 -101.63 102.13 20.97 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.605 0.717 . . . . 0.0 110.899 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.469 ' CD ' HD11 ' A' ' 129' ' ' LEU . 53.8 Cg_endo -69.78 -29.6 23.53 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.691 2.26 . . . . 0.0 112.33 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.584 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 19.6 m-85 -58.6 115.02 2.77 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.866 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -140.06 139.83 10.18 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.516 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 111.0 2.7 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.716 2.277 . . . . 0.0 112.305 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 107.18 0.9 35.64 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.487 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -137.85 142.09 40.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.849 0.356 . . . . 0.0 110.903 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.4 p90 -68.57 174.51 4.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.844 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.4 ' CD1' ' HE1' ' A' ' 103' ' ' PHE . 29.1 p90 -161.25 132.21 5.32 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.922 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -103.34 106.38 16.88 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.859 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.435 ' CD1' HG11 ' A' ' 122' ' ' VAL . 0.4 OUTLIER -109.16 138.39 45.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.912 -179.955 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 2.6 m -145.44 113.67 6.59 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.867 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.0 mp -93.55 136.82 24.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.108 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 50.1 mtt-85 -110.22 120.9 43.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.851 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . 0.444 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 26.3 t -92.06 122.21 34.35 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.918 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -123.62 -149.44 7.77 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.484 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 36.3 mt -109.37 -40.88 4.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.86 0.362 . . . . 0.0 110.904 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -80.72 -39.54 26.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.83 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -174.11 179.91 1.8 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.898 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.444 ' CE2' ' HB2' ' A' ' 115' ' ' CYS . 18.9 m-85 -97.95 155.04 17.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.877 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 15.5 mtpp -130.48 100.55 5.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.921 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . 0.435 HG11 ' CD1' ' A' ' 111' ' ' LEU . 21.3 t -88.16 128.61 40.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.116 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -120.59 149.79 41.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.909 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . 0.441 ' CB ' ' HG3' ' A' ' 102' ' ' PRO . . . -134.17 110.1 9.34 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.093 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 58.13 31.58 20.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.911 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.31 38.2 15.64 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.484 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 8.7 mm100 -143.77 128.88 18.66 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.868 0.366 . . . . 0.0 110.914 -179.854 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 35.6 t-80 -59.21 107.19 0.52 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.845 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . 0.469 HD11 ' CD ' ' A' ' 102' ' ' PRO . 8.5 tp -78.41 -66.12 0.89 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.899 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.472 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 5.3 p90 -166.42 169.53 13.86 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.861 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -115.21 149.71 37.28 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.917 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.579 ' CE1' ' O ' ' A' ' 133' ' ' ALA . 0.1 OUTLIER -117.73 108.02 14.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.899 -179.92 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.579 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -63.33 134.97 56.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.066 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 42.3 m-70 -63.34 107.3 1.06 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.884 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 67.6 mtt-85 -89.71 -48.85 7.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.849 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 12.2 tp -93.51 109.33 20.93 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.943 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 12.1 t -50.64 -33.37 22.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.868 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -87.19 33.55 0.68 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.107 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 8.2 p90 -50.74 -31.61 17.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.868 -179.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 6.1 pt20 -56.14 -46.46 79.22 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.885 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.433 ' O ' ' CG ' ' A' ' 143' ' ' ASP . 27.6 mtt-85 -47.5 -44.22 25.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.866 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.427 ' CG2' ' HB3' ' A' ' 69' ' ' ALA . 92.3 t -43.3 103.45 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.153 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.469 ' OD1' ' CA ' ' A' ' 36' ' ' GLY . 17.1 m-20 -128.19 31.48 5.05 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.841 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' THR . . . . . 0.593 ' HG1' ' N ' ' A' ' 63' ' ' GLY . 18.1 m -142.44 123.19 14.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.122 -179.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.571 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.6 tp -120.15 107.69 13.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.933 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -110.75 152.31 26.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.919 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 25.1 mt -139.58 112.77 6.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.177 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -123.57 171.29 9.64 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.928 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 113.03 -148.07 18.54 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.522 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 28.8 m-20 -111.56 89.1 2.96 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.859 0.361 . . . . 0.0 110.881 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.454 HG21 ' N ' ' A' ' 152' ' ' THR . 7.2 p -148.85 155.33 8.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.129 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' THR . . . . . 0.454 ' N ' HG21 ' A' ' 151' ' ' VAL . 16.9 m -116.21 94.51 4.68 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.16 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.457 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 78.6 mt -75.92 139.95 41.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.886 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 68.6 m -127.8 -35.57 2.09 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.858 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 39.6 t80 -146.93 125.08 12.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.942 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 79.4 t -138.97 106.33 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.118 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 13.9 tt0 -119.69 141.16 49.63 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.931 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' ILE . . . . . 0.466 ' CG2' ' NH1' ' A' ' 41' ' ' ARG . 15.6 mt -110.1 97.27 5.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.121 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 42.4 t -45.85 141.9 2.82 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.856 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -90.74 177.82 42.13 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.507 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -17.58 37.42 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.738 2.292 . . . . 0.0 112.309 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.8 m -132.26 133.24 43.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.839 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 25.8 t -133.0 132.48 41.94 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.876 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.493 -179.988 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 N-CA-C 112.534 -0.226 . . . . 0.0 112.534 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 69.0 m -114.88 -54.65 2.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.888 0.375 . . . . 0.0 110.897 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 59.6 p -130.76 153.31 49.17 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.869 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 153.29 95.25 0.11 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.466 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.0 m -124.12 157.45 34.61 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.881 0.372 . . . . 0.0 110.852 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 12.5 t -97.34 -48.67 5.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.906 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 111.84 117.94 3.66 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.476 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 28.2 p-80 -83.2 130.06 35.06 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.776 0.322 . . . . 0.0 110.822 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 91.3 mm-40 -78.53 88.67 4.47 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.883 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 41.4 tt0 -118.6 82.91 1.93 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.935 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 56.5 mt -117.44 44.06 2.21 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.911 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 74.3 m-80 -58.2 -39.77 79.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.897 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 29.5 p -105.56 158.06 16.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.836 -179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 97.1 mt -51.68 151.29 6.09 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-O 121.586 0.708 . . . . 0.0 110.916 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.7 -163.9 0.12 Allowed 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.665 2.243 . . . . 0.0 112.399 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.5 m -88.78 149.46 23.42 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.136 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' MET . . . . . 0.463 ' HE1' ' CA ' ' A' ' 31' ' ' GLY . 3.2 mpp? -95.99 102.03 13.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.833 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.4 163.25 14.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.863 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 77.89 -132.25 11.72 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.518 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 168.71 20.7 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.708 2.272 . . . . 0.0 112.366 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.69 -179.09 2.64 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.679 2.253 . . . . 0.0 112.344 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 1.2 t -97.8 148.86 22.96 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.129 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -138.92 127.83 23.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.92 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . 0.567 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 8.8 m-80 61.55 47.0 1.08 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.578 0.704 . . . . 0.0 110.901 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.567 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 54.0 Cg_endo -69.75 136.03 31.99 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.65 2.234 . . . . 0.0 112.312 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 -177.72 2.02 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.68 2.253 . . . . 0.0 112.331 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.524 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 97.0 t -141.72 138.09 16.87 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.685 0.755 . . . . 0.0 111.107 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.524 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.3 Cg_endo -69.77 144.33 76.38 Favored 'Cis proline' 0 C--N 1.342 0.198 0 C-N-CA 122.65 -1.812 . . . . 0.0 112.325 -0.027 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 8.2 t80 -97.47 117.15 31.09 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.933 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -100.66 102.3 13.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.884 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.463 ' CA ' ' HE1' ' A' ' 17' ' ' MET . . . -97.77 109.4 3.81 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.456 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 9.7 mmt180 -72.91 102.99 3.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.854 0.359 . . . . 0.0 110.876 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.432 HD13 ' N ' ' A' ' 144' ' ' THR . 5.6 mt -71.1 114.7 9.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.939 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 5.6 mm-40 -86.32 94.49 9.36 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.911 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 131.33 -32.75 2.9 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.453 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.405 ' CA ' ' OD1' ' A' ' 143' ' ' ASP . . . 88.69 173.45 46.87 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.51 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . 0.406 HD22 ' NH2' ' A' ' 41' ' ' ARG . 88.0 mt -57.18 104.97 0.19 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.854 0.359 . . . . 0.0 110.938 -179.9 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.402 ' O ' ' SG ' ' A' ' 115' ' ' CYS . 29.0 p -117.07 149.94 39.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.116 -180.0 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -59.71 -21.27 60.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.122 179.83 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 25.5 mmm-85 -104.42 26.46 8.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.884 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.406 ' NH2' HD22 ' A' ' 37' ' ' LEU . 23.4 ttt180 -116.97 142.86 46.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.863 -179.892 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 91.2 m -137.16 121.21 17.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.123 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 mp -90.86 132.46 35.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.156 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.433 ' CG2' ' HE2' ' A' ' 46' ' ' LYS . 70.1 mt -128.57 117.24 44.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.154 179.792 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 34.9 mt -116.15 107.59 22.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.168 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.433 ' HE2' ' CG2' ' A' ' 44' ' ' ILE . 22.3 mtmt -111.65 111.18 21.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.904 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -143.67 -143.62 4.12 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.484 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 0.405 ' O ' ' CD1' ' A' ' 48' ' ' TYR . 1.1 t80 -167.59 118.27 0.85 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.944 0.402 . . . . 0.0 110.896 -179.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 15.1 t -69.96 115.45 34.0 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.638 0.732 . . . . 0.0 111.135 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 159.02 54.96 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.714 2.276 . . . . 0.0 112.359 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -25.16 29.01 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.683 2.256 . . . . 0.0 112.328 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 67.1 p -100.74 15.41 28.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.134 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -109.89 119.4 5.4 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.489 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.418 ' O ' ' SD ' ' A' ' 76' ' ' MET . 24.8 mtpt -62.47 -58.91 5.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.816 0.341 . . . . 0.0 110.89 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 37.0 p -175.58 162.37 2.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.827 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.572 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 3.5 p90 -116.14 -174.98 2.65 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.87 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.482 ' CB ' ' OD1' ' A' ' 73' ' ' ASN . . . -156.91 137.38 13.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.119 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.459 HG21 ' CE1' ' A' ' 60' ' ' PHE . 4.6 mp -118.14 100.78 10.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.152 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -99.85 144.04 29.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.911 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.561 ' CE2' HD11 ' A' ' 145' ' ' LEU . 50.1 m-85 -115.04 97.69 6.37 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.881 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.456 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 35.5 ttmt -96.13 167.68 11.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.899 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.456 ' N ' ' HG2' ' A' ' 61' ' ' LYS . 43.6 t -100.61 122.52 52.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.102 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -58.58 -40.21 94.28 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.515 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.0 t -64.43 -70.74 0.21 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.941 0.4 . . . . 0.0 110.902 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 48.5 t -79.75 -75.06 0.27 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.875 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 131.43 41.37 0.21 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.487 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -114.71 141.47 47.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.833 0.349 . . . . 0.0 110.879 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 43.0 mt -88.05 119.55 35.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.111 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -90.25 -33.57 16.1 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.059 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.561 HD23 ' CD2' ' A' ' 132' ' ' PHE . 62.7 tp -138.44 131.2 29.43 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.898 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.497 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.3 OUTLIER -135.01 93.91 3.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.866 179.877 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 17.1 mt -98.09 133.16 41.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.096 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.482 ' OD1' ' CB ' ' A' ' 57' ' ' ALA . 0.2 OUTLIER -140.8 106.87 6.36 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.597 0.713 . . . . 0.0 110.871 179.937 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.579 ' HB3' ' CD2' ' A' ' 103' ' ' PHE . 53.8 Cg_endo -69.75 154.63 67.56 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.702 2.268 . . . . 0.0 112.383 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 46.0 mtp85 -132.96 94.58 3.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.892 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' MET . . . . . 0.418 ' SD ' ' O ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -47.52 -26.1 1.31 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.885 179.983 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -52.25 -94.83 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.466 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -89.54 19.75 4.37 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.852 0.358 . . . . 0.0 110.895 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.447 ' HA2' ' ND2' ' A' ' 101' ' ' ASN . . . 53.92 39.82 63.55 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.496 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 28.8 p -108.94 117.86 35.31 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.85 0.357 . . . . 0.0 111.114 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.2 t -99.35 110.46 26.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.149 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 67.6 t -82.71 145.45 8.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.113 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -125.84 124.15 40.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.895 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.497 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.4 m120 -135.49 177.12 8.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.889 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 87.1 p -160.67 105.13 1.4 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.826 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.566 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 22.9 tp -77.74 119.34 21.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.943 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 90' ' ' SER . 93.0 mt -96.71 161.48 13.86 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.915 179.876 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.539 HD21 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -37.91 101.67 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.864 179.895 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.51 -7.05 0.68 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.477 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.522 ' H ' ' C ' ' A' ' 88' ' ' ASN . 0.3 OUTLIER -117.54 170.03 9.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.856 0.36 . . . . 0.0 110.871 -179.748 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.566 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 20.7 m95 -128.58 161.1 30.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.927 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -93.14 -110.26 1.98 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.465 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 72.0 m -159.91 178.12 10.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.855 0.359 . . . . 0.0 110.87 -179.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.435 ' C ' ' OE2' ' A' ' 95' ' ' GLU . 30.2 mt-10 -103.07 123.62 47.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.887 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . 0.435 ' OE2' ' C ' ' A' ' 94' ' ' GLU . 3.5 mp0 -122.88 116.96 24.5 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.89 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 9.4 mtmp? -118.79 120.55 37.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.891 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -171.84 108.0 0.23 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.966 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.438 HG12 ' N ' ' A' ' 99' ' ' THR . 4.1 tt -147.66 152.3 12.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.119 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.438 ' N ' HG12 ' A' ' 98' ' ' ILE . 8.9 t -85.42 -47.18 10.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.162 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 1.7 p-80 -147.06 133.49 19.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.87 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . 0.447 ' ND2' ' HA2' ' A' ' 79' ' ' GLY . 7.4 t30 -103.67 98.17 12.34 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.674 0.749 . . . . 0.0 110.856 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.5 Cg_endo -69.75 -42.5 3.36 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.687 2.258 . . . . 0.0 112.331 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.579 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 11.7 m-85 -34.01 110.58 0.09 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.858 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -133.09 136.66 8.84 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.515 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 97.78 0.65 Allowed 'Trans proline' 0 N--CA 1.465 -0.151 0 C-N-CA 122.715 2.277 . . . . 0.0 112.371 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 119.97 1.92 12.8 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.473 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 9.4 pt20 -134.59 149.09 50.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.846 0.355 . . . . 0.0 110.911 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -66.52 168.39 9.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.901 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.41 ' O ' ' CG ' ' A' ' 109' ' ' PHE . 14.9 p90 -160.71 125.51 3.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.906 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -101.75 108.28 19.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.883 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.421 ' CD1' HD11 ' A' ' 113' ' ' ILE . 0.7 OUTLIER -111.81 139.01 47.65 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.932 -179.96 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.5 m -144.9 115.51 7.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.834 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.421 HD11 ' CD1' ' A' ' 111' ' ' LEU . 4.9 mp -97.28 132.03 42.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.135 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.535 ' O ' ' CD2' ' A' ' 120' ' ' PHE . 6.1 mtp-105 -104.53 133.39 49.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.879 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . 0.557 ' HA ' ' CE2' ' A' ' 120' ' ' PHE . 5.7 t -98.08 121.72 40.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.895 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -122.97 -163.04 11.69 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.521 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 7.6 mt -104.82 -28.75 10.96 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.784 0.326 . . . . 0.0 110.892 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . 0.4 ' C ' ' OD1' ' A' ' 118' ' ' ASP . 7.2 t0 -97.43 -39.91 8.94 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.886 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 29.4 ptt-85 -170.34 163.89 8.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.557 ' CE2' ' HA ' ' A' ' 115' ' ' CYS . 14.8 m-85 -88.23 154.78 20.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.86 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 13.6 mtpp -126.94 100.17 6.04 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.908 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . 0.436 HG23 ' CE1' ' A' ' 130' ' ' PHE . 39.3 t -87.44 132.28 33.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.128 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -123.79 146.59 48.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.919 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -134.74 111.89 10.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.111 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 55.64 35.18 24.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.865 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.57 39.57 21.25 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.492 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 9.8 mt-30 -145.99 129.11 16.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.837 0.351 . . . . 0.0 110.937 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 33.0 t-80 -60.76 99.29 0.08 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.889 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 9.8 tp -66.71 -69.62 0.3 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.93 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.482 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 4.9 p90 -163.29 171.38 16.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.913 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -116.49 148.09 41.12 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.86 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.561 ' CD2' HD23 ' A' ' 70' ' ' LEU . 0.3 OUTLIER -116.99 107.66 14.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.859 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.463 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -64.89 133.27 51.49 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.092 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 34.3 m-70 -60.68 109.09 0.95 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.846 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 32.0 mtt-85 -91.54 -51.38 5.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.891 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.0 tp -93.18 109.3 20.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.913 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 81.6 p -49.72 -35.22 21.26 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.83 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -82.22 39.44 0.58 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.115 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 7.5 p90 -60.68 -37.62 82.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.942 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -55.5 -32.68 63.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.915 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.421 ' C ' HG12 ' A' ' 62' ' ' VAL . 34.6 mtp85 -62.2 -37.72 86.39 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.879 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 93.5 t -49.08 104.12 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.087 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.405 ' OD1' ' CA ' ' A' ' 36' ' ' GLY . 0.9 OUTLIER -127.56 34.55 4.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.905 179.892 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' THR . . . . . 0.432 ' N ' HD13 ' A' ' 33' ' ' LEU . 18.7 m -146.89 112.93 5.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.144 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.561 HD11 ' CE2' ' A' ' 60' ' ' PHE . 5.3 tp -112.18 107.14 15.93 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.902 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -109.21 153.97 23.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.903 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 20.2 mt -140.03 107.23 2.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.146 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -115.69 171.5 7.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.932 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 110.64 -146.72 17.5 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.502 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -114.6 93.44 4.33 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.801 0.334 . . . . 0.0 110.896 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.475 HG22 ' N ' ' A' ' 152' ' ' THR . 4.0 p -151.2 142.09 16.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.144 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' THR . . . . . 0.475 ' N ' HG22 ' A' ' 151' ' ' VAL . 9.9 m -101.94 94.78 5.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.161 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.443 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 83.8 mt -77.33 138.1 39.15 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.89 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 16.6 m -122.35 -39.75 2.54 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.87 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 23.8 t80 -146.0 129.01 16.5 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.914 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 70.1 t -140.3 106.33 2.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.138 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 8.9 tt0 -120.8 132.89 55.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.928 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 14.1 mt -99.01 88.52 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.165 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 16.9 m -56.12 119.22 5.56 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.865 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -134.36 164.17 24.58 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.524 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -3.83 12.79 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.674 2.249 . . . . 0.0 112.336 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 9.0 t -113.26 172.21 7.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.889 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 80.5 p -163.83 110.53 1.11 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.865 -179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.273 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.518 -179.991 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 N-CA-C 112.508 -0.237 . . . . 0.0 112.508 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.6 m -46.42 -59.85 2.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.914 0.388 . . . . 0.0 110.849 -179.738 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.9 t -144.06 146.74 33.04 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.851 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.68 43.8 2.84 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.44 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 7.8 t -46.49 112.46 0.5 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.913 0.387 . . . . 0.0 110.891 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 72.8 m -50.99 -43.95 60.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.873 -179.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 49.99 53.23 23.5 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.485 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 5.2 p-80 -87.53 137.34 32.42 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.756 0.312 . . . . 0.0 110.856 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 21.1 mm-40 -109.22 105.39 14.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.926 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 8.2 pt20 -44.73 99.74 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.866 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 51.4 mt -144.22 156.01 44.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.2 p30 -86.48 -45.16 11.38 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 3.8 m -54.54 -174.47 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.84 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.441 ' HB2' ' HD2' ' A' ' 15' ' ' PRO . 0.4 OUTLIER -117.17 157.33 47.17 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.567 0.698 . . . . 0.0 110.966 179.977 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.441 ' HD2' ' HB2' ' A' ' 14' ' ' LEU . 53.6 Cg_endo -69.75 174.57 9.3 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.737 2.291 . . . . 0.0 112.305 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 6.1 t -92.66 -7.1 47.82 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.159 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' MET . . . . . 0.411 ' HE1' ' CA ' ' A' ' 31' ' ' GLY . 40.2 mtm 64.1 43.06 5.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.86 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -80.57 161.91 24.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.886 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.36 -136.63 13.42 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.477 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 170.0 17.63 Favored 'Trans proline' 0 C--O 1.231 0.13 0 C-N-CA 122.694 2.263 . . . . 0.0 112.3 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 -173.51 0.72 Allowed 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.687 2.258 . . . . 0.0 112.398 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.432 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.4 m -98.2 140.69 32.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.129 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -137.48 125.54 22.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . 0.501 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.2 t-20 52.15 50.69 8.59 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.583 0.706 . . . . 0.0 110.862 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.501 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.77 140.36 42.46 Favored 'Trans proline' 0 N--CA 1.465 -0.176 0 C-N-CA 122.678 2.252 . . . . 0.0 112.379 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 -178.4 2.3 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.709 2.273 . . . . 0.0 112.371 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.522 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 97.8 t -140.35 137.58 17.95 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.658 0.742 . . . . 0.0 111.085 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.522 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.8 Cg_endo -69.72 144.68 77.24 Favored 'Cis proline' 0 C--N 1.342 0.187 0 C-N-CA 122.658 -1.809 . . . . 0.0 112.338 -0.067 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 6.2 t80 -97.88 120.72 38.78 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.925 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -103.07 101.02 10.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.887 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.411 ' CA ' ' HE1' ' A' ' 17' ' ' MET . . . -106.62 109.69 3.15 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.477 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.427 ' CG ' HD11 ' A' ' 14' ' ' LEU . 8.3 mmt180 -74.04 109.34 7.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.841 0.353 . . . . 0.0 110.876 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.441 ' CD2' HG12 ' A' ' 158' ' ' ILE . 6.9 mt -67.54 101.08 0.94 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.88 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 24.3 mt-30 -73.36 100.35 3.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.867 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 132.81 -40.18 1.64 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.498 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.492 ' N ' ' OD2' ' A' ' 143' ' ' ASP . . . 89.84 161.45 37.48 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.466 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 91.3 mt -55.42 99.07 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.891 0.376 . . . . 0.0 110.893 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.405 ' O ' ' N ' ' A' ' 41' ' ' ARG . 26.9 p -117.94 145.95 44.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.167 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -41.7 -33.76 0.53 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.113 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 19.0 mmt180 -101.9 41.63 1.2 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.885 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.491 ' NE ' ' O ' ' A' ' 36' ' ' GLY . 29.7 ttm-85 -122.66 138.6 54.55 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 52.7 m -139.54 120.34 14.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.15 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.406 HD12 ' N ' ' A' ' 43' ' ' ILE . 4.8 mp -93.32 136.47 25.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.099 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 96.6 mt -128.46 137.0 58.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.125 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 55.0 mt -136.97 107.49 5.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.202 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 24.2 mtmt -110.64 108.69 18.69 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.877 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -139.84 -139.69 3.8 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.498 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -171.39 136.72 1.03 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.948 0.404 . . . . 0.0 110.913 -179.853 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 21.5 t -86.73 116.34 65.61 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.64 0.733 . . . . 0.0 111.121 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 158.97 55.13 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.687 2.258 . . . . 0.0 112.324 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 -14.88 36.6 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.642 2.228 . . . . 0.0 112.368 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 38.0 p -113.91 20.13 16.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.154 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -113.03 113.45 3.18 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.501 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 25.1 mtpt -58.89 -58.91 6.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.809 0.337 . . . . 0.0 110.89 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 40.5 p -174.22 162.45 3.68 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.862 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.574 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 6.0 p90 -119.37 -173.57 2.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.874 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.45 137.37 13.49 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.147 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.426 HD12 ' CE2' ' A' ' 56' ' ' PHE . 3.9 mp -114.24 104.26 16.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.11 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . 0.497 ' ND2' ' ND1' ' A' ' 71' ' ' HIS . 22.0 m120 -98.48 141.4 31.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.875 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.57 ' CE2' HD12 ' A' ' 145' ' ' LEU . 5.6 m-85 -115.88 97.16 5.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.881 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.428 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 35.2 ttmt -96.02 168.37 10.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.874 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.428 ' N ' ' HG2' ' A' ' 61' ' ' LYS . 49.0 t -99.78 124.33 53.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.086 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.412 ' HA3' ' NH1' ' A' ' 32' ' ' ARG . . . -62.25 -30.46 76.03 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.467 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 9.7 t -71.24 -71.63 0.25 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.846 0.355 . . . . 0.0 110.821 -179.703 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 22.8 t -83.87 -70.98 0.53 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 132.14 42.82 0.17 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.501 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.4 ' OD1' ' OD1' ' A' ' 88' ' ' ASN . 0.8 OUTLIER -114.02 141.74 47.05 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.808 0.337 . . . . 0.0 110.88 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 80.7 mt -86.6 120.2 35.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.14 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -90.09 -37.57 14.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.076 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.518 HD12 ' CD1' ' A' ' 132' ' ' PHE . 21.8 tp -139.26 133.48 31.33 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.902 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.518 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.2 OUTLIER -134.46 92.78 2.96 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.856 179.878 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 20.4 mt -93.52 135.66 27.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.126 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.5 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 1.1 t-20 -140.91 107.13 6.31 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.626 0.727 . . . . 0.0 110.881 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.574 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.8 Cg_endo -69.77 154.73 67.33 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.669 2.246 . . . . 0.0 112.373 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 45.4 mtp85 -131.67 98.46 4.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.919 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -58.74 -44.73 90.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.883 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -63.72 -92.56 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.492 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -43.35 -47.58 6.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.885 0.374 . . . . 0.0 110.88 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 96.63 38.06 4.56 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.483 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 16.9 p -138.11 117.92 13.22 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.807 0.337 . . . . 0.0 111.194 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 20.3 t -84.07 109.03 17.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.116 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 57.5 t -78.1 146.09 8.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.117 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -129.81 129.66 44.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.834 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.518 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.8 m120 -141.62 178.45 7.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.847 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 93.1 p -160.83 105.02 1.37 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.873 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.592 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 25.1 tp -77.77 118.79 20.46 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.899 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.521 ' N ' ' O ' ' A' ' 90' ' ' SER . 92.7 mt -95.88 162.22 13.67 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.905 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.439 ' C ' ' H ' ' A' ' 90' ' ' SER . 8.8 m-80 -40.76 101.87 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.878 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.03 -3.94 2.8 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.477 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.521 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -123.73 172.65 8.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.828 0.347 . . . . 0.0 110.885 -179.739 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.592 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 18.8 m95 -129.04 160.93 31.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.917 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -91.46 -106.65 1.47 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.52 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' SER . . . . . 0.419 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 3.5 m -163.06 174.83 11.75 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.787 0.327 . . . . 0.0 110.902 -179.759 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.462 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 24.7 mt-10 -99.53 121.74 41.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.844 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 25.0 mm-40 -120.97 109.55 15.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.895 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 39.6 mtmt -115.51 117.65 30.95 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.933 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 2.8 tppp? -168.59 107.1 0.47 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.887 179.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.435 HD12 ' CD1' ' A' ' 129' ' ' LEU . 8.7 tt -144.39 146.1 20.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.139 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.4 t -83.72 -38.34 21.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.109 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 5.2 p-80 -153.71 134.27 13.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.847 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . 0.441 ' OD1' ' C ' ' A' ' 101' ' ' ASN . 27.1 t-20 -107.86 96.92 18.67 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.604 0.716 . . . . 0.0 110.879 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -36.08 11.59 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.674 2.249 . . . . 0.0 112.36 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.463 ' CE2' ' HB3' ' A' ' 74' ' ' PRO . 5.7 m-85 -40.29 110.23 0.14 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.823 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -136.63 139.8 10.93 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.52 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 106.39 1.64 Allowed 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.694 2.263 . . . . 0.0 112.362 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 124.86 -11.47 7.82 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.51 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.9 pt20 -130.14 165.22 22.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.803 0.335 . . . . 0.0 110.925 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.3 p90 -87.48 169.26 12.37 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.889 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.48 ' CZ ' ' CZ ' ' A' ' 56' ' ' PHE . 30.0 p90 -153.63 124.75 7.41 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.898 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -94.34 103.38 15.38 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.843 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.471 ' CD1' ' N ' ' A' ' 112' ' ' SER . 0.5 OUTLIER -101.61 136.77 40.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.946 -179.965 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.471 ' N ' ' CD1' ' A' ' 111' ' ' LEU . 6.1 m -144.01 111.59 6.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.84 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.452 HD12 ' CD1' ' A' ' 111' ' ' LEU . 4.2 mp -93.53 141.72 14.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.103 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.427 ' O ' ' CG ' ' A' ' 120' ' ' PHE . 19.6 mtp180 -112.52 142.07 45.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.917 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . 0.577 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 3.1 t -114.0 109.41 18.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.892 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -107.53 -138.76 8.86 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.515 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.5 mt -118.69 -40.56 2.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.811 0.339 . . . . 0.0 110.903 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . 0.427 ' OD1' ' N ' ' A' ' 119' ' ' ARG . 19.8 p-10 -87.73 -34.09 18.49 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.831 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.427 ' N ' ' OD1' ' A' ' 118' ' ' ASP . 10.6 ptp85 -172.57 176.07 3.33 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.922 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.577 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.7 m-30 -98.98 166.08 11.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.893 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 26.2 mtpt -137.73 105.92 5.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.916 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 42.8 t -90.84 132.52 35.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.096 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 53.9 m-85 -122.2 155.97 34.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.916 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . 0.499 ' O ' ' ND2' ' A' ' 125' ' ' ASN . . . -141.15 118.96 11.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.104 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.499 ' ND2' ' O ' ' A' ' 124' ' ' ALA . 10.2 p30 50.87 30.75 5.42 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.894 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 82.88 30.96 30.46 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.475 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 33.3 mm-40 -135.6 139.51 43.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.797 0.332 . . . . 0.0 110.905 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 31.2 t-80 -67.7 112.54 4.86 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.857 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . 0.435 ' CD1' HD12 ' A' ' 98' ' ' ILE . 8.3 tp -84.23 -66.97 0.83 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.894 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.4 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 12.1 p90 -168.63 170.76 9.27 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.906 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -114.01 149.11 35.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.806 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.518 ' CD1' HD12 ' A' ' 70' ' ' LEU . 0.4 OUTLIER -111.6 105.09 13.54 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.906 -179.931 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.487 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -60.45 137.15 58.19 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.105 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 8.2 m-70 -66.35 110.41 3.07 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.861 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.419 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 71.6 mtt-85 -96.72 -46.6 6.22 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.859 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.4 tp -98.54 108.06 20.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.852 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 29.4 t -50.23 -33.64 20.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.858 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . 0.433 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.79 29.28 0.46 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.083 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.416 ' CG ' ' N ' ' A' ' 140' ' ' GLN . 33.8 p90 -49.66 -44.35 47.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.869 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' GLN . . . . . 0.416 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 7.8 pt20 -47.81 -39.13 17.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.913 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.433 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 67.3 mtp180 -56.45 -40.83 75.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.85 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 58.7 t -45.68 101.82 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.11 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.492 ' OD2' ' N ' ' A' ' 36' ' ' GLY . 0.7 OUTLIER -127.04 34.28 4.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.851 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 24.6 m -147.02 115.55 6.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.148 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.57 HD12 ' CE2' ' A' ' 60' ' ' PHE . 4.1 tp -114.69 114.55 25.79 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.908 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' GLU . . . . . 0.413 ' C ' HG13 ' A' ' 147' ' ' ILE . 4.1 pt-20 -114.38 158.12 21.94 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.868 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . 0.413 HG13 ' C ' ' A' ' 146' ' ' GLU . 30.7 mt -142.9 123.14 10.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.119 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -132.21 175.65 9.07 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.912 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 102.49 -151.64 18.24 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.475 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -103.66 92.5 4.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.87 0.367 . . . . 0.0 110.85 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.4 p -150.95 150.15 13.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.165 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 26.7 m -113.57 93.7 4.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.131 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.429 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 66.5 mt -75.5 138.27 41.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.925 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 36.7 m -122.43 -34.91 3.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.878 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 17.3 t80 -150.59 130.69 13.5 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.96 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 94.8 t -140.56 111.89 4.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.123 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 11.9 tt0 -134.05 129.21 35.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.944 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' ILE . . . . . 0.441 HG12 ' CD2' ' A' ' 33' ' ' LEU . 4.6 mp -90.23 90.58 3.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.17 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 2.8 m -44.7 138.54 3.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.884 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -178.84 -175.3 45.78 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.493 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 134.08 27.12 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.732 2.288 . . . . 0.0 112.306 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 18.0 m -92.84 -45.17 8.12 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.875 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 33.1 t -127.87 110.3 12.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.837 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.317 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.482 179.983 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.531 -0.228 . . . . 0.0 112.531 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 17.3 t -162.06 134.58 5.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.928 0.395 . . . . 0.0 110.866 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.6 t -167.6 135.65 2.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.862 -179.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 107.79 115.78 3.97 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.476 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.0 m -145.97 135.57 23.21 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.845 0.355 . . . . 0.0 110.877 -179.75 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 19.3 m -121.64 109.99 15.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.881 -179.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 156.75 133.1 1.58 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.482 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 91.1 m-70 -141.14 160.87 39.18 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.814 0.34 . . . . 0.0 110.862 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 59.1 mm-40 -98.79 151.38 20.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.921 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 7.8 mp0 -108.47 102.55 11.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.918 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.7 mt -141.76 157.47 44.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.893 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 15.1 p-10 -84.61 45.56 1.15 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.903 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 2.8 m -88.55 157.61 18.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.87 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 15.4 mt -42.64 151.59 0.38 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.619 0.723 . . . . 0.0 110.955 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.75 159.44 53.41 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.711 2.274 . . . . 0.0 112.346 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 9.6 t -82.83 139.55 33.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.132 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' MET . . . . . 0.41 ' CE ' HD12 ' A' ' 158' ' ' ILE . 23.9 ptt? -91.96 42.67 1.11 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.853 179.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -63.98 157.81 24.06 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.851 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 111.08 -135.34 12.78 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.509 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 166.97 25.77 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.742 2.294 . . . . 0.0 112.339 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 179.11 3.92 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.647 2.232 . . . . 0.0 112.351 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.512 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.6 m -93.18 152.1 19.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.158 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.512 ' CD1' ' O ' ' A' ' 22' ' ' THR . 10.2 m-85 -150.06 132.53 15.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.924 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . 0.565 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 22.1 m-80 50.74 46.58 3.83 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.607 0.718 . . . . 0.0 110.835 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.565 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.78 137.04 34.47 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.668 2.245 . . . . 0.0 112.378 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 179.88 3.38 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.674 2.249 . . . . 0.0 112.351 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.529 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 95.2 t -140.21 138.18 18.9 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.643 0.735 . . . . 0.0 111.11 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.529 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 54.1 Cg_endo -69.72 144.96 78.02 Favored 'Cis proline' 0 C--N 1.341 0.161 0 C-N-CA 122.658 -1.809 . . . . 0.0 112.353 -0.145 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 8.9 t80 -97.45 121.39 39.3 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.891 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 70.6 m-85 -108.02 101.65 10.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.86 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -116.33 104.61 1.27 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.487 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.54 130.48 40.73 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.848 0.356 . . . . 0.0 110.9 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.45 ' N ' ' O ' ' A' ' 143' ' ' ASP . 5.0 mt -74.2 147.47 42.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.905 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 55.8 mt-30 -107.81 89.59 3.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.903 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.78 -47.43 0.99 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.503 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 104.94 159.03 23.47 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.484 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 79.3 mt -53.32 110.73 0.58 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.88 0.372 . . . . 0.0 110.934 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.433 ' OG1' ' N ' ' A' ' 39' ' ' ALA . 0.0 OUTLIER -133.8 170.37 15.69 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.112 179.967 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.451 ' HB1' ' CD2' ' A' ' 117' ' ' LEU . . . -59.29 -41.93 90.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.085 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 6.5 mpt_? -94.5 51.07 1.4 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.862 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.41 ' NH1' ' CG2' ' A' ' 158' ' ' ILE . 20.4 ttm-85 -138.94 136.6 35.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 91.8 m -139.52 125.16 19.38 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.173 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.4 mp -96.31 138.79 20.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.152 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.475 HG23 ' N ' ' A' ' 45' ' ' ILE . 90.5 mt -131.57 138.38 53.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.143 179.83 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.475 ' N ' HG23 ' A' ' 44' ' ' ILE . 69.7 mt -135.42 107.56 7.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.152 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 8.7 mtmm -108.1 111.64 23.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -144.61 -144.92 4.25 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.495 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 0.568 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 1.3 t80 -170.65 123.87 0.66 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.853 0.359 . . . . 0.0 110.957 -179.82 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 13.1 t -73.58 115.28 40.07 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.584 0.707 . . . . 0.0 111.152 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 155.48 65.86 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.663 2.242 . . . . 0.0 112.337 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.85 -13.58 34.64 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.679 2.253 . . . . 0.0 112.305 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 32.9 p -111.71 14.51 21.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.114 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -111.02 122.07 6.03 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.51 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.4 mtpt -63.71 -59.81 4.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.809 0.338 . . . . 0.0 110.93 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 14.4 p -172.8 158.33 3.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.826 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.564 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 17.9 p90 -113.76 -172.62 2.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.846 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.463 ' CB ' ' OD1' ' A' ' 73' ' ' ASN . . . -155.68 140.98 17.62 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.098 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.441 HG21 ' CE1' ' A' ' 60' ' ' PHE . 7.2 mt -127.17 101.18 7.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.122 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . 0.415 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 5.4 m-80 -103.14 154.05 19.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.907 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.491 ' CE2' HD11 ' A' ' 145' ' ' LEU . 6.1 m-85 -122.4 102.01 7.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.857 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.8 ttmt -95.68 168.2 10.82 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.864 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 83.2 t -100.06 120.55 49.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.127 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -57.54 -30.25 61.85 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.479 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.1 m -72.84 -75.3 0.14 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.863 0.363 . . . . 0.0 110.882 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.3 t -79.33 -70.85 0.48 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.867 -179.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 131.18 40.51 0.23 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.486 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.402 ' OD1' ' OD1' ' A' ' 88' ' ' ASN . 0.5 OUTLIER -109.38 147.95 31.91 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.758 0.314 . . . . 0.0 110.854 -179.981 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 53.4 mt -94.35 113.7 29.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.153 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.47 ' HB2' ' CG2' ' A' ' 142' ' ' VAL . . . -86.02 -32.15 21.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.117 179.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.564 HD22 ' CD2' ' A' ' 132' ' ' PHE . 43.3 tp -138.83 131.09 28.4 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.487 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.8 OUTLIER -134.42 95.38 3.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.867 179.855 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 32.1 mt -100.05 131.53 47.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.133 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.491 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -141.17 107.58 6.21 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.644 0.735 . . . . 0.0 110.874 179.933 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.564 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.9 Cg_endo -69.78 155.23 66.38 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.651 2.234 . . . . 0.0 112.333 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 80.0 mtp180 -132.15 100.01 4.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.87 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' MET . . . . . 0.503 ' HE3' ' CE1' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -68.38 -40.36 81.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.905 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -45.33 -66.09 1.66 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.498 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.2 t30 -89.3 -54.09 4.26 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.905 0.383 . . . . 0.0 110.903 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 118.77 47.23 0.41 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.47 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 18.7 p -141.45 124.48 16.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.823 0.344 . . . . 0.0 111.135 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 18.4 t -94.39 109.72 22.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.184 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 41.5 t -81.88 145.25 8.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.137 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -126.45 123.92 38.96 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.888 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.487 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.7 OUTLIER -135.97 178.82 6.75 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.882 -179.935 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 50.7 p -160.07 106.29 1.58 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.855 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.559 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 24.4 tp -77.38 115.78 17.43 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.904 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.49 ' N ' ' O ' ' A' ' 90' ' ' SER . 24.0 mt -91.55 161.09 15.09 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.886 179.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.409 ' C ' ' H ' ' A' ' 90' ' ' SER . 12.3 m-80 -41.58 101.56 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.913 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 67.43 -3.56 4.53 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.46 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.49 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -124.26 172.25 9.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.836 0.351 . . . . 0.0 110.851 -179.709 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.559 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 21.0 m95 -129.43 158.63 38.66 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.908 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -89.22 -106.59 1.12 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.445 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 3.7 m -163.6 176.29 9.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.791 0.329 . . . . 0.0 110.887 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.449 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 16.1 mt-10 -99.04 119.65 38.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.908 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -119.23 116.4 26.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.883 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 39.8 mtmt -121.89 119.28 31.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.902 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 27.7 tttp -167.26 108.03 0.62 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.889 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 7.2 tt -149.4 147.21 16.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.165 179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 12.6 t -89.32 -47.47 8.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.134 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . 0.428 ' O ' ' CG ' ' A' ' 100' ' ' HIS . 4.2 p-80 -138.41 125.24 21.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.845 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -103.3 95.91 7.62 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.613 0.72 . . . . 0.0 110.898 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.82 -34.38 14.49 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.672 2.248 . . . . 0.0 112.303 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 -39.33 99.6 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.857 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -129.81 136.3 8.86 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.498 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 99.84 0.78 Allowed 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.658 2.239 . . . . 0.0 112.348 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 130.33 -8.38 5.95 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.48 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 -131.37 162.11 30.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.882 0.372 . . . . 0.0 110.896 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' PHE . . . . . 0.568 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 17.2 m-85 -80.27 172.1 14.2 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.858 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.483 ' CD1' ' O ' ' A' ' 109' ' ' PHE . 19.8 p90 -161.17 119.62 2.45 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.9 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -93.86 101.74 13.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.843 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.481 ' CD1' ' N ' ' A' ' 112' ' ' SER . 0.5 OUTLIER -101.2 136.75 40.53 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.909 -179.942 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.481 ' N ' ' CD1' ' A' ' 111' ' ' LEU . 10.4 m -141.6 112.88 7.5 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.882 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.433 HD11 ' CD1' ' A' ' 111' ' ' LEU . 4.1 mp -96.91 115.91 37.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.171 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 21.2 mtp85 -89.75 141.32 28.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.896 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . 0.578 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 13.6 t -113.41 115.25 27.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -111.76 -141.83 8.59 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.473 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.451 ' CD2' ' HB1' ' A' ' 39' ' ' ALA . 7.4 mt -115.2 -33.38 5.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.804 0.335 . . . . 0.0 110.922 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . 0.582 ' O ' ' CD2' ' A' ' 134' ' ' HIS . 6.3 m-20 -89.53 -42.27 11.54 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.904 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -166.22 -176.34 3.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.893 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.578 ' CE2' ' HB2' ' A' ' 115' ' ' CYS . 12.0 m-85 -102.44 156.2 17.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.897 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 23.2 mtpt -130.1 105.92 8.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.865 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . 0.429 HG22 ' CE1' ' A' ' 130' ' ' PHE . 46.8 t -91.3 131.73 37.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.109 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 79.5 m-85 -122.26 149.98 42.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.933 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -134.59 108.28 7.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.094 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 56.93 35.27 26.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.871 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.09 38.31 15.79 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.483 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 7.3 mt-30 -146.18 126.63 14.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.81 0.338 . . . . 0.0 110.924 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 -60.27 102.25 0.16 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.874 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 7.2 tp -70.19 -66.5 0.59 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.932 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.44 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 7.0 p90 -162.16 172.13 16.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.864 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 21.0 p-10 -118.1 145.79 44.6 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.847 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.587 ' CE1' ' O ' ' A' ' 133' ' ' ALA . 0.1 OUTLIER -112.92 107.02 15.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.833 -179.893 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.587 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -62.97 134.31 55.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.087 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' HIS . . . . . 0.582 ' CD2' ' O ' ' A' ' 118' ' ' ASP . 10.0 m-70 -60.54 101.68 0.15 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.883 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 12.3 mtt-85 -88.11 -45.97 9.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.875 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 10.0 tp -98.4 108.08 20.69 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.937 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 28.6 p -51.8 -31.23 26.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.858 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -82.71 29.08 0.46 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.08 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -49.59 -35.19 19.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.899 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' GLN . . . . . 0.454 ' HG2' ' N ' ' A' ' 141' ' ' ARG . 18.4 pm0 -60.17 -28.92 68.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.964 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.454 ' N ' ' HG2' ' A' ' 140' ' ' GLN . 52.9 mtp85 -65.27 -38.86 91.57 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.887 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.47 ' CG2' ' HB2' ' A' ' 69' ' ' ALA . 52.4 t -55.15 108.97 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.113 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.45 ' O ' ' N ' ' A' ' 33' ' ' LEU . 3.4 p30 -129.52 27.91 5.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.839 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -135.82 135.57 39.95 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.174 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.491 HD11 ' CE2' ' A' ' 60' ' ' PHE . 7.5 tp -131.13 103.9 6.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.9 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' GLU . . . . . 0.408 ' C ' HG13 ' A' ' 147' ' ' ILE . 2.6 pt-20 -106.51 151.22 25.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.874 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . 0.408 HG13 ' C ' ' A' ' 146' ' ' GLU . 15.7 mt -140.17 109.57 3.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.116 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -120.41 170.93 8.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.916 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 109.85 -150.68 17.42 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.517 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -107.5 91.36 3.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.886 0.374 . . . . 0.0 110.902 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.465 HG22 ' N ' ' A' ' 152' ' ' THR . 3.3 p -150.91 137.62 12.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.123 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' THR . . . . . 0.465 ' N ' HG22 ' A' ' 151' ' ' VAL . 24.7 m -96.96 93.65 6.74 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.119 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.463 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 61.3 mt -77.98 132.76 37.98 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.898 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 53.5 m -119.13 -40.86 2.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.894 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 36.4 t80 -141.74 129.53 21.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.948 -179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 75.3 t -140.77 105.65 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.159 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 19.3 tt0 -120.26 132.03 55.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.92 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' ILE . . . . . 0.41 HD12 ' CE ' ' A' ' 17' ' ' MET . 12.8 mt -102.9 88.23 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.161 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' SER . . . . . 0.407 ' O ' ' NH1' ' A' ' 41' ' ' ARG . 28.8 t -52.19 147.21 7.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.873 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -178.29 -177.98 47.39 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.513 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 143.15 49.91 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.682 2.255 . . . . 0.0 112.387 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 1.2 t -68.85 117.78 10.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.878 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 39.8 m -90.69 132.34 35.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.874 -179.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.46 179.989 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 N-CA-C 112.478 -0.249 . . . . 0.0 112.478 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 32.3 p -130.58 84.35 2.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.871 0.367 . . . . 0.0 110.909 -179.77 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 89.5 p -140.42 134.89 31.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.867 -179.804 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 137.13 131.86 3.0 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.491 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 33.2 t -165.03 131.52 2.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.923 0.392 . . . . 0.0 110.821 -179.731 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 21.5 m -43.8 -47.28 8.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.839 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -118.15 92.42 0.54 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.53 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 9.2 t60 -71.65 130.26 40.73 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.78 0.324 . . . . 0.0 110.871 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 75.3 mt-30 -146.11 111.96 5.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.883 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 17.7 tm0? -68.74 82.88 0.29 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.878 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 86.3 mt -129.37 80.68 1.98 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.897 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -162.78 121.62 2.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.88 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 64.2 m -124.55 155.34 39.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.884 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 20.0 mt -44.83 149.93 0.77 Allowed Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.577 0.703 . . . . 0.0 110.904 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 -178.58 2.41 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.701 2.268 . . . . 0.0 112.331 179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 11.7 t -83.71 146.39 28.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.099 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' MET . . . . . 0.444 ' CE ' HD13 ' A' ' 158' ' ' ILE . 4.4 ptp -95.55 30.87 2.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.895 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -49.98 -178.54 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.907 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 81.49 -145.32 25.09 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.513 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 168.82 20.43 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.693 2.262 . . . . 0.0 112.336 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 -166.36 0.18 Allowed 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.678 2.252 . . . . 0.0 112.348 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.55 ' CG2' ' N ' ' A' ' 23' ' ' PHE . 1.8 m -100.95 160.84 14.03 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.126 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.55 ' N ' ' CG2' ' A' ' 22' ' ' THR . 14.3 m-85 -154.52 136.18 14.37 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . 0.514 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 10.4 m-20 41.21 49.76 3.74 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.61 0.719 . . . . 0.0 110.858 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.514 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.8 Cg_endo -69.74 140.9 43.87 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.678 2.252 . . . . 0.0 112.341 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 178.4 4.61 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.663 2.242 . . . . 0.0 112.375 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.531 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 89.5 t -140.18 137.82 18.49 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.657 0.741 . . . . 0.0 111.123 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.531 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.4 Cg_endo -69.74 144.34 76.35 Favored 'Cis proline' 0 C--O 1.231 0.173 0 C-N-CA 122.7 -1.792 . . . . 0.0 112.345 -0.055 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 9.2 t80 -96.75 118.9 34.21 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.931 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 65.3 m-85 -104.8 101.12 10.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.888 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -112.83 102.05 1.26 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.456 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.437 ' O ' ' HG3' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -72.63 121.6 20.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.852 0.358 . . . . 0.0 110.923 -179.897 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.482 ' N ' ' O ' ' A' ' 143' ' ' ASP . 13.9 mt -65.71 149.62 49.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.914 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 10.4 mm-40 -110.68 82.06 1.53 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.919 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.447 ' C ' ' OD2' ' A' ' 143' ' ' ASP . . . 140.49 -46.87 0.9 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.504 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.42 ' CA ' ' OD1' ' A' ' 143' ' ' ASP . . . 109.54 166.55 20.14 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.505 -179.882 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . 0.43 ' CD1' ' HB ' ' A' ' 142' ' ' VAL . 49.8 mt -57.3 105.16 0.21 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.96 0.41 . . . . 0.0 110.891 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 2.1 p -116.76 151.81 35.67 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.148 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -58.07 -18.21 23.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.117 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 7.3 mpt_? -109.93 27.53 9.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.899 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.423 ' NH2' HD13 ' A' ' 33' ' ' LEU . 20.8 ttp85 -113.66 141.5 47.15 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.857 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 97.9 m -139.56 121.35 15.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.111 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.417 ' CD1' ' NH2' ' A' ' 41' ' ' ARG . 5.0 mp -90.95 143.64 10.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.125 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 89.3 mt -136.22 129.21 46.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.149 179.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 60.6 mt -130.05 107.74 15.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.152 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.492 ' HE3' ' CD1' ' A' ' 155' ' ' TYR . 18.5 mtmt -110.36 111.8 23.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.904 179.856 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -147.14 -145.54 4.21 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.505 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -166.81 126.14 1.47 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.884 0.374 . . . . 0.0 110.913 -179.815 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 24.6 t -74.82 117.02 59.3 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.643 0.735 . . . . 0.0 111.114 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 156.23 63.82 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.698 2.266 . . . . 0.0 112.331 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -15.44 37.1 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.657 2.238 . . . . 0.0 112.359 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 26.4 p -110.36 14.64 22.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.154 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -109.25 120.44 5.81 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.493 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 30.1 mtpt -61.65 -60.97 2.88 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.775 0.321 . . . . 0.0 110.914 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 9.2 p -174.19 156.51 2.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.823 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.589 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 11.1 p90 -111.0 -174.46 2.48 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.83 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.473 ' CB ' ' OD1' ' A' ' 73' ' ' ASN . . . -155.42 141.15 18.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.096 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.6 mp -121.24 100.08 8.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.136 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -102.56 148.08 25.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.887 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.555 ' CE2' HD12 ' A' ' 145' ' ' LEU . 34.7 m-85 -119.99 102.9 8.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.894 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 33.6 ttmt -95.62 166.95 11.59 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.91 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 91.4 t -98.2 125.54 51.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.166 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.463 ' N ' ' HG1' ' A' ' 144' ' ' THR . . . -61.26 -35.7 91.31 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.511 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.9 m -67.68 -73.27 0.14 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.896 0.379 . . . . 0.0 110.817 -179.708 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 32.3 t -80.37 -71.49 0.46 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.867 -179.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 130.7 41.69 0.22 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.464 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -112.58 146.37 38.69 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.782 0.325 . . . . 0.0 110.848 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 50.7 mt -91.65 121.23 41.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.135 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.471 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -91.3 -36.97 13.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.114 179.828 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.543 HD21 ' CD2' ' A' ' 132' ' ' PHE . 32.1 tp -134.87 130.4 35.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.919 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.487 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.3 OUTLIER -134.76 92.97 2.96 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.84 179.855 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.475 ' CG2' HG11 ' A' ' 81' ' ' VAL . 20.6 mt -96.69 134.08 35.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.17 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.508 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -140.93 107.42 6.32 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.591 0.71 . . . . 0.0 110.885 179.969 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.589 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.6 Cg_endo -69.76 155.05 66.93 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.679 2.253 . . . . 0.0 112.337 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 66.4 mtp85 -129.24 99.31 5.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.876 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -55.9 144.16 29.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.893 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 114.49 -88.33 0.47 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.493 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -75.52 -48.45 22.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.883 0.373 . . . . 0.0 110.866 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.475 ' HA2' ' ND2' ' A' ' 101' ' ' ASN . . . 112.14 47.14 0.72 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.495 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 32.9 p -115.92 119.16 35.04 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.799 0.333 . . . . 0.0 111.118 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.475 HG11 ' CG2' ' A' ' 72' ' ' ILE . 20.6 t -106.42 106.03 19.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.126 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 39.2 t -76.38 134.29 29.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.133 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . 0.415 ' NH1' ' O ' ' A' ' 95' ' ' GLU . 0.0 OUTLIER -120.57 123.52 43.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.881 -179.955 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.487 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.2 OUTLIER -134.25 -179.11 5.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.898 -179.934 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 93.5 p -160.57 105.54 1.44 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.839 -179.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.567 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 26.1 tp -77.26 117.04 18.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.921 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.501 ' N ' ' O ' ' A' ' 90' ' ' SER . 68.5 mt -93.97 160.9 14.52 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.887 179.897 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.533 HD21 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.72 101.35 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.87 179.913 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.93 -6.97 1.27 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.492 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.501 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -119.14 172.22 7.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.877 0.37 . . . . 0.0 110.832 -179.726 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.567 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 24.1 m95 -129.05 160.89 31.34 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.908 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -90.84 -93.94 1.26 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.513 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 2.4 m -174.49 169.46 3.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.841 0.353 . . . . 0.0 110.883 -179.727 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.41 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 27.3 mt-10 -100.84 118.4 36.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.895 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . 0.415 ' O ' ' NH1' ' A' ' 83' ' ' ARG . 5.3 mm-40 -123.19 134.81 54.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.881 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 40.9 mtmt -132.19 116.95 17.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.905 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 17.9 ttpp -164.48 110.4 1.01 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.934 179.862 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.408 HD11 ' C ' ' A' ' 100' ' ' HIS . 4.4 tt -148.72 153.04 11.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.134 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.448 HG23 ' N ' ' A' ' 100' ' ' HIS . 9.0 t -89.64 -48.52 7.23 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.118 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . 0.448 ' N ' HG23 ' A' ' 99' ' ' THR . 6.1 p-80 -141.24 125.41 17.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.858 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . 0.475 ' ND2' ' HA2' ' A' ' 79' ' ' GLY . 17.7 t-20 -104.46 96.83 10.79 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.633 0.73 . . . . 0.0 110.882 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 -30.46 22.07 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.725 2.283 . . . . 0.0 112.303 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.413 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 21.8 m-85 -43.94 104.64 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.887 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -132.65 135.86 8.38 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.489 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 97.79 0.66 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.69 2.26 . . . . 0.0 112.322 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 129.94 -3.67 6.03 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.524 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.2 pm0 -135.9 155.92 49.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.839 0.352 . . . . 0.0 110.908 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -77.85 171.16 15.4 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.887 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 29.8 p90 -160.03 133.21 6.81 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.897 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -103.1 103.79 13.89 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.874 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.476 ' CD1' ' N ' ' A' ' 112' ' ' SER . 0.6 OUTLIER -104.3 137.7 41.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.887 -179.919 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.476 ' N ' ' CD1' ' A' ' 111' ' ' LEU . 3.6 m -145.16 111.87 5.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.842 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.444 HD12 ' CD1' ' A' ' 111' ' ' LEU . 4.0 mp -92.99 140.38 16.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.165 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 18.9 mtp180 -113.24 137.67 51.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.86 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . 0.559 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 3.4 t -108.87 117.29 33.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -119.35 -140.97 6.35 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.464 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.5 mt -118.66 -36.09 3.56 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.844 0.354 . . . . 0.0 110.916 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 17.4 m-20 -87.2 -38.39 16.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.862 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 16.2 ptp180 -175.31 169.28 3.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.838 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.559 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.6 m-30 -92.02 147.71 22.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 24.9 mtpp -120.75 102.19 8.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.921 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 55.7 t -88.82 132.22 34.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.106 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 62.3 m-85 -118.9 156.66 29.13 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.947 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -142.21 109.45 5.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.097 179.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 56.3 28.78 13.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.888 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 85.67 30.52 23.8 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.466 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . 0.4 ' HB2' ' CE1' ' A' ' 100' ' ' HIS . 56.1 mm-40 -137.91 121.51 17.36 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.791 0.329 . . . . 0.0 110.949 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 29.1 t-80 -50.69 105.14 0.09 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.849 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 10.8 tp -72.84 -69.1 0.43 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.482 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 4.2 p90 -165.62 170.76 13.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.874 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 61.9 m-20 -114.96 148.76 38.32 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.876 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.574 ' CE1' ' O ' ' A' ' 133' ' ' ALA . 0.1 OUTLIER -115.01 107.88 15.95 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.88 -179.868 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.574 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -64.0 131.1 46.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.117 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 46.2 m-70 -56.62 100.58 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.847 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 17.6 mtt-85 -83.9 -51.45 7.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.865 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 14.2 tp -93.27 108.01 19.72 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.908 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 4.3 p -51.4 -30.26 18.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.829 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -87.28 24.23 1.66 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.114 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.426 ' CG ' ' N ' ' A' ' 140' ' ' GLN . 26.8 p90 -43.58 -44.67 6.31 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.911 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' GLN . . . . . 0.426 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 5.3 pt20 -44.7 -42.23 7.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.905 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . . . . . . . . . 21.5 mtt180 -52.07 -42.4 63.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.895 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.471 HG21 ' CB ' ' A' ' 69' ' ' ALA . 99.4 t -46.96 108.89 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.12 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.482 ' O ' ' N ' ' A' ' 33' ' ' LEU . 1.0 OUTLIER -129.8 20.43 5.52 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.902 179.903 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' THR . . . . . 0.463 ' HG1' ' N ' ' A' ' 63' ' ' GLY . 2.1 m -133.06 138.1 46.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.141 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.555 HD12 ' CE2' ' A' ' 60' ' ' PHE . 7.2 tp -132.41 116.08 16.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.949 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -118.59 151.8 37.23 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.838 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 24.8 mt -138.66 110.34 5.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.08 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 1.1 pm0 -120.17 171.99 8.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.888 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 111.28 -147.51 17.86 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.544 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -112.96 92.72 4.11 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.851 0.357 . . . . 0.0 110.858 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.453 HG23 ' N ' ' A' ' 152' ' ' THR . 4.3 p -151.02 141.9 16.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.145 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' THR . . . . . 0.453 ' N ' HG23 ' A' ' 151' ' ' VAL . 17.1 m -101.31 92.91 5.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.175 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.441 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 80.5 mt -76.03 139.85 41.66 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.913 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 58.1 m -125.01 -33.76 2.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.836 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . 0.492 ' CD1' ' HE3' ' A' ' 46' ' ' LYS . 36.3 t80 -150.46 130.97 13.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.917 -179.855 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 56.0 t -138.92 105.41 2.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.149 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 13.2 tt0 -114.17 120.67 41.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.92 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' ILE . . . . . 0.444 HD13 ' CE ' ' A' ' 17' ' ' MET . 83.1 mt -95.25 89.28 2.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.159 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 28.7 t -71.87 139.29 48.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.843 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 157.76 154.13 6.99 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.484 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 129.92 18.45 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.708 2.272 . . . . 0.0 112.316 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 40.1 p -132.4 103.62 6.29 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.883 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 90.2 p -160.14 175.3 13.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.902 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.502 -179.954 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 112.476 -0.25 . . . . 0.0 112.476 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.6 t -133.12 86.0 2.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.879 0.371 . . . . 0.0 110.842 -179.694 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 60.2 p -136.92 167.92 20.55 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.841 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -105.08 -145.15 13.38 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.498 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 73.1 m -120.85 176.25 5.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.836 0.35 . . . . 0.0 110.86 -179.751 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 36.4 m -133.25 169.32 17.07 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.846 -179.799 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -152.56 72.31 0.28 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.692 -0.765 . . . . 0.0 112.488 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 6.7 p80 -121.77 137.41 54.78 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.72 0.295 . . . . 0.0 110.87 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -87.27 153.76 21.22 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.901 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 9.6 mm100 -116.07 156.59 26.11 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.935 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.7 mt -98.23 146.88 25.18 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.878 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 23.7 t30 -100.09 88.69 3.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.864 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 5.1 m -166.74 168.98 13.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.891 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 65.2 mt -49.8 154.03 1.94 Allowed Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.585 0.707 . . . . 0.0 110.923 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 -166.11 0.17 Allowed 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.712 2.274 . . . . 0.0 112.343 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.405 ' CG2' ' N ' ' A' ' 17' ' ' MET . 1.3 m -88.21 152.0 22.28 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.183 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' MET . . . . . 0.482 ' O ' ' NE2' ' A' ' 34' ' ' GLN . 56.7 mtm -96.06 89.49 5.2 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.898 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 17.9 pt-20 -110.05 160.51 16.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.898 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.63 -140.26 14.94 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.465 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 170.22 17.03 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.659 2.24 . . . . 0.0 112.346 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.74 -169.64 0.34 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.681 2.254 . . . . 0.0 112.396 179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.485 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.5 m -103.49 153.38 20.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.174 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.485 ' CD1' ' O ' ' A' ' 22' ' ' THR . 9.3 m-85 -149.83 135.68 18.6 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.896 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . 0.558 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 4.1 t-20 46.1 47.25 3.95 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.625 0.726 . . . . 0.0 110.886 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.558 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.5 Cg_endo -69.78 138.69 38.35 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.669 2.246 . . . . 0.0 112.332 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -174.65 0.95 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.664 2.243 . . . . 0.0 112.344 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.528 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 93.5 t -142.45 138.25 16.24 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.62 0.724 . . . . 0.0 111.102 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.528 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.79 144.76 77.63 Favored 'Cis proline' 0 C--N 1.342 0.197 0 C-N-CA 122.642 -1.816 . . . . 0.0 112.354 -0.078 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -97.55 120.69 38.38 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.918 -179.886 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 86.3 m-85 -102.42 104.94 15.44 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.901 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -104.24 107.52 2.97 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.463 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.414 ' N ' ' HE3' ' A' ' 17' ' ' MET . 6.6 mmt180 -73.71 115.86 13.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.833 0.349 . . . . 0.0 110.903 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.422 HD23 ' NH1' ' A' ' 41' ' ' ARG . 5.0 mt -82.0 111.51 18.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.902 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.482 ' NE2' ' O ' ' A' ' 17' ' ' MET . 37.6 mt-30 -78.71 97.14 5.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.88 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 131.1 -51.22 0.86 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.515 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 107.96 168.39 21.51 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.496 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 68.4 mt -55.1 110.88 0.74 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.886 0.374 . . . . 0.0 110.902 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 81.6 p -128.69 146.37 50.9 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.181 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -51.67 -18.33 1.16 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.085 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 2.8 mpt_? -107.73 30.53 6.23 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.868 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.438 ' NH2' HD11 ' A' ' 43' ' ' ILE . 6.9 ttp85 -115.85 142.2 47.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.904 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 29.5 m -138.64 120.72 15.66 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.151 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.438 HD11 ' NH2' ' A' ' 41' ' ' ARG . 5.3 mp -94.39 134.21 32.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.135 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 76.7 mt -129.8 119.59 47.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.098 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 31.6 mt -119.11 107.36 21.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.159 179.822 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.418 ' HE3' ' CD1' ' A' ' 155' ' ' TYR . 16.5 mtmt -108.89 110.18 21.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.9 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -144.86 -147.94 4.74 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.473 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 0.559 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.7 OUTLIER -163.57 127.88 2.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.934 0.397 . . . . 0.0 110.955 -179.789 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 13.4 t -77.6 117.38 65.21 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 121.585 0.707 . . . . 0.0 111.14 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 154.91 67.1 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.7 2.266 . . . . 0.0 112.348 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -13.92 35.36 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.648 2.232 . . . . 0.0 112.353 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 70.6 p -112.64 16.78 19.58 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.163 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -110.09 123.24 6.63 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.497 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.402 ' O ' ' SD ' ' A' ' 76' ' ' MET . 19.2 mtpt -64.75 -61.72 2.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.801 0.334 . . . . 0.0 110.896 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 14.8 p -172.97 156.57 3.35 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.849 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.573 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 20.4 p90 -111.05 -174.57 2.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.874 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.82 135.37 11.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.126 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.403 HD12 ' CE2' ' A' ' 56' ' ' PHE . 5.3 mp -117.59 98.16 6.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.114 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -96.85 143.72 27.48 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.894 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.552 ' CE2' HD13 ' A' ' 145' ' ' LEU . 47.0 m-85 -115.24 97.62 6.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.906 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.417 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 31.3 ttmt -96.08 168.94 10.31 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.894 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.457 ' CG2' HG21 ' A' ' 142' ' ' VAL . 23.4 t -100.27 123.7 53.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.094 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.524 ' N ' ' HG1' ' A' ' 144' ' ' THR . . . -59.64 -29.17 66.46 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.506 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 11.5 t -75.18 -73.71 0.24 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.849 0.357 . . . . 0.0 110.854 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 5.3 t -77.53 -71.47 0.41 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.811 -179.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 128.65 39.7 0.32 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.492 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -112.81 139.15 48.67 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.801 0.334 . . . . 0.0 110.879 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 60.3 mt -84.7 120.65 35.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.145 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -90.16 -30.66 17.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.129 179.795 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.567 HD21 ' CD2' ' A' ' 132' ' ' PHE . 41.3 tp -143.11 132.34 23.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.921 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.494 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.7 OUTLIER -134.93 92.61 2.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.919 179.838 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 53.2 mt -94.85 132.7 38.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.107 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.503 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -139.12 105.66 7.29 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.661 0.743 . . . . 0.0 110.908 179.929 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.573 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.7 Cg_endo -69.74 154.84 67.34 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.72 2.28 . . . . 0.0 112.372 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 73.9 mtp85 -129.27 94.26 3.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.865 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' MET . . . . . 0.402 ' SD ' ' O ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -53.92 153.51 4.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.887 179.991 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 88.85 -87.46 1.49 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.476 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.421 ' ND2' HG23 ' A' ' 80' ' ' THR . 57.1 t30 -52.9 -65.66 0.52 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.853 0.359 . . . . 0.0 110.908 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 114.76 50.32 0.48 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.511 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.421 HG23 ' ND2' ' A' ' 78' ' ' ASN . 21.1 p -137.18 118.01 14.14 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.845 0.355 . . . . 0.0 111.161 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.4 t -102.79 107.29 21.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.128 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 99.9 t -76.15 144.36 11.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.087 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -126.19 124.65 40.94 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.887 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.494 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.8 OUTLIER -135.71 178.56 6.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.951 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 19.1 t -160.38 105.05 1.46 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 -179.837 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.566 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 25.4 tp -76.97 118.01 19.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.935 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.513 ' N ' ' O ' ' A' ' 90' ' ' SER . 69.9 mt -95.62 161.6 13.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.884 179.92 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.533 HD21 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.34 101.42 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.907 179.849 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.79 -6.58 0.87 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.441 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.513 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -118.42 170.57 8.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.874 0.369 . . . . 0.0 110.832 -179.727 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.566 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 23.7 m95 -128.82 161.05 30.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.929 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.31 -106.45 1.61 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.471 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 67.5 m -164.09 176.05 9.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.809 0.338 . . . . 0.0 110.915 -179.754 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -98.63 123.11 42.63 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.909 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 7.6 mm-40 -122.54 118.11 27.48 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.854 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -121.23 123.05 41.28 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.903 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 15.0 tptm -172.76 105.04 0.15 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.889 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 7.5 tt -147.66 151.32 13.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.152 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.42 ' CG2' ' N ' ' A' ' 100' ' ' HIS . 8.8 t -86.49 -50.54 6.79 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.149 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . 0.42 ' N ' ' CG2' ' A' ' 99' ' ' THR . 5.3 p-80 -141.75 135.67 29.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.843 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . 0.407 ' OD1' ' C ' ' A' ' 101' ' ' ASN . 6.9 t-20 -104.73 95.97 9.72 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.647 0.737 . . . . 0.0 110.918 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -31.18 21.12 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.692 2.261 . . . . 0.0 112.39 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -47.12 113.93 0.76 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.874 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -140.59 138.11 8.75 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.489 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.73 102.69 1.05 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.653 2.235 . . . . 0.0 112.336 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 122.86 -6.49 9.56 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.488 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -130.67 147.11 52.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.857 0.361 . . . . 0.0 110.855 -179.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' PHE . . . . . 0.559 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 54.5 m-85 -66.5 172.03 4.46 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.888 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 22.5 p90 -160.65 128.38 4.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.856 -179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -103.45 105.39 15.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.421 ' CD1' HD13 ' A' ' 113' ' ' ILE . 0.9 OUTLIER -107.32 137.97 44.38 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.946 -179.962 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 2.9 m -145.09 112.93 6.35 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.87 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.421 HD13 ' CD1' ' A' ' 111' ' ' LEU . 4.2 mp -94.29 134.64 31.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.113 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 57.1 mtt180 -109.14 123.19 48.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.853 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . 0.567 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 33.8 t -90.53 123.22 34.02 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -124.72 -153.76 8.65 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.501 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 7.8 mt -109.81 -37.96 5.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.804 0.335 . . . . 0.0 110.913 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -86.1 -37.73 18.52 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.853 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 22.8 ptt180 -174.75 168.56 3.64 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.894 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.567 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 2.9 m-30 -91.81 153.28 19.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.913 -179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 18.9 mtmt -127.29 106.41 9.21 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.897 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 45.9 t -90.41 137.69 21.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.166 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 40.4 m-85 -121.37 147.28 45.91 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.913 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -137.68 105.52 5.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.126 179.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 62.09 34.08 16.63 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.84 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.416 ' C ' ' HG2' ' A' ' 127' ' ' GLN . . . 79.62 38.94 19.23 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.467 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . 0.416 ' HG2' ' C ' ' A' ' 126' ' ' GLY . 15.4 mm-40 -148.32 132.25 17.14 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.807 0.337 . . . . 0.0 110.892 -179.865 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 26.9 t-80 -61.58 101.05 0.16 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.828 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 9.8 tp -66.31 -69.85 0.28 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.877 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.434 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 7.3 p90 -161.87 174.66 12.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.874 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -114.96 150.73 35.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.868 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.581 ' CE1' ' O ' ' A' ' 133' ' ' ALA . 0.1 OUTLIER -117.53 104.62 11.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.896 -179.912 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.581 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -59.91 134.68 57.27 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.106 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 63.1 m-70 -61.99 112.89 2.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.889 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 83.1 mtt-85 -96.36 -52.48 3.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.834 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 9.4 tp -93.57 108.22 19.96 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.921 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 94.3 p -50.69 -32.25 18.81 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.896 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . 0.442 ' HB2' ' CD ' ' A' ' 141' ' ' ARG . . . -83.79 23.56 0.98 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.135 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 14.2 p90 -47.06 -38.99 12.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.883 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 10.0 pt20 -53.52 -34.01 56.62 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.938 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.442 ' CD ' ' HB2' ' A' ' 138' ' ' ALA . 51.9 mtp85 -63.47 -37.69 88.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.849 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.457 HG21 ' CG2' ' A' ' 62' ' ' VAL . 92.7 t -46.9 109.36 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.156 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -132.3 31.39 4.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.86 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' THR . . . . . 0.524 ' HG1' ' N ' ' A' ' 63' ' ' GLY . 8.6 m -141.45 111.98 7.02 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.118 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.552 HD13 ' CE2' ' A' ' 60' ' ' PHE . 3.9 tp -110.51 109.79 20.27 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.945 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' GLU . . . . . 0.413 ' C ' HG13 ' A' ' 147' ' ' ILE . 3.3 pt-20 -112.8 153.81 27.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.843 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . 0.413 HG13 ' C ' ' A' ' 146' ' ' GLU . 20.2 mt -140.72 110.63 3.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.096 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -119.6 174.37 6.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.943 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.17 -142.87 16.03 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.533 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -116.54 94.0 4.44 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.837 0.351 . . . . 0.0 110.913 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.6 p -151.08 151.15 12.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.173 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 10.4 m -110.98 94.5 5.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.13 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.456 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 37.6 mt -77.7 137.84 38.72 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.888 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 3.3 t -122.2 -37.43 2.82 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.869 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . 0.418 ' CD1' ' HE3' ' A' ' 46' ' ' LYS . 19.4 t80 -149.75 130.6 14.21 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.921 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 98.8 t -140.61 105.18 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.096 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 10.9 tt0 -112.13 145.3 40.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.89 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' ILE . . . . . 0.428 HG23 ' NH1' ' A' ' 41' ' ' ARG . 30.1 mt -109.43 90.47 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.109 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 39.6 t -50.4 140.04 14.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -116.37 175.01 15.54 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.5 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 93.72 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.649 2.233 . . . . 0.0 112.367 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 4.5 t -164.33 150.35 10.78 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.835 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 93.1 p -97.04 149.51 21.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.851 -179.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.294 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.521 -179.971 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 N-CA-C 112.456 -0.258 . . . . 0.0 112.456 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.8 m -156.84 169.37 24.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.887 0.375 . . . . 0.0 110.875 -179.769 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 24.4 m -138.06 143.14 40.35 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.851 -179.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.84 -166.21 35.04 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.471 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 26.7 m -73.92 104.3 4.73 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.877 0.37 . . . . 0.0 110.868 -179.723 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 32.4 t -125.44 91.28 3.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.834 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -168.52 84.17 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.475 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 54.1 m80 -151.62 150.68 30.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.744 0.307 . . . . 0.0 110.862 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 84.8 mt-30 -71.04 173.78 7.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.907 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -111.93 111.05 21.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.893 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 96.6 mt -79.38 -49.26 12.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.949 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 56.7 m-20 -138.97 169.45 17.77 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.913 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 4.2 t -63.31 160.25 16.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.84 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 2.6 pp -42.95 155.55 0.27 Allowed Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.671 0.748 . . . . 0.0 110.868 -180.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -169.49 0.33 Allowed 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.684 2.256 . . . . 0.0 112.344 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.431 ' CG2' ' HG2' ' A' ' 18' ' ' GLU . 14.7 t -66.57 159.54 27.21 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.124 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' MET . . . . . 0.46 ' SD ' ' N ' ' A' ' 32' ' ' ARG . 36.6 mtp -100.28 44.94 1.0 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.894 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.431 ' HG2' ' CG2' ' A' ' 16' ' ' THR . 3.4 pt-20 -78.86 156.31 28.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.834 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 111.11 -156.33 15.61 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.494 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 170.01 17.58 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.645 2.23 . . . . 0.0 112.331 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 175.62 7.91 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.7 2.267 . . . . 0.0 112.341 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.4 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 7.6 t -91.41 158.76 16.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.187 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.4 ' CD1' ' O ' ' A' ' 22' ' ' THR . 7.0 m-85 -142.07 117.28 10.1 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.908 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . 0.516 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 9.0 m120 66.92 49.97 0.56 Allowed Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.633 0.73 . . . . 0.0 110.927 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.516 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.7 Cg_endo -69.73 131.35 21.09 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.662 2.241 . . . . 0.0 112.335 179.919 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 -174.03 0.84 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.643 2.229 . . . . 0.0 112.319 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.531 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 97.5 t -144.03 138.33 14.91 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.593 0.711 . . . . 0.0 111.129 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.531 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.78 144.72 77.48 Favored 'Cis proline' 0 C--O 1.232 0.177 0 C-N-CA 122.73 -1.779 . . . . 0.0 112.321 -0.025 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.6 t80 -98.04 119.12 36.11 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.942 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 75.7 m-85 -105.66 108.26 19.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.844 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -119.89 103.39 0.95 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.454 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.46 ' N ' ' SD ' ' A' ' 17' ' ' MET . 0.0 OUTLIER -73.45 128.28 35.05 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.813 0.34 . . . . 0.0 110.899 -179.886 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 6.1 mt -73.07 151.83 41.51 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.902 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 20.0 mt-30 -88.29 -63.36 1.31 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.934 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.447 ' O ' ' C ' ' A' ' 36' ' ' GLY . . . -96.94 43.56 2.02 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.54 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.483 ' N ' ' OD2' ' A' ' 143' ' ' ASP . . . 34.39 -152.68 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.499 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 52.4 mt -87.64 113.16 23.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.854 0.359 . . . . 0.0 110.934 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.411 HG23 ' NH1' ' A' ' 41' ' ' ARG . 24.7 p -121.01 153.16 37.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.113 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -59.75 -25.77 65.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.12 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 13.2 mmt180 -105.43 35.62 2.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.869 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.44 ' HB2' ' NH1' ' A' ' 41' ' ' ARG . 9.4 ttm105 -125.02 140.78 52.6 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.915 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 90.7 m -139.68 121.7 15.67 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.14 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 mp -90.99 134.25 30.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.128 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 77.6 mt -123.45 133.41 69.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.139 179.817 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 75.0 mt -131.41 107.8 13.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.153 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.1 mtmt -109.31 107.74 18.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.9 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.26 -146.25 4.79 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.536 179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 0.559 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.7 OUTLIER -167.91 129.29 1.44 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.904 0.383 . . . . 0.0 110.934 -179.798 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.437 HG22 ' CD1' ' A' ' 109' ' ' PHE . 11.8 t -77.88 116.74 60.96 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.6 0.714 . . . . 0.0 111.14 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 158.52 56.63 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.627 2.218 . . . . 0.0 112.346 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -14.54 36.26 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.654 2.236 . . . . 0.0 112.394 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 66.7 p -113.16 19.22 17.33 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.151 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -113.37 118.34 4.49 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.419 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 15.7 mtpp -62.96 -58.85 5.95 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.755 0.312 . . . . 0.0 110.877 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 25.3 p -173.04 159.73 4.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.877 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.572 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 10.9 p90 -114.84 -173.19 2.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.873 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.481 ' CB ' ' OD1' ' A' ' 73' ' ' ASN . . . -156.65 141.79 17.28 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.067 179.911 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.473 HG23 ' CE1' ' A' ' 60' ' ' PHE . 9.1 mt -127.59 98.38 4.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.12 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . 0.471 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 2.2 m-80 -100.47 150.48 22.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.917 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.536 ' CE2' HD13 ' A' ' 145' ' ' LEU . 4.3 m-85 -118.1 101.17 8.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.912 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.402 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 28.3 ttmt -95.58 169.85 9.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.901 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.402 ' N ' ' HG2' ' A' ' 61' ' ' LYS . 67.8 t -101.17 124.14 54.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.105 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -59.08 -39.87 94.89 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.507 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 15.0 m -66.19 -73.5 0.13 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.837 0.351 . . . . 0.0 110.858 -179.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 68.5 m -76.72 -75.38 0.2 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.833 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 133.31 35.13 0.3 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.475 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -106.61 143.94 34.0 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.823 0.344 . . . . 0.0 110.861 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 58.7 mt -88.24 122.56 39.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.154 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.481 ' CB ' HG22 ' A' ' 142' ' ' VAL . . . -92.8 -33.33 14.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.114 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.519 HD21 ' CD2' ' A' ' 132' ' ' PHE . 42.4 tp -139.15 131.61 28.62 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.913 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.505 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.0 OUTLIER -134.66 92.95 2.97 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.838 179.863 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.435 ' CG2' HG13 ' A' ' 81' ' ' VAL . 40.3 mt -98.64 130.96 46.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.152 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.481 ' OD1' ' CB ' ' A' ' 57' ' ' ALA . 0.2 OUTLIER -140.67 107.74 6.5 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.64 0.733 . . . . 0.0 110.914 179.934 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.572 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.4 Cg_endo -69.74 155.13 66.82 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.704 2.269 . . . . 0.0 112.349 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 71.3 mtp180 -130.61 96.36 4.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.858 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' MET . . . . . 0.472 ' HE1' ' CE1' ' A' ' 56' ' ' PHE . 0.0 OUTLIER -60.96 168.85 2.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.901 179.947 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 76.13 -54.94 3.13 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.49 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 7.7 t30 -86.17 -57.44 3.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.858 0.361 . . . . 0.0 110.889 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 103.38 53.57 0.87 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.472 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 7.6 p -145.03 118.71 9.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.788 0.327 . . . . 0.0 111.128 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.435 HG13 ' CG2' ' A' ' 72' ' ' ILE . 7.9 t -100.61 112.83 34.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.153 179.908 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 61.5 t -80.67 142.31 14.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.172 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -122.4 124.09 42.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.862 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.505 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.1 m120 -138.49 176.56 8.59 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.839 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 45.2 t -160.35 105.08 1.47 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.866 -179.854 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.587 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 24.8 tp -77.55 119.02 20.54 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.951 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.513 ' N ' ' O ' ' A' ' 90' ' ' SER . 76.0 mt -95.88 161.35 14.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.916 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.51 HD21 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.89 101.43 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.902 179.933 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.98 -5.83 1.14 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.493 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.513 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -120.0 171.36 8.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.827 0.346 . . . . 0.0 110.866 -179.763 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.587 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 23.8 m95 -129.12 159.82 34.81 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.925 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -93.31 -114.71 2.36 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.53 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' SER . . . . . 0.434 ' HB2' ' CZ ' ' A' ' 135' ' ' ARG . 3.6 m -151.96 169.36 22.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.825 0.345 . . . . 0.0 110.878 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.428 ' HG2' ' ND2' ' A' ' 84' ' ' ASN . 7.0 mt-10 -97.7 121.75 39.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.937 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -117.33 116.26 26.87 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.845 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 38.2 mtmt -122.32 117.21 25.54 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.896 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -169.37 108.96 0.44 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.896 179.843 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.431 ' CG1' ' N ' ' A' ' 99' ' ' THR . 3.5 tt -145.4 153.79 13.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.073 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.431 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 8.7 t -97.44 -38.74 9.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.169 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . 0.443 ' O ' ' CG ' ' A' ' 100' ' ' HIS . 3.3 p-80 -146.67 125.07 12.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.862 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 31.0 t-20 -102.56 96.82 7.93 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.633 0.73 . . . . 0.0 110.864 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.436 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.7 Cg_endo -69.83 -40.55 5.09 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.631 2.22 . . . . 0.0 112.357 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.436 ' C ' ' O ' ' A' ' 102' ' ' PRO . 32.0 m-85 -35.7 106.74 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.883 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -134.53 136.66 8.72 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.506 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 100.11 0.8 Allowed 'Trans proline' 0 C--N 1.34 0.124 0 C-N-CA 122.672 2.248 . . . . 0.0 112.299 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 124.9 -6.58 8.31 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.466 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 9.2 pt20 -131.01 147.29 52.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.852 0.358 . . . . 0.0 110.886 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' PHE . . . . . 0.559 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 66.0 m-85 -64.24 172.16 2.63 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.889 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.461 ' CG ' ' O ' ' A' ' 109' ' ' PHE . 21.8 p90 -160.73 117.97 2.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.882 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -93.64 106.8 18.74 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.848 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.438 ' CD1' ' N ' ' A' ' 112' ' ' SER . 0.5 OUTLIER -108.64 138.68 44.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.921 -179.961 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.438 ' N ' ' CD1' ' A' ' 111' ' ' LEU . 5.4 m -145.36 113.42 6.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.829 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.5 mp -93.66 137.5 22.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.125 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.596 ' O ' ' CD2' ' A' ' 120' ' ' PHE . 16.9 mtp180 -109.88 135.05 51.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.87 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . 0.547 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 20.7 t -103.74 116.19 31.87 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.903 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -115.34 -149.2 9.54 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.504 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.414 ' O ' ' CD2' ' A' ' 134' ' ' HIS . 8.6 mt -111.83 -39.04 4.67 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.794 0.331 . . . . 0.0 110.899 -179.921 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . 0.553 ' C ' ' CD2' ' A' ' 134' ' ' HIS . 8.1 m-20 -89.41 -35.45 16.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.86 179.833 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 13.4 ptt180 -171.3 175.04 4.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 -179.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.596 ' CD2' ' O ' ' A' ' 114' ' ' ARG . 9.2 m-85 -98.9 162.51 13.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.887 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 36.6 mtpt -133.37 104.46 6.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.911 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 41.5 t -91.04 125.02 43.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.105 179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 48.6 m-85 -115.52 146.32 41.82 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.885 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -131.57 108.62 9.67 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.061 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 58.62 35.54 24.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.835 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.46 40.61 22.79 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.487 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 13.9 mt-30 -146.39 130.22 17.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.83 0.348 . . . . 0.0 110.922 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 33.2 t-80 -60.08 99.47 0.07 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.849 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 8.7 tp -70.17 -69.64 0.34 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.946 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.469 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 5.4 p90 -163.44 169.63 18.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.879 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -113.66 151.08 32.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.872 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.533 ' CE1' ' O ' ' A' ' 133' ' ' ALA . 0.2 OUTLIER -115.7 105.83 13.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.89 -179.942 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.533 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -61.71 134.01 56.25 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.132 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' HIS . . . . . 0.553 ' CD2' ' C ' ' A' ' 118' ' ' ASP . 14.3 m-70 -62.64 94.53 0.06 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.827 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.434 ' CZ ' ' HB2' ' A' ' 93' ' ' SER . 61.3 mtt-85 -78.78 -41.48 30.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.87 -179.935 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 12.3 tp -100.55 108.32 20.22 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.884 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 59.8 p -51.86 -30.78 25.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.887 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . 0.435 ' CB ' ' HD2' ' A' ' 141' ' ' ARG . . . -89.72 30.61 1.02 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.078 179.915 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.577 ' CE1' ' HG3' ' A' ' 140' ' ' GLN . 2.9 p90 -41.39 -40.14 1.64 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.91 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' GLN . . . . . 0.577 ' HG3' ' CE1' ' A' ' 139' ' ' PHE . 0.0 OUTLIER -48.05 -52.52 19.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.943 -179.952 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.435 ' HD2' ' CB ' ' A' ' 138' ' ' ALA . 47.9 mtt180 -42.4 -39.41 2.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.89 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.481 HG22 ' CB ' ' A' ' 69' ' ' ALA . 66.6 t -52.7 105.12 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.17 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.483 ' OD2' ' N ' ' A' ' 36' ' ' GLY . 0.9 OUTLIER -130.27 31.08 4.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.877 179.93 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -140.43 129.84 23.94 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.149 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.536 HD13 ' CE2' ' A' ' 60' ' ' PHE . 6.0 tp -125.59 108.91 12.04 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.869 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' GLU . . . . . 0.403 ' C ' HG13 ' A' ' 147' ' ' ILE . 3.0 pt-20 -111.12 148.85 31.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.907 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . 0.403 HG13 ' C ' ' A' ' 146' ' ' GLU . 8.8 mt -138.69 105.32 2.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.138 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -117.87 176.69 5.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.907 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.96 -145.94 16.57 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.477 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -114.6 91.63 3.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.868 0.366 . . . . 0.0 110.896 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 4.7 p -150.76 151.21 12.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.109 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 28.7 m -109.67 93.17 4.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.134 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.465 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 66.8 mt -76.52 138.34 40.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.957 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 74.0 m -122.82 -37.97 2.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.85 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 26.9 t80 -145.96 129.42 16.9 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.922 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 55.0 t -140.71 105.37 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.093 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 13.0 tt0 -121.58 120.4 34.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.907 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' ILE . . . . . 0.457 ' O ' ' C ' ' A' ' 159' ' ' SER . 27.1 mt -89.84 89.48 3.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.123 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' SER . . . . . 0.457 ' C ' ' O ' ' A' ' 158' ' ' ILE . 28.2 t -33.96 138.03 0.09 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.878 -179.903 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 175.37 169.21 36.87 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.449 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 98.24 0.68 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.653 2.235 . . . . 0.0 112.339 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 3.1 m -86.68 139.78 30.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.894 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 2.3 t -78.41 155.01 30.2 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.832 -179.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.503 179.965 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 74.0 m -155.42 135.01 12.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.873 0.368 . . . . 0.0 110.873 -179.718 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.446 ' O ' ' C ' ' A' ' 4' ' ' GLY . 28.2 m -62.03 -51.17 69.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.873 -179.857 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.446 ' C ' ' O ' ' A' ' 3' ' ' SER . . . 34.53 -103.51 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.475 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 5.8 m -55.22 169.23 0.28 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.867 0.365 . . . . 0.0 110.893 -179.765 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.43 ' O ' ' C ' ' A' ' 7' ' ' GLY . 12.1 t -49.46 118.27 2.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.914 -179.815 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.43 ' C ' ' O ' ' A' ' 6' ' ' SER . . . -36.01 -57.31 1.06 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.496 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 42.6 p-80 -85.49 134.0 34.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.728 0.299 . . . . 0.0 110.881 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -110.11 139.33 45.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.869 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 1.8 pm0 -86.53 24.74 1.35 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.93 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.6 mt -138.36 157.5 46.11 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.945 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 -108.53 47.79 0.89 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.881 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 20.1 m -115.98 178.55 4.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.905 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 32.2 mt -74.09 153.19 88.59 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.592 0.71 . . . . 0.0 110.905 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 -165.96 0.17 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.684 2.256 . . . . 0.0 112.321 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.465 HG21 ' CG ' ' A' ' 34' ' ' GLN . 1.5 m -86.79 -13.48 45.02 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.089 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 3.4 ptt? 41.14 54.58 3.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.856 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -88.91 174.24 8.05 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.87 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 101.28 -138.16 13.7 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.469 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 170.13 17.35 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.632 2.222 . . . . 0.0 112.341 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.402 ' HB3' ' NE2' ' A' ' 157' ' ' GLN . 53.8 Cg_endo -69.76 170.93 15.43 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.67 2.247 . . . . 0.0 112.343 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.406 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 6.5 t -87.34 162.07 17.57 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.171 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.406 ' CD1' ' O ' ' A' ' 22' ' ' THR . 7.4 m-85 -142.68 116.86 9.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.92 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . 0.474 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 11.8 m120 61.68 52.23 2.25 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.671 0.748 . . . . 0.0 110.914 -179.889 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.474 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 54.2 Cg_endo -69.76 133.41 25.5 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.665 2.243 . . . . 0.0 112.387 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.42 ' C ' HG22 ' A' ' 27' ' ' VAL . 54.2 Cg_endo -69.75 -174.22 0.86 Allowed 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.707 2.272 . . . . 0.0 112.33 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.53 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 84.7 t -144.04 138.77 15.28 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.621 0.724 . . . . 0.0 111.113 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.53 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.79 145.27 79.01 Favored 'Cis proline' 0 C--N 1.342 0.186 0 C-N-CA 122.659 -1.809 . . . . 0.0 112.303 -0.048 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.0 t80 -100.96 117.1 34.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.931 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.493 ' CD2' ' HB3' ' A' ' 146' ' ' GLU . 58.2 m-85 -104.61 105.98 16.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.896 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -116.34 103.44 1.15 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.496 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.513 ' CD ' ' O ' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -72.61 114.08 10.36 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.799 0.333 . . . . 0.0 110.856 -179.873 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 3.9 mt -59.1 151.32 22.78 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.932 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.465 ' CG ' HG21 ' A' ' 16' ' ' THR . 3.0 mp0 -104.26 101.22 10.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.906 179.936 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.64 -58.62 0.52 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.493 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.492 ' N ' ' OD1' ' A' ' 143' ' ' ASP . . . 123.73 171.83 13.62 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.48 -179.872 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 93.7 mt -58.74 103.74 0.18 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.879 0.371 . . . . 0.0 110.949 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 22.0 p -118.98 150.16 40.4 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.098 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -54.83 -28.16 47.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.107 179.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 3.9 tpt180 -102.97 37.47 1.95 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.899 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 11.7 ttm180 -129.16 139.51 51.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.871 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 91.8 m -137.4 124.75 21.9 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.128 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 4.9 mp -92.67 134.05 31.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.161 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 89.7 mt -122.93 135.89 61.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.087 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 56.1 mt -133.98 107.92 10.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.132 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.3 mtmt -113.82 113.78 25.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.836 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.416 ' CA ' ' O ' ' A' ' 152' ' ' THR . . . -146.56 -140.6 3.47 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.519 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -170.55 137.45 1.38 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.916 0.389 . . . . 0.0 110.927 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 14.2 t -86.62 114.87 60.07 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.604 0.716 . . . . 0.0 111.124 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.83 155.71 65.0 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.685 2.256 . . . . 0.0 112.358 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 -13.9 35.46 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.701 2.267 . . . . 0.0 112.356 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 57.8 p -112.28 16.19 20.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.112 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -112.72 120.23 5.18 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.468 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 12.1 mtpt -61.62 -60.46 3.64 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.767 0.318 . . . . 0.0 110.857 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 25.8 p -173.16 158.4 3.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.85 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.555 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 8.2 p90 -112.01 -172.8 2.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.88 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.48 141.8 18.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.12 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.419 HD13 ' CE2' ' A' ' 56' ' ' PHE . 2.9 mp -123.01 102.23 11.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.105 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.5 m-80 -103.22 146.09 28.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.846 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.547 ' CE2' HD12 ' A' ' 145' ' ' LEU . 40.7 m-85 -117.63 101.16 8.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.905 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.412 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 33.1 ttmt -96.33 168.57 10.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.854 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.416 ' CG2' HG21 ' A' ' 142' ' ' VAL . 38.4 t -99.57 122.83 51.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.137 179.846 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.424 ' N ' ' OG1' ' A' ' 144' ' ' THR . . . -59.55 -28.69 65.46 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.482 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 t -77.53 -71.09 0.43 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.839 0.352 . . . . 0.0 110.856 -179.706 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.6 t -79.33 -75.51 0.24 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.818 -179.786 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 132.18 41.31 0.2 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.467 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -115.45 139.62 49.87 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.763 0.316 . . . . 0.0 110.855 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 37.6 mt -86.43 114.8 26.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.079 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.22 -34.69 21.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.092 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.539 HD13 ' CD1' ' A' ' 132' ' ' PHE . 32.1 tp -138.01 131.75 31.2 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.939 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.475 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.1 t60 -134.95 98.38 4.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.848 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.448 ' CG2' HG12 ' A' ' 81' ' ' VAL . 22.4 mt -96.42 129.27 46.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.129 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.503 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.2 OUTLIER -134.36 104.15 11.3 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.588 0.708 . . . . 0.0 110.927 179.966 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.555 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.6 Cg_endo -69.77 155.48 65.78 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.688 2.259 . . . . 0.0 112.341 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 81.6 mtt-85 -133.25 97.99 4.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.892 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' MET . . . . . 0.463 ' O ' ' N ' ' A' ' 78' ' ' ASN . 0.1 OUTLIER -54.41 177.25 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.914 179.931 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 60.81 -76.04 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.522 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.463 ' N ' ' O ' ' A' ' 76' ' ' MET . 45.1 t30 -56.99 -65.76 0.56 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.851 0.358 . . . . 0.0 110.884 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 107.28 51.78 0.75 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.46 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 13.8 p -141.84 117.83 10.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.845 0.355 . . . . 0.0 111.118 -179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.448 HG12 ' CG2' ' A' ' 72' ' ' ILE . 16.2 t -99.46 109.65 24.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.132 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.402 HG12 ' N ' ' A' ' 83' ' ' ARG . 82.5 t -79.24 140.19 17.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.123 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . 0.647 ' NH1' ' CD2' ' A' ' 130' ' ' PHE . 1.4 mpp_? -121.37 115.02 22.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.875 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.475 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.4 t-20 -125.98 179.75 5.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.896 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 94.7 p -160.95 110.07 1.64 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.869 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.574 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 24.5 tp -82.73 118.99 23.76 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.909 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.495 ' N ' ' O ' ' A' ' 90' ' ' SER . 96.8 mt -96.12 161.07 14.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.931 179.85 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.51 HD21 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.5 101.64 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.85 179.932 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.62 -7.0 1.11 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.481 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.502 ' H ' ' C ' ' A' ' 88' ' ' ASN . 0.3 OUTLIER -118.85 172.11 7.76 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.879 0.371 . . . . 0.0 110.85 -179.752 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.574 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 23.8 m95 -129.12 160.66 32.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.924 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.59 -114.7 2.19 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.454 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' SER . . . . . 0.424 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 4.5 m -152.78 167.56 28.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.806 0.336 . . . . 0.0 110.88 -179.728 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -97.66 120.46 38.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 20.8 mm-40 -119.63 128.22 53.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.875 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 47.4 mtmt -130.11 117.68 20.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.922 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 25.0 tptt -171.73 105.7 0.21 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.922 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.447 HG12 ' N ' ' A' ' 99' ' ' THR . 2.1 tt -145.23 151.09 15.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.101 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.447 ' N ' HG12 ' A' ' 98' ' ' ILE . 9.7 t -85.83 -50.35 7.19 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.168 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . 0.432 ' O ' ' CD1' ' A' ' 98' ' ' ILE . 9.7 p-80 -137.33 132.55 33.77 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.847 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . 0.41 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 43.2 t-20 -112.82 99.62 48.61 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.608 0.718 . . . . 0.0 110.907 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.442 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.6 Cg_endo -69.8 -41.1 4.51 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.705 2.27 . . . . 0.0 112.35 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.442 ' C ' ' O ' ' A' ' 102' ' ' PRO . 7.5 m-85 -35.32 101.91 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.866 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -131.5 136.5 8.83 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.522 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 97.9 0.66 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.675 2.25 . . . . 0.0 112.318 -179.87 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 133.56 -10.45 4.95 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.48 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -133.3 161.77 33.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.837 0.351 . . . . 0.0 110.879 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -82.23 175.08 10.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.864 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 23.0 p90 -161.81 127.26 3.54 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.866 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -98.39 104.49 16.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.85 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.479 ' CD1' ' N ' ' A' ' 112' ' ' SER . 0.6 OUTLIER -104.85 139.47 39.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.92 -179.945 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.479 ' N ' ' CD1' ' A' ' 111' ' ' LEU . 4.7 m -144.8 113.41 6.69 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.854 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.454 HD13 ' CD1' ' A' ' 111' ' ' LEU . 4.7 mp -93.36 136.16 25.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.175 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 42.7 mtt180 -111.68 120.22 41.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.901 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . 0.567 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 2.3 t -90.42 116.7 28.56 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.913 -179.929 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -113.03 -148.85 10.39 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.467 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 19.1 mt -112.76 -35.24 5.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.826 0.346 . . . . 0.0 110.903 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 52.4 m-20 -91.2 -33.14 15.51 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.893 179.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.2 ptp180 -174.77 176.2 2.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.867 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.567 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.9 m-30 -99.22 158.15 15.89 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 -179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.9 mtpt -130.75 100.82 5.42 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.9 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . 0.539 HG23 ' CZ ' ' A' ' 130' ' ' PHE . 25.1 t -87.83 126.67 41.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.136 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 85.2 m-85 -118.37 150.49 39.43 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.946 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . 0.403 ' C ' ' ND2' ' A' ' 125' ' ' ASN . . . -134.86 110.14 8.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.097 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.403 ' ND2' ' C ' ' A' ' 124' ' ' ALA . 0.6 OUTLIER 60.68 39.24 17.82 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.907 -179.889 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.402 ' C ' ' HG2' ' A' ' 127' ' ' GLN . . . 72.92 41.59 48.32 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.495 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . 0.402 ' HG2' ' C ' ' A' ' 126' ' ' GLY . 20.3 mm-40 -148.41 136.84 21.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.79 0.329 . . . . 0.0 110.917 -179.851 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 46.5 t-80 -63.1 107.39 1.02 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.856 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 11.8 tp -78.35 -64.24 1.21 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.914 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.647 ' CD2' ' NH1' ' A' ' 83' ' ' ARG . 24.7 p90 -166.84 -178.68 4.38 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.889 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -125.37 144.86 50.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.861 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.539 ' CD1' HD13 ' A' ' 70' ' ' LEU . 0.4 OUTLIER -113.06 106.42 14.65 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.905 -179.915 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.491 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -61.74 137.98 58.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.106 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 17.8 m-70 -66.31 100.74 0.66 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.8 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.424 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 60.5 mtt-85 -83.97 -55.1 4.41 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.855 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 4.9 tp -88.67 107.91 19.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.913 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 19.9 p -48.79 -34.4 12.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.858 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . 0.472 ' HB2' ' CD ' ' A' ' 141' ' ' ARG . . . -82.67 28.99 0.46 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.107 179.912 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.416 ' CG ' ' N ' ' A' ' 140' ' ' GLN . 27.0 p90 -50.94 -42.54 59.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.899 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' GLN . . . . . 0.416 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 7.3 pt20 -48.83 -37.25 18.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.907 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.472 ' CD ' ' HB2' ' A' ' 138' ' ' ALA . 45.4 mtp85 -58.17 -40.91 82.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.861 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.416 HG21 ' CG2' ' A' ' 62' ' ' VAL . 60.0 t -48.17 102.3 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.133 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.492 ' OD1' ' N ' ' A' ' 36' ' ' GLY . 22.6 t0 -124.26 24.91 7.93 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.869 179.868 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' THR . . . . . 0.424 ' OG1' ' N ' ' A' ' 63' ' ' GLY . 1.5 m -132.59 140.63 48.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.127 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.547 HD12 ' CE2' ' A' ' 60' ' ' PHE . 4.5 tp -135.91 113.81 11.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.875 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' GLU . . . . . 0.493 ' HB3' ' CD2' ' A' ' 30' ' ' PHE . 5.9 pt-20 -117.82 151.85 36.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.932 179.903 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 18.0 mt -139.19 118.35 13.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.117 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 1.1 pm0 -128.19 177.9 6.61 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.868 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 106.32 -137.5 13.88 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.474 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -122.54 92.48 3.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.816 0.341 . . . . 0.0 110.905 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.45 HG22 ' N ' ' A' ' 152' ' ' THR . 2.1 p -151.17 150.6 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.103 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' THR . . . . . 0.45 ' N ' HG22 ' A' ' 151' ' ' VAL . 23.7 m -107.48 93.52 4.59 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.114 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.466 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 67.8 mt -77.24 128.97 35.29 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.938 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 3.8 m -111.96 -41.66 3.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.901 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 35.2 t80 -143.87 130.62 20.26 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.942 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 72.9 t -140.7 105.29 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.122 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . 0.402 ' NE2' ' HB3' ' A' ' 21' ' ' PRO . 11.6 tt0 -120.66 129.62 53.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.879 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 16.6 mt -95.31 94.13 4.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.103 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 17.8 t -53.03 147.35 9.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.854 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -145.53 154.81 26.17 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.478 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -1.31 8.22 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.658 2.239 . . . . 0.0 112.358 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 14.8 m -54.85 91.03 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.861 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 32.6 p -39.48 134.4 1.26 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.877 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.471 -179.988 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.3 0 N-CA-C 112.473 -0.251 . . . . 0.0 112.473 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.3 m -140.19 125.49 18.83 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.851 0.358 . . . . 0.0 110.89 -179.762 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 28.7 m -102.84 142.73 33.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.869 -179.808 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.25 -174.57 13.89 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.526 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 93.1 p -136.85 136.15 38.5 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.894 0.378 . . . . 0.0 110.847 -179.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 14.8 m -88.95 140.89 28.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.858 -179.848 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -109.77 139.07 15.2 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.475 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.43 ' CD2' ' HG2' ' A' ' 10' ' ' GLN . 27.0 t60 -101.53 103.1 13.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.73 0.3 . . . . 0.0 110.833 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -86.51 86.24 7.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.924 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . 0.43 ' HG2' ' CD2' ' A' ' 8' ' ' HIS . 7.3 mm100 -76.12 84.14 2.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.942 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 51.6 mt -146.32 147.83 31.76 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.942 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 5.4 m120 -75.19 138.73 42.17 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.886 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 3.6 m -162.43 130.83 4.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.87 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.411 HD13 ' C ' ' A' ' 14' ' ' LEU . 0.9 OUTLIER -58.59 152.89 43.41 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.577 0.704 . . . . 0.0 110.96 179.989 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -172.47 0.58 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.634 2.222 . . . . 0.0 112.349 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -79.18 150.43 31.69 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.129 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 3.4 ptt? -110.58 69.71 0.7 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.842 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -83.53 160.13 21.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.897 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 117.05 -142.69 17.62 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.517 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 170.05 17.4 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.697 2.265 . . . . 0.0 112.378 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 176.57 6.61 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.696 2.264 . . . . 0.0 112.299 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.411 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.4 m -92.2 148.38 22.2 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.149 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.404 ' CD1' ' O ' ' A' ' 22' ' ' THR . 7.2 m-85 -142.52 134.47 27.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.854 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . 0.51 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.5 t-20 42.68 49.9 4.95 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.554 0.692 . . . . 0.0 110.878 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.51 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.8 Cg_endo -69.8 143.87 52.04 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.634 2.223 . . . . 0.0 112.378 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -178.74 2.49 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.701 2.267 . . . . 0.0 112.315 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.527 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 98.8 t -143.71 137.93 14.81 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.636 0.731 . . . . 0.0 111.106 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.527 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.77 144.65 77.25 Favored 'Cis proline' 0 C--O 1.231 0.171 0 C-N-CA 122.698 -1.792 . . . . 0.0 112.357 -0.066 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -98.8 118.12 34.83 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.954 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.417 ' CD1' ' HB3' ' A' ' 146' ' ' GLU . 63.8 m-85 -104.7 103.01 12.57 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.872 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -113.77 104.32 1.46 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.503 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.469 ' O ' ' HG3' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -73.44 121.89 21.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.876 0.37 . . . . 0.0 110.874 -179.868 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 5.4 mt -68.77 147.12 52.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.922 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 29.1 mt-30 -106.0 83.63 1.94 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.917 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 138.13 -49.0 0.86 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.49 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 109.35 166.98 20.33 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.454 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 87.5 mt -55.0 110.27 0.64 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.895 0.378 . . . . 0.0 110.901 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 61.7 p -129.93 145.4 51.62 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.178 179.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -47.37 -31.1 3.7 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.098 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 8.9 tpt180 -97.32 31.66 2.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.881 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 12.3 ttm180 -124.13 141.56 51.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.879 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 94.0 m -138.33 124.85 20.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.147 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.1 mp -96.85 130.15 45.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.112 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.417 HG21 ' N ' ' A' ' 45' ' ' ILE . 86.5 mt -123.49 134.04 67.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.132 179.812 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.417 ' N ' HG21 ' A' ' 44' ' ' ILE . 72.1 mt -133.32 107.39 11.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.156 179.903 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 25.9 mtmt -112.01 109.93 19.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.898 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.501 ' CA ' ' O ' ' A' ' 152' ' ' THR . . . -138.09 -139.89 3.93 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.492 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -173.63 119.4 0.29 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.947 0.404 . . . . 0.0 110.884 -179.777 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 21.9 t -70.77 113.52 19.37 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.615 0.721 . . . . 0.0 111.124 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 156.88 62.35 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.671 2.248 . . . . 0.0 112.344 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -14.48 36.18 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.669 2.246 . . . . 0.0 112.366 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 72.6 p -111.7 18.46 18.96 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.181 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -116.12 123.47 5.89 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.509 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 33.8 mtpt -65.39 -59.43 4.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.823 0.344 . . . . 0.0 110.891 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 34.9 p -174.03 160.74 3.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.833 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.58 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 3.4 p90 -114.19 -174.37 2.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.869 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.37 128.19 7.31 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.076 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 5.3 mp -112.22 102.28 13.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.155 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.3 m-80 -100.84 149.69 23.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.938 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 56.6 m-85 -118.65 101.08 7.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.872 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.409 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 34.9 ttmt -95.69 168.92 10.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.904 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.409 ' N ' ' HG2' ' A' ' 61' ' ' LYS . 55.2 t -100.48 124.83 54.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.124 179.856 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -60.48 -33.76 82.76 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.506 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 70.1 m -70.84 -71.05 0.27 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.837 0.351 . . . . 0.0 110.864 -179.738 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 82.6 p -82.07 -75.1 0.31 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.875 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 133.37 44.31 0.13 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.46 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.411 ' OD1' ' OD1' ' A' ' 88' ' ' ASN . 1.2 m-20 -113.65 144.83 42.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.798 0.332 . . . . 0.0 110.889 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 40.9 mt -90.22 113.85 26.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.124 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.408 ' HB2' ' CG2' ' A' ' 142' ' ' VAL . . . -87.17 -32.3 19.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.126 179.799 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.5 HD21 ' CD2' ' A' ' 132' ' ' PHE . 41.4 tp -136.83 129.73 30.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.9 -179.936 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.482 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.0 OUTLIER -134.61 94.42 3.19 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.869 179.836 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 44.7 mt -99.59 134.74 37.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.148 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.504 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -141.38 106.9 6.07 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.594 0.711 . . . . 0.0 110.859 179.955 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.58 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.0 Cg_endo -69.81 155.14 66.54 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.708 2.272 . . . . 0.0 112.362 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . 0.42 ' NH1' HG21 ' A' ' 82' ' ' VAL . 34.6 mtt85 -128.97 97.49 4.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.877 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -55.37 -32.33 62.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -43.0 -88.01 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.505 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -88.4 -41.62 12.7 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.821 0.343 . . . . 0.0 110.873 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.445 ' HA2' ' ND2' ' A' ' 101' ' ' ASN . . . 121.09 32.66 1.04 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.494 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 24.7 p -109.61 118.08 35.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.777 0.322 . . . . 0.0 111.164 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 13.8 t -97.79 113.58 32.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.131 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.42 HG21 ' NH1' ' A' ' 75' ' ' ARG . 58.2 t -83.12 144.81 9.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.111 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -123.89 125.46 44.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.873 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.482 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.7 OUTLIER -139.29 177.96 7.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.935 -179.955 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 92.4 p -160.67 107.68 1.53 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.868 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.564 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 24.6 tp -76.98 117.41 18.54 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.935 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.486 ' N ' ' O ' ' A' ' 90' ' ' SER . 25.9 mt -93.44 161.19 14.48 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.908 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.413 ' C ' ' H ' ' A' ' 90' ' ' SER . 10.6 m-80 -41.31 101.48 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.866 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.94 -3.25 4.11 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.471 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.486 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.4 OUTLIER -124.5 173.41 8.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.87 0.367 . . . . 0.0 110.831 -179.716 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.564 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 23.8 m95 -130.21 159.58 36.44 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.948 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -90.8 -109.3 1.47 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.478 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 3.4 m -159.92 176.03 12.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.839 0.352 . . . . 0.0 110.832 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.42 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 4.6 mt-10 -104.05 122.96 46.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.866 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -121.75 113.25 19.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.892 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 40.4 mtmt -114.34 118.41 33.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.868 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 12.1 tptm -172.13 105.27 0.18 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.879 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 2.4 tt -144.23 143.58 23.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.155 179.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.45 ' CG2' ' N ' ' A' ' 100' ' ' HIS . 10.3 t -77.25 -51.58 10.67 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.154 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . 0.45 ' N ' ' CG2' ' A' ' 99' ' ' THR . 21.3 p80 -140.55 134.21 30.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.85 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . 0.445 ' ND2' ' HA2' ' A' ' 79' ' ' GLY . 4.9 t-20 -101.65 99.13 10.88 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.608 0.718 . . . . 0.0 110.931 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.435 ' CD ' HD13 ' A' ' 129' ' ' LEU . 53.6 Cg_endo -69.76 -40.81 4.89 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.693 2.262 . . . . 0.0 112.328 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -41.02 111.86 0.25 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.885 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -134.08 133.85 7.1 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.511 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 96.5 0.6 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.632 2.222 . . . . 0.0 112.333 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 127.25 0.23 6.92 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.49 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -138.78 154.48 48.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.85 0.357 . . . . 0.0 110.952 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 -71.9 171.96 10.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.87 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 27.4 p90 -160.52 136.33 8.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.909 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.67 105.8 14.82 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.854 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.452 ' CD1' HD13 ' A' ' 113' ' ' ILE . 0.6 OUTLIER -107.14 139.72 41.11 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.9 -179.931 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.409 ' N ' ' CD1' ' A' ' 111' ' ' LEU . 3.6 m -144.88 114.88 7.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.839 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.452 HD13 ' CD1' ' A' ' 111' ' ' LEU . 4.6 mp -98.23 127.42 50.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.142 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 9.9 mtp180 -100.25 133.48 44.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.875 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 14.1 t -98.49 100.41 11.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.894 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -91.04 -140.51 8.87 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.469 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.3 mt -122.8 -38.55 2.62 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.845 0.355 . . . . 0.0 110.933 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.4 t0 -94.39 -21.43 18.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.867 179.848 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.402 ' CD ' ' C ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -175.18 -175.12 0.81 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.834 -179.902 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.404 ' CE1' ' HE1' ' A' ' 134' ' ' HIS . 20.4 m-85 -108.42 148.91 29.46 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.871 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 2.1 mmmm -120.17 101.95 8.18 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.866 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . 0.481 HG23 ' CE1' ' A' ' 130' ' ' PHE . 65.8 t -89.31 129.74 39.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.141 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 54.6 m-85 -116.16 160.7 20.01 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.925 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . 0.421 ' O ' ' N ' ' A' ' 127' ' ' GLN . . . -139.92 114.34 9.21 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.111 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 41.41 38.68 0.88 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.852 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 83.71 27.63 37.9 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.458 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . 0.421 ' N ' ' O ' ' A' ' 124' ' ' ALA . 9.4 mm100 -138.88 115.88 10.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.855 0.359 . . . . 0.0 110.897 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 34.4 t-80 -47.93 103.19 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.876 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . 0.435 HD13 ' CD ' ' A' ' 102' ' ' PRO . 13.5 tp -69.65 -68.48 0.41 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.894 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.481 ' CE1' HG23 ' A' ' 122' ' ' VAL . 9.4 p90 -164.2 175.8 9.81 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.912 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.48 ' OD1' ' N ' ' A' ' 132' ' ' PHE . 0.4 OUTLIER -117.06 156.73 27.05 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 179.967 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.605 ' CE1' ' O ' ' A' ' 133' ' ' ALA . 0.1 OUTLIER -128.31 106.12 8.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.889 -179.864 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.605 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -63.35 136.66 57.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.137 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' HIS . . . . . 0.404 ' HE1' ' CE1' ' A' ' 120' ' ' PHE . 15.8 m-70 -61.37 115.65 4.02 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.883 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 8.1 mtt-85 -95.9 -47.65 6.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.861 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 9.9 tp -96.56 108.19 20.74 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.905 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 78.9 p -47.73 -34.22 8.07 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.847 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -83.62 31.09 0.47 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.084 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -50.36 -34.89 25.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.871 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' GLN . . . . . 0.466 ' HG2' ' N ' ' A' ' 141' ' ' ARG . 18.1 pm0 -59.7 -29.41 68.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.923 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.466 ' N ' ' HG2' ' A' ' 140' ' ' GLN . 36.3 mtp85 -65.29 -39.64 92.81 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.408 ' CG2' ' HB2' ' A' ' 69' ' ' ALA . 84.3 t -50.62 103.94 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.151 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 9.3 p-10 -125.27 31.85 5.49 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.886 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.7 m -140.72 135.04 31.18 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.14 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . . . . . . . . . 6.4 tp -129.88 115.88 17.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.932 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' GLU . . . . . 0.417 ' HB3' ' CD1' ' A' ' 30' ' ' PHE . 5.1 pt-20 -120.0 150.95 39.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.885 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . 0.409 HG13 ' C ' ' A' ' 146' ' ' GLU . 15.0 mt -139.36 112.85 6.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.152 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -122.58 175.59 6.4 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.902 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 105.11 -146.36 16.06 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.498 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -111.69 92.51 4.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.886 0.374 . . . . 0.0 110.865 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.472 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 4.7 p -151.22 140.59 15.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.107 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' THR . . . . . 0.501 ' O ' ' CA ' ' A' ' 47' ' ' GLY . 14.1 m -100.52 94.15 5.99 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.16 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.446 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 80.4 mt -78.59 132.99 37.34 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.92 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 64.9 m -118.29 -34.38 4.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.889 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 13.8 t80 -149.98 130.36 13.79 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.941 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 86.3 t -140.77 106.14 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.152 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 16.0 tt0 -114.57 135.85 53.68 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.919 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 42.1 mt -104.11 88.46 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.166 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 16.4 m -62.32 136.2 57.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.876 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -162.41 178.09 38.32 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.46 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 125.76 12.53 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.662 2.241 . . . . 0.0 112.347 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 35.7 m -90.76 103.12 15.86 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.804 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 7.7 t 46.57 42.46 11.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.847 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.528 180.0 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 N-CA-C 112.501 -0.24 . . . . 0.0 112.501 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 15.7 m -96.21 90.91 5.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.845 0.355 . . . . 0.0 110.854 -179.762 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 23.6 t -70.91 147.61 48.59 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.858 -179.837 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 118.98 152.68 9.23 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.49 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 79.0 p -63.84 106.31 0.98 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.836 0.351 . . . . 0.0 110.814 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 93.0 p -156.61 149.65 24.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.865 -179.829 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 123.67 -130.67 7.76 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.49 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 55.2 m-70 -144.59 153.07 41.42 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.735 0.303 . . . . 0.0 110.868 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.7 tt0 -105.94 41.84 1.34 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.871 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 87.9 mt-30 -80.82 43.42 0.68 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.909 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 26.1 mt -151.44 161.72 42.21 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.856 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 20.2 t30 -121.31 130.43 53.64 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.841 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 19.8 m -158.94 156.0 28.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.808 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 4.3 pp -83.31 153.8 66.01 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.583 0.706 . . . . 0.0 110.951 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 175.75 7.65 Favored 'Trans proline' 0 C--O 1.232 0.21 0 C-N-CA 122.665 2.244 . . . . 0.0 112.378 179.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.407 ' CG2' ' HG2' ' A' ' 18' ' ' GLU . 9.6 t -50.96 178.98 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.157 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' MET . . . . . 0.403 ' O ' ' O ' ' A' ' 18' ' ' GLU . 23.8 mmm -118.17 7.37 12.12 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.894 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.407 ' HG2' ' CG2' ' A' ' 16' ' ' THR . 22.1 pt-20 -50.96 -176.08 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.923 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 76.85 -155.81 45.18 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.475 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 166.32 27.94 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.677 2.251 . . . . 0.0 112.34 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 178.35 4.66 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.667 2.245 . . . . 0.0 112.373 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.51 ' CG2' ' N ' ' A' ' 23' ' ' PHE . 1.3 m -92.14 157.26 16.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.115 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.51 ' N ' ' CG2' ' A' ' 22' ' ' THR . 8.4 m-85 -147.73 141.65 25.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.873 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . 0.485 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 15.8 m120 35.12 51.95 1.37 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.63 0.729 . . . . 0.0 110.88 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.485 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.6 Cg_endo -69.82 145.78 57.85 Favored 'Trans proline' 0 C--O 1.232 0.192 0 C-N-CA 122.693 2.262 . . . . 0.0 112.309 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.79 -178.25 2.27 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.663 2.242 . . . . 0.0 112.32 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.518 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 95.2 t -142.85 138.0 15.58 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.688 0.756 . . . . 0.0 111.081 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.518 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.9 Cg_endo -69.77 144.54 76.95 Favored 'Cis proline' 0 C--N 1.342 0.195 0 C-N-CA 122.656 -1.81 . . . . 0.0 112.347 -0.028 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 1.9 t80 -96.22 117.64 31.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.95 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -100.53 104.09 15.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.888 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -109.03 109.19 2.74 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.48 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 6.8 mmt85 -72.97 116.55 13.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.829 0.347 . . . . 0.0 110.887 -179.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 6.1 mt -75.69 94.61 3.27 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.913 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 22.2 mm-40 -67.22 92.55 0.27 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.886 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 138.21 -37.63 1.79 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.476 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.505 ' N ' ' OD2' ' A' ' 143' ' ' ASP . . . 88.92 157.48 32.85 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.493 -179.884 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 66.4 mt -51.08 95.77 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.914 0.388 . . . . 0.0 110.907 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 44.4 p -116.24 148.59 40.3 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.092 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -50.6 -21.27 1.48 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.106 179.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.453 ' HA ' ' NE ' ' A' ' 40' ' ' ARG . 3.8 mmp_? -106.88 34.28 3.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.859 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 14.7 ttt85 -125.9 140.06 52.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.904 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 99.9 m -139.36 119.81 13.95 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.168 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 4.9 mp -90.59 142.19 13.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.15 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.4 ' CG2' ' HZ1' ' A' ' 46' ' ' LYS . 82.4 mt -133.76 115.66 22.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.111 179.87 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 54.3 mt -114.92 107.59 23.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.123 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.4 ' HZ1' ' CG2' ' A' ' 44' ' ' ILE . 9.0 mtmm -110.18 109.3 19.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.885 179.877 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.59 -147.53 4.98 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.507 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 0.57 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.5 OUTLIER -168.14 127.13 1.22 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.892 0.377 . . . . 0.0 110.97 -179.806 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 11.3 t -75.97 115.38 46.06 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.627 0.727 . . . . 0.0 111.141 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 155.42 66.15 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.661 2.241 . . . . 0.0 112.423 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -14.83 36.61 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.657 2.238 . . . . 0.0 112.326 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 49.7 p -111.62 17.94 19.49 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.162 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -113.36 124.14 6.44 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.48 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 14.8 mttp -64.89 -62.6 1.46 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.802 0.334 . . . . 0.0 110.897 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 17.5 p -171.76 157.51 4.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.875 -179.869 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.576 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 9.1 p90 -113.1 -172.27 2.03 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.931 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.19 139.12 16.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.081 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.522 HG22 ' CE1' ' A' ' 60' ' ' PHE . 2.7 mp -118.95 99.03 7.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.139 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . 0.512 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 33.0 m-80 -101.22 141.67 33.77 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.897 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.522 ' CE1' HG22 ' A' ' 58' ' ' ILE . 26.8 m-85 -115.49 97.92 6.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.861 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.9 ttmt -95.59 169.91 9.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.94 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.426 HG12 ' C ' ' A' ' 141' ' ' ARG . 16.7 t -99.33 123.35 51.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.131 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -61.08 -22.87 61.05 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.497 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 30.7 t -81.73 -72.78 0.42 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.928 0.394 . . . . 0.0 110.855 -179.72 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 36.0 t -80.61 -72.79 0.4 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.839 -179.82 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 133.69 40.65 0.18 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.487 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.488 ' OD2' ' ND2' ' A' ' 88' ' ' ASN . 1.1 m-20 -110.29 137.54 47.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.796 0.331 . . . . 0.0 110.847 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 57.0 mt -85.84 112.46 22.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.155 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.43 ' CB ' HG23 ' A' ' 142' ' ' VAL . . . -80.7 -34.66 34.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.114 179.829 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.558 HD12 ' CD1' ' A' ' 132' ' ' PHE . 53.4 tp -140.69 132.16 26.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.951 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.512 ' CG ' ' OD1' ' A' ' 59' ' ' ASN . 3.3 t60 -134.92 92.3 2.86 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.857 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.459 ' CG2' HG13 ' A' ' 81' ' ' VAL . 20.3 mt -96.17 134.78 32.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.163 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.501 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -140.06 105.88 6.75 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.643 0.735 . . . . 0.0 110.904 179.968 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.576 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.2 Cg_endo -69.75 155.01 67.1 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.67 2.247 . . . . 0.0 112.364 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 36.7 mtp180 -131.85 94.72 3.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.854 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -61.57 148.93 40.63 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.877 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 99.98 -68.0 0.54 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.471 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 11.3 t-20 -78.84 -51.34 9.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.822 0.344 . . . . 0.0 110.89 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 102.36 56.96 0.81 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.467 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 13.7 p -144.04 117.85 9.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.807 0.337 . . . . 0.0 111.187 -179.883 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.459 HG13 ' CG2' ' A' ' 72' ' ' ILE . 29.4 t -104.43 109.47 27.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.119 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.448 HG21 ' CE ' ' A' ' 96' ' ' LYS . 58.2 t -80.01 135.53 25.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.107 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . 0.492 ' N ' ' HD3' ' A' ' 83' ' ' ARG . 0.7 OUTLIER -121.06 115.18 22.63 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.884 -179.989 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.434 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.2 t-20 -124.81 -176.82 3.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.911 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.406 ' CB ' ' HD2' ' A' ' 135' ' ' ARG . 47.5 t -161.17 106.45 1.36 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.883 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.562 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 28.9 tp -78.9 115.35 18.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.923 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.519 ' N ' ' O ' ' A' ' 90' ' ' SER . 73.2 mt -92.96 162.18 14.16 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.882 179.901 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.488 ' ND2' ' OD2' ' A' ' 67' ' ' ASP . 10.6 m-80 -40.66 101.64 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.891 179.902 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.77 -3.59 2.79 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.466 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.519 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -123.15 170.97 9.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.901 0.382 . . . . 0.0 110.833 -179.73 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.562 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 24.7 m95 -128.41 160.62 31.69 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.926 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -91.24 -108.26 1.5 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.483 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 2.9 m -163.07 169.5 19.38 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.851 0.358 . . . . 0.0 110.873 -179.73 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 71.6 mt-10 -93.58 119.19 32.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.901 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 -122.87 124.95 44.42 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.92 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.448 ' CE ' HG21 ' A' ' 82' ' ' VAL . 17.4 mttp -126.52 122.74 36.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.896 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.406 ' HB3' ' NH2' ' A' ' 83' ' ' ARG . 4.6 ttpm? -169.5 105.81 0.37 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.91 179.827 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 1.3 tt -147.75 150.2 14.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.144 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 11.5 t -86.52 -43.48 12.7 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.145 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 2.9 p-80 -149.64 127.2 11.58 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.898 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . 0.405 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 51.7 t-20 -99.51 101.01 11.91 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.604 0.716 . . . . 0.0 110.867 -179.89 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.405 ' HD2' ' HA ' ' A' ' 101' ' ' ASN . 53.8 Cg_endo -69.78 -31.81 19.72 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.738 2.292 . . . . 0.0 112.341 179.918 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.562 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 17.9 m-85 -44.2 102.48 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.837 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -132.06 135.18 8.02 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.482 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 98.26 0.67 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.672 2.248 . . . . 0.0 112.351 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 130.75 -5.87 5.82 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.44 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 -135.47 159.83 40.37 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.849 0.356 . . . . 0.0 110.91 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' PHE . . . . . 0.57 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 16.2 m-85 -77.64 174.56 10.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.876 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.544 ' CD1' ' O ' ' A' ' 109' ' ' PHE . 33.5 p90 -161.49 118.08 2.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.881 -179.872 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -92.5 106.93 18.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.892 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.468 HD13 ' N ' ' A' ' 112' ' ' SER . 0.3 OUTLIER -106.75 138.38 43.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.91 -179.948 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.468 ' N ' HD13 ' A' ' 111' ' ' LEU . 7.4 m -145.37 112.04 5.87 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.841 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.8 mp -94.55 134.12 33.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.116 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 70.7 mtt180 -111.79 123.35 50.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.844 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . 0.57 ' HB2' ' CZ ' ' A' ' 120' ' ' PHE . 3.5 t -93.91 100.87 12.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.89 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -93.11 -126.96 4.34 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.476 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.4 mt -132.74 -43.19 0.91 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.842 0.353 . . . . 0.0 110.885 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -86.04 -29.34 23.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.9 179.82 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 10.6 ptp85 -175.16 162.37 2.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.838 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.57 ' CZ ' ' HB2' ' A' ' 115' ' ' CYS . 3.0 m-30 -85.45 141.43 29.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.902 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 12.0 mmmt -113.67 105.01 12.8 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.941 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 48.8 t -95.18 133.2 36.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.12 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 11.0 m-85 -120.16 159.24 25.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.874 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -141.4 116.25 9.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.059 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 45.07 35.94 1.82 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.896 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 84.33 29.36 30.67 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.458 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 10.5 mm100 -140.96 116.11 9.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.789 0.328 . . . . 0.0 110.911 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 42.1 t-80 -51.27 105.02 0.09 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.831 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . 0.483 HD23 ' CE2' ' A' ' 130' ' ' PHE . 6.4 tp -72.13 -67.52 0.53 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.941 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.483 ' CE2' HD23 ' A' ' 129' ' ' LEU . 6.7 p90 -166.35 179.82 5.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.898 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -126.27 158.9 34.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.845 -179.979 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.595 ' CE1' ' O ' ' A' ' 133' ' ' ALA . 0.2 OUTLIER -115.4 110.24 19.05 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.89 -179.914 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.595 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -54.52 138.69 40.0 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.071 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 18.4 m-70 -78.15 69.22 4.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.83 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.406 ' HD2' ' CB ' ' A' ' 85' ' ' SER . 0.0 OUTLIER -66.33 -37.89 86.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.872 -179.948 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.8 tp -98.23 107.89 20.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.916 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 78.8 p -58.1 -25.12 60.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.859 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -91.06 39.71 1.0 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.114 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 28.9 p90 -65.47 -30.88 71.71 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.909 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 4.9 pt20 -59.32 -31.16 68.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.889 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.426 ' C ' HG12 ' A' ' 62' ' ' VAL . 27.4 mtt180 -64.26 -40.16 95.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.889 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.43 HG23 ' CB ' ' A' ' 69' ' ' ALA . 92.0 t -48.91 106.01 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.139 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.505 ' OD2' ' N ' ' A' ' 36' ' ' GLY . 0.7 OUTLIER -130.84 33.41 4.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.892 179.922 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 9.1 m -143.74 113.5 7.12 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.175 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.453 HD11 ' CE2' ' A' ' 60' ' ' PHE . 5.7 tp -111.19 106.99 16.17 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.905 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -108.59 153.91 22.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.901 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 21.3 mt -140.78 116.49 7.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.081 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -126.19 171.76 10.62 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.926 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 104.74 -157.07 16.84 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.459 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 64.6 m-20 -98.6 94.32 6.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.868 0.366 . . . . 0.0 110.844 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.466 HG23 ' N ' ' A' ' 152' ' ' THR . 10.4 p -151.07 141.5 16.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.142 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' THR . . . . . 0.466 ' N ' HG23 ' A' ' 151' ' ' VAL . 33.7 m -105.5 92.71 4.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.176 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.473 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 94.6 mt -71.75 133.65 45.71 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.895 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 3.6 m -114.61 -35.66 4.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.886 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . 0.462 ' C ' ' CD1' ' A' ' 155' ' ' TYR . 4.2 t80 -157.16 132.43 9.06 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.941 -179.885 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 85.0 t -140.47 133.79 33.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.113 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 8.0 tt0 -156.57 138.45 14.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.891 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' ILE . . . . . 0.455 ' O ' ' C ' ' A' ' 159' ' ' SER . 4.7 mp -97.29 96.82 5.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.141 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' SER . . . . . 0.455 ' C ' ' O ' ' A' ' 158' ' ' ILE . 74.9 m -33.63 -45.82 0.18 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.842 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . 0.442 ' C ' ' O ' ' A' ' 159' ' ' SER . . . -34.39 142.49 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.476 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 154.86 67.37 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.718 2.279 . . . . 0.0 112.363 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 83.1 p -69.5 109.88 4.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.904 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 3.5 t -96.68 104.13 16.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.873 -179.783 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.263 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.491 -179.979 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.9 t -78.47 112.54 15.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.907 0.384 . . . . 0.0 110.826 -179.744 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 93.9 p -41.27 104.49 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.881 -179.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 107.81 178.55 22.24 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.532 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.2 t -134.85 -49.59 0.76 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.853 0.359 . . . . 0.0 110.831 -179.714 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.2 m 45.94 41.82 8.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.846 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 89.93 -133.57 11.88 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.482 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 38.74 42.62 0.63 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.741 0.305 . . . . 0.0 110.874 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 8.9 mm100 -90.76 -60.33 1.94 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.939 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.6 tp60 -124.57 102.85 7.83 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.464 ' N ' HD21 ' A' ' 11' ' ' LEU . 0.3 OUTLIER -126.84 41.83 3.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.91 -179.998 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.6 m120 64.45 42.51 5.04 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.924 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 1.1 t -110.51 -176.46 2.98 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.839 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 10.7 mt -143.54 152.17 55.94 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.632 0.729 . . . . 0.0 110.931 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 159.83 51.95 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.683 2.255 . . . . 0.0 112.383 179.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 9.8 t -85.41 137.4 32.95 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.146 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' MET . . . . . 0.428 ' HE2' ' CA ' ' A' ' 31' ' ' GLY . 0.0 OUTLIER -98.36 37.98 1.39 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.889 179.933 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 -71.09 -176.29 1.37 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.885 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 73.77 -122.81 7.82 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.546 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.83 146.4 59.63 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.689 2.26 . . . . 0.0 112.301 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 161.88 44.22 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.64 2.226 . . . . 0.0 112.336 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 3.7 t -79.26 141.71 36.84 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.127 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -129.05 122.67 30.47 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.875 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . 0.555 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 6.3 t-20 74.11 47.76 0.21 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.589 0.709 . . . . 0.0 110.899 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.555 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.78 123.29 9.95 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.646 2.231 . . . . 0.0 112.375 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.78 -179.28 2.81 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.674 2.25 . . . . 0.0 112.363 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.532 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 90.8 t -140.97 138.5 18.11 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.592 0.711 . . . . 0.0 111.096 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.532 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.6 Cg_endo -69.76 144.22 76.05 Favored 'Cis proline' 0 C--O 1.231 0.174 0 C-N-CA 122.69 -1.796 . . . . 0.0 112.311 -0.056 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.6 t80 -97.29 114.32 26.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.942 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.411 ' CD1' ' HB3' ' A' ' 146' ' ' GLU . 66.6 m-85 -99.55 107.25 19.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.875 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.428 ' CA ' ' HE2' ' A' ' 17' ' ' MET . . . -115.29 100.44 0.97 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.513 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.483 ' O ' ' CG ' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -72.78 117.11 14.08 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.84 0.353 . . . . 0.0 110.895 -179.848 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 11.6 mt -63.45 150.11 44.47 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.937 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.455 ' OE1' ' NH1' ' A' ' 32' ' ' ARG . 7.3 mm100 -98.01 -46.44 5.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.943 179.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.41 ' O ' ' O ' ' A' ' 36' ' ' GLY . . . -103.47 33.22 6.76 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.486 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.41 ' O ' ' O ' ' A' ' 35' ' ' GLY . . . 37.21 -157.5 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.443 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 51.3 mt -88.43 106.7 18.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.832 0.348 . . . . 0.0 110.92 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 34.4 p -122.12 170.57 9.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.109 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.13 -11.81 59.99 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.074 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 12.2 mmm180 -110.64 22.39 15.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.841 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.529 ' NH2' ' CG1' ' A' ' 43' ' ' ILE . 27.8 ttt-85 -117.94 143.22 46.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.873 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 51.9 m -138.14 129.1 27.07 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.129 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.529 ' CG1' ' NH2' ' A' ' 41' ' ' ARG . 4.8 mp -94.64 145.73 7.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.133 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 76.6 mt -142.73 114.33 3.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.125 179.852 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 48.3 mt -115.93 107.71 23.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.143 179.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.5 mtmm -109.89 112.92 25.24 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.919 179.827 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.411 ' CA ' ' O ' ' A' ' 152' ' ' THR . . . -146.85 -142.89 3.78 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.534 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -167.58 130.64 1.67 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.874 0.368 . . . . 0.0 110.92 -179.827 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 16.0 t -78.98 115.74 54.69 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.661 0.743 . . . . 0.0 111.099 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 155.42 65.81 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.676 2.251 . . . . 0.0 112.326 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 -19.27 36.47 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.723 2.282 . . . . 0.0 112.319 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 69.5 p -106.15 16.84 24.39 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.167 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -114.66 125.91 7.01 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.489 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 15.7 mttp -66.25 -61.84 1.8 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.785 0.326 . . . . 0.0 110.895 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.0 p -172.56 158.2 4.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.883 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.571 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 8.1 p90 -108.88 -173.85 2.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.845 -179.928 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.32 140.79 16.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.092 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.1 mp -122.38 107.84 20.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.098 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -111.74 143.52 42.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.852 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.509 ' CE2' HD11 ' A' ' 145' ' ' LEU . 13.6 m-85 -113.67 102.04 9.88 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.91 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 31.9 ttmt -95.1 168.07 10.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.888 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.426 HG11 ' C ' ' A' ' 141' ' ' ARG . 25.5 t -98.94 122.37 50.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.106 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -60.22 -26.62 64.05 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.479 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 66.4 m -75.47 -70.88 0.4 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.869 0.366 . . . . 0.0 110.855 -179.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.8 m -85.23 -73.54 0.43 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.825 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 137.58 35.87 0.17 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.447 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.455 ' OD2' ' ND2' ' A' ' 88' ' ' ASN . 0.3 OUTLIER -104.11 146.87 28.11 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.766 0.317 . . . . 0.0 110.879 -179.972 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 60.4 mt -94.79 115.89 34.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.203 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.465 ' HB2' ' CG2' ' A' ' 142' ' ' VAL . . . -83.19 -39.11 21.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.075 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.526 HD22 ' CD2' ' A' ' 132' ' ' PHE . 38.8 tp -135.06 133.01 38.89 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.952 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.474 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.9 OUTLIER -134.34 93.09 3.01 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.827 179.885 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 59.3 mt -97.21 130.84 45.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.094 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.514 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -136.11 106.5 9.53 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.629 0.728 . . . . 0.0 110.942 179.87 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.571 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.1 Cg_endo -69.75 155.12 66.78 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.664 2.243 . . . . 0.0 112.399 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 25.9 mtp180 -132.35 101.48 5.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.822 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -58.61 -52.08 67.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.855 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . 0.418 ' O ' ' C ' ' A' ' 78' ' ' ASN . . . -63.36 -91.64 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.49 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.418 ' C ' ' O ' ' A' ' 77' ' ' GLY . 19.9 t-20 -35.95 -49.07 0.61 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.889 0.376 . . . . 0.0 110.914 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 92.43 40.75 4.99 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.491 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 25.1 p -144.8 118.26 9.08 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.823 0.344 . . . . 0.0 111.123 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 17.3 t -87.84 104.64 14.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.126 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.42 ' CG2' ' HD3' ' A' ' 96' ' ' LYS . 58.7 t -76.25 145.52 10.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.125 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -125.78 131.28 52.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.861 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.474 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.2 m120 -143.81 179.52 7.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.892 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.405 ' CB ' ' O ' ' A' ' 69' ' ' ALA . 96.6 p -160.7 107.29 1.49 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.816 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.57 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 28.5 tp -77.38 116.92 18.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.935 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.517 ' N ' ' O ' ' A' ' 90' ' ' SER . 66.7 mt -93.33 161.58 14.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.933 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.455 ' ND2' ' OD2' ' A' ' 67' ' ' ASP . 14.0 m-80 -41.63 101.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.869 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.86 -3.38 3.94 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.516 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.517 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -124.83 171.58 10.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.838 0.351 . . . . 0.0 110.868 -179.72 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.57 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 23.0 m95 -128.08 159.85 33.8 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.968 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -89.37 -105.82 1.12 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.478 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' SER . . . . . 0.416 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 25.2 m -165.91 166.15 17.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.86 0.362 . . . . 0.0 110.82 -179.76 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.407 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 5.6 mt-10 -88.32 119.99 29.26 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.867 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -120.03 116.44 25.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.85 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.42 ' HD3' ' CG2' ' A' ' 82' ' ' VAL . 46.5 mtmt -122.25 124.79 44.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.873 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 26.9 ttpt -172.53 107.95 0.19 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.919 179.882 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.482 ' CG1' ' N ' ' A' ' 99' ' ' THR . 7.1 tt -147.35 159.58 8.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.125 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.482 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 9.8 t -102.75 -34.23 9.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.13 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . 0.42 ' O ' ' ND1' ' A' ' 100' ' ' HIS . 1.7 p-80 -155.66 130.25 9.06 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.847 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . 0.411 ' CG ' HD13 ' A' ' 98' ' ' ILE . 11.6 m120 -101.71 97.72 8.41 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.61 0.719 . . . . 0.0 110.937 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.7 -31.06 21.54 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.698 2.265 . . . . 0.0 112.339 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -52.77 107.97 0.27 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.86 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -133.52 139.66 11.11 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.507 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 105.21 1.43 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.727 2.285 . . . . 0.0 112.38 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 122.97 -8.04 9.24 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.497 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.3 pt20 -132.97 153.85 51.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.83 0.348 . . . . 0.0 110.887 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -77.15 172.94 12.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.865 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 32.4 p90 -160.16 139.89 11.25 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.899 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -109.55 104.91 14.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.898 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.457 ' CD1' HD13 ' A' ' 113' ' ' ILE . 1.0 OUTLIER -105.51 138.17 42.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.919 -179.955 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 2.6 m -144.64 113.98 7.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.857 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.457 HD13 ' CD1' ' A' ' 111' ' ' LEU . 4.9 mp -95.32 131.62 41.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.116 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 15.7 mtp180 -106.38 128.01 53.71 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.842 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . 0.472 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 35.6 t -98.99 121.37 40.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.908 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -116.38 -138.13 6.22 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.477 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 9.7 mt -123.03 -31.38 3.63 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.806 0.336 . . . . 0.0 110.932 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . 0.423 ' C ' ' CD2' ' A' ' 134' ' ' HIS . 0.9 OUTLIER -96.66 -34.21 11.47 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.871 179.891 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 20.8 ptt-85 -172.91 171.48 4.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.472 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 4.1 m-30 -94.8 157.62 15.85 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.887 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 19.8 mtpp -130.49 99.77 5.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.891 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 42.2 t -84.46 133.97 28.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.131 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 81.5 m-85 -122.46 153.84 38.59 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.886 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . 0.435 ' O ' ' CG ' ' A' ' 125' ' ' ASN . . . -139.72 121.34 15.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.123 179.815 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.435 ' CG ' ' O ' ' A' ' 124' ' ' ALA . 10.7 p30 48.49 33.66 4.2 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.895 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.78 26.5 49.75 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.438 179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 37.0 mm-40 -129.76 168.02 17.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.842 0.353 . . . . 0.0 110.909 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 33.9 t-80 -91.16 116.09 28.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.829 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 9.0 tp -87.93 -68.32 0.77 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.957 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.49 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 3.9 p90 -168.68 172.21 8.15 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.862 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -115.43 156.73 25.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.853 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.526 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.2 OUTLIER -122.49 104.4 9.35 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.893 -179.94 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.514 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -60.08 134.13 56.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.13 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' HIS . . . . . 0.423 ' CD2' ' C ' ' A' ' 118' ' ' ASP . 25.7 m-70 -61.77 99.56 0.12 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.836 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.416 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 11.7 mtt-85 -82.12 -46.36 13.95 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 13.9 tp -97.55 113.67 25.42 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.906 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 90.8 p -56.05 -32.78 64.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.843 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . 0.412 ' CB ' ' HD2' ' A' ' 141' ' ' ARG . . . -85.69 37.88 0.72 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.061 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 4.7 p90 -56.13 -27.93 55.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.867 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' GLN . . . . . 0.465 ' HG2' ' N ' ' A' ' 141' ' ' ARG . 17.9 pm0 -63.48 -30.41 71.54 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.942 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.465 ' N ' ' HG2' ' A' ' 140' ' ' GLN . 22.5 mtt180 -65.38 -36.11 82.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.824 -179.866 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.465 ' CG2' ' HB2' ' A' ' 69' ' ' ALA . 90.5 t -56.55 105.0 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.119 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -126.01 35.7 4.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.879 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -144.58 137.98 27.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.138 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.509 HD11 ' CE2' ' A' ' 60' ' ' PHE . 5.0 tp -134.7 106.43 6.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.904 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' GLU . . . . . 0.411 ' HB3' ' CD1' ' A' ' 30' ' ' PHE . 4.9 pt-20 -109.22 149.16 29.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.934 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 12.7 mt -137.49 106.82 4.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.154 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -118.58 174.5 6.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.908 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 110.02 -140.81 15.99 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.482 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -117.86 91.92 3.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.811 0.338 . . . . 0.0 110.839 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.452 HG22 ' N ' ' A' ' 152' ' ' THR . 2.9 p -151.37 135.68 9.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.116 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' THR . . . . . 0.452 ' N ' HG22 ' A' ' 151' ' ' VAL . 17.7 m -95.93 92.82 6.68 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.171 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.475 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 93.3 mt -76.31 136.38 39.59 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.965 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 19.5 m -123.1 -39.27 2.5 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.858 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 37.3 t80 -141.81 127.07 18.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.905 -179.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 75.9 t -140.43 105.24 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.096 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -121.34 119.82 33.29 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.916 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 56.1 mt -91.87 88.77 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.107 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 24.9 p -72.49 132.34 43.72 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.878 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -176.06 -157.63 17.73 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.451 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.84 107.5 1.89 Allowed 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.662 2.241 . . . . 0.0 112.3 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 56.6 p -72.98 86.62 1.31 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.81 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 1.4 t -69.45 167.81 15.85 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.836 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.472 -179.994 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.29 0 N-CA-C 112.465 -0.254 . . . . 0.0 112.465 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 40.1 t 47.46 42.1 13.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.846 0.355 . . . . 0.0 110.856 -179.723 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 25.6 t -93.7 154.88 17.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.853 -179.795 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -116.86 -94.66 1.82 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.465 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 32.5 m -109.98 172.52 6.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.877 0.37 . . . . 0.0 110.842 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 37.1 p -120.91 160.12 24.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.854 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -66.45 -116.37 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.493 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 74.6 t60 -84.11 146.38 27.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.704 0.287 . . . . 0.0 110.883 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 15.5 tt0 -154.74 125.85 7.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.917 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 12.1 pt20 -105.46 127.81 53.2 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.9 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 8.4 mt -132.33 99.05 4.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.94 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.6 m-20 -69.32 -40.67 77.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.865 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 69.0 m -56.81 -178.39 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.81 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.447 ' HB2' ' HD2' ' A' ' 15' ' ' PRO . 0.5 OUTLIER -108.61 157.35 36.87 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.574 0.702 . . . . 0.0 110.927 -179.997 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.447 ' HD2' ' HB2' ' A' ' 14' ' ' LEU . 53.8 Cg_endo -69.78 -169.76 0.35 Allowed 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.664 2.242 . . . . 0.0 112.376 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.435 ' CG2' ' N ' ' A' ' 17' ' ' MET . 1.3 m -79.9 153.24 29.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.144 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' MET . . . . . 0.435 ' N ' ' CG2' ' A' ' 16' ' ' THR . 1.4 ptt? -83.97 68.54 10.05 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.859 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 18.2 mp0 -73.73 157.71 36.0 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.901 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.28 -135.07 12.31 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.51 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 170.08 17.34 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.727 2.285 . . . . 0.0 112.32 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.78 -173.66 0.76 Allowed 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.664 2.242 . . . . 0.0 112.349 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.433 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.5 m -96.29 137.33 35.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.127 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -137.35 120.18 16.35 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.907 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . 0.53 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 8.8 m120 60.27 49.03 1.94 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.57 0.7 . . . . 0.0 110.899 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.53 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.2 Cg_endo -69.82 141.75 45.8 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.646 2.23 . . . . 0.0 112.296 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -178.02 2.14 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.63 2.22 . . . . 0.0 112.387 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.531 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 96.6 t -142.35 137.89 16.01 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.651 0.739 . . . . 0.0 111.088 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.531 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.8 Cg_endo -69.78 145.23 78.87 Favored 'Cis proline' 0 C--O 1.232 0.192 0 C-N-CA 122.65 -1.812 . . . . 0.0 112.394 -0.057 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -97.52 123.03 41.24 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.885 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -107.74 102.79 11.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.853 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -108.5 110.66 3.12 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.508 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 9.0 mmt180 -73.14 113.36 10.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.87 0.366 . . . . 0.0 110.887 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 5.9 mt -73.25 97.9 2.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.909 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.417 ' CD ' HG21 ' A' ' 16' ' ' THR . 20.6 mt-30 -66.79 94.76 0.32 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.885 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 135.69 -42.94 1.29 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.481 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.484 ' O ' ' NE ' ' A' ' 41' ' ' ARG . . . 96.23 170.13 34.85 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.423 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 96.1 mt -60.26 105.09 0.38 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.914 0.388 . . . . 0.0 110.913 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 38.2 p -117.31 158.76 23.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.119 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -64.32 -16.12 61.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.106 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -114.96 23.92 12.16 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.821 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.504 ' NH1' ' CG2' ' A' ' 158' ' ' ILE . 44.4 ttm-85 -112.6 135.35 53.42 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.869 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 92.3 m -133.16 126.1 30.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.166 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.447 HG22 ' N ' ' A' ' 44' ' ' ILE . 4.6 mp -95.44 138.86 20.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.166 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.447 ' N ' HG22 ' A' ' 43' ' ' ILE . 88.7 mt -128.91 126.67 65.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.13 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 58.5 mt -126.08 107.59 17.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.117 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 23.2 mtmt -112.05 112.43 24.06 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.883 179.849 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -143.69 -141.91 3.87 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.436 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 0.572 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.6 OUTLIER -169.28 124.03 0.84 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.931 0.396 . . . . 0.0 110.928 -179.775 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.453 HG22 ' CE2' ' A' ' 109' ' ' PHE . 14.1 t -75.35 116.39 54.17 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.651 0.738 . . . . 0.0 111.113 179.923 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 158.94 55.28 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.671 2.247 . . . . 0.0 112.355 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 -21.93 32.93 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.711 2.274 . . . . 0.0 112.393 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 24.4 p -105.88 18.88 21.44 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.142 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -110.2 117.71 4.81 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.44 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 29.2 mtpt -61.58 -60.04 4.3 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.797 0.332 . . . . 0.0 110.891 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 10.5 p -174.59 154.87 2.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.882 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.56 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 5.2 p90 -109.54 -173.48 2.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.881 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.24 143.9 20.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.123 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.515 HG22 ' CE1' ' A' ' 60' ' ' PHE . 2.8 mp -123.91 99.0 5.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.142 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.7 m-80 -99.0 143.71 28.98 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.934 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.577 ' CE2' HD12 ' A' ' 145' ' ' LEU . 15.8 m-85 -118.24 97.26 5.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.864 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.422 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 31.5 ttmt -96.66 169.77 9.65 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.906 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.426 HG13 ' C ' ' A' ' 141' ' ' ARG . 28.4 t -101.42 124.75 55.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.097 179.871 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -59.72 -36.21 88.95 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.51 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 23.1 t -67.21 -73.57 0.13 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.86 0.362 . . . . 0.0 110.857 -179.75 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 10.6 t -78.17 -72.48 0.37 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 -179.795 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 129.51 42.33 0.23 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.459 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -115.12 140.89 48.69 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.817 0.341 . . . . 0.0 110.84 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 55.2 mt -86.08 122.17 38.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.113 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -92.93 -31.8 14.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.087 179.831 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.565 HD22 ' CD2' ' A' ' 132' ' ' PHE . 40.0 tp -140.44 131.1 25.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.903 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.488 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.5 OUTLIER -134.1 92.31 2.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.863 179.862 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 55.7 mt -95.84 130.53 44.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.142 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.505 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -137.79 106.0 8.23 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.632 0.729 . . . . 0.0 110.905 179.924 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.56 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.3 Cg_endo -69.71 155.45 66.06 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.698 2.265 . . . . 0.0 112.394 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 39.3 mtp180 -130.67 96.11 4.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.868 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' MET . . . . . 0.436 ' HE3' ' CE1' ' A' ' 56' ' ' PHE . 0.0 OUTLIER -55.5 156.73 4.36 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.85 179.995 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 83.2 -79.93 1.87 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.5 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -55.05 -66.64 0.37 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.852 0.358 . . . . 0.0 110.916 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 113.25 43.55 0.84 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.503 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.9 p -135.97 117.62 14.96 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.83 0.348 . . . . 0.0 111.112 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 20.6 t -99.67 108.38 22.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.169 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 47.3 t -76.95 143.1 13.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.133 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . 0.437 ' NH1' ' CD2' ' A' ' 130' ' ' PHE . 0.2 OUTLIER -126.93 129.87 49.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.873 -179.977 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.488 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.4 OUTLIER -140.6 179.65 6.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.905 -179.922 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 28.8 t -160.06 105.01 1.52 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.891 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.567 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 24.9 tp -76.92 118.29 19.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.93 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.51 ' N ' ' O ' ' A' ' 90' ' ' SER . 86.5 mt -95.8 161.63 13.94 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.901 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.512 ' C ' ' H ' ' A' ' 90' ' ' SER . 0.2 OUTLIER -38.64 101.81 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.911 179.931 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.33 -6.09 0.86 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.493 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.512 ' H ' ' C ' ' A' ' 88' ' ' ASN . 0.3 OUTLIER -118.47 169.24 9.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.879 0.371 . . . . 0.0 110.84 -179.705 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.567 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 20.5 m95 -128.39 161.29 29.81 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.939 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -93.96 -111.71 2.26 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.467 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' SER . . . . . 0.422 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 39.3 m -158.0 170.97 21.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.839 0.352 . . . . 0.0 110.844 -179.717 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -94.87 123.32 38.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.913 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -120.99 120.52 35.65 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.888 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 9.4 mtmp? -123.41 120.02 31.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.913 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -170.75 109.67 0.34 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.903 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.445 ' CG1' ' N ' ' A' ' 99' ' ' THR . 2.8 tt -148.84 154.2 10.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.127 179.86 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.445 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 9.0 t -93.95 -40.91 9.87 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.176 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 2.4 p-80 -147.18 128.44 14.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.865 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -103.32 95.62 7.23 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.652 0.739 . . . . 0.0 110.865 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.45 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.7 Cg_endo -69.79 -40.24 5.51 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.715 2.277 . . . . 0.0 112.324 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.458 ' CE2' ' HB3' ' A' ' 74' ' ' PRO . 8.1 m-85 -34.46 112.01 0.13 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.811 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -138.34 134.67 6.99 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.494 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 98.05 0.66 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.685 2.256 . . . . 0.0 112.337 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 126.01 -3.59 7.9 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.493 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.3 pt20 -132.46 149.39 52.34 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.806 0.336 . . . . 0.0 110.926 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' PHE . . . . . 0.572 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 79.8 m-85 -67.04 169.91 7.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.883 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.504 ' CD1' ' O ' ' A' ' 109' ' ' PHE . 19.6 p90 -161.1 120.02 2.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.847 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -96.6 107.13 19.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.895 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.416 ' CD1' HG12 ' A' ' 122' ' ' VAL . 0.6 OUTLIER -108.95 138.56 45.1 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.926 -179.921 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 3.7 m -145.27 115.4 7.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.854 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.1 mp -95.12 138.89 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.105 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 45.6 mtt-85 -113.19 123.74 50.92 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.874 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . 0.566 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 11.2 t -92.75 117.53 30.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.872 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.87 -142.41 7.83 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.468 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 17.4 mt -121.43 -35.99 3.16 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.788 0.328 . . . . 0.0 110.884 -179.9 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -92.32 -33.36 14.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.856 179.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -174.07 164.62 4.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.871 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.566 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 2.8 m-30 -90.52 156.8 17.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.921 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 23.2 mtpp -128.9 103.23 6.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.927 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . 0.416 HG12 ' CD1' ' A' ' 111' ' ' LEU . 46.3 t -92.7 127.95 44.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.121 179.92 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 14.7 m-85 -117.9 153.05 34.23 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.878 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -135.89 110.4 8.55 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.128 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 57.38 33.43 23.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.857 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 82.35 29.52 36.52 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.498 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 37.2 mm-40 -138.27 121.52 16.97 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.845 0.355 . . . . 0.0 110.907 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 26.4 t-80 -54.41 110.71 0.66 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.86 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 8.6 tp -76.81 -66.45 0.82 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.906 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.437 ' CD2' ' NH1' ' A' ' 83' ' ' ARG . 5.3 p90 -166.24 171.26 12.38 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.882 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -111.4 147.07 36.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.887 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.565 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -113.01 107.46 15.99 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.872 -179.872 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.557 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -64.0 130.95 46.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.132 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 33.7 m-70 -58.5 111.81 1.37 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.838 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.422 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 44.9 mtt-85 -96.08 -44.18 7.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.915 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 4.4 tp -100.96 109.35 21.26 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 97.4 p -49.37 -34.39 15.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . 0.464 ' HB3' ' CD ' ' A' ' 141' ' ' ARG . . . -83.27 31.53 0.45 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.086 179.893 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 3.9 p90 -50.44 -40.09 49.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.846 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 10.4 pt20 -52.87 -43.21 65.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.904 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.464 ' CD ' ' HB3' ' A' ' 138' ' ' ALA . 56.9 mtp85 -50.95 -42.76 60.04 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.874 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 97.1 t -44.35 106.12 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.121 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -130.43 29.44 4.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.838 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 25.4 m -139.92 112.65 7.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.124 -179.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.577 HD12 ' CE2' ' A' ' 60' ' ' PHE . 5.0 tp -110.54 108.03 17.86 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.929 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -111.67 153.59 26.18 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.858 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 16.9 mt -139.39 112.05 5.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.135 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -121.14 172.35 8.04 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.928 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 110.6 -142.47 16.71 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.452 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -117.49 93.57 4.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.88 0.371 . . . . 0.0 110.847 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.4 p -151.23 152.24 11.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.182 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 27.8 m -113.55 93.59 4.46 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.141 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.459 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 79.2 mt -73.03 141.4 47.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.94 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 50.1 m -125.83 -28.54 3.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.857 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 31.3 t80 -157.56 129.97 7.3 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 90.2 t -140.53 105.52 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.108 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 18.8 tt0 -121.13 140.56 51.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.855 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' ILE . . . . . 0.504 ' CG2' ' NH1' ' A' ' 41' ' ' ARG . 14.9 mt -111.0 94.59 3.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.092 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 5.7 p -59.43 125.61 24.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.844 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 150.9 -167.65 30.55 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.481 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 154.9 67.25 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.705 2.27 . . . . 0.0 112.325 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 18.3 m -119.15 -56.98 2.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.874 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 4.0 t -88.65 96.19 10.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.84 -179.82 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.483 -179.979 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.523 -0.231 . . . . 0.0 112.523 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 37.8 p 43.71 41.75 3.83 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.877 0.37 . . . . 0.0 110.874 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.7 m -63.72 114.47 4.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.836 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -165.67 172.35 41.13 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.496 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 57.6 m -151.66 143.87 23.99 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.836 0.351 . . . . 0.0 110.884 -179.74 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 67.1 p -49.8 -65.96 0.47 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.823 -179.814 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 80.12 114.7 0.28 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.503 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 7.4 p80 37.33 47.36 0.7 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.743 0.306 . . . . 0.0 110.829 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -106.59 -53.8 2.57 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.939 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 44.8 mm-40 -112.44 108.98 18.31 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.885 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 8.5 mt -40.14 141.87 0.43 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.873 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 74.9 m-20 -122.48 -44.96 2.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.905 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 36.8 p -119.26 -174.42 2.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.862 -179.851 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.427 ' HB2' ' HD2' ' A' ' 15' ' ' PRO . 0.5 OUTLIER -116.0 157.14 45.71 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.645 0.736 . . . . 0.0 110.918 179.952 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.427 ' HD2' ' HB2' ' A' ' 14' ' ' LEU . 53.9 Cg_endo -69.72 171.4 14.48 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.74 2.293 . . . . 0.0 112.327 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 11.3 t -77.23 150.92 35.36 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.162 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' MET . . . . . 0.469 ' HE2' ' CA ' ' A' ' 31' ' ' GLY . 72.9 mtm -88.82 35.57 0.79 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.891 179.872 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -60.24 169.08 1.73 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.899 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.15 -147.03 18.43 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.504 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 168.38 21.72 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.729 2.286 . . . . 0.0 112.324 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 177.98 5.04 Favored 'Trans proline' 0 C--O 1.233 0.23 0 C-N-CA 122.685 2.257 . . . . 0.0 112.359 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.421 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.9 m -89.75 145.08 25.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.15 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -143.18 137.32 28.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.824 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . 0.549 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 9.0 m120 45.44 47.94 4.51 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.61 0.719 . . . . 0.0 110.93 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.549 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 54.1 Cg_endo -69.71 139.26 39.96 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.641 2.227 . . . . 0.0 112.375 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -177.62 1.95 Allowed 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.693 2.262 . . . . 0.0 112.304 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.52 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 84.2 t -143.7 136.73 13.82 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.592 0.711 . . . . 0.0 111.124 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.52 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 53.4 Cg_endo -69.71 145.37 79.12 Favored 'Cis proline' 0 C--N 1.341 0.153 0 C-N-CA 122.681 -1.799 . . . . 0.0 112.373 -0.091 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 4.9 t80 -98.34 115.26 28.07 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.937 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -99.44 103.1 14.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.901 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.469 ' CA ' ' HE2' ' A' ' 17' ' ' MET . . . -118.09 102.16 0.95 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.488 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -73.45 128.47 35.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.843 0.354 . . . . 0.0 110.867 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.455 ' N ' ' O ' ' A' ' 143' ' ' ASP . 3.3 mt -74.0 150.25 40.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.885 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 10.6 mm100 -105.24 99.67 9.27 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.913 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 124.46 -55.92 0.7 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.488 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 119.47 169.65 14.3 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.515 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 87.5 mt -61.04 97.91 0.07 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.87 0.367 . . . . 0.0 110.953 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 48.4 p -109.5 160.73 15.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.159 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -58.1 -28.6 64.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.084 179.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 3.1 mpt_? -105.96 39.1 1.85 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.863 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 29.5 ttm-85 -117.76 137.62 52.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.872 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 93.6 m -138.41 120.84 16.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.155 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 4.7 mp -94.35 134.99 29.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.148 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 93.3 mt -125.24 138.41 54.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.116 179.839 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 42.9 mt -138.92 107.65 3.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.103 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 8.6 mtmm -110.04 111.32 22.62 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.924 179.823 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -142.23 -143.14 4.16 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.478 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 0.559 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 1.1 t80 -170.0 128.66 0.91 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.949 0.404 . . . . 0.0 110.91 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 4.4 t -80.41 115.96 58.55 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.624 0.726 . . . . 0.0 111.143 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.74 155.81 65.04 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.672 2.248 . . . . 0.0 112.369 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 -14.07 35.44 Favored 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.689 2.259 . . . . 0.0 112.33 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 46.8 p -112.24 15.91 20.25 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.107 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -112.06 118.88 4.85 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.491 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 14.1 mtpp -58.09 -62.78 1.57 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.77 0.319 . . . . 0.0 110.859 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 70.1 p -173.71 164.45 4.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.872 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.574 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 5.2 p90 -119.02 -173.27 2.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.879 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.56 138.73 15.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.105 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.7 mp -117.61 104.61 16.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.121 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 2.8 m-80 -105.24 147.94 27.51 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.883 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.521 ' CE2' HD12 ' A' ' 145' ' ' LEU . 2.4 m-85 -120.89 101.22 7.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.885 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.417 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 34.5 ttmt -95.78 167.26 11.37 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.901 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.466 HG22 ' N ' ' A' ' 142' ' ' VAL . 94.2 t -100.27 121.09 50.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.097 179.889 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -57.0 -41.2 92.27 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.481 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 10.8 t -62.18 -72.2 0.13 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.885 0.374 . . . . 0.0 110.89 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.4 t -80.56 -71.04 0.48 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.878 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 128.26 42.48 0.25 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.507 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.406 ' OD1' ' OD1' ' A' ' 88' ' ' ASN . 1.5 m-20 -115.02 144.14 44.08 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.824 0.345 . . . . 0.0 110.856 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 42.8 mt -88.74 122.59 40.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.145 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.461 ' HB3' ' CG2' ' A' ' 142' ' ' VAL . . . -92.82 -34.77 13.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.134 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.56 HD22 ' CD2' ' A' ' 132' ' ' PHE . 30.3 tp -139.17 130.4 26.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.928 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.473 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.2 OUTLIER -134.81 92.14 2.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.83 179.914 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.438 ' CG2' HG11 ' A' ' 81' ' ' VAL . 16.0 mt -94.25 137.61 22.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.111 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.5 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 1.0 OUTLIER -141.86 106.17 5.81 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.619 0.723 . . . . 0.0 110.923 179.949 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.574 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.8 Cg_endo -69.75 154.87 67.26 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.677 2.251 . . . . 0.0 112.302 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 63.7 mtt-85 -129.78 100.76 5.6 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.854 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -62.25 -43.39 98.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.92 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -66.36 -83.97 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.462 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 4.7 t30 -48.09 -57.09 6.3 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.825 0.345 . . . . 0.0 110.874 -179.881 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 106.57 40.59 1.87 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.542 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 20.7 p -143.94 121.79 11.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.803 0.335 . . . . 0.0 111.176 -179.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.438 HG11 ' CG2' ' A' ' 72' ' ' ILE . 18.5 t -86.59 111.01 20.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.121 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 61.4 t -82.84 139.81 17.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.097 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -126.94 124.46 39.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.865 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.473 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.5 OUTLIER -135.11 -178.15 4.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.885 -179.909 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 47.5 t -160.16 105.02 1.5 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.867 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.552 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 38.1 tp -77.09 116.71 17.98 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.932 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.518 ' N ' ' O ' ' A' ' 90' ' ' SER . 86.4 mt -94.84 162.07 13.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.9 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.428 ' C ' ' H ' ' A' ' 90' ' ' SER . 9.7 m-80 -40.88 102.0 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.86 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.49 -1.39 3.11 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.516 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.518 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -125.62 171.59 10.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.886 0.374 . . . . 0.0 110.841 -179.74 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.552 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 22.1 m95 -128.74 158.64 38.06 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.877 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -88.75 -96.3 1.02 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.427 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 2.0 m -174.68 164.76 3.66 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.894 0.378 . . . . 0.0 110.841 -179.711 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 14.2 mp0 -88.63 118.5 28.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.878 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 72.4 mm-40 -116.09 121.03 40.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.897 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 7.0 mtmp? -125.58 118.67 26.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.86 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -169.66 108.16 0.4 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.873 179.835 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.413 HD12 ' CD1' ' A' ' 129' ' ' LEU . 10.5 tt -147.89 151.19 13.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.132 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.9 t -91.64 -43.92 9.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.168 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . 0.413 ' O ' ' ND1' ' A' ' 100' ' ' HIS . 2.0 p-80 -145.0 127.58 16.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.896 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 38.6 t-20 -104.74 98.49 15.21 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.633 0.73 . . . . 0.0 110.835 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.404 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.8 Cg_endo -69.81 -37.14 9.45 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.674 2.25 . . . . 0.0 112.331 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.515 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 20.9 m-85 -37.96 112.83 0.24 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.892 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -137.92 137.98 9.26 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.468 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 100.21 0.81 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.69 2.26 . . . . 0.0 112.303 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 120.85 0.9 11.84 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.457 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -135.22 148.6 49.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.815 0.34 . . . . 0.0 110.93 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' PHE . . . . . 0.559 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 76.8 m-85 -68.23 171.08 7.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.822 -179.892 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 28.1 p90 -161.26 124.79 3.29 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.903 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -99.45 104.5 16.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.871 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.449 ' CD1' HD11 ' A' ' 113' ' ' ILE . 0.6 OUTLIER -104.68 136.83 43.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.903 -179.945 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 3.6 m -145.03 113.64 6.72 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.828 -179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.449 HD11 ' CD1' ' A' ' 111' ' ' LEU . 4.4 mp -96.56 137.22 24.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.111 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.497 ' O ' ' CD2' ' A' ' 120' ' ' PHE . 18.2 mtp180 -110.11 138.12 46.92 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.852 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . 0.471 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 17.7 t -105.13 120.11 40.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.917 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -115.02 -140.55 7.23 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.447 -179.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.5 mt -117.53 -38.08 3.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.785 0.326 . . . . 0.0 110.895 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . 0.58 ' O ' ' CD2' ' A' ' 134' ' ' HIS . 20.3 t70 -89.79 -45.69 9.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.895 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.431 ' HG3' ' C ' ' A' ' 118' ' ' ASP . 32.3 mtp180 -157.56 -177.07 6.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.879 -179.903 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.497 ' CD2' ' O ' ' A' ' 114' ' ' ARG . 12.4 m-85 -103.32 162.09 13.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.876 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 21.4 mtpp -134.26 105.15 6.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.906 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 57.8 t -90.44 136.48 23.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.1 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -124.85 143.57 50.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.955 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -131.13 106.93 8.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.039 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 59.1 35.83 23.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.918 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.69 40.55 17.76 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.448 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 18.9 mt-30 -146.84 135.64 22.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.868 0.366 . . . . 0.0 110.919 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 40.8 t-80 -66.77 100.75 0.73 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.89 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . 0.413 ' CD1' HD12 ' A' ' 98' ' ' ILE . 10.2 tp -69.1 -68.58 0.39 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.875 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.482 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 4.4 p90 -164.02 171.3 15.4 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.845 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 24.1 p-10 -110.65 158.79 18.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.906 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.56 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -129.86 104.49 7.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.85 -179.883 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.555 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -62.99 135.71 57.44 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.04 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' HIS . . . . . 0.58 ' CD2' ' O ' ' A' ' 118' ' ' ASP . 29.9 m-70 -62.82 108.22 1.14 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.859 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 4.9 mtp-105 -88.37 -48.71 7.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.891 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 8.5 tp -94.06 108.1 19.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.913 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 14.7 t -47.31 -36.0 8.71 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -83.47 33.32 0.46 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.101 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 28.5 p90 -50.05 -36.12 27.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.872 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 6.1 pt20 -53.45 -46.4 69.86 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.904 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.41 ' C ' HG13 ' A' ' 62' ' ' VAL . 31.5 mtt180 -49.7 -41.78 44.22 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.859 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.466 ' N ' HG22 ' A' ' 62' ' ' VAL . 61.9 t -48.71 100.3 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.138 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.455 ' O ' ' N ' ' A' ' 33' ' ' LEU . 3.9 p30 -124.95 26.24 7.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.906 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -132.1 131.72 42.62 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.142 -179.848 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.521 HD12 ' CE2' ' A' ' 60' ' ' PHE . 4.8 tp -128.82 104.85 7.86 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.922 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -108.88 151.57 26.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.904 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 15.5 mt -136.82 118.23 18.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.127 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -128.65 173.43 10.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.891 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.41 -151.34 16.91 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.519 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -107.23 92.75 4.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.855 0.36 . . . . 0.0 110.845 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.414 HG22 ' N ' ' A' ' 152' ' ' THR . 7.7 p -151.19 154.88 7.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.094 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' THR . . . . . 0.414 ' N ' HG22 ' A' ' 151' ' ' VAL . 23.3 m -114.83 93.91 4.53 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.151 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 50.1 mt -79.25 132.83 36.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.911 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 14.7 m -117.42 -40.88 3.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.851 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 59.7 t80 -140.37 130.13 24.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.947 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 89.8 t -140.53 105.15 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.092 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 13.8 tt0 -120.81 121.93 39.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.958 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 14.9 mt -88.96 93.32 4.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.169 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 28.0 t -65.89 142.49 57.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.889 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 171.41 170.58 35.65 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.499 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 137.96 36.66 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.706 2.27 . . . . 0.0 112.314 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 3.7 t -121.59 125.73 47.44 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.858 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 51.8 p 50.22 41.93 24.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.894 -179.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.451 179.987 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.262 0 N-CA-C 112.461 -0.256 . . . . 0.0 112.461 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 57.6 m -121.51 138.13 54.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.889 0.376 . . . . 0.0 110.85 -179.741 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 97.9 p -105.64 42.17 1.28 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.829 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -122.03 177.91 16.42 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.481 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 18.3 m -122.7 149.27 44.28 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.818 0.342 . . . . 0.0 110.896 -179.766 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 42.3 m -62.87 -44.15 96.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.841 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.92 112.95 4.54 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.45 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 35.0 m-70 -73.19 83.44 1.34 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.746 0.308 . . . . 0.0 110.804 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 60.5 mm-40 38.64 46.82 1.05 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.87 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -145.83 129.15 16.78 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.946 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.2 mt -113.26 -60.76 1.84 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.94 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 14.7 t30 -81.32 88.6 6.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.912 179.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 6.5 p -96.62 -174.71 3.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.873 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.426 ' HB2' ' HD2' ' A' ' 15' ' ' PRO . 0.5 OUTLIER -109.55 157.25 37.96 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.632 0.73 . . . . 0.0 110.898 -179.964 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.426 ' HD2' ' HB2' ' A' ' 14' ' ' LEU . 53.3 Cg_endo -69.73 162.86 40.42 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.702 2.268 . . . . 0.0 112.349 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 9.3 t -73.46 163.4 28.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.162 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' MET . . . . . 0.473 ' H ' ' NE2' ' A' ' 34' ' ' GLN . 36.6 mtm -96.46 34.87 1.56 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.892 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 15.6 mm-40 -69.74 -175.61 0.91 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.868 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 74.82 -138.5 23.88 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.49 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 162.78 40.76 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.642 2.228 . . . . 0.0 112.368 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -171.06 0.44 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.697 2.265 . . . . 0.0 112.335 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.558 ' CG2' ' N ' ' A' ' 23' ' ' PHE . 1.9 m -93.69 161.17 14.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.163 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.558 ' N ' ' CG2' ' A' ' 22' ' ' THR . 11.9 m-85 -156.01 135.95 12.75 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.908 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ASN . . . . . 0.544 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 72.3 m-20 42.9 48.42 3.7 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.645 0.736 . . . . 0.0 110.927 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.544 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.6 Cg_endo -69.74 137.96 36.75 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.709 2.273 . . . . 0.0 112.301 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -176.11 1.38 Allowed 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.646 2.231 . . . . 0.0 112.334 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.522 ' HA ' ' C ' ' A' ' 28' ' ' PRO . 98.4 t -142.97 137.87 15.33 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.668 0.747 . . . . 0.0 111.109 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.522 ' C ' ' HA ' ' A' ' 27' ' ' VAL . 54.0 Cg_endo -69.75 145.58 79.8 Favored 'Cis proline' 0 C--O 1.232 0.179 0 C-N-CA 122.71 -1.787 . . . . 0.0 112.342 -0.02 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 13.3 t80 -96.87 121.17 38.44 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.946 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -101.79 101.46 11.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.865 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -98.96 109.94 3.89 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.526 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 4.1 mmm180 -72.87 99.51 2.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.866 0.365 . . . . 0.0 110.877 -179.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 27.6 mt -66.94 93.05 0.25 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.905 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.473 ' NE2' ' H ' ' A' ' 17' ' ' MET . 18.7 mp0 -67.99 93.69 0.44 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.938 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.75 -37.77 1.9 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.501 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 91.19 175.07 43.71 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.454 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . 0.462 ' CD1' ' HB ' ' A' ' 142' ' ' VAL . 78.4 mt -65.4 93.43 0.15 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.859 0.361 . . . . 0.0 110.911 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 44.0 p -105.33 154.56 20.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.136 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -49.84 -30.61 10.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.061 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 2.6 mpt_? -105.13 34.93 2.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.875 -179.873 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 5.0 tpm_? -108.03 135.15 49.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 -179.878 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 85.3 m -136.87 116.35 12.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.193 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.0 mp -91.69 135.81 26.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.176 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.416 HG22 ' N ' ' A' ' 45' ' ' ILE . 96.8 mt -127.38 132.95 68.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.116 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.416 ' N ' HG22 ' A' ' 44' ' ' ILE . 50.7 mt -134.9 107.57 8.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.092 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 16.0 mtmt -111.2 111.4 22.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.864 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -142.88 -140.7 3.75 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.544 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 0.557 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.4 OUTLIER -172.08 119.95 0.43 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.937 0.399 . . . . 0.0 110.941 -179.8 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 40.5 t -69.16 117.09 48.7 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.638 0.732 . . . . 0.0 111.15 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 154.98 67.25 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.69 2.26 . . . . 0.0 112.333 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.72 -16.11 37.55 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.693 2.262 . . . . 0.0 112.358 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 70.6 p -110.41 18.6 19.66 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.122 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -113.54 123.23 6.06 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.465 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.403 ' O ' ' SD ' ' A' ' 76' ' ' MET . 22.2 mttt -63.03 -61.67 2.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.778 0.323 . . . . 0.0 110.859 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.8 p -174.03 157.9 3.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.886 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.574 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 12.3 p90 -111.16 -174.64 2.51 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.864 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -157.05 130.5 8.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.12 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 5.3 mp -112.91 101.78 12.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.11 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -101.2 143.59 31.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.913 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.553 ' CE2' HD12 ' A' ' 145' ' ' LEU . 16.0 m-85 -115.26 97.99 6.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.869 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.445 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 35.8 ttmt -96.79 167.88 10.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.886 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.448 ' CG2' HG22 ' A' ' 142' ' ' VAL . 59.1 t -100.94 123.88 54.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.089 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -59.79 -39.74 95.75 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.455 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 7.6 t -62.93 -70.67 0.19 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.868 0.366 . . . . 0.0 110.867 -179.728 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 60.0 m -82.33 -71.43 0.49 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.863 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 128.32 42.68 0.24 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.451 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.425 ' OD2' ' ND2' ' A' ' 88' ' ' ASN . 3.9 m-20 -112.78 143.7 43.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.81 0.338 . . . . 0.0 110.847 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 66.6 mt -89.1 113.35 25.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.135 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.433 ' O ' ' CB ' ' A' ' 85' ' ' SER . . . -81.75 -39.3 24.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.105 179.836 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.559 HD12 ' CD1' ' A' ' 132' ' ' PHE . 48.1 tp -136.82 134.53 37.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.964 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.495 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.4 OUTLIER -134.89 97.03 3.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.894 179.877 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 27.0 mt -101.26 133.56 44.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.134 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.503 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -140.53 106.51 6.5 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.674 0.749 . . . . 0.0 110.905 179.961 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.574 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.0 Cg_endo -69.67 154.7 67.76 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.713 2.275 . . . . 0.0 112.347 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 36.7 mtp180 -130.6 94.99 3.76 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.932 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' MET . . . . . 0.407 ' HE2' ' CE1' ' A' ' 56' ' ' PHE . 0.0 OUTLIER -53.07 -34.34 56.13 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.846 -179.991 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -39.51 -90.93 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.507 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -87.22 -40.89 14.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.88 0.371 . . . . 0.0 110.912 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 120.39 43.8 0.45 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.492 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 49.2 p -119.25 118.14 30.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.828 0.347 . . . . 0.0 111.142 -179.857 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 14.1 t -99.8 110.45 26.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.132 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.405 HG13 ' N ' ' A' ' 83' ' ' ARG . 32.7 t -82.52 144.78 9.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.13 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . 0.405 ' N ' HG13 ' A' ' 82' ' ' VAL . 0.0 OUTLIER -126.86 124.17 38.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.864 -179.986 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.495 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.3 m120 -136.32 178.59 6.94 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.914 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.433 ' CB ' ' O ' ' A' ' 69' ' ' ALA . 78.1 p -158.69 105.55 1.83 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.864 -179.84 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.581 ' HB2' ' CZ2' ' A' ' 91' ' ' TRP . 28.3 tp -78.06 117.34 19.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.917 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.532 ' N ' ' O ' ' A' ' 90' ' ' SER . 86.0 mt -95.38 162.54 13.62 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.936 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.426 ' C ' ' H ' ' A' ' 90' ' ' SER . 11.0 m-80 -40.97 102.14 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.878 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.35 -2.47 3.14 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.492 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.532 ' O ' ' N ' ' A' ' 87' ' ' LEU . 0.3 OUTLIER -124.63 170.54 10.85 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.81 0.338 . . . . 0.0 110.85 -179.72 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.581 ' CZ2' ' HB2' ' A' ' 86' ' ' LEU . 21.8 m95 -128.1 160.73 31.08 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.936 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -89.53 -100.31 1.06 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.487 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 16.4 m -172.4 167.97 5.57 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.819 0.343 . . . . 0.0 110.849 -179.753 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -89.99 121.85 32.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.904 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -122.22 115.33 22.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.88 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 9.9 mtmp? -119.68 119.79 34.73 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.904 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . 0.46 ' HE3' ' N ' ' A' ' 98' ' ' ILE . 0.0 OUTLIER -173.9 105.11 0.12 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.866 179.846 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . 0.46 ' N ' ' HE3' ' A' ' 97' ' ' LYS . 1.9 tt -141.76 149.86 19.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.172 179.862 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.425 HG23 ' N ' ' A' ' 100' ' ' HIS . 4.7 t -84.45 -41.06 16.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.084 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . 0.425 ' N ' HG23 ' A' ' 99' ' ' THR . 28.9 p80 -153.09 133.62 13.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.835 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' ASN . . . . . 0.407 ' OD1' ' C ' ' A' ' 101' ' ' ASN . 7.2 t-20 -103.47 95.84 7.74 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.597 0.713 . . . . 0.0 110.888 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.447 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.7 Cg_endo -69.77 -41.3 4.38 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.675 2.25 . . . . 0.0 112.368 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.534 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 10.2 m-85 -34.17 104.66 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.881 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -127.85 137.16 9.61 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.695 -0.765 . . . . 0.0 112.451 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 97.25 0.62 Allowed 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.715 2.277 . . . . 0.0 112.325 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 118.39 3.53 14.58 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.513 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 17.5 pt20 -133.73 137.82 45.44 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.819 0.343 . . . . 0.0 110.906 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' PHE . . . . . 0.557 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 79.7 m-85 -61.34 166.35 3.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.882 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 17.9 p90 -158.45 130.58 6.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.886 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -103.68 104.62 14.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.877 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' LEU . . . . . 0.468 ' CD1' HD12 ' A' ' 113' ' ' ILE . 0.7 OUTLIER -105.09 136.5 44.46 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.948 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 3.8 m -145.15 113.49 6.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.864 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.468 HD12 ' CD1' ' A' ' 111' ' ' LEU . 4.0 mp -95.47 140.05 17.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.142 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 15.6 mtp85 -112.78 137.63 50.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.899 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . 0.575 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 2.9 t -110.03 114.47 28.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.874 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -113.77 -136.03 6.29 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.496 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 12.2 mt -121.52 -39.06 2.69 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.829 0.347 . . . . 0.0 110.924 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 23.2 p-10 -85.63 -37.26 19.69 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.88 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.8 ptp180 -173.66 172.62 3.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.875 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.575 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.7 m-30 -93.32 155.06 17.63 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.887 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 26.6 mtpt -128.99 102.12 6.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.898 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 51.5 t -89.27 136.77 22.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.105 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 57.9 m-85 -120.29 152.95 37.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.958 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -136.55 107.12 6.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.097 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 53.56 35.61 21.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.929 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 84.09 29.26 31.67 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.477 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 20.0 mm-40 -140.77 119.53 12.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.819 0.342 . . . . 0.0 110.931 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 35.5 t-80 -52.06 103.85 0.07 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.846 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 10.6 tp -67.12 -67.71 0.43 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.923 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.441 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 6.0 p90 -163.67 177.02 9.06 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.86 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 41.1 p30 -118.02 149.92 40.16 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.851 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.559 ' CD1' HD12 ' A' ' 70' ' ' LEU . 0.2 OUTLIER -117.17 107.02 13.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.872 -179.937 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . 0.525 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -62.41 133.56 55.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.099 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 29.7 m-70 -60.03 110.84 1.29 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.811 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.4 ' CD ' ' OG ' ' A' ' 85' ' ' SER . 10.0 mtt-85 -93.93 -51.5 4.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.878 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 6.8 tp -96.06 108.39 20.8 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.906 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 27.1 t -49.44 -33.33 13.87 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.862 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . 0.438 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.45 25.76 0.6 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.073 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.406 ' CG ' ' N ' ' A' ' 140' ' ' GLN . 19.3 p90 -45.49 -41.78 9.96 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.895 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' GLN . . . . . 0.406 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 5.7 pt20 -49.75 -41.0 42.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.885 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.438 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 57.0 mtp180 -55.48 -39.74 70.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.874 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.462 ' HB ' ' CD1' ' A' ' 37' ' ' LEU . 85.6 t -48.11 106.8 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.14 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -131.81 34.08 3.91 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.867 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 16.2 m -141.38 115.32 9.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.167 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.553 HD12 ' CE2' ' A' ' 60' ' ' PHE . 5.2 tp -113.66 107.96 16.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.91 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 -113.0 150.7 31.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.896 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 17.0 mt -138.29 106.94 3.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.115 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -115.42 173.33 6.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.915 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.57 -146.37 16.22 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.469 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 46.7 m-20 -112.27 92.56 4.07 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.852 0.358 . . . . 0.0 110.843 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.461 HG23 ' N ' ' A' ' 152' ' ' THR . 5.8 p -151.28 138.06 12.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.124 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' THR . . . . . 0.461 ' N ' HG23 ' A' ' 151' ' ' VAL . 33.7 m -99.62 93.92 6.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.134 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.443 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 68.8 mt -74.88 137.85 42.06 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.903 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 20.5 m -119.76 -39.28 2.86 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.878 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . 0.472 ' CE1' ' HB2' ' A' ' 157' ' ' GLN . 43.6 t80 -148.07 135.45 20.55 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.938 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 70.8 t -140.18 109.42 3.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.141 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . 0.472 ' HB2' ' CE1' ' A' ' 155' ' ' TYR . 14.7 tt0 -121.47 136.57 54.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.902 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 18.6 mt -103.69 91.45 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.065 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 65.6 m -72.56 150.89 42.75 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.88 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 170.77 -156.95 27.66 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.526 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.81 160.22 50.49 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.674 2.249 . . . . 0.0 112.361 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 35.0 t -116.85 84.25 2.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.87 -179.819 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 2.5 t -75.28 126.89 31.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.869 -179.8 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.481 -179.952 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 2.3 t . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.836 0.35 . . . . 0.0 111.147 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -129.61 120.78 25.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ASN . . . . . 0.48 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 12.4 m120 61.78 52.18 2.19 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.616 0.722 . . . . 0.0 110.907 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.48 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.2 Cg_endo -69.81 138.67 38.23 Favored 'Trans proline' 0 N--CA 1.466 -0.13 0 C-N-CA 122.705 2.27 . . . . 0.0 112.328 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 178.7 4.3 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.633 2.222 . . . . 0.0 112.357 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.694 HG13 ' HA ' ' A' ' 28' ' ' PRO . 95.4 t -138.09 138.24 22.83 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.658 0.742 . . . . 0.0 111.115 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.694 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.7 Cg_endo -69.7 143.61 74.22 Favored 'Cis proline' 0 C--N 1.342 0.193 0 C-N-CA 122.741 -1.774 . . . . 0.0 112.345 -0.083 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' TYR . . . . . 0.473 ' CE1' HG11 ' A' ' 156' ' ' VAL . 2.2 t80 -95.82 116.68 29.27 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.886 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 72.3 m-85 -100.15 105.31 16.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.844 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -118.21 103.33 1.03 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.507 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.422 ' C ' ' HD2' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -72.44 135.4 45.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.84 0.352 . . . . 0.0 110.876 -179.837 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.894 HD23 HG12 ' A' ' 158' ' ' ILE . 4.9 mt -82.73 119.12 23.92 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.928 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 25.2 mt-30 -74.09 94.97 2.48 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.887 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 124.31 -55.81 0.7 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.483 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.443 ' O ' HG23 ' A' ' 38' ' ' THR . . . 120.37 176.3 15.69 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.51 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' LEU . . . . . 0.744 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 82.5 mt -62.6 101.37 0.24 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.936 0.398 . . . . 0.0 110.896 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.502 ' O ' ' N ' ' A' ' 41' ' ' ARG . 44.9 p -120.77 137.89 54.29 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.202 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.551 ' HB2' ' HG ' ' A' ' 117' ' ' LEU . . . -41.97 -23.39 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.119 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.444 ' N ' ' O ' ' A' ' 38' ' ' THR . 20.9 mmt180 -104.62 34.13 3.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.866 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.502 ' N ' ' O ' ' A' ' 38' ' ' THR . 4.6 ttt85 -121.05 139.86 52.74 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.931 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 85.9 m -137.66 117.55 13.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.154 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.1 mp -90.68 133.98 30.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.146 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 94.7 mt -127.55 134.33 65.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.123 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 48.5 mt -135.57 107.63 7.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.142 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.5 mtmt -109.35 108.19 18.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.917 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.52 -145.72 4.68 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.49 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' TYR . . . . . 0.564 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.7 OUTLIER -167.55 129.13 1.53 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.9 0.381 . . . . 0.0 110.912 -179.803 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 13.7 t -77.34 115.5 49.72 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.619 0.723 . . . . 0.0 111.116 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 155.54 65.7 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.681 2.254 . . . . 0.0 112.354 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -15.69 37.11 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.683 2.255 . . . . 0.0 112.344 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 52.8 p -109.65 14.2 23.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.13 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -111.22 122.82 6.25 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.523 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 17.5 mtpt -63.96 -60.21 3.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.798 0.332 . . . . 0.0 110.867 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.5 p -174.21 158.75 3.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.89 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.565 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 2.4 p90 -112.57 -173.72 2.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.851 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.067 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -155.56 135.57 12.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.157 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.454 HG22 ' CE1' ' A' ' 60' ' ' PHE . 3.6 mp -115.85 103.7 15.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.132 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.3 m-80 -104.41 143.13 33.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.904 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.726 ' CE2' HD13 ' A' ' 145' ' ' LEU . 6.7 m-85 -115.66 101.36 8.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.875 -179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.421 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 30.3 ttmt -95.33 169.08 10.32 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.89 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.61 HG22 ' HA ' ' A' ' 142' ' ' VAL . 35.0 t -100.24 123.73 53.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.136 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -60.59 -34.25 85.27 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.498 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.9 t -68.5 -71.54 0.21 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.926 0.393 . . . . 0.0 110.87 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 3.3 t -83.7 -71.34 0.51 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.856 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 131.6 40.82 0.22 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.5 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.598 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.9 m-20 -110.87 143.11 41.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.776 0.322 . . . . 0.0 110.853 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.629 HD12 ' HB3' ' A' ' 86' ' ' LEU . 39.2 mt -88.9 119.2 35.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.113 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.66 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -91.57 -33.12 15.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.109 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.616 HD22 ' CD2' ' A' ' 132' ' ' PHE . 52.5 tp -138.46 130.0 27.66 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.939 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.489 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.2 OUTLIER -134.82 92.71 2.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.844 179.891 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.579 HD11 HD21 ' A' ' 70' ' ' LEU . 29.0 mt -96.25 134.98 31.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.146 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 1.067 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 10.0 t-20 -140.33 107.76 6.7 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.596 0.712 . . . . 0.0 110.863 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.767 ' HA ' HG22 ' A' ' 81' ' ' VAL . 53.8 Cg_endo -69.79 154.87 67.1 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.665 2.243 . . . . 0.0 112.338 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 45.3 mtp85 -130.4 98.0 4.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.909 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.878 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 32.4 p . . . . . 0 C--O 1.232 0.168 0 CA-C-O 120.802 0.334 . . . . 0.0 111.122 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.767 HG22 ' HA ' ' A' ' 74' ' ' PRO . 36.0 t -91.44 108.54 20.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.136 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.566 HG22 ' HD3' ' A' ' 96' ' ' LYS . 48.7 t -79.93 146.69 7.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.11 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -128.87 130.21 46.57 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.845 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.489 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.9 OUTLIER -142.45 179.62 6.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.928 -179.971 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 89.5 p -157.99 107.25 2.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.901 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.892 HD13 ' NE1' ' A' ' 91' ' ' TRP . 27.6 tp -76.98 117.86 18.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.926 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.505 ' N ' ' O ' ' A' ' 90' ' ' SER . 82.7 mt -95.1 162.3 13.77 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.927 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.562 ' ND2' ' OD1' ' A' ' 67' ' ' ASP . 10.6 m120 -41.1 102.14 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.855 179.906 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.89 -1.49 3.37 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.51 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.828 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -125.63 172.49 9.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.839 0.352 . . . . 0.0 110.84 -179.722 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.892 ' NE1' HD13 ' A' ' 86' ' ' LEU . 25.0 m95 -129.4 160.67 32.37 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.932 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -90.34 -104.18 1.21 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.507 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 39.2 m -165.56 171.92 12.6 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.834 0.35 . . . . 0.0 110.852 -179.755 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -95.54 120.8 36.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.92 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 60.3 mt-10 -120.07 122.21 40.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.845 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.566 ' HD3' HG22 ' A' ' 82' ' ' VAL . 7.6 mtmp? -126.29 122.23 34.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.873 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 10.4 tptp -171.89 105.87 0.2 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.895 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.903 HD11 ' O ' ' A' ' 100' ' ' HIS . 2.0 tt -146.59 149.9 15.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.129 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.427 HG23 ' N ' ' A' ' 100' ' ' HIS . 9.2 t -91.65 -41.39 10.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.149 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' HIS . . . . . 0.903 ' O ' HD11 ' A' ' 98' ' ' ILE . 2.6 p-80 -144.06 131.64 21.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.834 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' ASN . . . . . 0.411 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 24.7 t30 -109.21 96.52 21.89 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.632 0.73 . . . . 0.0 110.881 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.44 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.8 Cg_endo -69.78 -41.27 4.39 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.648 2.232 . . . . 0.0 112.305 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.569 ' CZ ' HD21 ' A' ' 129' ' ' LEU . 6.2 m-85 -35.33 108.65 0.07 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.898 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -137.14 138.77 10.02 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.48 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 103.12 1.11 Allowed 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.689 2.26 . . . . 0.0 112.38 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 119.95 -2.32 13.24 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.541 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.3 pt20 -134.03 147.62 50.97 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.857 0.361 . . . . 0.0 110.902 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' PHE . . . . . 0.564 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 29.6 m-85 -67.21 172.82 4.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.877 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.422 ' O ' ' CG ' ' A' ' 109' ' ' PHE . 14.4 p90 -161.33 124.25 3.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.867 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -99.08 105.09 17.16 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.837 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.757 HD13 ' N ' ' A' ' 112' ' ' SER . 0.7 OUTLIER -105.18 136.89 43.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.92 -179.98 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.757 ' N ' HD13 ' A' ' 111' ' ' LEU . 3.4 m -144.8 113.63 6.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.847 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.445 ' CD1' HD12 ' A' ' 111' ' ' LEU . 4.7 mp -96.68 135.43 30.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.147 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 40.0 mtt180 -108.51 126.26 52.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.886 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' CYS . . . . . 0.534 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 11.7 t -93.06 120.42 33.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.902 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -122.31 -159.8 10.73 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.511 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.551 ' HG ' ' HB2' ' A' ' 39' ' ' ALA . 7.8 mt -101.83 -42.3 6.2 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.838 0.351 . . . . 0.0 110.943 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -82.19 -37.1 26.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.883 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.1 ptt180 -173.5 -178.2 1.61 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.889 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.744 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 3.2 m-30 -102.48 158.52 16.16 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.892 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 24.2 mtpt -132.13 104.86 7.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.921 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.486 HG13 HD11 ' A' ' 111' ' ' LEU . 60.6 t -90.98 133.58 32.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.125 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 74.7 m-85 -121.69 146.96 46.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.938 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.526 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -133.27 107.98 8.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.133 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 55.04 39.5 31.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.885 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.12 36.73 34.43 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.451 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 22.6 mt-30 -143.93 123.65 13.36 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.848 0.356 . . . . 0.0 110.898 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 32.6 t-80 -57.79 95.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.863 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.569 HD21 ' CZ ' ' A' ' 103' ' ' PHE . 9.4 tp -60.88 -68.75 0.28 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.929 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.473 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 4.5 p90 -164.96 175.87 9.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.903 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -116.32 155.74 27.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.894 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.616 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.2 OUTLIER -122.38 104.58 9.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.847 -179.874 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.531 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -60.6 134.8 57.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.077 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 17.8 m170 -62.4 98.8 0.12 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.894 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 17.6 mtt-85 -81.47 -47.59 12.97 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.842 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 136' ' ' LEU . . . . . 0.453 HD13 HD22 ' A' ' 87' ' ' LEU . 7.8 tp -98.72 107.8 20.33 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.924 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 15.0 m -49.35 -33.19 12.9 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.839 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.495 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -83.3 27.67 0.57 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.122 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.468 ' O ' HD12 ' A' ' 37' ' ' LEU . 17.6 p90 -47.21 -44.29 22.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.892 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 140' ' ' GLN . . . . . 0.44 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 9.2 pt20 -46.24 -40.63 11.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.931 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.577 ' O ' HG13 ' A' ' 62' ' ' VAL . 16.1 mtp180 -54.33 -41.71 69.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.875 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.66 HG21 ' CB ' ' A' ' 69' ' ' ALA . 88.7 t -50.3 104.72 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.167 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -127.38 28.83 5.64 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.877 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.3 m -137.67 131.96 32.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.168 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.726 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.4 tp -128.47 109.09 11.09 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.944 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 -112.3 152.31 28.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.901 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 19.8 mt -137.47 113.54 11.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.135 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -123.06 174.19 7.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.954 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.4 -144.5 15.99 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.512 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -114.71 92.1 3.84 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.871 0.367 . . . . 0.0 110.845 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.448 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 5.1 p -151.04 142.77 16.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.134 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 25.8 m -102.37 93.25 5.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.163 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.464 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 95.9 mt -74.31 136.73 42.58 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.899 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 5.1 m -117.18 -39.36 3.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.871 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 155' ' ' TYR . . . . . 0.426 ' C ' ' CD1' ' A' ' 155' ' ' TYR . 7.4 t80 -147.35 130.93 16.81 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.917 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.473 HG11 ' CE1' ' A' ' 29' ' ' TYR . 65.8 t -140.77 124.48 17.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.138 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 12.8 tt0 -148.85 132.95 17.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.908 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 158' ' ' ILE . . . . . 0.894 HG12 HD23 ' A' ' 33' ' ' LEU . 5.1 mp . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.152 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.468 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.6 m . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.857 0.36 . . . . 0.0 111.119 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.468 ' CD1' ' O ' ' A' ' 22' ' ' THR . 9.8 m-85 -150.71 137.15 18.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.887 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ASN . . . . . 0.601 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 52.8 m-80 51.37 44.48 2.16 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.663 0.744 . . . . 0.0 110.919 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.601 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.78 133.82 26.45 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.632 2.221 . . . . 0.0 112.316 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.85 179.36 3.8 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.673 2.249 . . . . 0.0 112.361 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.677 HG13 ' HA ' ' A' ' 28' ' ' PRO . 86.6 t -138.79 137.68 20.27 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.606 0.717 . . . . 0.0 111.134 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.677 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.2 Cg_endo -69.77 144.21 76.03 Favored 'Cis proline' 0 C--O 1.231 0.161 0 C-N-CA 122.668 -1.805 . . . . 0.0 112.338 -0.074 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 2.9 t80 -94.13 120.15 33.98 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.927 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -105.12 102.14 11.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.899 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -109.7 109.43 2.71 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.471 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 6.4 mmt85 -73.38 108.93 6.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.875 0.369 . . . . 0.0 110.873 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.429 ' HB3' ' NH1' ' A' ' 41' ' ' ARG . 5.3 mt -70.58 92.76 0.86 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.918 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 14.9 mm-40 -64.73 105.36 0.97 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.896 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 130.59 -46.89 1.05 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.477 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.661 ' O ' HG23 ' A' ' 38' ' ' THR . . . 98.67 161.36 29.98 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.51 -179.909 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' LEU . . . . . 0.646 HD12 ' O ' ' A' ' 139' ' ' PHE . 95.9 mt -54.81 107.14 0.26 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.903 0.383 . . . . 0.0 110.872 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.661 HG23 ' O ' ' A' ' 36' ' ' GLY . 73.0 p -118.71 149.04 42.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.128 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -49.8 -23.62 1.95 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.085 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.412 ' HB3' ' NH1' ' A' ' 40' ' ' ARG . 0.0 OUTLIER -108.81 34.19 3.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.882 -179.921 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.429 ' NH1' ' HB3' ' A' ' 33' ' ' LEU . 13.1 ttm180 -113.81 139.28 49.27 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.859 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 74.2 m -137.52 119.83 15.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.134 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 mp -91.92 136.27 24.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.109 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 97.0 mt -131.25 133.55 62.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.107 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 34.5 mt -136.53 111.52 10.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.143 179.861 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 16.1 mtmt -112.68 109.0 18.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.923 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -138.1 -142.95 4.42 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.44 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' TYR . . . . . 0.435 ' O ' ' CD1' ' A' ' 48' ' ' TYR . 0.5 OUTLIER -170.2 117.04 0.54 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.914 0.388 . . . . 0.0 110.939 -179.769 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 15.2 t -70.19 115.8 38.05 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.644 0.735 . . . . 0.0 111.139 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 157.52 60.12 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.678 2.252 . . . . 0.0 112.356 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -15.42 37.17 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.664 2.243 . . . . 0.0 112.34 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 21.5 p -109.71 17.11 21.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.18 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -110.69 118.99 5.13 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.511 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.3 mtpt -61.31 -60.63 3.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.778 0.323 . . . . 0.0 110.912 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 13.2 p -173.64 158.44 3.35 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.869 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.607 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 6.1 p90 -115.88 -174.68 2.58 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.864 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.067 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -154.81 145.3 22.17 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.126 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.526 HG22 ' CE1' ' A' ' 60' ' ' PHE . 3.2 mp -123.52 98.77 5.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.115 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.7 m-80 -98.86 141.98 30.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.914 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.526 ' CE1' HG22 ' A' ' 58' ' ' ILE . 10.5 m-85 -117.16 99.03 6.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.893 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.441 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 31.3 ttmt -96.62 169.24 10.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.878 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.658 HG22 ' HA ' ' A' ' 142' ' ' VAL . 38.7 t -101.44 119.59 49.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.129 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -55.22 -36.79 62.82 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.502 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.5 m -66.47 -72.86 0.15 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.889 0.376 . . . . 0.0 110.904 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 19.7 m -79.34 -74.68 0.28 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.868 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 132.92 38.58 0.23 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.523 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.414 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.5 m-20 -111.36 143.61 41.89 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.795 0.331 . . . . 0.0 110.846 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.572 HD12 ' HB3' ' A' ' 86' ' ' LEU . 47.4 mt -89.77 117.71 33.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.123 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.41 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -89.25 -31.07 18.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.122 179.783 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.663 HD22 ' CD2' ' A' ' 132' ' ' PHE . 53.2 tp -140.84 130.25 23.83 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.927 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.543 ' CD2' ' C ' ' A' ' 71' ' ' HIS . 2.7 t-160 -134.91 92.55 2.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.884 179.82 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.599 HD11 HD21 ' A' ' 70' ' ' LEU . 26.3 mt -96.36 133.81 36.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.149 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 1.067 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 9.1 t-20 -141.24 106.78 6.13 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.619 0.723 . . . . 0.0 110.853 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.607 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.8 Cg_endo -69.78 155.28 66.3 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.647 2.231 . . . . 0.0 112.364 179.902 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 68.3 mtp180 -130.55 99.35 4.95 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.899 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 16.9 p . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.795 0.331 . . . . 0.0 111.133 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.402 HG22 ' HA ' ' A' ' 74' ' ' PRO . 21.3 t -99.67 111.72 30.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.123 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.545 HG22 ' HD3' ' A' ' 96' ' ' LYS . 92.5 t -79.36 142.06 14.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.176 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ARG . . . . . 0.557 ' NH1' ' CD2' ' A' ' 130' ' ' PHE . 0.3 OUTLIER -126.19 125.52 42.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.885 -179.948 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.452 ' O ' ' N ' ' A' ' 71' ' ' HIS . 2.0 m-80 -137.39 177.82 7.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.883 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 28.9 t -158.92 105.08 1.76 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.814 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.938 HD12 ' O ' ' A' ' 90' ' ' SER . 25.6 tp -77.36 119.58 21.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.918 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.513 ' N ' ' O ' ' A' ' 90' ' ' SER . 77.7 mt -96.98 161.47 13.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.893 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.486 ' C ' ' H ' ' A' ' 90' ' ' SER . 16.8 p-10 -38.28 101.67 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.868 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.76 -7.12 0.73 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.488 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.938 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -118.13 170.74 8.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.885 0.374 . . . . 0.0 110.855 -179.719 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.828 ' NE1' HD13 ' A' ' 86' ' ' LEU . 21.4 m95 -128.31 160.89 30.75 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.959 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -94.16 -116.85 2.78 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.454 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 33.8 m -152.14 178.61 9.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.79 0.329 . . . . 0.0 110.898 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -103.73 126.05 50.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.891 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -123.36 105.37 9.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.893 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.545 ' HD3' HG22 ' A' ' 82' ' ' VAL . 18.2 mtmm -111.69 122.46 47.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.919 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -171.54 105.95 0.22 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.905 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.801 HD11 ' O ' ' A' ' 100' ' ' HIS . 3.0 tt -145.13 152.85 14.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.125 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.44 HG23 ' N ' ' A' ' 100' ' ' HIS . 9.5 t -96.39 -41.9 8.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.141 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' HIS . . . . . 0.801 ' O ' HD11 ' A' ' 98' ' ' ILE . 4.4 p-80 -142.89 128.57 19.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.852 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 -103.29 95.55 7.09 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.652 0.739 . . . . 0.0 110.882 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.444 ' HD2' HD11 ' A' ' 129' ' ' LEU . 53.2 Cg_endo -69.75 -40.41 5.38 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.702 2.268 . . . . 0.0 112.318 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -41.01 108.41 0.09 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.867 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -131.49 139.64 11.11 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.491 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 100.62 0.84 Allowed 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.714 2.276 . . . . 0.0 112.328 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 117.89 6.63 12.45 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.472 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 4.7 pt20 -137.17 143.92 42.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.78 0.324 . . . . 0.0 110.926 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -66.14 168.76 7.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.915 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 30.1 p90 -161.28 144.74 12.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.85 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -118.31 101.73 8.41 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.87 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.659 HD13 ' N ' ' A' ' 112' ' ' SER . 1.1 tm? -99.24 137.18 38.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.923 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.659 ' N ' HD13 ' A' ' 111' ' ' LEU . 6.2 m -144.98 111.27 5.61 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.864 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.64 HD11 HD12 ' A' ' 111' ' ' LEU . 4.8 mp -94.73 135.57 28.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.081 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -109.61 130.59 55.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.846 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 115' ' ' CYS . . . . . 0.581 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 11.9 t -101.19 116.02 31.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.876 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -115.26 -143.9 8.17 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.517 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.7 mt -116.02 -37.47 3.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.829 0.347 . . . . 0.0 110.88 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -87.66 -37.5 16.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.873 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.9 ptt180 -173.85 170.38 3.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.874 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.581 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.1 m-30 -90.71 158.23 17.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.85 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 30.5 mtpt -132.33 99.39 4.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.886 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 97.6 t -86.73 139.18 17.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.095 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 84.3 m-85 -129.4 148.96 51.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.947 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -137.12 109.77 7.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.096 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 57.97 34.66 24.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.849 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.9 40.5 21.23 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.494 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -144.84 134.86 23.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.81 0.338 . . . . 0.0 110.875 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 32.2 t-80 -68.06 101.31 1.12 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.865 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.444 HD11 ' HD2' ' A' ' 102' ' ' PRO . 8.0 tp -71.7 -67.39 0.53 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.898 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.557 ' CD2' ' NH1' ' A' ' 83' ' ' ARG . 5.1 p90 -166.89 173.44 9.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.886 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -116.12 155.69 27.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.663 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -120.15 104.47 10.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.896 -179.883 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.574 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -59.62 136.64 58.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.101 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 24.6 m80 -63.52 106.16 0.89 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.879 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 23.6 mtt-85 -91.73 -50.2 5.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.861 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 6.1 tp -95.43 109.02 21.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.923 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 41.3 t -51.67 -33.4 33.7 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.812 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.501 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.67 23.83 0.77 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.097 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.646 ' O ' HD12 ' A' ' 37' ' ' LEU . 32.0 p90 -45.57 -37.87 5.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.854 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -52.73 -46.97 67.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.918 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.501 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 70.6 mtp85 -48.63 -43.38 36.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.87 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.658 ' HA ' HG22 ' A' ' 62' ' ' VAL . 85.5 t -41.24 106.93 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.171 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -131.86 31.68 4.18 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.861 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 18.9 m -142.03 114.94 8.66 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.134 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.517 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.9 tp -111.89 108.46 17.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.917 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 146' ' ' GLU . . . . . 0.433 ' C ' HG13 ' A' ' 147' ' ' ILE . 3.6 pt-20 -111.77 155.29 23.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.91 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.442 HG12 HG23 ' A' ' 58' ' ' ILE . 35.2 mt -143.45 116.4 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.105 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -124.79 170.27 11.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.94 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.79 -153.47 16.8 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.496 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -104.17 93.28 4.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.808 0.337 . . . . 0.0 110.879 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 8.8 p -151.3 143.59 16.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.126 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 12.0 m -105.19 94.39 5.21 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.107 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 58.0 mt -78.51 134.4 37.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.88 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 58.6 m -119.25 -39.85 2.87 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.851 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 39.7 t80 -144.6 131.14 19.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.92 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 93.4 t -140.54 106.57 2.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.132 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 15.2 tt0 -118.42 138.97 52.1 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.922 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 18.4 mt . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.113 179.982 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.457 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.5 m . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.858 0.361 . . . . 0.0 111.145 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.435 ' C ' ' HD3' ' A' ' 25' ' ' PRO . 5.6 m-85 -142.95 133.63 25.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.893 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ASN . . . . . 0.585 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.6 m120 48.42 45.6 2.94 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.591 0.71 . . . . 0.0 110.867 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.585 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.3 Cg_endo -69.79 137.33 35.11 Favored 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 122.702 2.268 . . . . 0.0 112.34 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 -176.93 1.63 Allowed 'Trans proline' 0 N--CA 1.465 -0.164 0 C-N-CA 122.732 2.288 . . . . 0.0 112.357 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.669 HG13 ' HA ' ' A' ' 28' ' ' PRO . 88.1 t -142.28 137.64 15.84 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.616 0.722 . . . . 0.0 111.125 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.669 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.3 Cg_endo -69.81 143.88 75.21 Favored 'Cis proline' 0 C--N 1.341 0.179 0 C-N-CA 122.671 -1.804 . . . . 0.0 112.318 0.005 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.9 t80 -95.61 120.72 36.35 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.904 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -102.94 104.01 14.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.866 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -115.92 109.55 2.04 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.524 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 3.2 mmt85 -74.08 118.47 17.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.856 0.36 . . . . 0.0 110.84 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.544 HD23 HD13 ' A' ' 158' ' ' ILE . 8.0 mt -76.8 92.13 3.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.935 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 23.0 mm-40 -65.4 102.86 0.73 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.961 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.23 -37.96 1.89 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.453 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.86 ' O ' HG23 ' A' ' 38' ' ' THR . . . 88.28 156.19 30.44 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.469 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' LEU . . . . . 0.621 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 86.8 mt -52.43 100.0 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.905 0.383 . . . . 0.0 110.895 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.86 HG23 ' O ' ' A' ' 36' ' ' GLY . 29.7 p -116.73 153.84 31.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.176 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.462 ' HB2' ' CD2' ' A' ' 117' ' ' LEU . . . -51.34 -31.51 22.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.127 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.43 ' HA ' ' NE ' ' A' ' 40' ' ' ARG . 10.8 mmp_? -100.14 33.7 2.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.852 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 28.2 ttm-85 -118.73 137.99 52.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.867 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 96.6 m -139.37 118.22 12.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.135 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.479 ' N ' HD12 ' A' ' 43' ' ' ILE . 4.6 mp -91.58 136.28 24.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.099 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 89.0 mt -128.87 133.8 65.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.138 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.8 mt -134.26 107.61 9.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.113 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.3 mtmt -108.24 103.9 13.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -134.21 -148.35 5.78 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.517 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -169.17 127.56 1.0 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.98 0.419 . . . . 0.0 110.894 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 16.0 t -75.91 117.65 65.37 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.635 0.731 . . . . 0.0 111.158 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 154.01 68.35 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.687 2.258 . . . . 0.0 112.359 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -20.71 34.37 Favored 'Trans proline' 0 C--O 1.231 0.175 0 C-N-CA 122.674 2.249 . . . . 0.0 112.343 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 41.1 p -99.63 9.41 43.18 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.153 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -99.08 -172.16 31.28 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.491 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 4.1 mmmm -133.75 -64.56 0.7 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.787 0.327 . . . . 0.0 110.895 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 2.6 p -165.75 147.07 7.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.816 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.597 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 13.0 p90 -110.53 -175.35 2.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.898 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.852 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -154.98 143.58 20.59 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.123 179.878 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.566 HG22 ' CE1' ' A' ' 60' ' ' PHE . 3.2 mp -121.85 102.14 11.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.107 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.2 m-80 -102.06 143.57 31.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.888 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.566 ' CE1' HG22 ' A' ' 58' ' ' ILE . 5.4 m-85 -118.76 98.56 6.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.937 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.447 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 32.8 ttmt -96.93 169.25 9.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.892 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.624 HG23 ' O ' ' A' ' 67' ' ' ASP . 19.4 t -100.64 122.4 52.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.131 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -60.04 -34.24 82.75 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.509 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 10.1 t -67.15 -71.81 0.19 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.872 0.368 . . . . 0.0 110.89 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.4 t -81.86 -69.19 0.63 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.836 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 128.97 36.53 0.43 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.519 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.624 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.6 m-20 -110.22 140.99 43.78 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.853 0.359 . . . . 0.0 110.856 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.615 HD12 ' HB3' ' A' ' 86' ' ' LEU . 58.9 mt -85.86 122.0 37.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.133 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.631 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -93.13 -30.01 15.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.098 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.73 HD22 ' CD2' ' A' ' 132' ' ' PHE . 46.3 tp -144.2 130.1 19.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.946 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.472 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.3 OUTLIER -134.93 92.58 2.9 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.862 179.899 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.488 HD11 HD21 ' A' ' 70' ' ' LEU . 41.4 mt -94.55 134.69 31.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.173 179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.852 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 7.8 t-20 -139.02 106.24 7.36 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.612 0.72 . . . . 0.0 110.879 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.597 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.7 Cg_endo -69.73 155.25 66.52 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.683 2.255 . . . . 0.0 112.329 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 42.1 mtp180 -131.56 99.41 4.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.865 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.858 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 16.9 p . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.887 0.375 . . . . 0.0 111.108 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.575 HG22 ' HA ' ' A' ' 74' ' ' PRO . 39.5 t -101.76 107.24 21.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.125 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.673 HG22 ' HD3' ' A' ' 96' ' ' LYS . 24.6 t -78.29 138.52 20.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.171 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ARG . . . . . 0.628 HH12 ' N ' ' A' ' 97' ' ' LYS . 2.8 mpp_? -126.94 125.72 42.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.885 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.472 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.3 m120 -132.86 -176.23 4.04 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.854 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 30.3 t -159.31 105.18 1.68 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.864 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.93 HD12 ' O ' ' A' ' 90' ' ' SER . 25.8 tp -77.06 117.43 18.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.861 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 90' ' ' SER . 80.7 mt -95.28 161.63 14.01 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.913 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.476 ' C ' ' H ' ' A' ' 90' ' ' SER . 17.7 p-10 -38.42 101.59 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.863 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.83 -6.49 0.91 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.504 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.93 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -119.21 172.47 7.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.913 0.387 . . . . 0.0 110.833 -179.773 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.865 ' NE1' HD13 ' A' ' 86' ' ' LEU . 22.4 m95 -129.49 160.69 32.39 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.908 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -89.59 -92.5 1.17 Allowed Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.457 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 2.3 m -174.74 173.78 2.74 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.905 0.383 . . . . 0.0 110.838 -179.672 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.449 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 3.8 mt-10 -104.97 117.64 34.53 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.89 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 50.7 mm-40 -122.49 133.88 54.58 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.895 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.673 ' HD3' HG22 ' A' ' 82' ' ' VAL . 43.8 mtmt -131.1 128.13 39.54 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.91 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.628 ' N ' HH12 ' A' ' 83' ' ' ARG . 12.7 tmtt? -175.79 108.37 0.09 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.946 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.922 HD11 ' O ' ' A' ' 100' ' ' HIS . 4.1 tt -147.67 144.04 19.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.109 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.6 t -79.19 -39.58 32.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.141 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' HIS . . . . . 0.922 ' O ' HD11 ' A' ' 98' ' ' ILE . 3.1 p-80 -154.35 136.91 15.1 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.883 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' ASN . . . . . 0.617 ' CG ' HD13 ' A' ' 98' ' ' ILE . 8.1 m120 -105.11 95.78 9.98 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.573 0.702 . . . . 0.0 110.893 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.72 -35.04 13.49 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.674 2.249 . . . . 0.0 112.397 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.425 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 11.9 m-85 -45.84 113.69 0.65 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.898 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -144.91 142.19 10.64 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.484 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.75 109.56 2.34 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.723 2.282 . . . . 0.0 112.334 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 118.88 -8.55 12.73 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.5 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -133.29 150.63 51.89 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.851 0.358 . . . . 0.0 110.883 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 2.3 p90 -77.86 160.02 28.57 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.919 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.511 ' O ' ' CD1' ' A' ' 109' ' ' PHE . 29.6 p90 -145.3 122.36 11.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.874 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -92.89 101.94 14.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.911 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.718 HD13 ' N ' ' A' ' 112' ' ' SER . 1.0 OUTLIER -101.84 138.37 38.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.875 -179.911 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.718 ' N ' HD13 ' A' ' 111' ' ' LEU . 4.3 m -144.67 114.41 7.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.871 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.605 HD11 HD12 ' A' ' 111' ' ' LEU . 4.3 mp -99.16 122.22 50.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.157 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 7.7 mtp180 -97.16 132.72 42.66 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.842 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 115' ' ' CYS . . . . . 0.438 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 7.0 t -98.61 123.07 42.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.867 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.93 -141.23 7.46 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.494 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.462 ' CD2' ' HB2' ' A' ' 39' ' ' ALA . 7.9 mt -118.57 -33.4 4.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.792 0.329 . . . . 0.0 110.931 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 118' ' ' ASP . . . . . 0.428 ' C ' ' HG3' ' A' ' 119' ' ' ARG . 16.1 m-20 -97.6 -45.26 6.46 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.908 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.428 ' HG3' ' C ' ' A' ' 118' ' ' ASP . 47.7 mtt180 -152.36 -175.85 5.44 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.91 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.621 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 12.1 m-85 -107.66 158.59 17.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.905 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 19.1 mtpt -130.83 105.23 7.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.903 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.445 HG13 HD11 ' A' ' 111' ' ' LEU . 47.7 t -94.37 134.83 30.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.121 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -123.32 147.82 46.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.91 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.504 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -132.65 107.5 8.45 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.104 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 59.34 34.17 22.75 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.86 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.55 28.99 41.25 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.468 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 13.0 mm100 -136.38 119.61 16.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.8 0.333 . . . . 0.0 110.921 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 26.5 t-80 -51.58 101.53 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.831 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.504 HD13 ' CB ' ' A' ' 124' ' ' ALA . 10.5 tp -65.57 -69.16 0.31 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.933 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.462 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 4.5 p90 -164.66 175.54 9.66 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.884 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 41.0 m-20 -113.75 157.42 22.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.893 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.73 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -130.81 106.29 8.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.942 -179.911 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.545 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -64.54 131.77 47.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.075 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 31.1 m170 -56.65 117.49 3.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.85 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 71.9 mtt-85 -97.61 -49.48 4.85 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.84 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' LEU . . . . . 0.439 HD23 ' HB2' ' A' ' 69' ' ' ALA . 12.2 tp -95.37 109.08 21.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.941 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 79.3 p -48.74 -33.17 9.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.836 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.578 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -83.36 28.24 0.55 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.096 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -51.47 -34.56 35.99 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.838 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 140' ' ' GLN . . . . . 0.42 ' HG2' ' N ' ' A' ' 141' ' ' ARG . 19.7 pm0 -60.58 -27.19 67.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.945 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.578 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 33.1 mtp180 -69.27 -37.58 77.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.908 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.631 HG21 ' HB3' ' A' ' 69' ' ' ALA . 89.4 t -46.52 104.35 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.096 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -127.84 29.24 5.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.875 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 10.5 m -139.2 110.94 7.16 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.085 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.56 HD13 ' CE2' ' A' ' 60' ' ' PHE . 6.2 tp -109.55 105.71 15.13 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.952 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -110.11 152.49 25.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.856 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.406 HG12 HG23 ' A' ' 58' ' ' ILE . 29.4 mt -139.92 118.67 11.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.131 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -126.77 171.43 11.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.927 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 109.36 -152.28 17.12 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.518 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -106.52 92.04 3.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.802 0.334 . . . . 0.0 110.89 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 8.7 p -150.37 149.27 14.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.114 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 29.7 m -109.71 94.9 5.27 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.114 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.437 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 77.6 mt -76.93 132.22 38.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.917 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 3.0 m -117.37 -33.7 4.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.879 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 19.5 t80 -153.1 131.9 12.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.93 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 60.8 t -139.53 112.2 5.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.171 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 17.9 tt0 -124.92 136.56 53.88 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 158' ' ' ILE . . . . . 0.544 HD13 HD23 ' A' ' 33' ' ' LEU . 15.3 mt . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.129 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.525 ' CG2' ' N ' ' A' ' 23' ' ' PHE . 1.6 m . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.786 0.327 . . . . 0.0 111.132 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.525 ' N ' ' CG2' ' A' ' 22' ' ' THR . 8.6 m-85 -154.32 137.72 15.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.88 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ASN . . . . . 0.549 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 12.5 m120 44.27 47.99 4.03 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.648 0.737 . . . . 0.0 110.909 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.549 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.6 Cg_endo -69.79 140.09 41.73 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.688 2.259 . . . . 0.0 112.327 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 178.61 4.38 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.718 2.279 . . . . 0.0 112.357 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.703 HG13 ' HA ' ' A' ' 28' ' ' PRO . 96.4 t -139.36 138.31 20.36 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.605 0.717 . . . . 0.0 111.136 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.703 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.74 144.3 76.2 Favored 'Cis proline' 0 C--O 1.231 0.158 0 C-N-CA 122.72 -1.783 . . . . 0.0 112.334 -0.082 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -95.37 114.07 25.8 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.923 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -97.65 105.34 17.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.896 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -119.34 106.32 1.24 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.487 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.419 ' HA ' ' HA ' ' A' ' 144' ' ' THR . 0.0 OUTLIER -77.98 128.19 33.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.904 0.383 . . . . 0.0 110.848 -179.855 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.455 HD23 HD13 ' A' ' 158' ' ' ILE . 5.5 mt -71.8 122.02 19.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.89 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLN . . . . . 0.407 ' O ' ' NH2' ' A' ' 41' ' ' ARG . 3.5 mp0 -77.15 79.6 3.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.899 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 139.01 -47.51 0.91 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.525 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.963 ' O ' HG23 ' A' ' 38' ' ' THR . . . 108.47 164.98 20.98 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.467 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' LEU . . . . . 0.524 HD12 ' O ' ' A' ' 139' ' ' PHE . 68.7 mt -50.85 106.48 0.13 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.92 0.39 . . . . 0.0 110.898 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.963 HG23 ' O ' ' A' ' 36' ' ' GLY . 10.2 p -124.61 141.19 52.28 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.146 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -42.86 -27.78 0.21 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.15 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 14.4 mmt85 -105.03 43.61 1.09 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.919 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.407 ' NH2' ' O ' ' A' ' 34' ' ' GLN . 6.6 ttt85 -130.43 139.93 50.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.838 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 98.0 m -139.73 121.6 15.52 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.09 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.47 ' N ' HD12 ' A' ' 43' ' ' ILE . 4.7 mp -91.39 132.76 35.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.137 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.436 ' CG2' ' HE2' ' A' ' 46' ' ' LYS . 83.8 mt -125.16 117.01 48.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.113 179.893 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 46.6 mt -118.12 107.63 22.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.092 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.436 ' HE2' ' CG2' ' A' ' 44' ' ' ILE . 25.1 mtmt -111.06 112.12 23.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.907 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -145.04 -143.43 3.99 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.487 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -168.99 126.42 0.97 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.924 0.392 . . . . 0.0 110.957 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 21.6 t -75.99 116.89 59.75 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.642 0.734 . . . . 0.0 111.138 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.82 157.52 60.0 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.631 2.221 . . . . 0.0 112.302 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -16.88 37.63 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.685 2.257 . . . . 0.0 112.307 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 76.8 p -110.91 19.73 18.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.138 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -111.68 116.53 4.2 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.506 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 21.7 mtpp -59.24 -60.66 3.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.761 0.315 . . . . 0.0 110.904 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 21.7 p -174.06 157.43 2.89 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.888 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.595 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 5.7 p90 -112.52 -173.18 2.19 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.9 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.63 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -155.18 145.49 21.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.095 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 2.7 mp -125.52 100.01 6.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.087 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' ASN . . . . . 0.467 ' OD1' ' CD2' ' A' ' 71' ' ' HIS . 19.4 m-80 -101.9 144.76 30.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.882 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.779 ' CE2' HD13 ' A' ' 145' ' ' LEU . 32.7 m-85 -117.93 99.95 7.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.873 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.425 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 34.5 ttmt -95.65 168.16 10.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.945 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.645 HG22 ' HA ' ' A' ' 142' ' ' VAL . 22.6 t -99.72 122.86 52.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.147 179.842 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -58.23 -34.23 73.14 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.481 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.407 ' H ' HG12 ' A' ' 62' ' ' VAL . 26.1 m -70.22 -75.26 0.12 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.865 0.364 . . . . 0.0 110.813 -179.695 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 26.9 t -77.64 -71.93 0.39 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.866 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 129.3 43.4 0.21 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.469 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.505 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.1 m-20 -113.69 142.1 46.43 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.784 0.326 . . . . 0.0 110.866 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.6 HD12 ' HB3' ' A' ' 86' ' ' LEU . 44.9 mt -87.05 118.78 33.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.119 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.655 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -91.95 -30.09 16.29 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.089 179.835 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.645 HD22 ' CD2' ' A' ' 132' ' ' PHE . 58.2 tp -142.18 129.62 21.26 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.899 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.496 ' N ' ' O ' ' A' ' 84' ' ' ASN . 4.1 t-160 -134.81 92.8 2.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.842 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.555 HD11 HD21 ' A' ' 70' ' ' LEU . 28.3 mt -94.78 130.88 42.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.102 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.63 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 9.5 t-20 -136.04 104.79 9.62 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.643 0.735 . . . . 0.0 110.902 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.595 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.4 Cg_endo -69.78 155.66 65.3 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.644 2.229 . . . . 0.0 112.309 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 28.6 mtt-85 -130.77 101.92 5.87 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.859 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.879 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 7.0 p . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.827 0.346 . . . . 0.0 111.123 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.585 HG22 ' HA ' ' A' ' 74' ' ' PRO . 41.8 t -101.46 114.65 41.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.166 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.711 HG22 ' HD3' ' A' ' 96' ' ' LYS . 57.4 t -83.54 144.18 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.135 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -126.26 124.91 41.43 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.845 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.496 ' O ' ' N ' ' A' ' 71' ' ' HIS . 2.3 m-80 -135.17 176.3 8.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.867 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 40.4 t -157.72 105.01 1.99 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.892 -179.883 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.893 HD13 ' NE1' ' A' ' 91' ' ' TRP . 34.5 tp -77.14 117.73 18.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.919 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 90' ' ' SER . 85.0 mt -95.48 162.36 13.68 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.951 179.893 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.423 ' ND2' ' H ' ' A' ' 88' ' ' ASN . 10.6 m-80 -41.08 102.23 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.866 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.19 -1.15 3.0 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.49 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.826 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -125.71 171.64 10.46 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.849 0.357 . . . . 0.0 110.853 -179.715 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.893 ' NE1' HD13 ' A' ' 86' ' ' LEU . 22.2 m95 -128.93 160.63 32.08 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.921 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.57 -115.21 2.23 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.491 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' SER . . . . . 0.425 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 58.3 m -151.42 173.67 14.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.82 0.343 . . . . 0.0 110.852 -179.768 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -102.59 123.95 47.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.875 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -123.08 125.86 45.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.904 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.711 ' HD3' HG22 ' A' ' 82' ' ' VAL . 45.6 mtmt -129.52 118.99 22.96 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.886 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 1.3 tppp? -170.58 106.52 0.29 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.851 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.544 HD11 ' O ' ' A' ' 100' ' ' HIS . 7.4 tt -144.22 150.53 16.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.114 179.839 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.507 HG23 ' N ' ' A' ' 100' ' ' HIS . 8.8 t -87.26 -46.12 10.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.154 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' HIS . . . . . 0.544 ' O ' HD11 ' A' ' 98' ' ' ILE . 4.6 p-80 -147.37 125.78 12.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.886 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' ASN . . . . . 0.44 ' C ' ' OD1' ' A' ' 101' ' ' ASN . 27.1 t-20 -99.41 100.73 11.13 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.628 0.727 . . . . 0.0 110.906 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.425 ' HD2' ' HA ' ' A' ' 101' ' ' ASN . 54.1 Cg_endo -69.72 -36.44 10.89 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.751 2.301 . . . . 0.0 112.335 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -41.51 109.72 0.13 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.872 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -137.96 138.56 9.68 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.481 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 103.06 1.11 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.646 2.231 . . . . 0.0 112.363 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 121.44 -2.12 11.31 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.485 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -137.05 146.04 44.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.871 0.367 . . . . 0.0 110.874 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 2.3 p90 -70.93 172.76 8.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.861 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 30.0 p90 -160.25 137.5 9.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.884 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.59 107.8 18.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.863 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.699 HD13 ' N ' ' A' ' 112' ' ' SER . 0.7 OUTLIER -109.12 136.99 47.71 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.926 -179.938 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.699 ' N ' HD13 ' A' ' 111' ' ' LEU . 6.0 m -145.08 113.56 6.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.809 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.443 HG22 ' HD2' ' A' ' 120' ' ' PHE . 4.3 mp -93.92 137.42 22.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.129 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 114' ' ' ARG . . . . . 0.462 ' O ' ' CD2' ' A' ' 120' ' ' PHE . 14.5 mtp180 -109.56 133.93 52.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.855 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 9.0 t -101.45 115.29 30.18 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.86 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -110.94 -141.66 8.8 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.487 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 5.5 mt -118.58 -34.81 3.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.827 0.346 . . . . 0.0 110.948 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' ASP . . . . . 0.447 ' C ' ' HG3' ' A' ' 119' ' ' ARG . 2.0 m-20 -95.05 -45.83 7.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.856 179.858 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.447 ' HG3' ' C ' ' A' ' 118' ' ' ASP . 25.5 mtt180 -154.98 -179.72 8.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.462 ' CD2' ' O ' ' A' ' 114' ' ' ARG . 20.5 m-85 -103.41 157.59 16.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.919 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 32.9 mtpt -129.52 100.08 5.41 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.938 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.557 HG13 HD11 ' A' ' 111' ' ' LEU . 45.6 t -89.2 128.94 40.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.091 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -115.07 151.21 34.68 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.917 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -136.35 106.71 6.43 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.069 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 55.92 34.67 24.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.856 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 80.71 31.36 36.53 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.506 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 3.7 mm-40 -138.32 123.78 19.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.844 0.354 . . . . 0.0 110.938 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 39.6 t-80 -55.46 101.43 0.05 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.874 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.403 HD22 HD21 ' A' ' 111' ' ' LEU . 11.6 tp -69.85 -69.62 0.34 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.952 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.452 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 6.7 p90 -165.13 169.84 15.67 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -111.22 159.93 17.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.895 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.645 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -130.52 104.39 7.2 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.897 -179.883 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.507 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -62.5 134.96 57.14 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.108 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 134' ' ' HIS . . . . . 0.405 ' ND1' ' O ' ' A' ' 118' ' ' ASP . 26.3 m170 -58.72 104.62 0.24 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.875 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.425 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 8.8 mtt-85 -83.92 -53.65 5.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.867 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.7 tp -91.85 107.77 19.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.956 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 12.7 t -45.74 -36.14 4.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.893 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.416 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.72 29.97 0.44 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.09 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.524 ' O ' HD12 ' A' ' 37' ' ' LEU . 21.7 p90 -48.49 -45.82 37.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.886 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 140' ' ' GLN . . . . . 0.466 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 8.3 pt20 -47.8 -41.34 23.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.908 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.538 ' O ' HG13 ' A' ' 62' ' ' VAL . 30.7 mtp180 -54.21 -41.64 68.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.851 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.655 HG21 ' CB ' ' A' ' 69' ' ' ALA . 97.2 t -49.23 102.92 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.177 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -124.74 28.34 6.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.865 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 144' ' ' THR . . . . . 0.419 ' HA ' ' HA ' ' A' ' 32' ' ' ARG . 0.6 OUTLIER -135.29 125.44 26.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.138 -179.927 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.779 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.2 tp -123.97 106.79 10.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.922 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -110.37 153.44 24.94 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.911 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 17.2 mt -138.47 115.28 11.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.104 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -125.52 174.92 7.89 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.917 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.04 -143.78 15.84 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.502 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -114.81 92.39 3.93 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.888 0.375 . . . . 0.0 110.86 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.3 p -151.31 145.74 16.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.171 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 21.5 m -105.37 93.8 4.87 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.126 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.465 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 95.0 mt -75.76 131.43 39.81 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.869 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 7.5 m -113.62 -41.6 3.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.86 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 155' ' ' TYR . . . . . 0.413 ' CD1' ' C ' ' A' ' 155' ' ' TYR . 8.4 t80 -145.06 132.98 21.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.919 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 94.4 t -140.69 116.96 7.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.112 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 9.7 tt0 -134.18 125.13 27.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.941 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 158' ' ' ILE . . . . . 0.455 HD13 HD23 ' A' ' 33' ' ' LEU . 24.0 mt . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.139 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.494 HG22 ' H ' ' A' ' 156' ' ' VAL . 10.8 t . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.816 0.341 . . . . 0.0 111.151 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 7.8 m-85 -139.43 115.61 10.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.914 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ASN . . . . . 0.489 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 5.3 t-20 66.95 51.63 0.65 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.568 0.699 . . . . 0.0 110.845 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.489 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.75 132.65 23.79 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.679 2.253 . . . . 0.0 112.343 179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -178.43 2.34 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.68 2.253 . . . . 0.0 112.326 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.684 HG13 ' HA ' ' A' ' 28' ' ' PRO . 94.4 t -139.87 137.87 18.98 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.661 0.743 . . . . 0.0 111.146 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.684 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.8 Cg_endo -69.78 144.51 76.89 Favored 'Cis proline' 0 C--N 1.341 0.181 0 C-N-CA 122.731 -1.779 . . . . 0.0 112.292 0.009 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 14.4 t80 -94.87 118.2 31.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.973 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -102.33 100.76 10.95 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.905 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -107.54 109.58 3.01 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.464 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 10.2 mmt85 -75.35 117.65 17.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.85 0.357 . . . . 0.0 110.855 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 3.5 mt -78.17 93.22 4.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.897 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 7.3 mm100 -64.83 99.74 0.36 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.899 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.23 -41.55 1.45 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.54 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.592 ' O ' HG23 ' A' ' 38' ' ' THR . . . 95.21 164.59 34.97 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.499 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' LEU . . . . . 0.41 HD12 ' O ' ' A' ' 139' ' ' PHE . 87.5 mt -58.48 110.68 1.02 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.872 0.368 . . . . 0.0 110.903 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.592 HG23 ' O ' ' A' ' 36' ' ' GLY . 44.4 p -124.12 146.23 48.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.134 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -47.27 -22.69 0.44 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.088 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.02 35.22 3.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.861 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.417 ' NE ' ' O ' ' A' ' 36' ' ' GLY . 20.3 ttm-85 -114.59 138.81 50.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.872 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 88.2 m -136.31 114.55 11.59 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.143 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 4.8 mp -90.78 135.07 27.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.13 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 80.1 mt -130.26 132.61 64.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.127 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 55.8 mt -133.56 107.09 10.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.103 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 10.7 mttm -102.46 108.42 19.73 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.927 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.03 -156.06 6.78 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.454 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -161.98 127.87 3.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.941 0.4 . . . . 0.0 110.867 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 21.9 t -76.05 114.53 38.28 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.675 0.75 . . . . 0.0 111.13 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 158.5 56.7 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.662 2.241 . . . . 0.0 112.317 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -13.65 34.93 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.681 2.254 . . . . 0.0 112.341 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 40.7 p -114.08 19.0 16.8 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.146 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -114.12 116.6 3.89 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.517 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 19.0 mtpp -61.64 -57.5 11.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.801 0.334 . . . . 0.0 110.895 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 16.6 p -174.88 160.7 2.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.857 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 17.6 p90 -115.44 -174.41 2.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.85 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.071 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -156.5 130.3 8.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.113 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.7 HG22 ' CE1' ' A' ' 60' ' ' PHE . 5.3 mp -114.55 103.56 15.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.11 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.4 m-80 -101.44 146.22 27.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.865 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.7 ' CE1' HG22 ' A' ' 58' ' ' ILE . 3.4 m-85 -118.38 99.72 7.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.887 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.454 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 32.8 ttmt -97.47 169.23 9.88 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.884 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.631 HG22 ' HA ' ' A' ' 142' ' ' VAL . 39.8 t -101.23 120.4 50.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.133 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -56.54 -39.61 85.23 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.523 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 35.1 m -62.26 -72.33 0.13 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.875 0.369 . . . . 0.0 110.859 -179.735 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 40.6 p -80.17 -70.21 0.54 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.87 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 127.26 44.25 0.23 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.491 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.556 ' OD1' ' ND2' ' A' ' 88' ' ' ASN . 0.6 OUTLIER -117.37 142.63 46.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.834 0.349 . . . . 0.0 110.87 179.977 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.567 HD12 ' HB3' ' A' ' 86' ' ' LEU . 41.0 mt -86.11 111.2 20.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.128 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.624 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -82.23 -31.25 30.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.075 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.688 HD21 HD11 ' A' ' 72' ' ' ILE . 32.4 tp -142.37 132.46 24.59 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.93 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.441 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.8 OUTLIER -134.78 98.79 4.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.88 179.838 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.688 HD11 HD21 ' A' ' 70' ' ' LEU . 17.9 mt -101.74 133.57 44.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.102 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 1.071 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 9.5 t-20 -141.08 106.82 6.2 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.658 0.742 . . . . 0.0 110.878 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.2 Cg_endo -69.76 155.32 66.26 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.718 2.278 . . . . 0.0 112.332 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 38.4 mtp180 -132.37 96.56 3.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.875 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' MET . . . . . 0.422 ' HE2' ' HB3' ' A' ' 103' ' ' PHE . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.862 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.3 p . . . . . 0 N--CA 1.457 -0.112 0 CA-C-O 120.828 0.346 . . . . 0.0 111.139 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.48 HG22 ' HA ' ' A' ' 74' ' ' PRO . 21.7 t -100.93 112.85 35.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.128 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.648 HG22 ' HD3' ' A' ' 96' ' ' LYS . 30.2 t -82.3 144.85 9.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.137 179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -129.46 126.59 39.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.89 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.441 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.6 OUTLIER -137.07 -177.09 4.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.908 -179.943 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 40.1 t -158.65 105.32 1.82 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.855 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.897 HD13 ' CE2' ' A' ' 91' ' ' TRP . 35.9 tp -76.83 115.86 16.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.902 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.519 ' N ' ' O ' ' A' ' 90' ' ' SER . 83.2 mt -93.72 162.45 13.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.946 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.556 ' ND2' ' OD1' ' A' ' 67' ' ' ASP . 9.0 m120 -41.26 102.17 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.907 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.37 -0.49 3.74 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.51 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.81 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -126.45 171.16 11.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.919 0.39 . . . . 0.0 110.826 -179.713 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.897 ' CE2' HD13 ' A' ' 86' ' ' LEU . 26.6 m95 -128.25 160.72 31.24 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.899 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.85 -109.76 1.89 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.496 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' SER . . . . . 0.434 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 47.5 m -155.5 174.52 15.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.791 0.329 . . . . 0.0 110.905 -179.749 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -100.01 125.17 46.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.884 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -120.17 121.22 38.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.854 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.648 ' HD3' HG22 ' A' ' 82' ' ' VAL . 6.4 mtmp? -127.57 118.56 24.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.932 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 20.9 tttt -170.85 107.49 0.29 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.937 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.87 HD11 ' O ' ' A' ' 100' ' ' HIS . 2.3 tt -145.53 153.38 13.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.147 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.434 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 8.9 t -97.52 -36.2 10.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.128 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' HIS . . . . . 0.87 ' O ' HD11 ' A' ' 98' ' ' ILE . 2.3 p-80 -148.88 128.16 12.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.848 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -102.87 96.66 8.07 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.619 0.723 . . . . 0.0 110.874 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.406 ' O ' ' C ' ' A' ' 103' ' ' PHE . 54.2 Cg_endo -69.74 -42.98 2.95 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.693 2.262 . . . . 0.0 112.374 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.463 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 8.6 m-85 -37.84 105.13 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.868 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -133.21 139.22 10.75 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.481 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 104.21 1.29 Allowed 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.63 2.22 . . . . 0.0 112.352 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 124.41 -7.88 8.45 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.529 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.464 ' NE2' ' O ' ' A' ' 108' ' ' PHE . 0.0 OUTLIER -131.37 168.7 17.13 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.83 0.348 . . . . 0.0 110.922 -179.887 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 108' ' ' PHE . . . . . 0.464 ' O ' ' NE2' ' A' ' 107' ' ' GLN . 1.4 p90 -90.89 172.56 8.52 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.856 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 31.9 p90 -158.36 129.2 6.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.881 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -98.86 102.18 13.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.888 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.836 HD13 ' N ' ' A' ' 112' ' ' SER . 0.9 OUTLIER -99.85 137.51 38.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.876 -179.918 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.836 ' N ' HD13 ' A' ' 111' ' ' LEU . 2.4 m -145.14 111.71 5.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.9 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.529 HG23 HG22 ' A' ' 122' ' ' VAL . 3.9 mp -94.71 121.04 44.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.162 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 114' ' ' ARG . . . . . 0.59 ' HD3' ' CD1' ' A' ' 123' ' ' TYR . 0.2 OUTLIER -99.54 123.92 44.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.864 179.984 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 115' ' ' CYS . . . . . 0.583 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 7.9 t -90.11 126.66 35.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.907 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -123.35 -150.32 8.0 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.489 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 9.2 mt -111.8 -39.72 4.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.863 0.363 . . . . 0.0 110.946 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 29.0 t0 -88.78 -34.66 17.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.831 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.5 ptt180 -172.73 167.87 5.22 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.888 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.583 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.4 m-30 -93.18 158.68 15.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.865 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.43 ' HB3' ' CE1' ' A' ' 123' ' ' TYR . 17.9 mtpp -130.62 104.72 7.37 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.897 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.7 HG13 HD11 ' A' ' 111' ' ' LEU . 92.5 t -93.4 108.47 20.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.116 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 123' ' ' TYR . . . . . 0.59 ' CD1' ' HD3' ' A' ' 114' ' ' ARG . 32.9 m-85 -96.43 147.86 23.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.904 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.593 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -127.5 102.14 6.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.074 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 57.19 37.62 28.48 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.875 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.38 33.39 28.59 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.504 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -142.89 120.67 11.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.85 0.357 . . . . 0.0 110.895 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' HIS . . . . . 0.488 ' CE1' ' OD2' ' A' ' 131' ' ' ASP . 33.6 t-80 -53.22 99.86 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.884 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.593 HD13 ' CB ' ' A' ' 124' ' ' ALA . 10.5 tp -70.01 -67.41 0.49 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.883 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.524 ' HZ ' HD13 ' A' ' 72' ' ' ILE . 8.2 p90 -162.41 175.48 11.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.886 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.488 ' OD2' ' CE1' ' A' ' 128' ' ' HIS . 15.7 m-20 -120.21 150.17 41.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.864 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.597 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -115.86 107.81 15.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.848 -179.886 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.558 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -63.22 131.87 49.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.11 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 29.3 m170 -62.35 102.39 0.31 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.893 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.434 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 68.9 mtt-85 -89.34 -45.98 9.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.872 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 4.5 tp -99.7 108.16 20.44 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.907 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 58.2 p -50.88 -33.17 22.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.853 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.468 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.23 31.17 0.39 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.095 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.41 ' O ' HD12 ' A' ' 37' ' ' LEU . 40.0 p90 -52.37 -42.31 63.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.883 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 8.2 pt20 -48.68 -42.31 34.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.916 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.468 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 72.2 mtp180 -54.36 -40.96 68.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.895 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.631 ' HA ' HG22 ' A' ' 62' ' ' VAL . 69.8 t -44.99 105.43 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.148 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -129.92 34.32 4.28 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.898 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 11.6 m -143.04 116.68 9.21 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.126 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.59 HD13 ' CE2' ' A' ' 60' ' ' PHE . 7.1 tp -116.45 107.8 15.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.959 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 146' ' ' GLU . . . . . 0.418 ' C ' HG13 ' A' ' 147' ' ' ILE . 8.0 pt-20 -111.79 153.02 27.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.852 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.622 HG23 HG13 ' A' ' 58' ' ' ILE . 16.8 mt -139.95 109.8 3.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.172 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -118.54 173.64 6.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.911 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.46 -145.45 16.09 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.503 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -112.18 93.05 4.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.868 0.366 . . . . 0.0 110.879 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 5.6 p -151.12 149.13 14.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.138 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 40.0 m -110.23 95.06 5.34 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.132 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.473 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 84.6 mt -76.53 136.09 39.3 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.901 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 6.0 m -120.08 -36.54 3.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.897 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 53.5 t80 -150.64 130.94 13.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.909 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.494 ' H ' HG22 ' A' ' 22' ' ' THR . 44.8 t -139.72 105.0 2.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.123 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 12.2 tt0 -120.37 135.42 55.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.879 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 16.9 mt . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.135 179.964 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.473 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.9 m . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.785 0.326 . . . . 0.0 111.131 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.473 ' CD1' ' O ' ' A' ' 22' ' ' THR . 6.7 m-85 -147.37 124.59 11.5 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.891 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ASN . . . . . 0.575 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 4.6 t-20 58.93 46.23 1.48 Allowed Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.621 0.724 . . . . 0.0 110.883 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.575 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.77 134.47 28.04 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.679 2.252 . . . . 0.0 112.337 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -177.77 2.03 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.714 2.276 . . . . 0.0 112.301 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.707 HG13 ' HA ' ' A' ' 28' ' ' PRO . 96.0 t -142.25 138.72 16.9 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-O 121.634 0.731 . . . . 0.0 111.14 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.707 ' HA ' HG13 ' A' ' 27' ' ' VAL . 54.2 Cg_endo -69.72 144.39 76.44 Favored 'Cis proline' 0 C--N 1.341 0.17 0 C-N-CA 122.685 -1.798 . . . . 0.0 112.381 -0.11 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -98.37 115.68 28.98 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.925 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.489 ' CD2' ' HB3' ' A' ' 146' ' ' GLU . 63.7 m-85 -103.27 102.65 12.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.851 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -115.75 103.97 1.25 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.479 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.425 ' O ' ' HG3' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -72.34 132.03 43.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.836 0.35 . . . . 0.0 110.862 -179.848 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 143' ' ' ASP . 9.5 mt -76.87 142.57 40.13 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.942 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLN . . . . . 0.413 ' O ' ' NH2' ' A' ' 41' ' ' ARG . 6.4 mm100 -100.39 91.49 4.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.926 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 133.23 -50.02 0.89 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.53 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.968 ' O ' HG23 ' A' ' 38' ' ' THR . . . 108.56 161.56 20.34 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.504 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' LEU . . . . . 0.64 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 99.4 mt -50.31 105.32 0.09 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.881 0.372 . . . . 0.0 110.933 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.968 HG23 ' O ' ' A' ' 36' ' ' GLY . 12.1 p -123.12 146.27 47.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.11 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.431 ' HB2' HD21 ' A' ' 117' ' ' LEU . . . -44.59 -31.98 1.31 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.173 179.856 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -103.45 41.05 1.31 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.895 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.413 ' NH2' ' O ' ' A' ' 34' ' ' GLN . 45.5 ttm-85 -124.31 136.03 53.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.861 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 39.3 m -135.91 126.33 26.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.14 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 mp -98.94 132.48 44.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.101 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 95.3 mt -123.58 134.68 65.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.137 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 59.5 mt -135.95 107.88 7.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.144 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.4 mtmm -110.34 111.07 22.12 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.925 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.66 -143.45 4.31 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.51 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 1.6 t80 -170.16 126.78 0.82 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.851 0.357 . . . . 0.0 110.944 -179.84 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 11.2 t -77.36 116.13 55.11 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.616 0.722 . . . . 0.0 111.124 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 158.68 56.15 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.699 2.266 . . . . 0.0 112.331 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -19.36 36.38 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.733 2.288 . . . . 0.0 112.327 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 69.2 p -109.7 21.27 17.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.142 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -115.02 120.04 4.84 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.486 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 20.6 mtpp -61.27 -60.19 4.13 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.797 0.332 . . . . 0.0 110.897 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.7 p -175.29 157.59 2.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.886 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.501 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 4.0 p90 -108.47 -172.5 2.07 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.857 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.712 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -154.82 141.41 18.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.082 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.429 HD12 ' N ' ' A' ' 58' ' ' ILE . 2.6 mp -123.0 98.7 5.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.166 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.0 m-80 -101.07 144.84 29.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.908 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.546 ' CE2' HD13 ' A' ' 145' ' ' LEU . 29.6 m-85 -117.24 101.45 8.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.912 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.427 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 32.8 ttmt -95.83 168.39 10.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.863 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.591 HG22 ' HA ' ' A' ' 142' ' ' VAL . 61.4 t -100.41 122.27 52.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.171 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -57.08 -41.13 92.42 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.515 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 44.2 t -65.15 -73.04 0.13 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.888 0.375 . . . . 0.0 110.856 -179.75 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 39.0 t -77.99 -75.94 0.2 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.918 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 132.42 40.28 0.21 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.485 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.458 ' O ' HG23 ' A' ' 62' ' ' VAL . 0.7 OUTLIER -111.88 142.01 44.81 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.761 0.315 . . . . 0.0 110.892 -179.971 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.623 HD12 ' HB3' ' A' ' 86' ' ' LEU . 50.0 mt -86.41 120.11 35.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.152 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.527 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -92.24 -33.55 14.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.08 179.829 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.613 HD13 ' CD1' ' A' ' 132' ' ' PHE . 59.8 tp -138.85 130.61 27.65 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.907 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.492 ' N ' ' O ' ' A' ' 84' ' ' ASN . 3.6 t-160 -134.96 92.63 2.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.913 179.843 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.573 HD11 HD21 ' A' ' 70' ' ' LEU . 30.5 mt -94.99 128.37 46.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.117 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.712 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 9.1 t-20 -134.58 105.4 10.89 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.611 0.719 . . . . 0.0 110.897 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.501 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.2 Cg_endo -69.71 154.51 67.85 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.701 2.267 . . . . 0.0 112.354 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 36.1 mtp180 -130.32 96.94 4.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.876 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.845 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 34.8 p . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.838 0.352 . . . . 0.0 111.17 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.474 HG21 ' HE2' ' A' ' 103' ' ' PHE . 13.1 t -89.29 108.73 19.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.097 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.559 HG22 ' HD3' ' A' ' 96' ' ' LYS . 91.6 t -80.93 145.97 8.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.088 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -127.34 124.81 39.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.892 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.492 ' O ' ' N ' ' A' ' 71' ' ' HIS . 2.4 m-80 -135.22 179.3 6.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.901 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 46.1 t -160.78 105.63 1.4 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.861 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.929 HD12 ' O ' ' A' ' 90' ' ' SER . 27.0 tp -77.96 119.34 21.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.92 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.503 ' N ' ' O ' ' A' ' 90' ' ' SER . 87.0 mt -97.08 161.35 13.86 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.919 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.461 ' C ' ' H ' ' A' ' 90' ' ' SER . 17.0 p-10 -38.23 101.61 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.931 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.45 -6.41 0.82 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.501 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.929 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -118.96 172.06 7.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.834 0.349 . . . . 0.0 110.844 -179.725 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.837 ' NE1' HD13 ' A' ' 86' ' ' LEU . 22.0 m95 -129.43 161.07 31.21 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.929 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.09 -106.01 1.55 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.476 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 2.9 m -165.76 174.92 9.2 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.812 0.339 . . . . 0.0 110.835 -179.742 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -104.66 117.62 34.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.88 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -123.05 108.78 13.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.876 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.559 ' HD3' HG22 ' A' ' 82' ' ' VAL . 35.8 mtmt -105.57 131.32 53.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.864 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.479 ' HE3' ' N ' ' A' ' 98' ' ' ILE . 0.0 OUTLIER -174.31 105.23 0.11 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.903 179.889 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.933 HD11 ' O ' ' A' ' 100' ' ' HIS . 5.1 tt -148.09 154.25 10.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.12 179.895 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.488 HG23 ' N ' ' A' ' 100' ' ' HIS . 9.0 t -95.29 -44.62 7.51 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.143 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' HIS . . . . . 0.933 ' O ' HD11 ' A' ' 98' ' ' ILE . 4.9 p-80 -139.1 133.3 31.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.856 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' ASN . . . . . 0.402 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 44.2 t-20 -110.92 95.99 27.07 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.628 0.728 . . . . 0.0 110.892 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.434 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.4 Cg_endo -69.78 -42.6 3.24 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.646 2.231 . . . . 0.0 112.34 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.527 ' CZ ' HD21 ' A' ' 129' ' ' LEU . 5.2 m-85 -35.88 104.84 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.861 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -135.88 138.44 9.92 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.455 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 99.95 0.78 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.722 2.281 . . . . 0.0 112.319 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 130.45 -9.59 5.87 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.461 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.1 pt20 -131.49 159.22 38.76 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.806 0.336 . . . . 0.0 110.941 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -76.45 174.09 10.7 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.849 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.468 ' O ' ' CD2' ' A' ' 109' ' ' PHE . 23.4 p90 -161.55 117.87 2.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.887 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -94.76 102.08 13.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.878 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.739 HD13 ' N ' ' A' ' 112' ' ' SER . 0.9 OUTLIER -101.23 137.33 39.73 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.921 -179.943 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.739 ' N ' HD13 ' A' ' 111' ' ' LEU . 5.2 m -144.2 114.16 7.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.859 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.475 HD11 HD12 ' A' ' 111' ' ' LEU . 5.1 mp -96.47 140.71 16.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.147 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 24.6 mtt180 -115.57 124.93 52.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.879 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 115' ' ' CYS . . . . . 0.563 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 6.5 t -92.89 118.45 31.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.85 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.99 -144.82 8.51 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.434 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.431 HD21 ' HB2' ' A' ' 39' ' ' ALA . 13.6 mt -116.85 -36.95 3.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.838 0.351 . . . . 0.0 110.933 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -92.23 -34.69 14.17 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.833 179.861 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 17.8 ptp180 -171.77 172.83 4.75 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.885 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.64 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 3.6 m-30 -96.28 158.17 15.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.845 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 27.4 mtpt -129.82 100.34 5.44 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.917 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.459 HG13 HD11 ' A' ' 111' ' ' LEU . 88.0 t -86.18 137.07 21.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.133 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -126.54 152.72 46.16 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.884 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -140.83 111.17 6.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.069 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 56.78 29.71 16.45 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.9 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 83.37 32.12 26.11 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.503 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 32.0 mm-40 -139.01 125.77 20.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.872 0.368 . . . . 0.0 110.875 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' HIS . . . . . 0.445 ' CE1' ' OD1' ' A' ' 131' ' ' ASP . 31.3 t-80 -56.6 109.22 0.58 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.839 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.527 HD21 ' CZ ' ' A' ' 103' ' ' PHE . 10.7 tp -77.8 -68.38 0.63 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.939 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.437 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 7.6 p90 -165.18 171.48 13.66 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.883 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.445 ' OD1' ' CE1' ' A' ' 128' ' ' HIS . 1.4 m-20 -113.97 151.64 32.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.865 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.613 ' CD1' HD13 ' A' ' 70' ' ' LEU . 0.3 OUTLIER -116.8 108.58 16.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.929 -179.933 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.513 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -63.49 134.42 55.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.065 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 28.4 m170 -62.82 103.0 0.4 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.849 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 47.2 mtt-85 -87.1 -52.82 5.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.906 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 9.5 tp -91.54 108.34 19.83 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.934 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 99.2 p -50.5 -32.48 18.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.867 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.499 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.93 25.54 0.67 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.06 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.492 ' O ' HD12 ' A' ' 37' ' ' LEU . 12.5 p90 -45.44 -42.81 10.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.869 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 140' ' ' GLN . . . . . 0.436 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 10.7 pt20 -48.93 -40.06 28.65 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.894 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.499 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 41.0 mtp85 -55.9 -39.71 71.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.9 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.591 ' HA ' HG22 ' A' ' 62' ' ' VAL . 53.1 t -51.7 103.24 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.511 ' O ' ' N ' ' A' ' 33' ' ' LEU . 3.1 p30 -125.47 25.94 6.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.849 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 2.2 m -132.99 140.19 47.65 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.137 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.546 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.7 tp -134.64 108.32 7.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.947 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 146' ' ' GLU . . . . . 0.489 ' HB3' ' CD2' ' A' ' 30' ' ' PHE . 5.8 pt-20 -111.51 148.85 32.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.896 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.409 HG13 ' C ' ' A' ' 146' ' ' GLU . 9.9 mt -136.65 111.46 10.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.11 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -124.26 176.68 6.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.956 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 109.97 -139.48 15.41 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.495 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -120.47 90.82 3.4 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.848 0.356 . . . . 0.0 110.898 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.441 HG22 ' N ' ' A' ' 152' ' ' THR . 2.8 p -151.15 155.33 7.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.13 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 152' ' ' THR . . . . . 0.441 ' N ' HG22 ' A' ' 151' ' ' VAL . 38.0 m -113.32 93.7 4.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.156 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.478 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 68.2 mt -77.27 137.33 38.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.939 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 6.9 t -121.42 -39.55 2.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.888 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 19.3 t80 -143.49 129.17 19.26 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.929 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 76.3 t -141.05 105.42 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.128 179.895 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 14.6 tt0 -118.39 134.39 55.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.927 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 21.3 mt . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.158 179.947 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.538 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.6 m . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.867 0.365 . . . . 0.0 111.118 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.538 ' CD1' ' O ' ' A' ' 22' ' ' THR . 8.3 m-85 -150.84 127.4 10.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.887 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ASN . . . . . 0.59 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 3.4 m120 54.48 45.46 2.27 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.607 0.718 . . . . 0.0 110.893 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.59 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.6 Cg_endo -69.76 132.56 23.59 Favored 'Trans proline' 0 C--O 1.231 0.175 0 C-N-CA 122.655 2.236 . . . . 0.0 112.299 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.81 -175.11 1.06 Allowed 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.669 2.246 . . . . 0.0 112.394 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.658 HG13 ' HA ' ' A' ' 28' ' ' PRO . 86.9 t -143.17 137.63 14.95 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.616 0.722 . . . . 0.0 111.14 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.658 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.6 Cg_endo -69.79 144.63 77.27 Favored 'Cis proline' 0 C--N 1.341 0.184 0 C-N-CA 122.702 -1.791 . . . . 0.0 112.319 -0.017 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 6.4 t80 -98.31 121.99 40.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.938 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -102.17 101.95 12.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.842 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -100.82 108.77 3.52 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.455 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 6.8 mmt85 -73.28 123.29 23.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.856 0.36 . . . . 0.0 110.902 -179.865 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.406 HD22 ' CZ ' ' A' ' 41' ' ' ARG . 7.8 mt -87.05 113.73 23.05 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.929 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 5.7 mm100 -84.62 80.53 9.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.888 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 143.54 -36.83 1.51 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.501 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.469 ' CA ' ' OD1' ' A' ' 143' ' ' ASP . . . 93.72 -177.93 37.59 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.48 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' LEU . . . . . 0.791 HD23 ' HE ' ' A' ' 41' ' ' ARG . 89.0 mt -68.47 98.05 0.82 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.899 0.38 . . . . 0.0 110.885 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 34.6 p -107.77 161.85 14.52 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.1 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.437 ' HB2' HD21 ' A' ' 117' ' ' LEU . . . -62.18 -27.47 68.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.112 179.845 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 8.8 mpt_? -105.61 33.06 3.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.918 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.791 ' HE ' HD23 ' A' ' 37' ' ' LEU . 4.5 ttt85 -109.74 137.98 46.77 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 87.4 m -138.96 120.82 15.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.136 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.487 HD11 ' CZ ' ' A' ' 41' ' ' ARG . 5.4 mp -93.74 137.78 21.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.159 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 76.2 mt -128.96 118.65 47.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.084 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 71.9 mt -118.1 107.37 21.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.104 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 21.9 mtmt -113.69 109.49 18.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.928 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -143.2 -143.61 4.15 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.528 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -168.03 128.6 1.35 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.941 0.4 . . . . 0.0 110.944 -179.845 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 15.4 t -79.11 119.6 77.75 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.646 0.736 . . . . 0.0 111.17 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 158.91 55.29 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.683 2.255 . . . . 0.0 112.313 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -17.96 37.03 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.712 2.274 . . . . 0.0 112.304 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 30.2 p -109.52 18.77 20.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.126 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -115.74 121.18 5.17 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.477 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 20.2 mtpp -63.91 -58.78 5.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.78 0.324 . . . . 0.0 110.906 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.0 m -173.12 167.77 4.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.833 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.531 ' CE2' HD11 ' A' ' 58' ' ' ILE . 1.9 p90 -119.07 -172.2 2.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.86 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.067 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -154.67 133.82 12.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.106 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.531 HD11 ' CE2' ' A' ' 56' ' ' PHE . 3.6 mp -115.77 98.18 6.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.151 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' ASN . . . . . 0.415 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 6.0 m-80 -100.25 143.33 30.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.939 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.559 ' CE2' HD13 ' A' ' 145' ' ' LEU . 28.5 m-85 -115.32 98.38 6.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.904 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.431 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 33.7 ttmt -95.68 168.31 10.75 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.934 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.756 HG22 ' HA ' ' A' ' 142' ' ' VAL . 53.4 t -100.24 125.08 54.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.147 179.85 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -60.44 -36.88 92.25 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.509 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 69.7 m -65.95 -73.34 0.13 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.871 0.367 . . . . 0.0 110.897 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 58.0 m -81.18 -73.36 0.38 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.853 -179.874 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 133.62 39.8 0.19 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.491 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.554 ' OD1' ' ND2' ' A' ' 88' ' ' ASN . 1.2 m-20 -108.92 142.88 38.9 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.789 0.328 . . . . 0.0 110.886 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.525 HD12 ' HB3' ' A' ' 86' ' ' LEU . 35.8 mt -92.35 114.01 28.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.127 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -83.63 -31.49 26.19 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.112 179.817 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.74 HD21 HD11 ' A' ' 72' ' ' ILE . 56.0 tp -141.28 130.91 24.04 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.889 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.476 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.2 t60 -134.49 92.94 2.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.845 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.74 HD11 HD21 ' A' ' 70' ' ' LEU . 18.2 mt -97.31 132.97 40.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.112 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 1.067 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 12.7 t-20 -140.27 106.49 6.65 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.63 0.728 . . . . 0.0 110.899 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.618 ' HB3' ' CD2' ' A' ' 103' ' ' PHE . 54.0 Cg_endo -69.74 154.98 67.16 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.652 2.235 . . . . 0.0 112.335 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 57.8 mtp180 -131.49 100.57 5.19 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.887 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' MET . . . . . 0.422 ' SD ' ' HB2' ' A' ' 103' ' ' PHE . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.891 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.2 p . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.797 0.332 . . . . 0.0 111.167 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.408 HG22 ' HA ' ' A' ' 74' ' ' PRO . 15.2 t -102.54 114.26 41.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.13 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.572 HG22 ' HD3' ' A' ' 96' ' ' LYS . 37.1 t -84.53 143.34 11.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.127 179.897 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -125.4 124.88 42.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.853 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.476 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.7 OUTLIER -136.23 176.29 8.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.906 -179.975 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 47.7 t -156.15 105.07 2.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.891 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.893 HD13 ' NE1' ' A' ' 91' ' ' TRP . 39.0 tp -77.18 114.33 15.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.904 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.518 ' N ' ' O ' ' A' ' 90' ' ' SER . 79.7 mt -92.44 161.93 14.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.929 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.554 ' ND2' ' OD1' ' A' ' 67' ' ' ASP . 11.8 m120 -41.17 101.83 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.938 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.15 -1.55 3.61 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.485 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.829 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -125.31 170.59 11.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.828 0.347 . . . . 0.0 110.898 -179.815 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.893 ' NE1' HD13 ' A' ' 86' ' ' LEU . 23.1 m95 -128.12 160.57 31.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.903 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -91.97 -102.04 1.38 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.461 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 9.9 m -167.82 174.41 7.56 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.868 0.366 . . . . 0.0 110.823 -179.752 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -96.71 123.64 40.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.881 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 17.8 mm-40 -121.37 116.12 24.2 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.9 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.572 ' HD3' HG22 ' A' ' 82' ' ' VAL . 6.7 mtmp? -120.72 122.16 39.82 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.888 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -175.17 105.54 0.09 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.855 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.881 HD11 ' O ' ' A' ' 100' ' ' HIS . 6.4 tt -147.64 146.58 18.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.137 179.842 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.485 HG23 ' N ' ' A' ' 100' ' ' HIS . 10.2 t -81.34 -44.79 17.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' HIS . . . . . 0.881 ' O ' HD11 ' A' ' 98' ' ' ILE . 5.1 p-80 -148.5 141.26 24.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.9 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' ASN . . . . . 0.443 ' C ' ' OD1' ' A' ' 101' ' ' ASN . 4.9 t-20 -101.63 102.13 20.97 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.605 0.717 . . . . 0.0 110.899 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.476 ' CD ' HD11 ' A' ' 129' ' ' LEU . 53.8 Cg_endo -69.78 -29.6 23.53 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.691 2.26 . . . . 0.0 112.33 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.618 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 19.6 m-85 -58.6 115.02 2.77 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.866 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -140.06 139.83 10.18 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.516 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 111.0 2.7 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.716 2.277 . . . . 0.0 112.305 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 107.18 0.9 35.64 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.487 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -137.85 142.09 40.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.849 0.356 . . . . 0.0 110.903 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.4 p90 -68.57 174.51 4.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.844 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 29.1 p90 -161.25 132.21 5.32 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.922 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -103.34 106.38 16.88 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.859 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.794 HD13 ' N ' ' A' ' 112' ' ' SER . 0.4 OUTLIER -109.16 138.39 45.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.912 -179.955 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.794 ' N ' HD13 ' A' ' 111' ' ' LEU . 2.6 m -145.44 113.67 6.59 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.867 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.552 HG23 HG22 ' A' ' 122' ' ' VAL . 4.0 mp -93.55 136.82 24.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.108 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 50.1 mtt-85 -110.22 120.9 43.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.851 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 115' ' ' CYS . . . . . 0.431 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 26.3 t -92.06 122.21 34.35 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.918 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -123.62 -149.44 7.77 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.484 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.437 HD21 ' HB2' ' A' ' 39' ' ' ALA . 36.3 mt -109.37 -40.88 4.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.86 0.362 . . . . 0.0 110.904 -179.871 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -80.72 -39.54 26.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.83 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.418 ' HA ' ' CE1' ' A' ' 134' ' ' HIS . 0.0 OUTLIER -174.11 179.91 1.8 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.898 -179.865 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.542 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 18.9 m-85 -97.95 155.04 17.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.877 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 15.5 mtpp -130.48 100.55 5.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.921 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.781 ' CG1' HD11 ' A' ' 111' ' ' LEU . 21.3 t -88.16 128.61 40.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.116 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -120.59 149.79 41.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.909 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.45 ' CB ' ' HG3' ' A' ' 102' ' ' PRO . . . -134.17 110.1 9.34 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.093 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 58.13 31.58 20.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.911 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.31 38.2 15.64 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.484 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 28.4 mm-40 -143.77 128.88 18.66 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.868 0.366 . . . . 0.0 110.914 -179.854 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 35.6 t-80 -59.21 107.19 0.52 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.845 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.476 HD11 ' CD ' ' A' ' 102' ' ' PRO . 8.5 tp -78.41 -66.12 0.89 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.899 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.472 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 5.3 p90 -166.42 169.53 13.86 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.861 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -115.21 149.71 37.28 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.917 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.657 ' CG ' HD13 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -117.73 108.02 14.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.899 -179.92 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.579 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -63.33 134.97 56.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.066 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 134' ' ' HIS . . . . . 0.418 ' CE1' ' HA ' ' A' ' 119' ' ' ARG . 29.1 m170 -63.34 107.3 1.06 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.884 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 67.6 mtt-85 -89.71 -48.85 7.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.849 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' LEU . . . . . 0.422 HD13 HD22 ' A' ' 87' ' ' LEU . 12.2 tp -93.51 109.33 20.93 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.943 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 12.1 t -50.64 -33.37 22.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.868 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.518 ' HB1' ' HD2' ' A' ' 141' ' ' ARG . . . -87.19 33.55 0.68 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.107 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.647 ' O ' HD12 ' A' ' 37' ' ' LEU . 8.2 p90 -50.74 -31.61 17.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.868 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 6.1 pt20 -56.14 -46.46 79.22 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.885 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.518 ' HD2' ' HB1' ' A' ' 138' ' ' ALA . 27.6 mtt-85 -47.5 -44.22 25.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.866 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.756 ' HA ' HG22 ' A' ' 62' ' ' VAL . 92.3 t -43.3 103.45 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.153 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.469 ' OD1' ' CA ' ' A' ' 36' ' ' GLY . 17.1 m-20 -128.19 31.48 5.05 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.841 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 18.1 m -142.44 123.19 14.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.122 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.559 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.6 tp -120.15 107.69 13.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.933 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -110.75 152.31 26.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.919 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 25.1 mt -139.58 112.77 6.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.177 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -123.57 171.29 9.64 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.928 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 113.03 -148.07 18.54 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.522 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 28.8 m-20 -111.56 89.1 2.96 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.859 0.361 . . . . 0.0 110.881 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.448 HG22 ' N ' ' A' ' 152' ' ' THR . 7.2 p -148.85 155.33 8.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.129 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 152' ' ' THR . . . . . 0.448 ' N ' HG22 ' A' ' 151' ' ' VAL . 16.9 m -116.21 94.51 4.68 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.16 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.476 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 78.6 mt -75.92 139.95 41.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.886 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 68.6 m -127.8 -35.57 2.09 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.858 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 39.6 t80 -146.93 125.08 12.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.942 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 79.4 t -138.97 106.33 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.118 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 13.9 tt0 -119.69 141.16 49.63 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.931 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 158' ' ' ILE . . . . . 0.638 HG23 ' NH1' ' A' ' 41' ' ' ARG . 15.6 mt . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.121 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 1.2 t . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.828 0.347 . . . . 0.0 111.129 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -138.92 127.83 23.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.92 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ASN . . . . . 0.567 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 8.8 m-80 61.55 47.0 1.08 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.578 0.704 . . . . 0.0 110.901 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.567 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 54.0 Cg_endo -69.75 136.03 31.99 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.65 2.234 . . . . 0.0 112.312 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 -177.72 2.02 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.68 2.253 . . . . 0.0 112.331 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.686 HG13 ' HA ' ' A' ' 28' ' ' PRO . 97.0 t -141.72 138.09 16.87 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.685 0.755 . . . . 0.0 111.107 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.686 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.3 Cg_endo -69.77 144.33 76.38 Favored 'Cis proline' 0 C--N 1.342 0.198 0 C-N-CA 122.65 -1.812 . . . . 0.0 112.325 -0.027 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 8.2 t80 -97.47 117.15 31.09 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.933 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -100.66 102.3 13.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.884 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -97.77 109.4 3.81 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.456 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 9.7 mmt180 -72.91 102.99 3.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.854 0.359 . . . . 0.0 110.876 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.487 HD13 ' NH2' ' A' ' 41' ' ' ARG . 5.6 mt -71.1 114.7 9.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.939 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 5.6 mm-40 -86.32 94.49 9.36 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.911 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 131.33 -32.75 2.9 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.453 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.714 ' O ' HG23 ' A' ' 38' ' ' THR . . . 88.69 173.45 46.87 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.51 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' LEU . . . . . 0.676 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 88.0 mt -57.18 104.97 0.19 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.854 0.359 . . . . 0.0 110.938 -179.9 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.714 HG23 ' O ' ' A' ' 36' ' ' GLY . 29.0 p -117.07 149.94 39.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.116 -180.0 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -59.71 -21.27 60.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.122 179.83 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 25.5 mmm-85 -104.42 26.46 8.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.884 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.675 ' CZ ' HD23 ' A' ' 37' ' ' LEU . 23.4 ttt180 -116.97 142.86 46.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.863 -179.892 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 91.2 m -137.16 121.21 17.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.123 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 mp -90.86 132.46 35.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.156 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.459 ' CG2' ' HE2' ' A' ' 46' ' ' LYS . 70.1 mt -128.57 117.24 44.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.154 179.792 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 34.9 mt -116.15 107.59 22.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.168 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.459 ' HE2' ' CG2' ' A' ' 44' ' ' ILE . 22.3 mtmt -111.65 111.18 21.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.904 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -143.67 -143.62 4.12 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.484 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' TYR . . . . . 0.405 ' O ' ' CD1' ' A' ' 48' ' ' TYR . 1.1 t80 -167.59 118.27 0.85 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.944 0.402 . . . . 0.0 110.896 -179.847 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 15.1 t -69.96 115.45 34.0 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.638 0.732 . . . . 0.0 111.135 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 159.02 54.96 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.714 2.276 . . . . 0.0 112.359 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -25.16 29.01 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.683 2.256 . . . . 0.0 112.328 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 67.1 p -100.74 15.41 28.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.134 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -109.89 119.4 5.4 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.489 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.418 ' O ' ' SD ' ' A' ' 76' ' ' MET . 24.8 mtpt -62.47 -58.91 5.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.816 0.341 . . . . 0.0 110.89 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 37.0 p -175.58 162.37 2.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.827 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 3.5 p90 -116.14 -174.98 2.65 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.87 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.131 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -156.91 137.38 13.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.119 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.429 HD12 ' N ' ' A' ' 58' ' ' ILE . 4.6 mp -118.14 100.78 10.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.152 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -99.85 144.04 29.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.911 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.62 ' CE2' HD13 ' A' ' 145' ' ' LEU . 50.1 m-85 -115.04 97.69 6.37 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.881 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.47 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 35.5 ttmt -96.13 167.68 11.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.899 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.615 HG22 ' HA ' ' A' ' 142' ' ' VAL . 43.6 t -100.61 122.52 52.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.102 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -58.58 -40.21 94.28 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.515 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.0 t -64.43 -70.74 0.21 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.941 0.4 . . . . 0.0 110.902 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 48.5 t -79.75 -75.06 0.27 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.875 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 131.43 41.37 0.21 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.487 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.433 ' O ' HG23 ' A' ' 62' ' ' VAL . 0.8 OUTLIER -114.71 141.47 47.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.833 0.349 . . . . 0.0 110.879 179.995 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.479 HD12 ' HB3' ' A' ' 86' ' ' LEU . 43.0 mt -88.05 119.55 35.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.111 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -90.25 -33.57 16.1 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.059 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.712 HD21 HD11 ' A' ' 72' ' ' ILE . 62.7 tp -138.44 131.2 29.43 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.898 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.531 ' CD2' ' C ' ' A' ' 71' ' ' HIS . 3.0 t-160 -135.01 93.91 3.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.866 179.877 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.712 HD11 HD21 ' A' ' 70' ' ' LEU . 17.1 mt -98.09 133.16 41.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.096 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 1.131 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 12.9 t-20 -140.8 106.87 6.36 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.597 0.713 . . . . 0.0 110.871 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.611 ' HB3' ' CD2' ' A' ' 103' ' ' PHE . 53.8 Cg_endo -69.75 154.63 67.56 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.702 2.268 . . . . 0.0 112.383 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 46.0 mtp85 -132.96 94.58 3.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.892 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' MET . . . . . 0.418 ' SD ' ' O ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.885 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 28.8 p . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.85 0.357 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.2 t -99.35 110.46 26.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.149 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.525 HG22 ' HD3' ' A' ' 96' ' ' LYS . 67.6 t -82.71 145.45 8.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.113 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -125.84 124.15 40.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.895 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.497 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.2 m-80 -135.49 177.12 8.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.889 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 87.1 p -160.67 105.13 1.4 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.826 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.934 HD12 ' O ' ' A' ' 90' ' ' SER . 22.9 tp -77.74 119.34 21.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.943 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 90' ' ' SER . 93.0 mt -96.71 161.48 13.86 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.915 179.876 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.47 ' C ' ' H ' ' A' ' 90' ' ' SER . 17.8 p-10 -37.91 101.67 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.864 179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.51 -7.05 0.68 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.477 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.934 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -117.54 170.03 9.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.856 0.36 . . . . 0.0 110.871 -179.748 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.841 ' NE1' HD13 ' A' ' 86' ' ' LEU . 20.7 m95 -128.58 161.1 30.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.927 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -93.14 -110.26 1.98 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.465 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 72.0 m -159.91 178.12 10.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.855 0.359 . . . . 0.0 110.87 -179.781 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.435 ' C ' ' OE2' ' A' ' 95' ' ' GLU . 30.2 mt-10 -103.07 123.62 47.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.887 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' GLU . . . . . 0.435 ' OE2' ' C ' ' A' ' 94' ' ' GLU . 3.5 mp0 -122.88 116.96 24.5 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.89 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.525 ' HD3' HG22 ' A' ' 82' ' ' VAL . 9.4 mtmp? -118.79 120.55 37.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.891 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -171.84 108.0 0.23 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.966 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.788 HD11 ' O ' ' A' ' 100' ' ' HIS . 4.1 tt -147.66 152.3 12.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.119 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.523 HG23 ' N ' ' A' ' 100' ' ' HIS . 8.9 t -85.42 -47.18 10.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.162 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' HIS . . . . . 0.788 ' O ' HD11 ' A' ' 98' ' ' ILE . 1.7 p-80 -147.06 133.49 19.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.87 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' ASN . . . . . 0.41 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 7.4 t30 -103.67 98.17 12.34 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.674 0.749 . . . . 0.0 110.856 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.5 Cg_endo -69.75 -42.5 3.36 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.687 2.258 . . . . 0.0 112.331 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.611 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 11.7 m-85 -34.01 110.58 0.09 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.858 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -133.09 136.66 8.84 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.515 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 97.78 0.65 Allowed 'Trans proline' 0 N--CA 1.465 -0.151 0 C-N-CA 122.715 2.277 . . . . 0.0 112.371 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 119.97 1.92 12.8 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.473 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 9.4 pt20 -134.59 149.09 50.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.846 0.355 . . . . 0.0 110.911 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -66.52 168.39 9.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.901 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.41 ' O ' ' CG ' ' A' ' 109' ' ' PHE . 14.9 p90 -160.71 125.51 3.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.906 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -101.75 108.28 19.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.883 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.735 HD13 ' N ' ' A' ' 112' ' ' SER . 0.7 OUTLIER -111.81 139.01 47.65 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.932 -179.96 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.735 ' N ' HD13 ' A' ' 111' ' ' LEU . 1.5 m -144.9 115.51 7.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.834 -179.88 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.504 HG22 ' HD2' ' A' ' 120' ' ' PHE . 4.9 mp -97.28 132.03 42.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.135 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 114' ' ' ARG . . . . . 0.535 ' O ' ' CD2' ' A' ' 120' ' ' PHE . 6.1 mtp-105 -104.53 133.39 49.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.879 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 115' ' ' CYS . . . . . 0.559 ' HA ' ' CE2' ' A' ' 120' ' ' PHE . 5.7 t -98.08 121.72 40.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.895 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -122.97 -163.04 11.69 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.521 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 7.6 mt -104.82 -28.75 10.96 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.784 0.326 . . . . 0.0 110.892 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' ASP . . . . . 0.4 ' C ' ' OD1' ' A' ' 118' ' ' ASP . 7.2 t0 -97.43 -39.91 8.94 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.886 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 29.4 ptt-85 -170.34 163.89 8.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.676 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 14.8 m-85 -88.23 154.78 20.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.86 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 13.6 mtpp -126.94 100.17 6.04 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.908 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.524 HG13 HD11 ' A' ' 111' ' ' LEU . 39.3 t -87.44 132.28 33.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.128 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -123.79 146.59 48.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.919 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -134.74 111.89 10.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.111 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 55.64 35.18 24.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.865 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.57 39.57 21.25 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.492 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 9.8 mt-30 -145.99 129.11 16.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.837 0.351 . . . . 0.0 110.937 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 33.0 t-80 -60.76 99.29 0.08 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.889 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.538 HD22 HD21 ' A' ' 111' ' ' LEU . 9.8 tp -66.71 -69.62 0.3 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.93 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.482 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 4.9 p90 -163.29 171.38 16.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.913 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -116.49 148.09 41.12 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.86 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.673 ' CG ' HD13 ' A' ' 70' ' ' LEU . 0.3 OUTLIER -116.99 107.66 14.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.859 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.463 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -64.89 133.27 51.49 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.092 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 29.2 m170 -60.68 109.09 0.95 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.846 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 32.0 mtt-85 -91.54 -51.38 5.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.891 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.0 tp -93.18 109.3 20.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.913 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 81.6 p -49.72 -35.22 21.26 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.83 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -82.22 39.44 0.58 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.115 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.485 ' O ' HD12 ' A' ' 37' ' ' LEU . 7.5 p90 -60.68 -37.62 82.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.942 -179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -55.5 -32.68 63.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.915 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.509 ' O ' HG13 ' A' ' 62' ' ' VAL . 34.6 mtp85 -62.2 -37.72 86.39 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.879 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.615 ' HA ' HG22 ' A' ' 62' ' ' VAL . 93.5 t -49.08 104.12 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.087 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.405 ' OD1' ' CA ' ' A' ' 36' ' ' GLY . 0.9 OUTLIER -127.56 34.55 4.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.905 179.892 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 18.7 m -146.89 112.93 5.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.144 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.62 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.3 tp -112.18 107.14 15.93 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.902 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 146' ' ' GLU . . . . . 0.41 ' C ' HG13 ' A' ' 147' ' ' ILE . 2.0 pm0 -109.21 153.97 23.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.903 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.41 HG13 ' C ' ' A' ' 146' ' ' GLU . 20.2 mt -140.03 107.23 2.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.146 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -115.69 171.5 7.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.932 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 110.64 -146.72 17.5 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.502 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -114.6 93.44 4.33 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.801 0.334 . . . . 0.0 110.896 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 4.0 p -151.2 142.09 16.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.144 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 9.9 m -101.94 94.78 5.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.161 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.458 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 83.8 mt -77.33 138.1 39.15 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.89 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 16.6 m -122.35 -39.75 2.54 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.87 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 23.8 t80 -146.0 129.01 16.5 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.914 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 70.1 t -140.3 106.33 2.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.138 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 8.9 tt0 -120.8 132.89 55.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.928 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 14.1 mt . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.165 179.945 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.437 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.4 m . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.851 0.358 . . . . 0.0 111.129 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -137.48 125.54 22.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ASN . . . . . 0.501 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.2 t-20 52.15 50.69 8.59 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.583 0.706 . . . . 0.0 110.862 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.501 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.77 140.36 42.46 Favored 'Trans proline' 0 N--CA 1.465 -0.176 0 C-N-CA 122.678 2.252 . . . . 0.0 112.379 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 -178.4 2.3 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.709 2.273 . . . . 0.0 112.371 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.666 HG13 ' HA ' ' A' ' 28' ' ' PRO . 97.8 t -140.35 137.58 17.95 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.658 0.742 . . . . 0.0 111.085 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.666 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.8 Cg_endo -69.72 144.68 77.24 Favored 'Cis proline' 0 C--N 1.342 0.187 0 C-N-CA 122.658 -1.809 . . . . 0.0 112.338 -0.067 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 6.2 t80 -97.88 120.72 38.78 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.925 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -103.07 101.02 10.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.887 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -106.62 109.69 3.15 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.477 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.427 ' NH1' ' HA3' ' A' ' 63' ' ' GLY . 8.3 mmt180 -74.04 109.34 7.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.841 0.353 . . . . 0.0 110.876 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.639 HD23 HG12 ' A' ' 158' ' ' ILE . 6.9 mt -67.54 101.08 0.94 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.88 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 24.3 mt-30 -73.36 100.35 3.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.867 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 132.81 -40.18 1.64 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.498 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.785 ' O ' HG23 ' A' ' 38' ' ' THR . . . 89.84 161.45 37.48 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.466 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' LEU . . . . . 0.661 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 91.3 mt -55.42 99.07 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.891 0.376 . . . . 0.0 110.893 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.785 HG23 ' O ' ' A' ' 36' ' ' GLY . 26.9 p -117.94 145.95 44.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.167 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -41.7 -33.76 0.53 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.113 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 19.0 mmt180 -101.9 41.63 1.2 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.885 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.491 ' NE ' ' O ' ' A' ' 36' ' ' GLY . 29.7 ttm-85 -122.66 138.6 54.55 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 52.7 m -139.54 120.34 14.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.15 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.43 ' N ' HD12 ' A' ' 43' ' ' ILE . 4.8 mp -93.32 136.47 25.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.099 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 96.6 mt -128.46 137.0 58.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.125 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 55.0 mt -136.97 107.49 5.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.202 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 24.2 mtmt -110.64 108.69 18.69 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.877 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -139.84 -139.69 3.8 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.498 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -171.39 136.72 1.03 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.948 0.404 . . . . 0.0 110.913 -179.853 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.402 HG23 ' CD1' ' A' ' 109' ' ' PHE . 21.5 t -86.73 116.34 65.61 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.64 0.733 . . . . 0.0 111.121 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 158.97 55.13 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.687 2.258 . . . . 0.0 112.324 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 -14.88 36.6 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.642 2.228 . . . . 0.0 112.368 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 38.0 p -113.91 20.13 16.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.154 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -113.03 113.45 3.18 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.501 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 25.1 mtpt -58.89 -58.91 6.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.809 0.337 . . . . 0.0 110.89 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 40.5 p -174.22 162.45 3.68 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.862 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.604 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 6.0 p90 -119.37 -173.57 2.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.874 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.45 137.37 13.49 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.147 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.543 HG22 ' CE1' ' A' ' 60' ' ' PHE . 3.9 mp -114.24 104.26 16.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.11 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' ASN . . . . . 0.55 ' OD1' ' CD2' ' A' ' 71' ' ' HIS . 62.0 m-20 -98.48 141.4 31.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.875 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.567 ' CE2' HD13 ' A' ' 145' ' ' LEU . 5.6 m-85 -115.88 97.16 5.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.881 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.443 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 35.2 ttmt -96.02 168.37 10.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.874 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.671 HG22 ' HA ' ' A' ' 142' ' ' VAL . 49.0 t -99.78 124.33 53.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.086 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.427 ' HA3' ' NH1' ' A' ' 32' ' ' ARG . . . -62.25 -30.46 76.03 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.467 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.483 ' H ' HG12 ' A' ' 62' ' ' VAL . 9.7 t -71.24 -71.63 0.25 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.846 0.355 . . . . 0.0 110.821 -179.703 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 22.8 t -83.87 -70.98 0.53 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 132.14 42.82 0.17 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.501 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.555 ' OD1' ' ND2' ' A' ' 88' ' ' ASN . 0.8 OUTLIER -114.02 141.74 47.05 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.808 0.337 . . . . 0.0 110.88 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.448 HD12 ' HB3' ' A' ' 86' ' ' LEU . 80.7 mt -86.6 120.2 35.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.14 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.541 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -90.09 -37.57 14.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.076 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.775 HD21 HD11 ' A' ' 72' ' ' ILE . 21.8 tp -139.26 133.48 31.33 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.902 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.583 ' CD2' ' C ' ' A' ' 71' ' ' HIS . 2.4 t-160 -134.46 92.78 2.96 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.856 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.775 HD11 HD21 ' A' ' 70' ' ' LEU . 20.4 mt -93.52 135.66 27.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.126 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 5.1 t30 -140.91 107.13 6.31 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.626 0.727 . . . . 0.0 110.881 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.604 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.8 Cg_endo -69.77 154.73 67.33 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.669 2.246 . . . . 0.0 112.373 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 45.4 mtp85 -131.67 98.46 4.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.919 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.883 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 16.9 p . . . . . 0 N--CA 1.457 -0.113 0 CA-C-O 120.807 0.337 . . . . 0.0 111.194 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.579 HG22 ' HA ' ' A' ' 74' ' ' PRO . 20.3 t -84.07 109.03 17.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.116 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.706 HG22 ' HD3' ' A' ' 96' ' ' LYS . 57.5 t -78.1 146.09 8.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.117 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -129.81 129.66 44.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.834 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.518 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.5 m-80 -141.62 178.45 7.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.847 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 93.1 p -160.83 105.02 1.37 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.873 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.914 HD13 ' NE1' ' A' ' 91' ' ' TRP . 25.1 tp -77.77 118.79 20.46 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.899 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.521 ' N ' ' O ' ' A' ' 90' ' ' SER . 92.7 mt -95.88 162.22 13.67 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.905 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.555 ' ND2' ' OD1' ' A' ' 67' ' ' ASP . 9.6 m120 -40.76 101.87 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.878 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.03 -3.94 2.8 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.477 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.845 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -123.73 172.65 8.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.828 0.347 . . . . 0.0 110.885 -179.739 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.914 ' NE1' HD13 ' A' ' 86' ' ' LEU . 18.8 m95 -129.04 160.93 31.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.917 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -91.46 -106.65 1.47 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.52 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' SER . . . . . 0.441 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 3.5 m -163.06 174.83 11.75 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.787 0.327 . . . . 0.0 110.902 -179.759 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -99.53 121.74 41.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.844 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 25.0 mm-40 -120.97 109.55 15.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.895 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.706 ' HD3' HG22 ' A' ' 82' ' ' VAL . 39.6 mtmt -115.51 117.65 30.95 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.933 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 2.8 tppp? -168.59 107.1 0.47 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.887 179.848 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.79 HD11 ' O ' ' A' ' 100' ' ' HIS . 8.7 tt -144.39 146.1 20.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.139 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.4 t -83.72 -38.34 21.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.109 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' HIS . . . . . 0.79 ' O ' HD11 ' A' ' 98' ' ' ILE . 5.2 p-80 -153.71 134.27 13.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.847 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' ASN . . . . . 0.441 ' C ' ' OD1' ' A' ' 101' ' ' ASN . 27.1 t-20 -107.86 96.92 18.67 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.604 0.716 . . . . 0.0 110.879 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 101' ' ' ASN . 53.8 Cg_endo -69.72 -36.08 11.59 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.674 2.249 . . . . 0.0 112.36 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.483 ' CE2' ' HB3' ' A' ' 74' ' ' PRO . 5.7 m-85 -40.29 110.23 0.14 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.823 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -136.63 139.8 10.93 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.52 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 106.39 1.64 Allowed 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.694 2.263 . . . . 0.0 112.362 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 124.86 -11.47 7.82 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.51 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.9 pt20 -130.14 165.22 22.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.803 0.335 . . . . 0.0 110.925 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.3 p90 -87.48 169.26 12.37 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.889 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.48 ' CZ ' ' CZ ' ' A' ' 56' ' ' PHE . 30.0 p90 -153.63 124.75 7.41 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.898 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -94.34 103.38 15.38 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.843 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.859 HD13 ' N ' ' A' ' 112' ' ' SER . 0.5 OUTLIER -101.61 136.77 40.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.946 -179.965 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.859 ' N ' HD13 ' A' ' 111' ' ' LEU . 6.1 m -144.01 111.59 6.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.84 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.411 HG23 HG22 ' A' ' 122' ' ' VAL . 4.2 mp -93.53 141.72 14.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.103 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 114' ' ' ARG . . . . . 0.427 ' O ' ' CG ' ' A' ' 120' ' ' PHE . 19.6 mtp180 -112.52 142.07 45.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.917 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 115' ' ' CYS . . . . . 0.585 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 3.1 t -114.0 109.41 18.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.892 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -107.53 -138.76 8.86 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.515 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.5 mt -118.69 -40.56 2.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.811 0.339 . . . . 0.0 110.903 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' ASP . . . . . 0.427 ' OD1' ' N ' ' A' ' 119' ' ' ARG . 19.8 p-10 -87.73 -34.09 18.49 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.831 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.427 ' N ' ' OD1' ' A' ' 118' ' ' ASP . 10.6 ptp85 -172.57 176.07 3.33 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.922 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.661 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 3.7 m-30 -98.98 166.08 11.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.893 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 26.2 mtpt -137.73 105.92 5.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.916 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.63 HG13 HD11 ' A' ' 111' ' ' LEU . 42.8 t -90.84 132.52 35.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.096 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 53.9 m-85 -122.2 155.97 34.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.916 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.499 ' O ' ' ND2' ' A' ' 125' ' ' ASN . . . -141.15 118.96 11.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.104 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.499 ' ND2' ' O ' ' A' ' 124' ' ' ALA . 10.2 p30 50.87 30.75 5.42 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.894 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 82.88 30.96 30.46 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.475 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 33.3 mm-40 -135.6 139.51 43.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.797 0.332 . . . . 0.0 110.905 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 31.2 t-80 -67.7 112.54 4.86 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.857 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 8.3 tp -84.23 -66.97 0.83 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.894 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.4 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 12.1 p90 -168.63 170.76 9.27 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.906 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -114.01 149.11 35.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.806 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.603 ' CD1' HD13 ' A' ' 70' ' ' LEU . 0.4 OUTLIER -111.6 105.09 13.54 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.906 -179.931 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.487 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -60.45 137.15 58.19 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.105 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 31.3 m170 -66.35 110.41 3.07 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.861 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.441 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 71.6 mtt-85 -96.72 -46.6 6.22 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.859 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.4 tp -98.54 108.06 20.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.852 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 29.4 t -50.23 -33.64 20.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.858 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.453 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.79 29.28 0.46 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.083 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.416 ' CG ' ' N ' ' A' ' 140' ' ' GLN . 33.8 p90 -49.66 -44.35 47.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.869 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 140' ' ' GLN . . . . . 0.416 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 7.8 pt20 -47.81 -39.13 17.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.913 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.453 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 67.3 mtp180 -56.45 -40.83 75.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.85 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.671 ' HA ' HG22 ' A' ' 62' ' ' VAL . 58.7 t -45.68 101.82 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.11 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.492 ' OD2' ' N ' ' A' ' 36' ' ' GLY . 0.7 OUTLIER -127.04 34.28 4.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.851 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 24.6 m -147.02 115.55 6.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.148 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.567 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.1 tp -114.69 114.55 25.79 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.908 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 146' ' ' GLU . . . . . 0.428 ' C ' HG13 ' A' ' 147' ' ' ILE . 4.1 pt-20 -114.38 158.12 21.94 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.868 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.428 HG13 ' C ' ' A' ' 146' ' ' GLU . 30.7 mt -142.9 123.14 10.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.119 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -132.21 175.65 9.07 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.912 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 102.49 -151.64 18.24 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.475 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -103.66 92.5 4.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.87 0.367 . . . . 0.0 110.85 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.4 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 7.4 p -150.95 150.15 13.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.165 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 26.7 m -113.57 93.7 4.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.131 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.445 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 66.5 mt -75.5 138.27 41.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.925 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 36.7 m -122.43 -34.91 3.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.878 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 17.3 t80 -150.59 130.69 13.5 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.96 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 94.8 t -140.56 111.89 4.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.123 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 11.9 tt0 -134.05 129.21 35.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.944 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 158' ' ' ILE . . . . . 0.639 HG12 HD23 ' A' ' 33' ' ' LEU . 4.6 mp . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.17 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.512 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.6 m . . . . . 0 C--O 1.232 0.149 0 CA-C-O 120.861 0.363 . . . . 0.0 111.158 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.512 ' CD1' ' O ' ' A' ' 22' ' ' THR . 10.2 m-85 -150.06 132.53 15.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.924 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ASN . . . . . 0.565 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 22.1 m-80 50.74 46.58 3.83 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.607 0.718 . . . . 0.0 110.835 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.565 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.78 137.04 34.47 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.668 2.245 . . . . 0.0 112.378 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 179.88 3.38 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.674 2.249 . . . . 0.0 112.351 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.686 HG13 ' HA ' ' A' ' 28' ' ' PRO . 95.2 t -140.21 138.18 18.9 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.643 0.735 . . . . 0.0 111.11 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.686 ' HA ' HG13 ' A' ' 27' ' ' VAL . 54.1 Cg_endo -69.72 144.96 78.02 Favored 'Cis proline' 0 C--N 1.341 0.161 0 C-N-CA 122.658 -1.809 . . . . 0.0 112.353 -0.145 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 8.9 t80 -97.45 121.39 39.3 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.891 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 70.6 m-85 -108.02 101.65 10.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.86 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -116.33 104.61 1.27 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.487 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.401 ' HD2' ' C ' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -72.54 130.48 40.73 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.848 0.356 . . . . 0.0 110.9 -179.893 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.44 ' N ' ' O ' ' A' ' 143' ' ' ASP . 5.0 mt -74.2 147.47 42.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.905 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 55.8 mt-30 -107.81 89.59 3.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.903 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.78 -47.43 0.99 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.503 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.636 ' O ' HG22 ' A' ' 38' ' ' THR . . . 104.94 159.03 23.47 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.484 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' LEU . . . . . 0.506 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 79.3 mt -53.32 110.73 0.58 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.88 0.372 . . . . 0.0 110.934 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.707 HG23 ' HB2' ' A' ' 41' ' ' ARG . 0.0 OUTLIER -133.8 170.37 15.69 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.112 179.967 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.713 ' HB2' HD21 ' A' ' 117' ' ' LEU . . . -59.29 -41.93 90.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.085 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 6.5 mpt_? -94.5 51.07 1.4 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.862 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.722 ' NH1' HG22 ' A' ' 158' ' ' ILE . 20.4 ttm-85 -138.94 136.6 35.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 91.8 m -139.52 125.16 19.38 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.173 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.4 mp -96.31 138.79 20.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.152 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 90.5 mt -131.57 138.38 53.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.143 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 69.7 mt -135.42 107.56 7.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.152 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.409 ' HE3' ' CD1' ' A' ' 155' ' ' TYR . 8.7 mtmm -108.1 111.64 23.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 179.865 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -144.61 -144.92 4.25 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.495 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' TYR . . . . . 0.58 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 1.3 t80 -170.65 123.87 0.66 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.853 0.359 . . . . 0.0 110.957 -179.82 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 13.1 t -73.58 115.28 40.07 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.584 0.707 . . . . 0.0 111.152 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 155.48 65.86 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.663 2.242 . . . . 0.0 112.337 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.85 -13.58 34.64 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.679 2.253 . . . . 0.0 112.305 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 32.9 p -111.71 14.51 21.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.114 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -111.02 122.07 6.03 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.51 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.4 mtpt -63.71 -59.81 4.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.809 0.338 . . . . 0.0 110.93 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 14.4 p -172.8 158.33 3.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.826 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.588 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 17.9 p90 -113.76 -172.62 2.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.846 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.051 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -155.68 140.98 17.62 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.098 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.441 HG23 HG12 ' A' ' 147' ' ' ILE . 7.2 mt -127.17 101.18 7.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.122 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' ASN . . . . . 0.415 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 5.4 m-80 -103.14 154.05 19.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.907 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.624 ' CE2' HD13 ' A' ' 145' ' ' LEU . 6.1 m-85 -122.4 102.01 7.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.857 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.401 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 32.8 ttmt -95.68 168.2 10.82 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.864 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.713 HG22 ' HA ' ' A' ' 142' ' ' VAL . 83.2 t -100.06 120.55 49.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.127 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -57.54 -30.25 61.85 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.479 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.484 ' H ' HG12 ' A' ' 62' ' ' VAL . 2.1 m -72.84 -75.3 0.14 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.863 0.363 . . . . 0.0 110.882 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.3 t -79.33 -70.85 0.48 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.867 -179.837 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 131.18 40.51 0.23 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.486 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.543 ' OD1' ' ND2' ' A' ' 88' ' ' ASN . 0.5 OUTLIER -109.38 147.95 31.91 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.758 0.314 . . . . 0.0 110.854 -179.981 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.427 HD12 ' HB3' ' A' ' 86' ' ' LEU . 53.4 mt -94.35 113.7 29.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.153 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.634 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -86.02 -32.15 21.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.117 179.805 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.589 HD22 ' CD2' ' A' ' 132' ' ' PHE . 43.3 tp -138.83 131.09 28.4 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.487 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.8 OUTLIER -134.42 95.38 3.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.867 179.855 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.566 HD11 HD21 ' A' ' 70' ' ' LEU . 32.1 mt -100.05 131.53 47.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.133 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 1.051 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 8.8 t-20 -141.17 107.58 6.21 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.644 0.735 . . . . 0.0 110.874 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.588 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.9 Cg_endo -69.78 155.23 66.38 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.651 2.234 . . . . 0.0 112.333 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 80.0 mtp180 -132.15 100.01 4.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.87 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' MET . . . . . 0.453 ' HE3' ' HB3' ' A' ' 103' ' ' PHE . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.905 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 18.7 p . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.823 0.344 . . . . 0.0 111.135 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.497 HG21 ' HE2' ' A' ' 103' ' ' PHE . 18.4 t -94.39 109.72 22.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.184 179.859 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.593 HG22 ' HD3' ' A' ' 96' ' ' LYS . 41.5 t -81.88 145.25 8.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.137 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -126.45 123.92 38.96 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.888 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.487 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.7 OUTLIER -135.97 178.82 6.75 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.882 -179.935 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 50.7 p -160.07 106.29 1.58 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.855 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.904 HD13 ' NE1' ' A' ' 91' ' ' TRP . 24.4 tp -77.38 115.78 17.43 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.904 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.494 HD22 HD13 ' A' ' 136' ' ' LEU . 24.0 mt -91.55 161.09 15.09 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.886 179.902 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.543 ' ND2' ' OD1' ' A' ' 67' ' ' ASP . 11.4 m120 -41.58 101.56 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.913 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 67.43 -3.56 4.53 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.46 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.858 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -124.26 172.25 9.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.836 0.351 . . . . 0.0 110.851 -179.709 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.904 ' NE1' HD13 ' A' ' 86' ' ' LEU . 21.0 m95 -129.43 158.63 38.66 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.908 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -89.22 -106.59 1.12 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.445 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 3.7 m -163.6 176.29 9.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.791 0.329 . . . . 0.0 110.887 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.455 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 16.1 mt-10 -99.04 119.65 38.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.908 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -119.23 116.4 26.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.883 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.593 ' HD3' HG22 ' A' ' 82' ' ' VAL . 39.8 mtmt -121.89 119.28 31.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.902 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 27.7 tttp -167.26 108.03 0.62 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.889 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.554 HD11 ' O ' ' A' ' 100' ' ' HIS . 7.2 tt -149.4 147.21 16.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.165 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.543 HG23 ' N ' ' A' ' 100' ' ' HIS . 12.6 t -89.32 -47.47 8.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.134 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' HIS . . . . . 0.554 ' O ' HD11 ' A' ' 98' ' ' ILE . 4.2 p-80 -138.41 125.24 21.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.845 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -103.3 95.91 7.62 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.613 0.72 . . . . 0.0 110.898 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.82 -34.38 14.49 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.672 2.248 . . . . 0.0 112.303 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.497 ' HE2' HG21 ' A' ' 81' ' ' VAL . 19.0 m-85 -39.33 99.6 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.857 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -129.81 136.3 8.86 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.498 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 99.84 0.78 Allowed 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.658 2.239 . . . . 0.0 112.348 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 130.33 -8.38 5.95 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.48 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 -131.37 162.11 30.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.882 0.372 . . . . 0.0 110.896 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' PHE . . . . . 0.58 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 17.2 m-85 -80.27 172.1 14.2 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.858 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.483 ' O ' ' CD1' ' A' ' 109' ' ' PHE . 19.8 p90 -161.17 119.62 2.45 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.9 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -93.86 101.74 13.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.843 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.875 HD13 ' N ' ' A' ' 112' ' ' SER . 0.5 OUTLIER -101.2 136.75 40.53 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.909 -179.942 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.875 ' N ' HD13 ' A' ' 111' ' ' LEU . 10.4 m -141.6 112.88 7.5 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.882 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.608 HG22 ' HD2' ' A' ' 120' ' ' PHE . 4.1 mp -96.91 115.91 37.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.171 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 21.2 mtp85 -89.75 141.32 28.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.896 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 115' ' ' CYS . . . . . 0.573 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 13.6 t -113.41 115.25 27.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -111.76 -141.83 8.59 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.473 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.713 HD21 ' HB2' ' A' ' 39' ' ' ALA . 7.4 mt -115.2 -33.38 5.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.804 0.335 . . . . 0.0 110.922 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -89.53 -42.27 11.54 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.904 179.831 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -166.22 -176.34 3.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.893 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.608 ' HD2' HG22 ' A' ' 113' ' ' ILE . 12.0 m-85 -102.44 156.2 17.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.897 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 23.2 mtpt -130.1 105.92 8.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.865 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.715 HG13 HD11 ' A' ' 111' ' ' LEU . 46.8 t -91.3 131.73 37.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.109 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 79.5 m-85 -122.26 149.98 42.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.933 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.442 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -134.59 108.28 7.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.094 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 56.93 35.27 26.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.871 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.09 38.31 15.79 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.483 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 7.3 mt-30 -146.18 126.63 14.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.81 0.338 . . . . 0.0 110.924 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 -60.27 102.25 0.16 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.874 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.442 HD13 ' CB ' ' A' ' 124' ' ' ALA . 7.2 tp -70.19 -66.5 0.59 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.932 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.44 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 7.0 p90 -162.16 172.13 16.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.864 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 21.0 p-10 -118.1 145.79 44.6 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.847 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.589 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -112.92 107.02 15.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.833 -179.893 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.587 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -62.97 134.31 55.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.087 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 28.1 m170 -60.54 101.68 0.15 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.883 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 12.3 mtt-85 -88.11 -45.97 9.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.875 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' LEU . . . . . 0.494 HD13 HD22 ' A' ' 87' ' ' LEU . 10.0 tp -98.4 108.08 20.69 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.937 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 28.6 p -51.8 -31.23 26.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.858 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.651 ' HB1' ' HG3' ' A' ' 141' ' ' ARG . . . -82.71 29.08 0.46 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.08 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -49.59 -35.19 19.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.899 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 140' ' ' GLN . . . . . 0.443 ' HG2' ' N ' ' A' ' 141' ' ' ARG . 18.4 pm0 -60.17 -28.92 68.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.964 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.651 ' HG3' ' HB1' ' A' ' 138' ' ' ALA . 52.9 mtp85 -65.27 -38.86 91.57 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.887 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.713 ' HA ' HG22 ' A' ' 62' ' ' VAL . 52.4 t -55.15 108.97 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.113 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.44 ' O ' ' N ' ' A' ' 33' ' ' LEU . 3.4 p30 -129.52 27.91 5.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.839 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -135.82 135.57 39.95 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.174 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.624 HD13 ' CE2' ' A' ' 60' ' ' PHE . 7.5 tp -131.13 103.9 6.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.9 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 146' ' ' GLU . . . . . 0.428 ' C ' HG13 ' A' ' 147' ' ' ILE . 2.6 pt-20 -106.51 151.22 25.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.874 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.441 HG12 HG23 ' A' ' 58' ' ' ILE . 15.7 mt -140.17 109.57 3.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.116 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -120.41 170.93 8.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.916 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 109.85 -150.68 17.42 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.517 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -107.5 91.36 3.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.886 0.374 . . . . 0.0 110.902 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.447 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 3.3 p -150.91 137.62 12.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.123 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 24.7 m -96.96 93.65 6.74 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.119 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.481 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 61.3 mt -77.98 132.76 37.98 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.898 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 53.5 m -119.13 -40.86 2.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.894 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 155' ' ' TYR . . . . . 0.409 ' CD1' ' HE3' ' A' ' 46' ' ' LYS . 36.4 t80 -141.74 129.53 21.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.948 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 75.3 t -140.77 105.65 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.159 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 19.3 tt0 -120.26 132.03 55.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.92 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 158' ' ' ILE . . . . . 0.722 HG22 ' NH1' ' A' ' 41' ' ' ARG . 12.8 mt . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.161 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.55 ' CG2' ' N ' ' A' ' 23' ' ' PHE . 1.8 m . . . . . 0 N--CA 1.457 -0.11 0 CA-C-O 120.804 0.335 . . . . 0.0 111.126 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.55 ' N ' ' CG2' ' A' ' 22' ' ' THR . 14.3 m-85 -154.52 136.18 14.37 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ASN . . . . . 0.514 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 10.4 m-20 41.21 49.76 3.74 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.61 0.719 . . . . 0.0 110.858 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.514 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.8 Cg_endo -69.74 140.9 43.87 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.678 2.252 . . . . 0.0 112.341 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 178.4 4.61 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.663 2.242 . . . . 0.0 112.375 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.67 HG13 ' HA ' ' A' ' 28' ' ' PRO . 89.5 t -140.18 137.82 18.49 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.657 0.741 . . . . 0.0 111.123 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.67 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.4 Cg_endo -69.74 144.34 76.35 Favored 'Cis proline' 0 C--O 1.231 0.173 0 C-N-CA 122.7 -1.792 . . . . 0.0 112.345 -0.055 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 9.2 t80 -96.75 118.9 34.21 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.931 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 65.3 m-85 -104.8 101.12 10.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.888 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -112.83 102.05 1.26 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.456 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.419 ' O ' ' HG3' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -72.63 121.6 20.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.852 0.358 . . . . 0.0 110.923 -179.897 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.482 ' N ' ' O ' ' A' ' 143' ' ' ASP . 13.9 mt -65.71 149.62 49.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.914 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 9.4 mm100 -110.68 82.06 1.53 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.919 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.447 ' C ' ' OD2' ' A' ' 143' ' ' ASP . . . 140.49 -46.87 0.9 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.504 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.754 ' O ' HG23 ' A' ' 38' ' ' THR . . . 109.54 166.55 20.14 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.505 -179.882 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' LEU . . . . . 0.501 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 49.8 mt -57.3 105.16 0.21 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.96 0.41 . . . . 0.0 110.891 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.754 HG23 ' O ' ' A' ' 36' ' ' GLY . 2.1 p -116.76 151.81 35.67 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.148 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -58.07 -18.21 23.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.117 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 7.3 mpt_? -109.93 27.53 9.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.899 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.718 ' NH2' HD11 ' A' ' 43' ' ' ILE . 20.8 ttp85 -113.66 141.5 47.15 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.857 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 97.9 m -139.56 121.35 15.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.111 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.718 HD11 ' NH2' ' A' ' 41' ' ' ARG . 5.0 mp -90.95 143.64 10.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.125 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 89.3 mt -136.22 129.21 46.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.149 179.849 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 60.6 mt -130.05 107.74 15.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.152 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.506 ' HE3' ' CD1' ' A' ' 155' ' ' TYR . 18.5 mtmt -110.36 111.8 23.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.904 179.856 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -147.14 -145.54 4.21 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.505 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -166.81 126.14 1.47 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.884 0.374 . . . . 0.0 110.913 -179.815 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 24.6 t -74.82 117.02 59.3 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.643 0.735 . . . . 0.0 111.114 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 156.23 63.82 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.698 2.266 . . . . 0.0 112.331 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -15.44 37.1 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.657 2.238 . . . . 0.0 112.359 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 26.4 p -110.36 14.64 22.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.154 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -109.25 120.44 5.81 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.493 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 30.1 mtpt -61.65 -60.97 2.88 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.775 0.321 . . . . 0.0 110.914 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 9.2 p -174.19 156.51 2.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.823 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.616 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 11.1 p90 -111.0 -174.46 2.48 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.83 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.111 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -155.42 141.15 18.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.096 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.508 HD11 ' CE2' ' A' ' 56' ' ' PHE . 3.6 mp -121.24 100.08 8.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.136 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -102.56 148.08 25.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.887 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.924 ' CE2' HD13 ' A' ' 145' ' ' LEU . 34.7 m-85 -119.99 102.9 8.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.894 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.404 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 33.6 ttmt -95.62 166.95 11.59 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.91 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.741 HG22 ' HA ' ' A' ' 142' ' ' VAL . 91.4 t -98.2 125.54 51.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.166 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -61.26 -35.7 91.31 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.511 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.9 m -67.68 -73.27 0.14 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.896 0.379 . . . . 0.0 110.817 -179.708 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 32.3 t -80.37 -71.49 0.46 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.867 -179.794 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 130.7 41.69 0.22 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.464 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -112.58 146.37 38.69 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.782 0.325 . . . . 0.0 110.848 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.514 HD12 ' HB3' ' A' ' 86' ' ' LEU . 50.7 mt -91.65 121.23 41.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.135 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.505 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -91.3 -36.97 13.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.114 179.828 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.637 HD21 HD11 ' A' ' 72' ' ' ILE . 32.1 tp -134.87 130.4 35.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.919 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.487 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.3 OUTLIER -134.76 92.97 2.96 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.84 179.855 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.637 HD11 HD21 ' A' ' 70' ' ' LEU . 20.6 mt -96.69 134.08 35.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.17 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 1.111 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 10.1 t-20 -140.93 107.42 6.32 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.591 0.71 . . . . 0.0 110.885 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.616 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.6 Cg_endo -69.76 155.05 66.93 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.679 2.253 . . . . 0.0 112.337 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 66.4 mtp85 -129.24 99.31 5.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.876 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.893 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 32.9 p . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.799 0.333 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.447 ' CG1' ' CG2' ' A' ' 72' ' ' ILE . 20.6 t -106.42 106.03 19.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.126 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.619 HG22 ' HD3' ' A' ' 96' ' ' LYS . 39.2 t -76.38 134.29 29.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.133 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' ARG . . . . . 0.415 ' NH1' ' O ' ' A' ' 95' ' ' GLU . 0.0 OUTLIER -120.57 123.52 43.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.881 -179.955 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.487 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.2 OUTLIER -134.25 -179.11 5.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.898 -179.934 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 93.5 p -160.57 105.54 1.44 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.839 -179.871 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.942 HD12 ' O ' ' A' ' 90' ' ' SER . 26.1 tp -77.26 117.04 18.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.921 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.503 HD22 HD13 ' A' ' 136' ' ' LEU . 68.5 mt -93.97 160.9 14.52 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.887 179.897 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.448 ' C ' ' H ' ' A' ' 90' ' ' SER . 18.0 p-10 -38.72 101.35 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.87 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.93 -6.97 1.27 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.492 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.942 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -119.14 172.22 7.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.877 0.37 . . . . 0.0 110.832 -179.726 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.833 ' NE1' HD13 ' A' ' 86' ' ' LEU . 24.1 m95 -129.05 160.89 31.34 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.908 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -90.84 -93.94 1.26 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.513 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' SER . . . . . 0.408 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 2.4 m -174.49 169.46 3.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.841 0.353 . . . . 0.0 110.883 -179.727 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.411 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 27.3 mt-10 -100.84 118.4 36.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.895 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' GLU . . . . . 0.415 ' O ' ' NH1' ' A' ' 83' ' ' ARG . 5.3 mm-40 -123.19 134.81 54.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.881 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.619 ' HD3' HG22 ' A' ' 82' ' ' VAL . 40.9 mtmt -132.19 116.95 17.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.905 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 17.9 ttpp -164.48 110.4 1.01 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.934 179.862 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.688 HD11 ' O ' ' A' ' 100' ' ' HIS . 4.4 tt -148.72 153.04 11.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.134 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.554 HG23 ' N ' ' A' ' 100' ' ' HIS . 9.0 t -89.64 -48.52 7.23 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.118 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 100' ' ' HIS . . . . . 0.688 ' O ' HD11 ' A' ' 98' ' ' ILE . 6.1 p-80 -141.24 125.41 17.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.858 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -104.46 96.83 10.79 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.633 0.73 . . . . 0.0 110.882 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 -30.46 22.07 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.725 2.283 . . . . 0.0 112.303 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.444 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 21.8 m-85 -43.94 104.64 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.887 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -132.65 135.86 8.38 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.489 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 97.79 0.66 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.69 2.26 . . . . 0.0 112.322 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 129.94 -3.67 6.03 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.524 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.2 pm0 -135.9 155.92 49.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.839 0.352 . . . . 0.0 110.908 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -77.85 171.16 15.4 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.887 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 29.8 p90 -160.03 133.21 6.81 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.897 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -103.1 103.79 13.89 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.874 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.886 HD13 ' N ' ' A' ' 112' ' ' SER . 0.6 OUTLIER -104.3 137.7 41.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.887 -179.919 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.886 ' N ' HD13 ' A' ' 111' ' ' LEU . 3.6 m -145.16 111.87 5.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.842 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.589 HG23 HG22 ' A' ' 122' ' ' VAL . 4.0 mp -92.99 140.38 16.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.165 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 18.9 mtp180 -113.24 137.67 51.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.86 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 115' ' ' CYS . . . . . 0.568 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 3.4 t -108.87 117.29 33.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -119.35 -140.97 6.35 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.464 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.5 mt -118.66 -36.09 3.56 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.844 0.354 . . . . 0.0 110.916 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 17.4 m-20 -87.2 -38.39 16.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.862 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 16.2 ptp180 -175.31 169.28 3.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.838 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.568 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.6 m-30 -92.02 147.71 22.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 24.9 mtpp -120.75 102.19 8.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.921 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.616 HG13 HD11 ' A' ' 111' ' ' LEU . 55.7 t -88.82 132.22 34.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.106 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 62.3 m-85 -118.9 156.66 29.13 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.947 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.416 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -142.21 109.45 5.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.097 179.834 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 56.3 28.78 13.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.888 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 85.67 30.52 23.8 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.466 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 127' ' ' GLN . . . . . 0.422 ' HB2' ' CE1' ' A' ' 100' ' ' HIS . 56.1 mm-40 -137.91 121.51 17.36 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.791 0.329 . . . . 0.0 110.949 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 29.1 t-80 -50.69 105.14 0.09 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.849 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.439 HD22 ' CD2' ' A' ' 111' ' ' LEU . 10.8 tp -72.84 -69.1 0.43 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.547 ' HZ ' HD13 ' A' ' 72' ' ' ILE . 4.2 p90 -165.62 170.76 13.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.874 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 61.9 m-20 -114.96 148.76 38.32 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.876 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.574 ' CE1' ' O ' ' A' ' 133' ' ' ALA . 0.1 OUTLIER -115.01 107.88 15.95 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.88 -179.868 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.574 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -64.0 131.1 46.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.117 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 46.2 m-70 -56.62 100.58 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.847 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.408 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 17.6 mtt-85 -83.9 -51.45 7.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.865 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 136' ' ' LEU . . . . . 0.503 HD13 HD22 ' A' ' 87' ' ' LEU . 14.2 tp -93.27 108.01 19.72 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.908 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 4.3 p -51.4 -30.26 18.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.829 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.579 ' HB1' ' HG3' ' A' ' 141' ' ' ARG . . . -87.28 24.23 1.66 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.114 179.9 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.5 ' O ' HD12 ' A' ' 37' ' ' LEU . 26.8 p90 -43.58 -44.67 6.31 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.911 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 140' ' ' GLN . . . . . 0.426 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 5.3 pt20 -44.7 -42.23 7.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.905 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.579 ' HG3' ' HB1' ' A' ' 138' ' ' ALA . 21.5 mtt180 -52.07 -42.4 63.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.895 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.741 ' HA ' HG22 ' A' ' 62' ' ' VAL . 99.4 t -46.96 108.89 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.12 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.482 ' O ' ' N ' ' A' ' 33' ' ' LEU . 1.0 OUTLIER -129.8 20.43 5.52 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.902 179.903 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 2.1 m -133.06 138.1 46.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.141 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.924 HD13 ' CE2' ' A' ' 60' ' ' PHE . 7.2 tp -132.41 116.08 16.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.949 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -118.59 151.8 37.23 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.838 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.457 HG12 HG23 ' A' ' 58' ' ' ILE . 24.8 mt -138.66 110.34 5.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.08 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -120.17 171.99 8.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.888 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 111.28 -147.51 17.86 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.544 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -112.96 92.72 4.11 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.851 0.357 . . . . 0.0 110.858 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 4.3 p -151.02 141.9 16.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.145 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 17.1 m -101.31 92.91 5.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.175 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.459 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 80.5 mt -76.03 139.85 41.66 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.913 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 58.1 m -125.01 -33.76 2.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.836 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 155' ' ' TYR . . . . . 0.506 ' CD1' ' HE3' ' A' ' 46' ' ' LYS . 36.3 t80 -150.46 130.97 13.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.917 -179.855 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 56.0 t -138.92 105.41 2.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.149 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 157' ' ' GLN . . . . . 0.412 ' HB2' ' CE1' ' A' ' 155' ' ' TYR . 13.2 tt0 -114.17 120.67 41.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.92 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 158' ' ' ILE . . . . . 0.547 HG23 ' NH1' ' A' ' 41' ' ' ARG . 83.1 mt . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.159 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.485 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.5 m . . . . . 0 C--O 1.232 0.151 0 CA-C-O 120.778 0.323 . . . . 0.0 111.174 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.485 ' CD1' ' O ' ' A' ' 22' ' ' THR . 9.3 m-85 -149.83 135.68 18.6 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.896 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ASN . . . . . 0.558 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 4.1 t-20 46.1 47.25 3.95 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.625 0.726 . . . . 0.0 110.886 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.558 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.5 Cg_endo -69.78 138.69 38.35 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.669 2.246 . . . . 0.0 112.332 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -174.65 0.95 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.664 2.243 . . . . 0.0 112.344 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.684 HG13 ' HA ' ' A' ' 28' ' ' PRO . 93.5 t -142.45 138.25 16.24 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.62 0.724 . . . . 0.0 111.102 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.684 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.79 144.76 77.63 Favored 'Cis proline' 0 C--N 1.342 0.197 0 C-N-CA 122.642 -1.816 . . . . 0.0 112.354 -0.078 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -97.55 120.69 38.38 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.918 -179.886 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 86.3 m-85 -102.42 104.94 15.44 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.901 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -104.24 107.52 2.97 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.463 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 6.6 mmt180 -73.71 115.86 13.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.833 0.349 . . . . 0.0 110.903 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.485 HD22 ' NH1' ' A' ' 41' ' ' ARG . 5.0 mt -82.0 111.51 18.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.902 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 37.6 mt-30 -78.71 97.14 5.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.88 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 131.1 -51.22 0.86 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.515 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.529 ' O ' HG23 ' A' ' 38' ' ' THR . . . 107.96 168.39 21.51 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.496 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' LEU . . . . . 0.596 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 68.4 mt -55.1 110.88 0.74 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.886 0.374 . . . . 0.0 110.902 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.529 HG23 ' O ' ' A' ' 36' ' ' GLY . 81.6 p -128.69 146.37 50.9 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.181 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -51.67 -18.33 1.16 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.085 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 2.8 mpt_? -107.73 30.53 6.23 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.868 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.486 ' HE ' HD23 ' A' ' 37' ' ' LEU . 6.9 ttp85 -115.85 142.2 47.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.904 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 29.5 m -138.64 120.72 15.66 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.151 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.456 HD11 ' NH2' ' A' ' 41' ' ' ARG . 5.3 mp -94.39 134.21 32.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.135 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 76.7 mt -129.8 119.59 47.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.098 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 31.6 mt -119.11 107.36 21.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.159 179.822 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.43 ' HE3' ' CD1' ' A' ' 155' ' ' TYR . 16.5 mtmt -108.89 110.18 21.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.9 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -144.86 -147.94 4.74 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.473 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' TYR . . . . . 0.571 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.7 OUTLIER -163.57 127.88 2.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.934 0.397 . . . . 0.0 110.955 -179.789 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.411 HG23 ' CD2' ' A' ' 109' ' ' PHE . 13.4 t -77.6 117.38 65.21 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 121.585 0.707 . . . . 0.0 111.14 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 154.91 67.1 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.7 2.266 . . . . 0.0 112.348 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -13.92 35.36 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.648 2.232 . . . . 0.0 112.353 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 70.6 p -112.64 16.78 19.58 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.163 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -110.09 123.24 6.63 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.497 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.402 ' O ' ' SD ' ' A' ' 76' ' ' MET . 19.2 mtpt -64.75 -61.72 2.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.801 0.334 . . . . 0.0 110.896 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 14.8 p -172.97 156.57 3.35 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.849 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.599 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 20.4 p90 -111.05 -174.57 2.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.874 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.732 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -156.82 135.37 11.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.126 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.484 HG22 ' CE1' ' A' ' 60' ' ' PHE . 5.3 mp -117.59 98.16 6.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.114 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -96.85 143.72 27.48 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.894 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.711 ' CE2' HD13 ' A' ' 145' ' ' LEU . 47.0 m-85 -115.24 97.62 6.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.906 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.433 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 31.3 ttmt -96.08 168.94 10.31 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.894 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.6 HG22 ' HA ' ' A' ' 142' ' ' VAL . 23.4 t -100.27 123.7 53.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.094 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -59.64 -29.17 66.46 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.506 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.52 ' H ' HG12 ' A' ' 62' ' ' VAL . 11.5 t -75.18 -73.71 0.24 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.849 0.357 . . . . 0.0 110.854 -179.729 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 5.3 t -77.53 -71.47 0.41 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.811 -179.767 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 128.65 39.7 0.32 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.492 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.44 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.1 m-20 -112.81 139.15 48.67 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.801 0.334 . . . . 0.0 110.879 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.613 HD12 ' HB3' ' A' ' 86' ' ' LEU . 60.3 mt -84.7 120.65 35.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.145 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.451 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -90.16 -30.66 17.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.129 179.795 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.698 HD22 ' CD2' ' A' ' 132' ' ' PHE . 41.3 tp -143.11 132.34 23.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.921 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.494 ' N ' ' O ' ' A' ' 84' ' ' ASN . 3.9 t-160 -134.93 92.61 2.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.919 179.838 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.524 HD11 HD21 ' A' ' 70' ' ' LEU . 53.2 mt -94.85 132.7 38.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.107 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.732 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 9.6 t-20 -139.12 105.66 7.29 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.661 0.743 . . . . 0.0 110.908 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.599 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.7 Cg_endo -69.74 154.84 67.34 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.72 2.28 . . . . 0.0 112.372 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 73.9 mtp85 -129.27 94.26 3.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.865 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' MET . . . . . 0.402 ' SD ' ' O ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.887 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 21.1 p . . . . . 0 N--CA 1.456 -0.132 0 CA-C-O 120.845 0.355 . . . . 0.0 111.161 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.418 HG22 ' HA ' ' A' ' 74' ' ' PRO . 21.4 t -102.79 107.29 21.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.128 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.542 HG22 ' HD3' ' A' ' 96' ' ' LYS . 99.9 t -76.15 144.36 11.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.087 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -126.19 124.65 40.94 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.887 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.494 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.6 OUTLIER -135.71 178.56 6.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.951 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 19.1 t -160.38 105.05 1.46 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 -179.837 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.916 HD12 ' O ' ' A' ' 90' ' ' SER . 25.4 tp -76.97 118.01 19.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.935 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.513 ' N ' ' O ' ' A' ' 90' ' ' SER . 69.9 mt -95.62 161.6 13.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.884 179.92 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.461 ' C ' ' H ' ' A' ' 90' ' ' SER . 17.2 p-10 -38.34 101.42 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.907 179.849 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.79 -6.58 0.87 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.441 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.916 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -118.42 170.57 8.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.874 0.369 . . . . 0.0 110.832 -179.727 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.857 ' NE1' HD13 ' A' ' 86' ' ' LEU . 23.7 m95 -128.82 161.05 30.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.929 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.31 -106.45 1.61 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.471 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 67.5 m -164.09 176.05 9.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.809 0.338 . . . . 0.0 110.915 -179.754 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -98.63 123.11 42.63 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.909 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 7.6 mm-40 -122.54 118.11 27.48 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.854 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.542 ' HD3' HG22 ' A' ' 82' ' ' VAL . 9.5 mtmp? -121.23 123.05 41.28 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.903 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 15.0 tptm -172.76 105.04 0.15 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.889 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.665 HD11 ' O ' ' A' ' 100' ' ' HIS . 7.5 tt -147.66 151.32 13.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.152 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.585 HG23 ' N ' ' A' ' 100' ' ' HIS . 8.8 t -86.49 -50.54 6.79 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.149 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' HIS . . . . . 0.665 ' O ' HD11 ' A' ' 98' ' ' ILE . 5.3 p-80 -141.75 135.67 29.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.843 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' ASN . . . . . 0.407 ' OD1' ' C ' ' A' ' 101' ' ' ASN . 6.9 t-20 -104.73 95.97 9.72 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.647 0.737 . . . . 0.0 110.918 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.464 ' HG3' ' HB1' ' A' ' 124' ' ' ALA . 53.8 Cg_endo -69.74 -31.18 21.12 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.692 2.261 . . . . 0.0 112.39 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.515 ' CZ ' HD21 ' A' ' 129' ' ' LEU . 6.7 m-85 -47.12 113.93 0.76 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.874 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -140.59 138.11 8.75 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.489 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.73 102.69 1.05 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.653 2.235 . . . . 0.0 112.336 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 122.86 -6.49 9.56 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.488 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -130.67 147.11 52.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.857 0.361 . . . . 0.0 110.855 -179.864 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 108' ' ' PHE . . . . . 0.571 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 54.5 m-85 -66.5 172.03 4.46 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.888 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.411 ' CD2' HG23 ' A' ' 49' ' ' VAL . 22.5 p90 -160.65 128.38 4.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.856 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -103.45 105.39 15.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.813 HD13 ' N ' ' A' ' 112' ' ' SER . 0.9 OUTLIER -107.32 137.97 44.38 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.946 -179.962 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.813 ' N ' HD13 ' A' ' 111' ' ' LEU . 2.9 m -145.09 112.93 6.35 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.87 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.2 mp -94.29 134.64 31.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.113 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 57.1 mtt180 -109.14 123.19 48.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.853 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 115' ' ' CYS . . . . . 0.577 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 33.8 t -90.53 123.22 34.02 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -124.72 -153.76 8.65 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.501 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 7.8 mt -109.81 -37.96 5.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.804 0.335 . . . . 0.0 110.913 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -86.1 -37.73 18.52 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.853 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 22.8 ptt180 -174.75 168.56 3.64 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.894 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.596 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 2.9 m-30 -91.81 153.28 19.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.913 -179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 18.9 mtmt -127.29 106.41 9.21 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.897 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.668 HG13 HD11 ' A' ' 111' ' ' LEU . 45.9 t -90.41 137.69 21.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.166 179.844 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 123' ' ' TYR . . . . . 0.421 ' O ' HD22 ' A' ' 111' ' ' LEU . 40.4 m-85 -121.37 147.28 45.91 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.913 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.545 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -137.68 105.52 5.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.126 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.4 m120 62.09 34.08 16.63 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.84 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.403 ' C ' ' HG2' ' A' ' 127' ' ' GLN . . . 79.62 38.94 19.23 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.467 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 127' ' ' GLN . . . . . 0.403 ' HG2' ' C ' ' A' ' 126' ' ' GLY . 15.4 mm-40 -148.32 132.25 17.14 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.807 0.337 . . . . 0.0 110.892 -179.865 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 26.9 t-80 -61.58 101.05 0.16 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.828 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.545 HD13 ' CB ' ' A' ' 124' ' ' ALA . 9.8 tp -66.31 -69.85 0.28 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.877 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.434 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 7.3 p90 -161.87 174.66 12.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.874 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -114.96 150.73 35.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.868 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.698 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -117.53 104.62 11.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.896 -179.912 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.581 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -59.91 134.68 57.27 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.106 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 63.1 m-70 -61.99 112.89 2.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.889 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 83.1 mtt-85 -96.36 -52.48 3.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.834 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 9.4 tp -93.57 108.22 19.96 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.921 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 94.3 p -50.69 -32.25 18.81 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.896 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.465 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -83.79 23.56 0.98 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.135 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.525 ' O ' HD12 ' A' ' 37' ' ' LEU . 14.2 p90 -47.06 -38.99 12.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.883 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 10.0 pt20 -53.52 -34.01 56.62 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.938 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.465 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 51.9 mtp85 -63.47 -37.69 88.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.849 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.6 ' HA ' HG22 ' A' ' 62' ' ' VAL . 92.7 t -46.9 109.36 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.156 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -132.3 31.39 4.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.86 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 8.6 m -141.45 111.98 7.02 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.118 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.711 HD13 ' CE2' ' A' ' 60' ' ' PHE . 3.9 tp -110.51 109.79 20.27 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.945 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 146' ' ' GLU . . . . . 0.428 ' C ' HG13 ' A' ' 147' ' ' ILE . 3.3 pt-20 -112.8 153.81 27.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.843 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.428 HG13 ' C ' ' A' ' 146' ' ' GLU . 20.2 mt -140.72 110.63 3.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.096 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -119.6 174.37 6.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.943 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.17 -142.87 16.03 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.533 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -116.54 94.0 4.44 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.837 0.351 . . . . 0.0 110.913 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.6 p -151.08 151.15 12.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.173 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 10.4 m -110.98 94.5 5.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.13 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.47 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 37.6 mt -77.7 137.84 38.72 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.888 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 3.3 t -122.2 -37.43 2.82 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.869 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 155' ' ' TYR . . . . . 0.43 ' CD1' ' HE3' ' A' ' 46' ' ' LYS . 19.4 t80 -149.75 130.6 14.21 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.921 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 98.8 t -140.61 105.18 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.096 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 10.9 tt0 -112.13 145.3 40.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.89 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 158' ' ' ILE . . . . . 0.418 HG23 ' NH1' ' A' ' 41' ' ' ARG . 30.1 mt . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.109 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.418 HG22 ' H ' ' A' ' 156' ' ' VAL . 7.6 t . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.803 0.335 . . . . 0.0 111.187 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.4 ' CD1' ' O ' ' A' ' 22' ' ' THR . 7.0 m-85 -142.07 117.28 10.1 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.908 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ASN . . . . . 0.516 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 9.0 m120 66.92 49.97 0.56 Allowed Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.633 0.73 . . . . 0.0 110.927 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.516 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.7 Cg_endo -69.73 131.35 21.09 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.662 2.241 . . . . 0.0 112.335 179.919 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 -174.03 0.84 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.643 2.229 . . . . 0.0 112.319 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.696 HG13 ' HA ' ' A' ' 28' ' ' PRO . 97.5 t -144.03 138.33 14.91 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.593 0.711 . . . . 0.0 111.129 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.696 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.78 144.72 77.48 Favored 'Cis proline' 0 C--O 1.232 0.177 0 C-N-CA 122.73 -1.779 . . . . 0.0 112.321 -0.025 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.6 t80 -98.04 119.12 36.11 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.942 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 75.7 m-85 -105.66 108.26 19.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.844 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -119.89 103.39 0.95 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.454 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.4 ' HG3' ' O ' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -73.45 128.28 35.05 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.813 0.34 . . . . 0.0 110.899 -179.886 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.551 HD23 HD13 ' A' ' 158' ' ' ILE . 6.1 mt -73.07 151.83 41.51 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.902 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 20.0 mt-30 -88.29 -63.36 1.31 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.934 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.527 ' O ' HG23 ' A' ' 38' ' ' THR . . . -96.94 43.56 2.02 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.54 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.483 ' N ' ' OD2' ' A' ' 143' ' ' ASP . . . 34.39 -152.68 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.499 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' LEU . . . . . 0.505 HD12 ' O ' ' A' ' 139' ' ' PHE . 52.4 mt -87.64 113.16 23.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.854 0.359 . . . . 0.0 110.934 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.527 HG23 ' O ' ' A' ' 35' ' ' GLY . 24.7 p -121.01 153.16 37.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.113 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -59.75 -25.77 65.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.12 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 13.2 mmt180 -105.43 35.62 2.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.869 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.445 ' HB2' ' NH1' ' A' ' 41' ' ' ARG . 9.4 ttm105 -125.02 140.78 52.6 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.915 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 90.7 m -139.68 121.7 15.67 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.14 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 mp -90.99 134.25 30.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.128 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 77.6 mt -123.45 133.41 69.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.139 179.817 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 75.0 mt -131.41 107.8 13.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.153 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.1 mtmt -109.31 107.74 18.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.9 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.26 -146.25 4.79 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.536 179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' TYR . . . . . 0.57 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.7 OUTLIER -167.91 129.29 1.44 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.904 0.383 . . . . 0.0 110.934 -179.798 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 11.8 t -77.88 116.74 60.96 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.6 0.714 . . . . 0.0 111.14 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 158.52 56.63 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.627 2.218 . . . . 0.0 112.346 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -14.54 36.26 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.654 2.236 . . . . 0.0 112.394 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 66.7 p -113.16 19.22 17.33 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.151 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -113.37 118.34 4.49 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.419 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 15.7 mtpp -62.96 -58.85 5.95 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.755 0.312 . . . . 0.0 110.877 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 25.3 p -173.04 159.73 4.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.877 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.598 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 10.9 p90 -114.84 -173.19 2.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.873 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.104 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -156.65 141.79 17.28 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.067 179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.431 HG22 ' CE1' ' A' ' 60' ' ' PHE . 9.1 mt -127.59 98.38 4.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.12 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' ASN . . . . . 0.471 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 2.2 m-80 -100.47 150.48 22.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.917 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.504 ' CE2' HD13 ' A' ' 145' ' ' LEU . 4.3 m-85 -118.1 101.17 8.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.912 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.415 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 28.3 ttmt -95.58 169.85 9.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.901 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.704 HG22 ' HA ' ' A' ' 142' ' ' VAL . 67.8 t -101.17 124.14 54.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.105 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -59.08 -39.87 94.89 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.507 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 15.0 m -66.19 -73.5 0.13 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.837 0.351 . . . . 0.0 110.858 -179.745 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 68.5 m -76.72 -75.38 0.2 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.833 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 133.31 35.13 0.3 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.475 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.42 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.4 m-20 -106.61 143.94 34.0 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.823 0.344 . . . . 0.0 110.861 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.56 HD12 ' HB3' ' A' ' 86' ' ' LEU . 58.7 mt -88.24 122.56 39.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.154 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.72 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -92.8 -33.33 14.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.114 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.575 HD21 HD11 ' A' ' 72' ' ' ILE . 42.4 tp -139.15 131.61 28.62 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.913 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.5 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.0 OUTLIER -134.66 92.95 2.97 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.838 179.863 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.575 HD11 HD21 ' A' ' 70' ' ' LEU . 40.3 mt -98.64 130.96 46.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.152 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 1.104 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 11.9 t-20 -140.67 107.74 6.5 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.64 0.733 . . . . 0.0 110.914 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.598 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.4 Cg_endo -69.74 155.13 66.82 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.704 2.269 . . . . 0.0 112.349 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 71.3 mtp180 -130.61 96.36 4.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.858 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' MET . . . . . 0.483 ' HE3' ' HB3' ' A' ' 103' ' ' PHE . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.901 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 7.6 p . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.788 0.327 . . . . 0.0 111.128 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.9 t -100.61 112.83 34.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.153 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.703 HG22 ' HD3' ' A' ' 96' ' ' LYS . 61.5 t -80.67 142.31 14.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.172 179.922 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -122.4 124.09 42.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.862 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.5 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.1 m120 -138.49 176.56 8.59 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.839 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 45.2 t -160.35 105.08 1.47 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.866 -179.854 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.915 HD12 ' O ' ' A' ' 90' ' ' SER . 24.8 tp -77.55 119.02 20.54 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.951 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.513 ' N ' ' O ' ' A' ' 90' ' ' SER . 76.0 mt -95.88 161.35 14.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.916 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.465 ' C ' ' H ' ' A' ' 90' ' ' SER . 15.6 p-10 -38.89 101.43 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.902 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.98 -5.83 1.14 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.493 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.915 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -120.0 171.36 8.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.827 0.346 . . . . 0.0 110.866 -179.763 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.866 ' NE1' HD13 ' A' ' 86' ' ' LEU . 23.8 m95 -129.12 159.82 34.81 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.925 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -93.31 -114.71 2.36 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.53 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' SER . . . . . 0.449 ' HB2' ' CZ ' ' A' ' 135' ' ' ARG . 3.6 m -151.96 169.36 22.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.825 0.345 . . . . 0.0 110.878 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.421 ' HG2' ' ND2' ' A' ' 84' ' ' ASN . 7.0 mt-10 -97.7 121.75 39.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.937 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -117.33 116.26 26.87 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.845 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.703 ' HD3' HG22 ' A' ' 82' ' ' VAL . 38.2 mtmt -122.32 117.21 25.54 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.896 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -169.37 108.96 0.44 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.896 179.843 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.784 HD11 ' O ' ' A' ' 100' ' ' HIS . 3.5 tt -145.4 153.79 13.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.073 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.431 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 8.7 t -97.44 -38.74 9.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.169 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 100' ' ' HIS . . . . . 0.784 ' O ' HD11 ' A' ' 98' ' ' ILE . 3.3 p-80 -146.67 125.07 12.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.862 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' ASN . . . . . 0.403 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 31.0 t-20 -102.56 96.82 7.93 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.633 0.73 . . . . 0.0 110.864 -179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.436 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.7 Cg_endo -69.83 -40.55 5.09 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.631 2.22 . . . . 0.0 112.357 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.483 ' HB3' ' HE3' ' A' ' 76' ' ' MET . 32.0 m-85 -35.7 106.74 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.883 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -134.53 136.66 8.72 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.506 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 100.11 0.8 Allowed 'Trans proline' 0 C--N 1.34 0.124 0 C-N-CA 122.672 2.248 . . . . 0.0 112.299 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 124.9 -6.58 8.31 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.466 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 9.2 pt20 -131.01 147.29 52.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.852 0.358 . . . . 0.0 110.886 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' PHE . . . . . 0.57 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 66.0 m-85 -64.24 172.16 2.63 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.889 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.461 ' CG ' ' O ' ' A' ' 109' ' ' PHE . 21.8 p90 -160.73 117.97 2.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.882 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -93.64 106.8 18.74 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.848 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.842 HD13 ' N ' ' A' ' 112' ' ' SER . 0.5 OUTLIER -108.64 138.68 44.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.921 -179.961 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.842 ' N ' HD13 ' A' ' 111' ' ' LEU . 5.4 m -145.36 113.42 6.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.829 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.541 HG22 ' HD2' ' A' ' 120' ' ' PHE . 4.5 mp -93.66 137.5 22.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.125 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 114' ' ' ARG . . . . . 0.596 ' O ' ' CD2' ' A' ' 120' ' ' PHE . 16.9 mtp180 -109.88 135.05 51.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.87 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 115' ' ' CYS . . . . . 0.543 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 20.7 t -103.74 116.19 31.87 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.903 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -115.34 -149.2 9.54 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.504 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.6 mt -111.83 -39.04 4.67 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.794 0.331 . . . . 0.0 110.899 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -89.41 -35.45 16.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.86 179.833 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 13.4 ptt180 -171.3 175.04 4.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 -179.901 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.596 ' CD2' ' O ' ' A' ' 114' ' ' ARG . 9.2 m-85 -98.9 162.51 13.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.887 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 36.6 mtpt -133.37 104.46 6.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.911 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.679 HG13 HD11 ' A' ' 111' ' ' LEU . 41.5 t -91.04 125.02 43.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.105 179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 48.6 m-85 -115.52 146.32 41.82 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.885 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.505 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -131.57 108.62 9.67 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.061 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 58.62 35.54 24.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.835 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.46 40.61 22.79 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.487 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 13.9 mt-30 -146.39 130.22 17.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.83 0.348 . . . . 0.0 110.922 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 33.2 t-80 -60.08 99.47 0.07 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.849 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.505 HD13 ' CB ' ' A' ' 124' ' ' ALA . 8.7 tp -70.17 -69.64 0.34 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.946 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.539 ' HZ ' HD13 ' A' ' 72' ' ' ILE . 5.4 p90 -163.44 169.63 18.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.879 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -113.66 151.08 32.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.872 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.55 ' CG ' HD13 ' A' ' 70' ' ' LEU . 0.2 OUTLIER -115.7 105.83 13.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.89 -179.942 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.533 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -61.71 134.01 56.25 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.132 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 29.9 m170 -62.64 94.53 0.06 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.827 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.449 ' CZ ' ' HB2' ' A' ' 93' ' ' SER . 61.3 mtt-85 -78.78 -41.48 30.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.87 -179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 12.3 tp -100.55 108.32 20.22 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.884 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 59.8 p -51.86 -30.78 25.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.887 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.535 ' HB1' ' HD2' ' A' ' 141' ' ' ARG . . . -89.72 30.61 1.02 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.078 179.915 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.587 ' CE1' ' HG3' ' A' ' 140' ' ' GLN . 2.9 p90 -41.39 -40.14 1.64 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.91 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 140' ' ' GLN . . . . . 0.587 ' HG3' ' CE1' ' A' ' 139' ' ' PHE . 0.0 OUTLIER -48.05 -52.52 19.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.943 -179.952 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.659 ' O ' HG13 ' A' ' 62' ' ' VAL . 47.9 mtt180 -42.4 -39.41 2.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.89 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.72 HG21 ' CB ' ' A' ' 69' ' ' ALA . 66.6 t -52.7 105.12 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.17 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.483 ' OD2' ' N ' ' A' ' 36' ' ' GLY . 0.9 OUTLIER -130.27 31.08 4.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.877 179.93 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -140.43 129.84 23.94 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.149 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.504 HD13 ' CE2' ' A' ' 60' ' ' PHE . 6.0 tp -125.59 108.91 12.04 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.869 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 146' ' ' GLU . . . . . 0.424 ' C ' HG13 ' A' ' 147' ' ' ILE . 3.0 pt-20 -111.12 148.85 31.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.907 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.424 HG13 ' C ' ' A' ' 146' ' ' GLU . 8.8 mt -138.69 105.32 2.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.138 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -117.87 176.69 5.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.907 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.96 -145.94 16.57 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.477 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -114.6 91.63 3.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.868 0.366 . . . . 0.0 110.896 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 4.7 p -150.76 151.21 12.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.109 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 28.7 m -109.67 93.17 4.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.134 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.485 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 66.8 mt -76.52 138.34 40.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.957 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 74.0 m -122.82 -37.97 2.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.85 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 26.9 t80 -145.96 129.42 16.9 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.922 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.418 ' H ' HG22 ' A' ' 22' ' ' THR . 55.0 t -140.71 105.37 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.093 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 13.0 tt0 -121.58 120.4 34.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.907 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 158' ' ' ILE . . . . . 0.551 HD13 HD23 ' A' ' 33' ' ' LEU . 27.1 mt . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.123 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.45 HG22 ' H ' ' A' ' 156' ' ' VAL . 6.5 t . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.793 0.33 . . . . 0.0 111.171 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.406 ' CD1' ' O ' ' A' ' 22' ' ' THR . 7.4 m-85 -142.68 116.86 9.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.92 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ASN . . . . . 0.474 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 11.8 m120 61.68 52.23 2.25 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.671 0.748 . . . . 0.0 110.914 -179.889 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.487 ' HG2' ' CB ' ' A' ' 153' ' ' LEU . 54.2 Cg_endo -69.76 133.41 25.5 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.665 2.243 . . . . 0.0 112.387 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 -174.22 0.86 Allowed 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.707 2.272 . . . . 0.0 112.33 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.708 HG13 ' HA ' ' A' ' 28' ' ' PRO . 84.7 t -144.04 138.77 15.28 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.621 0.724 . . . . 0.0 111.113 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.708 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.79 145.27 79.01 Favored 'Cis proline' 0 C--N 1.342 0.186 0 C-N-CA 122.659 -1.809 . . . . 0.0 112.303 -0.048 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.0 t80 -100.96 117.1 34.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.931 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.513 ' CD2' ' HB3' ' A' ' 146' ' ' GLU . 58.2 m-85 -104.61 105.98 16.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.896 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -116.34 103.44 1.15 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.496 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.513 ' O ' ' CD ' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -72.61 114.08 10.36 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.799 0.333 . . . . 0.0 110.856 -179.873 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.425 HD12 ' N ' ' A' ' 144' ' ' THR . 3.9 mt -59.1 151.32 22.78 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.932 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 3.0 mp0 -104.26 101.22 10.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.906 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.64 -58.62 0.52 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.493 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.711 ' O ' HG23 ' A' ' 38' ' ' THR . . . 123.73 171.83 13.62 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.48 -179.872 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' LEU . . . . . 0.721 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 93.7 mt -58.74 103.74 0.18 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.879 0.371 . . . . 0.0 110.949 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.711 HG23 ' O ' ' A' ' 36' ' ' GLY . 22.0 p -118.98 150.16 40.4 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.098 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -54.83 -28.16 47.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.107 179.827 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 3.9 tpt180 -102.97 37.47 1.95 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.899 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 11.7 ttm180 -129.16 139.51 51.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.871 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 91.8 m -137.4 124.75 21.9 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.128 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.414 ' N ' HD12 ' A' ' 43' ' ' ILE . 4.9 mp -92.67 134.05 31.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.161 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 89.7 mt -122.93 135.89 61.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.087 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 56.1 mt -133.98 107.92 10.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.132 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.3 mtmt -113.82 113.78 25.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.836 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.416 ' CA ' ' O ' ' A' ' 152' ' ' THR . . . -146.56 -140.6 3.47 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.519 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -170.55 137.45 1.38 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.916 0.389 . . . . 0.0 110.927 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 14.2 t -86.62 114.87 60.07 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.604 0.716 . . . . 0.0 111.124 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.83 155.71 65.0 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.685 2.256 . . . . 0.0 112.358 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 -13.9 35.46 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.701 2.267 . . . . 0.0 112.356 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 57.8 p -112.28 16.19 20.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.112 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -112.72 120.23 5.18 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.468 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 12.1 mtpt -61.62 -60.46 3.64 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.767 0.318 . . . . 0.0 110.857 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 25.8 p -173.16 158.4 3.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.85 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.596 ' CE2' HD11 ' A' ' 58' ' ' ILE . 8.2 p90 -112.01 -172.8 2.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.88 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.445 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -155.48 141.8 18.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.12 179.936 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.596 HD11 ' CE2' ' A' ' 56' ' ' PHE . 2.9 mp -123.01 102.23 11.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.105 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.5 m-80 -103.22 146.09 28.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.846 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.6 ' CE2' HD13 ' A' ' 145' ' ' LEU . 40.7 m-85 -117.63 101.16 8.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.905 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.427 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 33.1 ttmt -96.33 168.57 10.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.854 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.589 HG22 ' HA ' ' A' ' 142' ' ' VAL . 38.4 t -99.57 122.83 51.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.137 179.846 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.424 ' N ' ' OG1' ' A' ' 144' ' ' THR . . . -59.55 -28.69 65.46 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.482 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.541 ' H ' HG12 ' A' ' 62' ' ' VAL . 1.4 t -77.53 -71.09 0.43 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.839 0.352 . . . . 0.0 110.856 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.6 t -79.33 -75.51 0.24 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.818 -179.786 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 132.18 41.31 0.2 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.467 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.437 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.4 m-20 -115.45 139.62 49.87 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.763 0.316 . . . . 0.0 110.855 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.507 HD12 ' HB3' ' A' ' 86' ' ' LEU . 37.6 mt -86.43 114.8 26.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.079 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.22 -34.69 21.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.092 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.651 HD22 ' CD2' ' A' ' 132' ' ' PHE . 32.1 tp -138.01 131.75 31.2 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.939 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.467 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.1 t60 -134.95 98.38 4.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.848 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.554 HD11 HD21 ' A' ' 70' ' ' LEU . 22.4 mt -96.42 129.27 46.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.129 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.445 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 10.9 t-20 -134.36 104.15 11.3 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.588 0.708 . . . . 0.0 110.927 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.585 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.6 Cg_endo -69.77 155.48 65.78 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.688 2.259 . . . . 0.0 112.341 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 81.6 mtt-85 -133.25 97.99 4.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.892 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.914 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 13.8 p . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.845 0.355 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.441 HG21 ' HE2' ' A' ' 103' ' ' PHE . 16.2 t -99.46 109.65 24.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.132 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.593 HG22 ' HD3' ' A' ' 96' ' ' LYS . 82.5 t -79.24 140.19 17.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.123 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' ARG . . . . . 0.647 ' NH1' ' CD2' ' A' ' 130' ' ' PHE . 1.4 mpp_? -121.37 115.02 22.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.875 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.467 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.4 t-20 -125.98 179.75 5.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.896 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 94.7 p -160.95 110.07 1.64 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.869 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.95 HD12 ' O ' ' A' ' 90' ' ' SER . 24.5 tp -82.73 118.99 23.76 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.909 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.495 ' N ' ' O ' ' A' ' 90' ' ' SER . 96.8 mt -96.12 161.07 14.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.931 179.85 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.457 ' C ' ' H ' ' A' ' 90' ' ' SER . 16.3 p-10 -38.5 101.64 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.85 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.62 -7.0 1.11 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.481 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.95 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -118.85 172.11 7.76 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.879 0.371 . . . . 0.0 110.85 -179.752 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.836 ' NE1' HD13 ' A' ' 86' ' ' LEU . 23.8 m95 -129.12 160.66 32.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.924 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.59 -114.7 2.19 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.454 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' SER . . . . . 0.439 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 4.5 m -152.78 167.56 28.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.806 0.336 . . . . 0.0 110.88 -179.728 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -97.66 120.46 38.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 20.8 mm-40 -119.63 128.22 53.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.875 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.593 ' HD3' HG22 ' A' ' 82' ' ' VAL . 47.4 mtmt -130.11 117.68 20.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.922 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 25.0 tptt -171.73 105.7 0.21 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.922 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.932 HD11 ' O ' ' A' ' 100' ' ' HIS . 2.1 tt -145.23 151.09 15.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.101 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.594 HG23 ' N ' ' A' ' 100' ' ' HIS . 9.7 t -85.83 -50.35 7.19 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.168 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 100' ' ' HIS . . . . . 0.932 ' O ' HD11 ' A' ' 98' ' ' ILE . 9.7 p-80 -137.33 132.55 33.77 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.847 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' ASN . . . . . 0.435 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 43.2 t-20 -112.82 99.62 48.61 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.608 0.718 . . . . 0.0 110.907 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.456 ' HG3' ' HB1' ' A' ' 124' ' ' ALA . 53.6 Cg_endo -69.8 -41.1 4.51 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.705 2.27 . . . . 0.0 112.35 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.442 ' C ' ' O ' ' A' ' 102' ' ' PRO . 7.5 m-85 -35.32 101.91 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.866 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -131.5 136.5 8.83 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.522 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 97.9 0.66 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.675 2.25 . . . . 0.0 112.318 -179.87 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 133.56 -10.45 4.95 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.48 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -133.3 161.77 33.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.837 0.351 . . . . 0.0 110.879 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -82.23 175.08 10.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.864 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 23.0 p90 -161.81 127.26 3.54 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.866 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -98.39 104.49 16.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.85 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.895 HD13 ' N ' ' A' ' 112' ' ' SER . 0.6 OUTLIER -104.85 139.47 39.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.92 -179.945 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.895 ' N ' HD13 ' A' ' 111' ' ' LEU . 4.7 m -144.8 113.41 6.69 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.854 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.7 mp -93.36 136.16 25.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.175 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 42.7 mtt180 -111.68 120.22 41.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.901 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 115' ' ' CYS . . . . . 0.576 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 2.3 t -90.42 116.7 28.56 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.913 -179.929 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -113.03 -148.85 10.39 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.467 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 19.1 mt -112.76 -35.24 5.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.826 0.346 . . . . 0.0 110.903 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 52.4 m-20 -91.2 -33.14 15.51 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.893 179.812 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.2 ptp180 -174.77 176.2 2.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.867 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.721 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 3.9 m-30 -99.22 158.15 15.89 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 -179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.9 mtpt -130.75 100.82 5.42 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.9 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.847 HG13 HD11 ' A' ' 111' ' ' LEU . 25.1 t -87.83 126.67 41.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.136 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 123' ' ' TYR . . . . . 0.411 ' O ' HD22 ' A' ' 111' ' ' LEU . 85.2 m-85 -118.37 150.49 39.43 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.946 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.456 ' HB1' ' HG3' ' A' ' 102' ' ' PRO . . . -134.86 110.14 8.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.097 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.403 ' ND2' ' C ' ' A' ' 124' ' ' ALA . 0.6 OUTLIER 60.68 39.24 17.82 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.907 -179.889 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 72.92 41.59 48.32 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.495 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 20.3 mm-40 -148.41 136.84 21.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.79 0.329 . . . . 0.0 110.917 -179.851 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 46.5 t-80 -63.1 107.39 1.02 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.856 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.498 HD22 HD21 ' A' ' 111' ' ' LEU . 11.8 tp -78.35 -64.24 1.21 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.914 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.647 ' CD2' ' NH1' ' A' ' 83' ' ' ARG . 24.7 p90 -166.84 -178.68 4.38 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.889 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -125.37 144.86 50.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.861 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.651 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.4 OUTLIER -113.06 106.42 14.65 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.905 -179.915 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.491 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -61.74 137.98 58.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.106 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 22.6 m170 -66.31 100.74 0.66 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.8 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.439 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 60.5 mtt-85 -83.97 -55.1 4.41 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.855 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 4.9 tp -88.67 107.91 19.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.913 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 19.9 p -48.79 -34.4 12.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.858 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.516 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.67 28.99 0.46 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.107 179.912 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.535 ' O ' HD12 ' A' ' 37' ' ' LEU . 27.0 p90 -50.94 -42.54 59.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.899 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 140' ' ' GLN . . . . . 0.416 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 7.3 pt20 -48.83 -37.25 18.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.907 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.516 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 45.4 mtp85 -58.17 -40.91 82.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.861 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.589 ' HA ' HG22 ' A' ' 62' ' ' VAL . 60.0 t -48.17 102.3 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.133 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.492 ' OD1' ' N ' ' A' ' 36' ' ' GLY . 22.6 t0 -124.26 24.91 7.93 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.869 179.868 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 144' ' ' THR . . . . . 0.425 ' N ' HD12 ' A' ' 33' ' ' LEU . 1.5 m -132.59 140.63 48.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.127 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.6 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.5 tp -135.91 113.81 11.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.875 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 146' ' ' GLU . . . . . 0.513 ' HB3' ' CD2' ' A' ' 30' ' ' PHE . 5.9 pt-20 -117.82 151.85 36.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.932 179.903 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.528 HG12 HG23 ' A' ' 58' ' ' ILE . 18.0 mt -139.19 118.35 13.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.117 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -128.19 177.9 6.61 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.868 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 106.32 -137.5 13.88 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.474 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -122.54 92.48 3.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.816 0.341 . . . . 0.0 110.905 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.406 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 2.1 p -151.17 150.6 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.103 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 152' ' ' THR . . . . . 0.416 ' O ' ' CA ' ' A' ' 47' ' ' GLY . 23.7 m -107.48 93.52 4.59 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.114 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.487 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 67.8 mt -77.24 128.97 35.29 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.938 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 3.8 m -111.96 -41.66 3.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.901 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 35.2 t80 -143.87 130.62 20.26 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.942 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.45 ' H ' HG22 ' A' ' 22' ' ' THR . 72.9 t -140.7 105.29 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.122 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -120.66 129.62 53.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.879 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 16.6 mt . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.103 179.979 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.416 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.4 m . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.844 0.354 . . . . 0.0 111.149 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.404 ' CD1' ' O ' ' A' ' 22' ' ' THR . 7.2 m-85 -142.52 134.47 27.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.854 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ASN . . . . . 0.51 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.5 t-20 42.68 49.9 4.95 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.554 0.692 . . . . 0.0 110.878 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.51 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.8 Cg_endo -69.8 143.87 52.04 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.634 2.223 . . . . 0.0 112.378 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -178.74 2.49 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.701 2.267 . . . . 0.0 112.315 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.675 HG13 ' HA ' ' A' ' 28' ' ' PRO . 98.8 t -143.71 137.93 14.81 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.636 0.731 . . . . 0.0 111.106 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.675 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.77 144.65 77.25 Favored 'Cis proline' 0 C--O 1.231 0.171 0 C-N-CA 122.698 -1.792 . . . . 0.0 112.357 -0.066 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -98.8 118.12 34.83 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.954 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.438 ' CD1' ' HB3' ' A' ' 146' ' ' GLU . 63.8 m-85 -104.7 103.01 12.57 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.872 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -113.77 104.32 1.46 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.503 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.449 ' O ' ' HG3' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -73.44 121.89 21.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.876 0.37 . . . . 0.0 110.874 -179.868 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.419 HD12 ' N ' ' A' ' 144' ' ' THR . 5.4 mt -68.77 147.12 52.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.922 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 29.1 mt-30 -106.0 83.63 1.94 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.917 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 138.13 -49.0 0.86 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.49 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.561 ' O ' HG23 ' A' ' 38' ' ' THR . . . 109.35 166.98 20.33 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.454 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' LEU . . . . . 0.451 HD13 ' CZ ' ' A' ' 120' ' ' PHE . 87.5 mt -55.0 110.27 0.64 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.895 0.378 . . . . 0.0 110.901 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.561 HG23 ' O ' ' A' ' 36' ' ' GLY . 61.7 p -129.93 145.4 51.62 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.178 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -47.37 -31.1 3.7 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.098 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 8.9 tpt180 -97.32 31.66 2.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.881 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 12.3 ttm180 -124.13 141.56 51.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.879 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 94.0 m -138.33 124.85 20.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.147 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.1 mp -96.85 130.15 45.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.112 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 86.5 mt -123.49 134.04 67.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.132 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 72.1 mt -133.32 107.39 11.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.156 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 25.9 mtmt -112.01 109.93 19.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.898 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.501 ' CA ' ' O ' ' A' ' 152' ' ' THR . . . -138.09 -139.89 3.93 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.492 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -173.63 119.4 0.29 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.947 0.404 . . . . 0.0 110.884 -179.777 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 21.9 t -70.77 113.52 19.37 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.615 0.721 . . . . 0.0 111.124 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 156.88 62.35 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.671 2.248 . . . . 0.0 112.344 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -14.48 36.18 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.669 2.246 . . . . 0.0 112.366 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 72.6 p -111.7 18.46 18.96 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.181 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -116.12 123.47 5.89 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.509 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 33.8 mtpt -65.39 -59.43 4.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.823 0.344 . . . . 0.0 110.891 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 34.9 p -174.03 160.74 3.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.833 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.608 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 3.4 p90 -114.19 -174.37 2.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.869 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.012 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -156.37 128.19 7.31 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.076 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.534 HG13 HG23 ' A' ' 147' ' ' ILE . 5.3 mp -112.22 102.28 13.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.155 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.3 m-80 -100.84 149.69 23.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.938 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.698 ' CE2' HD13 ' A' ' 145' ' ' LEU . 56.6 m-85 -118.65 101.08 7.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.872 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.425 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 34.9 ttmt -95.69 168.92 10.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.904 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.672 HG22 ' HA ' ' A' ' 142' ' ' VAL . 55.2 t -100.48 124.83 54.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.124 179.856 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -60.48 -33.76 82.76 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.506 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.442 ' H ' HG12 ' A' ' 62' ' ' VAL . 70.1 m -70.84 -71.05 0.27 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.837 0.351 . . . . 0.0 110.864 -179.738 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 82.6 p -82.07 -75.1 0.31 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.875 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 133.37 44.31 0.13 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.46 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.551 ' OD1' ' ND2' ' A' ' 88' ' ' ASN . 1.2 m-20 -113.65 144.83 42.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.798 0.332 . . . . 0.0 110.889 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.431 HD12 ' HB3' ' A' ' 86' ' ' LEU . 40.9 mt -90.22 113.85 26.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.124 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.571 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -87.17 -32.3 19.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.126 179.799 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.738 HD22 ' CD2' ' A' ' 132' ' ' PHE . 41.4 tp -136.83 129.73 30.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.9 -179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.482 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.0 OUTLIER -134.61 94.42 3.19 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.869 179.836 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.541 HD13 ' HZ ' ' A' ' 130' ' ' PHE . 44.7 mt -99.59 134.74 37.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.148 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 1.012 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 8.9 t-20 -141.38 106.9 6.07 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.594 0.711 . . . . 0.0 110.859 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.608 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.0 Cg_endo -69.81 155.14 66.54 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.708 2.272 . . . . 0.0 112.362 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 34.6 mtt85 -128.97 97.49 4.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.877 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' MET . . . . . 0.522 ' HE3' ' HB3' ' A' ' 103' ' ' PHE . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 24.7 p . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.777 0.322 . . . . 0.0 111.164 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.508 HG22 ' HA ' ' A' ' 74' ' ' PRO . 13.8 t -97.79 113.58 32.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.131 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.499 HG22 ' HD3' ' A' ' 96' ' ' LYS . 58.2 t -83.12 144.81 9.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.111 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -123.89 125.46 44.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.873 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.482 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.7 OUTLIER -139.29 177.96 7.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.935 -179.955 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 92.4 p -160.67 107.68 1.53 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.868 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.897 HD13 ' NE1' ' A' ' 91' ' ' TRP . 24.6 tp -76.98 117.41 18.54 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.935 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.486 ' N ' ' O ' ' A' ' 90' ' ' SER . 25.9 mt -93.44 161.19 14.48 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.908 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.551 ' ND2' ' OD1' ' A' ' 67' ' ' ASP . 10.5 m120 -41.31 101.48 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.866 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.94 -3.25 4.11 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.471 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.851 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.4 OUTLIER -124.5 173.41 8.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.87 0.367 . . . . 0.0 110.831 -179.716 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.897 ' NE1' HD13 ' A' ' 86' ' ' LEU . 23.8 m95 -130.21 159.58 36.44 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.948 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -90.8 -109.3 1.47 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.478 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 3.4 m -159.92 176.03 12.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.839 0.352 . . . . 0.0 110.832 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.424 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 4.6 mt-10 -104.05 122.96 46.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.866 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -121.75 113.25 19.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.892 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.499 ' HD3' HG22 ' A' ' 82' ' ' VAL . 40.4 mtmt -114.34 118.41 33.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.868 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 12.1 tptm -172.13 105.27 0.18 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.879 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.793 HD11 ' O ' ' A' ' 100' ' ' HIS . 2.4 tt -144.23 143.58 23.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.155 179.836 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.606 HG23 ' N ' ' A' ' 100' ' ' HIS . 10.3 t -77.25 -51.58 10.67 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.154 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' HIS . . . . . 0.793 ' O ' HD11 ' A' ' 98' ' ' ILE . 21.3 p80 -140.55 134.21 30.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.85 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' ASN . . . . . 0.404 ' C ' ' OD1' ' A' ' 101' ' ' ASN . 4.9 t-20 -101.65 99.13 10.88 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.608 0.718 . . . . 0.0 110.931 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.403 ' HD2' HD11 ' A' ' 129' ' ' LEU . 53.6 Cg_endo -69.76 -40.81 4.89 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.693 2.262 . . . . 0.0 112.328 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.522 ' HB3' ' HE3' ' A' ' 76' ' ' MET . 6.7 m-85 -41.02 111.86 0.25 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.885 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -134.08 133.85 7.1 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.511 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 96.5 0.6 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.632 2.222 . . . . 0.0 112.333 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 127.25 0.23 6.92 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.49 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -138.78 154.48 48.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.85 0.357 . . . . 0.0 110.952 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 -71.9 171.96 10.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.87 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 27.4 p90 -160.52 136.33 8.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.909 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.67 105.8 14.82 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.854 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.827 HD13 ' N ' ' A' ' 112' ' ' SER . 0.6 OUTLIER -107.14 139.72 41.11 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.9 -179.931 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.827 ' N ' HD13 ' A' ' 111' ' ' LEU . 3.6 m -144.88 114.88 7.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.839 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.422 HG22 ' HD2' ' A' ' 120' ' ' PHE . 4.6 mp -98.23 127.42 50.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.142 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 9.9 mtp180 -100.25 133.48 44.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.875 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 14.1 t -98.49 100.41 11.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.894 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -91.04 -140.51 8.87 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.469 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.3 mt -122.8 -38.55 2.62 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.845 0.355 . . . . 0.0 110.933 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.4 t0 -94.39 -21.43 18.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.867 179.848 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.402 ' CD ' ' C ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -175.18 -175.12 0.81 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.834 -179.902 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.451 ' CZ ' HD13 ' A' ' 37' ' ' LEU . 20.4 m-85 -108.42 148.91 29.46 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.871 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 2.1 mmmm -120.17 101.95 8.18 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.866 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.6 HG13 HD11 ' A' ' 111' ' ' LEU . 65.8 t -89.31 129.74 39.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.141 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 54.6 m-85 -116.16 160.7 20.01 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.925 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.473 ' HB2' HD13 ' A' ' 129' ' ' LEU . . . -139.92 114.34 9.21 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.111 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 41.41 38.68 0.88 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.852 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 83.71 27.63 37.9 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.458 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' GLN . . . . . 0.421 ' N ' ' O ' ' A' ' 124' ' ' ALA . 9.4 mm100 -138.88 115.88 10.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.855 0.359 . . . . 0.0 110.897 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 34.4 t-80 -47.93 103.19 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.876 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.619 HD22 HD21 ' A' ' 111' ' ' LEU . 13.5 tp -69.65 -68.48 0.41 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.894 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.541 ' HZ ' HD13 ' A' ' 72' ' ' ILE . 9.4 p90 -164.2 175.8 9.81 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.912 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.48 ' OD1' ' N ' ' A' ' 132' ' ' PHE . 0.4 OUTLIER -117.06 156.73 27.05 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 179.967 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.738 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -128.31 106.12 8.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.889 -179.864 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.605 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -63.35 136.66 57.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.137 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 27.5 m170 -61.37 115.65 4.02 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.883 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 8.1 mtt-85 -95.9 -47.65 6.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.861 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 9.9 tp -96.56 108.19 20.74 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.905 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 78.9 p -47.73 -34.22 8.07 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.847 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.668 ' HB1' ' HG3' ' A' ' 141' ' ' ARG . . . -83.62 31.09 0.47 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.084 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -50.36 -34.89 25.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.871 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 140' ' ' GLN . . . . . 0.456 ' HG2' ' N ' ' A' ' 141' ' ' ARG . 18.1 pm0 -59.7 -29.41 68.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.923 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.668 ' HG3' ' HB1' ' A' ' 138' ' ' ALA . 36.3 mtp85 -65.29 -39.64 92.81 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.672 ' HA ' HG22 ' A' ' 62' ' ' VAL . 84.3 t -50.62 103.94 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.151 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 9.3 p-10 -125.27 31.85 5.49 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.886 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 144' ' ' THR . . . . . 0.419 ' N ' HD12 ' A' ' 33' ' ' LEU . 1.7 m -140.72 135.04 31.18 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.14 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.698 HD13 ' CE2' ' A' ' 60' ' ' PHE . 6.4 tp -129.88 115.88 17.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.932 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 146' ' ' GLU . . . . . 0.438 ' HB3' ' CD1' ' A' ' 30' ' ' PHE . 5.1 pt-20 -120.0 150.95 39.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.885 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.534 HG23 HG13 ' A' ' 58' ' ' ILE . 15.0 mt -139.36 112.85 6.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.152 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -122.58 175.59 6.4 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.902 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 105.11 -146.36 16.06 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.498 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -111.69 92.51 4.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.886 0.374 . . . . 0.0 110.865 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.483 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 4.7 p -151.22 140.59 15.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.107 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 152' ' ' THR . . . . . 0.501 ' O ' ' CA ' ' A' ' 47' ' ' GLY . 14.1 m -100.52 94.15 5.99 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.16 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.463 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 80.4 mt -78.59 132.99 37.34 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.92 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 64.9 m -118.29 -34.38 4.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.889 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 13.8 t80 -149.98 130.36 13.79 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.941 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 86.3 t -140.77 106.14 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.152 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 16.0 tt0 -114.57 135.85 53.68 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.919 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 158' ' ' ILE . . . . . 0.412 ' O ' HG22 ' A' ' 158' ' ' ILE . 42.1 mt . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.166 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.51 ' CG2' ' N ' ' A' ' 23' ' ' PHE . 1.3 m . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.853 0.358 . . . . 0.0 111.115 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.51 ' N ' ' CG2' ' A' ' 22' ' ' THR . 8.4 m-85 -147.73 141.65 25.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.873 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ASN . . . . . 0.485 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 15.8 m120 35.12 51.95 1.37 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.63 0.729 . . . . 0.0 110.88 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.491 ' HG2' ' CB ' ' A' ' 153' ' ' LEU . 53.6 Cg_endo -69.82 145.78 57.85 Favored 'Trans proline' 0 C--O 1.232 0.192 0 C-N-CA 122.693 2.262 . . . . 0.0 112.309 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.79 -178.25 2.27 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.663 2.242 . . . . 0.0 112.32 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.681 HG13 ' HA ' ' A' ' 28' ' ' PRO . 95.2 t -142.85 138.0 15.58 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.688 0.756 . . . . 0.0 111.081 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.681 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.9 Cg_endo -69.77 144.54 76.95 Favored 'Cis proline' 0 C--N 1.342 0.195 0 C-N-CA 122.656 -1.81 . . . . 0.0 112.347 -0.028 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 1.9 t80 -96.22 117.64 31.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.95 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -100.53 104.09 15.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.888 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -109.03 109.19 2.74 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.48 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 6.8 mmt85 -72.97 116.55 13.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.829 0.347 . . . . 0.0 110.887 -179.893 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.482 HD23 HG12 ' A' ' 158' ' ' ILE . 6.1 mt -75.69 94.61 3.27 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.913 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 22.2 mm-40 -67.22 92.55 0.27 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.886 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 138.21 -37.63 1.79 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.476 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.816 ' O ' HG23 ' A' ' 38' ' ' THR . . . 88.92 157.48 32.85 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.493 -179.884 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' LEU . . . . . 0.423 HD12 ' O ' ' A' ' 139' ' ' PHE . 66.4 mt -51.08 95.77 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.914 0.388 . . . . 0.0 110.907 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.816 HG23 ' O ' ' A' ' 36' ' ' GLY . 44.4 p -116.24 148.59 40.3 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.092 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -50.6 -21.27 1.48 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.106 179.813 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.455 ' HA ' ' NE ' ' A' ' 40' ' ' ARG . 3.8 mmp_? -106.88 34.28 3.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.859 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 14.7 ttt85 -125.9 140.06 52.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.904 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 99.9 m -139.36 119.81 13.95 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.168 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 4.9 mp -90.59 142.19 13.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.15 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 82.4 mt -133.76 115.66 22.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.111 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 54.3 mt -114.92 107.59 23.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.123 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.0 mtmm -110.18 109.3 19.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.885 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.59 -147.53 4.98 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.507 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' TYR . . . . . 0.587 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.5 OUTLIER -168.14 127.13 1.22 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.892 0.377 . . . . 0.0 110.97 -179.806 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 11.3 t -75.97 115.38 46.06 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.627 0.727 . . . . 0.0 111.141 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 155.42 66.15 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.661 2.241 . . . . 0.0 112.423 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -14.83 36.61 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.657 2.238 . . . . 0.0 112.326 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 49.7 p -111.62 17.94 19.49 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.162 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -113.36 124.14 6.44 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.48 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 14.8 mttp -64.89 -62.6 1.46 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.802 0.334 . . . . 0.0 110.897 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 17.5 p -171.76 157.51 4.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.875 -179.869 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.6 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 9.1 p90 -113.1 -172.27 2.03 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.931 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.785 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -155.19 139.12 16.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.081 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.575 HD11 ' CE2' ' A' ' 56' ' ' PHE . 2.7 mp -118.95 99.03 7.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.139 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' ASN . . . . . 0.512 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 33.0 m-80 -101.22 141.67 33.77 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.897 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.678 ' CE2' HD13 ' A' ' 145' ' ' LEU . 26.8 m-85 -115.49 97.92 6.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.861 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.404 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 32.9 ttmt -95.59 169.91 9.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.94 179.918 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.595 HG13 ' O ' ' A' ' 141' ' ' ARG . 16.7 t -99.33 123.35 51.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.131 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -61.08 -22.87 61.05 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.497 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.584 ' H ' HG12 ' A' ' 62' ' ' VAL . 30.7 t -81.73 -72.78 0.42 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.928 0.394 . . . . 0.0 110.855 -179.72 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 36.0 t -80.61 -72.79 0.4 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.839 -179.82 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 133.69 40.65 0.18 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.487 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.555 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.1 m-20 -110.29 137.54 47.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.796 0.331 . . . . 0.0 110.847 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.538 HD12 ' HB3' ' A' ' 86' ' ' LEU . 57.0 mt -85.84 112.46 22.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.155 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.587 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -80.7 -34.66 34.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.114 179.829 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.713 HD21 HD11 ' A' ' 72' ' ' ILE . 53.4 tp -140.69 132.16 26.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.951 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.512 ' CG ' ' OD1' ' A' ' 59' ' ' ASN . 3.3 t60 -134.92 92.3 2.86 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.857 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.713 HD11 HD21 ' A' ' 70' ' ' LEU . 20.3 mt -96.17 134.78 32.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.163 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.785 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 9.4 t-20 -140.06 105.88 6.75 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.643 0.735 . . . . 0.0 110.904 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.6 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.2 Cg_endo -69.75 155.01 67.1 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.67 2.247 . . . . 0.0 112.364 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 36.7 mtp180 -131.85 94.72 3.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.854 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' MET . . . . . 0.431 ' HE3' ' HB3' ' A' ' 103' ' ' PHE . 0.3 OUTLIER . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.877 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 13.7 p . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.807 0.337 . . . . 0.0 111.187 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.53 HG22 ' HA ' ' A' ' 74' ' ' PRO . 29.4 t -104.43 109.47 27.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.119 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.741 HG22 ' CE ' ' A' ' 96' ' ' LYS . 58.2 t -80.01 135.53 25.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.107 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' ARG . . . . . 0.483 ' HD3' ' N ' ' A' ' 83' ' ' ARG . 0.7 OUTLIER -121.06 115.18 22.63 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.884 -179.989 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.434 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.2 t-20 -124.81 -176.82 3.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.911 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.431 ' CB ' ' HD2' ' A' ' 135' ' ' ARG . 47.5 t -161.17 106.45 1.36 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.883 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.904 HD13 ' NE1' ' A' ' 91' ' ' TRP . 28.9 tp -78.9 115.35 18.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.923 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.519 ' N ' ' O ' ' A' ' 90' ' ' SER . 73.2 mt -92.96 162.18 14.16 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.882 179.901 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.488 ' ND2' ' OD2' ' A' ' 67' ' ' ASP . 10.6 m-80 -40.66 101.64 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.891 179.902 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.77 -3.59 2.79 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.466 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.854 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -123.15 170.97 9.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.901 0.382 . . . . 0.0 110.833 -179.73 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.904 ' NE1' HD13 ' A' ' 86' ' ' LEU . 24.7 m95 -128.41 160.62 31.69 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.926 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -91.24 -108.26 1.5 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.483 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 2.9 m -163.07 169.5 19.38 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.851 0.358 . . . . 0.0 110.873 -179.73 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 71.6 mt-10 -93.58 119.19 32.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.901 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 -122.87 124.95 44.42 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.92 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.741 ' CE ' HG22 ' A' ' 82' ' ' VAL . 17.4 mttp -126.52 122.74 36.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.896 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.413 ' HB3' ' NH2' ' A' ' 83' ' ' ARG . 4.6 ttpm? -169.5 105.81 0.37 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.91 179.827 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.737 HD11 ' O ' ' A' ' 100' ' ' HIS . 1.3 tt -147.75 150.2 14.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.144 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.48 HG23 ' N ' ' A' ' 100' ' ' HIS . 11.5 t -86.52 -43.48 12.7 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.145 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 100' ' ' HIS . . . . . 0.737 ' O ' HD11 ' A' ' 98' ' ' ILE . 2.9 p-80 -149.64 127.2 11.58 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.898 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' ASN . . . . . 0.43 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 51.7 t-20 -99.51 101.01 11.91 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.604 0.716 . . . . 0.0 110.867 -179.89 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.456 ' HD2' HD11 ' A' ' 129' ' ' LEU . 53.8 Cg_endo -69.78 -31.81 19.72 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.738 2.292 . . . . 0.0 112.341 179.918 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.593 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 17.9 m-85 -44.2 102.48 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.837 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -132.06 135.18 8.02 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.482 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 98.26 0.67 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.672 2.248 . . . . 0.0 112.351 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 130.75 -5.87 5.82 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.44 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 -135.47 159.83 40.37 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.849 0.356 . . . . 0.0 110.91 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' PHE . . . . . 0.587 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 16.2 m-85 -77.64 174.56 10.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.876 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.544 ' O ' ' CD1' ' A' ' 109' ' ' PHE . 33.5 p90 -161.49 118.08 2.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.881 -179.872 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -92.5 106.93 18.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.892 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.817 HD13 ' N ' ' A' ' 112' ' ' SER . 0.3 OUTLIER -106.75 138.38 43.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.91 -179.948 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.817 ' N ' HD13 ' A' ' 111' ' ' LEU . 7.4 m -145.37 112.04 5.87 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.841 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.8 mp -94.55 134.12 33.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.116 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 70.7 mtt180 -111.79 123.35 50.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.844 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 115' ' ' CYS . . . . . 0.576 ' HA ' ' CD1' ' A' ' 120' ' ' PHE . 3.5 t -93.91 100.87 12.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.89 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -93.11 -126.96 4.34 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.476 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.4 mt -132.74 -43.19 0.91 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.842 0.353 . . . . 0.0 110.885 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -86.04 -29.34 23.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.9 179.82 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 10.6 ptp85 -175.16 162.37 2.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.838 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.576 ' CD1' ' HA ' ' A' ' 115' ' ' CYS . 3.0 m-30 -85.45 141.43 29.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.902 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 12.0 mmmt -113.67 105.01 12.8 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.941 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.591 HG13 HD11 ' A' ' 111' ' ' LEU . 48.8 t -95.18 133.2 36.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.12 179.898 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 11.0 m-85 -120.16 159.24 25.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.874 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.53 ' HB2' HD13 ' A' ' 129' ' ' LEU . . . -141.4 116.25 9.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.059 179.872 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 45.07 35.94 1.82 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.896 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 84.33 29.36 30.67 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.458 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 4.8 mm-40 -140.96 116.11 9.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.789 0.328 . . . . 0.0 110.911 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 42.1 t-80 -51.27 105.02 0.09 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.831 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.53 HD13 ' HB2' ' A' ' 124' ' ' ALA . 6.4 tp -72.13 -67.52 0.53 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.941 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.629 ' HZ ' HD13 ' A' ' 72' ' ' ILE . 6.7 p90 -166.35 179.82 5.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.898 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -126.27 158.9 34.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.845 -179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.638 ' CD1' HD13 ' A' ' 70' ' ' LEU . 0.2 OUTLIER -115.4 110.24 19.05 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.89 -179.914 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.595 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -54.52 138.69 40.0 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.071 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 22.9 m170 -78.15 69.22 4.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.83 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.431 ' HD2' ' CB ' ' A' ' 85' ' ' SER . 0.0 OUTLIER -66.33 -37.89 86.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.872 -179.948 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.8 tp -98.23 107.89 20.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.916 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 78.8 p -58.1 -25.12 60.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.859 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.67 ' HB1' ' HD2' ' A' ' 141' ' ' ARG . . . -91.06 39.71 1.0 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.114 179.894 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.423 ' O ' HD12 ' A' ' 37' ' ' LEU . 28.9 p90 -65.47 -30.88 71.71 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.909 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 4.9 pt20 -59.32 -31.16 68.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.889 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.67 ' HD2' ' HB1' ' A' ' 138' ' ' ALA . 27.4 mtt180 -64.26 -40.16 95.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.889 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.587 HG21 ' CB ' ' A' ' 69' ' ' ALA . 92.0 t -48.91 106.01 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.139 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.505 ' OD2' ' N ' ' A' ' 36' ' ' GLY . 0.7 OUTLIER -130.84 33.41 4.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.892 179.922 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 9.1 m -143.74 113.5 7.12 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.175 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.678 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.7 tp -111.19 106.99 16.17 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.905 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 146' ' ' GLU . . . . . 0.417 ' C ' HG13 ' A' ' 147' ' ' ILE . 3.1 pt-20 -108.59 153.91 22.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.901 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.417 HG13 ' C ' ' A' ' 146' ' ' GLU . 21.3 mt -140.78 116.49 7.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.081 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -126.19 171.76 10.62 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.926 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 104.74 -157.07 16.84 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.459 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 64.6 m-20 -98.6 94.32 6.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.868 0.366 . . . . 0.0 110.844 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 10.4 p -151.07 141.5 16.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.142 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 33.7 m -105.5 92.71 4.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.176 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.491 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 94.6 mt -71.75 133.65 45.71 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.895 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 3.6 m -114.61 -35.66 4.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.886 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 155' ' ' TYR . . . . . 0.462 ' C ' ' CD1' ' A' ' 155' ' ' TYR . 4.2 t80 -157.16 132.43 9.06 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.941 -179.885 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 85.0 t -140.47 133.79 33.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.113 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 8.0 tt0 -156.57 138.45 14.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.891 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 158' ' ' ILE . . . . . 0.482 HG12 HD23 ' A' ' 33' ' ' LEU . 4.7 mp . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.141 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 3.7 t . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.839 0.352 . . . . 0.0 111.127 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -129.05 122.67 30.47 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.875 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ASN . . . . . 0.555 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 6.3 t-20 74.11 47.76 0.21 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.589 0.709 . . . . 0.0 110.899 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.555 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.78 123.29 9.95 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.646 2.231 . . . . 0.0 112.375 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.78 -179.28 2.81 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.674 2.25 . . . . 0.0 112.363 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.704 HG13 ' HA ' ' A' ' 28' ' ' PRO . 90.8 t -140.97 138.5 18.11 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.592 0.711 . . . . 0.0 111.096 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.704 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.6 Cg_endo -69.76 144.22 76.05 Favored 'Cis proline' 0 C--O 1.231 0.174 0 C-N-CA 122.69 -1.796 . . . . 0.0 112.311 -0.056 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.6 t80 -97.29 114.32 26.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.942 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.432 ' CD1' ' HB3' ' A' ' 146' ' ' GLU . 66.6 m-85 -99.55 107.25 19.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.875 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -115.29 100.44 0.97 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.513 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.483 ' O ' ' CG ' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -72.78 117.11 14.08 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.84 0.353 . . . . 0.0 110.895 -179.848 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.4 ' O ' ' HD3' ' A' ' 32' ' ' ARG . 11.6 mt -63.45 150.11 44.47 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.937 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' GLN . . . . . 0.455 ' OE1' ' NH1' ' A' ' 32' ' ' ARG . 7.3 mm100 -98.01 -46.44 5.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.943 179.892 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.557 ' O ' HG23 ' A' ' 38' ' ' THR . . . -103.47 33.22 6.76 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.486 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.41 ' O ' ' O ' ' A' ' 35' ' ' GLY . . . 37.21 -157.5 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.443 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 51.3 mt -88.43 106.7 18.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.832 0.348 . . . . 0.0 110.92 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.557 HG23 ' O ' ' A' ' 35' ' ' GLY . 34.4 p -122.12 170.57 9.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.109 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.495 ' HB2' ' HG ' ' A' ' 117' ' ' LEU . . . -79.13 -11.81 59.99 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.074 179.884 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 12.2 mmm180 -110.64 22.39 15.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.841 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.817 ' CZ ' HD11 ' A' ' 43' ' ' ILE . 27.8 ttt-85 -117.94 143.22 46.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.873 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 51.9 m -138.14 129.1 27.07 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.129 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.817 HD11 ' CZ ' ' A' ' 41' ' ' ARG . 4.8 mp -94.64 145.73 7.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.133 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 76.6 mt -142.73 114.33 3.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.125 179.852 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 48.3 mt -115.93 107.71 23.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.143 179.82 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.5 mtmm -109.89 112.92 25.24 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.919 179.827 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.411 ' CA ' ' O ' ' A' ' 152' ' ' THR . . . -146.85 -142.89 3.78 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.534 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -167.58 130.64 1.67 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.874 0.368 . . . . 0.0 110.92 -179.827 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 16.0 t -78.98 115.74 54.69 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.661 0.743 . . . . 0.0 111.099 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 155.42 65.81 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.676 2.251 . . . . 0.0 112.326 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 -19.27 36.47 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.723 2.282 . . . . 0.0 112.319 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 69.5 p -106.15 16.84 24.39 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.167 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -114.66 125.91 7.01 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.489 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 15.7 mttp -66.25 -61.84 1.8 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.785 0.326 . . . . 0.0 110.895 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.0 p -172.56 158.2 4.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.883 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.596 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 8.1 p90 -108.88 -173.85 2.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.845 -179.928 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.804 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -156.32 140.79 16.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.092 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.56 HG23 HG12 ' A' ' 147' ' ' ILE . 3.1 mp -122.38 107.84 20.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.098 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -111.74 143.52 42.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.852 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.687 ' CE2' HD13 ' A' ' 145' ' ' LEU . 13.6 m-85 -113.67 102.04 9.88 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.91 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.411 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 31.9 ttmt -95.1 168.07 10.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.888 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.78 HG13 ' O ' ' A' ' 141' ' ' ARG . 25.5 t -98.94 122.37 50.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.106 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -60.22 -26.62 64.05 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.479 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.564 ' H ' HG12 ' A' ' 62' ' ' VAL . 66.4 m -75.47 -70.88 0.4 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.869 0.366 . . . . 0.0 110.855 -179.76 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.8 m -85.23 -73.54 0.43 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.825 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 137.58 35.87 0.17 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.447 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.534 ' O ' HG23 ' A' ' 62' ' ' VAL . 0.3 OUTLIER -104.11 146.87 28.11 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.766 0.317 . . . . 0.0 110.879 -179.972 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 60.4 mt -94.79 115.89 34.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.203 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.7 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -83.19 -39.11 21.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.075 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.687 HD13 ' CG ' ' A' ' 132' ' ' PHE . 38.8 tp -135.06 133.01 38.89 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.952 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.474 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.9 OUTLIER -134.34 93.09 3.01 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.827 179.885 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.543 HD11 HD21 ' A' ' 70' ' ' LEU . 59.3 mt -97.21 130.84 45.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.094 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.804 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 8.1 t-20 -136.11 106.5 9.53 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.629 0.728 . . . . 0.0 110.942 179.87 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.643 ' HA ' HG22 ' A' ' 81' ' ' VAL . 54.1 Cg_endo -69.75 155.12 66.78 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.664 2.243 . . . . 0.0 112.399 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 25.9 mtp180 -132.35 101.48 5.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.822 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.855 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 25.1 p . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.823 0.344 . . . . 0.0 111.123 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.643 HG22 ' HA ' ' A' ' 74' ' ' PRO . 17.3 t -87.84 104.64 14.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.126 179.888 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.712 HG22 ' HD3' ' A' ' 96' ' ' LYS . 58.7 t -76.25 145.52 10.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.125 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -125.78 131.28 52.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.861 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.474 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.2 m120 -143.81 179.52 7.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.892 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.405 ' CB ' ' O ' ' A' ' 69' ' ' ALA . 96.6 p -160.7 107.29 1.49 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.816 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.888 HD13 ' NE1' ' A' ' 91' ' ' TRP . 28.5 tp -77.38 116.92 18.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.935 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.534 HD22 HD13 ' A' ' 136' ' ' LEU . 66.7 mt -93.33 161.58 14.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.933 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.455 ' ND2' ' OD2' ' A' ' 67' ' ' ASP . 14.0 m-80 -41.63 101.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.869 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.86 -3.38 3.94 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.516 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.843 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -124.83 171.58 10.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.838 0.351 . . . . 0.0 110.868 -179.72 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.888 ' NE1' HD13 ' A' ' 86' ' ' LEU . 23.0 m95 -128.08 159.85 33.8 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.968 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -89.37 -105.82 1.12 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.478 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' SER . . . . . 0.424 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 25.2 m -165.91 166.15 17.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.86 0.362 . . . . 0.0 110.82 -179.76 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.412 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 5.6 mt-10 -88.32 119.99 29.26 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.867 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -120.03 116.44 25.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.85 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.712 ' HD3' HG22 ' A' ' 82' ' ' VAL . 46.5 mtmt -122.25 124.79 44.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.873 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 26.9 ttpt -172.53 107.95 0.19 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.919 179.882 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.825 HD11 ' O ' ' A' ' 100' ' ' HIS . 7.1 tt -147.35 159.58 8.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.125 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.482 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 9.8 t -102.75 -34.23 9.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.13 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 100' ' ' HIS . . . . . 0.825 ' O ' HD11 ' A' ' 98' ' ' ILE . 1.7 p-80 -155.66 130.25 9.06 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.847 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' ASN . . . . . 0.627 ' CG ' HD13 ' A' ' 98' ' ' ILE . 11.2 m-80 -101.71 97.72 8.41 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.61 0.719 . . . . 0.0 110.937 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.403 ' HD3' ' O ' ' A' ' 100' ' ' HIS . 53.7 Cg_endo -69.7 -31.06 21.54 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.698 2.265 . . . . 0.0 112.339 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.543 ' CZ ' HD21 ' A' ' 129' ' ' LEU . 5.8 m-85 -52.77 107.97 0.27 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.86 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -133.52 139.66 11.11 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.507 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 105.21 1.43 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.727 2.285 . . . . 0.0 112.38 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 122.97 -8.04 9.24 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.497 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.3 pt20 -132.97 153.85 51.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.83 0.348 . . . . 0.0 110.887 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -77.15 172.94 12.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.865 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 32.4 p90 -160.16 139.89 11.25 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.899 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -109.55 104.91 14.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.898 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.694 HD13 ' N ' ' A' ' 112' ' ' SER . 1.0 OUTLIER -105.51 138.17 42.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.919 -179.955 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.694 ' N ' HD13 ' A' ' 111' ' ' LEU . 2.6 m -144.64 113.98 7.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.857 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.464 HD11 HD12 ' A' ' 111' ' ' LEU . 4.9 mp -95.32 131.62 41.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.116 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 15.7 mtp180 -106.38 128.01 53.71 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.842 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 115' ' ' CYS . . . . . 0.481 ' HA ' ' CD1' ' A' ' 120' ' ' PHE . 35.6 t -98.99 121.37 40.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.908 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -116.38 -138.13 6.22 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.477 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.495 ' HG ' ' HB2' ' A' ' 39' ' ' ALA . 9.7 mt -123.03 -31.38 3.63 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.806 0.336 . . . . 0.0 110.932 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -96.66 -34.21 11.47 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.871 179.891 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 20.8 ptt-85 -172.91 171.48 4.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.481 ' CD1' ' HA ' ' A' ' 115' ' ' CYS . 4.1 m-30 -94.8 157.62 15.85 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.887 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 19.8 mtpp -130.49 99.77 5.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.891 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.486 HG13 HD11 ' A' ' 111' ' ' LEU . 42.2 t -84.46 133.97 28.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.131 179.867 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 123' ' ' TYR . . . . . 0.449 ' O ' HD22 ' A' ' 111' ' ' LEU . 81.5 m-85 -122.46 153.84 38.59 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.886 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.435 ' O ' ' CG ' ' A' ' 125' ' ' ASN . . . -139.72 121.34 15.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.123 179.815 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.435 ' CG ' ' O ' ' A' ' 124' ' ' ALA . 10.7 p30 48.49 33.66 4.2 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.895 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.78 26.5 49.75 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.438 179.949 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 37.0 mm-40 -129.76 168.02 17.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.842 0.353 . . . . 0.0 110.909 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 33.9 t-80 -91.16 116.09 28.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.829 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.543 HD21 ' CZ ' ' A' ' 103' ' ' PHE . 9.0 tp -87.93 -68.32 0.77 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.957 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.49 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 3.9 p90 -168.68 172.21 8.15 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.862 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -115.43 156.73 25.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.853 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.687 ' CG ' HD13 ' A' ' 70' ' ' LEU . 0.2 OUTLIER -122.49 104.4 9.35 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.893 -179.94 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.514 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -60.08 134.13 56.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.13 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 20.4 m170 -61.77 99.56 0.12 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.836 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.424 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 11.7 mtt-85 -82.12 -46.36 13.95 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 136' ' ' LEU . . . . . 0.534 HD13 HD22 ' A' ' 87' ' ' LEU . 13.9 tp -97.55 113.67 25.42 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.906 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 90.8 p -56.05 -32.78 64.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.843 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.647 ' HB1' ' HG3' ' A' ' 141' ' ' ARG . . . -85.69 37.88 0.72 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.061 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 4.7 p90 -56.13 -27.93 55.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.867 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 140' ' ' GLN . . . . . 0.464 ' HG2' ' N ' ' A' ' 141' ' ' ARG . 17.9 pm0 -63.48 -30.41 71.54 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.942 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.78 ' O ' HG13 ' A' ' 62' ' ' VAL . 22.5 mtt180 -65.38 -36.11 82.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.824 -179.866 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.7 HG21 ' CB ' ' A' ' 69' ' ' ALA . 90.5 t -56.55 105.0 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.119 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -126.01 35.7 4.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.879 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 144' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 32' ' ' ARG . 0.6 OUTLIER -144.58 137.98 27.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.138 -179.874 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.687 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.0 tp -134.7 106.43 6.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.904 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 146' ' ' GLU . . . . . 0.432 ' HB3' ' CD1' ' A' ' 30' ' ' PHE . 4.9 pt-20 -109.22 149.16 29.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.934 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.56 HG12 HG23 ' A' ' 58' ' ' ILE . 12.7 mt -137.49 106.82 4.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.154 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -118.58 174.5 6.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.908 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 110.02 -140.81 15.99 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.482 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -117.86 91.92 3.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.811 0.338 . . . . 0.0 110.839 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.426 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 2.9 p -151.37 135.68 9.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.116 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 152' ' ' THR . . . . . 0.411 ' O ' ' CA ' ' A' ' 47' ' ' GLY . 17.7 m -95.93 92.82 6.68 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.171 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.494 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 93.3 mt -76.31 136.38 39.59 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.965 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 19.5 m -123.1 -39.27 2.5 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.858 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 37.3 t80 -141.81 127.07 18.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.905 -179.828 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 75.9 t -140.43 105.24 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.096 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -121.34 119.82 33.29 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.916 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 56.1 mt . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.107 -179.993 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.439 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.5 m . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.835 0.35 . . . . 0.0 111.127 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -137.35 120.18 16.35 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.907 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ASN . . . . . 0.53 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 8.8 m120 60.27 49.03 1.94 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.57 0.7 . . . . 0.0 110.899 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.53 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.2 Cg_endo -69.82 141.75 45.8 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.646 2.23 . . . . 0.0 112.296 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -178.02 2.14 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.63 2.22 . . . . 0.0 112.387 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.684 HG13 ' HA ' ' A' ' 28' ' ' PRO . 96.6 t -142.35 137.89 16.01 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.651 0.739 . . . . 0.0 111.088 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.684 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.8 Cg_endo -69.78 145.23 78.87 Favored 'Cis proline' 0 C--O 1.232 0.192 0 C-N-CA 122.65 -1.812 . . . . 0.0 112.394 -0.057 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -97.52 123.03 41.24 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.885 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -107.74 102.79 11.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.853 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -108.5 110.66 3.12 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.508 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.413 ' NH1' ' HA3' ' A' ' 63' ' ' GLY . 9.0 mmt180 -73.14 113.36 10.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.87 0.366 . . . . 0.0 110.887 -179.859 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 5.9 mt -73.25 97.9 2.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.909 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 20.6 mt-30 -66.79 94.76 0.32 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.885 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 135.69 -42.94 1.29 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.481 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.592 ' O ' HG23 ' A' ' 38' ' ' THR . . . 96.23 170.13 34.85 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.423 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' LEU . . . . . 0.768 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 96.1 mt -60.26 105.09 0.38 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.914 0.388 . . . . 0.0 110.913 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.592 HG23 ' O ' ' A' ' 36' ' ' GLY . 38.2 p -117.31 158.76 23.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.119 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -64.32 -16.12 61.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.106 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -114.96 23.92 12.16 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.821 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.504 ' NH1' ' CG2' ' A' ' 158' ' ' ILE . 44.4 ttm-85 -112.6 135.35 53.42 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.869 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 92.3 m -133.16 126.1 30.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.166 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.466 ' N ' HD12 ' A' ' 43' ' ' ILE . 4.6 mp -95.44 138.86 20.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.166 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 88.7 mt -128.91 126.67 65.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.13 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 58.5 mt -126.08 107.59 17.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.117 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 23.2 mtmt -112.05 112.43 24.06 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.883 179.849 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -143.69 -141.91 3.87 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.436 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' TYR . . . . . 0.586 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.6 OUTLIER -169.28 124.03 0.84 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.931 0.396 . . . . 0.0 110.928 -179.775 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.543 HG23 ' CD2' ' A' ' 109' ' ' PHE . 14.1 t -75.35 116.39 54.17 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.651 0.738 . . . . 0.0 111.113 179.923 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 158.94 55.28 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.671 2.247 . . . . 0.0 112.355 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 -21.93 32.93 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.711 2.274 . . . . 0.0 112.393 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 24.4 p -105.88 18.88 21.44 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.142 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -110.2 117.71 4.81 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.44 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 29.2 mtpt -61.58 -60.04 4.3 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.797 0.332 . . . . 0.0 110.891 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 10.5 p -174.59 154.87 2.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.882 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.585 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 5.2 p90 -109.54 -173.48 2.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.881 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.846 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -155.24 143.9 20.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.123 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.465 HG22 ' CE1' ' A' ' 60' ' ' PHE . 2.8 mp -123.91 99.0 5.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.142 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.7 m-80 -99.0 143.71 28.98 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.934 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.551 ' HB3' HG11 ' A' ' 142' ' ' VAL . 15.8 m-85 -118.24 97.26 5.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.864 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.437 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 31.5 ttmt -96.66 169.77 9.65 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.906 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.623 HG22 ' HA ' ' A' ' 142' ' ' VAL . 28.4 t -101.42 124.75 55.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.097 179.871 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.413 ' HA3' ' NH1' ' A' ' 32' ' ' ARG . . . -59.72 -36.21 88.95 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.51 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 23.1 t -67.21 -73.57 0.13 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.86 0.362 . . . . 0.0 110.857 -179.75 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 10.6 t -78.17 -72.48 0.37 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 -179.795 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 129.51 42.33 0.23 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.459 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.431 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.1 m-20 -115.12 140.89 48.69 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.817 0.341 . . . . 0.0 110.84 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.615 HD12 ' HB3' ' A' ' 86' ' ' LEU . 55.2 mt -86.08 122.17 38.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.113 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.517 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -92.93 -31.8 14.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.087 179.831 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.655 HD22 ' CD2' ' A' ' 132' ' ' PHE . 40.0 tp -140.44 131.1 25.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.903 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.488 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.5 OUTLIER -134.1 92.31 2.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.863 179.862 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.515 HD11 HD21 ' A' ' 70' ' ' LEU . 55.7 mt -95.84 130.53 44.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.142 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.846 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 8.5 t-20 -137.79 106.0 8.23 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.632 0.729 . . . . 0.0 110.905 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.585 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.3 Cg_endo -69.71 155.45 66.06 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.698 2.265 . . . . 0.0 112.394 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 39.3 mtp180 -130.67 96.11 4.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.868 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' MET . . . . . 0.4 ' HE3' ' HB3' ' A' ' 103' ' ' PHE . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.85 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.9 p . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.83 0.348 . . . . 0.0 111.112 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.455 HG21 ' HE2' ' A' ' 103' ' ' PHE . 20.6 t -99.67 108.38 22.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.169 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.641 HG22 ' HD3' ' A' ' 96' ' ' LYS . 47.3 t -76.95 143.1 13.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.133 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' ARG . . . . . 0.437 ' NH1' ' CD2' ' A' ' 130' ' ' PHE . 0.2 OUTLIER -126.93 129.87 49.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.873 -179.977 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.488 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.4 OUTLIER -140.6 179.65 6.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.905 -179.922 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 28.8 t -160.06 105.01 1.52 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.891 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.904 HD12 ' O ' ' A' ' 90' ' ' SER . 24.9 tp -76.92 118.29 19.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.93 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.51 ' N ' ' O ' ' A' ' 90' ' ' SER . 86.5 mt -95.8 161.63 13.94 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.901 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.462 ' C ' ' H ' ' A' ' 90' ' ' SER . 0.2 OUTLIER -38.64 101.81 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.911 179.931 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.33 -6.09 0.86 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.493 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.904 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -118.47 169.24 9.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.879 0.371 . . . . 0.0 110.84 -179.705 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.862 ' NE1' HD13 ' A' ' 86' ' ' LEU . 20.5 m95 -128.39 161.29 29.81 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.939 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -93.96 -111.71 2.26 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.467 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' SER . . . . . 0.433 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 39.3 m -158.0 170.97 21.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.839 0.352 . . . . 0.0 110.844 -179.717 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -94.87 123.32 38.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.913 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -120.99 120.52 35.65 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.888 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.641 ' HD3' HG22 ' A' ' 82' ' ' VAL . 9.4 mtmp? -123.41 120.02 31.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.913 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -170.75 109.67 0.34 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.903 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.843 HD11 ' O ' ' A' ' 100' ' ' HIS . 2.8 tt -148.84 154.2 10.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.127 179.86 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.445 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 9.0 t -93.95 -40.91 9.87 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.176 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 100' ' ' HIS . . . . . 0.843 ' O ' HD11 ' A' ' 98' ' ' ILE . 2.4 p-80 -147.18 128.44 14.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.865 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -103.32 95.62 7.23 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.652 0.739 . . . . 0.0 110.865 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.45 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.7 Cg_endo -69.79 -40.24 5.51 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.715 2.277 . . . . 0.0 112.324 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.477 ' CE2' ' HB3' ' A' ' 74' ' ' PRO . 8.1 m-85 -34.46 112.01 0.13 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.811 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -138.34 134.67 6.99 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.494 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 98.05 0.66 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.685 2.256 . . . . 0.0 112.337 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 126.01 -3.59 7.9 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.493 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.3 pt20 -132.46 149.39 52.34 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.806 0.336 . . . . 0.0 110.926 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' PHE . . . . . 0.586 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 79.8 m-85 -67.04 169.91 7.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.883 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.543 ' CD2' HG23 ' A' ' 49' ' ' VAL . 19.6 p90 -161.1 120.02 2.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.847 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -96.6 107.13 19.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.895 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.786 HD13 ' N ' ' A' ' 112' ' ' SER . 0.6 OUTLIER -108.95 138.56 45.1 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.926 -179.921 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.786 ' N ' HD13 ' A' ' 111' ' ' LEU . 3.7 m -145.27 115.4 7.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.854 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.509 HG23 HG22 ' A' ' 122' ' ' VAL . 4.1 mp -95.12 138.89 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.105 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 45.6 mtt-85 -113.19 123.74 50.92 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.874 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 115' ' ' CYS . . . . . 0.578 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 11.2 t -92.75 117.53 30.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.872 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.87 -142.41 7.83 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.468 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 17.4 mt -121.43 -35.99 3.16 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.788 0.328 . . . . 0.0 110.884 -179.9 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -92.32 -33.36 14.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.856 179.842 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -174.07 164.62 4.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.871 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.768 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 2.8 m-30 -90.52 156.8 17.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.921 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 23.2 mtpp -128.9 103.23 6.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.927 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.737 HG13 HD11 ' A' ' 111' ' ' LEU . 46.3 t -92.7 127.95 44.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.121 179.92 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 14.7 m-85 -117.9 153.05 34.23 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.878 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -135.89 110.4 8.55 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.128 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 57.38 33.43 23.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.857 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 82.35 29.52 36.52 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.498 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 37.2 mm-40 -138.27 121.52 16.97 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.845 0.355 . . . . 0.0 110.907 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 26.4 t-80 -54.41 110.71 0.66 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.86 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.446 HD21 ' CZ ' ' A' ' 103' ' ' PHE . 8.6 tp -76.81 -66.45 0.82 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.906 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.437 ' CD2' ' NH1' ' A' ' 83' ' ' ARG . 5.3 p90 -166.24 171.26 12.38 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.882 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -111.4 147.07 36.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.887 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.655 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -113.01 107.46 15.99 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.872 -179.872 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.557 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -64.0 130.95 46.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.132 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 26.1 m170 -58.5 111.81 1.37 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.838 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.433 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 44.9 mtt-85 -96.08 -44.18 7.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.915 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 4.4 tp -100.96 109.35 21.26 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 97.4 p -49.37 -34.39 15.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.512 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -83.27 31.53 0.45 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.086 179.893 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.533 ' O ' HD12 ' A' ' 37' ' ' LEU . 3.9 p90 -50.44 -40.09 49.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.846 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 10.4 pt20 -52.87 -43.21 65.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.904 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.512 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 56.9 mtp85 -50.95 -42.76 60.04 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.874 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.623 ' HA ' HG22 ' A' ' 62' ' ' VAL . 97.1 t -44.35 106.12 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.121 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -130.43 29.44 4.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.838 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 25.4 m -139.92 112.65 7.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.124 -179.89 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.537 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.0 tp -110.54 108.03 17.86 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.929 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 146' ' ' GLU . . . . . 0.406 ' C ' HG13 ' A' ' 147' ' ' ILE . 1.2 pm0 -111.67 153.59 26.18 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.858 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.406 HG13 ' C ' ' A' ' 146' ' ' GLU . 16.9 mt -139.39 112.05 5.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.135 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -121.14 172.35 8.04 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.928 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 110.6 -142.47 16.71 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.452 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -117.49 93.57 4.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.88 0.371 . . . . 0.0 110.847 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.4 p -151.23 152.24 11.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.182 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 27.8 m -113.55 93.59 4.46 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.141 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.477 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 79.2 mt -73.03 141.4 47.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.94 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 50.1 m -125.83 -28.54 3.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.857 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 31.3 t80 -157.56 129.97 7.3 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 90.2 t -140.53 105.52 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.108 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 18.8 tt0 -121.13 140.56 51.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.855 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 158' ' ' ILE . . . . . 0.504 ' CG2' ' NH1' ' A' ' 41' ' ' ARG . 14.9 mt . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.092 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.429 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.9 m . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.83 0.347 . . . . 0.0 111.15 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -143.18 137.32 28.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.824 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ASN . . . . . 0.549 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 9.0 m120 45.44 47.94 4.51 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.61 0.719 . . . . 0.0 110.93 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.549 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 54.1 Cg_endo -69.71 139.26 39.96 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.641 2.227 . . . . 0.0 112.375 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -177.62 1.95 Allowed 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.693 2.262 . . . . 0.0 112.304 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.633 HG13 ' HA ' ' A' ' 28' ' ' PRO . 84.2 t -143.7 136.73 13.82 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.592 0.711 . . . . 0.0 111.124 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.633 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.4 Cg_endo -69.71 145.37 79.12 Favored 'Cis proline' 0 C--N 1.341 0.153 0 C-N-CA 122.681 -1.799 . . . . 0.0 112.373 -0.091 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 4.9 t80 -98.34 115.26 28.07 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.937 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -99.44 103.1 14.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.901 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -118.09 102.16 0.95 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.488 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.4 ' HA ' ' HA ' ' A' ' 144' ' ' THR . 0.0 OUTLIER -73.45 128.47 35.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.843 0.354 . . . . 0.0 110.867 -179.886 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.455 ' N ' ' O ' ' A' ' 143' ' ' ASP . 3.3 mt -74.0 150.25 40.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.885 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 10.6 mm100 -105.24 99.67 9.27 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.913 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 124.46 -55.92 0.7 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.488 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.538 ' O ' HG23 ' A' ' 38' ' ' THR . . . 119.47 169.65 14.3 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.515 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' LEU . . . . . 0.516 HD12 ' O ' ' A' ' 139' ' ' PHE . 87.5 mt -61.04 97.91 0.07 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.87 0.367 . . . . 0.0 110.953 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.538 HG23 ' O ' ' A' ' 36' ' ' GLY . 48.4 p -109.5 160.73 15.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.159 179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -58.1 -28.6 64.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.084 179.892 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 3.1 mpt_? -105.96 39.1 1.85 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.863 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 29.5 ttm-85 -117.76 137.62 52.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.872 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 93.6 m -138.41 120.84 16.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.155 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.46 ' N ' HD12 ' A' ' 43' ' ' ILE . 4.7 mp -94.35 134.99 29.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.148 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 93.3 mt -125.24 138.41 54.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.116 179.839 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 42.9 mt -138.92 107.65 3.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.103 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 8.6 mtmm -110.04 111.32 22.62 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.924 179.823 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -142.23 -143.14 4.16 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.478 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' TYR . . . . . 0.57 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 1.1 t80 -170.0 128.66 0.91 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.949 0.404 . . . . 0.0 110.91 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 4.4 t -80.41 115.96 58.55 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.624 0.726 . . . . 0.0 111.143 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.74 155.81 65.04 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.672 2.248 . . . . 0.0 112.369 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 -14.07 35.44 Favored 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.689 2.259 . . . . 0.0 112.33 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 46.8 p -112.24 15.91 20.25 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.107 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -112.06 118.88 4.85 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.491 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 14.1 mtpp -58.09 -62.78 1.57 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.77 0.319 . . . . 0.0 110.859 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 70.1 p -173.71 164.45 4.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.872 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.604 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 5.2 p90 -119.02 -173.27 2.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.879 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.56 138.73 15.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.105 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.598 HD11 ' CE2' ' A' ' 56' ' ' PHE . 3.7 mp -117.61 104.61 16.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.121 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 2.8 m-80 -105.24 147.94 27.51 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.883 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.571 ' CE1' HG22 ' A' ' 58' ' ' ILE . 2.4 m-85 -120.89 101.22 7.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.885 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.43 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 34.5 ttmt -95.78 167.26 11.37 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.901 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.774 HG22 ' HA ' ' A' ' 142' ' ' VAL . 94.2 t -100.27 121.09 50.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.097 179.889 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -57.0 -41.2 92.27 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.481 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 10.8 t -62.18 -72.2 0.13 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.885 0.374 . . . . 0.0 110.89 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.4 t -80.56 -71.04 0.48 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.878 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 128.26 42.48 0.25 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.507 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.549 ' OD1' ' ND2' ' A' ' 88' ' ' ASN . 1.5 m-20 -115.02 144.14 44.08 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.824 0.345 . . . . 0.0 110.856 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.609 HD12 ' HB3' ' A' ' 86' ' ' LEU . 42.8 mt -88.74 122.59 40.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.145 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.536 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -92.82 -34.77 13.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.134 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.708 HD21 HD11 ' A' ' 72' ' ' ILE . 30.3 tp -139.17 130.4 26.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.928 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.473 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.2 OUTLIER -134.81 92.14 2.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.83 179.914 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.708 HD11 HD21 ' A' ' 70' ' ' LEU . 16.0 mt -94.25 137.61 22.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.111 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -141.86 106.17 5.81 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.619 0.723 . . . . 0.0 110.923 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.604 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.8 Cg_endo -69.75 154.87 67.26 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.677 2.251 . . . . 0.0 112.302 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 63.7 mtt-85 -129.78 100.76 5.6 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.854 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.92 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 20.7 p . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.803 0.335 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.429 ' CG1' ' CG2' ' A' ' 72' ' ' ILE . 18.5 t -86.59 111.01 20.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.121 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.519 HG22 ' HD3' ' A' ' 96' ' ' LYS . 61.4 t -82.84 139.81 17.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.097 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -126.94 124.46 39.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.865 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.473 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.5 OUTLIER -135.11 -178.15 4.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.885 -179.909 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 47.5 t -160.16 105.02 1.5 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.867 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.9 HD13 ' NE1' ' A' ' 91' ' ' TRP . 38.1 tp -77.09 116.71 17.98 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.932 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.518 ' N ' ' O ' ' A' ' 90' ' ' SER . 86.4 mt -94.84 162.07 13.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.9 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.549 ' ND2' ' OD1' ' A' ' 67' ' ' ASP . 9.7 m120 -40.88 102.0 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.86 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.49 -1.39 3.11 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.516 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.84 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -125.62 171.59 10.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.886 0.374 . . . . 0.0 110.841 -179.74 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.9 ' NE1' HD13 ' A' ' 86' ' ' LEU . 22.1 m95 -128.74 158.64 38.06 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.877 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -88.75 -96.3 1.02 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.427 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 2.0 m -174.68 164.76 3.66 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.894 0.378 . . . . 0.0 110.841 -179.711 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.404 ' HG3' ' ND2' ' A' ' 84' ' ' ASN . 14.2 mp0 -88.63 118.5 28.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.878 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 72.4 mm-40 -116.09 121.03 40.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.897 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.519 ' HD3' HG22 ' A' ' 82' ' ' VAL . 7.0 mtmp? -125.58 118.67 26.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.86 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -169.66 108.16 0.4 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.873 179.835 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.583 HD11 ' O ' ' A' ' 100' ' ' HIS . 10.5 tt -147.89 151.19 13.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.132 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.476 HG23 ' N ' ' A' ' 100' ' ' HIS . 8.9 t -91.64 -43.92 9.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.168 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 100' ' ' HIS . . . . . 0.583 ' O ' HD11 ' A' ' 98' ' ' ILE . 2.0 p-80 -145.0 127.58 16.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.896 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' ASN . . . . . 0.414 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 38.6 t-20 -104.74 98.49 15.21 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.633 0.73 . . . . 0.0 110.835 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.414 ' HD2' ' HA ' ' A' ' 101' ' ' ASN . 53.8 Cg_endo -69.81 -37.14 9.45 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.674 2.25 . . . . 0.0 112.331 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.547 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 20.9 m-85 -37.96 112.83 0.24 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.892 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -137.92 137.98 9.26 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.468 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 100.21 0.81 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.69 2.26 . . . . 0.0 112.303 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 120.85 0.9 11.84 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.457 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -135.22 148.6 49.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.815 0.34 . . . . 0.0 110.93 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 108' ' ' PHE . . . . . 0.57 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 76.8 m-85 -68.23 171.08 7.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.822 -179.892 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 28.1 p90 -161.26 124.79 3.29 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.903 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -99.45 104.5 16.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.871 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.78 HD13 ' N ' ' A' ' 112' ' ' SER . 0.6 OUTLIER -104.68 136.83 43.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.903 -179.945 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.78 ' N ' HD13 ' A' ' 111' ' ' LEU . 3.6 m -145.03 113.64 6.72 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.828 -179.864 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.5 HG22 ' HD2' ' A' ' 120' ' ' PHE . 4.4 mp -96.56 137.22 24.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.111 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 114' ' ' ARG . . . . . 0.497 ' O ' ' CD2' ' A' ' 120' ' ' PHE . 18.2 mtp180 -110.11 138.12 46.92 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.852 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 115' ' ' CYS . . . . . 0.465 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 17.7 t -105.13 120.11 40.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.917 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -115.02 -140.55 7.23 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.447 -179.867 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.5 mt -117.53 -38.08 3.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.785 0.326 . . . . 0.0 110.895 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 118' ' ' ASP . . . . . 0.444 ' C ' ' HG3' ' A' ' 119' ' ' ARG . 20.3 t70 -89.79 -45.69 9.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.895 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.444 ' HG3' ' C ' ' A' ' 118' ' ' ASP . 32.3 mtp180 -157.56 -177.07 6.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.879 -179.903 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.5 ' HD2' HG22 ' A' ' 113' ' ' ILE . 12.4 m-85 -103.32 162.09 13.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.876 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 21.4 mtpp -134.26 105.15 6.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.906 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.577 HG13 HD11 ' A' ' 111' ' ' LEU . 57.8 t -90.44 136.48 23.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.1 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -124.85 143.57 50.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.955 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.405 ' HB1' ' HG3' ' A' ' 102' ' ' PRO . . . -131.13 106.93 8.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.039 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 59.1 35.83 23.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.918 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.69 40.55 17.76 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.448 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 18.9 mt-30 -146.84 135.64 22.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.868 0.366 . . . . 0.0 110.919 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 40.8 t-80 -66.77 100.75 0.73 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.89 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 10.2 tp -69.1 -68.58 0.39 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.875 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.482 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 4.4 p90 -164.02 171.3 15.4 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.845 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 24.1 p-10 -110.65 158.79 18.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.906 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.589 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -129.86 104.49 7.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.85 -179.883 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.555 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -62.99 135.71 57.44 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.04 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 29.7 m170 -62.82 108.22 1.14 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.859 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 4.9 mtp-105 -88.37 -48.71 7.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.891 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 8.5 tp -94.06 108.1 19.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.913 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 14.7 t -47.31 -36.0 8.71 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.494 ' HB1' ' HG3' ' A' ' 141' ' ' ARG . . . -83.47 33.32 0.46 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.101 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.516 ' O ' HD12 ' A' ' 37' ' ' LEU . 28.5 p90 -50.05 -36.12 27.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.872 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 6.1 pt20 -53.45 -46.4 69.86 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.904 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.494 ' HG3' ' HB1' ' A' ' 138' ' ' ALA . 31.5 mtt180 -49.7 -41.78 44.22 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.859 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.774 ' HA ' HG22 ' A' ' 62' ' ' VAL . 61.9 t -48.71 100.3 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.138 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.455 ' O ' ' N ' ' A' ' 33' ' ' LEU . 3.9 p30 -124.95 26.24 7.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.906 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 144' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 32' ' ' ARG . 0.8 OUTLIER -132.1 131.72 42.62 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.142 -179.848 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.477 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.8 tp -128.82 104.85 7.86 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.922 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -108.88 151.57 26.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.904 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 15.5 mt -136.82 118.23 18.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.127 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -128.65 173.43 10.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.891 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.41 -151.34 16.91 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.519 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -107.23 92.75 4.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.855 0.36 . . . . 0.0 110.845 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.435 HG22 ' N ' ' A' ' 152' ' ' THR . 7.7 p -151.19 154.88 7.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.094 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 152' ' ' THR . . . . . 0.435 ' N ' HG22 ' A' ' 151' ' ' VAL . 23.3 m -114.83 93.91 4.53 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.151 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.406 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 50.1 mt -79.25 132.83 36.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.911 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 14.7 m -117.42 -40.88 3.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.851 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 59.7 t80 -140.37 130.13 24.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.947 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 89.8 t -140.53 105.15 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.092 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 13.8 tt0 -120.81 121.93 39.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.958 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 14.9 mt . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.169 179.957 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.558 ' CG2' ' N ' ' A' ' 23' ' ' PHE . 1.9 m . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.786 0.327 . . . . 0.0 111.163 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.558 ' N ' ' CG2' ' A' ' 22' ' ' THR . 11.9 m-85 -156.01 135.95 12.75 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.908 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ASN . . . . . 0.544 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 72.3 m-20 42.9 48.42 3.7 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.645 0.736 . . . . 0.0 110.927 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.544 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.6 Cg_endo -69.74 137.96 36.75 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.709 2.273 . . . . 0.0 112.301 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -176.11 1.38 Allowed 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.646 2.231 . . . . 0.0 112.334 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.675 HG13 ' HA ' ' A' ' 28' ' ' PRO . 98.4 t -142.97 137.87 15.33 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.668 0.747 . . . . 0.0 111.109 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.675 ' HA ' HG13 ' A' ' 27' ' ' VAL . 54.0 Cg_endo -69.75 145.58 79.8 Favored 'Cis proline' 0 C--O 1.232 0.179 0 C-N-CA 122.71 -1.787 . . . . 0.0 112.342 -0.02 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 13.3 t80 -96.87 121.17 38.44 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.946 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -101.79 101.46 11.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.865 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -98.96 109.94 3.89 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.526 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 4.1 mmm180 -72.87 99.51 2.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.866 0.365 . . . . 0.0 110.877 -179.864 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 27.6 mt -66.94 93.05 0.25 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.905 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 18.7 mp0 -67.99 93.69 0.44 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.938 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.75 -37.77 1.9 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.501 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 91.19 175.07 43.71 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.454 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' LEU . . . . . 0.498 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 78.4 mt -65.4 93.43 0.15 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.859 0.361 . . . . 0.0 110.911 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 44.0 p -105.33 154.56 20.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.136 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -49.84 -30.61 10.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.061 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 2.6 mpt_? -105.13 34.93 2.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.875 -179.873 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 5.0 tpm_? -108.03 135.15 49.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 -179.878 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 85.3 m -136.87 116.35 12.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.193 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.0 mp -91.69 135.81 26.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.176 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 96.8 mt -127.38 132.95 68.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.116 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 50.7 mt -134.9 107.57 8.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.092 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 16.0 mtmt -111.2 111.4 22.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.864 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -142.88 -140.7 3.75 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.544 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' TYR . . . . . 0.568 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.4 OUTLIER -172.08 119.95 0.43 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.937 0.399 . . . . 0.0 110.941 -179.8 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 40.5 t -69.16 117.09 48.7 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.638 0.732 . . . . 0.0 111.15 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 154.98 67.25 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.69 2.26 . . . . 0.0 112.333 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.72 -16.11 37.55 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.693 2.262 . . . . 0.0 112.358 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 70.6 p -110.41 18.6 19.66 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.122 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -113.54 123.23 6.06 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.465 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.403 ' O ' ' SD ' ' A' ' 76' ' ' MET . 22.2 mttt -63.03 -61.67 2.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.778 0.323 . . . . 0.0 110.859 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.8 p -174.03 157.9 3.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.886 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.599 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 12.3 p90 -111.16 -174.64 2.51 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.864 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.998 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -157.05 130.5 8.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.12 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.558 HG22 ' CE1' ' A' ' 60' ' ' PHE . 5.3 mp -112.91 101.78 12.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.11 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -101.2 143.59 31.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.913 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.558 ' CE1' HG22 ' A' ' 58' ' ' ILE . 16.0 m-85 -115.26 97.99 6.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.869 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.459 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 35.8 ttmt -96.79 167.88 10.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.886 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.781 HG22 ' HA ' ' A' ' 142' ' ' VAL . 59.1 t -100.94 123.88 54.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.089 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -59.79 -39.74 95.75 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.455 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 7.6 t -62.93 -70.67 0.19 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.868 0.366 . . . . 0.0 110.867 -179.728 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 60.0 m -82.33 -71.43 0.49 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.863 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 128.32 42.68 0.24 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.451 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' ASP . . . . . 0.549 ' OD1' ' ND2' ' A' ' 88' ' ' ASN . 3.9 m-20 -112.78 143.7 43.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.81 0.338 . . . . 0.0 110.847 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 66.6 mt -89.1 113.35 25.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.135 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.47 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -81.75 -39.3 24.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.105 179.836 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.738 HD21 HD11 ' A' ' 72' ' ' ILE . 48.1 tp -136.82 134.53 37.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.964 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.495 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.4 OUTLIER -134.89 97.03 3.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.894 179.877 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.738 HD11 HD21 ' A' ' 70' ' ' LEU . 27.0 mt -101.26 133.56 44.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.134 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.998 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 8.6 t-20 -140.53 106.51 6.5 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.674 0.749 . . . . 0.0 110.905 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.599 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.0 Cg_endo -69.67 154.7 67.76 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.713 2.275 . . . . 0.0 112.347 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 36.7 mtp180 -130.6 94.99 3.76 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.932 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' MET . . . . . 0.403 ' SD ' ' O ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.846 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 49.2 p . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.828 0.347 . . . . 0.0 111.142 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.514 HG22 ' HA ' ' A' ' 74' ' ' PRO . 14.1 t -99.8 110.45 26.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.132 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.558 HG22 ' HD3' ' A' ' 96' ' ' LYS . 32.7 t -82.52 144.78 9.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.13 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.86 124.17 38.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.864 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.495 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.3 m120 -136.32 178.59 6.94 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.914 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.433 ' CB ' ' O ' ' A' ' 69' ' ' ALA . 78.1 p -158.69 105.55 1.83 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.864 -179.84 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.921 HD13 ' NE1' ' A' ' 91' ' ' TRP . 28.3 tp -78.06 117.34 19.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.917 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.532 ' N ' ' O ' ' A' ' 90' ' ' SER . 86.0 mt -95.38 162.54 13.62 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.936 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.549 ' ND2' ' OD1' ' A' ' 67' ' ' ASP . 10.5 m120 -40.97 102.14 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.878 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.35 -2.47 3.14 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.492 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.813 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -124.63 170.54 10.85 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.81 0.338 . . . . 0.0 110.85 -179.72 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.921 ' NE1' HD13 ' A' ' 86' ' ' LEU . 21.8 m95 -128.1 160.73 31.08 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.936 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -89.53 -100.31 1.06 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.487 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 16.4 m -172.4 167.97 5.57 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.819 0.343 . . . . 0.0 110.849 -179.753 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -89.99 121.85 32.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.904 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -122.22 115.33 22.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.88 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.558 ' HD3' HG22 ' A' ' 82' ' ' VAL . 9.9 mtmp? -119.68 119.79 34.73 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.904 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 97' ' ' LYS . . . . . 0.478 ' HE3' ' N ' ' A' ' 98' ' ' ILE . 0.0 OUTLIER -173.9 105.11 0.12 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.866 179.846 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.912 HD11 ' O ' ' A' ' 100' ' ' HIS . 1.9 tt -141.76 149.86 19.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.172 179.862 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.461 HG23 ' CD2' ' A' ' 100' ' ' HIS . 4.7 t -84.45 -41.06 16.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.084 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 100' ' ' HIS . . . . . 0.912 ' O ' HD11 ' A' ' 98' ' ' ILE . 28.9 p80 -153.09 133.62 13.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.835 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 101' ' ' ASN . . . . . 0.407 ' C ' ' OD1' ' A' ' 101' ' ' ASN . 7.2 t-20 -103.47 95.84 7.74 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.597 0.713 . . . . 0.0 110.888 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.447 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.7 Cg_endo -69.77 -41.3 4.38 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.675 2.25 . . . . 0.0 112.368 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.564 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 10.2 m-85 -34.17 104.66 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.881 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -127.85 137.16 9.61 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.695 -0.765 . . . . 0.0 112.451 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 97.25 0.62 Allowed 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.715 2.277 . . . . 0.0 112.325 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 118.39 3.53 14.58 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.513 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 17.5 pt20 -133.73 137.82 45.44 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.819 0.343 . . . . 0.0 110.906 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 108' ' ' PHE . . . . . 0.568 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 79.7 m-85 -61.34 166.35 3.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.882 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 17.9 p90 -158.45 130.58 6.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.886 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -103.68 104.62 14.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.877 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 111' ' ' LEU . . . . . 0.775 HD13 ' N ' ' A' ' 112' ' ' SER . 0.7 OUTLIER -105.09 136.5 44.46 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.948 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 112' ' ' SER . . . . . 0.775 ' N ' HD13 ' A' ' 111' ' ' LEU . 3.8 m -145.15 113.49 6.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.864 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.601 HG23 HG22 ' A' ' 122' ' ' VAL . 4.0 mp -95.47 140.05 17.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.142 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 15.6 mtp85 -112.78 137.63 50.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.899 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 115' ' ' CYS . . . . . 0.582 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 2.9 t -110.03 114.47 28.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.874 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -113.77 -136.03 6.29 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.496 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 12.2 mt -121.52 -39.06 2.69 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.829 0.347 . . . . 0.0 110.924 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 23.2 p-10 -85.63 -37.26 19.69 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.88 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.8 ptp180 -173.66 172.62 3.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.875 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.582 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.7 m-30 -93.32 155.06 17.63 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.887 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 26.6 mtpt -128.99 102.12 6.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.898 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.601 HG22 HG23 ' A' ' 113' ' ' ILE . 51.5 t -89.27 136.77 22.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.105 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 57.9 m-85 -120.29 152.95 37.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.958 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 124' ' ' ALA . . . . . 0.604 ' HB2' HD13 ' A' ' 129' ' ' LEU . . . -136.55 107.12 6.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.097 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 53.56 35.61 21.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.929 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 84.09 29.26 31.67 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.477 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 20.0 mm-40 -140.77 119.53 12.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.819 0.342 . . . . 0.0 110.931 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 35.5 t-80 -52.06 103.85 0.07 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.846 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.604 HD13 ' HB2' ' A' ' 124' ' ' ALA . 10.6 tp -67.12 -67.71 0.43 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.923 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.499 ' HZ ' HD13 ' A' ' 72' ' ' ILE . 6.0 p90 -163.67 177.02 9.06 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.86 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 41.1 p30 -118.02 149.92 40.16 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.851 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.677 ' CD1' HD13 ' A' ' 70' ' ' LEU . 0.2 OUTLIER -117.17 107.02 13.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.872 -179.937 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.525 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -62.41 133.56 55.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.099 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 20.1 m170 -60.03 110.84 1.29 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.811 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.4 ' CD ' ' OG ' ' A' ' 85' ' ' SER . 10.0 mtt-85 -93.93 -51.5 4.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.878 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 6.8 tp -96.06 108.39 20.8 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.906 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 27.1 t -49.44 -33.33 13.87 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.862 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.468 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.45 25.76 0.6 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.073 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.406 ' CG ' ' N ' ' A' ' 140' ' ' GLN . 19.3 p90 -45.49 -41.78 9.96 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.895 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 140' ' ' GLN . . . . . 0.406 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 5.7 pt20 -49.75 -41.0 42.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.885 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.468 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 57.0 mtp180 -55.48 -39.74 70.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.874 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.781 ' HA ' HG22 ' A' ' 62' ' ' VAL . 85.6 t -48.11 106.8 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.14 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -131.81 34.08 3.91 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.867 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 16.2 m -141.38 115.32 9.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.167 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.52 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.2 tp -113.66 107.96 16.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.91 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 -113.0 150.7 31.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.896 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.423 HG23 HG13 ' A' ' 58' ' ' ILE . 17.0 mt -138.29 106.94 3.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.115 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -115.42 173.33 6.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.915 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.57 -146.37 16.22 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.469 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 46.7 m-20 -112.27 92.56 4.07 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.852 0.358 . . . . 0.0 110.843 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 5.8 p -151.28 138.06 12.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.124 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 33.7 m -99.62 93.92 6.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.134 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.462 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 68.8 mt -74.88 137.85 42.06 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.903 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 20.5 m -119.76 -39.28 2.86 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.878 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 155' ' ' TYR . . . . . 0.494 ' CE1' ' HB2' ' A' ' 157' ' ' GLN . 43.6 t80 -148.07 135.45 20.55 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.938 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 70.8 t -140.18 109.42 3.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.141 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 157' ' ' GLN . . . . . 0.494 ' HB2' ' CE1' ' A' ' 155' ' ' TYR . 14.7 tt0 -121.47 136.57 54.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.902 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 18.6 mt . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.065 -179.955 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 112.471 -0.252 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.2 m -158.13 138.23 12.42 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.85 0.357 . . . . 0.0 110.883 -179.74 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 39.2 m -129.96 161.94 29.79 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.855 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 91.76 140.09 9.02 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.48 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.3 m -160.43 137.53 9.22 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.832 0.349 . . . . 0.0 110.865 -179.708 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 44.2 t -66.24 -52.56 46.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.84 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 47.84 95.55 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.518 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 18.4 p80 -132.49 101.13 5.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.763 0.316 . . . . 0.0 110.88 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -49.44 -41.05 38.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.89 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 27.1 mt-30 -150.83 122.21 7.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.957 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.616 ' H ' HD12 ' A' ' 11' ' ' LEU . 5.2 mp -50.67 124.54 11.12 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.928 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.8 m120 -144.8 176.13 9.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.926 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 60.9 p -108.67 143.7 37.41 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.876 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.428 ' O ' HD12 ' A' ' 14' ' ' LEU . 3.4 pp -59.76 154.68 45.6 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.615 0.721 . . . . 0.0 110.9 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.72 -176.57 1.52 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.686 2.257 . . . . 0.0 112.337 179.858 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.483 HG23 ' H ' ' A' ' 18' ' ' GLU . 7.0 t -63.87 159.95 18.59 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.132 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' MET . . . . . 0.456 ' HE2' ' O ' ' A' ' 32' ' ' ARG . 17.7 mtm -98.76 43.53 1.06 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.872 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.483 ' H ' HG23 ' A' ' 16' ' ' THR . 7.1 mm-40 -79.91 -179.06 6.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.913 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 84.84 -156.78 31.71 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.474 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 169.49 18.82 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.653 2.235 . . . . 0.0 112.363 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.491 ' HB2' ' CE2' ' A' ' 155' ' ' TYR . 54.0 Cg_endo -69.8 160.68 48.81 Favored 'Trans proline' 0 C--O 1.232 0.213 0 C-N-CA 122.68 2.253 . . . . 0.0 112.334 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 2.3 t -78.77 148.29 33.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.147 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -129.61 120.78 25.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ASN . . . . . 0.48 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 12.4 m120 61.78 52.18 2.19 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.616 0.722 . . . . 0.0 110.907 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.48 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.2 Cg_endo -69.81 138.67 38.23 Favored 'Trans proline' 0 N--CA 1.466 -0.13 0 C-N-CA 122.705 2.27 . . . . 0.0 112.328 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 178.7 4.3 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.633 2.222 . . . . 0.0 112.357 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.694 HG13 ' HA ' ' A' ' 28' ' ' PRO . 95.4 t -138.09 138.24 22.83 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.658 0.742 . . . . 0.0 111.115 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.694 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.7 Cg_endo -69.7 143.61 74.22 Favored 'Cis proline' 0 C--N 1.342 0.193 0 C-N-CA 122.741 -1.774 . . . . 0.0 112.345 -0.083 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.473 ' CE1' HG11 ' A' ' 156' ' ' VAL . 2.2 t80 -95.82 116.68 29.27 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.886 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 72.3 m-85 -100.15 105.31 16.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.844 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -118.21 103.33 1.03 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.507 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.456 ' O ' ' HE2' ' A' ' 17' ' ' MET . 0.0 OUTLIER -72.44 135.4 45.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.84 0.352 . . . . 0.0 110.876 -179.837 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.894 HD23 HG12 ' A' ' 158' ' ' ILE . 4.9 mt -82.73 119.12 23.92 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.928 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 25.2 mt-30 -74.09 94.97 2.48 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.887 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 124.31 -55.81 0.7 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.483 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.443 ' O ' HG23 ' A' ' 38' ' ' THR . . . 120.37 176.3 15.69 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.51 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' LEU . . . . . 0.744 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 82.5 mt -62.6 101.37 0.24 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.936 0.398 . . . . 0.0 110.896 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.502 ' O ' ' N ' ' A' ' 41' ' ' ARG . 44.9 p -120.77 137.89 54.29 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.202 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.551 ' HB2' ' HG ' ' A' ' 117' ' ' LEU . . . -41.97 -23.39 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.119 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.444 ' N ' ' O ' ' A' ' 38' ' ' THR . 20.9 mmt180 -104.62 34.13 3.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.866 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.502 ' N ' ' O ' ' A' ' 38' ' ' THR . 4.6 ttt85 -121.05 139.86 52.74 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.931 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 85.9 m -137.66 117.55 13.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.154 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.1 mp -90.68 133.98 30.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.146 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 94.7 mt -127.55 134.33 65.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.123 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 48.5 mt -135.57 107.63 7.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.142 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.5 mtmt -109.35 108.19 18.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.917 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.52 -145.72 4.68 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.49 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' TYR . . . . . 0.564 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.7 OUTLIER -167.55 129.13 1.53 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.9 0.381 . . . . 0.0 110.912 -179.803 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 13.7 t -77.34 115.5 49.72 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.619 0.723 . . . . 0.0 111.116 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 155.54 65.7 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.681 2.254 . . . . 0.0 112.354 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -15.69 37.11 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.683 2.255 . . . . 0.0 112.344 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 52.8 p -109.65 14.2 23.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.13 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -111.22 122.82 6.25 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.523 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 17.5 mtpt -63.96 -60.21 3.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.798 0.332 . . . . 0.0 110.867 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.5 p -174.21 158.75 3.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.89 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.565 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 2.4 p90 -112.57 -173.72 2.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.851 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.067 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -155.56 135.57 12.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.157 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.454 HG22 ' CE1' ' A' ' 60' ' ' PHE . 3.6 mp -115.85 103.7 15.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.132 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.3 m-80 -104.41 143.13 33.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.904 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.726 ' CE2' HD13 ' A' ' 145' ' ' LEU . 6.7 m-85 -115.66 101.36 8.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.875 -179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.421 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 30.3 ttmt -95.33 169.08 10.32 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.89 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.61 HG22 ' HA ' ' A' ' 142' ' ' VAL . 35.0 t -100.24 123.73 53.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.136 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -60.59 -34.25 85.27 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.498 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.9 t -68.5 -71.54 0.21 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.926 0.393 . . . . 0.0 110.87 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 3.3 t -83.7 -71.34 0.51 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.856 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 131.6 40.82 0.22 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.5 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.598 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.9 m-20 -110.87 143.11 41.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.776 0.322 . . . . 0.0 110.853 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.629 HD12 ' HB3' ' A' ' 86' ' ' LEU . 39.2 mt -88.9 119.2 35.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.113 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.66 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -91.57 -33.12 15.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.109 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.616 HD22 ' CD2' ' A' ' 132' ' ' PHE . 52.5 tp -138.46 130.0 27.66 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.939 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.489 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.2 OUTLIER -134.82 92.71 2.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.844 179.891 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.579 HD11 HD21 ' A' ' 70' ' ' LEU . 29.0 mt -96.25 134.98 31.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.146 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 1.067 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 10.0 t-20 -140.33 107.76 6.7 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.596 0.712 . . . . 0.0 110.863 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.767 ' HA ' HG22 ' A' ' 81' ' ' VAL . 53.8 Cg_endo -69.79 154.87 67.1 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.665 2.243 . . . . 0.0 112.338 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 45.3 mtp85 -130.4 98.0 4.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.909 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -61.28 -39.99 92.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.878 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -60.63 -91.27 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.493 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 56.6 t30 -50.28 -56.41 11.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.933 0.397 . . . . 0.0 110.896 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 112.53 37.79 1.4 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.53 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 32.4 p -137.64 122.23 18.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.802 0.334 . . . . 0.0 111.122 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.767 HG22 ' HA ' ' A' ' 74' ' ' PRO . 36.0 t -91.44 108.54 20.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.136 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.566 HG22 ' HD3' ' A' ' 96' ' ' LYS . 48.7 t -79.93 146.69 7.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.11 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -128.87 130.21 46.57 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.845 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.489 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.9 OUTLIER -142.45 179.62 6.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.928 -179.971 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 89.5 p -157.99 107.25 2.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.901 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.892 HD13 ' NE1' ' A' ' 91' ' ' TRP . 27.6 tp -76.98 117.86 18.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.926 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.505 ' N ' ' O ' ' A' ' 90' ' ' SER . 82.7 mt -95.1 162.3 13.77 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.927 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.562 ' ND2' ' OD1' ' A' ' 67' ' ' ASP . 10.6 m120 -41.1 102.14 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.855 179.906 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.89 -1.49 3.37 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.51 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.828 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -125.63 172.49 9.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.839 0.352 . . . . 0.0 110.84 -179.722 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.892 ' NE1' HD13 ' A' ' 86' ' ' LEU . 25.0 m95 -129.4 160.67 32.37 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.932 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -90.34 -104.18 1.21 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.507 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 39.2 m -165.56 171.92 12.6 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.834 0.35 . . . . 0.0 110.852 -179.755 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -95.54 120.8 36.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.92 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 60.3 mt-10 -120.07 122.21 40.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.845 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.566 ' HD3' HG22 ' A' ' 82' ' ' VAL . 7.6 mtmp? -126.29 122.23 34.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.873 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 10.4 tptp -171.89 105.87 0.2 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.895 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.903 HD11 ' O ' ' A' ' 100' ' ' HIS . 2.0 tt -146.59 149.9 15.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.129 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.427 HG23 ' N ' ' A' ' 100' ' ' HIS . 9.2 t -91.65 -41.39 10.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.149 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' HIS . . . . . 0.903 ' O ' HD11 ' A' ' 98' ' ' ILE . 2.6 p-80 -144.06 131.64 21.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.834 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ASN . . . . . 0.411 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 24.7 t30 -109.21 96.52 21.89 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.632 0.73 . . . . 0.0 110.881 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.44 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.8 Cg_endo -69.78 -41.27 4.39 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.648 2.232 . . . . 0.0 112.305 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.569 ' CZ ' HD21 ' A' ' 129' ' ' LEU . 6.2 m-85 -35.33 108.65 0.07 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.898 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -137.14 138.77 10.02 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.48 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 103.12 1.11 Allowed 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.689 2.26 . . . . 0.0 112.38 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 119.95 -2.32 13.24 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.541 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.3 pt20 -134.03 147.62 50.97 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.857 0.361 . . . . 0.0 110.902 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' PHE . . . . . 0.564 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 29.6 m-85 -67.21 172.82 4.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.877 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.422 ' O ' ' CG ' ' A' ' 109' ' ' PHE . 14.4 p90 -161.33 124.25 3.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.867 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -99.08 105.09 17.16 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.837 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.757 HD13 ' N ' ' A' ' 112' ' ' SER . 0.7 OUTLIER -105.18 136.89 43.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.92 -179.98 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.757 ' N ' HD13 ' A' ' 111' ' ' LEU . 3.4 m -144.8 113.63 6.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.847 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.445 ' CD1' HD12 ' A' ' 111' ' ' LEU . 4.7 mp -96.68 135.43 30.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.147 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 40.0 mtt180 -108.51 126.26 52.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.886 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' CYS . . . . . 0.534 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 11.7 t -93.06 120.42 33.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.902 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -122.31 -159.8 10.73 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.511 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.551 ' HG ' ' HB2' ' A' ' 39' ' ' ALA . 7.8 mt -101.83 -42.3 6.2 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.838 0.351 . . . . 0.0 110.943 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -82.19 -37.1 26.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.883 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.1 ptt180 -173.5 -178.2 1.61 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.889 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.744 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 3.2 m-30 -102.48 158.52 16.16 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.892 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 24.2 mtpt -132.13 104.86 7.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.921 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.486 HG13 HD11 ' A' ' 111' ' ' LEU . 60.6 t -90.98 133.58 32.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.125 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 74.7 m-85 -121.69 146.96 46.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.938 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.526 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -133.27 107.98 8.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.133 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 55.04 39.5 31.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.885 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.12 36.73 34.43 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.451 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 22.6 mt-30 -143.93 123.65 13.36 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.848 0.356 . . . . 0.0 110.898 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 32.6 t-80 -57.79 95.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.863 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.569 HD21 ' CZ ' ' A' ' 103' ' ' PHE . 9.4 tp -60.88 -68.75 0.28 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.929 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.473 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 4.5 p90 -164.96 175.87 9.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.903 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -116.32 155.74 27.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.894 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.616 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.2 OUTLIER -122.38 104.58 9.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.847 -179.874 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.531 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -60.6 134.8 57.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.077 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 17.8 m170 -62.4 98.8 0.12 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.894 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 17.6 mtt-85 -81.47 -47.59 12.97 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.842 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' LEU . . . . . 0.453 HD13 HD22 ' A' ' 87' ' ' LEU . 7.8 tp -98.72 107.8 20.33 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.924 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 15.0 m -49.35 -33.19 12.9 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.839 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.495 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -83.3 27.67 0.57 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.122 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.468 ' O ' HD12 ' A' ' 37' ' ' LEU . 17.6 p90 -47.21 -44.29 22.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.892 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 140' ' ' GLN . . . . . 0.44 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 9.2 pt20 -46.24 -40.63 11.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.931 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.577 ' O ' HG13 ' A' ' 62' ' ' VAL . 16.1 mtp180 -54.33 -41.71 69.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.875 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.66 HG21 ' CB ' ' A' ' 69' ' ' ALA . 88.7 t -50.3 104.72 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.167 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -127.38 28.83 5.64 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.877 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.3 m -137.67 131.96 32.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.168 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.726 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.4 tp -128.47 109.09 11.09 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.944 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 -112.3 152.31 28.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.901 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 19.8 mt -137.47 113.54 11.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.135 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -123.06 174.19 7.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.954 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.4 -144.5 15.99 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.512 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -114.71 92.1 3.84 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.871 0.367 . . . . 0.0 110.845 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.448 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 5.1 p -151.04 142.77 16.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.134 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 25.8 m -102.37 93.25 5.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.163 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.464 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 95.9 mt -74.31 136.73 42.58 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.899 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 5.1 m -117.18 -39.36 3.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.871 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 155' ' ' TYR . . . . . 0.491 ' CE2' ' HB2' ' A' ' 21' ' ' PRO . 7.4 t80 -147.35 130.93 16.81 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.917 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.473 HG11 ' CE1' ' A' ' 29' ' ' TYR . 65.8 t -140.77 124.48 17.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.138 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 12.8 tt0 -148.85 132.95 17.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.908 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 158' ' ' ILE . . . . . 0.894 HG12 HD23 ' A' ' 33' ' ' LEU . 5.1 mp -92.82 88.61 2.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.152 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 20.2 m -55.66 131.04 45.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.81 -179.885 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -129.03 -157.57 9.3 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.449 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -1.38 8.38 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.694 2.263 . . . . 0.0 112.328 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 29.9 t -44.73 -63.74 0.85 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.844 -179.848 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 28.8 t -59.77 115.76 3.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.871 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.487 -179.992 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 63.2 p -153.94 156.16 36.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.874 0.368 . . . . 0.0 110.845 -179.737 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.7 t -109.72 125.71 52.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.875 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -157.8 173.83 35.13 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.49 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.1 t -157.22 155.1 30.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.907 0.384 . . . . 0.0 110.86 -179.764 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 30.9 t -137.95 148.42 45.23 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.813 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.61 -140.53 4.86 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.461 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 30.3 m170 -115.13 145.21 42.58 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.762 0.315 . . . . 0.0 110.868 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 50.8 mt-30 -146.52 143.87 29.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.917 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -54.25 155.08 3.95 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.916 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.562 ' C ' HD12 ' A' ' 11' ' ' LEU . 1.0 OUTLIER -101.94 -37.05 8.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.92 -179.978 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -56.87 -45.58 82.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.882 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 42.2 p -164.63 128.09 2.44 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.848 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.503 ' O ' HD12 ' A' ' 14' ' ' LEU . 4.2 pp -68.62 153.42 95.83 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.568 0.699 . . . . 0.0 110.93 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -164.91 0.14 Allowed 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.657 2.238 . . . . 0.0 112.338 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.502 HG23 ' HG3' ' A' ' 34' ' ' GLN . 1.3 m -88.57 151.54 22.43 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.16 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 25.4 mtp -85.25 89.9 7.77 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.916 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -125.73 160.51 29.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.886 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.411 ' HA3' ' HD2' ' A' ' 20' ' ' PRO . . . 95.22 -136.45 12.92 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.468 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.411 ' HD2' ' HA3' ' A' ' 19' ' ' GLY . 54.5 Cg_endo -69.71 168.64 20.92 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.689 2.26 . . . . 0.0 112.361 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.74 -175.37 1.13 Allowed 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.695 2.263 . . . . 0.0 112.354 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.468 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.6 m -95.53 151.41 19.34 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.119 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.468 ' CD1' ' O ' ' A' ' 22' ' ' THR . 9.8 m-85 -150.71 137.15 18.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.887 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ASN . . . . . 0.601 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 52.8 m-80 51.37 44.48 2.16 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.663 0.744 . . . . 0.0 110.919 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.601 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.78 133.82 26.45 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.632 2.221 . . . . 0.0 112.316 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.85 179.36 3.8 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.673 2.249 . . . . 0.0 112.361 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.677 HG13 ' HA ' ' A' ' 28' ' ' PRO . 86.6 t -138.79 137.68 20.27 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.606 0.717 . . . . 0.0 111.134 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.677 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.2 Cg_endo -69.77 144.21 76.03 Favored 'Cis proline' 0 C--O 1.231 0.161 0 C-N-CA 122.668 -1.805 . . . . 0.0 112.338 -0.074 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 2.9 t80 -94.13 120.15 33.98 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.927 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -105.12 102.14 11.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.899 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -109.7 109.43 2.71 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.471 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 6.4 mmt85 -73.38 108.93 6.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.875 0.369 . . . . 0.0 110.873 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.429 ' HB3' ' NH1' ' A' ' 41' ' ' ARG . 5.3 mt -70.58 92.76 0.86 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.918 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.502 ' HG3' HG23 ' A' ' 16' ' ' THR . 14.9 mm-40 -64.73 105.36 0.97 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.896 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 130.59 -46.89 1.05 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.477 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.661 ' O ' HG23 ' A' ' 38' ' ' THR . . . 98.67 161.36 29.98 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.51 -179.909 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' LEU . . . . . 0.646 HD12 ' O ' ' A' ' 139' ' ' PHE . 95.9 mt -54.81 107.14 0.26 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.903 0.383 . . . . 0.0 110.872 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.661 HG23 ' O ' ' A' ' 36' ' ' GLY . 73.0 p -118.71 149.04 42.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.128 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -49.8 -23.62 1.95 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.085 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.412 ' HB3' ' NH1' ' A' ' 40' ' ' ARG . 0.0 OUTLIER -108.81 34.19 3.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.882 -179.921 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.429 ' NH1' ' HB3' ' A' ' 33' ' ' LEU . 13.1 ttm180 -113.81 139.28 49.27 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.859 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 74.2 m -137.52 119.83 15.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.134 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 mp -91.92 136.27 24.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.109 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 97.0 mt -131.25 133.55 62.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.107 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 34.5 mt -136.53 111.52 10.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.143 179.861 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 16.1 mtmt -112.68 109.0 18.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.923 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -138.1 -142.95 4.42 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.44 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' TYR . . . . . 0.435 ' O ' ' CD1' ' A' ' 48' ' ' TYR . 0.5 OUTLIER -170.2 117.04 0.54 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.914 0.388 . . . . 0.0 110.939 -179.769 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 15.2 t -70.19 115.8 38.05 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.644 0.735 . . . . 0.0 111.139 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 157.52 60.12 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.678 2.252 . . . . 0.0 112.356 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -15.42 37.17 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.664 2.243 . . . . 0.0 112.34 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 21.5 p -109.71 17.11 21.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.18 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -110.69 118.99 5.13 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.511 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.3 mtpt -61.31 -60.63 3.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.778 0.323 . . . . 0.0 110.912 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 13.2 p -173.64 158.44 3.35 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.869 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.607 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 6.1 p90 -115.88 -174.68 2.58 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.864 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.067 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -154.81 145.3 22.17 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.126 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.526 HG22 ' CE1' ' A' ' 60' ' ' PHE . 3.2 mp -123.52 98.77 5.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.115 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.7 m-80 -98.86 141.98 30.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.914 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.526 ' CE1' HG22 ' A' ' 58' ' ' ILE . 10.5 m-85 -117.16 99.03 6.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.893 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.441 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 31.3 ttmt -96.62 169.24 10.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.878 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.658 HG22 ' HA ' ' A' ' 142' ' ' VAL . 38.7 t -101.44 119.59 49.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.129 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -55.22 -36.79 62.82 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.502 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.5 m -66.47 -72.86 0.15 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.889 0.376 . . . . 0.0 110.904 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 19.7 m -79.34 -74.68 0.28 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.868 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 132.92 38.58 0.23 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.523 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.414 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.5 m-20 -111.36 143.61 41.89 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.795 0.331 . . . . 0.0 110.846 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.572 HD12 ' HB3' ' A' ' 86' ' ' LEU . 47.4 mt -89.77 117.71 33.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.123 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.41 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -89.25 -31.07 18.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.122 179.783 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.663 HD22 ' CD2' ' A' ' 132' ' ' PHE . 53.2 tp -140.84 130.25 23.83 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.927 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.543 ' CD2' ' C ' ' A' ' 71' ' ' HIS . 2.7 t-160 -134.91 92.55 2.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.884 179.82 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.599 HD11 HD21 ' A' ' 70' ' ' LEU . 26.3 mt -96.36 133.81 36.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.149 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 1.067 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 9.1 t-20 -141.24 106.78 6.13 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.619 0.723 . . . . 0.0 110.853 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.607 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.8 Cg_endo -69.78 155.28 66.3 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.647 2.231 . . . . 0.0 112.364 179.902 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 68.3 mtp180 -130.55 99.35 4.95 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -57.49 148.64 23.11 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.899 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 87.16 -89.89 1.65 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.495 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 10.6 t-20 -42.78 -56.0 3.39 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.908 0.385 . . . . 0.0 110.873 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 98.57 54.59 1.14 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.467 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 16.9 p -147.7 118.19 7.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.795 0.331 . . . . 0.0 111.133 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.402 HG22 ' HA ' ' A' ' 74' ' ' PRO . 21.3 t -99.67 111.72 30.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.123 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.545 HG22 ' HD3' ' A' ' 96' ' ' LYS . 92.5 t -79.36 142.06 14.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.176 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ARG . . . . . 0.557 ' NH1' ' CD2' ' A' ' 130' ' ' PHE . 0.3 OUTLIER -126.19 125.52 42.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.885 -179.948 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.452 ' O ' ' N ' ' A' ' 71' ' ' HIS . 2.0 m-80 -137.39 177.82 7.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.883 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 28.9 t -158.92 105.08 1.76 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.814 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.938 HD12 ' O ' ' A' ' 90' ' ' SER . 25.6 tp -77.36 119.58 21.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.918 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.513 ' N ' ' O ' ' A' ' 90' ' ' SER . 77.7 mt -96.98 161.47 13.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.893 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.486 ' C ' ' H ' ' A' ' 90' ' ' SER . 16.8 p-10 -38.28 101.67 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.868 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.76 -7.12 0.73 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.488 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.938 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -118.13 170.74 8.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.885 0.374 . . . . 0.0 110.855 -179.719 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.828 ' NE1' HD13 ' A' ' 86' ' ' LEU . 21.4 m95 -128.31 160.89 30.75 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.959 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -94.16 -116.85 2.78 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.454 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 33.8 m -152.14 178.61 9.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.79 0.329 . . . . 0.0 110.898 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -103.73 126.05 50.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.891 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -123.36 105.37 9.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.893 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.545 ' HD3' HG22 ' A' ' 82' ' ' VAL . 18.2 mtmm -111.69 122.46 47.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.919 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -171.54 105.95 0.22 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.905 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.801 HD11 ' O ' ' A' ' 100' ' ' HIS . 3.0 tt -145.13 152.85 14.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.125 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.44 HG23 ' N ' ' A' ' 100' ' ' HIS . 9.5 t -96.39 -41.9 8.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.141 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' HIS . . . . . 0.801 ' O ' HD11 ' A' ' 98' ' ' ILE . 4.4 p-80 -142.89 128.57 19.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.852 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 -103.29 95.55 7.09 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.652 0.739 . . . . 0.0 110.882 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.444 ' HD2' HD11 ' A' ' 129' ' ' LEU . 53.2 Cg_endo -69.75 -40.41 5.38 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.702 2.268 . . . . 0.0 112.318 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -41.01 108.41 0.09 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.867 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -131.49 139.64 11.11 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.491 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 100.62 0.84 Allowed 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.714 2.276 . . . . 0.0 112.328 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 117.89 6.63 12.45 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.472 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 4.7 pt20 -137.17 143.92 42.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.78 0.324 . . . . 0.0 110.926 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -66.14 168.76 7.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.915 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 30.1 p90 -161.28 144.74 12.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.85 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -118.31 101.73 8.41 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.87 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.659 HD13 ' N ' ' A' ' 112' ' ' SER . 1.1 tm? -99.24 137.18 38.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.923 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.659 ' N ' HD13 ' A' ' 111' ' ' LEU . 6.2 m -144.98 111.27 5.61 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.864 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.64 HD11 HD12 ' A' ' 111' ' ' LEU . 4.8 mp -94.73 135.57 28.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.081 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -109.61 130.59 55.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.846 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' CYS . . . . . 0.581 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 11.9 t -101.19 116.02 31.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.876 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -115.26 -143.9 8.17 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.517 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.7 mt -116.02 -37.47 3.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.829 0.347 . . . . 0.0 110.88 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -87.66 -37.5 16.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.873 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.9 ptt180 -173.85 170.38 3.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.874 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.581 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.1 m-30 -90.71 158.23 17.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.85 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 30.5 mtpt -132.33 99.39 4.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.886 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 97.6 t -86.73 139.18 17.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.095 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 84.3 m-85 -129.4 148.96 51.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.947 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -137.12 109.77 7.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.096 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 57.97 34.66 24.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.849 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.9 40.5 21.23 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.494 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -144.84 134.86 23.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.81 0.338 . . . . 0.0 110.875 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 32.2 t-80 -68.06 101.31 1.12 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.865 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.444 HD11 ' HD2' ' A' ' 102' ' ' PRO . 8.0 tp -71.7 -67.39 0.53 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.898 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.557 ' CD2' ' NH1' ' A' ' 83' ' ' ARG . 5.1 p90 -166.89 173.44 9.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.886 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -116.12 155.69 27.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.663 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -120.15 104.47 10.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.896 -179.883 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.574 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -59.62 136.64 58.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.101 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 24.6 m80 -63.52 106.16 0.89 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.879 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 23.6 mtt-85 -91.73 -50.2 5.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.861 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 6.1 tp -95.43 109.02 21.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.923 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 41.3 t -51.67 -33.4 33.7 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.812 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.501 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.67 23.83 0.77 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.097 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.646 ' O ' HD12 ' A' ' 37' ' ' LEU . 32.0 p90 -45.57 -37.87 5.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.854 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -52.73 -46.97 67.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.918 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.501 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 70.6 mtp85 -48.63 -43.38 36.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.87 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.658 ' HA ' HG22 ' A' ' 62' ' ' VAL . 85.5 t -41.24 106.93 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.171 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -131.86 31.68 4.18 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.861 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 18.9 m -142.03 114.94 8.66 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.134 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.517 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.9 tp -111.89 108.46 17.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.917 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 146' ' ' GLU . . . . . 0.433 ' C ' HG13 ' A' ' 147' ' ' ILE . 3.6 pt-20 -111.77 155.29 23.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.91 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.442 HG12 HG23 ' A' ' 58' ' ' ILE . 35.2 mt -143.45 116.4 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.105 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -124.79 170.27 11.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.94 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.79 -153.47 16.8 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.496 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -104.17 93.28 4.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.808 0.337 . . . . 0.0 110.879 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 8.8 p -151.3 143.59 16.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.126 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 12.0 m -105.19 94.39 5.21 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.107 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 58.0 mt -78.51 134.4 37.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.88 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 58.6 m -119.25 -39.85 2.87 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.851 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 39.7 t80 -144.6 131.14 19.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.92 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 93.4 t -140.54 106.57 2.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.132 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 15.2 tt0 -118.42 138.97 52.1 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.922 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 18.4 mt -106.73 93.51 2.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.113 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 46.1 t -61.7 149.12 40.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.882 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 135.45 -166.15 24.56 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.479 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 100.67 0.83 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.682 2.255 . . . . 0.0 112.361 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 31.2 t -81.54 153.92 26.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.858 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 87.5 p -104.27 152.72 21.87 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.868 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.544 179.983 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.27 0 N-CA-C 112.498 -0.241 . . . . 0.0 112.498 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.1 m -85.58 105.34 16.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.912 0.387 . . . . 0.0 110.838 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 4.0 t -174.16 107.08 0.12 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.868 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 166.62 107.12 0.2 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.527 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 5.2 m -147.68 155.65 41.97 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.812 0.339 . . . . 0.0 110.859 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.1 m -68.76 174.94 3.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.874 -179.84 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.442 ' O ' ' N ' ' A' ' 9' ' ' GLN . . . -139.36 -38.59 0.1 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.528 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 39.7 m80 -59.51 81.55 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.698 0.285 . . . . 0.0 110.825 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.442 ' N ' ' O ' ' A' ' 7' ' ' GLY . 38.9 mt-30 -136.82 157.56 46.48 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.919 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 10.2 pt20 -96.92 65.72 2.12 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.93 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 18.4 mt -145.04 176.93 9.14 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.937 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 20.2 m-80 -105.75 140.59 38.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.858 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 59.6 p -151.6 157.48 42.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.866 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.537 HD11 ' HB2' ' A' ' 32' ' ' ARG . 2.1 pp -121.97 156.22 59.85 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.682 0.753 . . . . 0.0 110.886 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 157.28 60.96 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.726 2.284 . . . . 0.0 112.339 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 8.8 t -48.86 146.35 3.3 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.166 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 45.7 mtm -96.86 31.05 2.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.832 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -59.65 163.52 4.24 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.887 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 101.15 -149.4 18.37 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.474 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 168.59 21.1 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.67 2.247 . . . . 0.0 112.383 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.82 174.74 9.12 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.654 2.236 . . . . 0.0 112.293 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.457 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.5 m -84.68 144.99 28.2 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.145 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.435 ' C ' ' HD3' ' A' ' 25' ' ' PRO . 5.6 m-85 -142.95 133.63 25.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.893 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ASN . . . . . 0.585 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.6 m120 48.42 45.6 2.94 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.591 0.71 . . . . 0.0 110.867 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.585 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.3 Cg_endo -69.79 137.33 35.11 Favored 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 122.702 2.268 . . . . 0.0 112.34 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 -176.93 1.63 Allowed 'Trans proline' 0 N--CA 1.465 -0.164 0 C-N-CA 122.732 2.288 . . . . 0.0 112.357 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.669 HG13 ' HA ' ' A' ' 28' ' ' PRO . 88.1 t -142.28 137.64 15.84 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.616 0.722 . . . . 0.0 111.125 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.669 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.3 Cg_endo -69.81 143.88 75.21 Favored 'Cis proline' 0 C--N 1.341 0.179 0 C-N-CA 122.671 -1.804 . . . . 0.0 112.318 0.005 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.9 t80 -95.61 120.72 36.35 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.904 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -102.94 104.01 14.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.866 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -115.92 109.55 2.04 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.524 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.537 ' HB2' HD11 ' A' ' 14' ' ' LEU . 3.2 mmt85 -74.08 118.47 17.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.856 0.36 . . . . 0.0 110.84 -179.825 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.544 HD23 HD13 ' A' ' 158' ' ' ILE . 8.0 mt -76.8 92.13 3.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.935 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 23.0 mm-40 -65.4 102.86 0.73 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.961 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.23 -37.96 1.89 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.453 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.86 ' O ' HG23 ' A' ' 38' ' ' THR . . . 88.28 156.19 30.44 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.469 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' LEU . . . . . 0.621 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 86.8 mt -52.43 100.0 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.905 0.383 . . . . 0.0 110.895 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.86 HG23 ' O ' ' A' ' 36' ' ' GLY . 29.7 p -116.73 153.84 31.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.176 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.462 ' HB2' ' CD2' ' A' ' 117' ' ' LEU . . . -51.34 -31.51 22.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.127 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.43 ' HA ' ' NE ' ' A' ' 40' ' ' ARG . 10.8 mmp_? -100.14 33.7 2.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.852 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 28.2 ttm-85 -118.73 137.99 52.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.867 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 96.6 m -139.37 118.22 12.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.135 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.479 ' N ' HD12 ' A' ' 43' ' ' ILE . 4.6 mp -91.58 136.28 24.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.099 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 89.0 mt -128.87 133.8 65.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.138 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.8 mt -134.26 107.61 9.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.113 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.3 mtmt -108.24 103.9 13.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -134.21 -148.35 5.78 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.517 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -169.17 127.56 1.0 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.98 0.419 . . . . 0.0 110.894 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 16.0 t -75.91 117.65 65.37 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.635 0.731 . . . . 0.0 111.158 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 154.01 68.35 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.687 2.258 . . . . 0.0 112.359 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -20.71 34.37 Favored 'Trans proline' 0 C--O 1.231 0.175 0 C-N-CA 122.674 2.249 . . . . 0.0 112.343 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 41.1 p -99.63 9.41 43.18 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.153 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -99.08 -172.16 31.28 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.491 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 4.1 mmmm -133.75 -64.56 0.7 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.787 0.327 . . . . 0.0 110.895 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 2.6 p -165.75 147.07 7.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.816 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.597 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 13.0 p90 -110.53 -175.35 2.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.898 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.852 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -154.98 143.58 20.59 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.123 179.878 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.566 HG22 ' CE1' ' A' ' 60' ' ' PHE . 3.2 mp -121.85 102.14 11.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.107 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.2 m-80 -102.06 143.57 31.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.888 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.566 ' CE1' HG22 ' A' ' 58' ' ' ILE . 5.4 m-85 -118.76 98.56 6.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.937 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.447 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 32.8 ttmt -96.93 169.25 9.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.892 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.624 HG23 ' O ' ' A' ' 67' ' ' ASP . 19.4 t -100.64 122.4 52.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.131 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -60.04 -34.24 82.75 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.509 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 10.1 t -67.15 -71.81 0.19 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.872 0.368 . . . . 0.0 110.89 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.4 t -81.86 -69.19 0.63 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.836 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 128.97 36.53 0.43 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.519 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.624 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.6 m-20 -110.22 140.99 43.78 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.853 0.359 . . . . 0.0 110.856 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.615 HD12 ' HB3' ' A' ' 86' ' ' LEU . 58.9 mt -85.86 122.0 37.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.133 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.631 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -93.13 -30.01 15.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.098 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.73 HD22 ' CD2' ' A' ' 132' ' ' PHE . 46.3 tp -144.2 130.1 19.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.946 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.472 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.3 OUTLIER -134.93 92.58 2.9 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.862 179.899 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.488 HD11 HD21 ' A' ' 70' ' ' LEU . 41.4 mt -94.55 134.69 31.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.173 179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.852 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 7.8 t-20 -139.02 106.24 7.36 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.612 0.72 . . . . 0.0 110.879 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.597 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.7 Cg_endo -69.73 155.25 66.52 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.683 2.255 . . . . 0.0 112.329 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 42.1 mtp180 -131.56 99.41 4.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.865 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -59.34 148.4 32.47 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.858 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 88.83 -81.98 1.51 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.464 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 28.9 t-20 -49.62 -67.57 0.25 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.877 0.37 . . . . 0.0 110.869 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.425 ' HA2' ' CG ' ' A' ' 101' ' ' ASN . . . 113.58 41.86 0.92 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.508 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 16.9 p -137.29 117.92 13.94 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.887 0.375 . . . . 0.0 111.108 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.575 HG22 ' HA ' ' A' ' 74' ' ' PRO . 39.5 t -101.76 107.24 21.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.125 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.673 HG22 ' HD3' ' A' ' 96' ' ' LYS . 24.6 t -78.29 138.52 20.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.171 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ARG . . . . . 0.628 HH12 ' N ' ' A' ' 97' ' ' LYS . 2.8 mpp_? -126.94 125.72 42.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.885 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.472 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.3 m120 -132.86 -176.23 4.04 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.854 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 30.3 t -159.31 105.18 1.68 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.864 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.93 HD12 ' O ' ' A' ' 90' ' ' SER . 25.8 tp -77.06 117.43 18.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.861 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 90' ' ' SER . 80.7 mt -95.28 161.63 14.01 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.913 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.476 ' C ' ' H ' ' A' ' 90' ' ' SER . 17.7 p-10 -38.42 101.59 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.863 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.83 -6.49 0.91 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.504 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.93 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -119.21 172.47 7.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.913 0.387 . . . . 0.0 110.833 -179.773 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.865 ' NE1' HD13 ' A' ' 86' ' ' LEU . 22.4 m95 -129.49 160.69 32.39 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.908 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -89.59 -92.5 1.17 Allowed Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.457 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 2.3 m -174.74 173.78 2.74 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.905 0.383 . . . . 0.0 110.838 -179.672 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.449 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 3.8 mt-10 -104.97 117.64 34.53 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.89 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 50.7 mm-40 -122.49 133.88 54.58 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.895 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.673 ' HD3' HG22 ' A' ' 82' ' ' VAL . 43.8 mtmt -131.1 128.13 39.54 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.91 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.628 ' N ' HH12 ' A' ' 83' ' ' ARG . 12.7 tmtt? -175.79 108.37 0.09 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.946 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.922 HD11 ' O ' ' A' ' 100' ' ' HIS . 4.1 tt -147.67 144.04 19.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.109 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.6 t -79.19 -39.58 32.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.141 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' HIS . . . . . 0.922 ' O ' HD11 ' A' ' 98' ' ' ILE . 3.1 p-80 -154.35 136.91 15.1 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.883 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ASN . . . . . 0.617 ' CG ' HD13 ' A' ' 98' ' ' ILE . 8.1 m120 -105.11 95.78 9.98 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.573 0.702 . . . . 0.0 110.893 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.72 -35.04 13.49 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.674 2.249 . . . . 0.0 112.397 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.425 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 11.9 m-85 -45.84 113.69 0.65 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.898 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -144.91 142.19 10.64 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.484 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.75 109.56 2.34 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.723 2.282 . . . . 0.0 112.334 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 118.88 -8.55 12.73 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.5 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -133.29 150.63 51.89 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.851 0.358 . . . . 0.0 110.883 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 2.3 p90 -77.86 160.02 28.57 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.919 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.511 ' O ' ' CD1' ' A' ' 109' ' ' PHE . 29.6 p90 -145.3 122.36 11.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.874 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -92.89 101.94 14.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.911 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.718 HD13 ' N ' ' A' ' 112' ' ' SER . 1.0 OUTLIER -101.84 138.37 38.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.875 -179.911 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.718 ' N ' HD13 ' A' ' 111' ' ' LEU . 4.3 m -144.67 114.41 7.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.871 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.605 HD11 HD12 ' A' ' 111' ' ' LEU . 4.3 mp -99.16 122.22 50.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.157 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 7.7 mtp180 -97.16 132.72 42.66 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.842 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' CYS . . . . . 0.438 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 7.0 t -98.61 123.07 42.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.867 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.93 -141.23 7.46 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.494 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.462 ' CD2' ' HB2' ' A' ' 39' ' ' ALA . 7.9 mt -118.57 -33.4 4.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.792 0.329 . . . . 0.0 110.931 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 118' ' ' ASP . . . . . 0.428 ' C ' ' HG3' ' A' ' 119' ' ' ARG . 16.1 m-20 -97.6 -45.26 6.46 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.908 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.428 ' HG3' ' C ' ' A' ' 118' ' ' ASP . 47.7 mtt180 -152.36 -175.85 5.44 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.91 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.621 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 12.1 m-85 -107.66 158.59 17.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.905 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 19.1 mtpt -130.83 105.23 7.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.903 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.445 HG13 HD11 ' A' ' 111' ' ' LEU . 47.7 t -94.37 134.83 30.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.121 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -123.32 147.82 46.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.91 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.504 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -132.65 107.5 8.45 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.104 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 59.34 34.17 22.75 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.86 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.55 28.99 41.25 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.468 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 13.0 mm100 -136.38 119.61 16.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.8 0.333 . . . . 0.0 110.921 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 26.5 t-80 -51.58 101.53 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.831 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.504 HD13 ' CB ' ' A' ' 124' ' ' ALA . 10.5 tp -65.57 -69.16 0.31 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.933 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.462 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 4.5 p90 -164.66 175.54 9.66 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.884 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 41.0 m-20 -113.75 157.42 22.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.893 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.73 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -130.81 106.29 8.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.942 -179.911 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.545 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -64.54 131.77 47.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.075 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 31.1 m170 -56.65 117.49 3.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.85 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 71.9 mtt-85 -97.61 -49.48 4.85 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.84 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' LEU . . . . . 0.439 HD23 ' HB2' ' A' ' 69' ' ' ALA . 12.2 tp -95.37 109.08 21.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.941 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 79.3 p -48.74 -33.17 9.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.836 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.578 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -83.36 28.24 0.55 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.096 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -51.47 -34.56 35.99 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.838 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 140' ' ' GLN . . . . . 0.42 ' HG2' ' N ' ' A' ' 141' ' ' ARG . 19.7 pm0 -60.58 -27.19 67.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.945 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.578 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 33.1 mtp180 -69.27 -37.58 77.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.908 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.631 HG21 ' HB3' ' A' ' 69' ' ' ALA . 89.4 t -46.52 104.35 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.096 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -127.84 29.24 5.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.875 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 10.5 m -139.2 110.94 7.16 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.085 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.56 HD13 ' CE2' ' A' ' 60' ' ' PHE . 6.2 tp -109.55 105.71 15.13 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.952 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -110.11 152.49 25.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.856 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.406 HG12 HG23 ' A' ' 58' ' ' ILE . 29.4 mt -139.92 118.67 11.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.131 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -126.77 171.43 11.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.927 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 109.36 -152.28 17.12 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.518 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -106.52 92.04 3.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.802 0.334 . . . . 0.0 110.89 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 8.7 p -150.37 149.27 14.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.114 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 29.7 m -109.71 94.9 5.27 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.114 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.437 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 77.6 mt -76.93 132.22 38.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.917 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 3.0 m -117.37 -33.7 4.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.879 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 19.5 t80 -153.1 131.9 12.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.93 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 60.8 t -139.53 112.2 5.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.171 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 17.9 tt0 -124.92 136.56 53.88 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 158' ' ' ILE . . . . . 0.544 HD13 HD23 ' A' ' 33' ' ' LEU . 15.3 mt -107.17 90.69 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.129 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 23.3 t -43.03 135.51 3.11 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.89 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 172.64 156.38 12.56 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.498 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 138.87 38.88 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.685 2.257 . . . . 0.0 112.306 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 58.2 m -81.67 164.33 21.88 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.829 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 6.9 m 58.98 41.81 20.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.871 -179.852 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.362 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.512 -179.927 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 N-CA-C 112.506 -0.238 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 16.1 m 53.83 42.11 31.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.912 0.387 . . . . 0.0 110.893 -179.716 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 42.6 t -148.19 155.62 41.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.865 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 171.03 100.11 0.13 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.454 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 68.2 m -156.08 135.09 12.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.88 0.371 . . . . 0.0 110.871 -179.749 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 98.4 p -123.05 109.35 13.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.9 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 179.63 73.35 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.47 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 29.1 m-70 -116.85 81.81 1.7 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.722 0.296 . . . . 0.0 110.825 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 61.6 tt0 -47.82 -48.12 30.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.963 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 64.8 mm-40 -138.1 131.0 29.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.922 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 11.7 mt -102.93 120.27 40.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.95 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.7 p-10 -108.59 -64.28 1.25 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.845 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 32.5 p -161.27 152.43 18.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.836 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 2.4 pp -56.53 154.82 15.62 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.59 0.709 . . . . 0.0 110.92 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -163.67 0.11 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.7 2.267 . . . . 0.0 112.323 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.4 m -85.6 149.02 25.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.154 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 42.8 mtm -89.03 88.26 7.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.883 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -112.86 167.09 10.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.884 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 87.57 -143.89 18.72 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.469 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 169.72 18.22 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.69 2.26 . . . . 0.0 112.353 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 -179.62 3.06 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.67 2.247 . . . . 0.0 112.336 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.525 ' CG2' ' N ' ' A' ' 23' ' ' PHE . 1.6 m -90.81 158.74 16.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.132 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.525 ' N ' ' CG2' ' A' ' 22' ' ' THR . 8.6 m-85 -154.32 137.72 15.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.88 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ASN . . . . . 0.549 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 12.5 m120 44.27 47.99 4.03 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.648 0.737 . . . . 0.0 110.909 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.549 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.6 Cg_endo -69.79 140.09 41.73 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.688 2.259 . . . . 0.0 112.327 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 178.61 4.38 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.718 2.279 . . . . 0.0 112.357 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.703 HG13 ' HA ' ' A' ' 28' ' ' PRO . 96.4 t -139.36 138.31 20.36 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.605 0.717 . . . . 0.0 111.136 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.703 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.74 144.3 76.2 Favored 'Cis proline' 0 C--O 1.231 0.158 0 C-N-CA 122.72 -1.783 . . . . 0.0 112.334 -0.082 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -95.37 114.07 25.8 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.923 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -97.65 105.34 17.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.896 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -119.34 106.32 1.24 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.487 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.419 ' HA ' ' HA ' ' A' ' 144' ' ' THR . 0.0 OUTLIER -77.98 128.19 33.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.904 0.383 . . . . 0.0 110.848 -179.855 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.455 HD23 HD13 ' A' ' 158' ' ' ILE . 5.5 mt -71.8 122.02 19.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.89 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.407 ' O ' ' NH2' ' A' ' 41' ' ' ARG . 3.5 mp0 -77.15 79.6 3.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.899 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 139.01 -47.51 0.91 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.525 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.963 ' O ' HG23 ' A' ' 38' ' ' THR . . . 108.47 164.98 20.98 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.467 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' LEU . . . . . 0.524 HD12 ' O ' ' A' ' 139' ' ' PHE . 68.7 mt -50.85 106.48 0.13 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.92 0.39 . . . . 0.0 110.898 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.963 HG23 ' O ' ' A' ' 36' ' ' GLY . 10.2 p -124.61 141.19 52.28 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.146 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -42.86 -27.78 0.21 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.15 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 14.4 mmt85 -105.03 43.61 1.09 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.919 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.407 ' NH2' ' O ' ' A' ' 34' ' ' GLN . 6.6 ttt85 -130.43 139.93 50.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.838 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 98.0 m -139.73 121.6 15.52 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.09 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.47 ' N ' HD12 ' A' ' 43' ' ' ILE . 4.7 mp -91.39 132.76 35.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.137 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.436 ' CG2' ' HE2' ' A' ' 46' ' ' LYS . 83.8 mt -125.16 117.01 48.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.113 179.893 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 46.6 mt -118.12 107.63 22.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.092 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.436 ' HE2' ' CG2' ' A' ' 44' ' ' ILE . 25.1 mtmt -111.06 112.12 23.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.907 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -145.04 -143.43 3.99 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.487 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -168.99 126.42 0.97 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.924 0.392 . . . . 0.0 110.957 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 21.6 t -75.99 116.89 59.75 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.642 0.734 . . . . 0.0 111.138 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.82 157.52 60.0 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.631 2.221 . . . . 0.0 112.302 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -16.88 37.63 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.685 2.257 . . . . 0.0 112.307 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 76.8 p -110.91 19.73 18.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.138 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -111.68 116.53 4.2 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.506 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 21.7 mtpp -59.24 -60.66 3.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.761 0.315 . . . . 0.0 110.904 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 21.7 p -174.06 157.43 2.89 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.888 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.595 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 5.7 p90 -112.52 -173.18 2.19 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.9 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.63 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -155.18 145.49 21.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.095 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 2.7 mp -125.52 100.01 6.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.087 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ASN . . . . . 0.467 ' OD1' ' CD2' ' A' ' 71' ' ' HIS . 19.4 m-80 -101.9 144.76 30.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.882 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.779 ' CE2' HD13 ' A' ' 145' ' ' LEU . 32.7 m-85 -117.93 99.95 7.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.873 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.425 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 34.5 ttmt -95.65 168.16 10.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.945 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.645 HG22 ' HA ' ' A' ' 142' ' ' VAL . 22.6 t -99.72 122.86 52.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.147 179.842 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -58.23 -34.23 73.14 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.481 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.407 ' H ' HG12 ' A' ' 62' ' ' VAL . 26.1 m -70.22 -75.26 0.12 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.865 0.364 . . . . 0.0 110.813 -179.695 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 26.9 t -77.64 -71.93 0.39 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.866 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 129.3 43.4 0.21 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.469 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.505 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.1 m-20 -113.69 142.1 46.43 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.784 0.326 . . . . 0.0 110.866 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.6 HD12 ' HB3' ' A' ' 86' ' ' LEU . 44.9 mt -87.05 118.78 33.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.119 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.655 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -91.95 -30.09 16.29 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.089 179.835 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.645 HD22 ' CD2' ' A' ' 132' ' ' PHE . 58.2 tp -142.18 129.62 21.26 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.899 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.496 ' N ' ' O ' ' A' ' 84' ' ' ASN . 4.1 t-160 -134.81 92.8 2.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.842 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.555 HD11 HD21 ' A' ' 70' ' ' LEU . 28.3 mt -94.78 130.88 42.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.102 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.63 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 9.5 t-20 -136.04 104.79 9.62 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.643 0.735 . . . . 0.0 110.902 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.595 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.4 Cg_endo -69.78 155.66 65.3 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.644 2.229 . . . . 0.0 112.309 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 28.6 mtt-85 -130.77 101.92 5.87 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.859 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -59.68 150.04 28.84 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.879 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 87.49 -87.88 1.55 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.497 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 12.7 t30 -47.34 -54.31 11.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.907 0.384 . . . . 0.0 110.9 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 97.87 52.85 1.35 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.498 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 7.0 p -143.15 118.01 9.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.827 0.346 . . . . 0.0 111.123 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.585 HG22 ' HA ' ' A' ' 74' ' ' PRO . 41.8 t -101.46 114.65 41.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.166 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.711 HG22 ' HD3' ' A' ' 96' ' ' LYS . 57.4 t -83.54 144.18 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.135 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -126.26 124.91 41.43 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.845 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.496 ' O ' ' N ' ' A' ' 71' ' ' HIS . 2.3 m-80 -135.17 176.3 8.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.867 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 40.4 t -157.72 105.01 1.99 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.892 -179.883 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.893 HD13 ' NE1' ' A' ' 91' ' ' TRP . 34.5 tp -77.14 117.73 18.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.919 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 90' ' ' SER . 85.0 mt -95.48 162.36 13.68 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.951 179.893 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.423 ' ND2' ' H ' ' A' ' 88' ' ' ASN . 10.6 m-80 -41.08 102.23 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.866 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.19 -1.15 3.0 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.49 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.826 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -125.71 171.64 10.46 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.849 0.357 . . . . 0.0 110.853 -179.715 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.893 ' NE1' HD13 ' A' ' 86' ' ' LEU . 22.2 m95 -128.93 160.63 32.08 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.921 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.57 -115.21 2.23 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.491 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' SER . . . . . 0.425 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 58.3 m -151.42 173.67 14.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.82 0.343 . . . . 0.0 110.852 -179.768 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -102.59 123.95 47.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.875 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -123.08 125.86 45.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.904 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.711 ' HD3' HG22 ' A' ' 82' ' ' VAL . 45.6 mtmt -129.52 118.99 22.96 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.886 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 1.3 tppp? -170.58 106.52 0.29 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.851 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.544 HD11 ' O ' ' A' ' 100' ' ' HIS . 7.4 tt -144.22 150.53 16.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.114 179.839 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.507 HG23 ' N ' ' A' ' 100' ' ' HIS . 8.8 t -87.26 -46.12 10.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.154 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' HIS . . . . . 0.544 ' O ' HD11 ' A' ' 98' ' ' ILE . 4.6 p-80 -147.37 125.78 12.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.886 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ASN . . . . . 0.44 ' C ' ' OD1' ' A' ' 101' ' ' ASN . 27.1 t-20 -99.41 100.73 11.13 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.628 0.727 . . . . 0.0 110.906 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.425 ' HD2' ' HA ' ' A' ' 101' ' ' ASN . 54.1 Cg_endo -69.72 -36.44 10.89 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.751 2.301 . . . . 0.0 112.335 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -41.51 109.72 0.13 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.872 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -137.96 138.56 9.68 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.481 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 103.06 1.11 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.646 2.231 . . . . 0.0 112.363 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 121.44 -2.12 11.31 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.485 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -137.05 146.04 44.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.871 0.367 . . . . 0.0 110.874 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 2.3 p90 -70.93 172.76 8.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.861 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 30.0 p90 -160.25 137.5 9.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.884 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.59 107.8 18.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.863 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.699 HD13 ' N ' ' A' ' 112' ' ' SER . 0.7 OUTLIER -109.12 136.99 47.71 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.926 -179.938 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.699 ' N ' HD13 ' A' ' 111' ' ' LEU . 6.0 m -145.08 113.56 6.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.809 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.443 HG22 ' HD2' ' A' ' 120' ' ' PHE . 4.3 mp -93.92 137.42 22.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.129 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.462 ' O ' ' CD2' ' A' ' 120' ' ' PHE . 14.5 mtp180 -109.56 133.93 52.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.855 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 9.0 t -101.45 115.29 30.18 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.86 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -110.94 -141.66 8.8 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.487 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 5.5 mt -118.58 -34.81 3.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.827 0.346 . . . . 0.0 110.948 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' ASP . . . . . 0.447 ' C ' ' HG3' ' A' ' 119' ' ' ARG . 2.0 m-20 -95.05 -45.83 7.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.856 179.858 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.447 ' HG3' ' C ' ' A' ' 118' ' ' ASP . 25.5 mtt180 -154.98 -179.72 8.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.462 ' CD2' ' O ' ' A' ' 114' ' ' ARG . 20.5 m-85 -103.41 157.59 16.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.919 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 32.9 mtpt -129.52 100.08 5.41 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.938 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.557 HG13 HD11 ' A' ' 111' ' ' LEU . 45.6 t -89.2 128.94 40.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.091 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -115.07 151.21 34.68 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.917 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -136.35 106.71 6.43 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.069 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 55.92 34.67 24.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.856 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 80.71 31.36 36.53 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.506 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 3.7 mm-40 -138.32 123.78 19.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.844 0.354 . . . . 0.0 110.938 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 39.6 t-80 -55.46 101.43 0.05 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.874 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.403 HD22 HD21 ' A' ' 111' ' ' LEU . 11.6 tp -69.85 -69.62 0.34 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.952 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.452 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 6.7 p90 -165.13 169.84 15.67 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -111.22 159.93 17.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.895 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.645 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -130.52 104.39 7.2 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.897 -179.883 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.507 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -62.5 134.96 57.14 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.108 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 134' ' ' HIS . . . . . 0.405 ' ND1' ' O ' ' A' ' 118' ' ' ASP . 26.3 m170 -58.72 104.62 0.24 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.875 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.425 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 8.8 mtt-85 -83.92 -53.65 5.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.867 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.7 tp -91.85 107.77 19.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.956 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 12.7 t -45.74 -36.14 4.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.893 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.416 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.72 29.97 0.44 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.09 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.524 ' O ' HD12 ' A' ' 37' ' ' LEU . 21.7 p90 -48.49 -45.82 37.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.886 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 140' ' ' GLN . . . . . 0.466 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 8.3 pt20 -47.8 -41.34 23.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.908 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.538 ' O ' HG13 ' A' ' 62' ' ' VAL . 30.7 mtp180 -54.21 -41.64 68.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.851 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.655 HG21 ' CB ' ' A' ' 69' ' ' ALA . 97.2 t -49.23 102.92 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.177 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -124.74 28.34 6.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.865 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 144' ' ' THR . . . . . 0.419 ' HA ' ' HA ' ' A' ' 32' ' ' ARG . 0.6 OUTLIER -135.29 125.44 26.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.138 -179.927 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.779 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.2 tp -123.97 106.79 10.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.922 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -110.37 153.44 24.94 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.911 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 17.2 mt -138.47 115.28 11.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.104 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -125.52 174.92 7.89 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.917 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.04 -143.78 15.84 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.502 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -114.81 92.39 3.93 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.888 0.375 . . . . 0.0 110.86 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.3 p -151.31 145.74 16.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.171 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 21.5 m -105.37 93.8 4.87 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.126 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.465 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 95.0 mt -75.76 131.43 39.81 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.869 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 7.5 m -113.62 -41.6 3.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.86 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 155' ' ' TYR . . . . . 0.413 ' CD1' ' C ' ' A' ' 155' ' ' TYR . 8.4 t80 -145.06 132.98 21.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.919 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 94.4 t -140.69 116.96 7.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.112 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 9.7 tt0 -134.18 125.13 27.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.941 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 158' ' ' ILE . . . . . 0.455 HD13 HD23 ' A' ' 33' ' ' LEU . 24.0 mt -96.95 88.92 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.139 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 53.3 p -69.65 136.65 51.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.821 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -139.08 -173.63 13.11 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.504 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 126.93 13.91 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.698 2.265 . . . . 0.0 112.359 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 3.8 m -154.56 120.84 5.33 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.855 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 22.6 t -110.25 133.87 52.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.865 -179.765 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.276 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.457 -179.999 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.484 -0.246 . . . . 0.0 112.484 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.8 t 59.53 42.16 17.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.912 0.387 . . . . 0.0 110.855 -179.743 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 36.4 m -88.92 119.51 29.5 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.837 -179.831 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 116.47 77.31 0.65 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.496 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.0 t -100.93 166.01 11.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.949 0.404 . . . . 0.0 110.814 -179.72 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.0 m -159.86 158.72 31.45 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.852 -179.778 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 85.18 -168.75 43.06 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.443 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 13.9 t-80 46.88 43.03 12.97 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.75 0.309 . . . . 0.0 110.858 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 42.7 tt0 -88.21 139.83 30.09 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.929 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 48.4 mt-30 -146.39 149.98 34.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.885 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.666 ' H ' HD23 ' A' ' 11' ' ' LEU . 0.1 OUTLIER -70.27 105.25 2.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.88 -179.985 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 5.0 m120 -130.57 168.62 16.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.904 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 6.0 m -70.89 158.18 36.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.879 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.418 ' O ' HD12 ' A' ' 14' ' ' LEU . 1.7 pp -38.54 155.95 0.12 Allowed Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.611 0.72 . . . . 0.0 110.926 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -170.7 0.41 Allowed 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.701 2.267 . . . . 0.0 112.334 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.2 m -86.64 150.47 24.18 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.128 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' MET . . . . . 0.461 ' HE3' HD12 ' A' ' 158' ' ' ILE . 5.9 ptt? -99.91 79.61 2.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.835 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -104.17 148.09 26.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.819 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.417 ' HA3' ' HD2' ' A' ' 20' ' ' PRO . . . 115.86 -137.03 13.43 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.442 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.417 ' HD2' ' HA3' ' A' ' 19' ' ' GLY . 53.8 Cg_endo -69.73 169.94 17.72 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.673 2.249 . . . . 0.0 112.365 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.578 ' HB2' ' CE2' ' A' ' 155' ' ' TYR . 53.5 Cg_endo -69.72 176.86 6.18 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.709 2.272 . . . . 0.0 112.324 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.494 HG22 ' H ' ' A' ' 156' ' ' VAL . 10.8 t -93.74 157.32 16.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.151 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 7.8 m-85 -139.43 115.61 10.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.914 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ASN . . . . . 0.489 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 5.3 t-20 66.95 51.63 0.65 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.568 0.699 . . . . 0.0 110.845 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.489 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.75 132.65 23.79 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.679 2.253 . . . . 0.0 112.343 179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -178.43 2.34 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.68 2.253 . . . . 0.0 112.326 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.684 HG13 ' HA ' ' A' ' 28' ' ' PRO . 94.4 t -139.87 137.87 18.98 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.661 0.743 . . . . 0.0 111.146 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.684 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.8 Cg_endo -69.78 144.51 76.89 Favored 'Cis proline' 0 C--N 1.341 0.181 0 C-N-CA 122.731 -1.779 . . . . 0.0 112.292 0.009 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 14.4 t80 -94.87 118.2 31.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.973 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -102.33 100.76 10.95 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.905 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -107.54 109.58 3.01 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.464 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 10.2 mmt85 -75.35 117.65 17.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.85 0.357 . . . . 0.0 110.855 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 3.5 mt -78.17 93.22 4.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.897 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.8 mm-40 -64.83 99.74 0.36 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.899 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.23 -41.55 1.45 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.54 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.592 ' O ' HG23 ' A' ' 38' ' ' THR . . . 95.21 164.59 34.97 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.499 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' LEU . . . . . 0.41 HD12 ' O ' ' A' ' 139' ' ' PHE . 87.5 mt -58.48 110.68 1.02 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.872 0.368 . . . . 0.0 110.903 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.592 HG23 ' O ' ' A' ' 36' ' ' GLY . 44.4 p -124.12 146.23 48.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.134 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -47.27 -22.69 0.44 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.088 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.02 35.22 3.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.861 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.417 ' NE ' ' O ' ' A' ' 36' ' ' GLY . 20.3 ttm-85 -114.59 138.81 50.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.872 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 88.2 m -136.31 114.55 11.59 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.143 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 4.8 mp -90.78 135.07 27.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.13 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 80.1 mt -130.26 132.61 64.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.127 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 55.8 mt -133.56 107.09 10.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.103 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 10.7 mttm -102.46 108.42 19.73 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.927 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.03 -156.06 6.78 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.454 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -161.98 127.87 3.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.941 0.4 . . . . 0.0 110.867 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 21.9 t -76.05 114.53 38.28 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.675 0.75 . . . . 0.0 111.13 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 158.5 56.7 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.662 2.241 . . . . 0.0 112.317 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -13.65 34.93 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.681 2.254 . . . . 0.0 112.341 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 40.7 p -114.08 19.0 16.8 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.146 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -114.12 116.6 3.89 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.517 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 19.0 mtpp -61.64 -57.5 11.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.801 0.334 . . . . 0.0 110.895 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 16.6 p -174.88 160.7 2.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.857 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 17.6 p90 -115.44 -174.41 2.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.85 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.071 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -156.5 130.3 8.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.113 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.7 HG22 ' CE1' ' A' ' 60' ' ' PHE . 5.3 mp -114.55 103.56 15.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.11 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.4 m-80 -101.44 146.22 27.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.865 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.7 ' CE1' HG22 ' A' ' 58' ' ' ILE . 3.4 m-85 -118.38 99.72 7.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.887 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.454 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 32.8 ttmt -97.47 169.23 9.88 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.884 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.631 HG22 ' HA ' ' A' ' 142' ' ' VAL . 39.8 t -101.23 120.4 50.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.133 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -56.54 -39.61 85.23 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.523 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 35.1 m -62.26 -72.33 0.13 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.875 0.369 . . . . 0.0 110.859 -179.735 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 40.6 p -80.17 -70.21 0.54 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.87 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 127.26 44.25 0.23 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.491 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.556 ' OD1' ' ND2' ' A' ' 88' ' ' ASN . 0.6 OUTLIER -117.37 142.63 46.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.834 0.349 . . . . 0.0 110.87 179.977 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.567 HD12 ' HB3' ' A' ' 86' ' ' LEU . 41.0 mt -86.11 111.2 20.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.128 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.624 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -82.23 -31.25 30.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.075 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.688 HD21 HD11 ' A' ' 72' ' ' ILE . 32.4 tp -142.37 132.46 24.59 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.93 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.441 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.8 OUTLIER -134.78 98.79 4.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.88 179.838 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.688 HD11 HD21 ' A' ' 70' ' ' LEU . 17.9 mt -101.74 133.57 44.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.102 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 1.071 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 9.5 t-20 -141.08 106.82 6.2 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.658 0.742 . . . . 0.0 110.878 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.2 Cg_endo -69.76 155.32 66.26 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.718 2.278 . . . . 0.0 112.332 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 38.4 mtp180 -132.37 96.56 3.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.875 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' MET . . . . . 0.422 ' HE2' ' HB3' ' A' ' 103' ' ' PHE . 0.2 OUTLIER -55.4 168.08 0.41 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.862 179.93 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 70.86 -73.29 0.66 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.507 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 35.1 t30 -58.85 -63.54 1.26 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.833 0.349 . . . . 0.0 110.86 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 106.76 39.85 1.96 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.533 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.3 p -134.76 118.18 16.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.828 0.346 . . . . 0.0 111.139 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.48 HG22 ' HA ' ' A' ' 74' ' ' PRO . 21.7 t -100.93 112.85 35.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.128 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.648 HG22 ' HD3' ' A' ' 96' ' ' LYS . 30.2 t -82.3 144.85 9.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.137 179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -129.46 126.59 39.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.89 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.441 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.6 OUTLIER -137.07 -177.09 4.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.908 -179.943 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 40.1 t -158.65 105.32 1.82 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.855 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.897 HD13 ' CE2' ' A' ' 91' ' ' TRP . 35.9 tp -76.83 115.86 16.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.902 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.519 ' N ' ' O ' ' A' ' 90' ' ' SER . 83.2 mt -93.72 162.45 13.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.946 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.556 ' ND2' ' OD1' ' A' ' 67' ' ' ASP . 9.0 m120 -41.26 102.17 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.907 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.37 -0.49 3.74 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.51 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.81 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -126.45 171.16 11.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.919 0.39 . . . . 0.0 110.826 -179.713 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.897 ' CE2' HD13 ' A' ' 86' ' ' LEU . 26.6 m95 -128.25 160.72 31.24 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.899 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.85 -109.76 1.89 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.496 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' SER . . . . . 0.434 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 47.5 m -155.5 174.52 15.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.791 0.329 . . . . 0.0 110.905 -179.749 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -100.01 125.17 46.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.884 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -120.17 121.22 38.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.854 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.648 ' HD3' HG22 ' A' ' 82' ' ' VAL . 6.4 mtmp? -127.57 118.56 24.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.932 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 20.9 tttt -170.85 107.49 0.29 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.937 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.87 HD11 ' O ' ' A' ' 100' ' ' HIS . 2.3 tt -145.53 153.38 13.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.147 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.434 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 8.9 t -97.52 -36.2 10.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.128 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' HIS . . . . . 0.87 ' O ' HD11 ' A' ' 98' ' ' ILE . 2.3 p-80 -148.88 128.16 12.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.848 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -102.87 96.66 8.07 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.619 0.723 . . . . 0.0 110.874 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.406 ' O ' ' C ' ' A' ' 103' ' ' PHE . 54.2 Cg_endo -69.74 -42.98 2.95 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.693 2.262 . . . . 0.0 112.374 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.463 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 8.6 m-85 -37.84 105.13 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.868 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -133.21 139.22 10.75 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.481 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 104.21 1.29 Allowed 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.63 2.22 . . . . 0.0 112.352 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 124.41 -7.88 8.45 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.529 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.464 ' NE2' ' O ' ' A' ' 108' ' ' PHE . 0.0 OUTLIER -131.37 168.7 17.13 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.83 0.348 . . . . 0.0 110.922 -179.887 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 108' ' ' PHE . . . . . 0.464 ' O ' ' NE2' ' A' ' 107' ' ' GLN . 1.4 p90 -90.89 172.56 8.52 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.856 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 31.9 p90 -158.36 129.2 6.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.881 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -98.86 102.18 13.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.888 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.836 HD13 ' N ' ' A' ' 112' ' ' SER . 0.9 OUTLIER -99.85 137.51 38.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.876 -179.918 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.836 ' N ' HD13 ' A' ' 111' ' ' LEU . 2.4 m -145.14 111.71 5.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.9 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.529 HG23 HG22 ' A' ' 122' ' ' VAL . 3.9 mp -94.71 121.04 44.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.162 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.59 ' HD3' ' CD1' ' A' ' 123' ' ' TYR . 0.2 OUTLIER -99.54 123.92 44.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.864 179.984 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 115' ' ' CYS . . . . . 0.583 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 7.9 t -90.11 126.66 35.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.907 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -123.35 -150.32 8.0 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.489 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 9.2 mt -111.8 -39.72 4.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.863 0.363 . . . . 0.0 110.946 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 29.0 t0 -88.78 -34.66 17.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.831 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.5 ptt180 -172.73 167.87 5.22 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.888 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.583 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.4 m-30 -93.18 158.68 15.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.865 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.43 ' HB3' ' CE1' ' A' ' 123' ' ' TYR . 17.9 mtpp -130.62 104.72 7.37 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.897 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.7 HG13 HD11 ' A' ' 111' ' ' LEU . 92.5 t -93.4 108.47 20.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.116 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 123' ' ' TYR . . . . . 0.59 ' CD1' ' HD3' ' A' ' 114' ' ' ARG . 32.9 m-85 -96.43 147.86 23.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.904 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.593 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -127.5 102.14 6.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.074 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 57.19 37.62 28.48 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.875 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.38 33.39 28.59 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.504 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -142.89 120.67 11.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.85 0.357 . . . . 0.0 110.895 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' HIS . . . . . 0.488 ' CE1' ' OD2' ' A' ' 131' ' ' ASP . 33.6 t-80 -53.22 99.86 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.884 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.593 HD13 ' CB ' ' A' ' 124' ' ' ALA . 10.5 tp -70.01 -67.41 0.49 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.883 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.524 ' HZ ' HD13 ' A' ' 72' ' ' ILE . 8.2 p90 -162.41 175.48 11.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.886 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.488 ' OD2' ' CE1' ' A' ' 128' ' ' HIS . 15.7 m-20 -120.21 150.17 41.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.864 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.597 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -115.86 107.81 15.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.848 -179.886 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.558 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -63.22 131.87 49.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.11 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 29.3 m170 -62.35 102.39 0.31 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.893 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.434 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 68.9 mtt-85 -89.34 -45.98 9.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.872 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 4.5 tp -99.7 108.16 20.44 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.907 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 58.2 p -50.88 -33.17 22.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.853 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.468 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.23 31.17 0.39 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.095 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.41 ' O ' HD12 ' A' ' 37' ' ' LEU . 40.0 p90 -52.37 -42.31 63.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.883 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 8.2 pt20 -48.68 -42.31 34.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.916 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.468 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 72.2 mtp180 -54.36 -40.96 68.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.895 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.631 ' HA ' HG22 ' A' ' 62' ' ' VAL . 69.8 t -44.99 105.43 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.148 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -129.92 34.32 4.28 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.898 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 11.6 m -143.04 116.68 9.21 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.126 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.59 HD13 ' CE2' ' A' ' 60' ' ' PHE . 7.1 tp -116.45 107.8 15.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.959 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 146' ' ' GLU . . . . . 0.418 ' C ' HG13 ' A' ' 147' ' ' ILE . 8.0 pt-20 -111.79 153.02 27.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.852 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.622 HG23 HG13 ' A' ' 58' ' ' ILE . 16.8 mt -139.95 109.8 3.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.172 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -118.54 173.64 6.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.911 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.46 -145.45 16.09 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.503 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -112.18 93.05 4.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.868 0.366 . . . . 0.0 110.879 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 5.6 p -151.12 149.13 14.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.138 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 40.0 m -110.23 95.06 5.34 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.132 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.473 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 84.6 mt -76.53 136.09 39.3 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.901 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 6.0 m -120.08 -36.54 3.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.897 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 155' ' ' TYR . . . . . 0.578 ' CE2' ' HB2' ' A' ' 21' ' ' PRO . 53.5 t80 -150.64 130.94 13.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.909 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.494 ' H ' HG22 ' A' ' 22' ' ' THR . 44.8 t -139.72 105.0 2.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.123 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 12.2 tt0 -120.37 135.42 55.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.879 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 158' ' ' ILE . . . . . 0.461 HD12 ' HE3' ' A' ' 17' ' ' MET . 16.9 mt -104.38 94.36 3.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.135 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 36.9 t -56.99 152.06 13.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.882 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 171.36 -174.4 44.96 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.523 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 152.42 69.22 Favored 'Trans proline' 0 C--O 1.231 0.139 0 C-N-CA 122.671 2.247 . . . . 0.0 112.334 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 19.9 m -61.47 -48.84 79.28 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.875 -179.836 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 38.6 m -125.8 177.4 6.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.849 -179.833 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.3 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.505 -179.975 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.517 -0.233 . . . . 0.0 112.517 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.3 t 47.93 42.84 16.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.918 0.389 . . . . 0.0 110.871 -179.758 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 97.8 p -117.85 135.29 54.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.865 -179.828 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.15 169.77 28.12 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.515 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 71.0 m -106.08 123.1 47.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.862 0.363 . . . . 0.0 110.878 -179.736 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 28.7 t -89.63 98.73 11.93 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.875 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 162.29 137.86 2.29 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.489 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 22.2 p80 -160.51 163.08 33.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.766 0.317 . . . . 0.0 110.89 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 21.1 mm-40 -110.53 130.37 55.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.88 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -85.77 15.46 4.78 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.884 -179.909 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 8.2 mp -88.59 162.37 16.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.96 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ASN . . . . . 0.444 ' O ' ' C ' ' A' ' 13' ' ' SER . 8.5 m-80 -40.68 -47.38 2.78 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.848 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.444 ' C ' ' O ' ' A' ' 12' ' ' ASN . 34.3 m -34.49 147.46 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.856 -179.838 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.579 HD11 ' HG2' ' A' ' 32' ' ' ARG . 4.6 pp -99.99 153.81 37.57 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.62 0.724 . . . . 0.0 110.901 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.548 ' O ' HD12 ' A' ' 14' ' ' LEU . 53.8 Cg_endo -69.75 -165.64 0.16 Allowed 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.649 2.233 . . . . 0.0 112.391 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.432 ' CG2' ' N ' ' A' ' 17' ' ' MET . 1.5 m -82.9 152.67 25.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.162 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' MET . . . . . 0.432 ' N ' ' CG2' ' A' ' 16' ' ' THR . 20.1 mtm -106.72 74.84 1.02 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.841 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -109.22 -176.84 3.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.878 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.4 ' HA3' ' HD2' ' A' ' 20' ' ' PRO . . . 87.49 -144.46 19.08 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.53 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.4 ' HD2' ' HA3' ' A' ' 19' ' ' GLY . 53.5 Cg_endo -69.79 165.47 30.88 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.664 2.243 . . . . 0.0 112.33 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 174.91 8.82 Favored 'Trans proline' 0 C--O 1.232 0.213 0 C-N-CA 122.683 2.255 . . . . 0.0 112.398 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.473 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.9 m -84.95 147.02 26.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.131 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.473 ' CD1' ' O ' ' A' ' 22' ' ' THR . 6.7 m-85 -147.37 124.59 11.5 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.891 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ASN . . . . . 0.575 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 4.6 t-20 58.93 46.23 1.48 Allowed Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.621 0.724 . . . . 0.0 110.883 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.575 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.77 134.47 28.04 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.679 2.252 . . . . 0.0 112.337 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -177.77 2.03 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.714 2.276 . . . . 0.0 112.301 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.707 HG13 ' HA ' ' A' ' 28' ' ' PRO . 96.0 t -142.25 138.72 16.9 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-O 121.634 0.731 . . . . 0.0 111.14 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.707 ' HA ' HG13 ' A' ' 27' ' ' VAL . 54.2 Cg_endo -69.72 144.39 76.44 Favored 'Cis proline' 0 C--N 1.341 0.17 0 C-N-CA 122.685 -1.798 . . . . 0.0 112.381 -0.11 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -98.37 115.68 28.98 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.925 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.489 ' CD2' ' HB3' ' A' ' 146' ' ' GLU . 63.7 m-85 -103.27 102.65 12.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.851 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -115.75 103.97 1.25 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.479 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.579 ' HG2' HD11 ' A' ' 14' ' ' LEU . 0.0 OUTLIER -72.34 132.03 43.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.836 0.35 . . . . 0.0 110.862 -179.848 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 143' ' ' ASP . 9.5 mt -76.87 142.57 40.13 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.942 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.413 ' O ' ' NH2' ' A' ' 41' ' ' ARG . 6.4 mm100 -100.39 91.49 4.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.926 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 133.23 -50.02 0.89 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.53 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.968 ' O ' HG23 ' A' ' 38' ' ' THR . . . 108.56 161.56 20.34 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.504 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' LEU . . . . . 0.64 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 99.4 mt -50.31 105.32 0.09 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.881 0.372 . . . . 0.0 110.933 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.968 HG23 ' O ' ' A' ' 36' ' ' GLY . 12.1 p -123.12 146.27 47.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.11 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.431 ' HB2' HD21 ' A' ' 117' ' ' LEU . . . -44.59 -31.98 1.31 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.173 179.856 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -103.45 41.05 1.31 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.895 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.413 ' NH2' ' O ' ' A' ' 34' ' ' GLN . 45.5 ttm-85 -124.31 136.03 53.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.861 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 39.3 m -135.91 126.33 26.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.14 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 mp -98.94 132.48 44.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.101 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 95.3 mt -123.58 134.68 65.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.137 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 59.5 mt -135.95 107.88 7.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.144 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.4 mtmm -110.34 111.07 22.12 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.925 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.66 -143.45 4.31 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.51 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 1.6 t80 -170.16 126.78 0.82 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.851 0.357 . . . . 0.0 110.944 -179.84 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 11.2 t -77.36 116.13 55.11 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.616 0.722 . . . . 0.0 111.124 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 158.68 56.15 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.699 2.266 . . . . 0.0 112.331 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -19.36 36.38 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.733 2.288 . . . . 0.0 112.327 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 69.2 p -109.7 21.27 17.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.142 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -115.02 120.04 4.84 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.486 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 20.6 mtpp -61.27 -60.19 4.13 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.797 0.332 . . . . 0.0 110.897 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.7 p -175.29 157.59 2.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.886 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.501 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 4.0 p90 -108.47 -172.5 2.07 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.857 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.712 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -154.82 141.41 18.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.082 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.429 HD12 ' N ' ' A' ' 58' ' ' ILE . 2.6 mp -123.0 98.7 5.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.166 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.0 m-80 -101.07 144.84 29.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.908 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.546 ' CE2' HD13 ' A' ' 145' ' ' LEU . 29.6 m-85 -117.24 101.45 8.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.912 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.427 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 32.8 ttmt -95.83 168.39 10.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.863 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.591 HG22 ' HA ' ' A' ' 142' ' ' VAL . 61.4 t -100.41 122.27 52.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.171 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -57.08 -41.13 92.42 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.515 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 44.2 t -65.15 -73.04 0.13 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.888 0.375 . . . . 0.0 110.856 -179.75 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 39.0 t -77.99 -75.94 0.2 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.918 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 132.42 40.28 0.21 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.485 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.458 ' O ' HG23 ' A' ' 62' ' ' VAL . 0.7 OUTLIER -111.88 142.01 44.81 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.761 0.315 . . . . 0.0 110.892 -179.971 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.623 HD12 ' HB3' ' A' ' 86' ' ' LEU . 50.0 mt -86.41 120.11 35.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.152 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.527 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -92.24 -33.55 14.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.08 179.829 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.613 HD13 ' CD1' ' A' ' 132' ' ' PHE . 59.8 tp -138.85 130.61 27.65 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.907 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.492 ' N ' ' O ' ' A' ' 84' ' ' ASN . 3.6 t-160 -134.96 92.63 2.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.913 179.843 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.573 HD11 HD21 ' A' ' 70' ' ' LEU . 30.5 mt -94.99 128.37 46.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.117 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.712 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 9.1 t-20 -134.58 105.4 10.89 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.611 0.719 . . . . 0.0 110.897 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.501 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.2 Cg_endo -69.71 154.51 67.85 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.701 2.267 . . . . 0.0 112.354 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 36.1 mtp180 -130.32 96.94 4.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.876 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -61.42 -43.14 99.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.845 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -55.2 -86.42 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.461 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 30.3 t30 -55.1 -60.09 3.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.884 0.374 . . . . 0.0 110.92 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 116.38 50.44 0.42 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.447 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 34.8 p -151.21 122.92 8.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.838 0.352 . . . . 0.0 111.17 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.474 HG21 ' HE2' ' A' ' 103' ' ' PHE . 13.1 t -89.29 108.73 19.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.097 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.559 HG22 ' HD3' ' A' ' 96' ' ' LYS . 91.6 t -80.93 145.97 8.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.088 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -127.34 124.81 39.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.892 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.492 ' O ' ' N ' ' A' ' 71' ' ' HIS . 2.4 m-80 -135.22 179.3 6.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.901 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 46.1 t -160.78 105.63 1.4 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.861 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.929 HD12 ' O ' ' A' ' 90' ' ' SER . 27.0 tp -77.96 119.34 21.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.92 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.503 ' N ' ' O ' ' A' ' 90' ' ' SER . 87.0 mt -97.08 161.35 13.86 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.919 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.461 ' C ' ' H ' ' A' ' 90' ' ' SER . 17.0 p-10 -38.23 101.61 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.931 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.45 -6.41 0.82 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.501 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.929 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -118.96 172.06 7.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.834 0.349 . . . . 0.0 110.844 -179.725 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.837 ' NE1' HD13 ' A' ' 86' ' ' LEU . 22.0 m95 -129.43 161.07 31.21 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.929 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.09 -106.01 1.55 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.476 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 2.9 m -165.76 174.92 9.2 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.812 0.339 . . . . 0.0 110.835 -179.742 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -104.66 117.62 34.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.88 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -123.05 108.78 13.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.876 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.559 ' HD3' HG22 ' A' ' 82' ' ' VAL . 35.8 mtmt -105.57 131.32 53.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.864 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.479 ' HE3' ' N ' ' A' ' 98' ' ' ILE . 0.0 OUTLIER -174.31 105.23 0.11 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.903 179.889 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.933 HD11 ' O ' ' A' ' 100' ' ' HIS . 5.1 tt -148.09 154.25 10.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.12 179.895 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.488 HG23 ' N ' ' A' ' 100' ' ' HIS . 9.0 t -95.29 -44.62 7.51 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.143 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' HIS . . . . . 0.933 ' O ' HD11 ' A' ' 98' ' ' ILE . 4.9 p-80 -139.1 133.3 31.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.856 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ASN . . . . . 0.402 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 44.2 t-20 -110.92 95.99 27.07 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.628 0.728 . . . . 0.0 110.892 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.434 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.4 Cg_endo -69.78 -42.6 3.24 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.646 2.231 . . . . 0.0 112.34 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.527 ' CZ ' HD21 ' A' ' 129' ' ' LEU . 5.2 m-85 -35.88 104.84 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.861 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -135.88 138.44 9.92 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.455 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 99.95 0.78 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.722 2.281 . . . . 0.0 112.319 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 130.45 -9.59 5.87 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.461 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.1 pt20 -131.49 159.22 38.76 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.806 0.336 . . . . 0.0 110.941 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -76.45 174.09 10.7 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.849 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.468 ' O ' ' CD2' ' A' ' 109' ' ' PHE . 23.4 p90 -161.55 117.87 2.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.887 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -94.76 102.08 13.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.878 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.739 HD13 ' N ' ' A' ' 112' ' ' SER . 0.9 OUTLIER -101.23 137.33 39.73 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.921 -179.943 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.739 ' N ' HD13 ' A' ' 111' ' ' LEU . 5.2 m -144.2 114.16 7.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.859 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.475 HD11 HD12 ' A' ' 111' ' ' LEU . 5.1 mp -96.47 140.71 16.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.147 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 24.6 mtt180 -115.57 124.93 52.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.879 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' CYS . . . . . 0.563 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 6.5 t -92.89 118.45 31.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.85 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.99 -144.82 8.51 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.434 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.431 HD21 ' HB2' ' A' ' 39' ' ' ALA . 13.6 mt -116.85 -36.95 3.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.838 0.351 . . . . 0.0 110.933 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -92.23 -34.69 14.17 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.833 179.861 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 17.8 ptp180 -171.77 172.83 4.75 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.885 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.64 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 3.6 m-30 -96.28 158.17 15.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.845 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 27.4 mtpt -129.82 100.34 5.44 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.917 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.459 HG13 HD11 ' A' ' 111' ' ' LEU . 88.0 t -86.18 137.07 21.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.133 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -126.54 152.72 46.16 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.884 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -140.83 111.17 6.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.069 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 56.78 29.71 16.45 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.9 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 83.37 32.12 26.11 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.503 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 32.0 mm-40 -139.01 125.77 20.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.872 0.368 . . . . 0.0 110.875 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' HIS . . . . . 0.445 ' CE1' ' OD1' ' A' ' 131' ' ' ASP . 31.3 t-80 -56.6 109.22 0.58 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.839 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.527 HD21 ' CZ ' ' A' ' 103' ' ' PHE . 10.7 tp -77.8 -68.38 0.63 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.939 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.437 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 7.6 p90 -165.18 171.48 13.66 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.883 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.445 ' OD1' ' CE1' ' A' ' 128' ' ' HIS . 1.4 m-20 -113.97 151.64 32.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.865 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.613 ' CD1' HD13 ' A' ' 70' ' ' LEU . 0.3 OUTLIER -116.8 108.58 16.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.929 -179.933 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.513 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -63.49 134.42 55.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.065 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 28.4 m170 -62.82 103.0 0.4 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.849 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 47.2 mtt-85 -87.1 -52.82 5.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.906 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 9.5 tp -91.54 108.34 19.83 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.934 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 99.2 p -50.5 -32.48 18.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.867 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.499 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.93 25.54 0.67 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.06 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.492 ' O ' HD12 ' A' ' 37' ' ' LEU . 12.5 p90 -45.44 -42.81 10.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.869 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 140' ' ' GLN . . . . . 0.436 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 10.7 pt20 -48.93 -40.06 28.65 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.894 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.499 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 41.0 mtp85 -55.9 -39.71 71.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.9 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.591 ' HA ' HG22 ' A' ' 62' ' ' VAL . 53.1 t -51.7 103.24 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.511 ' O ' ' N ' ' A' ' 33' ' ' LEU . 3.1 p30 -125.47 25.94 6.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.849 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 2.2 m -132.99 140.19 47.65 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.137 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.546 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.7 tp -134.64 108.32 7.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.947 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 146' ' ' GLU . . . . . 0.489 ' HB3' ' CD2' ' A' ' 30' ' ' PHE . 5.8 pt-20 -111.51 148.85 32.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.896 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.409 HG13 ' C ' ' A' ' 146' ' ' GLU . 9.9 mt -136.65 111.46 10.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.11 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -124.26 176.68 6.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.956 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 109.97 -139.48 15.41 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.495 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -120.47 90.82 3.4 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.848 0.356 . . . . 0.0 110.898 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.441 HG22 ' N ' ' A' ' 152' ' ' THR . 2.8 p -151.15 155.33 7.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.13 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 152' ' ' THR . . . . . 0.441 ' N ' HG22 ' A' ' 151' ' ' VAL . 38.0 m -113.32 93.7 4.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.156 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.478 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 68.2 mt -77.27 137.33 38.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.939 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 6.9 t -121.42 -39.55 2.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.888 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 19.3 t80 -143.49 129.17 19.26 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.929 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 76.3 t -141.05 105.42 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.128 179.895 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 14.6 tt0 -118.39 134.39 55.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.927 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 21.3 mt -105.22 90.44 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.158 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 27.4 p -60.39 176.14 0.38 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.872 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 151.36 -156.74 26.84 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.503 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 178.68 4.32 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.701 2.267 . . . . 0.0 112.335 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 4.3 t -110.94 113.01 25.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.898 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 97.0 p -101.68 41.4 1.21 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.836 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.275 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.5 -179.997 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.305 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 25.4 t -129.25 81.05 2.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.877 0.37 . . . . 0.0 110.882 -179.751 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 23.2 t -43.76 102.12 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.839 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -142.03 90.37 0.18 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.492 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.8 m -109.02 86.23 2.24 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.919 0.39 . . . . 0.0 110.873 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.2 t -93.56 129.48 39.78 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.887 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -125.86 157.46 19.86 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.468 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 25.3 p80 -38.83 152.24 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.74 0.305 . . . . 0.0 110.894 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -84.66 163.84 18.99 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.89 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 50.9 mt-30 -72.58 105.17 4.12 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.963 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.576 ' H ' HD23 ' A' ' 11' ' ' LEU . 0.1 OUTLIER -65.53 -28.77 69.41 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.92 -179.993 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 4.6 m120 -113.75 119.41 37.29 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.902 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 17.5 m -125.06 171.81 9.96 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.838 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 2.8 pp -119.56 155.23 54.55 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.653 0.739 . . . . 0.0 110.917 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.71 175.73 7.67 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.685 2.257 . . . . 0.0 112.366 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 9.2 t -70.24 148.37 48.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.108 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 4.0 ptt? -99.08 40.3 1.22 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.89 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -77.54 -176.64 4.36 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.841 -179.898 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.65 -131.08 10.52 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.476 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 166.52 27.26 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.701 2.267 . . . . 0.0 112.332 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -175.5 1.18 Allowed 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.684 2.256 . . . . 0.0 112.354 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.538 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.6 m -96.09 151.95 18.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.118 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.538 ' CD1' ' O ' ' A' ' 22' ' ' THR . 8.3 m-85 -150.84 127.4 10.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.887 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ASN . . . . . 0.59 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 3.4 m120 54.48 45.46 2.27 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.607 0.718 . . . . 0.0 110.893 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.59 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.6 Cg_endo -69.76 132.56 23.59 Favored 'Trans proline' 0 C--O 1.231 0.175 0 C-N-CA 122.655 2.236 . . . . 0.0 112.299 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.81 -175.11 1.06 Allowed 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.669 2.246 . . . . 0.0 112.394 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.658 HG13 ' HA ' ' A' ' 28' ' ' PRO . 86.9 t -143.17 137.63 14.95 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.616 0.722 . . . . 0.0 111.14 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.658 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.6 Cg_endo -69.79 144.63 77.27 Favored 'Cis proline' 0 C--N 1.341 0.184 0 C-N-CA 122.702 -1.791 . . . . 0.0 112.319 -0.017 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 6.4 t80 -98.31 121.99 40.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.938 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -102.17 101.95 12.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.842 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -100.82 108.77 3.52 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.455 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 6.8 mmt85 -73.28 123.29 23.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.856 0.36 . . . . 0.0 110.902 -179.865 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.406 HD22 ' CZ ' ' A' ' 41' ' ' ARG . 7.8 mt -87.05 113.73 23.05 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.929 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 5.7 mm100 -84.62 80.53 9.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.888 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 143.54 -36.83 1.51 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.501 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.469 ' CA ' ' OD1' ' A' ' 143' ' ' ASP . . . 93.72 -177.93 37.59 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.48 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' LEU . . . . . 0.791 HD23 ' HE ' ' A' ' 41' ' ' ARG . 89.0 mt -68.47 98.05 0.82 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.899 0.38 . . . . 0.0 110.885 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 34.6 p -107.77 161.85 14.52 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.1 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.437 ' HB2' HD21 ' A' ' 117' ' ' LEU . . . -62.18 -27.47 68.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.112 179.845 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 8.8 mpt_? -105.61 33.06 3.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.918 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.791 ' HE ' HD23 ' A' ' 37' ' ' LEU . 4.5 ttt85 -109.74 137.98 46.77 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 87.4 m -138.96 120.82 15.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.136 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.487 HD11 ' CZ ' ' A' ' 41' ' ' ARG . 5.4 mp -93.74 137.78 21.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.159 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 76.2 mt -128.96 118.65 47.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.084 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 71.9 mt -118.1 107.37 21.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.104 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 21.9 mtmt -113.69 109.49 18.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.928 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -143.2 -143.61 4.15 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.528 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -168.03 128.6 1.35 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.941 0.4 . . . . 0.0 110.944 -179.845 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 15.4 t -79.11 119.6 77.75 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.646 0.736 . . . . 0.0 111.17 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 158.91 55.29 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.683 2.255 . . . . 0.0 112.313 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -17.96 37.03 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.712 2.274 . . . . 0.0 112.304 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 30.2 p -109.52 18.77 20.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.126 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -115.74 121.18 5.17 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.477 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 20.2 mtpp -63.91 -58.78 5.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.78 0.324 . . . . 0.0 110.906 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.0 m -173.12 167.77 4.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.833 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.531 ' CE2' HD11 ' A' ' 58' ' ' ILE . 1.9 p90 -119.07 -172.2 2.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.86 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.067 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -154.67 133.82 12.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.106 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.531 HD11 ' CE2' ' A' ' 56' ' ' PHE . 3.6 mp -115.77 98.18 6.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.151 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ASN . . . . . 0.415 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 6.0 m-80 -100.25 143.33 30.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.939 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.559 ' CE2' HD13 ' A' ' 145' ' ' LEU . 28.5 m-85 -115.32 98.38 6.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.904 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.431 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 33.7 ttmt -95.68 168.31 10.75 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.934 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.756 HG22 ' HA ' ' A' ' 142' ' ' VAL . 53.4 t -100.24 125.08 54.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.147 179.85 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -60.44 -36.88 92.25 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.509 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 69.7 m -65.95 -73.34 0.13 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.871 0.367 . . . . 0.0 110.897 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 58.0 m -81.18 -73.36 0.38 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.853 -179.874 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 133.62 39.8 0.19 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.491 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.554 ' OD1' ' ND2' ' A' ' 88' ' ' ASN . 1.2 m-20 -108.92 142.88 38.9 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.789 0.328 . . . . 0.0 110.886 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.525 HD12 ' HB3' ' A' ' 86' ' ' LEU . 35.8 mt -92.35 114.01 28.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.127 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -83.63 -31.49 26.19 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.112 179.817 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.74 HD21 HD11 ' A' ' 72' ' ' ILE . 56.0 tp -141.28 130.91 24.04 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.889 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.476 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.2 t60 -134.49 92.94 2.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.845 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.74 HD11 HD21 ' A' ' 70' ' ' LEU . 18.2 mt -97.31 132.97 40.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.112 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 1.067 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 12.7 t-20 -140.27 106.49 6.65 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.63 0.728 . . . . 0.0 110.899 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.618 ' HB3' ' CD2' ' A' ' 103' ' ' PHE . 54.0 Cg_endo -69.74 154.98 67.16 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.652 2.235 . . . . 0.0 112.335 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 57.8 mtp180 -131.49 100.57 5.19 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.887 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' MET . . . . . 0.422 ' SD ' ' HB2' ' A' ' 103' ' ' PHE . 0.0 OUTLIER -63.63 161.62 14.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.891 179.952 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 85.28 -67.8 3.57 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.457 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -75.43 -57.83 3.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.848 0.356 . . . . 0.0 110.887 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 105.73 48.89 0.99 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.513 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.2 p -136.95 118.15 14.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.797 0.332 . . . . 0.0 111.167 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.408 HG22 ' HA ' ' A' ' 74' ' ' PRO . 15.2 t -102.54 114.26 41.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.13 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.572 HG22 ' HD3' ' A' ' 96' ' ' LYS . 37.1 t -84.53 143.34 11.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.127 179.897 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -125.4 124.88 42.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.853 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.476 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.7 OUTLIER -136.23 176.29 8.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.906 -179.975 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 47.7 t -156.15 105.07 2.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.891 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.893 HD13 ' NE1' ' A' ' 91' ' ' TRP . 39.0 tp -77.18 114.33 15.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.904 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.518 ' N ' ' O ' ' A' ' 90' ' ' SER . 79.7 mt -92.44 161.93 14.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.929 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.554 ' ND2' ' OD1' ' A' ' 67' ' ' ASP . 11.8 m120 -41.17 101.83 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.938 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.15 -1.55 3.61 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.485 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.829 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -125.31 170.59 11.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.828 0.347 . . . . 0.0 110.898 -179.815 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.893 ' NE1' HD13 ' A' ' 86' ' ' LEU . 23.1 m95 -128.12 160.57 31.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.903 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -91.97 -102.04 1.38 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.461 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 9.9 m -167.82 174.41 7.56 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.868 0.366 . . . . 0.0 110.823 -179.752 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -96.71 123.64 40.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.881 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 17.8 mm-40 -121.37 116.12 24.2 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.9 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.572 ' HD3' HG22 ' A' ' 82' ' ' VAL . 6.7 mtmp? -120.72 122.16 39.82 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.888 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -175.17 105.54 0.09 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.855 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.881 HD11 ' O ' ' A' ' 100' ' ' HIS . 6.4 tt -147.64 146.58 18.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.137 179.842 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.485 HG23 ' N ' ' A' ' 100' ' ' HIS . 10.2 t -81.34 -44.79 17.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' HIS . . . . . 0.881 ' O ' HD11 ' A' ' 98' ' ' ILE . 5.1 p-80 -148.5 141.26 24.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.9 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ASN . . . . . 0.443 ' C ' ' OD1' ' A' ' 101' ' ' ASN . 4.9 t-20 -101.63 102.13 20.97 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.605 0.717 . . . . 0.0 110.899 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.476 ' CD ' HD11 ' A' ' 129' ' ' LEU . 53.8 Cg_endo -69.78 -29.6 23.53 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.691 2.26 . . . . 0.0 112.33 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.618 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 19.6 m-85 -58.6 115.02 2.77 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.866 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -140.06 139.83 10.18 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.516 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 111.0 2.7 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.716 2.277 . . . . 0.0 112.305 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 107.18 0.9 35.64 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.487 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -137.85 142.09 40.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.849 0.356 . . . . 0.0 110.903 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.4 p90 -68.57 174.51 4.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.844 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 29.1 p90 -161.25 132.21 5.32 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.922 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -103.34 106.38 16.88 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.859 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.794 HD13 ' N ' ' A' ' 112' ' ' SER . 0.4 OUTLIER -109.16 138.39 45.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.912 -179.955 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.794 ' N ' HD13 ' A' ' 111' ' ' LEU . 2.6 m -145.44 113.67 6.59 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.867 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.552 HG23 HG22 ' A' ' 122' ' ' VAL . 4.0 mp -93.55 136.82 24.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.108 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 50.1 mtt-85 -110.22 120.9 43.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.851 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' CYS . . . . . 0.431 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 26.3 t -92.06 122.21 34.35 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.918 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -123.62 -149.44 7.77 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.484 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.437 HD21 ' HB2' ' A' ' 39' ' ' ALA . 36.3 mt -109.37 -40.88 4.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.86 0.362 . . . . 0.0 110.904 -179.871 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -80.72 -39.54 26.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.83 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.418 ' HA ' ' CE1' ' A' ' 134' ' ' HIS . 0.0 OUTLIER -174.11 179.91 1.8 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.898 -179.865 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.542 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 18.9 m-85 -97.95 155.04 17.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.877 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 15.5 mtpp -130.48 100.55 5.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.921 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.781 ' CG1' HD11 ' A' ' 111' ' ' LEU . 21.3 t -88.16 128.61 40.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.116 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -120.59 149.79 41.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.909 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.45 ' CB ' ' HG3' ' A' ' 102' ' ' PRO . . . -134.17 110.1 9.34 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.093 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 58.13 31.58 20.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.911 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.31 38.2 15.64 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.484 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 28.4 mm-40 -143.77 128.88 18.66 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.868 0.366 . . . . 0.0 110.914 -179.854 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 35.6 t-80 -59.21 107.19 0.52 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.845 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.476 HD11 ' CD ' ' A' ' 102' ' ' PRO . 8.5 tp -78.41 -66.12 0.89 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.899 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.472 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 5.3 p90 -166.42 169.53 13.86 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.861 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -115.21 149.71 37.28 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.917 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.657 ' CG ' HD13 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -117.73 108.02 14.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.899 -179.92 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.579 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -63.33 134.97 56.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.066 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' HIS . . . . . 0.418 ' CE1' ' HA ' ' A' ' 119' ' ' ARG . 29.1 m170 -63.34 107.3 1.06 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.884 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 67.6 mtt-85 -89.71 -48.85 7.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.849 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' LEU . . . . . 0.422 HD13 HD22 ' A' ' 87' ' ' LEU . 12.2 tp -93.51 109.33 20.93 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.943 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 12.1 t -50.64 -33.37 22.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.868 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.518 ' HB1' ' HD2' ' A' ' 141' ' ' ARG . . . -87.19 33.55 0.68 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.107 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.647 ' O ' HD12 ' A' ' 37' ' ' LEU . 8.2 p90 -50.74 -31.61 17.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.868 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 6.1 pt20 -56.14 -46.46 79.22 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.885 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.518 ' HD2' ' HB1' ' A' ' 138' ' ' ALA . 27.6 mtt-85 -47.5 -44.22 25.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.866 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.756 ' HA ' HG22 ' A' ' 62' ' ' VAL . 92.3 t -43.3 103.45 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.153 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.469 ' OD1' ' CA ' ' A' ' 36' ' ' GLY . 17.1 m-20 -128.19 31.48 5.05 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.841 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 18.1 m -142.44 123.19 14.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.122 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.559 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.6 tp -120.15 107.69 13.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.933 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -110.75 152.31 26.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.919 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 25.1 mt -139.58 112.77 6.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.177 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -123.57 171.29 9.64 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.928 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 113.03 -148.07 18.54 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.522 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 28.8 m-20 -111.56 89.1 2.96 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.859 0.361 . . . . 0.0 110.881 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.448 HG22 ' N ' ' A' ' 152' ' ' THR . 7.2 p -148.85 155.33 8.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.129 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 152' ' ' THR . . . . . 0.448 ' N ' HG22 ' A' ' 151' ' ' VAL . 16.9 m -116.21 94.51 4.68 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.16 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.476 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 78.6 mt -75.92 139.95 41.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.886 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 68.6 m -127.8 -35.57 2.09 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.858 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 39.6 t80 -146.93 125.08 12.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.942 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 79.4 t -138.97 106.33 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.118 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 13.9 tt0 -119.69 141.16 49.63 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.931 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 158' ' ' ILE . . . . . 0.638 HG23 ' NH1' ' A' ' 41' ' ' ARG . 15.6 mt -110.1 97.27 5.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.121 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 42.4 t -45.85 141.9 2.82 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.856 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -90.74 177.82 42.13 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.507 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -17.58 37.42 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.738 2.292 . . . . 0.0 112.309 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.8 m -132.26 133.24 43.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.839 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 25.8 t -133.0 132.48 41.94 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.876 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.493 -179.988 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 N-CA-C 112.534 -0.226 . . . . 0.0 112.534 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 69.0 m -114.88 -54.65 2.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.888 0.375 . . . . 0.0 110.897 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 59.6 p -130.76 153.31 49.17 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.869 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 153.29 95.25 0.11 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.466 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.0 m -124.12 157.45 34.61 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.881 0.372 . . . . 0.0 110.852 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 12.5 t -97.34 -48.67 5.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.906 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 111.84 117.94 3.66 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.476 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 28.2 p-80 -83.2 130.06 35.06 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.776 0.322 . . . . 0.0 110.822 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 91.3 mm-40 -78.53 88.67 4.47 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.883 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 41.4 tt0 -118.6 82.91 1.93 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.935 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 56.5 mt -117.44 44.06 2.21 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.911 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 74.3 m-80 -58.2 -39.77 79.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.897 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 29.5 p -105.56 158.06 16.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.836 -179.852 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 97.1 mt -51.68 151.29 6.09 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-O 121.586 0.708 . . . . 0.0 110.916 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.7 -163.9 0.12 Allowed 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.665 2.243 . . . . 0.0 112.399 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.5 m -88.78 149.46 23.42 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.136 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' MET . . . . . 0.507 ' HE3' ' CA ' ' A' ' 31' ' ' GLY . 3.2 mpp? -95.99 102.03 13.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.833 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.4 163.25 14.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.863 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.41 ' HA3' ' HD2' ' A' ' 20' ' ' PRO . . . 77.89 -132.25 11.72 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.518 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.41 ' HD2' ' HA3' ' A' ' 19' ' ' GLY . 53.9 Cg_endo -69.71 168.71 20.7 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.708 2.272 . . . . 0.0 112.366 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.69 -179.09 2.64 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.679 2.253 . . . . 0.0 112.344 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 1.2 t -97.8 148.86 22.96 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.129 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -138.92 127.83 23.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.92 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ASN . . . . . 0.567 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 8.8 m-80 61.55 47.0 1.08 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.578 0.704 . . . . 0.0 110.901 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.567 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 54.0 Cg_endo -69.75 136.03 31.99 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.65 2.234 . . . . 0.0 112.312 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 -177.72 2.02 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.68 2.253 . . . . 0.0 112.331 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.686 HG13 ' HA ' ' A' ' 28' ' ' PRO . 97.0 t -141.72 138.09 16.87 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.685 0.755 . . . . 0.0 111.107 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.686 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.3 Cg_endo -69.77 144.33 76.38 Favored 'Cis proline' 0 C--N 1.342 0.198 0 C-N-CA 122.65 -1.812 . . . . 0.0 112.325 -0.027 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 8.2 t80 -97.47 117.15 31.09 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.933 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -100.66 102.3 13.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.884 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.507 ' CA ' ' HE3' ' A' ' 17' ' ' MET . . . -97.77 109.4 3.81 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.456 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 9.7 mmt180 -72.91 102.99 3.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.854 0.359 . . . . 0.0 110.876 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.487 HD13 ' NH2' ' A' ' 41' ' ' ARG . 5.6 mt -71.1 114.7 9.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.939 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 5.6 mm-40 -86.32 94.49 9.36 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.911 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 131.33 -32.75 2.9 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.453 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.714 ' O ' HG23 ' A' ' 38' ' ' THR . . . 88.69 173.45 46.87 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.51 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' LEU . . . . . 0.676 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 88.0 mt -57.18 104.97 0.19 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.854 0.359 . . . . 0.0 110.938 -179.9 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.714 HG23 ' O ' ' A' ' 36' ' ' GLY . 29.0 p -117.07 149.94 39.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.116 -180.0 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -59.71 -21.27 60.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.122 179.83 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 25.5 mmm-85 -104.42 26.46 8.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.884 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.675 ' CZ ' HD23 ' A' ' 37' ' ' LEU . 23.4 ttt180 -116.97 142.86 46.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.863 -179.892 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 91.2 m -137.16 121.21 17.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.123 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 mp -90.86 132.46 35.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.156 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.459 ' CG2' ' HE2' ' A' ' 46' ' ' LYS . 70.1 mt -128.57 117.24 44.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.154 179.792 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 34.9 mt -116.15 107.59 22.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.168 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.459 ' HE2' ' CG2' ' A' ' 44' ' ' ILE . 22.3 mtmt -111.65 111.18 21.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.904 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -143.67 -143.62 4.12 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.484 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' TYR . . . . . 0.405 ' O ' ' CD1' ' A' ' 48' ' ' TYR . 1.1 t80 -167.59 118.27 0.85 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.944 0.402 . . . . 0.0 110.896 -179.847 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 15.1 t -69.96 115.45 34.0 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.638 0.732 . . . . 0.0 111.135 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 159.02 54.96 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.714 2.276 . . . . 0.0 112.359 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -25.16 29.01 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.683 2.256 . . . . 0.0 112.328 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 67.1 p -100.74 15.41 28.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.134 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -109.89 119.4 5.4 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.489 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.418 ' O ' ' SD ' ' A' ' 76' ' ' MET . 24.8 mtpt -62.47 -58.91 5.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.816 0.341 . . . . 0.0 110.89 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 37.0 p -175.58 162.37 2.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.827 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 3.5 p90 -116.14 -174.98 2.65 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.87 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.131 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -156.91 137.38 13.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.119 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.429 HD12 ' N ' ' A' ' 58' ' ' ILE . 4.6 mp -118.14 100.78 10.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.152 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -99.85 144.04 29.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.911 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.62 ' CE2' HD13 ' A' ' 145' ' ' LEU . 50.1 m-85 -115.04 97.69 6.37 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.881 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.47 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 35.5 ttmt -96.13 167.68 11.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.899 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.615 HG22 ' HA ' ' A' ' 142' ' ' VAL . 43.6 t -100.61 122.52 52.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.102 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -58.58 -40.21 94.28 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.515 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.0 t -64.43 -70.74 0.21 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.941 0.4 . . . . 0.0 110.902 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 48.5 t -79.75 -75.06 0.27 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.875 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 131.43 41.37 0.21 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.487 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.433 ' O ' HG23 ' A' ' 62' ' ' VAL . 0.8 OUTLIER -114.71 141.47 47.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.833 0.349 . . . . 0.0 110.879 179.995 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.479 HD12 ' HB3' ' A' ' 86' ' ' LEU . 43.0 mt -88.05 119.55 35.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.111 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -90.25 -33.57 16.1 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.059 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.712 HD21 HD11 ' A' ' 72' ' ' ILE . 62.7 tp -138.44 131.2 29.43 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.898 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.531 ' CD2' ' C ' ' A' ' 71' ' ' HIS . 3.0 t-160 -135.01 93.91 3.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.866 179.877 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.712 HD11 HD21 ' A' ' 70' ' ' LEU . 17.1 mt -98.09 133.16 41.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.096 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 1.131 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 12.9 t-20 -140.8 106.87 6.36 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.597 0.713 . . . . 0.0 110.871 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.611 ' HB3' ' CD2' ' A' ' 103' ' ' PHE . 53.8 Cg_endo -69.75 154.63 67.56 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.702 2.268 . . . . 0.0 112.383 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 46.0 mtp85 -132.96 94.58 3.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.892 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' MET . . . . . 0.418 ' SD ' ' O ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -47.52 -26.1 1.31 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.885 179.983 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -52.25 -94.83 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.466 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -89.54 19.75 4.37 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.852 0.358 . . . . 0.0 110.895 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.462 ' HA2' ' ND2' ' A' ' 101' ' ' ASN . . . 53.92 39.82 63.55 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.496 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 28.8 p -108.94 117.86 35.31 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.85 0.357 . . . . 0.0 111.114 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.2 t -99.35 110.46 26.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.149 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.525 HG22 ' HD3' ' A' ' 96' ' ' LYS . 67.6 t -82.71 145.45 8.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.113 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -125.84 124.15 40.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.895 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.497 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.2 m-80 -135.49 177.12 8.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.889 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 87.1 p -160.67 105.13 1.4 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.826 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.934 HD12 ' O ' ' A' ' 90' ' ' SER . 22.9 tp -77.74 119.34 21.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.943 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 90' ' ' SER . 93.0 mt -96.71 161.48 13.86 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.915 179.876 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.47 ' C ' ' H ' ' A' ' 90' ' ' SER . 17.8 p-10 -37.91 101.67 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.864 179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.51 -7.05 0.68 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.477 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.934 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -117.54 170.03 9.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.856 0.36 . . . . 0.0 110.871 -179.748 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.841 ' NE1' HD13 ' A' ' 86' ' ' LEU . 20.7 m95 -128.58 161.1 30.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.927 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -93.14 -110.26 1.98 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.465 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 72.0 m -159.91 178.12 10.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.855 0.359 . . . . 0.0 110.87 -179.781 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.435 ' C ' ' OE2' ' A' ' 95' ' ' GLU . 30.2 mt-10 -103.07 123.62 47.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.887 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' GLU . . . . . 0.435 ' OE2' ' C ' ' A' ' 94' ' ' GLU . 3.5 mp0 -122.88 116.96 24.5 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.89 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.525 ' HD3' HG22 ' A' ' 82' ' ' VAL . 9.4 mtmp? -118.79 120.55 37.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.891 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -171.84 108.0 0.23 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.966 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.788 HD11 ' O ' ' A' ' 100' ' ' HIS . 4.1 tt -147.66 152.3 12.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.119 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.523 HG23 ' N ' ' A' ' 100' ' ' HIS . 8.9 t -85.42 -47.18 10.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.162 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' HIS . . . . . 0.788 ' O ' HD11 ' A' ' 98' ' ' ILE . 1.7 p-80 -147.06 133.49 19.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.87 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ASN . . . . . 0.462 ' ND2' ' HA2' ' A' ' 79' ' ' GLY . 7.4 t30 -103.67 98.17 12.34 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.674 0.749 . . . . 0.0 110.856 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.5 Cg_endo -69.75 -42.5 3.36 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.687 2.258 . . . . 0.0 112.331 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.611 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 11.7 m-85 -34.01 110.58 0.09 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.858 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -133.09 136.66 8.84 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.515 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 97.78 0.65 Allowed 'Trans proline' 0 N--CA 1.465 -0.151 0 C-N-CA 122.715 2.277 . . . . 0.0 112.371 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 119.97 1.92 12.8 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.473 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 9.4 pt20 -134.59 149.09 50.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.846 0.355 . . . . 0.0 110.911 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -66.52 168.39 9.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.901 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.41 ' O ' ' CG ' ' A' ' 109' ' ' PHE . 14.9 p90 -160.71 125.51 3.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.906 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -101.75 108.28 19.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.883 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.735 HD13 ' N ' ' A' ' 112' ' ' SER . 0.7 OUTLIER -111.81 139.01 47.65 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.932 -179.96 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.735 ' N ' HD13 ' A' ' 111' ' ' LEU . 1.5 m -144.9 115.51 7.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.834 -179.88 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.504 HG22 ' HD2' ' A' ' 120' ' ' PHE . 4.9 mp -97.28 132.03 42.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.135 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.535 ' O ' ' CD2' ' A' ' 120' ' ' PHE . 6.1 mtp-105 -104.53 133.39 49.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.879 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 115' ' ' CYS . . . . . 0.559 ' HA ' ' CE2' ' A' ' 120' ' ' PHE . 5.7 t -98.08 121.72 40.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.895 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -122.97 -163.04 11.69 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.521 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 7.6 mt -104.82 -28.75 10.96 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.784 0.326 . . . . 0.0 110.892 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' ASP . . . . . 0.4 ' C ' ' OD1' ' A' ' 118' ' ' ASP . 7.2 t0 -97.43 -39.91 8.94 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.886 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 29.4 ptt-85 -170.34 163.89 8.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.676 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 14.8 m-85 -88.23 154.78 20.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.86 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 13.6 mtpp -126.94 100.17 6.04 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.908 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.524 HG13 HD11 ' A' ' 111' ' ' LEU . 39.3 t -87.44 132.28 33.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.128 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -123.79 146.59 48.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.919 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -134.74 111.89 10.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.111 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 55.64 35.18 24.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.865 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.57 39.57 21.25 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.492 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 9.8 mt-30 -145.99 129.11 16.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.837 0.351 . . . . 0.0 110.937 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 33.0 t-80 -60.76 99.29 0.08 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.889 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.538 HD22 HD21 ' A' ' 111' ' ' LEU . 9.8 tp -66.71 -69.62 0.3 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.93 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.482 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 4.9 p90 -163.29 171.38 16.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.913 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -116.49 148.09 41.12 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.86 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.673 ' CG ' HD13 ' A' ' 70' ' ' LEU . 0.3 OUTLIER -116.99 107.66 14.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.859 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.463 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -64.89 133.27 51.49 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.092 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 29.2 m170 -60.68 109.09 0.95 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.846 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 32.0 mtt-85 -91.54 -51.38 5.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.891 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.0 tp -93.18 109.3 20.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.913 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 81.6 p -49.72 -35.22 21.26 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.83 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -82.22 39.44 0.58 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.115 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.485 ' O ' HD12 ' A' ' 37' ' ' LEU . 7.5 p90 -60.68 -37.62 82.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.942 -179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -55.5 -32.68 63.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.915 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.509 ' O ' HG13 ' A' ' 62' ' ' VAL . 34.6 mtp85 -62.2 -37.72 86.39 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.879 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.615 ' HA ' HG22 ' A' ' 62' ' ' VAL . 93.5 t -49.08 104.12 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.087 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.405 ' OD1' ' CA ' ' A' ' 36' ' ' GLY . 0.9 OUTLIER -127.56 34.55 4.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.905 179.892 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 18.7 m -146.89 112.93 5.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.144 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.62 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.3 tp -112.18 107.14 15.93 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.902 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 146' ' ' GLU . . . . . 0.41 ' C ' HG13 ' A' ' 147' ' ' ILE . 2.0 pm0 -109.21 153.97 23.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.903 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.41 HG13 ' C ' ' A' ' 146' ' ' GLU . 20.2 mt -140.03 107.23 2.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.146 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -115.69 171.5 7.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.932 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 110.64 -146.72 17.5 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.502 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -114.6 93.44 4.33 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.801 0.334 . . . . 0.0 110.896 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 4.0 p -151.2 142.09 16.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.144 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 9.9 m -101.94 94.78 5.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.161 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.458 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 83.8 mt -77.33 138.1 39.15 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.89 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 16.6 m -122.35 -39.75 2.54 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.87 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 23.8 t80 -146.0 129.01 16.5 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.914 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 70.1 t -140.3 106.33 2.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.138 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 8.9 tt0 -120.8 132.89 55.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.928 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 14.1 mt -99.01 88.52 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.165 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 16.9 m -56.12 119.22 5.56 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.865 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -134.36 164.17 24.58 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.524 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -3.83 12.79 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.674 2.249 . . . . 0.0 112.336 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 9.0 t -113.26 172.21 7.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.889 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 80.5 p -163.83 110.53 1.11 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.865 -179.852 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.273 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.518 -179.991 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 N-CA-C 112.508 -0.237 . . . . 0.0 112.508 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.6 m -46.42 -59.85 2.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.914 0.388 . . . . 0.0 110.849 -179.738 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.9 t -144.06 146.74 33.04 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.851 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.68 43.8 2.84 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.44 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 7.8 t -46.49 112.46 0.5 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.913 0.387 . . . . 0.0 110.891 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 72.8 m -50.99 -43.95 60.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.873 -179.808 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 49.99 53.23 23.5 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.485 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 3.2 p80 -87.53 137.34 32.42 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.756 0.312 . . . . 0.0 110.856 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 21.1 mm-40 -109.22 105.39 14.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.926 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 8.2 pt20 -44.73 99.74 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.866 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 51.4 mt -144.22 156.01 44.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.2 p30 -86.48 -45.16 11.38 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 3.8 m -54.54 -174.47 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.84 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.551 HD11 ' HG2' ' A' ' 32' ' ' ARG . 0.4 OUTLIER -117.17 157.33 47.17 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.567 0.698 . . . . 0.0 110.966 179.977 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.442 ' HD2' ' HB2' ' A' ' 14' ' ' LEU . 53.6 Cg_endo -69.75 174.57 9.3 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.737 2.291 . . . . 0.0 112.305 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 6.1 t -92.66 -7.1 47.82 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.159 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 40.2 mtm 64.1 43.06 5.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.86 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -80.57 161.91 24.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.886 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.36 -136.63 13.42 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.477 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 170.0 17.63 Favored 'Trans proline' 0 C--O 1.231 0.13 0 C-N-CA 122.694 2.263 . . . . 0.0 112.3 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 -173.51 0.72 Allowed 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.687 2.258 . . . . 0.0 112.398 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.437 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.4 m -98.2 140.69 32.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.129 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -137.48 125.54 22.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ASN . . . . . 0.501 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.2 t-20 52.15 50.69 8.59 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.583 0.706 . . . . 0.0 110.862 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.501 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.77 140.36 42.46 Favored 'Trans proline' 0 N--CA 1.465 -0.176 0 C-N-CA 122.678 2.252 . . . . 0.0 112.379 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 -178.4 2.3 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.709 2.273 . . . . 0.0 112.371 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.666 HG13 ' HA ' ' A' ' 28' ' ' PRO . 97.8 t -140.35 137.58 17.95 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.658 0.742 . . . . 0.0 111.085 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.666 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.8 Cg_endo -69.72 144.68 77.24 Favored 'Cis proline' 0 C--N 1.342 0.187 0 C-N-CA 122.658 -1.809 . . . . 0.0 112.338 -0.067 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 6.2 t80 -97.88 120.72 38.78 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.925 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -103.07 101.02 10.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.887 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -106.62 109.69 3.15 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.477 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.551 ' HG2' HD11 ' A' ' 14' ' ' LEU . 8.3 mmt180 -74.04 109.34 7.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.841 0.353 . . . . 0.0 110.876 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.639 HD23 HG12 ' A' ' 158' ' ' ILE . 6.9 mt -67.54 101.08 0.94 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.88 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 46.1 mt-30 -73.36 100.35 3.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.867 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 132.81 -40.18 1.64 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.498 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.785 ' O ' HG23 ' A' ' 38' ' ' THR . . . 89.84 161.45 37.48 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.466 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' LEU . . . . . 0.661 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 91.3 mt -55.42 99.07 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.891 0.376 . . . . 0.0 110.893 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.785 HG23 ' O ' ' A' ' 36' ' ' GLY . 26.9 p -117.94 145.95 44.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.167 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -41.7 -33.76 0.53 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.113 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 19.0 mmt180 -101.9 41.63 1.2 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.885 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.491 ' NE ' ' O ' ' A' ' 36' ' ' GLY . 29.7 ttm-85 -122.66 138.6 54.55 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 52.7 m -139.54 120.34 14.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.15 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.43 ' N ' HD12 ' A' ' 43' ' ' ILE . 4.8 mp -93.32 136.47 25.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.099 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 96.6 mt -128.46 137.0 58.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.125 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 55.0 mt -136.97 107.49 5.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.202 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 24.2 mtmt -110.64 108.69 18.69 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.877 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -139.84 -139.69 3.8 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.498 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -171.39 136.72 1.03 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.948 0.404 . . . . 0.0 110.913 -179.853 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.402 HG23 ' CD1' ' A' ' 109' ' ' PHE . 21.5 t -86.73 116.34 65.61 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.64 0.733 . . . . 0.0 111.121 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 158.97 55.13 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.687 2.258 . . . . 0.0 112.324 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 -14.88 36.6 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.642 2.228 . . . . 0.0 112.368 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 38.0 p -113.91 20.13 16.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.154 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -113.03 113.45 3.18 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.501 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 25.1 mtpt -58.89 -58.91 6.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.809 0.337 . . . . 0.0 110.89 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 40.5 p -174.22 162.45 3.68 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.862 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.604 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 6.0 p90 -119.37 -173.57 2.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.874 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.45 137.37 13.49 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.147 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.543 HG22 ' CE1' ' A' ' 60' ' ' PHE . 3.9 mp -114.24 104.26 16.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.11 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ASN . . . . . 0.55 ' OD1' ' CD2' ' A' ' 71' ' ' HIS . 62.0 m-20 -98.48 141.4 31.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.875 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.567 ' CE2' HD13 ' A' ' 145' ' ' LEU . 5.6 m-85 -115.88 97.16 5.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.881 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.443 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 35.2 ttmt -96.02 168.37 10.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.874 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.671 HG22 ' HA ' ' A' ' 142' ' ' VAL . 49.0 t -99.78 124.33 53.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.086 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.427 ' HA3' ' NH1' ' A' ' 32' ' ' ARG . . . -62.25 -30.46 76.03 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.467 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.483 ' H ' HG12 ' A' ' 62' ' ' VAL . 9.7 t -71.24 -71.63 0.25 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.846 0.355 . . . . 0.0 110.821 -179.703 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 22.8 t -83.87 -70.98 0.53 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 132.14 42.82 0.17 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.501 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.555 ' OD1' ' ND2' ' A' ' 88' ' ' ASN . 0.8 OUTLIER -114.02 141.74 47.05 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.808 0.337 . . . . 0.0 110.88 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.448 HD12 ' HB3' ' A' ' 86' ' ' LEU . 80.7 mt -86.6 120.2 35.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.14 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.541 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -90.09 -37.57 14.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.076 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.775 HD21 HD11 ' A' ' 72' ' ' ILE . 21.8 tp -139.26 133.48 31.33 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.902 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.583 ' CD2' ' C ' ' A' ' 71' ' ' HIS . 2.4 t-160 -134.46 92.78 2.96 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.856 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.775 HD11 HD21 ' A' ' 70' ' ' LEU . 20.4 mt -93.52 135.66 27.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.126 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 5.1 t30 -140.91 107.13 6.31 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.626 0.727 . . . . 0.0 110.881 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.604 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.8 Cg_endo -69.77 154.73 67.33 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.669 2.246 . . . . 0.0 112.373 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 45.4 mtp85 -131.67 98.46 4.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.919 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -58.74 -44.73 90.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.883 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -63.72 -92.56 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.492 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 10.9 t-20 -43.35 -47.58 6.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.885 0.374 . . . . 0.0 110.88 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 96.63 38.06 4.56 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.483 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 16.9 p -138.11 117.92 13.22 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.807 0.337 . . . . 0.0 111.194 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.579 HG22 ' HA ' ' A' ' 74' ' ' PRO . 20.3 t -84.07 109.03 17.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.116 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.706 HG22 ' HD3' ' A' ' 96' ' ' LYS . 57.5 t -78.1 146.09 8.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.117 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -129.81 129.66 44.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.834 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.518 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.5 m-80 -141.62 178.45 7.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.847 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 93.1 p -160.83 105.02 1.37 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.873 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.914 HD13 ' NE1' ' A' ' 91' ' ' TRP . 25.1 tp -77.77 118.79 20.46 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.899 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.521 ' N ' ' O ' ' A' ' 90' ' ' SER . 92.7 mt -95.88 162.22 13.67 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.905 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.555 ' ND2' ' OD1' ' A' ' 67' ' ' ASP . 9.6 m120 -40.76 101.87 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.878 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.03 -3.94 2.8 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.477 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.845 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -123.73 172.65 8.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.828 0.347 . . . . 0.0 110.885 -179.739 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.914 ' NE1' HD13 ' A' ' 86' ' ' LEU . 18.8 m95 -129.04 160.93 31.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.917 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -91.46 -106.65 1.47 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.52 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' SER . . . . . 0.441 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 3.5 m -163.06 174.83 11.75 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.787 0.327 . . . . 0.0 110.902 -179.759 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -99.53 121.74 41.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.844 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 25.0 mm-40 -120.97 109.55 15.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.895 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.706 ' HD3' HG22 ' A' ' 82' ' ' VAL . 39.6 mtmt -115.51 117.65 30.95 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.933 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 2.8 tppp? -168.59 107.1 0.47 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.887 179.848 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.79 HD11 ' O ' ' A' ' 100' ' ' HIS . 8.7 tt -144.39 146.1 20.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.139 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.4 t -83.72 -38.34 21.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.109 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' HIS . . . . . 0.79 ' O ' HD11 ' A' ' 98' ' ' ILE . 5.2 p-80 -153.71 134.27 13.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.847 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ASN . . . . . 0.441 ' C ' ' OD1' ' A' ' 101' ' ' ASN . 27.1 t-20 -107.86 96.92 18.67 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.604 0.716 . . . . 0.0 110.879 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 101' ' ' ASN . 53.8 Cg_endo -69.72 -36.08 11.59 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.674 2.249 . . . . 0.0 112.36 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.483 ' CE2' ' HB3' ' A' ' 74' ' ' PRO . 5.7 m-85 -40.29 110.23 0.14 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.823 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -136.63 139.8 10.93 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.52 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 106.39 1.64 Allowed 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.694 2.263 . . . . 0.0 112.362 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 124.86 -11.47 7.82 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.51 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.9 pt20 -130.14 165.22 22.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.803 0.335 . . . . 0.0 110.925 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.3 p90 -87.48 169.26 12.37 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.889 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.48 ' CZ ' ' CZ ' ' A' ' 56' ' ' PHE . 30.0 p90 -153.63 124.75 7.41 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.898 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -94.34 103.38 15.38 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.843 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.859 HD13 ' N ' ' A' ' 112' ' ' SER . 0.5 OUTLIER -101.61 136.77 40.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.946 -179.965 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.859 ' N ' HD13 ' A' ' 111' ' ' LEU . 6.1 m -144.01 111.59 6.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.84 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.411 HG23 HG22 ' A' ' 122' ' ' VAL . 4.2 mp -93.53 141.72 14.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.103 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.427 ' O ' ' CG ' ' A' ' 120' ' ' PHE . 19.6 mtp180 -112.52 142.07 45.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.917 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 115' ' ' CYS . . . . . 0.585 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 3.1 t -114.0 109.41 18.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.892 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -107.53 -138.76 8.86 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.515 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.5 mt -118.69 -40.56 2.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.811 0.339 . . . . 0.0 110.903 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' ASP . . . . . 0.427 ' OD1' ' N ' ' A' ' 119' ' ' ARG . 19.8 p-10 -87.73 -34.09 18.49 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.831 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.427 ' N ' ' OD1' ' A' ' 118' ' ' ASP . 10.6 ptp85 -172.57 176.07 3.33 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.922 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.661 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 3.7 m-30 -98.98 166.08 11.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.893 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 26.2 mtpt -137.73 105.92 5.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.916 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.63 HG13 HD11 ' A' ' 111' ' ' LEU . 42.8 t -90.84 132.52 35.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.096 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 53.9 m-85 -122.2 155.97 34.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.916 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.499 ' O ' ' ND2' ' A' ' 125' ' ' ASN . . . -141.15 118.96 11.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.104 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.499 ' ND2' ' O ' ' A' ' 124' ' ' ALA . 10.2 p30 50.87 30.75 5.42 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.894 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 82.88 30.96 30.46 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.475 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 33.3 mm-40 -135.6 139.51 43.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.797 0.332 . . . . 0.0 110.905 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 31.2 t-80 -67.7 112.54 4.86 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.857 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 8.3 tp -84.23 -66.97 0.83 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.894 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.4 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 12.1 p90 -168.63 170.76 9.27 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.906 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -114.01 149.11 35.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.806 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.603 ' CD1' HD13 ' A' ' 70' ' ' LEU . 0.4 OUTLIER -111.6 105.09 13.54 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.906 -179.931 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.487 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -60.45 137.15 58.19 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.105 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 31.3 m170 -66.35 110.41 3.07 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.861 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.441 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 71.6 mtt-85 -96.72 -46.6 6.22 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.859 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.4 tp -98.54 108.06 20.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.852 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 29.4 t -50.23 -33.64 20.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.858 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.453 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.79 29.28 0.46 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.083 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.416 ' CG ' ' N ' ' A' ' 140' ' ' GLN . 33.8 p90 -49.66 -44.35 47.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.869 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 140' ' ' GLN . . . . . 0.416 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 7.8 pt20 -47.81 -39.13 17.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.913 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.453 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 67.3 mtp180 -56.45 -40.83 75.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.85 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.671 ' HA ' HG22 ' A' ' 62' ' ' VAL . 58.7 t -45.68 101.82 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.11 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.492 ' OD2' ' N ' ' A' ' 36' ' ' GLY . 0.7 OUTLIER -127.04 34.28 4.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.851 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 24.6 m -147.02 115.55 6.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.148 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.567 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.1 tp -114.69 114.55 25.79 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.908 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 146' ' ' GLU . . . . . 0.428 ' C ' HG13 ' A' ' 147' ' ' ILE . 4.1 pt-20 -114.38 158.12 21.94 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.868 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.428 HG13 ' C ' ' A' ' 146' ' ' GLU . 30.7 mt -142.9 123.14 10.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.119 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -132.21 175.65 9.07 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.912 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 102.49 -151.64 18.24 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.475 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -103.66 92.5 4.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.87 0.367 . . . . 0.0 110.85 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.4 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 7.4 p -150.95 150.15 13.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.165 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 26.7 m -113.57 93.7 4.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.131 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.445 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 66.5 mt -75.5 138.27 41.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.925 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 36.7 m -122.43 -34.91 3.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.878 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 17.3 t80 -150.59 130.69 13.5 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.96 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 94.8 t -140.56 111.89 4.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.123 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 11.9 tt0 -134.05 129.21 35.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.944 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 158' ' ' ILE . . . . . 0.639 HG12 HD23 ' A' ' 33' ' ' LEU . 4.6 mp -90.23 90.58 3.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.17 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 2.8 m -44.7 138.54 3.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.884 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -178.84 -175.3 45.78 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.493 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 134.08 27.12 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.732 2.288 . . . . 0.0 112.306 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 18.0 m -92.84 -45.17 8.12 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.875 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 33.1 t -127.87 110.3 12.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.837 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.317 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.482 179.983 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.531 -0.228 . . . . 0.0 112.531 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 17.3 t -162.06 134.58 5.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.928 0.395 . . . . 0.0 110.866 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.6 t -167.6 135.65 2.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.862 -179.801 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 107.79 115.78 3.97 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.476 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.0 m -145.97 135.57 23.21 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.845 0.355 . . . . 0.0 110.877 -179.75 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 19.3 m -121.64 109.99 15.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.881 -179.835 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 156.75 133.1 1.58 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.482 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 91.1 m-70 -141.14 160.87 39.18 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.814 0.34 . . . . 0.0 110.862 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 59.1 mm-40 -98.79 151.38 20.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.921 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 7.8 mp0 -108.47 102.55 11.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.918 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.7 mt -141.76 157.47 44.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.893 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 15.1 p-10 -84.61 45.56 1.15 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.903 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 2.8 m -88.55 157.61 18.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.87 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 15.4 mt -42.64 151.59 0.38 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.619 0.723 . . . . 0.0 110.955 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.75 159.44 53.41 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.711 2.274 . . . . 0.0 112.346 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 9.6 t -82.83 139.55 33.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.132 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' MET . . . . . 0.493 ' CE ' HD12 ' A' ' 158' ' ' ILE . 23.9 ptt? -91.96 42.67 1.11 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.853 179.902 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -63.98 157.81 24.06 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.851 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.412 ' HA3' ' HD2' ' A' ' 20' ' ' PRO . . . 111.08 -135.34 12.78 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.509 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.412 ' HD2' ' HA3' ' A' ' 19' ' ' GLY . 54.3 Cg_endo -69.73 166.97 25.77 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.742 2.294 . . . . 0.0 112.339 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 179.11 3.92 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.647 2.232 . . . . 0.0 112.351 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.512 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.6 m -93.18 152.1 19.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.158 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.512 ' CD1' ' O ' ' A' ' 22' ' ' THR . 10.2 m-85 -150.06 132.53 15.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.924 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ASN . . . . . 0.565 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 22.1 m-80 50.74 46.58 3.83 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.607 0.718 . . . . 0.0 110.835 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.565 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.78 137.04 34.47 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.668 2.245 . . . . 0.0 112.378 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 179.88 3.38 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.674 2.249 . . . . 0.0 112.351 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.686 HG13 ' HA ' ' A' ' 28' ' ' PRO . 95.2 t -140.21 138.18 18.9 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.643 0.735 . . . . 0.0 111.11 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.686 ' HA ' HG13 ' A' ' 27' ' ' VAL . 54.1 Cg_endo -69.72 144.96 78.02 Favored 'Cis proline' 0 C--N 1.341 0.161 0 C-N-CA 122.658 -1.809 . . . . 0.0 112.353 -0.145 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 8.9 t80 -97.45 121.39 39.3 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.891 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 70.6 m-85 -108.02 101.65 10.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.86 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -116.33 104.61 1.27 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.487 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.401 ' HD2' ' C ' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -72.54 130.48 40.73 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.848 0.356 . . . . 0.0 110.9 -179.893 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.44 ' N ' ' O ' ' A' ' 143' ' ' ASP . 5.0 mt -74.2 147.47 42.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.905 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 55.8 mt-30 -107.81 89.59 3.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.903 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.78 -47.43 0.99 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.503 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.636 ' O ' HG22 ' A' ' 38' ' ' THR . . . 104.94 159.03 23.47 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.484 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' LEU . . . . . 0.506 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 79.3 mt -53.32 110.73 0.58 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.88 0.372 . . . . 0.0 110.934 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.707 HG23 ' HB2' ' A' ' 41' ' ' ARG . 0.0 OUTLIER -133.8 170.37 15.69 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.112 179.967 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.713 ' HB2' HD21 ' A' ' 117' ' ' LEU . . . -59.29 -41.93 90.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.085 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 6.5 mpt_? -94.5 51.07 1.4 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.862 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.722 ' NH1' HG22 ' A' ' 158' ' ' ILE . 20.4 ttm-85 -138.94 136.6 35.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 91.8 m -139.52 125.16 19.38 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.173 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.4 mp -96.31 138.79 20.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.152 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 90.5 mt -131.57 138.38 53.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.143 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 69.7 mt -135.42 107.56 7.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.152 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.409 ' HE3' ' CD1' ' A' ' 155' ' ' TYR . 8.7 mtmm -108.1 111.64 23.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 179.865 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -144.61 -144.92 4.25 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.495 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' TYR . . . . . 0.58 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 1.3 t80 -170.65 123.87 0.66 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.853 0.359 . . . . 0.0 110.957 -179.82 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 13.1 t -73.58 115.28 40.07 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.584 0.707 . . . . 0.0 111.152 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 155.48 65.86 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.663 2.242 . . . . 0.0 112.337 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.85 -13.58 34.64 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.679 2.253 . . . . 0.0 112.305 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 32.9 p -111.71 14.51 21.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.114 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -111.02 122.07 6.03 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.51 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.4 mtpt -63.71 -59.81 4.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.809 0.338 . . . . 0.0 110.93 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 14.4 p -172.8 158.33 3.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.826 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.588 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 17.9 p90 -113.76 -172.62 2.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.846 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.051 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -155.68 140.98 17.62 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.098 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.441 HG23 HG12 ' A' ' 147' ' ' ILE . 7.2 mt -127.17 101.18 7.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.122 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ASN . . . . . 0.415 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 5.4 m-80 -103.14 154.05 19.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.907 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.624 ' CE2' HD13 ' A' ' 145' ' ' LEU . 6.1 m-85 -122.4 102.01 7.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.857 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.401 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 32.8 ttmt -95.68 168.2 10.82 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.864 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.713 HG22 ' HA ' ' A' ' 142' ' ' VAL . 83.2 t -100.06 120.55 49.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.127 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -57.54 -30.25 61.85 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.479 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.484 ' H ' HG12 ' A' ' 62' ' ' VAL . 2.1 m -72.84 -75.3 0.14 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.863 0.363 . . . . 0.0 110.882 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.3 t -79.33 -70.85 0.48 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.867 -179.837 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 131.18 40.51 0.23 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.486 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.543 ' OD1' ' ND2' ' A' ' 88' ' ' ASN . 0.5 OUTLIER -109.38 147.95 31.91 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.758 0.314 . . . . 0.0 110.854 -179.981 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.427 HD12 ' HB3' ' A' ' 86' ' ' LEU . 53.4 mt -94.35 113.7 29.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.153 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.634 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -86.02 -32.15 21.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.117 179.805 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.589 HD22 ' CD2' ' A' ' 132' ' ' PHE . 43.3 tp -138.83 131.09 28.4 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.487 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.8 OUTLIER -134.42 95.38 3.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.867 179.855 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.566 HD11 HD21 ' A' ' 70' ' ' LEU . 32.1 mt -100.05 131.53 47.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.133 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 1.051 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 8.8 t-20 -141.17 107.58 6.21 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.644 0.735 . . . . 0.0 110.874 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.588 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.9 Cg_endo -69.78 155.23 66.38 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.651 2.234 . . . . 0.0 112.333 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 80.0 mtp180 -132.15 100.01 4.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.87 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' MET . . . . . 0.453 ' HE3' ' HB3' ' A' ' 103' ' ' PHE . 0.1 OUTLIER -68.38 -40.36 81.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.905 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -45.33 -66.09 1.66 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.498 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.2 t30 -89.3 -54.09 4.26 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.905 0.383 . . . . 0.0 110.903 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 118.77 47.23 0.41 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.47 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 18.7 p -141.45 124.48 16.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.823 0.344 . . . . 0.0 111.135 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.497 HG21 ' HE2' ' A' ' 103' ' ' PHE . 18.4 t -94.39 109.72 22.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.184 179.859 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.593 HG22 ' HD3' ' A' ' 96' ' ' LYS . 41.5 t -81.88 145.25 8.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.137 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -126.45 123.92 38.96 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.888 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.487 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.7 OUTLIER -135.97 178.82 6.75 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.882 -179.935 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 50.7 p -160.07 106.29 1.58 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.855 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.904 HD13 ' NE1' ' A' ' 91' ' ' TRP . 24.4 tp -77.38 115.78 17.43 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.904 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.494 HD22 HD13 ' A' ' 136' ' ' LEU . 24.0 mt -91.55 161.09 15.09 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.886 179.902 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.543 ' ND2' ' OD1' ' A' ' 67' ' ' ASP . 11.4 m120 -41.58 101.56 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.913 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 67.43 -3.56 4.53 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.46 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.858 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -124.26 172.25 9.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.836 0.351 . . . . 0.0 110.851 -179.709 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.904 ' NE1' HD13 ' A' ' 86' ' ' LEU . 21.0 m95 -129.43 158.63 38.66 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.908 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -89.22 -106.59 1.12 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.445 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 3.7 m -163.6 176.29 9.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.791 0.329 . . . . 0.0 110.887 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.455 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 16.1 mt-10 -99.04 119.65 38.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.908 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -119.23 116.4 26.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.883 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.593 ' HD3' HG22 ' A' ' 82' ' ' VAL . 39.8 mtmt -121.89 119.28 31.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.902 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 27.7 tttp -167.26 108.03 0.62 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.889 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.554 HD11 ' O ' ' A' ' 100' ' ' HIS . 7.2 tt -149.4 147.21 16.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.165 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.543 HG23 ' N ' ' A' ' 100' ' ' HIS . 12.6 t -89.32 -47.47 8.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.134 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' HIS . . . . . 0.554 ' O ' HD11 ' A' ' 98' ' ' ILE . 4.2 p-80 -138.41 125.24 21.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.845 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -103.3 95.91 7.62 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.613 0.72 . . . . 0.0 110.898 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.82 -34.38 14.49 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.672 2.248 . . . . 0.0 112.303 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.497 ' HE2' HG21 ' A' ' 81' ' ' VAL . 19.0 m-85 -39.33 99.6 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.857 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -129.81 136.3 8.86 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.498 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 99.84 0.78 Allowed 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.658 2.239 . . . . 0.0 112.348 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 130.33 -8.38 5.95 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.48 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 -131.37 162.11 30.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.882 0.372 . . . . 0.0 110.896 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' PHE . . . . . 0.58 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 17.2 m-85 -80.27 172.1 14.2 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.858 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.483 ' O ' ' CD1' ' A' ' 109' ' ' PHE . 19.8 p90 -161.17 119.62 2.45 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.9 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -93.86 101.74 13.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.843 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.875 HD13 ' N ' ' A' ' 112' ' ' SER . 0.5 OUTLIER -101.2 136.75 40.53 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.909 -179.942 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.875 ' N ' HD13 ' A' ' 111' ' ' LEU . 10.4 m -141.6 112.88 7.5 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.882 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.608 HG22 ' HD2' ' A' ' 120' ' ' PHE . 4.1 mp -96.91 115.91 37.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.171 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 21.2 mtp85 -89.75 141.32 28.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.896 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' CYS . . . . . 0.573 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 13.6 t -113.41 115.25 27.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -111.76 -141.83 8.59 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.473 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.713 HD21 ' HB2' ' A' ' 39' ' ' ALA . 7.4 mt -115.2 -33.38 5.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.804 0.335 . . . . 0.0 110.922 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -89.53 -42.27 11.54 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.904 179.831 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -166.22 -176.34 3.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.893 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.608 ' HD2' HG22 ' A' ' 113' ' ' ILE . 12.0 m-85 -102.44 156.2 17.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.897 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 23.2 mtpt -130.1 105.92 8.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.865 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.715 HG13 HD11 ' A' ' 111' ' ' LEU . 46.8 t -91.3 131.73 37.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.109 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 79.5 m-85 -122.26 149.98 42.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.933 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.442 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -134.59 108.28 7.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.094 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 56.93 35.27 26.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.871 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.09 38.31 15.79 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.483 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 7.3 mt-30 -146.18 126.63 14.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.81 0.338 . . . . 0.0 110.924 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 -60.27 102.25 0.16 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.874 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.442 HD13 ' CB ' ' A' ' 124' ' ' ALA . 7.2 tp -70.19 -66.5 0.59 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.932 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.44 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 7.0 p90 -162.16 172.13 16.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.864 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 21.0 p-10 -118.1 145.79 44.6 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.847 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.589 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -112.92 107.02 15.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.833 -179.893 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.587 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -62.97 134.31 55.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.087 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 28.1 m170 -60.54 101.68 0.15 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.883 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 12.3 mtt-85 -88.11 -45.97 9.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.875 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' LEU . . . . . 0.494 HD13 HD22 ' A' ' 87' ' ' LEU . 10.0 tp -98.4 108.08 20.69 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.937 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 28.6 p -51.8 -31.23 26.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.858 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.651 ' HB1' ' HG3' ' A' ' 141' ' ' ARG . . . -82.71 29.08 0.46 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.08 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -49.59 -35.19 19.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.899 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 140' ' ' GLN . . . . . 0.443 ' HG2' ' N ' ' A' ' 141' ' ' ARG . 18.4 pm0 -60.17 -28.92 68.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.964 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.651 ' HG3' ' HB1' ' A' ' 138' ' ' ALA . 52.9 mtp85 -65.27 -38.86 91.57 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.887 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.713 ' HA ' HG22 ' A' ' 62' ' ' VAL . 52.4 t -55.15 108.97 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.113 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.44 ' O ' ' N ' ' A' ' 33' ' ' LEU . 3.4 p30 -129.52 27.91 5.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.839 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -135.82 135.57 39.95 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.174 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.624 HD13 ' CE2' ' A' ' 60' ' ' PHE . 7.5 tp -131.13 103.9 6.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.9 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 146' ' ' GLU . . . . . 0.428 ' C ' HG13 ' A' ' 147' ' ' ILE . 2.6 pt-20 -106.51 151.22 25.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.874 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.441 HG12 HG23 ' A' ' 58' ' ' ILE . 15.7 mt -140.17 109.57 3.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.116 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -120.41 170.93 8.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.916 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 109.85 -150.68 17.42 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.517 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -107.5 91.36 3.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.886 0.374 . . . . 0.0 110.902 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.447 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 3.3 p -150.91 137.62 12.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.123 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 24.7 m -96.96 93.65 6.74 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.119 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.481 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 61.3 mt -77.98 132.76 37.98 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.898 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 53.5 m -119.13 -40.86 2.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.894 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 155' ' ' TYR . . . . . 0.409 ' CD1' ' HE3' ' A' ' 46' ' ' LYS . 36.4 t80 -141.74 129.53 21.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.948 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 75.3 t -140.77 105.65 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.159 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 16.0 tt0 -120.26 132.03 55.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.92 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 158' ' ' ILE . . . . . 0.722 HG22 ' NH1' ' A' ' 41' ' ' ARG . 12.8 mt -102.9 88.23 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.161 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 159' ' ' SER . . . . . 0.407 ' O ' ' NH1' ' A' ' 41' ' ' ARG . 28.8 t -52.19 147.21 7.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.873 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -178.29 -177.98 47.39 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.513 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 143.15 49.91 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.682 2.255 . . . . 0.0 112.387 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 1.2 t -68.85 117.78 10.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.878 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 39.8 m -90.69 132.34 35.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.874 -179.835 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.46 179.989 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 N-CA-C 112.478 -0.249 . . . . 0.0 112.478 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 32.3 p -130.58 84.35 2.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.871 0.367 . . . . 0.0 110.909 -179.77 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 89.5 p -140.42 134.89 31.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.867 -179.804 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 137.13 131.86 3.0 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.491 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 33.2 t -165.03 131.52 2.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.923 0.392 . . . . 0.0 110.821 -179.731 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 21.5 m -43.8 -47.28 8.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.839 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -118.15 92.42 0.54 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.53 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 9.2 t60 -71.65 130.26 40.73 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.78 0.324 . . . . 0.0 110.871 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 75.3 mt-30 -146.11 111.96 5.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.883 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 17.7 tm0? -68.74 82.88 0.29 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.878 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 86.3 mt -129.37 80.68 1.98 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.897 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -162.78 121.62 2.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.88 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 64.2 m -124.55 155.34 39.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.884 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 20.0 mt -44.83 149.93 0.77 Allowed Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.577 0.703 . . . . 0.0 110.904 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 -178.58 2.41 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.701 2.268 . . . . 0.0 112.331 179.881 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 11.7 t -83.71 146.39 28.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.099 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' MET . . . . . 0.549 ' CE ' HD12 ' A' ' 158' ' ' ILE . 4.4 ptp -95.55 30.87 2.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.895 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -49.98 -178.54 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.907 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.416 ' HA3' ' HD2' ' A' ' 20' ' ' PRO . . . 81.49 -145.32 25.09 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.513 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.416 ' HD2' ' HA3' ' A' ' 19' ' ' GLY . 54.0 Cg_endo -69.73 168.82 20.43 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.693 2.262 . . . . 0.0 112.336 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 -166.36 0.18 Allowed 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.678 2.252 . . . . 0.0 112.348 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.55 ' CG2' ' N ' ' A' ' 23' ' ' PHE . 1.8 m -100.95 160.84 14.03 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.126 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.55 ' N ' ' CG2' ' A' ' 22' ' ' THR . 14.3 m-85 -154.52 136.18 14.37 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ASN . . . . . 0.514 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 10.4 m-20 41.21 49.76 3.74 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.61 0.719 . . . . 0.0 110.858 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.514 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.8 Cg_endo -69.74 140.9 43.87 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.678 2.252 . . . . 0.0 112.341 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 178.4 4.61 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.663 2.242 . . . . 0.0 112.375 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.67 HG13 ' HA ' ' A' ' 28' ' ' PRO . 89.5 t -140.18 137.82 18.49 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.657 0.741 . . . . 0.0 111.123 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.67 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.4 Cg_endo -69.74 144.34 76.35 Favored 'Cis proline' 0 C--O 1.231 0.173 0 C-N-CA 122.7 -1.792 . . . . 0.0 112.345 -0.055 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 9.2 t80 -96.75 118.9 34.21 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.931 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 65.3 m-85 -104.8 101.12 10.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.888 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -112.83 102.05 1.26 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.456 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.419 ' O ' ' HG3' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -72.63 121.6 20.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.852 0.358 . . . . 0.0 110.923 -179.897 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.482 ' N ' ' O ' ' A' ' 143' ' ' ASP . 13.9 mt -65.71 149.62 49.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.914 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 9.4 mm100 -110.68 82.06 1.53 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.919 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.447 ' C ' ' OD2' ' A' ' 143' ' ' ASP . . . 140.49 -46.87 0.9 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.504 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.754 ' O ' HG23 ' A' ' 38' ' ' THR . . . 109.54 166.55 20.14 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.505 -179.882 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' LEU . . . . . 0.501 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 49.8 mt -57.3 105.16 0.21 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.96 0.41 . . . . 0.0 110.891 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.754 HG23 ' O ' ' A' ' 36' ' ' GLY . 2.1 p -116.76 151.81 35.67 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.148 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -58.07 -18.21 23.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.117 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 7.3 mpt_? -109.93 27.53 9.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.899 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.718 ' NH2' HD11 ' A' ' 43' ' ' ILE . 20.8 ttp85 -113.66 141.5 47.15 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.857 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 97.9 m -139.56 121.35 15.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.111 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.718 HD11 ' NH2' ' A' ' 41' ' ' ARG . 5.0 mp -90.95 143.64 10.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.125 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 89.3 mt -136.22 129.21 46.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.149 179.849 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 60.6 mt -130.05 107.74 15.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.152 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.506 ' HE3' ' CD1' ' A' ' 155' ' ' TYR . 18.5 mtmt -110.36 111.8 23.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.904 179.856 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -147.14 -145.54 4.21 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.505 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -166.81 126.14 1.47 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.884 0.374 . . . . 0.0 110.913 -179.815 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 24.6 t -74.82 117.02 59.3 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.643 0.735 . . . . 0.0 111.114 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 156.23 63.82 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.698 2.266 . . . . 0.0 112.331 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -15.44 37.1 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.657 2.238 . . . . 0.0 112.359 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 26.4 p -110.36 14.64 22.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.154 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -109.25 120.44 5.81 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.493 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 30.1 mtpt -61.65 -60.97 2.88 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.775 0.321 . . . . 0.0 110.914 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 9.2 p -174.19 156.51 2.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.823 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.616 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 11.1 p90 -111.0 -174.46 2.48 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.83 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.111 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -155.42 141.15 18.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.096 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.508 HD11 ' CE2' ' A' ' 56' ' ' PHE . 3.6 mp -121.24 100.08 8.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.136 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -102.56 148.08 25.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.887 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.924 ' CE2' HD13 ' A' ' 145' ' ' LEU . 34.7 m-85 -119.99 102.9 8.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.894 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.404 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 33.6 ttmt -95.62 166.95 11.59 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.91 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.741 HG22 ' HA ' ' A' ' 142' ' ' VAL . 91.4 t -98.2 125.54 51.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.166 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -61.26 -35.7 91.31 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.511 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.9 m -67.68 -73.27 0.14 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.896 0.379 . . . . 0.0 110.817 -179.708 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 32.3 t -80.37 -71.49 0.46 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.867 -179.794 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 130.7 41.69 0.22 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.464 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -112.58 146.37 38.69 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.782 0.325 . . . . 0.0 110.848 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.514 HD12 ' HB3' ' A' ' 86' ' ' LEU . 50.7 mt -91.65 121.23 41.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.135 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.505 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -91.3 -36.97 13.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.114 179.828 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.637 HD21 HD11 ' A' ' 72' ' ' ILE . 32.1 tp -134.87 130.4 35.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.919 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.487 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.3 OUTLIER -134.76 92.97 2.96 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.84 179.855 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.637 HD11 HD21 ' A' ' 70' ' ' LEU . 20.6 mt -96.69 134.08 35.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.17 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 1.111 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 10.1 t-20 -140.93 107.42 6.32 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.591 0.71 . . . . 0.0 110.885 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.616 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.6 Cg_endo -69.76 155.05 66.93 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.679 2.253 . . . . 0.0 112.337 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 66.4 mtp85 -129.24 99.31 5.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.876 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -55.9 144.16 29.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.893 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 114.49 -88.33 0.47 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.493 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -75.52 -48.45 22.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.883 0.373 . . . . 0.0 110.866 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.482 ' HA2' ' ND2' ' A' ' 101' ' ' ASN . . . 112.14 47.14 0.72 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.495 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 32.9 p -115.92 119.16 35.04 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.799 0.333 . . . . 0.0 111.118 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.447 ' CG1' ' CG2' ' A' ' 72' ' ' ILE . 20.6 t -106.42 106.03 19.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.126 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.619 HG22 ' HD3' ' A' ' 96' ' ' LYS . 39.2 t -76.38 134.29 29.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.133 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ARG . . . . . 0.415 ' NH1' ' O ' ' A' ' 95' ' ' GLU . 0.0 OUTLIER -120.57 123.52 43.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.881 -179.955 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.487 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.2 OUTLIER -134.25 -179.11 5.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.898 -179.934 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 93.5 p -160.57 105.54 1.44 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.839 -179.871 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.942 HD12 ' O ' ' A' ' 90' ' ' SER . 26.1 tp -77.26 117.04 18.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.921 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.503 HD22 HD13 ' A' ' 136' ' ' LEU . 68.5 mt -93.97 160.9 14.52 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.887 179.897 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.448 ' C ' ' H ' ' A' ' 90' ' ' SER . 18.0 p-10 -38.72 101.35 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.87 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.93 -6.97 1.27 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.492 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.942 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -119.14 172.22 7.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.877 0.37 . . . . 0.0 110.832 -179.726 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.833 ' NE1' HD13 ' A' ' 86' ' ' LEU . 24.1 m95 -129.05 160.89 31.34 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.908 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -90.84 -93.94 1.26 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.513 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' SER . . . . . 0.408 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 2.4 m -174.49 169.46 3.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.841 0.353 . . . . 0.0 110.883 -179.727 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.411 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 27.3 mt-10 -100.84 118.4 36.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.895 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' GLU . . . . . 0.415 ' O ' ' NH1' ' A' ' 83' ' ' ARG . 5.3 mm-40 -123.19 134.81 54.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.881 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.619 ' HD3' HG22 ' A' ' 82' ' ' VAL . 40.9 mtmt -132.19 116.95 17.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.905 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 17.9 ttpp -164.48 110.4 1.01 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.934 179.862 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.688 HD11 ' O ' ' A' ' 100' ' ' HIS . 4.4 tt -148.72 153.04 11.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.134 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.554 HG23 ' N ' ' A' ' 100' ' ' HIS . 9.0 t -89.64 -48.52 7.23 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.118 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 100' ' ' HIS . . . . . 0.688 ' O ' HD11 ' A' ' 98' ' ' ILE . 6.1 p-80 -141.24 125.41 17.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.858 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' ASN . . . . . 0.482 ' ND2' ' HA2' ' A' ' 79' ' ' GLY . 17.7 t-20 -104.46 96.83 10.79 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.633 0.73 . . . . 0.0 110.882 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 -30.46 22.07 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.725 2.283 . . . . 0.0 112.303 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.444 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 21.8 m-85 -43.94 104.64 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.887 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -132.65 135.86 8.38 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.489 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 97.79 0.66 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.69 2.26 . . . . 0.0 112.322 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 129.94 -3.67 6.03 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.524 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.2 pm0 -135.9 155.92 49.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.839 0.352 . . . . 0.0 110.908 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -77.85 171.16 15.4 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.887 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 29.8 p90 -160.03 133.21 6.81 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.897 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -103.1 103.79 13.89 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.874 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.886 HD13 ' N ' ' A' ' 112' ' ' SER . 0.6 OUTLIER -104.3 137.7 41.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.887 -179.919 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.886 ' N ' HD13 ' A' ' 111' ' ' LEU . 3.6 m -145.16 111.87 5.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.842 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.589 HG23 HG22 ' A' ' 122' ' ' VAL . 4.0 mp -92.99 140.38 16.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.165 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 18.9 mtp180 -113.24 137.67 51.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.86 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' CYS . . . . . 0.568 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 3.4 t -108.87 117.29 33.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -119.35 -140.97 6.35 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.464 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.5 mt -118.66 -36.09 3.56 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.844 0.354 . . . . 0.0 110.916 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 17.4 m-20 -87.2 -38.39 16.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.862 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 16.2 ptp180 -175.31 169.28 3.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.838 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.568 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.6 m-30 -92.02 147.71 22.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 24.9 mtpp -120.75 102.19 8.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.921 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.616 HG13 HD11 ' A' ' 111' ' ' LEU . 55.7 t -88.82 132.22 34.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.106 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 62.3 m-85 -118.9 156.66 29.13 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.947 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.416 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -142.21 109.45 5.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.097 179.834 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 56.3 28.78 13.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.888 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 85.67 30.52 23.8 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.466 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' GLN . . . . . 0.422 ' HB2' ' CE1' ' A' ' 100' ' ' HIS . 56.1 mm-40 -137.91 121.51 17.36 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.791 0.329 . . . . 0.0 110.949 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 29.1 t-80 -50.69 105.14 0.09 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.849 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.439 HD22 ' CD2' ' A' ' 111' ' ' LEU . 10.8 tp -72.84 -69.1 0.43 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.547 ' HZ ' HD13 ' A' ' 72' ' ' ILE . 4.2 p90 -165.62 170.76 13.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.874 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 61.9 m-20 -114.96 148.76 38.32 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.876 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.574 ' CE1' ' O ' ' A' ' 133' ' ' ALA . 0.1 OUTLIER -115.01 107.88 15.95 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.88 -179.868 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.574 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -64.0 131.1 46.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.117 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 46.2 m-70 -56.62 100.58 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.847 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.408 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 17.6 mtt-85 -83.9 -51.45 7.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.865 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 136' ' ' LEU . . . . . 0.503 HD13 HD22 ' A' ' 87' ' ' LEU . 14.2 tp -93.27 108.01 19.72 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.908 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 4.3 p -51.4 -30.26 18.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.829 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.579 ' HB1' ' HG3' ' A' ' 141' ' ' ARG . . . -87.28 24.23 1.66 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.114 179.9 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.5 ' O ' HD12 ' A' ' 37' ' ' LEU . 26.8 p90 -43.58 -44.67 6.31 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.911 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 140' ' ' GLN . . . . . 0.426 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 5.3 pt20 -44.7 -42.23 7.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.905 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.579 ' HG3' ' HB1' ' A' ' 138' ' ' ALA . 21.5 mtt180 -52.07 -42.4 63.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.895 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.741 ' HA ' HG22 ' A' ' 62' ' ' VAL . 99.4 t -46.96 108.89 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.12 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.482 ' O ' ' N ' ' A' ' 33' ' ' LEU . 1.0 OUTLIER -129.8 20.43 5.52 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.902 179.903 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 2.1 m -133.06 138.1 46.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.141 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.924 HD13 ' CE2' ' A' ' 60' ' ' PHE . 7.2 tp -132.41 116.08 16.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.949 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -118.59 151.8 37.23 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.838 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.457 HG12 HG23 ' A' ' 58' ' ' ILE . 24.8 mt -138.66 110.34 5.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.08 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -120.17 171.99 8.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.888 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 111.28 -147.51 17.86 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.544 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -112.96 92.72 4.11 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.851 0.357 . . . . 0.0 110.858 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 4.3 p -151.02 141.9 16.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.145 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 17.1 m -101.31 92.91 5.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.175 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.459 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 80.5 mt -76.03 139.85 41.66 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.913 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 58.1 m -125.01 -33.76 2.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.836 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 155' ' ' TYR . . . . . 0.506 ' CD1' ' HE3' ' A' ' 46' ' ' LYS . 36.3 t80 -150.46 130.97 13.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.917 -179.855 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 56.0 t -138.92 105.41 2.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.149 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 157' ' ' GLN . . . . . 0.412 ' HB2' ' CE1' ' A' ' 155' ' ' TYR . 13.2 tt0 -114.17 120.67 41.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.92 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 158' ' ' ILE . . . . . 0.549 HD12 ' CE ' ' A' ' 17' ' ' MET . 83.1 mt -95.25 89.28 2.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.159 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 28.7 t -71.87 139.29 48.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.843 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 157.76 154.13 6.99 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.484 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 129.92 18.45 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.708 2.272 . . . . 0.0 112.316 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 40.1 p -132.4 103.62 6.29 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.883 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 90.2 p -160.14 175.3 13.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.902 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.502 -179.954 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 112.476 -0.25 . . . . 0.0 112.476 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.6 t -133.12 86.0 2.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.879 0.371 . . . . 0.0 110.842 -179.694 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 60.2 p -136.92 167.92 20.55 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.841 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -105.08 -145.15 13.38 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.498 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 73.1 m -120.85 176.25 5.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.836 0.35 . . . . 0.0 110.86 -179.751 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 36.4 m -133.25 169.32 17.07 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.846 -179.799 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -152.56 72.31 0.28 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.692 -0.765 . . . . 0.0 112.488 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 6.7 p80 -121.77 137.41 54.78 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.72 0.295 . . . . 0.0 110.87 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -87.27 153.76 21.22 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.901 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 9.6 mm100 -116.07 156.59 26.11 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.935 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.7 mt -98.23 146.88 25.18 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.878 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 23.7 t30 -100.09 88.69 3.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.864 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 5.1 m -166.74 168.98 13.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.891 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 65.2 mt -49.8 154.03 1.94 Allowed Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.585 0.707 . . . . 0.0 110.923 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 -166.11 0.17 Allowed 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.712 2.274 . . . . 0.0 112.343 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.405 ' CG2' ' N ' ' A' ' 17' ' ' MET . 1.3 m -88.21 152.0 22.28 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.183 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' MET . . . . . 0.482 ' O ' ' NE2' ' A' ' 34' ' ' GLN . 56.7 mtm -96.06 89.49 5.2 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.898 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 17.9 pt-20 -110.05 160.51 16.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.898 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.63 -140.26 14.94 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.465 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 170.22 17.03 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.659 2.24 . . . . 0.0 112.346 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.74 -169.64 0.34 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.681 2.254 . . . . 0.0 112.396 179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.485 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.5 m -103.49 153.38 20.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.174 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.485 ' CD1' ' O ' ' A' ' 22' ' ' THR . 9.3 m-85 -149.83 135.68 18.6 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.896 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ASN . . . . . 0.558 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 4.1 t-20 46.1 47.25 3.95 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.625 0.726 . . . . 0.0 110.886 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.558 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.5 Cg_endo -69.78 138.69 38.35 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.669 2.246 . . . . 0.0 112.332 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -174.65 0.95 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.664 2.243 . . . . 0.0 112.344 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.684 HG13 ' HA ' ' A' ' 28' ' ' PRO . 93.5 t -142.45 138.25 16.24 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.62 0.724 . . . . 0.0 111.102 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.684 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.79 144.76 77.63 Favored 'Cis proline' 0 C--N 1.342 0.197 0 C-N-CA 122.642 -1.816 . . . . 0.0 112.354 -0.078 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -97.55 120.69 38.38 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.918 -179.886 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 86.3 m-85 -102.42 104.94 15.44 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.901 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -104.24 107.52 2.97 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.463 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 6.6 mmt180 -73.71 115.86 13.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.833 0.349 . . . . 0.0 110.903 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.485 HD22 ' NH1' ' A' ' 41' ' ' ARG . 5.0 mt -82.0 111.51 18.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.902 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.482 ' NE2' ' O ' ' A' ' 17' ' ' MET . 37.6 mt-30 -78.71 97.14 5.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.88 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 131.1 -51.22 0.86 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.515 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.529 ' O ' HG23 ' A' ' 38' ' ' THR . . . 107.96 168.39 21.51 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.496 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' LEU . . . . . 0.596 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 68.4 mt -55.1 110.88 0.74 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.886 0.374 . . . . 0.0 110.902 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.529 HG23 ' O ' ' A' ' 36' ' ' GLY . 81.6 p -128.69 146.37 50.9 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.181 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -51.67 -18.33 1.16 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.085 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 2.8 mpt_? -107.73 30.53 6.23 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.868 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.486 ' HE ' HD23 ' A' ' 37' ' ' LEU . 6.9 ttp85 -115.85 142.2 47.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.904 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 29.5 m -138.64 120.72 15.66 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.151 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.456 HD11 ' NH2' ' A' ' 41' ' ' ARG . 5.3 mp -94.39 134.21 32.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.135 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 76.7 mt -129.8 119.59 47.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.098 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 31.6 mt -119.11 107.36 21.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.159 179.822 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.43 ' HE3' ' CD1' ' A' ' 155' ' ' TYR . 16.5 mtmt -108.89 110.18 21.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.9 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -144.86 -147.94 4.74 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.473 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' TYR . . . . . 0.571 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.7 OUTLIER -163.57 127.88 2.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.934 0.397 . . . . 0.0 110.955 -179.789 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.411 HG23 ' CD2' ' A' ' 109' ' ' PHE . 13.4 t -77.6 117.38 65.21 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 121.585 0.707 . . . . 0.0 111.14 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 154.91 67.1 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.7 2.266 . . . . 0.0 112.348 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -13.92 35.36 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.648 2.232 . . . . 0.0 112.353 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 70.6 p -112.64 16.78 19.58 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.163 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -110.09 123.24 6.63 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.497 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.402 ' O ' ' SD ' ' A' ' 76' ' ' MET . 19.2 mtpt -64.75 -61.72 2.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.801 0.334 . . . . 0.0 110.896 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 14.8 p -172.97 156.57 3.35 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.849 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.599 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 20.4 p90 -111.05 -174.57 2.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.874 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.732 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -156.82 135.37 11.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.126 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.484 HG22 ' CE1' ' A' ' 60' ' ' PHE . 5.3 mp -117.59 98.16 6.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.114 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -96.85 143.72 27.48 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.894 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.711 ' CE2' HD13 ' A' ' 145' ' ' LEU . 47.0 m-85 -115.24 97.62 6.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.906 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.433 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 31.3 ttmt -96.08 168.94 10.31 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.894 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.6 HG22 ' HA ' ' A' ' 142' ' ' VAL . 23.4 t -100.27 123.7 53.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.094 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -59.64 -29.17 66.46 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.506 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.52 ' H ' HG12 ' A' ' 62' ' ' VAL . 11.5 t -75.18 -73.71 0.24 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.849 0.357 . . . . 0.0 110.854 -179.729 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 5.3 t -77.53 -71.47 0.41 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.811 -179.767 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 128.65 39.7 0.32 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.492 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.44 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.1 m-20 -112.81 139.15 48.67 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.801 0.334 . . . . 0.0 110.879 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.613 HD12 ' HB3' ' A' ' 86' ' ' LEU . 60.3 mt -84.7 120.65 35.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.145 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.451 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -90.16 -30.66 17.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.129 179.795 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.698 HD22 ' CD2' ' A' ' 132' ' ' PHE . 41.3 tp -143.11 132.34 23.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.921 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.494 ' N ' ' O ' ' A' ' 84' ' ' ASN . 3.9 t-160 -134.93 92.61 2.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.919 179.838 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.524 HD11 HD21 ' A' ' 70' ' ' LEU . 53.2 mt -94.85 132.7 38.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.107 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.732 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 9.6 t-20 -139.12 105.66 7.29 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.661 0.743 . . . . 0.0 110.908 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.599 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.7 Cg_endo -69.74 154.84 67.34 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.72 2.28 . . . . 0.0 112.372 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 73.9 mtp85 -129.27 94.26 3.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.865 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' MET . . . . . 0.402 ' SD ' ' O ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -53.92 153.51 4.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.887 179.991 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 88.85 -87.46 1.49 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.476 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 57.1 t30 -52.9 -65.66 0.52 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.853 0.359 . . . . 0.0 110.908 -179.869 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 114.76 50.32 0.48 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.511 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 21.1 p -137.18 118.01 14.14 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.845 0.355 . . . . 0.0 111.161 -179.842 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.418 HG22 ' HA ' ' A' ' 74' ' ' PRO . 21.4 t -102.79 107.29 21.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.128 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.542 HG22 ' HD3' ' A' ' 96' ' ' LYS . 99.9 t -76.15 144.36 11.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.087 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -126.19 124.65 40.94 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.887 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.494 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.6 OUTLIER -135.71 178.56 6.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.951 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 19.1 t -160.38 105.05 1.46 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 -179.837 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.916 HD12 ' O ' ' A' ' 90' ' ' SER . 25.4 tp -76.97 118.01 19.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.935 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.513 ' N ' ' O ' ' A' ' 90' ' ' SER . 69.9 mt -95.62 161.6 13.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.884 179.92 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.461 ' C ' ' H ' ' A' ' 90' ' ' SER . 17.2 p-10 -38.34 101.42 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.907 179.849 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.79 -6.58 0.87 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.441 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.916 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -118.42 170.57 8.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.874 0.369 . . . . 0.0 110.832 -179.727 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.857 ' NE1' HD13 ' A' ' 86' ' ' LEU . 23.7 m95 -128.82 161.05 30.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.929 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.31 -106.45 1.61 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.471 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 67.5 m -164.09 176.05 9.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.809 0.338 . . . . 0.0 110.915 -179.754 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -98.63 123.11 42.63 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.909 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 7.6 mm-40 -122.54 118.11 27.48 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.854 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.542 ' HD3' HG22 ' A' ' 82' ' ' VAL . 9.5 mtmp? -121.23 123.05 41.28 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.903 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 15.0 tptm -172.76 105.04 0.15 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.889 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.665 HD11 ' O ' ' A' ' 100' ' ' HIS . 7.5 tt -147.66 151.32 13.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.152 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.585 HG23 ' N ' ' A' ' 100' ' ' HIS . 8.8 t -86.49 -50.54 6.79 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.149 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' HIS . . . . . 0.665 ' O ' HD11 ' A' ' 98' ' ' ILE . 5.3 p-80 -141.75 135.67 29.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.843 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' ASN . . . . . 0.407 ' OD1' ' C ' ' A' ' 101' ' ' ASN . 6.9 t-20 -104.73 95.97 9.72 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.647 0.737 . . . . 0.0 110.918 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.464 ' HG3' ' HB1' ' A' ' 124' ' ' ALA . 53.8 Cg_endo -69.74 -31.18 21.12 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.692 2.261 . . . . 0.0 112.39 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.515 ' CZ ' HD21 ' A' ' 129' ' ' LEU . 6.7 m-85 -47.12 113.93 0.76 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.874 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -140.59 138.11 8.75 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.489 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.73 102.69 1.05 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.653 2.235 . . . . 0.0 112.336 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 122.86 -6.49 9.56 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.488 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -130.67 147.11 52.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.857 0.361 . . . . 0.0 110.855 -179.864 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' PHE . . . . . 0.571 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 54.5 m-85 -66.5 172.03 4.46 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.888 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.411 ' CD2' HG23 ' A' ' 49' ' ' VAL . 22.5 p90 -160.65 128.38 4.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.856 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -103.45 105.39 15.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.813 HD13 ' N ' ' A' ' 112' ' ' SER . 0.9 OUTLIER -107.32 137.97 44.38 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.946 -179.962 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.813 ' N ' HD13 ' A' ' 111' ' ' LEU . 2.9 m -145.09 112.93 6.35 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.87 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.2 mp -94.29 134.64 31.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.113 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 57.1 mtt180 -109.14 123.19 48.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.853 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' CYS . . . . . 0.577 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 33.8 t -90.53 123.22 34.02 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -124.72 -153.76 8.65 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.501 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 7.8 mt -109.81 -37.96 5.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.804 0.335 . . . . 0.0 110.913 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -86.1 -37.73 18.52 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.853 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 22.8 ptt180 -174.75 168.56 3.64 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.894 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.596 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 2.9 m-30 -91.81 153.28 19.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.913 -179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 18.9 mtmt -127.29 106.41 9.21 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.897 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.668 HG13 HD11 ' A' ' 111' ' ' LEU . 45.9 t -90.41 137.69 21.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.166 179.844 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 123' ' ' TYR . . . . . 0.421 ' O ' HD22 ' A' ' 111' ' ' LEU . 40.4 m-85 -121.37 147.28 45.91 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.913 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.545 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -137.68 105.52 5.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.126 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.4 m120 62.09 34.08 16.63 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.84 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.403 ' C ' ' HG2' ' A' ' 127' ' ' GLN . . . 79.62 38.94 19.23 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.467 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 127' ' ' GLN . . . . . 0.403 ' HG2' ' C ' ' A' ' 126' ' ' GLY . 15.4 mm-40 -148.32 132.25 17.14 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.807 0.337 . . . . 0.0 110.892 -179.865 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 26.9 t-80 -61.58 101.05 0.16 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.828 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.545 HD13 ' CB ' ' A' ' 124' ' ' ALA . 9.8 tp -66.31 -69.85 0.28 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.877 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.434 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 7.3 p90 -161.87 174.66 12.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.874 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -114.96 150.73 35.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.868 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.698 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -117.53 104.62 11.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.896 -179.912 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.581 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -59.91 134.68 57.27 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.106 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 63.1 m-70 -61.99 112.89 2.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.889 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 83.1 mtt-85 -96.36 -52.48 3.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.834 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 9.4 tp -93.57 108.22 19.96 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.921 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 94.3 p -50.69 -32.25 18.81 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.896 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.465 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -83.79 23.56 0.98 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.135 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.525 ' O ' HD12 ' A' ' 37' ' ' LEU . 14.2 p90 -47.06 -38.99 12.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.883 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 10.0 pt20 -53.52 -34.01 56.62 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.938 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.465 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 51.9 mtp85 -63.47 -37.69 88.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.849 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.6 ' HA ' HG22 ' A' ' 62' ' ' VAL . 92.7 t -46.9 109.36 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.156 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -132.3 31.39 4.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.86 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 8.6 m -141.45 111.98 7.02 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.118 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.711 HD13 ' CE2' ' A' ' 60' ' ' PHE . 3.9 tp -110.51 109.79 20.27 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.945 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 146' ' ' GLU . . . . . 0.428 ' C ' HG13 ' A' ' 147' ' ' ILE . 3.3 pt-20 -112.8 153.81 27.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.843 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.428 HG13 ' C ' ' A' ' 146' ' ' GLU . 20.2 mt -140.72 110.63 3.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.096 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -119.6 174.37 6.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.943 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.17 -142.87 16.03 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.533 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -116.54 94.0 4.44 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.837 0.351 . . . . 0.0 110.913 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.6 p -151.08 151.15 12.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.173 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 10.4 m -110.98 94.5 5.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.13 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.47 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 37.6 mt -77.7 137.84 38.72 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.888 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 3.3 t -122.2 -37.43 2.82 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.869 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 155' ' ' TYR . . . . . 0.43 ' CD1' ' HE3' ' A' ' 46' ' ' LYS . 19.4 t80 -149.75 130.6 14.21 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.921 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 98.8 t -140.61 105.18 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.096 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 10.9 tt0 -112.13 145.3 40.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.89 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 158' ' ' ILE . . . . . 0.418 HG23 ' NH1' ' A' ' 41' ' ' ARG . 30.1 mt -109.43 90.47 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.109 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 39.6 t -50.4 140.04 14.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -116.37 175.01 15.54 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.5 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 93.72 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.649 2.233 . . . . 0.0 112.367 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 4.5 t -164.33 150.35 10.78 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.835 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 93.1 p -97.04 149.51 21.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.851 -179.845 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.294 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.521 -179.971 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 N-CA-C 112.456 -0.258 . . . . 0.0 112.456 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.8 m -156.84 169.37 24.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.887 0.375 . . . . 0.0 110.875 -179.769 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 24.4 m -138.06 143.14 40.35 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.851 -179.803 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.84 -166.21 35.04 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.471 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 26.7 m -73.92 104.3 4.73 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.877 0.37 . . . . 0.0 110.868 -179.723 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 32.4 t -125.44 91.28 3.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.834 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -168.52 84.17 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.475 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 54.1 m80 -151.62 150.68 30.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.744 0.307 . . . . 0.0 110.862 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 84.8 mt-30 -71.04 173.78 7.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.907 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -111.93 111.05 21.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.893 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 96.6 mt -79.38 -49.26 12.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.949 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 56.7 m-20 -138.97 169.45 17.77 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.913 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 4.2 t -63.31 160.25 16.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.84 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 2.6 pp -42.95 155.55 0.27 Allowed Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.671 0.748 . . . . 0.0 110.868 -180.0 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -169.49 0.33 Allowed 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.684 2.256 . . . . 0.0 112.344 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.607 HG23 ' HG2' ' A' ' 18' ' ' GLU . 14.7 t -66.57 159.54 27.21 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.124 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' MET . . . . . 0.46 ' SD ' ' N ' ' A' ' 32' ' ' ARG . 36.6 mtp -100.28 44.94 1.0 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.894 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.607 ' HG2' HG23 ' A' ' 16' ' ' THR . 3.4 pt-20 -78.86 156.31 28.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.834 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 111.11 -156.33 15.61 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.494 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 170.01 17.58 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.645 2.23 . . . . 0.0 112.331 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 175.62 7.91 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.7 2.267 . . . . 0.0 112.341 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.418 HG22 ' H ' ' A' ' 156' ' ' VAL . 7.6 t -91.41 158.76 16.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.187 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.4 ' CD1' ' O ' ' A' ' 22' ' ' THR . 7.0 m-85 -142.07 117.28 10.1 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.908 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ASN . . . . . 0.516 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 9.0 m120 66.92 49.97 0.56 Allowed Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.633 0.73 . . . . 0.0 110.927 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.516 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.7 Cg_endo -69.73 131.35 21.09 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.662 2.241 . . . . 0.0 112.335 179.919 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 -174.03 0.84 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.643 2.229 . . . . 0.0 112.319 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.696 HG13 ' HA ' ' A' ' 28' ' ' PRO . 97.5 t -144.03 138.33 14.91 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.593 0.711 . . . . 0.0 111.129 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.696 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.78 144.72 77.48 Favored 'Cis proline' 0 C--O 1.232 0.177 0 C-N-CA 122.73 -1.779 . . . . 0.0 112.321 -0.025 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.6 t80 -98.04 119.12 36.11 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.942 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 75.7 m-85 -105.66 108.26 19.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.844 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -119.89 103.39 0.95 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.454 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.46 ' N ' ' SD ' ' A' ' 17' ' ' MET . 0.0 OUTLIER -73.45 128.28 35.05 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.813 0.34 . . . . 0.0 110.899 -179.886 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.551 HD23 HD13 ' A' ' 158' ' ' ILE . 6.1 mt -73.07 151.83 41.51 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.902 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 20.0 mt-30 -88.29 -63.36 1.31 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.934 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.527 ' O ' HG23 ' A' ' 38' ' ' THR . . . -96.94 43.56 2.02 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.54 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.483 ' N ' ' OD2' ' A' ' 143' ' ' ASP . . . 34.39 -152.68 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.499 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' LEU . . . . . 0.505 HD12 ' O ' ' A' ' 139' ' ' PHE . 52.4 mt -87.64 113.16 23.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.854 0.359 . . . . 0.0 110.934 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.527 HG23 ' O ' ' A' ' 35' ' ' GLY . 24.7 p -121.01 153.16 37.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.113 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -59.75 -25.77 65.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.12 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 13.2 mmt180 -105.43 35.62 2.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.869 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.445 ' HB2' ' NH1' ' A' ' 41' ' ' ARG . 9.4 ttm105 -125.02 140.78 52.6 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.915 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 90.7 m -139.68 121.7 15.67 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.14 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 mp -90.99 134.25 30.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.128 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 77.6 mt -123.45 133.41 69.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.139 179.817 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 75.0 mt -131.41 107.8 13.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.153 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.1 mtmt -109.31 107.74 18.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.9 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.26 -146.25 4.79 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.536 179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' TYR . . . . . 0.57 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.7 OUTLIER -167.91 129.29 1.44 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.904 0.383 . . . . 0.0 110.934 -179.798 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 11.8 t -77.88 116.74 60.96 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.6 0.714 . . . . 0.0 111.14 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 158.52 56.63 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.627 2.218 . . . . 0.0 112.346 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -14.54 36.26 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.654 2.236 . . . . 0.0 112.394 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 66.7 p -113.16 19.22 17.33 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.151 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -113.37 118.34 4.49 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.419 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 15.7 mtpp -62.96 -58.85 5.95 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.755 0.312 . . . . 0.0 110.877 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 25.3 p -173.04 159.73 4.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.877 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.598 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 10.9 p90 -114.84 -173.19 2.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.873 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.104 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -156.65 141.79 17.28 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.067 179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.431 HG22 ' CE1' ' A' ' 60' ' ' PHE . 9.1 mt -127.59 98.38 4.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.12 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' ASN . . . . . 0.471 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 2.2 m-80 -100.47 150.48 22.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.917 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.504 ' CE2' HD13 ' A' ' 145' ' ' LEU . 4.3 m-85 -118.1 101.17 8.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.912 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.415 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 28.3 ttmt -95.58 169.85 9.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.901 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.704 HG22 ' HA ' ' A' ' 142' ' ' VAL . 67.8 t -101.17 124.14 54.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.105 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -59.08 -39.87 94.89 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.507 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 15.0 m -66.19 -73.5 0.13 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.837 0.351 . . . . 0.0 110.858 -179.745 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 68.5 m -76.72 -75.38 0.2 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.833 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 133.31 35.13 0.3 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.475 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.42 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.4 m-20 -106.61 143.94 34.0 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.823 0.344 . . . . 0.0 110.861 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.56 HD12 ' HB3' ' A' ' 86' ' ' LEU . 58.7 mt -88.24 122.56 39.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.154 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.72 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -92.8 -33.33 14.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.114 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.575 HD21 HD11 ' A' ' 72' ' ' ILE . 42.4 tp -139.15 131.61 28.62 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.913 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.5 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.0 OUTLIER -134.66 92.95 2.97 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.838 179.863 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.575 HD11 HD21 ' A' ' 70' ' ' LEU . 40.3 mt -98.64 130.96 46.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.152 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 1.104 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 11.9 t-20 -140.67 107.74 6.5 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.64 0.733 . . . . 0.0 110.914 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.598 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.4 Cg_endo -69.74 155.13 66.82 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.704 2.269 . . . . 0.0 112.349 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 71.3 mtp180 -130.61 96.36 4.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.858 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' MET . . . . . 0.483 ' HE3' ' HB3' ' A' ' 103' ' ' PHE . 0.0 OUTLIER -60.96 168.85 2.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.901 179.947 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 76.13 -54.94 3.13 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.49 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 7.7 t30 -86.17 -57.44 3.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.858 0.361 . . . . 0.0 110.889 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 103.38 53.57 0.87 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.472 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 7.6 p -145.03 118.71 9.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.788 0.327 . . . . 0.0 111.128 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.9 t -100.61 112.83 34.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.153 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.703 HG22 ' HD3' ' A' ' 96' ' ' LYS . 61.5 t -80.67 142.31 14.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.172 179.922 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -122.4 124.09 42.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.862 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.5 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.1 m120 -138.49 176.56 8.59 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.839 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 45.2 t -160.35 105.08 1.47 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.866 -179.854 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.915 HD12 ' O ' ' A' ' 90' ' ' SER . 24.8 tp -77.55 119.02 20.54 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.951 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.513 ' N ' ' O ' ' A' ' 90' ' ' SER . 76.0 mt -95.88 161.35 14.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.916 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.465 ' C ' ' H ' ' A' ' 90' ' ' SER . 15.6 p-10 -38.89 101.43 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.902 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.98 -5.83 1.14 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.493 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.915 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -120.0 171.36 8.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.827 0.346 . . . . 0.0 110.866 -179.763 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.866 ' NE1' HD13 ' A' ' 86' ' ' LEU . 23.8 m95 -129.12 159.82 34.81 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.925 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -93.31 -114.71 2.36 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.53 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' SER . . . . . 0.449 ' HB2' ' CZ ' ' A' ' 135' ' ' ARG . 3.6 m -151.96 169.36 22.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.825 0.345 . . . . 0.0 110.878 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.421 ' HG2' ' ND2' ' A' ' 84' ' ' ASN . 7.0 mt-10 -97.7 121.75 39.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.937 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -117.33 116.26 26.87 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.845 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.703 ' HD3' HG22 ' A' ' 82' ' ' VAL . 38.2 mtmt -122.32 117.21 25.54 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.896 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -169.37 108.96 0.44 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.896 179.843 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.784 HD11 ' O ' ' A' ' 100' ' ' HIS . 3.5 tt -145.4 153.79 13.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.073 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.431 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 8.7 t -97.44 -38.74 9.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.169 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' HIS . . . . . 0.784 ' O ' HD11 ' A' ' 98' ' ' ILE . 3.3 p-80 -146.67 125.07 12.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.862 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' ASN . . . . . 0.403 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 31.0 t-20 -102.56 96.82 7.93 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.633 0.73 . . . . 0.0 110.864 -179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.436 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.7 Cg_endo -69.83 -40.55 5.09 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.631 2.22 . . . . 0.0 112.357 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.483 ' HB3' ' HE3' ' A' ' 76' ' ' MET . 32.0 m-85 -35.7 106.74 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.883 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -134.53 136.66 8.72 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.506 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 100.11 0.8 Allowed 'Trans proline' 0 C--N 1.34 0.124 0 C-N-CA 122.672 2.248 . . . . 0.0 112.299 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 124.9 -6.58 8.31 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.466 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 9.2 pt20 -131.01 147.29 52.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.852 0.358 . . . . 0.0 110.886 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' PHE . . . . . 0.57 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 66.0 m-85 -64.24 172.16 2.63 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.889 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.461 ' CG ' ' O ' ' A' ' 109' ' ' PHE . 21.8 p90 -160.73 117.97 2.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.882 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -93.64 106.8 18.74 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.848 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.842 HD13 ' N ' ' A' ' 112' ' ' SER . 0.5 OUTLIER -108.64 138.68 44.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.921 -179.961 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.842 ' N ' HD13 ' A' ' 111' ' ' LEU . 5.4 m -145.36 113.42 6.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.829 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.541 HG22 ' HD2' ' A' ' 120' ' ' PHE . 4.5 mp -93.66 137.5 22.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.125 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.596 ' O ' ' CD2' ' A' ' 120' ' ' PHE . 16.9 mtp180 -109.88 135.05 51.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.87 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 115' ' ' CYS . . . . . 0.543 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 20.7 t -103.74 116.19 31.87 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.903 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -115.34 -149.2 9.54 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.504 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.6 mt -111.83 -39.04 4.67 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.794 0.331 . . . . 0.0 110.899 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -89.41 -35.45 16.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.86 179.833 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 13.4 ptt180 -171.3 175.04 4.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 -179.901 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.596 ' CD2' ' O ' ' A' ' 114' ' ' ARG . 9.2 m-85 -98.9 162.51 13.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.887 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 36.6 mtpt -133.37 104.46 6.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.911 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.679 HG13 HD11 ' A' ' 111' ' ' LEU . 41.5 t -91.04 125.02 43.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.105 179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 48.6 m-85 -115.52 146.32 41.82 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.885 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.505 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -131.57 108.62 9.67 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.061 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 58.62 35.54 24.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.835 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.46 40.61 22.79 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.487 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 13.9 mt-30 -146.39 130.22 17.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.83 0.348 . . . . 0.0 110.922 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 33.2 t-80 -60.08 99.47 0.07 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.849 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.505 HD13 ' CB ' ' A' ' 124' ' ' ALA . 8.7 tp -70.17 -69.64 0.34 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.946 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.539 ' HZ ' HD13 ' A' ' 72' ' ' ILE . 5.4 p90 -163.44 169.63 18.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.879 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -113.66 151.08 32.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.872 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.55 ' CG ' HD13 ' A' ' 70' ' ' LEU . 0.2 OUTLIER -115.7 105.83 13.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.89 -179.942 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.533 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -61.71 134.01 56.25 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.132 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 29.9 m170 -62.64 94.53 0.06 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.827 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.449 ' CZ ' ' HB2' ' A' ' 93' ' ' SER . 61.3 mtt-85 -78.78 -41.48 30.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.87 -179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 12.3 tp -100.55 108.32 20.22 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.884 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 59.8 p -51.86 -30.78 25.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.887 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.535 ' HB1' ' HD2' ' A' ' 141' ' ' ARG . . . -89.72 30.61 1.02 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.078 179.915 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.587 ' CE1' ' HG3' ' A' ' 140' ' ' GLN . 2.9 p90 -41.39 -40.14 1.64 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.91 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 140' ' ' GLN . . . . . 0.587 ' HG3' ' CE1' ' A' ' 139' ' ' PHE . 0.0 OUTLIER -48.05 -52.52 19.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.943 -179.952 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.659 ' O ' HG13 ' A' ' 62' ' ' VAL . 47.9 mtt180 -42.4 -39.41 2.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.89 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.72 HG21 ' CB ' ' A' ' 69' ' ' ALA . 66.6 t -52.7 105.12 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.17 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.483 ' OD2' ' N ' ' A' ' 36' ' ' GLY . 0.9 OUTLIER -130.27 31.08 4.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.877 179.93 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -140.43 129.84 23.94 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.149 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.504 HD13 ' CE2' ' A' ' 60' ' ' PHE . 6.0 tp -125.59 108.91 12.04 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.869 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 146' ' ' GLU . . . . . 0.424 ' C ' HG13 ' A' ' 147' ' ' ILE . 3.0 pt-20 -111.12 148.85 31.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.907 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.424 HG13 ' C ' ' A' ' 146' ' ' GLU . 8.8 mt -138.69 105.32 2.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.138 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -117.87 176.69 5.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.907 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.96 -145.94 16.57 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.477 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -114.6 91.63 3.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.868 0.366 . . . . 0.0 110.896 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 4.7 p -150.76 151.21 12.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.109 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 28.7 m -109.67 93.17 4.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.134 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.485 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 66.8 mt -76.52 138.34 40.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.957 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 74.0 m -122.82 -37.97 2.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.85 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 26.9 t80 -145.96 129.42 16.9 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.922 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.418 ' H ' HG22 ' A' ' 22' ' ' THR . 55.0 t -140.71 105.37 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.093 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 13.0 tt0 -121.58 120.4 34.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.907 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 158' ' ' ILE . . . . . 0.551 HD13 HD23 ' A' ' 33' ' ' LEU . 27.1 mt -89.84 89.48 3.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.123 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 159' ' ' SER . . . . . 0.457 ' C ' ' O ' ' A' ' 158' ' ' ILE . 28.2 t -33.96 138.03 0.09 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.878 -179.903 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 175.37 169.21 36.87 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.449 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 98.24 0.68 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.653 2.235 . . . . 0.0 112.339 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 3.1 m -86.68 139.78 30.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.894 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 2.3 t -78.41 155.01 30.2 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.832 -179.796 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.503 179.965 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 74.0 m -155.42 135.01 12.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.873 0.368 . . . . 0.0 110.873 -179.718 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.446 ' O ' ' C ' ' A' ' 4' ' ' GLY . 28.2 m -62.03 -51.17 69.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.873 -179.857 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.446 ' C ' ' O ' ' A' ' 3' ' ' SER . . . 34.53 -103.51 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.475 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 5.8 m -55.22 169.23 0.28 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.867 0.365 . . . . 0.0 110.893 -179.765 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.43 ' O ' ' C ' ' A' ' 7' ' ' GLY . 12.1 t -49.46 118.27 2.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.914 -179.815 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.43 ' C ' ' O ' ' A' ' 6' ' ' SER . . . -36.01 -57.31 1.06 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.496 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 42.6 p-80 -85.49 134.0 34.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.728 0.299 . . . . 0.0 110.881 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -110.11 139.33 45.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.869 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 1.8 pm0 -86.53 24.74 1.35 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.93 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.6 mt -138.36 157.5 46.11 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.945 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 -108.53 47.79 0.89 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.881 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 20.1 m -115.98 178.55 4.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.905 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 32.2 mt -74.09 153.19 88.59 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.592 0.71 . . . . 0.0 110.905 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 -165.96 0.17 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.684 2.256 . . . . 0.0 112.321 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.467 HG23 ' CG ' ' A' ' 34' ' ' GLN . 1.5 m -86.79 -13.48 45.02 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.089 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 3.4 ptt? 41.14 54.58 3.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.856 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.419 ' CD ' ' H ' ' A' ' 18' ' ' GLU . 1.3 pm0 -88.91 174.24 8.05 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.87 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 101.28 -138.16 13.7 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.469 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 170.13 17.35 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.632 2.222 . . . . 0.0 112.341 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 170.93 15.43 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.67 2.247 . . . . 0.0 112.343 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.45 HG22 ' H ' ' A' ' 156' ' ' VAL . 6.5 t -87.34 162.07 17.57 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.171 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.406 ' CD1' ' O ' ' A' ' 22' ' ' THR . 7.4 m-85 -142.68 116.86 9.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.92 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ASN . . . . . 0.474 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 11.8 m120 61.68 52.23 2.25 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.671 0.748 . . . . 0.0 110.914 -179.889 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.487 ' HG2' ' CB ' ' A' ' 153' ' ' LEU . 54.2 Cg_endo -69.76 133.41 25.5 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.665 2.243 . . . . 0.0 112.387 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 -174.22 0.86 Allowed 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.707 2.272 . . . . 0.0 112.33 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.708 HG13 ' HA ' ' A' ' 28' ' ' PRO . 84.7 t -144.04 138.77 15.28 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.621 0.724 . . . . 0.0 111.113 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.708 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.79 145.27 79.01 Favored 'Cis proline' 0 C--N 1.342 0.186 0 C-N-CA 122.659 -1.809 . . . . 0.0 112.303 -0.048 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.0 t80 -100.96 117.1 34.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.931 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.513 ' CD2' ' HB3' ' A' ' 146' ' ' GLU . 58.2 m-85 -104.61 105.98 16.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.896 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -116.34 103.44 1.15 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.496 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.513 ' O ' ' CD ' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -72.61 114.08 10.36 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.799 0.333 . . . . 0.0 110.856 -179.873 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.425 HD12 ' N ' ' A' ' 144' ' ' THR . 3.9 mt -59.1 151.32 22.78 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.932 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.467 ' CG ' HG23 ' A' ' 16' ' ' THR . 3.0 mp0 -104.26 101.22 10.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.906 179.936 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.64 -58.62 0.52 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.493 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.711 ' O ' HG23 ' A' ' 38' ' ' THR . . . 123.73 171.83 13.62 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.48 -179.872 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' LEU . . . . . 0.721 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 93.7 mt -58.74 103.74 0.18 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.879 0.371 . . . . 0.0 110.949 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.711 HG23 ' O ' ' A' ' 36' ' ' GLY . 22.0 p -118.98 150.16 40.4 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.098 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -54.83 -28.16 47.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.107 179.827 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 3.9 tpt180 -102.97 37.47 1.95 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.899 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 11.7 ttm180 -129.16 139.51 51.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.871 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 91.8 m -137.4 124.75 21.9 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.128 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.414 ' N ' HD12 ' A' ' 43' ' ' ILE . 4.9 mp -92.67 134.05 31.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.161 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 89.7 mt -122.93 135.89 61.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.087 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 56.1 mt -133.98 107.92 10.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.132 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.3 mtmt -113.82 113.78 25.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.836 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.416 ' CA ' ' O ' ' A' ' 152' ' ' THR . . . -146.56 -140.6 3.47 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.519 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -170.55 137.45 1.38 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.916 0.389 . . . . 0.0 110.927 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 14.2 t -86.62 114.87 60.07 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.604 0.716 . . . . 0.0 111.124 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.83 155.71 65.0 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.685 2.256 . . . . 0.0 112.358 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 -13.9 35.46 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.701 2.267 . . . . 0.0 112.356 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 57.8 p -112.28 16.19 20.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.112 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -112.72 120.23 5.18 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.468 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 12.1 mtpt -61.62 -60.46 3.64 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.767 0.318 . . . . 0.0 110.857 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 25.8 p -173.16 158.4 3.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.85 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.596 ' CE2' HD11 ' A' ' 58' ' ' ILE . 8.2 p90 -112.01 -172.8 2.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.88 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.445 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -155.48 141.8 18.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.12 179.936 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.596 HD11 ' CE2' ' A' ' 56' ' ' PHE . 2.9 mp -123.01 102.23 11.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.105 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.5 m-80 -103.22 146.09 28.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.846 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.6 ' CE2' HD13 ' A' ' 145' ' ' LEU . 40.7 m-85 -117.63 101.16 8.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.905 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.427 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 33.1 ttmt -96.33 168.57 10.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.854 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.589 HG22 ' HA ' ' A' ' 142' ' ' VAL . 38.4 t -99.57 122.83 51.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.137 179.846 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.424 ' N ' ' OG1' ' A' ' 144' ' ' THR . . . -59.55 -28.69 65.46 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.482 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.541 ' H ' HG12 ' A' ' 62' ' ' VAL . 1.4 t -77.53 -71.09 0.43 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.839 0.352 . . . . 0.0 110.856 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.6 t -79.33 -75.51 0.24 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.818 -179.786 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 132.18 41.31 0.2 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.467 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.437 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.4 m-20 -115.45 139.62 49.87 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.763 0.316 . . . . 0.0 110.855 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.507 HD12 ' HB3' ' A' ' 86' ' ' LEU . 37.6 mt -86.43 114.8 26.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.079 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.22 -34.69 21.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.092 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.651 HD22 ' CD2' ' A' ' 132' ' ' PHE . 32.1 tp -138.01 131.75 31.2 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.939 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.467 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.1 t60 -134.95 98.38 4.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.848 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.554 HD11 HD21 ' A' ' 70' ' ' LEU . 22.4 mt -96.42 129.27 46.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.129 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.445 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 10.9 t-20 -134.36 104.15 11.3 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.588 0.708 . . . . 0.0 110.927 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.585 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.6 Cg_endo -69.77 155.48 65.78 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.688 2.259 . . . . 0.0 112.341 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 81.6 mtt-85 -133.25 97.99 4.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.892 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' MET . . . . . 0.463 ' O ' ' N ' ' A' ' 78' ' ' ASN . 0.1 OUTLIER -54.41 177.25 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.914 179.931 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 60.81 -76.04 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.522 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.463 ' N ' ' O ' ' A' ' 76' ' ' MET . 45.1 t30 -56.99 -65.76 0.56 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.851 0.358 . . . . 0.0 110.884 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 107.28 51.78 0.75 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.46 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 13.8 p -141.84 117.83 10.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.845 0.355 . . . . 0.0 111.118 -179.875 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.441 HG21 ' HE2' ' A' ' 103' ' ' PHE . 16.2 t -99.46 109.65 24.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.132 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.593 HG22 ' HD3' ' A' ' 96' ' ' LYS . 82.5 t -79.24 140.19 17.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.123 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ARG . . . . . 0.647 ' NH1' ' CD2' ' A' ' 130' ' ' PHE . 1.4 mpp_? -121.37 115.02 22.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.875 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.467 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.4 t-20 -125.98 179.75 5.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.896 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 94.7 p -160.95 110.07 1.64 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.869 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.95 HD12 ' O ' ' A' ' 90' ' ' SER . 24.5 tp -82.73 118.99 23.76 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.909 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.495 ' N ' ' O ' ' A' ' 90' ' ' SER . 96.8 mt -96.12 161.07 14.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.931 179.85 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.457 ' C ' ' H ' ' A' ' 90' ' ' SER . 16.3 p-10 -38.5 101.64 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.85 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.62 -7.0 1.11 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.481 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.95 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -118.85 172.11 7.76 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.879 0.371 . . . . 0.0 110.85 -179.752 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.836 ' NE1' HD13 ' A' ' 86' ' ' LEU . 23.8 m95 -129.12 160.66 32.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.924 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.59 -114.7 2.19 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.454 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' SER . . . . . 0.439 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 4.5 m -152.78 167.56 28.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.806 0.336 . . . . 0.0 110.88 -179.728 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -97.66 120.46 38.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 20.8 mm-40 -119.63 128.22 53.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.875 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.593 ' HD3' HG22 ' A' ' 82' ' ' VAL . 47.4 mtmt -130.11 117.68 20.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.922 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 25.0 tptt -171.73 105.7 0.21 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.922 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.932 HD11 ' O ' ' A' ' 100' ' ' HIS . 2.1 tt -145.23 151.09 15.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.101 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.594 HG23 ' N ' ' A' ' 100' ' ' HIS . 9.7 t -85.83 -50.35 7.19 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.168 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' HIS . . . . . 0.932 ' O ' HD11 ' A' ' 98' ' ' ILE . 9.7 p-80 -137.33 132.55 33.77 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.847 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' ASN . . . . . 0.435 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 43.2 t-20 -112.82 99.62 48.61 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.608 0.718 . . . . 0.0 110.907 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.456 ' HG3' ' HB1' ' A' ' 124' ' ' ALA . 53.6 Cg_endo -69.8 -41.1 4.51 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.705 2.27 . . . . 0.0 112.35 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.442 ' C ' ' O ' ' A' ' 102' ' ' PRO . 7.5 m-85 -35.32 101.91 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.866 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -131.5 136.5 8.83 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.522 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 97.9 0.66 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.675 2.25 . . . . 0.0 112.318 -179.87 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 133.56 -10.45 4.95 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.48 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -133.3 161.77 33.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.837 0.351 . . . . 0.0 110.879 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -82.23 175.08 10.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.864 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 23.0 p90 -161.81 127.26 3.54 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.866 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -98.39 104.49 16.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.85 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.895 HD13 ' N ' ' A' ' 112' ' ' SER . 0.6 OUTLIER -104.85 139.47 39.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.92 -179.945 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.895 ' N ' HD13 ' A' ' 111' ' ' LEU . 4.7 m -144.8 113.41 6.69 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.854 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.7 mp -93.36 136.16 25.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.175 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 42.7 mtt180 -111.68 120.22 41.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.901 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' CYS . . . . . 0.576 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 2.3 t -90.42 116.7 28.56 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.913 -179.929 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -113.03 -148.85 10.39 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.467 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 19.1 mt -112.76 -35.24 5.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.826 0.346 . . . . 0.0 110.903 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 52.4 m-20 -91.2 -33.14 15.51 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.893 179.812 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.2 ptp180 -174.77 176.2 2.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.867 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.721 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 3.9 m-30 -99.22 158.15 15.89 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 -179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.9 mtpt -130.75 100.82 5.42 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.9 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.847 HG13 HD11 ' A' ' 111' ' ' LEU . 25.1 t -87.83 126.67 41.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.136 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 123' ' ' TYR . . . . . 0.411 ' O ' HD22 ' A' ' 111' ' ' LEU . 85.2 m-85 -118.37 150.49 39.43 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.946 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.456 ' HB1' ' HG3' ' A' ' 102' ' ' PRO . . . -134.86 110.14 8.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.097 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.403 ' ND2' ' C ' ' A' ' 124' ' ' ALA . 0.6 OUTLIER 60.68 39.24 17.82 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.907 -179.889 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 72.92 41.59 48.32 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.495 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 20.3 mm-40 -148.41 136.84 21.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.79 0.329 . . . . 0.0 110.917 -179.851 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 46.5 t-80 -63.1 107.39 1.02 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.856 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.498 HD22 HD21 ' A' ' 111' ' ' LEU . 11.8 tp -78.35 -64.24 1.21 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.914 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.647 ' CD2' ' NH1' ' A' ' 83' ' ' ARG . 24.7 p90 -166.84 -178.68 4.38 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.889 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -125.37 144.86 50.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.861 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.651 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.4 OUTLIER -113.06 106.42 14.65 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.905 -179.915 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.491 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -61.74 137.98 58.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.106 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 22.6 m170 -66.31 100.74 0.66 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.8 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.439 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 60.5 mtt-85 -83.97 -55.1 4.41 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.855 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 4.9 tp -88.67 107.91 19.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.913 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 19.9 p -48.79 -34.4 12.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.858 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.516 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.67 28.99 0.46 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.107 179.912 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.535 ' O ' HD12 ' A' ' 37' ' ' LEU . 27.0 p90 -50.94 -42.54 59.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.899 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 140' ' ' GLN . . . . . 0.416 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 7.3 pt20 -48.83 -37.25 18.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.907 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.516 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 45.4 mtp85 -58.17 -40.91 82.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.861 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.589 ' HA ' HG22 ' A' ' 62' ' ' VAL . 60.0 t -48.17 102.3 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.133 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.492 ' OD1' ' N ' ' A' ' 36' ' ' GLY . 22.6 t0 -124.26 24.91 7.93 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.869 179.868 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 144' ' ' THR . . . . . 0.425 ' N ' HD12 ' A' ' 33' ' ' LEU . 1.5 m -132.59 140.63 48.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.127 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.6 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.5 tp -135.91 113.81 11.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.875 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 146' ' ' GLU . . . . . 0.513 ' HB3' ' CD2' ' A' ' 30' ' ' PHE . 5.9 pt-20 -117.82 151.85 36.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.932 179.903 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.528 HG12 HG23 ' A' ' 58' ' ' ILE . 18.0 mt -139.19 118.35 13.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.117 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -128.19 177.9 6.61 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.868 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 106.32 -137.5 13.88 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.474 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -122.54 92.48 3.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.816 0.341 . . . . 0.0 110.905 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.406 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 2.1 p -151.17 150.6 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.103 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 152' ' ' THR . . . . . 0.416 ' O ' ' CA ' ' A' ' 47' ' ' GLY . 23.7 m -107.48 93.52 4.59 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.114 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.487 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 67.8 mt -77.24 128.97 35.29 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.938 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 3.8 m -111.96 -41.66 3.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.901 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 35.2 t80 -143.87 130.62 20.26 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.942 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.45 ' H ' HG22 ' A' ' 22' ' ' THR . 72.9 t -140.7 105.29 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.122 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 16.6 tt0 -120.66 129.62 53.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.879 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 16.6 mt -95.31 94.13 4.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.103 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 17.8 t -53.03 147.35 9.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.854 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -145.53 154.81 26.17 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.478 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -1.31 8.22 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.658 2.239 . . . . 0.0 112.358 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 14.8 m -54.85 91.03 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.861 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 32.6 p -39.48 134.4 1.26 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.877 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.471 -179.988 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.3 0 N-CA-C 112.473 -0.251 . . . . 0.0 112.473 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.3 m -140.19 125.49 18.83 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.851 0.358 . . . . 0.0 110.89 -179.762 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 28.7 m -102.84 142.73 33.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.869 -179.808 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.25 -174.57 13.89 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.526 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 93.1 p -136.85 136.15 38.5 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.894 0.378 . . . . 0.0 110.847 -179.717 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 14.8 m -88.95 140.89 28.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.858 -179.848 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -109.77 139.07 15.2 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.475 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 6.1 t-80 -101.53 103.1 13.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.73 0.3 . . . . 0.0 110.833 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -86.51 86.24 7.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.924 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 7.3 mm100 -76.12 84.14 2.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.942 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 51.6 mt -146.32 147.83 31.76 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.942 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 5.4 m120 -75.19 138.73 42.17 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.886 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 3.6 m -162.43 130.83 4.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.87 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.742 ' O ' HD12 ' A' ' 14' ' ' LEU . 0.9 OUTLIER -58.59 152.89 43.41 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.577 0.704 . . . . 0.0 110.96 179.989 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -172.47 0.58 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.634 2.222 . . . . 0.0 112.349 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -79.18 150.43 31.69 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.129 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 3.4 ptt? -110.58 69.71 0.7 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.842 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -83.53 160.13 21.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.897 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 117.05 -142.69 17.62 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.517 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 170.05 17.4 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.697 2.265 . . . . 0.0 112.378 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 176.57 6.61 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.696 2.264 . . . . 0.0 112.299 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.416 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.4 m -92.2 148.38 22.2 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.149 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.404 ' CD1' ' O ' ' A' ' 22' ' ' THR . 7.2 m-85 -142.52 134.47 27.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.854 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ASN . . . . . 0.51 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.5 t-20 42.68 49.9 4.95 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.554 0.692 . . . . 0.0 110.878 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.51 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.8 Cg_endo -69.8 143.87 52.04 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.634 2.223 . . . . 0.0 112.378 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -178.74 2.49 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.701 2.267 . . . . 0.0 112.315 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.675 HG13 ' HA ' ' A' ' 28' ' ' PRO . 98.8 t -143.71 137.93 14.81 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.636 0.731 . . . . 0.0 111.106 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.675 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.77 144.65 77.25 Favored 'Cis proline' 0 C--O 1.231 0.171 0 C-N-CA 122.698 -1.792 . . . . 0.0 112.357 -0.066 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -98.8 118.12 34.83 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.954 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.438 ' CD1' ' HB3' ' A' ' 146' ' ' GLU . 63.8 m-85 -104.7 103.01 12.57 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.872 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -113.77 104.32 1.46 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.503 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.449 ' O ' ' HG3' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -73.44 121.89 21.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.876 0.37 . . . . 0.0 110.874 -179.868 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.419 HD12 ' N ' ' A' ' 144' ' ' THR . 5.4 mt -68.77 147.12 52.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.922 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 31.9 mt-30 -106.0 83.63 1.94 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.917 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 138.13 -49.0 0.86 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.49 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.561 ' O ' HG23 ' A' ' 38' ' ' THR . . . 109.35 166.98 20.33 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.454 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' LEU . . . . . 0.451 HD13 ' CZ ' ' A' ' 120' ' ' PHE . 87.5 mt -55.0 110.27 0.64 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.895 0.378 . . . . 0.0 110.901 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.561 HG23 ' O ' ' A' ' 36' ' ' GLY . 61.7 p -129.93 145.4 51.62 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.178 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -47.37 -31.1 3.7 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.098 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 8.9 tpt180 -97.32 31.66 2.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.881 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 12.3 ttm180 -124.13 141.56 51.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.879 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 94.0 m -138.33 124.85 20.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.147 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.1 mp -96.85 130.15 45.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.112 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 86.5 mt -123.49 134.04 67.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.132 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 72.1 mt -133.32 107.39 11.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.156 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 25.9 mtmt -112.01 109.93 19.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.898 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.501 ' CA ' ' O ' ' A' ' 152' ' ' THR . . . -138.09 -139.89 3.93 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.492 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -173.63 119.4 0.29 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.947 0.404 . . . . 0.0 110.884 -179.777 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 21.9 t -70.77 113.52 19.37 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.615 0.721 . . . . 0.0 111.124 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 156.88 62.35 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.671 2.248 . . . . 0.0 112.344 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -14.48 36.18 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.669 2.246 . . . . 0.0 112.366 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 72.6 p -111.7 18.46 18.96 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.181 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -116.12 123.47 5.89 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.509 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 33.8 mtpt -65.39 -59.43 4.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.823 0.344 . . . . 0.0 110.891 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 34.9 p -174.03 160.74 3.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.833 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.608 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 3.4 p90 -114.19 -174.37 2.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.869 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.012 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -156.37 128.19 7.31 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.076 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.534 HG13 HG23 ' A' ' 147' ' ' ILE . 5.3 mp -112.22 102.28 13.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.155 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.3 m-80 -100.84 149.69 23.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.938 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.698 ' CE2' HD13 ' A' ' 145' ' ' LEU . 56.6 m-85 -118.65 101.08 7.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.872 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.425 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 34.9 ttmt -95.69 168.92 10.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.904 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.672 HG22 ' HA ' ' A' ' 142' ' ' VAL . 55.2 t -100.48 124.83 54.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.124 179.856 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -60.48 -33.76 82.76 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.506 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.442 ' H ' HG12 ' A' ' 62' ' ' VAL . 70.1 m -70.84 -71.05 0.27 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.837 0.351 . . . . 0.0 110.864 -179.738 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 82.6 p -82.07 -75.1 0.31 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.875 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 133.37 44.31 0.13 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.46 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.551 ' OD1' ' ND2' ' A' ' 88' ' ' ASN . 1.2 m-20 -113.65 144.83 42.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.798 0.332 . . . . 0.0 110.889 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.431 HD12 ' HB3' ' A' ' 86' ' ' LEU . 40.9 mt -90.22 113.85 26.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.124 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.571 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -87.17 -32.3 19.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.126 179.799 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.738 HD22 ' CD2' ' A' ' 132' ' ' PHE . 41.4 tp -136.83 129.73 30.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.9 -179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.482 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.0 OUTLIER -134.61 94.42 3.19 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.869 179.836 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.541 HD13 ' HZ ' ' A' ' 130' ' ' PHE . 44.7 mt -99.59 134.74 37.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.148 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 1.012 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 8.9 t-20 -141.38 106.9 6.07 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.594 0.711 . . . . 0.0 110.859 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.608 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.0 Cg_endo -69.81 155.14 66.54 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.708 2.272 . . . . 0.0 112.362 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 34.6 mtt85 -128.97 97.49 4.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.877 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' MET . . . . . 0.522 ' HE3' ' HB3' ' A' ' 103' ' ' PHE . 0.0 OUTLIER -55.37 -32.33 62.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 179.945 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -43.0 -88.01 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.505 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -88.4 -41.62 12.7 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.821 0.343 . . . . 0.0 110.873 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 121.09 32.66 1.04 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.494 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 24.7 p -109.61 118.08 35.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.777 0.322 . . . . 0.0 111.164 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.508 HG22 ' HA ' ' A' ' 74' ' ' PRO . 13.8 t -97.79 113.58 32.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.131 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.499 HG22 ' HD3' ' A' ' 96' ' ' LYS . 58.2 t -83.12 144.81 9.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.111 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -123.89 125.46 44.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.873 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.482 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.7 OUTLIER -139.29 177.96 7.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.935 -179.955 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 92.4 p -160.67 107.68 1.53 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.868 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.897 HD13 ' NE1' ' A' ' 91' ' ' TRP . 24.6 tp -76.98 117.41 18.54 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.935 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.486 ' N ' ' O ' ' A' ' 90' ' ' SER . 25.9 mt -93.44 161.19 14.48 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.908 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.551 ' ND2' ' OD1' ' A' ' 67' ' ' ASP . 10.5 m120 -41.31 101.48 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.866 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.94 -3.25 4.11 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.471 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.851 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.4 OUTLIER -124.5 173.41 8.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.87 0.367 . . . . 0.0 110.831 -179.716 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.897 ' NE1' HD13 ' A' ' 86' ' ' LEU . 23.8 m95 -130.21 159.58 36.44 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.948 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -90.8 -109.3 1.47 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.478 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 3.4 m -159.92 176.03 12.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.839 0.352 . . . . 0.0 110.832 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.424 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 4.6 mt-10 -104.05 122.96 46.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.866 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -121.75 113.25 19.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.892 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.499 ' HD3' HG22 ' A' ' 82' ' ' VAL . 40.4 mtmt -114.34 118.41 33.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.868 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 12.1 tptm -172.13 105.27 0.18 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.879 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.793 HD11 ' O ' ' A' ' 100' ' ' HIS . 2.4 tt -144.23 143.58 23.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.155 179.836 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.606 HG23 ' N ' ' A' ' 100' ' ' HIS . 10.3 t -77.25 -51.58 10.67 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.154 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' HIS . . . . . 0.793 ' O ' HD11 ' A' ' 98' ' ' ILE . 21.3 p80 -140.55 134.21 30.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.85 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' ASN . . . . . 0.649 HD21 ' C ' ' A' ' 101' ' ' ASN . 0.1 OUTLIER -101.65 99.13 10.88 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.608 0.718 . . . . 0.0 110.931 -179.961 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.403 ' HD2' HD11 ' A' ' 129' ' ' LEU . 53.6 Cg_endo -69.76 -40.81 4.89 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.693 2.262 . . . . 0.0 112.328 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.522 ' HB3' ' HE3' ' A' ' 76' ' ' MET . 6.7 m-85 -41.02 111.86 0.25 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.885 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -134.08 133.85 7.1 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.511 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 96.5 0.6 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.632 2.222 . . . . 0.0 112.333 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 127.25 0.23 6.92 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.49 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -138.78 154.48 48.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.85 0.357 . . . . 0.0 110.952 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 -71.9 171.96 10.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.87 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 27.4 p90 -160.52 136.33 8.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.909 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.67 105.8 14.82 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.854 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.827 HD13 ' N ' ' A' ' 112' ' ' SER . 0.6 OUTLIER -107.14 139.72 41.11 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.9 -179.931 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.827 ' N ' HD13 ' A' ' 111' ' ' LEU . 3.6 m -144.88 114.88 7.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.839 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.422 HG22 ' HD2' ' A' ' 120' ' ' PHE . 4.6 mp -98.23 127.42 50.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.142 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 9.9 mtp180 -100.25 133.48 44.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.875 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 14.1 t -98.49 100.41 11.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.894 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -91.04 -140.51 8.87 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.469 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.3 mt -122.8 -38.55 2.62 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.845 0.355 . . . . 0.0 110.933 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.4 t0 -94.39 -21.43 18.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.867 179.848 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.402 ' CD ' ' C ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -175.18 -175.12 0.81 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.834 -179.902 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.451 ' CZ ' HD13 ' A' ' 37' ' ' LEU . 20.4 m-85 -108.42 148.91 29.46 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.871 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 2.1 mmmm -120.17 101.95 8.18 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.866 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.6 HG13 HD11 ' A' ' 111' ' ' LEU . 65.8 t -89.31 129.74 39.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.141 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 54.6 m-85 -116.16 160.7 20.01 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.925 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.473 ' HB2' HD13 ' A' ' 129' ' ' LEU . . . -139.92 114.34 9.21 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.111 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 41.41 38.68 0.88 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.852 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 83.71 27.63 37.9 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.458 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' GLN . . . . . 0.421 ' N ' ' O ' ' A' ' 124' ' ' ALA . 9.4 mm100 -138.88 115.88 10.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.855 0.359 . . . . 0.0 110.897 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 34.4 t-80 -47.93 103.19 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.876 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.619 HD22 HD21 ' A' ' 111' ' ' LEU . 13.5 tp -69.65 -68.48 0.41 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.894 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.541 ' HZ ' HD13 ' A' ' 72' ' ' ILE . 9.4 p90 -164.2 175.8 9.81 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.912 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.48 ' OD1' ' N ' ' A' ' 132' ' ' PHE . 0.4 OUTLIER -117.06 156.73 27.05 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 179.967 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.738 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -128.31 106.12 8.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.889 -179.864 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.605 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -63.35 136.66 57.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.137 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 27.5 m170 -61.37 115.65 4.02 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.883 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 8.1 mtt-85 -95.9 -47.65 6.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.861 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 9.9 tp -96.56 108.19 20.74 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.905 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 78.9 p -47.73 -34.22 8.07 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.847 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.668 ' HB1' ' HG3' ' A' ' 141' ' ' ARG . . . -83.62 31.09 0.47 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.084 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -50.36 -34.89 25.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.871 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 140' ' ' GLN . . . . . 0.456 ' HG2' ' N ' ' A' ' 141' ' ' ARG . 18.1 pm0 -59.7 -29.41 68.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.923 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.668 ' HG3' ' HB1' ' A' ' 138' ' ' ALA . 36.3 mtp85 -65.29 -39.64 92.81 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.672 ' HA ' HG22 ' A' ' 62' ' ' VAL . 84.3 t -50.62 103.94 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.151 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 9.3 p-10 -125.27 31.85 5.49 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.886 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 144' ' ' THR . . . . . 0.419 ' N ' HD12 ' A' ' 33' ' ' LEU . 1.7 m -140.72 135.04 31.18 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.14 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.698 HD13 ' CE2' ' A' ' 60' ' ' PHE . 6.4 tp -129.88 115.88 17.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.932 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 146' ' ' GLU . . . . . 0.438 ' HB3' ' CD1' ' A' ' 30' ' ' PHE . 5.1 pt-20 -120.0 150.95 39.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.885 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.534 HG23 HG13 ' A' ' 58' ' ' ILE . 15.0 mt -139.36 112.85 6.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.152 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -122.58 175.59 6.4 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.902 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 105.11 -146.36 16.06 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.498 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -111.69 92.51 4.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.886 0.374 . . . . 0.0 110.865 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.483 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 4.7 p -151.22 140.59 15.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.107 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 152' ' ' THR . . . . . 0.501 ' O ' ' CA ' ' A' ' 47' ' ' GLY . 14.1 m -100.52 94.15 5.99 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.16 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.463 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 80.4 mt -78.59 132.99 37.34 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.92 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 64.9 m -118.29 -34.38 4.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.889 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 13.8 t80 -149.98 130.36 13.79 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.941 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 86.3 t -140.77 106.14 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.152 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 16.0 tt0 -114.57 135.85 53.68 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.919 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 158' ' ' ILE . . . . . 0.412 ' O ' HG22 ' A' ' 158' ' ' ILE . 42.1 mt -104.11 88.46 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.166 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 16.4 m -62.32 136.2 57.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.876 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -162.41 178.09 38.32 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.46 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 125.76 12.53 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.662 2.241 . . . . 0.0 112.347 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 35.7 m -90.76 103.12 15.86 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.804 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 7.7 t 46.57 42.46 11.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.847 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.528 180.0 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 N-CA-C 112.501 -0.24 . . . . 0.0 112.501 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 15.7 m -96.21 90.91 5.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.845 0.355 . . . . 0.0 110.854 -179.762 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 23.6 t -70.91 147.61 48.59 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.858 -179.837 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 118.98 152.68 9.23 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.49 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 79.0 p -63.84 106.31 0.98 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.836 0.351 . . . . 0.0 110.814 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 93.0 p -156.61 149.65 24.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.865 -179.829 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 123.67 -130.67 7.76 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.49 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 70.0 m80 -144.59 153.07 41.42 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.735 0.303 . . . . 0.0 110.868 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.7 tt0 -105.94 41.84 1.34 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.871 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 87.9 mt-30 -80.82 43.42 0.68 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.909 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 26.1 mt -151.44 161.72 42.21 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.856 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 20.2 t30 -121.31 130.43 53.64 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.841 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 19.8 m -158.94 156.0 28.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.808 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.603 HD11 ' HB2' ' A' ' 32' ' ' ARG . 4.3 pp -83.31 153.8 66.01 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.583 0.706 . . . . 0.0 110.951 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 175.75 7.65 Favored 'Trans proline' 0 C--O 1.232 0.21 0 C-N-CA 122.665 2.244 . . . . 0.0 112.378 179.865 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.403 ' CG2' ' HG2' ' A' ' 18' ' ' GLU . 9.6 t -50.96 178.98 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.157 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' MET . . . . . 0.403 ' O ' ' O ' ' A' ' 18' ' ' GLU . 23.8 mmm -118.17 7.37 12.12 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.894 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.403 ' HG2' ' CG2' ' A' ' 16' ' ' THR . 22.1 pt-20 -50.96 -176.08 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.923 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 76.85 -155.81 45.18 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.475 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 166.32 27.94 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.677 2.251 . . . . 0.0 112.34 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 178.35 4.66 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.667 2.245 . . . . 0.0 112.373 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.51 ' CG2' ' N ' ' A' ' 23' ' ' PHE . 1.3 m -92.14 157.26 16.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.115 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.51 ' N ' ' CG2' ' A' ' 22' ' ' THR . 8.4 m-85 -147.73 141.65 25.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.873 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ASN . . . . . 0.485 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 15.8 m120 35.12 51.95 1.37 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.63 0.729 . . . . 0.0 110.88 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.491 ' HG2' ' CB ' ' A' ' 153' ' ' LEU . 53.6 Cg_endo -69.82 145.78 57.85 Favored 'Trans proline' 0 C--O 1.232 0.192 0 C-N-CA 122.693 2.262 . . . . 0.0 112.309 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.79 -178.25 2.27 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.663 2.242 . . . . 0.0 112.32 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.681 HG13 ' HA ' ' A' ' 28' ' ' PRO . 95.2 t -142.85 138.0 15.58 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.688 0.756 . . . . 0.0 111.081 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.681 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.9 Cg_endo -69.77 144.54 76.95 Favored 'Cis proline' 0 C--N 1.342 0.195 0 C-N-CA 122.656 -1.81 . . . . 0.0 112.347 -0.028 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 1.9 t80 -96.22 117.64 31.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.95 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -100.53 104.09 15.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.888 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -109.03 109.19 2.74 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.48 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.603 ' HB2' HD11 ' A' ' 14' ' ' LEU . 6.8 mmt85 -72.97 116.55 13.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.829 0.347 . . . . 0.0 110.887 -179.893 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.482 HD23 HG12 ' A' ' 158' ' ' ILE . 6.1 mt -75.69 94.61 3.27 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.913 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 22.2 mm-40 -67.22 92.55 0.27 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.886 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 138.21 -37.63 1.79 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.476 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.816 ' O ' HG23 ' A' ' 38' ' ' THR . . . 88.92 157.48 32.85 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.493 -179.884 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' LEU . . . . . 0.423 HD12 ' O ' ' A' ' 139' ' ' PHE . 66.4 mt -51.08 95.77 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.914 0.388 . . . . 0.0 110.907 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.816 HG23 ' O ' ' A' ' 36' ' ' GLY . 44.4 p -116.24 148.59 40.3 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.092 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -50.6 -21.27 1.48 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.106 179.813 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.455 ' HA ' ' NE ' ' A' ' 40' ' ' ARG . 3.8 mmp_? -106.88 34.28 3.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.859 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 14.7 ttt85 -125.9 140.06 52.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.904 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 99.9 m -139.36 119.81 13.95 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.168 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 4.9 mp -90.59 142.19 13.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.15 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 82.4 mt -133.76 115.66 22.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.111 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 54.3 mt -114.92 107.59 23.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.123 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.0 mtmm -110.18 109.3 19.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.885 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.59 -147.53 4.98 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.507 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' TYR . . . . . 0.587 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.5 OUTLIER -168.14 127.13 1.22 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.892 0.377 . . . . 0.0 110.97 -179.806 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 11.3 t -75.97 115.38 46.06 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.627 0.727 . . . . 0.0 111.141 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 155.42 66.15 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.661 2.241 . . . . 0.0 112.423 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -14.83 36.61 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.657 2.238 . . . . 0.0 112.326 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 49.7 p -111.62 17.94 19.49 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.162 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -113.36 124.14 6.44 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.48 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 14.8 mttp -64.89 -62.6 1.46 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.802 0.334 . . . . 0.0 110.897 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 17.5 p -171.76 157.51 4.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.875 -179.869 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.6 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 9.1 p90 -113.1 -172.27 2.03 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.931 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.785 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -155.19 139.12 16.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.081 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.575 HD11 ' CE2' ' A' ' 56' ' ' PHE . 2.7 mp -118.95 99.03 7.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.139 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' ASN . . . . . 0.512 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 33.0 m-80 -101.22 141.67 33.77 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.897 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.678 ' CE2' HD13 ' A' ' 145' ' ' LEU . 26.8 m-85 -115.49 97.92 6.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.861 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.404 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 32.9 ttmt -95.59 169.91 9.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.94 179.918 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.595 HG13 ' O ' ' A' ' 141' ' ' ARG . 16.7 t -99.33 123.35 51.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.131 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -61.08 -22.87 61.05 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.497 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.584 ' H ' HG12 ' A' ' 62' ' ' VAL . 30.7 t -81.73 -72.78 0.42 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.928 0.394 . . . . 0.0 110.855 -179.72 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 36.0 t -80.61 -72.79 0.4 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.839 -179.82 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 133.69 40.65 0.18 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.487 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.555 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.1 m-20 -110.29 137.54 47.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.796 0.331 . . . . 0.0 110.847 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.538 HD12 ' HB3' ' A' ' 86' ' ' LEU . 57.0 mt -85.84 112.46 22.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.155 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.587 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -80.7 -34.66 34.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.114 179.829 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.713 HD21 HD11 ' A' ' 72' ' ' ILE . 53.4 tp -140.69 132.16 26.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.951 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.512 ' CG ' ' OD1' ' A' ' 59' ' ' ASN . 3.3 t60 -134.92 92.3 2.86 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.857 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.713 HD11 HD21 ' A' ' 70' ' ' LEU . 20.3 mt -96.17 134.78 32.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.163 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.785 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 9.4 t-20 -140.06 105.88 6.75 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.643 0.735 . . . . 0.0 110.904 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.6 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.2 Cg_endo -69.75 155.01 67.1 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.67 2.247 . . . . 0.0 112.364 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 36.7 mtp180 -131.85 94.72 3.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.854 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' MET . . . . . 0.431 ' HE3' ' HB3' ' A' ' 103' ' ' PHE . 0.3 OUTLIER -61.57 148.93 40.63 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.877 179.95 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 99.98 -68.0 0.54 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.471 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 11.3 t-20 -78.84 -51.34 9.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.822 0.344 . . . . 0.0 110.89 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 102.36 56.96 0.81 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.467 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 13.7 p -144.04 117.85 9.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.807 0.337 . . . . 0.0 111.187 -179.883 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.53 HG22 ' HA ' ' A' ' 74' ' ' PRO . 29.4 t -104.43 109.47 27.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.119 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.741 HG22 ' CE ' ' A' ' 96' ' ' LYS . 58.2 t -80.01 135.53 25.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.107 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' ARG . . . . . 0.483 ' HD3' ' N ' ' A' ' 83' ' ' ARG . 0.7 OUTLIER -121.06 115.18 22.63 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.884 -179.989 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.434 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.2 t-20 -124.81 -176.82 3.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.911 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.431 ' CB ' ' HD2' ' A' ' 135' ' ' ARG . 47.5 t -161.17 106.45 1.36 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.883 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.904 HD13 ' NE1' ' A' ' 91' ' ' TRP . 28.9 tp -78.9 115.35 18.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.923 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.519 ' N ' ' O ' ' A' ' 90' ' ' SER . 73.2 mt -92.96 162.18 14.16 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.882 179.901 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.488 ' ND2' ' OD2' ' A' ' 67' ' ' ASP . 10.6 m-80 -40.66 101.64 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.891 179.902 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.77 -3.59 2.79 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.466 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.854 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -123.15 170.97 9.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.901 0.382 . . . . 0.0 110.833 -179.73 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.904 ' NE1' HD13 ' A' ' 86' ' ' LEU . 24.7 m95 -128.41 160.62 31.69 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.926 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -91.24 -108.26 1.5 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.483 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 2.9 m -163.07 169.5 19.38 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.851 0.358 . . . . 0.0 110.873 -179.73 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 71.6 mt-10 -93.58 119.19 32.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.901 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 -122.87 124.95 44.42 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.92 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.741 ' CE ' HG22 ' A' ' 82' ' ' VAL . 17.4 mttp -126.52 122.74 36.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.896 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.413 ' HB3' ' NH2' ' A' ' 83' ' ' ARG . 4.6 ttpm? -169.5 105.81 0.37 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.91 179.827 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.737 HD11 ' O ' ' A' ' 100' ' ' HIS . 1.3 tt -147.75 150.2 14.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.144 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.48 HG23 ' N ' ' A' ' 100' ' ' HIS . 11.5 t -86.52 -43.48 12.7 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.145 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 100' ' ' HIS . . . . . 0.737 ' O ' HD11 ' A' ' 98' ' ' ILE . 2.9 p-80 -149.64 127.2 11.58 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.898 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' ASN . . . . . 0.43 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 51.7 t-20 -99.51 101.01 11.91 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.604 0.716 . . . . 0.0 110.867 -179.89 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.456 ' HD2' HD11 ' A' ' 129' ' ' LEU . 53.8 Cg_endo -69.78 -31.81 19.72 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.738 2.292 . . . . 0.0 112.341 179.918 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.593 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 17.9 m-85 -44.2 102.48 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.837 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -132.06 135.18 8.02 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.482 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 98.26 0.67 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.672 2.248 . . . . 0.0 112.351 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 130.75 -5.87 5.82 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.44 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 -135.47 159.83 40.37 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.849 0.356 . . . . 0.0 110.91 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' PHE . . . . . 0.587 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 16.2 m-85 -77.64 174.56 10.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.876 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.544 ' O ' ' CD1' ' A' ' 109' ' ' PHE . 33.5 p90 -161.49 118.08 2.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.881 -179.872 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -92.5 106.93 18.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.892 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.817 HD13 ' N ' ' A' ' 112' ' ' SER . 0.3 OUTLIER -106.75 138.38 43.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.91 -179.948 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.817 ' N ' HD13 ' A' ' 111' ' ' LEU . 7.4 m -145.37 112.04 5.87 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.841 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.8 mp -94.55 134.12 33.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.116 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 70.7 mtt180 -111.79 123.35 50.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.844 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' CYS . . . . . 0.576 ' HA ' ' CD1' ' A' ' 120' ' ' PHE . 3.5 t -93.91 100.87 12.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.89 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -93.11 -126.96 4.34 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.476 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.4 mt -132.74 -43.19 0.91 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.842 0.353 . . . . 0.0 110.885 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -86.04 -29.34 23.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.9 179.82 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 10.6 ptp85 -175.16 162.37 2.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.838 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.576 ' CD1' ' HA ' ' A' ' 115' ' ' CYS . 3.0 m-30 -85.45 141.43 29.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.902 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 12.0 mmmt -113.67 105.01 12.8 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.941 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.591 HG13 HD11 ' A' ' 111' ' ' LEU . 48.8 t -95.18 133.2 36.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.12 179.898 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 11.0 m-85 -120.16 159.24 25.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.874 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.53 ' HB2' HD13 ' A' ' 129' ' ' LEU . . . -141.4 116.25 9.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.059 179.872 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 45.07 35.94 1.82 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.896 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 84.33 29.36 30.67 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.458 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 4.8 mm-40 -140.96 116.11 9.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.789 0.328 . . . . 0.0 110.911 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 42.1 t-80 -51.27 105.02 0.09 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.831 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.53 HD13 ' HB2' ' A' ' 124' ' ' ALA . 6.4 tp -72.13 -67.52 0.53 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.941 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.629 ' HZ ' HD13 ' A' ' 72' ' ' ILE . 6.7 p90 -166.35 179.82 5.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.898 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -126.27 158.9 34.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.845 -179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.638 ' CD1' HD13 ' A' ' 70' ' ' LEU . 0.2 OUTLIER -115.4 110.24 19.05 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.89 -179.914 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.595 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -54.52 138.69 40.0 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.071 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 22.9 m170 -78.15 69.22 4.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.83 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.431 ' HD2' ' CB ' ' A' ' 85' ' ' SER . 0.0 OUTLIER -66.33 -37.89 86.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.872 -179.948 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.8 tp -98.23 107.89 20.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.916 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 78.8 p -58.1 -25.12 60.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.859 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.67 ' HB1' ' HD2' ' A' ' 141' ' ' ARG . . . -91.06 39.71 1.0 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.114 179.894 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.423 ' O ' HD12 ' A' ' 37' ' ' LEU . 28.9 p90 -65.47 -30.88 71.71 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.909 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 4.9 pt20 -59.32 -31.16 68.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.889 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.67 ' HD2' ' HB1' ' A' ' 138' ' ' ALA . 27.4 mtt180 -64.26 -40.16 95.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.889 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.587 HG21 ' CB ' ' A' ' 69' ' ' ALA . 92.0 t -48.91 106.01 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.139 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.505 ' OD2' ' N ' ' A' ' 36' ' ' GLY . 0.7 OUTLIER -130.84 33.41 4.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.892 179.922 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 9.1 m -143.74 113.5 7.12 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.175 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.678 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.7 tp -111.19 106.99 16.17 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.905 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 146' ' ' GLU . . . . . 0.417 ' C ' HG13 ' A' ' 147' ' ' ILE . 3.1 pt-20 -108.59 153.91 22.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.901 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.417 HG13 ' C ' ' A' ' 146' ' ' GLU . 21.3 mt -140.78 116.49 7.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.081 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -126.19 171.76 10.62 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.926 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 104.74 -157.07 16.84 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.459 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 64.6 m-20 -98.6 94.32 6.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.868 0.366 . . . . 0.0 110.844 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 10.4 p -151.07 141.5 16.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.142 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 33.7 m -105.5 92.71 4.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.176 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.491 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 94.6 mt -71.75 133.65 45.71 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.895 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 3.6 m -114.61 -35.66 4.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.886 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 155' ' ' TYR . . . . . 0.462 ' C ' ' CD1' ' A' ' 155' ' ' TYR . 4.2 t80 -157.16 132.43 9.06 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.941 -179.885 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 85.0 t -140.47 133.79 33.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.113 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 8.0 tt0 -156.57 138.45 14.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.891 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 158' ' ' ILE . . . . . 0.482 HG12 HD23 ' A' ' 33' ' ' LEU . 4.7 mp -97.29 96.82 5.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.141 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 159' ' ' SER . . . . . 0.455 ' C ' ' O ' ' A' ' 158' ' ' ILE . 74.9 m -33.63 -45.82 0.18 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.842 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 160' ' ' GLY . . . . . 0.442 ' C ' ' O ' ' A' ' 159' ' ' SER . . . -34.39 142.49 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.476 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 154.86 67.37 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.718 2.279 . . . . 0.0 112.363 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 83.1 p -69.5 109.88 4.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.904 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 3.5 t -96.68 104.13 16.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.873 -179.783 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.263 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.491 -179.979 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.9 t -78.47 112.54 15.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.907 0.384 . . . . 0.0 110.826 -179.744 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 93.9 p -41.27 104.49 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.881 -179.844 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 107.81 178.55 22.24 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.532 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.2 t -134.85 -49.59 0.76 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.853 0.359 . . . . 0.0 110.831 -179.714 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.2 m 45.94 41.82 8.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.846 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 89.93 -133.57 11.88 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.482 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 38.74 42.62 0.63 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.741 0.305 . . . . 0.0 110.874 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 8.9 mm100 -90.76 -60.33 1.94 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.939 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.6 tp60 -124.57 102.85 7.83 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.584 HD23 ' N ' ' A' ' 11' ' ' LEU . 0.3 OUTLIER -126.84 41.83 3.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.91 -179.998 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.6 m120 64.45 42.51 5.04 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.924 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 1.1 t -110.51 -176.46 2.98 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.839 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 10.7 mt -143.54 152.17 55.94 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.632 0.729 . . . . 0.0 110.931 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 159.83 51.95 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.683 2.255 . . . . 0.0 112.383 179.853 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 9.8 t -85.41 137.4 32.95 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.146 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' MET . . . . . 0.4 ' HE3' ' CA ' ' A' ' 31' ' ' GLY . 0.0 OUTLIER -98.36 37.98 1.39 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.889 179.933 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 -71.09 -176.29 1.37 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.885 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 73.77 -122.81 7.82 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.546 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.83 146.4 59.63 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.689 2.26 . . . . 0.0 112.301 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.432 ' HB2' ' CE2' ' A' ' 155' ' ' TYR . 53.7 Cg_endo -69.72 161.88 44.22 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.64 2.226 . . . . 0.0 112.336 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 3.7 t -79.26 141.71 36.84 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.127 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -129.05 122.67 30.47 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.875 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ASN . . . . . 0.555 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 6.3 t-20 74.11 47.76 0.21 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.589 0.709 . . . . 0.0 110.899 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.555 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.78 123.29 9.95 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.646 2.231 . . . . 0.0 112.375 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.78 -179.28 2.81 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.674 2.25 . . . . 0.0 112.363 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.704 HG13 ' HA ' ' A' ' 28' ' ' PRO . 90.8 t -140.97 138.5 18.11 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.592 0.711 . . . . 0.0 111.096 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.704 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.6 Cg_endo -69.76 144.22 76.05 Favored 'Cis proline' 0 C--O 1.231 0.174 0 C-N-CA 122.69 -1.796 . . . . 0.0 112.311 -0.056 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.6 t80 -97.29 114.32 26.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.942 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.432 ' CD1' ' HB3' ' A' ' 146' ' ' GLU . 66.6 m-85 -99.55 107.25 19.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.875 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.4 ' CA ' ' HE3' ' A' ' 17' ' ' MET . . . -115.29 100.44 0.97 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.513 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.483 ' O ' ' CG ' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -72.78 117.11 14.08 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.84 0.353 . . . . 0.0 110.895 -179.848 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.4 ' O ' ' HD3' ' A' ' 32' ' ' ARG . 11.6 mt -63.45 150.11 44.47 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.937 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.455 ' OE1' ' NH1' ' A' ' 32' ' ' ARG . 7.3 mm100 -98.01 -46.44 5.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.943 179.892 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.557 ' O ' HG23 ' A' ' 38' ' ' THR . . . -103.47 33.22 6.76 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.486 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.41 ' O ' ' O ' ' A' ' 35' ' ' GLY . . . 37.21 -157.5 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.443 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 51.3 mt -88.43 106.7 18.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.832 0.348 . . . . 0.0 110.92 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.557 HG23 ' O ' ' A' ' 35' ' ' GLY . 34.4 p -122.12 170.57 9.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.109 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.495 ' HB2' ' HG ' ' A' ' 117' ' ' LEU . . . -79.13 -11.81 59.99 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.074 179.884 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 12.2 mmm180 -110.64 22.39 15.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.841 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.817 ' CZ ' HD11 ' A' ' 43' ' ' ILE . 27.8 ttt-85 -117.94 143.22 46.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.873 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 51.9 m -138.14 129.1 27.07 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.129 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.817 HD11 ' CZ ' ' A' ' 41' ' ' ARG . 4.8 mp -94.64 145.73 7.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.133 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 76.6 mt -142.73 114.33 3.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.125 179.852 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 48.3 mt -115.93 107.71 23.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.143 179.82 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.5 mtmm -109.89 112.92 25.24 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.919 179.827 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.411 ' CA ' ' O ' ' A' ' 152' ' ' THR . . . -146.85 -142.89 3.78 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.534 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -167.58 130.64 1.67 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.874 0.368 . . . . 0.0 110.92 -179.827 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 16.0 t -78.98 115.74 54.69 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.661 0.743 . . . . 0.0 111.099 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 155.42 65.81 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.676 2.251 . . . . 0.0 112.326 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 -19.27 36.47 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.723 2.282 . . . . 0.0 112.319 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 69.5 p -106.15 16.84 24.39 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.167 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -114.66 125.91 7.01 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.489 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 15.7 mttp -66.25 -61.84 1.8 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.785 0.326 . . . . 0.0 110.895 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.0 p -172.56 158.2 4.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.883 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.596 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 8.1 p90 -108.88 -173.85 2.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.845 -179.928 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.804 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -156.32 140.79 16.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.092 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.56 HG23 HG12 ' A' ' 147' ' ' ILE . 3.1 mp -122.38 107.84 20.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.098 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -111.74 143.52 42.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.852 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.687 ' CE2' HD13 ' A' ' 145' ' ' LEU . 13.6 m-85 -113.67 102.04 9.88 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.91 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.411 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 31.9 ttmt -95.1 168.07 10.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.888 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.78 HG13 ' O ' ' A' ' 141' ' ' ARG . 25.5 t -98.94 122.37 50.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.106 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -60.22 -26.62 64.05 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.479 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.564 ' H ' HG12 ' A' ' 62' ' ' VAL . 66.4 m -75.47 -70.88 0.4 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.869 0.366 . . . . 0.0 110.855 -179.76 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.8 m -85.23 -73.54 0.43 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.825 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 137.58 35.87 0.17 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.447 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.534 ' O ' HG23 ' A' ' 62' ' ' VAL . 0.3 OUTLIER -104.11 146.87 28.11 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.766 0.317 . . . . 0.0 110.879 -179.972 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 60.4 mt -94.79 115.89 34.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.203 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.7 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -83.19 -39.11 21.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.075 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.687 HD13 ' CG ' ' A' ' 132' ' ' PHE . 38.8 tp -135.06 133.01 38.89 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.952 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.474 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.9 OUTLIER -134.34 93.09 3.01 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.827 179.885 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.543 HD11 HD21 ' A' ' 70' ' ' LEU . 59.3 mt -97.21 130.84 45.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.094 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.804 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 8.1 t-20 -136.11 106.5 9.53 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.629 0.728 . . . . 0.0 110.942 179.87 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.643 ' HA ' HG22 ' A' ' 81' ' ' VAL . 54.1 Cg_endo -69.75 155.12 66.78 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.664 2.243 . . . . 0.0 112.399 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 25.9 mtp180 -132.35 101.48 5.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.822 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -58.61 -52.08 67.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.855 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.418 ' O ' ' C ' ' A' ' 78' ' ' ASN . . . -63.36 -91.64 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.49 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.418 ' C ' ' O ' ' A' ' 77' ' ' GLY . 19.9 t-20 -35.95 -49.07 0.61 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.889 0.376 . . . . 0.0 110.914 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 92.43 40.75 4.99 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.491 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 25.1 p -144.8 118.26 9.08 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.823 0.344 . . . . 0.0 111.123 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.643 HG22 ' HA ' ' A' ' 74' ' ' PRO . 17.3 t -87.84 104.64 14.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.126 179.888 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.712 HG22 ' HD3' ' A' ' 96' ' ' LYS . 58.7 t -76.25 145.52 10.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.125 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -125.78 131.28 52.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.861 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.474 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.2 m120 -143.81 179.52 7.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.892 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.405 ' CB ' ' O ' ' A' ' 69' ' ' ALA . 96.6 p -160.7 107.29 1.49 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.816 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.888 HD13 ' NE1' ' A' ' 91' ' ' TRP . 28.5 tp -77.38 116.92 18.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.935 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.534 HD22 HD13 ' A' ' 136' ' ' LEU . 66.7 mt -93.33 161.58 14.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.933 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.455 ' ND2' ' OD2' ' A' ' 67' ' ' ASP . 14.0 m-80 -41.63 101.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.869 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.86 -3.38 3.94 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.516 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.843 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -124.83 171.58 10.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.838 0.351 . . . . 0.0 110.868 -179.72 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.888 ' NE1' HD13 ' A' ' 86' ' ' LEU . 23.0 m95 -128.08 159.85 33.8 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.968 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -89.37 -105.82 1.12 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.478 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' SER . . . . . 0.424 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 25.2 m -165.91 166.15 17.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.86 0.362 . . . . 0.0 110.82 -179.76 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.412 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 5.6 mt-10 -88.32 119.99 29.26 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.867 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -120.03 116.44 25.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.85 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.712 ' HD3' HG22 ' A' ' 82' ' ' VAL . 46.5 mtmt -122.25 124.79 44.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.873 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 26.9 ttpt -172.53 107.95 0.19 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.919 179.882 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.825 HD11 ' O ' ' A' ' 100' ' ' HIS . 7.1 tt -147.35 159.58 8.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.125 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.482 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 9.8 t -102.75 -34.23 9.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.13 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 100' ' ' HIS . . . . . 0.825 ' O ' HD11 ' A' ' 98' ' ' ILE . 1.7 p-80 -155.66 130.25 9.06 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.847 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' ASN . . . . . 0.627 ' CG ' HD13 ' A' ' 98' ' ' ILE . 11.2 m-80 -101.71 97.72 8.41 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.61 0.719 . . . . 0.0 110.937 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.403 ' HD3' ' O ' ' A' ' 100' ' ' HIS . 53.7 Cg_endo -69.7 -31.06 21.54 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.698 2.265 . . . . 0.0 112.339 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.543 ' CZ ' HD21 ' A' ' 129' ' ' LEU . 5.8 m-85 -52.77 107.97 0.27 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.86 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -133.52 139.66 11.11 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.507 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 105.21 1.43 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.727 2.285 . . . . 0.0 112.38 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 122.97 -8.04 9.24 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.497 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.3 pt20 -132.97 153.85 51.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.83 0.348 . . . . 0.0 110.887 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -77.15 172.94 12.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.865 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 32.4 p90 -160.16 139.89 11.25 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.899 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -109.55 104.91 14.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.898 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.694 HD13 ' N ' ' A' ' 112' ' ' SER . 1.0 OUTLIER -105.51 138.17 42.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.919 -179.955 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.694 ' N ' HD13 ' A' ' 111' ' ' LEU . 2.6 m -144.64 113.98 7.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.857 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.464 HD11 HD12 ' A' ' 111' ' ' LEU . 4.9 mp -95.32 131.62 41.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.116 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 15.7 mtp180 -106.38 128.01 53.71 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.842 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' CYS . . . . . 0.481 ' HA ' ' CD1' ' A' ' 120' ' ' PHE . 35.6 t -98.99 121.37 40.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.908 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -116.38 -138.13 6.22 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.477 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.495 ' HG ' ' HB2' ' A' ' 39' ' ' ALA . 9.7 mt -123.03 -31.38 3.63 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.806 0.336 . . . . 0.0 110.932 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -96.66 -34.21 11.47 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.871 179.891 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 20.8 ptt-85 -172.91 171.48 4.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.481 ' CD1' ' HA ' ' A' ' 115' ' ' CYS . 4.1 m-30 -94.8 157.62 15.85 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.887 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 19.8 mtpp -130.49 99.77 5.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.891 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.486 HG13 HD11 ' A' ' 111' ' ' LEU . 42.2 t -84.46 133.97 28.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.131 179.867 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 123' ' ' TYR . . . . . 0.449 ' O ' HD22 ' A' ' 111' ' ' LEU . 81.5 m-85 -122.46 153.84 38.59 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.886 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.435 ' O ' ' CG ' ' A' ' 125' ' ' ASN . . . -139.72 121.34 15.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.123 179.815 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.435 ' CG ' ' O ' ' A' ' 124' ' ' ALA . 10.7 p30 48.49 33.66 4.2 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.895 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.78 26.5 49.75 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.438 179.949 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 37.0 mm-40 -129.76 168.02 17.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.842 0.353 . . . . 0.0 110.909 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 33.9 t-80 -91.16 116.09 28.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.829 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.543 HD21 ' CZ ' ' A' ' 103' ' ' PHE . 9.0 tp -87.93 -68.32 0.77 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.957 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.49 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 3.9 p90 -168.68 172.21 8.15 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.862 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -115.43 156.73 25.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.853 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.687 ' CG ' HD13 ' A' ' 70' ' ' LEU . 0.2 OUTLIER -122.49 104.4 9.35 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.893 -179.94 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.514 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -60.08 134.13 56.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.13 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 20.4 m170 -61.77 99.56 0.12 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.836 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.424 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 11.7 mtt-85 -82.12 -46.36 13.95 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 136' ' ' LEU . . . . . 0.534 HD13 HD22 ' A' ' 87' ' ' LEU . 13.9 tp -97.55 113.67 25.42 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.906 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 90.8 p -56.05 -32.78 64.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.843 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.647 ' HB1' ' HG3' ' A' ' 141' ' ' ARG . . . -85.69 37.88 0.72 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.061 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 4.7 p90 -56.13 -27.93 55.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.867 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 140' ' ' GLN . . . . . 0.464 ' HG2' ' N ' ' A' ' 141' ' ' ARG . 17.9 pm0 -63.48 -30.41 71.54 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.942 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.78 ' O ' HG13 ' A' ' 62' ' ' VAL . 22.5 mtt180 -65.38 -36.11 82.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.824 -179.866 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.7 HG21 ' CB ' ' A' ' 69' ' ' ALA . 90.5 t -56.55 105.0 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.119 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -126.01 35.7 4.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.879 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 144' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 32' ' ' ARG . 0.6 OUTLIER -144.58 137.98 27.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.138 -179.874 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.687 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.0 tp -134.7 106.43 6.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.904 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 146' ' ' GLU . . . . . 0.432 ' HB3' ' CD1' ' A' ' 30' ' ' PHE . 4.9 pt-20 -109.22 149.16 29.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.934 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.56 HG12 HG23 ' A' ' 58' ' ' ILE . 12.7 mt -137.49 106.82 4.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.154 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -118.58 174.5 6.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.908 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 110.02 -140.81 15.99 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.482 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -117.86 91.92 3.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.811 0.338 . . . . 0.0 110.839 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.426 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 2.9 p -151.37 135.68 9.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.116 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 152' ' ' THR . . . . . 0.411 ' O ' ' CA ' ' A' ' 47' ' ' GLY . 17.7 m -95.93 92.82 6.68 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.171 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.494 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 93.3 mt -76.31 136.38 39.59 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.965 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 19.5 m -123.1 -39.27 2.5 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.858 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 155' ' ' TYR . . . . . 0.432 ' CE2' ' HB2' ' A' ' 21' ' ' PRO . 37.3 t80 -141.81 127.07 18.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.905 -179.828 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 75.9 t -140.43 105.24 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.096 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -121.34 119.82 33.29 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.916 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 56.1 mt -91.87 88.77 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.107 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 24.9 p -72.49 132.34 43.72 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.878 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -176.06 -157.63 17.73 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.451 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.84 107.5 1.89 Allowed 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.662 2.241 . . . . 0.0 112.3 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 56.6 p -72.98 86.62 1.31 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.81 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 1.4 t -69.45 167.81 15.85 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.836 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.472 -179.994 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.29 0 N-CA-C 112.465 -0.254 . . . . 0.0 112.465 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 40.1 t 47.46 42.1 13.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.846 0.355 . . . . 0.0 110.856 -179.723 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 25.6 t -93.7 154.88 17.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.853 -179.795 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -116.86 -94.66 1.82 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.465 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 32.5 m -109.98 172.52 6.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.877 0.37 . . . . 0.0 110.842 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 37.1 p -120.91 160.12 24.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.854 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -66.45 -116.37 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.493 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 74.6 t60 -84.11 146.38 27.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.704 0.287 . . . . 0.0 110.883 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -154.74 125.85 7.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.917 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 12.1 pt20 -105.46 127.81 53.2 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.9 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 8.4 mt -132.33 99.05 4.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.94 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.6 m-20 -69.32 -40.67 77.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.865 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 69.0 m -56.81 -178.39 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.81 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.452 ' HB2' ' HD2' ' A' ' 15' ' ' PRO . 0.5 OUTLIER -108.61 157.35 36.87 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.574 0.702 . . . . 0.0 110.927 -179.997 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.452 ' HD2' ' HB2' ' A' ' 14' ' ' LEU . 53.8 Cg_endo -69.78 -169.76 0.35 Allowed 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.664 2.242 . . . . 0.0 112.376 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.435 ' CG2' ' N ' ' A' ' 17' ' ' MET . 1.3 m -79.9 153.24 29.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.144 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' MET . . . . . 0.435 ' N ' ' CG2' ' A' ' 16' ' ' THR . 1.4 ptt? -83.97 68.54 10.05 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.859 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 18.2 mp0 -73.73 157.71 36.0 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.901 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.28 -135.07 12.31 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.51 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 170.08 17.34 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.727 2.285 . . . . 0.0 112.32 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.78 -173.66 0.76 Allowed 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.664 2.242 . . . . 0.0 112.349 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.439 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.5 m -96.29 137.33 35.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.127 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -137.35 120.18 16.35 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.907 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ASN . . . . . 0.53 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 8.8 m120 60.27 49.03 1.94 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.57 0.7 . . . . 0.0 110.899 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.53 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.2 Cg_endo -69.82 141.75 45.8 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.646 2.23 . . . . 0.0 112.296 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -178.02 2.14 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.63 2.22 . . . . 0.0 112.387 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.684 HG13 ' HA ' ' A' ' 28' ' ' PRO . 96.6 t -142.35 137.89 16.01 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.651 0.739 . . . . 0.0 111.088 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.684 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.8 Cg_endo -69.78 145.23 78.87 Favored 'Cis proline' 0 C--O 1.232 0.192 0 C-N-CA 122.65 -1.812 . . . . 0.0 112.394 -0.057 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -97.52 123.03 41.24 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.885 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -107.74 102.79 11.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.853 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -108.5 110.66 3.12 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.508 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.413 ' NH1' ' HA3' ' A' ' 63' ' ' GLY . 9.0 mmt180 -73.14 113.36 10.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.87 0.366 . . . . 0.0 110.887 -179.859 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 5.9 mt -73.25 97.9 2.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.909 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.402 ' CD ' HG21 ' A' ' 16' ' ' THR . 20.6 mt-30 -66.79 94.76 0.32 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.885 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 135.69 -42.94 1.29 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.481 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.592 ' O ' HG23 ' A' ' 38' ' ' THR . . . 96.23 170.13 34.85 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.423 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' LEU . . . . . 0.768 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 96.1 mt -60.26 105.09 0.38 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.914 0.388 . . . . 0.0 110.913 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.592 HG23 ' O ' ' A' ' 36' ' ' GLY . 38.2 p -117.31 158.76 23.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.119 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -64.32 -16.12 61.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.106 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -114.96 23.92 12.16 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.821 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.504 ' NH1' ' CG2' ' A' ' 158' ' ' ILE . 44.4 ttm-85 -112.6 135.35 53.42 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.869 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 92.3 m -133.16 126.1 30.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.166 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.466 ' N ' HD12 ' A' ' 43' ' ' ILE . 4.6 mp -95.44 138.86 20.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.166 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 88.7 mt -128.91 126.67 65.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.13 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 58.5 mt -126.08 107.59 17.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.117 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 23.2 mtmt -112.05 112.43 24.06 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.883 179.849 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -143.69 -141.91 3.87 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.436 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' TYR . . . . . 0.586 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.6 OUTLIER -169.28 124.03 0.84 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.931 0.396 . . . . 0.0 110.928 -179.775 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.543 HG23 ' CD2' ' A' ' 109' ' ' PHE . 14.1 t -75.35 116.39 54.17 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.651 0.738 . . . . 0.0 111.113 179.923 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 158.94 55.28 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.671 2.247 . . . . 0.0 112.355 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 -21.93 32.93 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.711 2.274 . . . . 0.0 112.393 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 24.4 p -105.88 18.88 21.44 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.142 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -110.2 117.71 4.81 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.44 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 29.2 mtpt -61.58 -60.04 4.3 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.797 0.332 . . . . 0.0 110.891 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 10.5 p -174.59 154.87 2.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.882 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.585 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 5.2 p90 -109.54 -173.48 2.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.881 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.846 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -155.24 143.9 20.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.123 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.465 HG22 ' CE1' ' A' ' 60' ' ' PHE . 2.8 mp -123.91 99.0 5.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.142 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.7 m-80 -99.0 143.71 28.98 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.934 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.551 ' HB3' HG11 ' A' ' 142' ' ' VAL . 15.8 m-85 -118.24 97.26 5.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.864 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.437 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 31.5 ttmt -96.66 169.77 9.65 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.906 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.623 HG22 ' HA ' ' A' ' 142' ' ' VAL . 28.4 t -101.42 124.75 55.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.097 179.871 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.413 ' HA3' ' NH1' ' A' ' 32' ' ' ARG . . . -59.72 -36.21 88.95 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.51 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 23.1 t -67.21 -73.57 0.13 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.86 0.362 . . . . 0.0 110.857 -179.75 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 10.6 t -78.17 -72.48 0.37 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 -179.795 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 129.51 42.33 0.23 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.459 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.431 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.1 m-20 -115.12 140.89 48.69 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.817 0.341 . . . . 0.0 110.84 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.615 HD12 ' HB3' ' A' ' 86' ' ' LEU . 55.2 mt -86.08 122.17 38.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.113 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.517 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -92.93 -31.8 14.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.087 179.831 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.655 HD22 ' CD2' ' A' ' 132' ' ' PHE . 40.0 tp -140.44 131.1 25.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.903 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.488 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.5 OUTLIER -134.1 92.31 2.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.863 179.862 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.515 HD11 HD21 ' A' ' 70' ' ' LEU . 55.7 mt -95.84 130.53 44.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.142 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.846 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 8.5 t-20 -137.79 106.0 8.23 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.632 0.729 . . . . 0.0 110.905 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.585 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.3 Cg_endo -69.71 155.45 66.06 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.698 2.265 . . . . 0.0 112.394 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 39.3 mtp180 -130.67 96.11 4.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.868 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' MET . . . . . 0.4 ' HE3' ' HB3' ' A' ' 103' ' ' PHE . 0.0 OUTLIER -55.5 156.73 4.36 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.85 179.995 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 83.2 -79.93 1.87 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.5 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -55.05 -66.64 0.37 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.852 0.358 . . . . 0.0 110.916 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 113.25 43.55 0.84 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.503 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.9 p -135.97 117.62 14.96 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.83 0.348 . . . . 0.0 111.112 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.455 HG21 ' HE2' ' A' ' 103' ' ' PHE . 20.6 t -99.67 108.38 22.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.169 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.641 HG22 ' HD3' ' A' ' 96' ' ' LYS . 47.3 t -76.95 143.1 13.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.133 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' ARG . . . . . 0.437 ' NH1' ' CD2' ' A' ' 130' ' ' PHE . 0.2 OUTLIER -126.93 129.87 49.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.873 -179.977 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.488 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.4 OUTLIER -140.6 179.65 6.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.905 -179.922 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 28.8 t -160.06 105.01 1.52 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.891 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.904 HD12 ' O ' ' A' ' 90' ' ' SER . 24.9 tp -76.92 118.29 19.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.93 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.51 ' N ' ' O ' ' A' ' 90' ' ' SER . 86.5 mt -95.8 161.63 13.94 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.901 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.462 ' C ' ' H ' ' A' ' 90' ' ' SER . 0.2 OUTLIER -38.64 101.81 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.911 179.931 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.33 -6.09 0.86 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.493 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.904 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -118.47 169.24 9.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.879 0.371 . . . . 0.0 110.84 -179.705 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.862 ' NE1' HD13 ' A' ' 86' ' ' LEU . 20.5 m95 -128.39 161.29 29.81 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.939 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -93.96 -111.71 2.26 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.467 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' SER . . . . . 0.433 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 39.3 m -158.0 170.97 21.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.839 0.352 . . . . 0.0 110.844 -179.717 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -94.87 123.32 38.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.913 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -120.99 120.52 35.65 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.888 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.641 ' HD3' HG22 ' A' ' 82' ' ' VAL . 9.4 mtmp? -123.41 120.02 31.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.913 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -170.75 109.67 0.34 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.903 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.843 HD11 ' O ' ' A' ' 100' ' ' HIS . 2.8 tt -148.84 154.2 10.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.127 179.86 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.445 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 9.0 t -93.95 -40.91 9.87 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.176 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' HIS . . . . . 0.843 ' O ' HD11 ' A' ' 98' ' ' ILE . 2.4 p-80 -147.18 128.44 14.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.865 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -103.32 95.62 7.23 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.652 0.739 . . . . 0.0 110.865 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.45 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.7 Cg_endo -69.79 -40.24 5.51 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.715 2.277 . . . . 0.0 112.324 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.477 ' CE2' ' HB3' ' A' ' 74' ' ' PRO . 8.1 m-85 -34.46 112.01 0.13 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.811 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -138.34 134.67 6.99 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.494 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 98.05 0.66 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.685 2.256 . . . . 0.0 112.337 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 126.01 -3.59 7.9 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.493 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.3 pt20 -132.46 149.39 52.34 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.806 0.336 . . . . 0.0 110.926 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' PHE . . . . . 0.586 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 79.8 m-85 -67.04 169.91 7.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.883 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.543 ' CD2' HG23 ' A' ' 49' ' ' VAL . 19.6 p90 -161.1 120.02 2.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.847 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -96.6 107.13 19.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.895 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.786 HD13 ' N ' ' A' ' 112' ' ' SER . 0.6 OUTLIER -108.95 138.56 45.1 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.926 -179.921 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.786 ' N ' HD13 ' A' ' 111' ' ' LEU . 3.7 m -145.27 115.4 7.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.854 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.509 HG23 HG22 ' A' ' 122' ' ' VAL . 4.1 mp -95.12 138.89 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.105 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 45.6 mtt-85 -113.19 123.74 50.92 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.874 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' CYS . . . . . 0.578 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 11.2 t -92.75 117.53 30.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.872 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.87 -142.41 7.83 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.468 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 17.4 mt -121.43 -35.99 3.16 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.788 0.328 . . . . 0.0 110.884 -179.9 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -92.32 -33.36 14.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.856 179.842 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -174.07 164.62 4.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.871 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.768 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 2.8 m-30 -90.52 156.8 17.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.921 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 23.2 mtpp -128.9 103.23 6.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.927 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.737 HG13 HD11 ' A' ' 111' ' ' LEU . 46.3 t -92.7 127.95 44.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.121 179.92 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 14.7 m-85 -117.9 153.05 34.23 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.878 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -135.89 110.4 8.55 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.128 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 57.38 33.43 23.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.857 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 82.35 29.52 36.52 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.498 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 37.2 mm-40 -138.27 121.52 16.97 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.845 0.355 . . . . 0.0 110.907 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 26.4 t-80 -54.41 110.71 0.66 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.86 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.446 HD21 ' CZ ' ' A' ' 103' ' ' PHE . 8.6 tp -76.81 -66.45 0.82 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.906 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.437 ' CD2' ' NH1' ' A' ' 83' ' ' ARG . 5.3 p90 -166.24 171.26 12.38 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.882 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -111.4 147.07 36.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.887 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.655 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -113.01 107.46 15.99 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.872 -179.872 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.557 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -64.0 130.95 46.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.132 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 26.1 m170 -58.5 111.81 1.37 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.838 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.433 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 44.9 mtt-85 -96.08 -44.18 7.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.915 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 4.4 tp -100.96 109.35 21.26 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 97.4 p -49.37 -34.39 15.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.512 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -83.27 31.53 0.45 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.086 179.893 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.533 ' O ' HD12 ' A' ' 37' ' ' LEU . 3.9 p90 -50.44 -40.09 49.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.846 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 10.4 pt20 -52.87 -43.21 65.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.904 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.512 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 56.9 mtp85 -50.95 -42.76 60.04 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.874 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.623 ' HA ' HG22 ' A' ' 62' ' ' VAL . 97.1 t -44.35 106.12 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.121 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -130.43 29.44 4.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.838 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 25.4 m -139.92 112.65 7.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.124 -179.89 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.537 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.0 tp -110.54 108.03 17.86 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.929 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 146' ' ' GLU . . . . . 0.406 ' C ' HG13 ' A' ' 147' ' ' ILE . 1.2 pm0 -111.67 153.59 26.18 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.858 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.406 HG13 ' C ' ' A' ' 146' ' ' GLU . 16.9 mt -139.39 112.05 5.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.135 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -121.14 172.35 8.04 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.928 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 110.6 -142.47 16.71 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.452 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -117.49 93.57 4.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.88 0.371 . . . . 0.0 110.847 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.4 p -151.23 152.24 11.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.182 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 27.8 m -113.55 93.59 4.46 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.141 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.477 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 79.2 mt -73.03 141.4 47.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.94 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 50.1 m -125.83 -28.54 3.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.857 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 31.3 t80 -157.56 129.97 7.3 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 90.2 t -140.53 105.52 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.108 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 19.8 tt0 -121.13 140.56 51.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.855 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 158' ' ' ILE . . . . . 0.504 ' CG2' ' NH1' ' A' ' 41' ' ' ARG . 14.9 mt -111.0 94.59 3.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.092 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 5.7 p -59.43 125.61 24.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.844 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 150.9 -167.65 30.55 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.481 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 154.9 67.25 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.705 2.27 . . . . 0.0 112.325 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 18.3 m -119.15 -56.98 2.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.874 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 4.0 t -88.65 96.19 10.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.84 -179.82 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.483 -179.979 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.523 -0.231 . . . . 0.0 112.523 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 37.8 p 43.71 41.75 3.83 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.877 0.37 . . . . 0.0 110.874 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.7 m -63.72 114.47 4.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.836 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -165.67 172.35 41.13 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.496 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 57.6 m -151.66 143.87 23.99 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.836 0.351 . . . . 0.0 110.884 -179.74 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 67.1 p -49.8 -65.96 0.47 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.823 -179.814 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 80.12 114.7 0.28 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.503 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 20.4 p-80 37.33 47.36 0.7 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.743 0.306 . . . . 0.0 110.829 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -106.59 -53.8 2.57 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.939 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 44.8 mm-40 -112.44 108.98 18.31 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.885 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 8.5 mt -40.14 141.87 0.43 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.873 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 74.9 m-20 -122.48 -44.96 2.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.905 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 36.8 p -119.26 -174.42 2.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.862 -179.851 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.434 ' HB2' ' HD2' ' A' ' 15' ' ' PRO . 0.5 OUTLIER -116.0 157.14 45.71 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.645 0.736 . . . . 0.0 110.918 179.952 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.434 ' HD2' ' HB2' ' A' ' 14' ' ' LEU . 53.9 Cg_endo -69.72 171.4 14.48 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.74 2.293 . . . . 0.0 112.327 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.538 HG23 ' HG2' ' A' ' 18' ' ' GLU . 11.3 t -77.23 150.92 35.36 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.162 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 72.9 mtm -88.82 35.57 0.79 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.891 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.538 ' HG2' HG23 ' A' ' 16' ' ' THR . 11.3 pt-20 -60.24 169.08 1.73 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.899 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.409 ' HA3' ' HD2' ' A' ' 20' ' ' PRO . . . 94.15 -147.03 18.43 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.504 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.409 ' HD2' ' HA3' ' A' ' 19' ' ' GLY . 53.7 Cg_endo -69.75 168.38 21.72 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.729 2.286 . . . . 0.0 112.324 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 177.98 5.04 Favored 'Trans proline' 0 C--O 1.233 0.23 0 C-N-CA 122.685 2.257 . . . . 0.0 112.359 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.429 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.9 m -89.75 145.08 25.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.15 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -143.18 137.32 28.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.824 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ASN . . . . . 0.549 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 9.0 m120 45.44 47.94 4.51 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.61 0.719 . . . . 0.0 110.93 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.549 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 54.1 Cg_endo -69.71 139.26 39.96 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.641 2.227 . . . . 0.0 112.375 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -177.62 1.95 Allowed 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.693 2.262 . . . . 0.0 112.304 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.633 HG13 ' HA ' ' A' ' 28' ' ' PRO . 84.2 t -143.7 136.73 13.82 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.592 0.711 . . . . 0.0 111.124 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.633 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.4 Cg_endo -69.71 145.37 79.12 Favored 'Cis proline' 0 C--N 1.341 0.153 0 C-N-CA 122.681 -1.799 . . . . 0.0 112.373 -0.091 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 4.9 t80 -98.34 115.26 28.07 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.937 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -99.44 103.1 14.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.901 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -118.09 102.16 0.95 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.488 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.4 ' HA ' ' HA ' ' A' ' 144' ' ' THR . 0.0 OUTLIER -73.45 128.47 35.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.843 0.354 . . . . 0.0 110.867 -179.886 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.455 ' N ' ' O ' ' A' ' 143' ' ' ASP . 3.3 mt -74.0 150.25 40.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.885 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 10.6 mm100 -105.24 99.67 9.27 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.913 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 124.46 -55.92 0.7 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.488 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.538 ' O ' HG23 ' A' ' 38' ' ' THR . . . 119.47 169.65 14.3 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.515 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' LEU . . . . . 0.516 HD12 ' O ' ' A' ' 139' ' ' PHE . 87.5 mt -61.04 97.91 0.07 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.87 0.367 . . . . 0.0 110.953 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.538 HG23 ' O ' ' A' ' 36' ' ' GLY . 48.4 p -109.5 160.73 15.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.159 179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -58.1 -28.6 64.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.084 179.892 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 3.1 mpt_? -105.96 39.1 1.85 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.863 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 29.5 ttm-85 -117.76 137.62 52.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.872 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 93.6 m -138.41 120.84 16.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.155 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.46 ' N ' HD12 ' A' ' 43' ' ' ILE . 4.7 mp -94.35 134.99 29.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.148 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 93.3 mt -125.24 138.41 54.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.116 179.839 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 42.9 mt -138.92 107.65 3.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.103 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 8.6 mtmm -110.04 111.32 22.62 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.924 179.823 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -142.23 -143.14 4.16 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.478 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' TYR . . . . . 0.57 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 1.1 t80 -170.0 128.66 0.91 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.949 0.404 . . . . 0.0 110.91 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 4.4 t -80.41 115.96 58.55 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.624 0.726 . . . . 0.0 111.143 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.74 155.81 65.04 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.672 2.248 . . . . 0.0 112.369 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 -14.07 35.44 Favored 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.689 2.259 . . . . 0.0 112.33 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 46.8 p -112.24 15.91 20.25 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.107 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -112.06 118.88 4.85 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.491 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 14.1 mtpp -58.09 -62.78 1.57 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.77 0.319 . . . . 0.0 110.859 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 70.1 p -173.71 164.45 4.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.872 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.604 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 5.2 p90 -119.02 -173.27 2.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.879 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.56 138.73 15.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.105 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.598 HD11 ' CE2' ' A' ' 56' ' ' PHE . 3.7 mp -117.61 104.61 16.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.121 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 2.8 m-80 -105.24 147.94 27.51 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.883 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.571 ' CE1' HG22 ' A' ' 58' ' ' ILE . 2.4 m-85 -120.89 101.22 7.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.885 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.43 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 34.5 ttmt -95.78 167.26 11.37 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.901 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.774 HG22 ' HA ' ' A' ' 142' ' ' VAL . 94.2 t -100.27 121.09 50.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.097 179.889 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -57.0 -41.2 92.27 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.481 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 10.8 t -62.18 -72.2 0.13 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.885 0.374 . . . . 0.0 110.89 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.4 t -80.56 -71.04 0.48 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.878 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 128.26 42.48 0.25 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.507 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.549 ' OD1' ' ND2' ' A' ' 88' ' ' ASN . 1.5 m-20 -115.02 144.14 44.08 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.824 0.345 . . . . 0.0 110.856 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.609 HD12 ' HB3' ' A' ' 86' ' ' LEU . 42.8 mt -88.74 122.59 40.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.145 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.536 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -92.82 -34.77 13.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.134 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.708 HD21 HD11 ' A' ' 72' ' ' ILE . 30.3 tp -139.17 130.4 26.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.928 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.473 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.2 OUTLIER -134.81 92.14 2.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.83 179.914 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.708 HD11 HD21 ' A' ' 70' ' ' LEU . 16.0 mt -94.25 137.61 22.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.111 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -141.86 106.17 5.81 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.619 0.723 . . . . 0.0 110.923 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.604 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.8 Cg_endo -69.75 154.87 67.26 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.677 2.251 . . . . 0.0 112.302 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 63.7 mtt-85 -129.78 100.76 5.6 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.854 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -62.25 -43.39 98.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.92 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -66.36 -83.97 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.462 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 4.7 t30 -48.09 -57.09 6.3 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.825 0.345 . . . . 0.0 110.874 -179.881 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 106.57 40.59 1.87 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.542 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 20.7 p -143.94 121.79 11.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.803 0.335 . . . . 0.0 111.176 -179.891 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.429 ' CG1' ' CG2' ' A' ' 72' ' ' ILE . 18.5 t -86.59 111.01 20.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.121 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.519 HG22 ' HD3' ' A' ' 96' ' ' LYS . 61.4 t -82.84 139.81 17.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.097 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -126.94 124.46 39.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.865 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.473 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.5 OUTLIER -135.11 -178.15 4.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.885 -179.909 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 47.5 t -160.16 105.02 1.5 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.867 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.9 HD13 ' NE1' ' A' ' 91' ' ' TRP . 38.1 tp -77.09 116.71 17.98 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.932 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.518 ' N ' ' O ' ' A' ' 90' ' ' SER . 86.4 mt -94.84 162.07 13.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.9 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.549 ' ND2' ' OD1' ' A' ' 67' ' ' ASP . 9.7 m120 -40.88 102.0 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.86 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.49 -1.39 3.11 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.516 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.84 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -125.62 171.59 10.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.886 0.374 . . . . 0.0 110.841 -179.74 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.9 ' NE1' HD13 ' A' ' 86' ' ' LEU . 22.1 m95 -128.74 158.64 38.06 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.877 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -88.75 -96.3 1.02 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.427 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 2.0 m -174.68 164.76 3.66 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.894 0.378 . . . . 0.0 110.841 -179.711 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.404 ' HG3' ' ND2' ' A' ' 84' ' ' ASN . 14.2 mp0 -88.63 118.5 28.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.878 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 72.4 mm-40 -116.09 121.03 40.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.897 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.519 ' HD3' HG22 ' A' ' 82' ' ' VAL . 7.0 mtmp? -125.58 118.67 26.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.86 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -169.66 108.16 0.4 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.873 179.835 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.583 HD11 ' O ' ' A' ' 100' ' ' HIS . 10.5 tt -147.89 151.19 13.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.132 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.476 HG23 ' N ' ' A' ' 100' ' ' HIS . 8.9 t -91.64 -43.92 9.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.168 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' HIS . . . . . 0.583 ' O ' HD11 ' A' ' 98' ' ' ILE . 2.0 p-80 -145.0 127.58 16.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.896 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' ASN . . . . . 0.414 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 38.6 t-20 -104.74 98.49 15.21 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.633 0.73 . . . . 0.0 110.835 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.414 ' HD2' ' HA ' ' A' ' 101' ' ' ASN . 53.8 Cg_endo -69.81 -37.14 9.45 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.674 2.25 . . . . 0.0 112.331 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.547 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 20.9 m-85 -37.96 112.83 0.24 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.892 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -137.92 137.98 9.26 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.468 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 100.21 0.81 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.69 2.26 . . . . 0.0 112.303 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 120.85 0.9 11.84 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.457 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -135.22 148.6 49.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.815 0.34 . . . . 0.0 110.93 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' PHE . . . . . 0.57 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 76.8 m-85 -68.23 171.08 7.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.822 -179.892 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 28.1 p90 -161.26 124.79 3.29 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.903 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -99.45 104.5 16.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.871 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.78 HD13 ' N ' ' A' ' 112' ' ' SER . 0.6 OUTLIER -104.68 136.83 43.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.903 -179.945 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.78 ' N ' HD13 ' A' ' 111' ' ' LEU . 3.6 m -145.03 113.64 6.72 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.828 -179.864 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.5 HG22 ' HD2' ' A' ' 120' ' ' PHE . 4.4 mp -96.56 137.22 24.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.111 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.497 ' O ' ' CD2' ' A' ' 120' ' ' PHE . 18.2 mtp180 -110.11 138.12 46.92 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.852 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 115' ' ' CYS . . . . . 0.465 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 17.7 t -105.13 120.11 40.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.917 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -115.02 -140.55 7.23 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.447 -179.867 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.5 mt -117.53 -38.08 3.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.785 0.326 . . . . 0.0 110.895 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' ASP . . . . . 0.444 ' C ' ' HG3' ' A' ' 119' ' ' ARG . 20.3 t70 -89.79 -45.69 9.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.895 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.444 ' HG3' ' C ' ' A' ' 118' ' ' ASP . 32.3 mtp180 -157.56 -177.07 6.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.879 -179.903 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.5 ' HD2' HG22 ' A' ' 113' ' ' ILE . 12.4 m-85 -103.32 162.09 13.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.876 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 21.4 mtpp -134.26 105.15 6.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.906 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.577 HG13 HD11 ' A' ' 111' ' ' LEU . 57.8 t -90.44 136.48 23.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.1 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -124.85 143.57 50.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.955 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.405 ' HB1' ' HG3' ' A' ' 102' ' ' PRO . . . -131.13 106.93 8.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.039 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 59.1 35.83 23.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.918 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.69 40.55 17.76 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.448 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 18.9 mt-30 -146.84 135.64 22.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.868 0.366 . . . . 0.0 110.919 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 40.8 t-80 -66.77 100.75 0.73 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.89 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 10.2 tp -69.1 -68.58 0.39 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.875 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.482 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 4.4 p90 -164.02 171.3 15.4 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.845 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 24.1 p-10 -110.65 158.79 18.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.906 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.589 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -129.86 104.49 7.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.85 -179.883 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.555 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -62.99 135.71 57.44 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.04 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 29.7 m170 -62.82 108.22 1.14 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.859 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 4.9 mtp-105 -88.37 -48.71 7.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.891 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 8.5 tp -94.06 108.1 19.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.913 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 14.7 t -47.31 -36.0 8.71 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.494 ' HB1' ' HG3' ' A' ' 141' ' ' ARG . . . -83.47 33.32 0.46 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.101 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.516 ' O ' HD12 ' A' ' 37' ' ' LEU . 28.5 p90 -50.05 -36.12 27.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.872 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 6.1 pt20 -53.45 -46.4 69.86 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.904 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.494 ' HG3' ' HB1' ' A' ' 138' ' ' ALA . 31.5 mtt180 -49.7 -41.78 44.22 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.859 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.774 ' HA ' HG22 ' A' ' 62' ' ' VAL . 61.9 t -48.71 100.3 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.138 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.455 ' O ' ' N ' ' A' ' 33' ' ' LEU . 3.9 p30 -124.95 26.24 7.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.906 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 144' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 32' ' ' ARG . 0.8 OUTLIER -132.1 131.72 42.62 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.142 -179.848 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.477 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.8 tp -128.82 104.85 7.86 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.922 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -108.88 151.57 26.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.904 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 15.5 mt -136.82 118.23 18.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.127 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -128.65 173.43 10.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.891 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.41 -151.34 16.91 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.519 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -107.23 92.75 4.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.855 0.36 . . . . 0.0 110.845 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.435 HG22 ' N ' ' A' ' 152' ' ' THR . 7.7 p -151.19 154.88 7.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.094 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 152' ' ' THR . . . . . 0.435 ' N ' HG22 ' A' ' 151' ' ' VAL . 23.3 m -114.83 93.91 4.53 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.151 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.406 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 50.1 mt -79.25 132.83 36.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.911 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 14.7 m -117.42 -40.88 3.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.851 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 59.7 t80 -140.37 130.13 24.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.947 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 89.8 t -140.53 105.15 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.092 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 13.8 tt0 -120.81 121.93 39.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.958 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 14.9 mt -88.96 93.32 4.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.169 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 28.0 t -65.89 142.49 57.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.889 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 171.41 170.58 35.65 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.499 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 137.96 36.66 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.706 2.27 . . . . 0.0 112.314 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 3.7 t -121.59 125.73 47.44 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.858 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 51.8 p 50.22 41.93 24.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.894 -179.801 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.451 179.987 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.262 0 N-CA-C 112.461 -0.256 . . . . 0.0 112.461 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 57.6 m -121.51 138.13 54.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.889 0.376 . . . . 0.0 110.85 -179.741 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 97.9 p -105.64 42.17 1.28 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.829 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -122.03 177.91 16.42 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.481 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 18.3 m -122.7 149.27 44.28 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.818 0.342 . . . . 0.0 110.896 -179.766 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 42.3 m -62.87 -44.15 96.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.841 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.92 112.95 4.54 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.45 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 35.0 m-70 -73.19 83.44 1.34 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.746 0.308 . . . . 0.0 110.804 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 60.5 mm-40 38.64 46.82 1.05 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.87 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -145.83 129.15 16.78 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.946 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.2 mt -113.26 -60.76 1.84 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.94 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 14.7 t30 -81.32 88.6 6.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.912 179.89 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 6.5 p -96.62 -174.71 3.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.873 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.43 ' HB2' ' HD2' ' A' ' 15' ' ' PRO . 0.5 OUTLIER -109.55 157.25 37.96 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.632 0.73 . . . . 0.0 110.898 -179.964 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.43 ' HD2' ' HB2' ' A' ' 14' ' ' LEU . 53.3 Cg_endo -69.73 162.86 40.42 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.702 2.268 . . . . 0.0 112.349 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 9.3 t -73.46 163.4 28.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.162 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 36.6 mtm -96.46 34.87 1.56 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.892 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 15.6 mm-40 -69.74 -175.61 0.91 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.868 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 74.82 -138.5 23.88 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.49 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 162.78 40.76 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.642 2.228 . . . . 0.0 112.368 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -171.06 0.44 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.697 2.265 . . . . 0.0 112.335 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.558 ' CG2' ' N ' ' A' ' 23' ' ' PHE . 1.9 m -93.69 161.17 14.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.163 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.558 ' N ' ' CG2' ' A' ' 22' ' ' THR . 11.9 m-85 -156.01 135.95 12.75 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.908 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ASN . . . . . 0.544 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 72.3 m-20 42.9 48.42 3.7 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.645 0.736 . . . . 0.0 110.927 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.544 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.6 Cg_endo -69.74 137.96 36.75 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.709 2.273 . . . . 0.0 112.301 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -176.11 1.38 Allowed 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.646 2.231 . . . . 0.0 112.334 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.675 HG13 ' HA ' ' A' ' 28' ' ' PRO . 98.4 t -142.97 137.87 15.33 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.668 0.747 . . . . 0.0 111.109 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.675 ' HA ' HG13 ' A' ' 27' ' ' VAL . 54.0 Cg_endo -69.75 145.58 79.8 Favored 'Cis proline' 0 C--O 1.232 0.179 0 C-N-CA 122.71 -1.787 . . . . 0.0 112.342 -0.02 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 13.3 t80 -96.87 121.17 38.44 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.946 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -101.79 101.46 11.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.865 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -98.96 109.94 3.89 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.526 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 4.1 mmm180 -72.87 99.51 2.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.866 0.365 . . . . 0.0 110.877 -179.864 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 27.6 mt -66.94 93.05 0.25 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.905 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.4 HE21 ' HB2' ' A' ' 34' ' ' GLN . 0.1 OUTLIER -67.99 93.69 0.44 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.938 179.924 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.75 -37.77 1.9 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.501 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 91.19 175.07 43.71 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.454 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' LEU . . . . . 0.498 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 78.4 mt -65.4 93.43 0.15 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.859 0.361 . . . . 0.0 110.911 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 44.0 p -105.33 154.56 20.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.136 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -49.84 -30.61 10.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.061 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 2.6 mpt_? -105.13 34.93 2.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.875 -179.873 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 5.0 tpm_? -108.03 135.15 49.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 -179.878 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 85.3 m -136.87 116.35 12.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.193 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.0 mp -91.69 135.81 26.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.176 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 96.8 mt -127.38 132.95 68.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.116 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 50.7 mt -134.9 107.57 8.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.092 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 16.0 mtmt -111.2 111.4 22.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.864 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -142.88 -140.7 3.75 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.544 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' TYR . . . . . 0.568 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.4 OUTLIER -172.08 119.95 0.43 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.937 0.399 . . . . 0.0 110.941 -179.8 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 40.5 t -69.16 117.09 48.7 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.638 0.732 . . . . 0.0 111.15 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 154.98 67.25 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.69 2.26 . . . . 0.0 112.333 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.72 -16.11 37.55 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.693 2.262 . . . . 0.0 112.358 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 70.6 p -110.41 18.6 19.66 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.122 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -113.54 123.23 6.06 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.465 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.403 ' O ' ' SD ' ' A' ' 76' ' ' MET . 22.2 mttt -63.03 -61.67 2.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.778 0.323 . . . . 0.0 110.859 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.8 p -174.03 157.9 3.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.886 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.599 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 12.3 p90 -111.16 -174.64 2.51 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.864 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.998 ' HB2' ' ND2' ' A' ' 73' ' ' ASN . . . -157.05 130.5 8.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.12 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.558 HG22 ' CE1' ' A' ' 60' ' ' PHE . 5.3 mp -112.91 101.78 12.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.11 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -101.2 143.59 31.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.913 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.558 ' CE1' HG22 ' A' ' 58' ' ' ILE . 16.0 m-85 -115.26 97.99 6.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.869 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.459 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 35.8 ttmt -96.79 167.88 10.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.886 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.781 HG22 ' HA ' ' A' ' 142' ' ' VAL . 59.1 t -100.94 123.88 54.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.089 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -59.79 -39.74 95.75 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.455 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 7.6 t -62.93 -70.67 0.19 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.868 0.366 . . . . 0.0 110.867 -179.728 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 60.0 m -82.33 -71.43 0.49 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.863 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 128.32 42.68 0.24 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.451 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.549 ' OD1' ' ND2' ' A' ' 88' ' ' ASN . 3.9 m-20 -112.78 143.7 43.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.81 0.338 . . . . 0.0 110.847 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 66.6 mt -89.1 113.35 25.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.135 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.47 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -81.75 -39.3 24.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.105 179.836 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.738 HD21 HD11 ' A' ' 72' ' ' ILE . 48.1 tp -136.82 134.53 37.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.964 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.495 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.4 OUTLIER -134.89 97.03 3.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.894 179.877 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.738 HD11 HD21 ' A' ' 70' ' ' LEU . 27.0 mt -101.26 133.56 44.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.134 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.998 ' ND2' ' HB2' ' A' ' 57' ' ' ALA . 8.6 t-20 -140.53 106.51 6.5 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.674 0.749 . . . . 0.0 110.905 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.599 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.0 Cg_endo -69.67 154.7 67.76 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.713 2.275 . . . . 0.0 112.347 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 36.7 mtp180 -130.6 94.99 3.76 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.932 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' MET . . . . . 0.403 ' SD ' ' O ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -53.07 -34.34 56.13 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.846 -179.991 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -39.51 -90.93 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.507 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -87.22 -40.89 14.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.88 0.371 . . . . 0.0 110.912 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 120.39 43.8 0.45 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.492 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 49.2 p -119.25 118.14 30.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.828 0.347 . . . . 0.0 111.142 -179.857 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.514 HG22 ' HA ' ' A' ' 74' ' ' PRO . 14.1 t -99.8 110.45 26.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.132 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.558 HG22 ' HD3' ' A' ' 96' ' ' LYS . 32.7 t -82.52 144.78 9.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.13 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.86 124.17 38.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.864 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.495 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.3 m120 -136.32 178.59 6.94 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.914 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.433 ' CB ' ' O ' ' A' ' 69' ' ' ALA . 78.1 p -158.69 105.55 1.83 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.864 -179.84 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.921 HD13 ' NE1' ' A' ' 91' ' ' TRP . 28.3 tp -78.06 117.34 19.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.917 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.532 ' N ' ' O ' ' A' ' 90' ' ' SER . 86.0 mt -95.38 162.54 13.62 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.936 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.549 ' ND2' ' OD1' ' A' ' 67' ' ' ASP . 10.5 m120 -40.97 102.14 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.878 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.35 -2.47 3.14 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.492 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.813 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -124.63 170.54 10.85 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.81 0.338 . . . . 0.0 110.85 -179.72 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.921 ' NE1' HD13 ' A' ' 86' ' ' LEU . 21.8 m95 -128.1 160.73 31.08 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.936 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -89.53 -100.31 1.06 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.487 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 16.4 m -172.4 167.97 5.57 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.819 0.343 . . . . 0.0 110.849 -179.753 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -89.99 121.85 32.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.904 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -122.22 115.33 22.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.88 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.558 ' HD3' HG22 ' A' ' 82' ' ' VAL . 9.9 mtmp? -119.68 119.79 34.73 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.904 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' LYS . . . . . 0.478 ' HE3' ' N ' ' A' ' 98' ' ' ILE . 0.0 OUTLIER -173.9 105.11 0.12 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.866 179.846 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.912 HD11 ' O ' ' A' ' 100' ' ' HIS . 1.9 tt -141.76 149.86 19.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.172 179.862 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.461 HG23 ' CD2' ' A' ' 100' ' ' HIS . 4.7 t -84.45 -41.06 16.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.084 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 100' ' ' HIS . . . . . 0.912 ' O ' HD11 ' A' ' 98' ' ' ILE . 28.9 p80 -153.09 133.62 13.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.835 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' ASN . . . . . 0.407 ' C ' ' OD1' ' A' ' 101' ' ' ASN . 7.2 t-20 -103.47 95.84 7.74 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.597 0.713 . . . . 0.0 110.888 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.447 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.7 Cg_endo -69.77 -41.3 4.38 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.675 2.25 . . . . 0.0 112.368 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.564 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 10.2 m-85 -34.17 104.66 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.881 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -127.85 137.16 9.61 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.695 -0.765 . . . . 0.0 112.451 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 97.25 0.62 Allowed 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.715 2.277 . . . . 0.0 112.325 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 118.39 3.53 14.58 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.513 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 17.5 pt20 -133.73 137.82 45.44 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.819 0.343 . . . . 0.0 110.906 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' PHE . . . . . 0.568 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 79.7 m-85 -61.34 166.35 3.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.882 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 17.9 p90 -158.45 130.58 6.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.886 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -103.68 104.62 14.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.877 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' LEU . . . . . 0.775 HD13 ' N ' ' A' ' 112' ' ' SER . 0.7 OUTLIER -105.09 136.5 44.46 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.948 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 112' ' ' SER . . . . . 0.775 ' N ' HD13 ' A' ' 111' ' ' LEU . 3.8 m -145.15 113.49 6.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.864 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.601 HG23 HG22 ' A' ' 122' ' ' VAL . 4.0 mp -95.47 140.05 17.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.142 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 15.6 mtp85 -112.78 137.63 50.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.899 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' CYS . . . . . 0.582 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 2.9 t -110.03 114.47 28.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.874 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -113.77 -136.03 6.29 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.496 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 12.2 mt -121.52 -39.06 2.69 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.829 0.347 . . . . 0.0 110.924 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 23.2 p-10 -85.63 -37.26 19.69 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.88 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.8 ptp180 -173.66 172.62 3.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.875 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.582 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.7 m-30 -93.32 155.06 17.63 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.887 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 26.6 mtpt -128.99 102.12 6.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.898 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.601 HG22 HG23 ' A' ' 113' ' ' ILE . 51.5 t -89.27 136.77 22.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.105 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 57.9 m-85 -120.29 152.95 37.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.958 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' ALA . . . . . 0.604 ' HB2' HD13 ' A' ' 129' ' ' LEU . . . -136.55 107.12 6.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.097 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 53.56 35.61 21.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.929 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 84.09 29.26 31.67 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.477 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 20.0 mm-40 -140.77 119.53 12.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.819 0.342 . . . . 0.0 110.931 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 35.5 t-80 -52.06 103.85 0.07 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.846 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.604 HD13 ' HB2' ' A' ' 124' ' ' ALA . 10.6 tp -67.12 -67.71 0.43 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.923 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.499 ' HZ ' HD13 ' A' ' 72' ' ' ILE . 6.0 p90 -163.67 177.02 9.06 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.86 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 41.1 p30 -118.02 149.92 40.16 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.851 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.677 ' CD1' HD13 ' A' ' 70' ' ' LEU . 0.2 OUTLIER -117.17 107.02 13.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.872 -179.937 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.525 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -62.41 133.56 55.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.099 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 20.1 m170 -60.03 110.84 1.29 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.811 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.4 ' CD ' ' OG ' ' A' ' 85' ' ' SER . 10.0 mtt-85 -93.93 -51.5 4.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.878 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 6.8 tp -96.06 108.39 20.8 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.906 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 27.1 t -49.44 -33.33 13.87 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.862 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.468 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.45 25.76 0.6 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.073 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.406 ' CG ' ' N ' ' A' ' 140' ' ' GLN . 19.3 p90 -45.49 -41.78 9.96 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.895 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 140' ' ' GLN . . . . . 0.406 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 5.7 pt20 -49.75 -41.0 42.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.885 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.468 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 57.0 mtp180 -55.48 -39.74 70.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.874 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.781 ' HA ' HG22 ' A' ' 62' ' ' VAL . 85.6 t -48.11 106.8 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.14 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -131.81 34.08 3.91 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.867 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 16.2 m -141.38 115.32 9.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.167 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.52 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.2 tp -113.66 107.96 16.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.91 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 -113.0 150.7 31.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.896 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.423 HG23 HG13 ' A' ' 58' ' ' ILE . 17.0 mt -138.29 106.94 3.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.115 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -115.42 173.33 6.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.915 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.57 -146.37 16.22 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.469 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 46.7 m-20 -112.27 92.56 4.07 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.852 0.358 . . . . 0.0 110.843 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 5.8 p -151.28 138.06 12.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.124 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 33.7 m -99.62 93.92 6.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.134 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.462 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 68.8 mt -74.88 137.85 42.06 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.903 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 20.5 m -119.76 -39.28 2.86 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.878 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 155' ' ' TYR . . . . . 0.494 ' CE1' ' HB2' ' A' ' 157' ' ' GLN . 43.6 t80 -148.07 135.45 20.55 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.938 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 70.8 t -140.18 109.42 3.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.141 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 157' ' ' GLN . . . . . 0.494 ' HB2' ' CE1' ' A' ' 155' ' ' TYR . 10.8 tt0 -121.47 136.57 54.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.902 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 18.6 mt -103.69 91.45 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.065 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 65.6 m -72.56 150.89 42.75 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.88 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 170.77 -156.95 27.66 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.526 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.81 160.22 50.49 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.674 2.249 . . . . 0.0 112.361 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 35.0 t -116.85 84.25 2.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.87 -179.819 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 2.5 t -75.28 126.89 31.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.869 -179.8 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.481 -179.952 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 2.3 t . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.836 0.35 . . . . 0.0 111.147 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -129.61 120.78 25.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . 0.48 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 12.4 m120 61.78 52.18 2.19 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.616 0.722 . . . . 0.0 110.907 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.48 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.2 Cg_endo -69.81 138.67 38.23 Favored 'Trans proline' 0 N--CA 1.466 -0.13 0 C-N-CA 122.705 2.27 . . . . 0.0 112.328 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 178.7 4.3 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.633 2.222 . . . . 0.0 112.357 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.694 HG13 ' HA ' ' A' ' 28' ' ' PRO . 95.4 t -138.09 138.24 22.83 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.658 0.742 . . . . 0.0 111.115 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.694 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.7 Cg_endo -69.7 143.61 74.22 Favored 'Cis proline' 0 C--N 1.342 0.193 0 C-N-CA 122.741 -1.774 . . . . 0.0 112.345 -0.083 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . 0.473 ' CE1' HG11 ' A' ' 156' ' ' VAL . 2.2 t80 -95.82 116.68 29.27 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.886 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 72.3 m-85 -100.15 105.31 16.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.844 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -118.21 103.33 1.03 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.507 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.422 ' C ' ' HD2' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -72.44 135.4 45.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.84 0.352 . . . . 0.0 110.876 -179.837 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.894 HD23 HG12 ' A' ' 158' ' ' ILE . 4.9 mt -82.73 119.12 23.92 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.928 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 25.2 mt-30 -74.09 94.97 2.48 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.887 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 124.31 -55.81 0.7 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.483 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.443 ' O ' HG23 ' A' ' 38' ' ' THR . . . 120.37 176.3 15.69 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.51 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . 0.744 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 82.5 mt -62.6 101.37 0.24 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.936 0.398 . . . . 0.0 110.896 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.502 ' O ' ' N ' ' A' ' 41' ' ' ARG . 44.9 p -120.77 137.89 54.29 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.202 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.551 ' HB2' ' HG ' ' A' ' 117' ' ' LEU . . . -41.97 -23.39 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.119 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.444 ' N ' ' O ' ' A' ' 38' ' ' THR . 20.9 mmt180 -104.62 34.13 3.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.866 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.502 ' N ' ' O ' ' A' ' 38' ' ' THR . 4.6 ttt85 -121.05 139.86 52.74 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.931 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 85.9 m -137.66 117.55 13.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.154 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.1 mp -90.68 133.98 30.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.146 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 94.7 mt -127.55 134.33 65.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.123 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 48.5 mt -135.57 107.63 7.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.142 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.5 mtmt -109.35 108.19 18.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.917 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.52 -145.72 4.68 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.49 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . 0.564 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.7 OUTLIER -167.55 129.13 1.53 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.9 0.381 . . . . 0.0 110.912 -179.803 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 13.7 t -77.34 115.5 49.72 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.619 0.723 . . . . 0.0 111.116 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 155.54 65.7 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.681 2.254 . . . . 0.0 112.354 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -15.69 37.11 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.683 2.255 . . . . 0.0 112.344 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 52.8 p -109.65 14.2 23.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.13 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -111.22 122.82 6.25 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.523 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 17.5 mtpt -63.96 -60.21 3.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.798 0.332 . . . . 0.0 110.867 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.5 p -174.21 158.75 3.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.89 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.565 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 2.4 p90 -112.57 -173.72 2.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.851 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.924 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -155.56 135.57 12.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.157 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.454 HG22 ' CE1' ' A' ' 60' ' ' PHE . 3.6 mp -115.85 103.7 15.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.132 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.3 m-80 -104.41 143.13 33.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.904 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.726 ' CE2' HD13 ' A' ' 145' ' ' LEU . 6.7 m-85 -115.66 101.36 8.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.875 -179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.421 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 30.3 ttmt -95.33 169.08 10.32 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.89 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.61 HG22 ' HA ' ' A' ' 142' ' ' VAL . 35.0 t -100.24 123.73 53.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.136 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -60.59 -34.25 85.27 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.498 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.9 t -68.5 -71.54 0.21 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.926 0.393 . . . . 0.0 110.87 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 3.3 t -83.7 -71.34 0.51 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.856 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 131.6 40.82 0.22 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.5 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.598 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.9 m-20 -110.87 143.11 41.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.776 0.322 . . . . 0.0 110.853 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.629 HD12 ' HB3' ' A' ' 86' ' ' LEU . 39.2 mt -88.9 119.2 35.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.113 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.66 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -91.57 -33.12 15.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.109 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.616 HD22 ' CD2' ' A' ' 132' ' ' PHE . 52.5 tp -138.46 130.0 27.66 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.939 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.489 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.2 OUTLIER -134.82 92.71 2.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.844 179.891 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.579 HD11 HD21 ' A' ' 70' ' ' LEU . 29.0 mt -96.25 134.98 31.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.146 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.924 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -140.33 107.76 6.7 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.596 0.712 . . . . 0.0 110.863 179.946 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.767 ' HA ' HG22 ' A' ' 81' ' ' VAL . 53.8 Cg_endo -69.79 154.87 67.1 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.665 2.243 . . . . 0.0 112.338 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 45.3 mtp85 -130.4 98.0 4.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.909 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.878 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 32.4 p . . . . . 0 C--O 1.232 0.168 0 CA-C-O 120.802 0.334 . . . . 0.0 111.122 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.767 HG22 ' HA ' ' A' ' 74' ' ' PRO . 36.0 t -91.44 108.54 20.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.136 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.566 HG22 ' HD3' ' A' ' 96' ' ' LYS . 48.7 t -79.93 146.69 7.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.11 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -128.87 130.21 46.57 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.845 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.489 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.9 OUTLIER -142.45 179.62 6.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.928 -179.971 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 89.5 p -157.99 107.25 2.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.901 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.892 HD13 ' NE1' ' A' ' 91' ' ' TRP . 27.6 tp -76.98 117.86 18.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.926 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.505 ' N ' ' O ' ' A' ' 90' ' ' SER . 82.7 mt -95.1 162.3 13.77 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.927 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.412 ' OD1' ' OD1' ' A' ' 67' ' ' ASP . 11.7 m-80 -41.1 102.14 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.855 179.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.89 -1.49 3.37 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.51 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.828 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -125.63 172.49 9.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.839 0.352 . . . . 0.0 110.84 -179.722 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.892 ' NE1' HD13 ' A' ' 86' ' ' LEU . 25.0 m95 -129.4 160.67 32.37 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.932 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -90.34 -104.18 1.21 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.507 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 39.2 m -165.56 171.92 12.6 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.834 0.35 . . . . 0.0 110.852 -179.755 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -95.54 120.8 36.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.92 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 60.3 mt-10 -120.07 122.21 40.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.845 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.566 ' HD3' HG22 ' A' ' 82' ' ' VAL . 7.6 mtmp? -126.29 122.23 34.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.873 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 10.4 tptp -171.89 105.87 0.2 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.895 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.903 HD11 ' O ' ' A' ' 100' ' ' HIS . 2.0 tt -146.59 149.9 15.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.129 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.427 HG23 ' N ' ' A' ' 100' ' ' HIS . 9.2 t -91.65 -41.39 10.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.149 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . 0.903 ' O ' HD11 ' A' ' 98' ' ' ILE . 2.6 p-80 -144.06 131.64 21.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.834 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . 0.411 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 24.7 t30 -109.21 96.52 21.89 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.632 0.73 . . . . 0.0 110.881 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.44 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.8 Cg_endo -69.78 -41.27 4.39 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.648 2.232 . . . . 0.0 112.305 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.569 ' CZ ' HD21 ' A' ' 129' ' ' LEU . 6.2 m-85 -35.33 108.65 0.07 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.898 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -137.14 138.77 10.02 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.48 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 103.12 1.11 Allowed 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.689 2.26 . . . . 0.0 112.38 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 119.95 -2.32 13.24 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.541 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.3 pt20 -134.03 147.62 50.97 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.857 0.361 . . . . 0.0 110.902 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' PHE . . . . . 0.564 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 29.6 m-85 -67.21 172.82 4.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.877 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.422 ' O ' ' CG ' ' A' ' 109' ' ' PHE . 14.4 p90 -161.33 124.25 3.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.867 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -99.08 105.09 17.16 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.837 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.757 HD13 ' N ' ' A' ' 112' ' ' SER . 0.7 OUTLIER -105.18 136.89 43.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.92 -179.98 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.757 ' N ' HD13 ' A' ' 111' ' ' LEU . 3.4 m -144.8 113.63 6.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.847 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.445 ' CD1' HD12 ' A' ' 111' ' ' LEU . 4.7 mp -96.68 135.43 30.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.147 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 40.0 mtt180 -108.51 126.26 52.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.886 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . 0.534 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 11.7 t -93.06 120.42 33.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.902 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -122.31 -159.8 10.73 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.511 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.551 ' HG ' ' HB2' ' A' ' 39' ' ' ALA . 7.8 mt -101.83 -42.3 6.2 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.838 0.351 . . . . 0.0 110.943 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -82.19 -37.1 26.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.883 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.1 ptt180 -173.5 -178.2 1.61 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.889 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.744 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 3.2 m-30 -102.48 158.52 16.16 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.892 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 24.2 mtpt -132.13 104.86 7.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.921 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.486 HG13 HD11 ' A' ' 111' ' ' LEU . 60.6 t -90.98 133.58 32.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.125 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 74.7 m-85 -121.69 146.96 46.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.938 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.526 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -133.27 107.98 8.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.133 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 55.04 39.5 31.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.885 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.12 36.73 34.43 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.451 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 22.6 mt-30 -143.93 123.65 13.36 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.848 0.356 . . . . 0.0 110.898 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 32.6 t-80 -57.79 95.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.863 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.569 HD21 ' CZ ' ' A' ' 103' ' ' PHE . 9.4 tp -60.88 -68.75 0.28 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.929 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.473 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 4.5 p90 -164.96 175.87 9.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.903 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -116.32 155.74 27.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.894 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.616 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.2 OUTLIER -122.38 104.58 9.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.847 -179.874 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.531 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -60.6 134.8 57.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.077 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' HIS . . . . . 0.437 ' CD2' ' O ' ' A' ' 117' ' ' LEU . 18.4 m-70 -62.4 98.8 0.12 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.894 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 17.6 mtt-85 -81.47 -47.59 12.97 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.842 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . 0.453 HD13 HD22 ' A' ' 87' ' ' LEU . 7.8 tp -98.72 107.8 20.33 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.924 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 15.0 m -49.35 -33.19 12.9 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.839 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.495 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -83.3 27.67 0.57 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.122 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.468 ' O ' HD12 ' A' ' 37' ' ' LEU . 17.6 p90 -47.21 -44.29 22.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.892 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' GLN . . . . . 0.44 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 9.2 pt20 -46.24 -40.63 11.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.931 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.577 ' O ' HG13 ' A' ' 62' ' ' VAL . 16.1 mtp180 -54.33 -41.71 69.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.875 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.66 HG21 ' CB ' ' A' ' 69' ' ' ALA . 88.7 t -50.3 104.72 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.167 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -127.38 28.83 5.64 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.877 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.3 m -137.67 131.96 32.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.168 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.726 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.4 tp -128.47 109.09 11.09 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.944 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 -112.3 152.31 28.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.901 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 19.8 mt -137.47 113.54 11.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.135 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -123.06 174.19 7.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.954 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.4 -144.5 15.99 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.512 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -114.71 92.1 3.84 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.871 0.367 . . . . 0.0 110.845 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.448 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 5.1 p -151.04 142.77 16.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.134 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 25.8 m -102.37 93.25 5.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.163 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.464 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 95.9 mt -74.31 136.73 42.58 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.899 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 5.1 m -117.18 -39.36 3.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.871 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . 0.426 ' C ' ' CD1' ' A' ' 155' ' ' TYR . 7.4 t80 -147.35 130.93 16.81 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.917 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.473 HG11 ' CE1' ' A' ' 29' ' ' TYR . 65.8 t -140.77 124.48 17.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.138 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 12.8 tt0 -148.85 132.95 17.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.908 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' ILE . . . . . 0.894 HG12 HD23 ' A' ' 33' ' ' LEU . 5.1 mp . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.152 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.468 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.6 m . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.857 0.36 . . . . 0.0 111.119 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.468 ' CD1' ' O ' ' A' ' 22' ' ' THR . 9.8 m-85 -150.71 137.15 18.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.887 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . 0.601 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 52.8 m-80 51.37 44.48 2.16 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.663 0.744 . . . . 0.0 110.919 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.601 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.78 133.82 26.45 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.632 2.221 . . . . 0.0 112.316 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.85 179.36 3.8 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.673 2.249 . . . . 0.0 112.361 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.677 HG13 ' HA ' ' A' ' 28' ' ' PRO . 86.6 t -138.79 137.68 20.27 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.606 0.717 . . . . 0.0 111.134 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.677 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.2 Cg_endo -69.77 144.21 76.03 Favored 'Cis proline' 0 C--O 1.231 0.161 0 C-N-CA 122.668 -1.805 . . . . 0.0 112.338 -0.074 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 2.9 t80 -94.13 120.15 33.98 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.927 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -105.12 102.14 11.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.899 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -109.7 109.43 2.71 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.471 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 6.4 mmt85 -73.38 108.93 6.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.875 0.369 . . . . 0.0 110.873 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.429 ' HB3' ' NH1' ' A' ' 41' ' ' ARG . 5.3 mt -70.58 92.76 0.86 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.918 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 14.9 mm-40 -64.73 105.36 0.97 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.896 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 130.59 -46.89 1.05 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.477 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.661 ' O ' HG23 ' A' ' 38' ' ' THR . . . 98.67 161.36 29.98 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.51 -179.909 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . 0.646 HD12 ' O ' ' A' ' 139' ' ' PHE . 95.9 mt -54.81 107.14 0.26 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.903 0.383 . . . . 0.0 110.872 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.661 HG23 ' O ' ' A' ' 36' ' ' GLY . 73.0 p -118.71 149.04 42.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.128 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -49.8 -23.62 1.95 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.085 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.412 ' HB3' ' NH1' ' A' ' 40' ' ' ARG . 0.0 OUTLIER -108.81 34.19 3.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.882 -179.921 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.429 ' NH1' ' HB3' ' A' ' 33' ' ' LEU . 13.1 ttm180 -113.81 139.28 49.27 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.859 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 74.2 m -137.52 119.83 15.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.134 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 mp -91.92 136.27 24.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.109 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 97.0 mt -131.25 133.55 62.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.107 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 34.5 mt -136.53 111.52 10.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.143 179.861 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 16.1 mtmt -112.68 109.0 18.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.923 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -138.1 -142.95 4.42 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.44 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . 0.435 ' O ' ' CD1' ' A' ' 48' ' ' TYR . 0.5 OUTLIER -170.2 117.04 0.54 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.914 0.388 . . . . 0.0 110.939 -179.769 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 15.2 t -70.19 115.8 38.05 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.644 0.735 . . . . 0.0 111.139 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 157.52 60.12 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.678 2.252 . . . . 0.0 112.356 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -15.42 37.17 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.664 2.243 . . . . 0.0 112.34 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 21.5 p -109.71 17.11 21.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.18 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -110.69 118.99 5.13 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.511 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.3 mtpt -61.31 -60.63 3.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.778 0.323 . . . . 0.0 110.912 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 13.2 p -173.64 158.44 3.35 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.869 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.607 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 6.1 p90 -115.88 -174.68 2.58 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.864 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.937 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -154.81 145.3 22.17 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.126 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.526 HG22 ' CE1' ' A' ' 60' ' ' PHE . 3.2 mp -123.52 98.77 5.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.115 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.7 m-80 -98.86 141.98 30.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.914 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.526 ' CE1' HG22 ' A' ' 58' ' ' ILE . 10.5 m-85 -117.16 99.03 6.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.893 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.441 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 31.3 ttmt -96.62 169.24 10.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.878 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.658 HG22 ' HA ' ' A' ' 142' ' ' VAL . 38.7 t -101.44 119.59 49.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.129 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -55.22 -36.79 62.82 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.502 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.5 m -66.47 -72.86 0.15 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.889 0.376 . . . . 0.0 110.904 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 19.7 m -79.34 -74.68 0.28 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.868 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 132.92 38.58 0.23 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.523 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.414 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.5 m-20 -111.36 143.61 41.89 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.795 0.331 . . . . 0.0 110.846 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.572 HD12 ' HB3' ' A' ' 86' ' ' LEU . 47.4 mt -89.77 117.71 33.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.123 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.41 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -89.25 -31.07 18.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.122 179.783 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.663 HD22 ' CD2' ' A' ' 132' ' ' PHE . 53.2 tp -140.84 130.25 23.83 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.927 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.452 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.3 OUTLIER -134.91 92.55 2.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.884 179.82 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.599 HD11 HD21 ' A' ' 70' ' ' LEU . 26.3 mt -96.36 133.81 36.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.149 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.937 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -141.24 106.78 6.13 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.619 0.723 . . . . 0.0 110.853 179.978 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.607 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.8 Cg_endo -69.78 155.28 66.3 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.647 2.231 . . . . 0.0 112.364 179.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 68.3 mtp180 -130.55 99.35 4.95 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.899 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 16.9 p . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.795 0.331 . . . . 0.0 111.133 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.402 HG22 ' HA ' ' A' ' 74' ' ' PRO . 21.3 t -99.67 111.72 30.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.123 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.545 HG22 ' HD3' ' A' ' 96' ' ' LYS . 92.5 t -79.36 142.06 14.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.176 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . 0.557 ' NH1' ' CD2' ' A' ' 130' ' ' PHE . 0.3 OUTLIER -126.19 125.52 42.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.885 -179.948 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.452 ' O ' ' N ' ' A' ' 71' ' ' HIS . 2.3 m120 -137.39 177.82 7.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.883 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 28.9 t -158.92 105.08 1.76 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.814 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.938 HD12 ' O ' ' A' ' 90' ' ' SER . 25.6 tp -77.36 119.58 21.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.918 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.513 ' N ' ' O ' ' A' ' 90' ' ' SER . 77.7 mt -96.98 161.47 13.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.893 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.545 HD22 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.28 101.67 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.868 179.938 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.76 -7.12 0.73 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.488 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.938 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -118.13 170.74 8.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.885 0.374 . . . . 0.0 110.855 -179.719 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.828 ' NE1' HD13 ' A' ' 86' ' ' LEU . 21.4 m95 -128.31 160.89 30.75 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.959 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -94.16 -116.85 2.78 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.454 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 33.8 m -152.14 178.61 9.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.79 0.329 . . . . 0.0 110.898 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.424 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 11.9 mt-10 -103.73 126.05 50.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.891 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -123.36 105.37 9.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.893 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.545 ' HD3' HG22 ' A' ' 82' ' ' VAL . 18.2 mtmm -111.69 122.46 47.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.919 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -171.54 105.95 0.22 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.905 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.801 HD11 ' O ' ' A' ' 100' ' ' HIS . 3.0 tt -145.13 152.85 14.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.125 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.44 HG23 ' N ' ' A' ' 100' ' ' HIS . 9.5 t -96.39 -41.9 8.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.141 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . 0.801 ' O ' HD11 ' A' ' 98' ' ' ILE . 4.4 p-80 -142.89 128.57 19.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.852 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 -103.29 95.55 7.09 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.652 0.739 . . . . 0.0 110.882 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.444 ' HD2' HD11 ' A' ' 129' ' ' LEU . 53.2 Cg_endo -69.75 -40.41 5.38 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.702 2.268 . . . . 0.0 112.318 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -41.01 108.41 0.09 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.867 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -131.49 139.64 11.11 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.491 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 100.62 0.84 Allowed 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.714 2.276 . . . . 0.0 112.328 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 117.89 6.63 12.45 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.472 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 4.7 pt20 -137.17 143.92 42.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.78 0.324 . . . . 0.0 110.926 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -66.14 168.76 7.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.915 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 30.1 p90 -161.28 144.74 12.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.85 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -118.31 101.73 8.41 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.87 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.659 HD13 ' N ' ' A' ' 112' ' ' SER . 1.1 tm? -99.24 137.18 38.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.923 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.659 ' N ' HD13 ' A' ' 111' ' ' LEU . 6.2 m -144.98 111.27 5.61 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.864 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.64 HD11 HD12 ' A' ' 111' ' ' LEU . 4.8 mp -94.73 135.57 28.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.081 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -109.61 130.59 55.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.846 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . 0.581 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 11.9 t -101.19 116.02 31.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.876 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -115.26 -143.9 8.17 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.517 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.7 mt -116.02 -37.47 3.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.829 0.347 . . . . 0.0 110.88 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -87.66 -37.5 16.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.873 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.9 ptt180 -173.85 170.38 3.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.874 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.581 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.1 m-30 -90.71 158.23 17.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.85 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 30.5 mtpt -132.33 99.39 4.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.886 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 97.6 t -86.73 139.18 17.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.095 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 84.3 m-85 -129.4 148.96 51.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.947 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -137.12 109.77 7.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.096 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 57.97 34.66 24.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.849 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.9 40.5 21.23 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.494 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -144.84 134.86 23.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.81 0.338 . . . . 0.0 110.875 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 32.2 t-80 -68.06 101.31 1.12 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.865 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.444 HD11 ' HD2' ' A' ' 102' ' ' PRO . 8.0 tp -71.7 -67.39 0.53 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.898 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.557 ' CD2' ' NH1' ' A' ' 83' ' ' ARG . 5.1 p90 -166.89 173.44 9.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.886 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -116.12 155.69 27.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.663 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -120.15 104.47 10.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.896 -179.883 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.574 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -59.62 136.64 58.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.101 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 55.4 m-70 -63.52 106.16 0.89 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.879 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 23.6 mtt-85 -91.73 -50.2 5.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.861 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 6.1 tp -95.43 109.02 21.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.923 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 41.3 t -51.67 -33.4 33.7 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.812 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.501 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.67 23.83 0.77 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.097 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.646 ' O ' HD12 ' A' ' 37' ' ' LEU . 32.0 p90 -45.57 -37.87 5.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.854 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -52.73 -46.97 67.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.918 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.501 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 70.6 mtp85 -48.63 -43.38 36.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.87 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.658 ' HA ' HG22 ' A' ' 62' ' ' VAL . 85.5 t -41.24 106.93 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.171 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -131.86 31.68 4.18 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.861 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 18.9 m -142.03 114.94 8.66 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.134 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.517 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.9 tp -111.89 108.46 17.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.917 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' GLU . . . . . 0.433 ' C ' HG13 ' A' ' 147' ' ' ILE . 3.6 pt-20 -111.77 155.29 23.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.91 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.442 HG12 HG23 ' A' ' 58' ' ' ILE . 35.2 mt -143.45 116.4 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.105 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -124.79 170.27 11.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.94 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.79 -153.47 16.8 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.496 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -104.17 93.28 4.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.808 0.337 . . . . 0.0 110.879 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 8.8 p -151.3 143.59 16.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.126 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 12.0 m -105.19 94.39 5.21 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.107 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 58.0 mt -78.51 134.4 37.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.88 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 58.6 m -119.25 -39.85 2.87 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.851 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 39.7 t80 -144.6 131.14 19.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.92 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 93.4 t -140.54 106.57 2.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.132 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 15.2 tt0 -118.42 138.97 52.1 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.922 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 18.4 mt . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.113 179.982 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.457 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.5 m . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.858 0.361 . . . . 0.0 111.145 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.435 ' C ' ' HD3' ' A' ' 25' ' ' PRO . 5.6 m-85 -142.95 133.63 25.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.893 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . 0.585 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.6 m120 48.42 45.6 2.94 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.591 0.71 . . . . 0.0 110.867 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.585 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.3 Cg_endo -69.79 137.33 35.11 Favored 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 122.702 2.268 . . . . 0.0 112.34 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 -176.93 1.63 Allowed 'Trans proline' 0 N--CA 1.465 -0.164 0 C-N-CA 122.732 2.288 . . . . 0.0 112.357 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.669 HG13 ' HA ' ' A' ' 28' ' ' PRO . 88.1 t -142.28 137.64 15.84 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.616 0.722 . . . . 0.0 111.125 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.669 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.3 Cg_endo -69.81 143.88 75.21 Favored 'Cis proline' 0 C--N 1.341 0.179 0 C-N-CA 122.671 -1.804 . . . . 0.0 112.318 0.005 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.9 t80 -95.61 120.72 36.35 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.904 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -102.94 104.01 14.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.866 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -115.92 109.55 2.04 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.524 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 3.2 mmt85 -74.08 118.47 17.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.856 0.36 . . . . 0.0 110.84 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.544 HD23 HD13 ' A' ' 158' ' ' ILE . 8.0 mt -76.8 92.13 3.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.935 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 23.0 mm-40 -65.4 102.86 0.73 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.961 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.23 -37.96 1.89 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.453 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.86 ' O ' HG23 ' A' ' 38' ' ' THR . . . 88.28 156.19 30.44 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.469 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . 0.621 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 86.8 mt -52.43 100.0 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.905 0.383 . . . . 0.0 110.895 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.86 HG23 ' O ' ' A' ' 36' ' ' GLY . 29.7 p -116.73 153.84 31.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.176 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.462 ' HB2' ' CD2' ' A' ' 117' ' ' LEU . . . -51.34 -31.51 22.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.127 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.43 ' HA ' ' NE ' ' A' ' 40' ' ' ARG . 10.8 mmp_? -100.14 33.7 2.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.852 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 28.2 ttm-85 -118.73 137.99 52.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.867 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 96.6 m -139.37 118.22 12.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.135 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.479 ' N ' HD12 ' A' ' 43' ' ' ILE . 4.6 mp -91.58 136.28 24.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.099 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 89.0 mt -128.87 133.8 65.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.138 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.8 mt -134.26 107.61 9.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.113 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.3 mtmt -108.24 103.9 13.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -134.21 -148.35 5.78 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.517 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -169.17 127.56 1.0 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.98 0.419 . . . . 0.0 110.894 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 16.0 t -75.91 117.65 65.37 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.635 0.731 . . . . 0.0 111.158 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 154.01 68.35 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.687 2.258 . . . . 0.0 112.359 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -20.71 34.37 Favored 'Trans proline' 0 C--O 1.231 0.175 0 C-N-CA 122.674 2.249 . . . . 0.0 112.343 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 41.1 p -99.63 9.41 43.18 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.153 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -99.08 -172.16 31.28 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.491 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 4.1 mmmm -133.75 -64.56 0.7 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.787 0.327 . . . . 0.0 110.895 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 2.6 p -165.75 147.07 7.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.816 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.597 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 13.0 p90 -110.53 -175.35 2.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.898 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.702 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -154.98 143.58 20.59 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.123 179.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.566 HG22 ' CE1' ' A' ' 60' ' ' PHE . 3.2 mp -121.85 102.14 11.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.107 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.2 m-80 -102.06 143.57 31.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.888 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.566 ' CE1' HG22 ' A' ' 58' ' ' ILE . 5.4 m-85 -118.76 98.56 6.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.937 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.447 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 32.8 ttmt -96.93 169.25 9.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.892 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.624 HG23 ' O ' ' A' ' 67' ' ' ASP . 19.4 t -100.64 122.4 52.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.131 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -60.04 -34.24 82.75 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.509 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 10.1 t -67.15 -71.81 0.19 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.872 0.368 . . . . 0.0 110.89 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.4 t -81.86 -69.19 0.63 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.836 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 128.97 36.53 0.43 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.519 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.624 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.6 m-20 -110.22 140.99 43.78 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.853 0.359 . . . . 0.0 110.856 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.615 HD12 ' HB3' ' A' ' 86' ' ' LEU . 58.9 mt -85.86 122.0 37.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.133 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.631 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -93.13 -30.01 15.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.098 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.73 HD22 ' CD2' ' A' ' 132' ' ' PHE . 46.3 tp -144.2 130.1 19.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.946 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.472 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.3 OUTLIER -134.93 92.58 2.9 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.862 179.899 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.488 HD11 HD21 ' A' ' 70' ' ' LEU . 41.4 mt -94.55 134.69 31.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.173 179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.702 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -139.02 106.24 7.36 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.612 0.72 . . . . 0.0 110.879 179.959 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.597 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.7 Cg_endo -69.73 155.25 66.52 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.683 2.255 . . . . 0.0 112.329 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 42.1 mtp180 -131.56 99.41 4.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.865 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.858 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 16.9 p . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.887 0.375 . . . . 0.0 111.108 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.575 HG22 ' HA ' ' A' ' 74' ' ' PRO . 39.5 t -101.76 107.24 21.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.125 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.673 HG22 ' HD3' ' A' ' 96' ' ' LYS . 24.6 t -78.29 138.52 20.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.171 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . 0.628 HH12 ' N ' ' A' ' 97' ' ' LYS . 2.8 mpp_? -126.94 125.72 42.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.885 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.472 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.3 m120 -132.86 -176.23 4.04 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.854 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 30.3 t -159.31 105.18 1.68 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.864 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.93 HD12 ' O ' ' A' ' 90' ' ' SER . 25.8 tp -77.06 117.43 18.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.861 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 90' ' ' SER . 80.7 mt -95.28 161.63 14.01 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.913 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.555 HD22 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.42 101.59 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.863 179.98 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.83 -6.49 0.91 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.504 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.93 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -119.21 172.47 7.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.913 0.387 . . . . 0.0 110.833 -179.773 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.865 ' NE1' HD13 ' A' ' 86' ' ' LEU . 22.4 m95 -129.49 160.69 32.39 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.908 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -89.59 -92.5 1.17 Allowed Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.457 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 2.3 m -174.74 173.78 2.74 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.905 0.383 . . . . 0.0 110.838 -179.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.449 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 3.8 mt-10 -104.97 117.64 34.53 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.89 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 50.7 mm-40 -122.49 133.88 54.58 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.895 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.673 ' HD3' HG22 ' A' ' 82' ' ' VAL . 43.8 mtmt -131.1 128.13 39.54 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.91 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.628 ' N ' HH12 ' A' ' 83' ' ' ARG . 12.7 tmtt? -175.79 108.37 0.09 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.946 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.922 HD11 ' O ' ' A' ' 100' ' ' HIS . 4.1 tt -147.67 144.04 19.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.109 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.6 t -79.19 -39.58 32.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.141 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . 0.922 ' O ' HD11 ' A' ' 98' ' ' ILE . 3.1 p-80 -154.35 136.91 15.1 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.883 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . 0.617 ' CG ' HD13 ' A' ' 98' ' ' ILE . 8.1 m120 -105.11 95.78 9.98 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.573 0.702 . . . . 0.0 110.893 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.72 -35.04 13.49 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.674 2.249 . . . . 0.0 112.397 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.425 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 11.9 m-85 -45.84 113.69 0.65 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.898 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -144.91 142.19 10.64 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.484 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.75 109.56 2.34 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.723 2.282 . . . . 0.0 112.334 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 118.88 -8.55 12.73 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.5 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -133.29 150.63 51.89 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.851 0.358 . . . . 0.0 110.883 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 2.3 p90 -77.86 160.02 28.57 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.919 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.511 ' O ' ' CD1' ' A' ' 109' ' ' PHE . 29.6 p90 -145.3 122.36 11.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.874 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -92.89 101.94 14.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.911 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.718 HD13 ' N ' ' A' ' 112' ' ' SER . 1.0 OUTLIER -101.84 138.37 38.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.875 -179.911 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.718 ' N ' HD13 ' A' ' 111' ' ' LEU . 4.3 m -144.67 114.41 7.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.871 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.605 HD11 HD12 ' A' ' 111' ' ' LEU . 4.3 mp -99.16 122.22 50.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.157 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 7.7 mtp180 -97.16 132.72 42.66 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.842 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . 0.438 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 7.0 t -98.61 123.07 42.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.867 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.93 -141.23 7.46 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.494 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.462 ' CD2' ' HB2' ' A' ' 39' ' ' ALA . 7.9 mt -118.57 -33.4 4.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.792 0.329 . . . . 0.0 110.931 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . 0.598 ' O ' ' CD2' ' A' ' 134' ' ' HIS . 16.1 m-20 -97.6 -45.26 6.46 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.908 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.428 ' HG3' ' C ' ' A' ' 118' ' ' ASP . 47.7 mtt180 -152.36 -175.85 5.44 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.91 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.621 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 12.1 m-85 -107.66 158.59 17.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.905 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 19.1 mtpt -130.83 105.23 7.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.903 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.445 HG13 HD11 ' A' ' 111' ' ' LEU . 47.7 t -94.37 134.83 30.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.121 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -123.32 147.82 46.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.91 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.504 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -132.65 107.5 8.45 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.104 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 59.34 34.17 22.75 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.86 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.55 28.99 41.25 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.468 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 13.0 mm100 -136.38 119.61 16.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.8 0.333 . . . . 0.0 110.921 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 26.5 t-80 -51.58 101.53 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.831 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.504 HD13 ' CB ' ' A' ' 124' ' ' ALA . 10.5 tp -65.57 -69.16 0.31 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.933 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.462 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 4.5 p90 -164.66 175.54 9.66 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.884 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 41.0 m-20 -113.75 157.42 22.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.893 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.73 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -130.81 106.29 8.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.942 -179.911 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.545 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -64.54 131.77 47.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.075 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' HIS . . . . . 0.598 ' CD2' ' O ' ' A' ' 118' ' ' ASP . 16.7 m-70 -56.65 117.49 3.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.85 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 71.9 mtt-85 -97.61 -49.48 4.85 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.84 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . 0.439 HD23 ' HB2' ' A' ' 69' ' ' ALA . 12.2 tp -95.37 109.08 21.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.941 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 79.3 p -48.74 -33.17 9.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.836 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.578 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -83.36 28.24 0.55 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.096 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -51.47 -34.56 35.99 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.838 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' GLN . . . . . 0.42 ' HG2' ' N ' ' A' ' 141' ' ' ARG . 19.7 pm0 -60.58 -27.19 67.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.945 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.578 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 33.1 mtp180 -69.27 -37.58 77.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.908 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.631 HG21 ' HB3' ' A' ' 69' ' ' ALA . 89.4 t -46.52 104.35 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.096 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -127.84 29.24 5.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.875 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 10.5 m -139.2 110.94 7.16 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.085 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.56 HD13 ' CE2' ' A' ' 60' ' ' PHE . 6.2 tp -109.55 105.71 15.13 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.952 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -110.11 152.49 25.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.856 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.406 HG12 HG23 ' A' ' 58' ' ' ILE . 29.4 mt -139.92 118.67 11.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.131 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -126.77 171.43 11.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.927 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 109.36 -152.28 17.12 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.518 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -106.52 92.04 3.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.802 0.334 . . . . 0.0 110.89 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 8.7 p -150.37 149.27 14.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.114 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 29.7 m -109.71 94.9 5.27 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.114 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.437 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 77.6 mt -76.93 132.22 38.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.917 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 3.0 m -117.37 -33.7 4.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.879 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 19.5 t80 -153.1 131.9 12.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.93 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 60.8 t -139.53 112.2 5.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.171 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 17.9 tt0 -124.92 136.56 53.88 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' ILE . . . . . 0.544 HD13 HD23 ' A' ' 33' ' ' LEU . 15.3 mt . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.129 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.525 ' CG2' ' N ' ' A' ' 23' ' ' PHE . 1.6 m . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.786 0.327 . . . . 0.0 111.132 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.525 ' N ' ' CG2' ' A' ' 22' ' ' THR . 8.6 m-85 -154.32 137.72 15.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.88 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . 0.549 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 12.5 m120 44.27 47.99 4.03 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.648 0.737 . . . . 0.0 110.909 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.549 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.6 Cg_endo -69.79 140.09 41.73 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.688 2.259 . . . . 0.0 112.327 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 178.61 4.38 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.718 2.279 . . . . 0.0 112.357 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.703 HG13 ' HA ' ' A' ' 28' ' ' PRO . 96.4 t -139.36 138.31 20.36 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.605 0.717 . . . . 0.0 111.136 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.703 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.74 144.3 76.2 Favored 'Cis proline' 0 C--O 1.231 0.158 0 C-N-CA 122.72 -1.783 . . . . 0.0 112.334 -0.082 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -95.37 114.07 25.8 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.923 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -97.65 105.34 17.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.896 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -119.34 106.32 1.24 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.487 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.482 ' O ' ' NE2' ' A' ' 34' ' ' GLN . 0.0 OUTLIER -77.98 128.19 33.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.904 0.383 . . . . 0.0 110.848 -179.855 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.455 HD23 HD13 ' A' ' 158' ' ' ILE . 5.5 mt -71.8 122.02 19.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.89 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . 0.482 ' NE2' ' O ' ' A' ' 32' ' ' ARG . 24.5 mp0 -77.15 79.6 3.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.899 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 139.01 -47.51 0.91 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.525 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.963 ' O ' HG23 ' A' ' 38' ' ' THR . . . 108.47 164.98 20.98 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.467 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . 0.524 HD12 ' O ' ' A' ' 139' ' ' PHE . 68.7 mt -50.85 106.48 0.13 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.92 0.39 . . . . 0.0 110.898 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.963 HG23 ' O ' ' A' ' 36' ' ' GLY . 10.2 p -124.61 141.19 52.28 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.146 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -42.86 -27.78 0.21 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.15 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 14.4 mmt85 -105.03 43.61 1.09 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.919 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.407 ' NH2' ' O ' ' A' ' 34' ' ' GLN . 6.6 ttt85 -130.43 139.93 50.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.838 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 98.0 m -139.73 121.6 15.52 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.09 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.47 ' N ' HD12 ' A' ' 43' ' ' ILE . 4.7 mp -91.39 132.76 35.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.137 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.436 ' CG2' ' HE2' ' A' ' 46' ' ' LYS . 83.8 mt -125.16 117.01 48.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.113 179.893 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 46.6 mt -118.12 107.63 22.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.092 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.436 ' HE2' ' CG2' ' A' ' 44' ' ' ILE . 25.1 mtmt -111.06 112.12 23.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.907 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -145.04 -143.43 3.99 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.487 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -168.99 126.42 0.97 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.924 0.392 . . . . 0.0 110.957 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 21.6 t -75.99 116.89 59.75 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.642 0.734 . . . . 0.0 111.138 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.82 157.52 60.0 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.631 2.221 . . . . 0.0 112.302 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -16.88 37.63 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.685 2.257 . . . . 0.0 112.307 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 76.8 p -110.91 19.73 18.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.138 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -111.68 116.53 4.2 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.506 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 21.7 mtpp -59.24 -60.66 3.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.761 0.315 . . . . 0.0 110.904 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 21.7 p -174.06 157.43 2.89 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.888 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.595 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 5.7 p90 -112.52 -173.18 2.19 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.9 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.472 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -155.18 145.49 21.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.095 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 2.7 mp -125.52 100.01 6.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.087 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . 0.443 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 19.4 m-80 -101.9 144.76 30.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.882 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.779 ' CE2' HD13 ' A' ' 145' ' ' LEU . 32.7 m-85 -117.93 99.95 7.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.873 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.425 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 34.5 ttmt -95.65 168.16 10.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.945 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.645 HG22 ' HA ' ' A' ' 142' ' ' VAL . 22.6 t -99.72 122.86 52.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.147 179.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -58.23 -34.23 73.14 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.481 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.407 ' H ' HG12 ' A' ' 62' ' ' VAL . 26.1 m -70.22 -75.26 0.12 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.865 0.364 . . . . 0.0 110.813 -179.695 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 26.9 t -77.64 -71.93 0.39 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.866 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 129.3 43.4 0.21 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.469 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.505 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.1 m-20 -113.69 142.1 46.43 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.784 0.326 . . . . 0.0 110.866 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.6 HD12 ' HB3' ' A' ' 86' ' ' LEU . 44.9 mt -87.05 118.78 33.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.119 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.655 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -91.95 -30.09 16.29 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.089 179.835 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.645 HD22 ' CD2' ' A' ' 132' ' ' PHE . 58.2 tp -142.18 129.62 21.26 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.899 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.496 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.2 t60 -134.81 92.8 2.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.842 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.555 HD11 HD21 ' A' ' 70' ' ' LEU . 28.3 mt -94.78 130.88 42.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.102 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.499 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -136.04 104.79 9.62 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.643 0.735 . . . . 0.0 110.902 179.9 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.595 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.4 Cg_endo -69.78 155.66 65.3 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.644 2.229 . . . . 0.0 112.309 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 28.6 mtt-85 -130.77 101.92 5.87 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.859 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.879 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 7.0 p . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.827 0.346 . . . . 0.0 111.123 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.585 HG22 ' HA ' ' A' ' 74' ' ' PRO . 41.8 t -101.46 114.65 41.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.166 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.711 HG22 ' HD3' ' A' ' 96' ' ' LYS . 57.4 t -83.54 144.18 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.135 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -126.26 124.91 41.43 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.845 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.496 ' O ' ' N ' ' A' ' 71' ' ' HIS . 2.6 m120 -135.17 176.3 8.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.867 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 40.4 t -157.72 105.01 1.99 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.892 -179.883 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.893 HD13 ' NE1' ' A' ' 91' ' ' TRP . 34.5 tp -77.14 117.73 18.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.919 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 90' ' ' SER . 85.0 mt -95.48 162.36 13.68 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.951 179.893 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.423 ' ND2' ' H ' ' A' ' 88' ' ' ASN . 10.6 m-80 -41.08 102.23 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.866 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.19 -1.15 3.0 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.49 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.826 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -125.71 171.64 10.46 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.849 0.357 . . . . 0.0 110.853 -179.715 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.893 ' NE1' HD13 ' A' ' 86' ' ' LEU . 22.2 m95 -128.93 160.63 32.08 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.921 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.57 -115.21 2.23 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.491 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . 0.425 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 58.3 m -151.42 173.67 14.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.82 0.343 . . . . 0.0 110.852 -179.768 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.412 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 14.4 mt-10 -102.59 123.95 47.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.875 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -123.08 125.86 45.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.904 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.711 ' HD3' HG22 ' A' ' 82' ' ' VAL . 45.6 mtmt -129.52 118.99 22.96 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.886 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 1.3 tppp? -170.58 106.52 0.29 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.851 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.544 HD11 ' O ' ' A' ' 100' ' ' HIS . 7.4 tt -144.22 150.53 16.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.114 179.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.507 HG23 ' N ' ' A' ' 100' ' ' HIS . 8.8 t -87.26 -46.12 10.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.154 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . 0.544 ' O ' HD11 ' A' ' 98' ' ' ILE . 4.6 p-80 -147.37 125.78 12.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.886 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . 0.44 ' C ' ' OD1' ' A' ' 101' ' ' ASN . 27.1 t-20 -99.41 100.73 11.13 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.628 0.727 . . . . 0.0 110.906 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.425 ' HD2' ' HA ' ' A' ' 101' ' ' ASN . 54.1 Cg_endo -69.72 -36.44 10.89 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.751 2.301 . . . . 0.0 112.335 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -41.51 109.72 0.13 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.872 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -137.96 138.56 9.68 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.481 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 103.06 1.11 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.646 2.231 . . . . 0.0 112.363 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 121.44 -2.12 11.31 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.485 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -137.05 146.04 44.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.871 0.367 . . . . 0.0 110.874 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 2.3 p90 -70.93 172.76 8.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.861 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 30.0 p90 -160.25 137.5 9.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.884 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.59 107.8 18.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.863 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.699 HD13 ' N ' ' A' ' 112' ' ' SER . 0.7 OUTLIER -109.12 136.99 47.71 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.926 -179.938 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.699 ' N ' HD13 ' A' ' 111' ' ' LEU . 6.0 m -145.08 113.56 6.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.809 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.443 HG22 ' HD2' ' A' ' 120' ' ' PHE . 4.3 mp -93.92 137.42 22.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.129 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . 0.462 ' O ' ' CD2' ' A' ' 120' ' ' PHE . 14.5 mtp180 -109.56 133.93 52.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.855 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 9.0 t -101.45 115.29 30.18 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.86 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -110.94 -141.66 8.8 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.487 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 5.5 mt -118.58 -34.81 3.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.827 0.346 . . . . 0.0 110.948 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . 0.605 ' O ' ' CD2' ' A' ' 134' ' ' HIS . 2.0 m-20 -95.05 -45.83 7.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.856 179.858 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.447 ' HG3' ' C ' ' A' ' 118' ' ' ASP . 25.5 mtt180 -154.98 -179.72 8.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.462 ' CD2' ' O ' ' A' ' 114' ' ' ARG . 20.5 m-85 -103.41 157.59 16.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.919 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 32.9 mtpt -129.52 100.08 5.41 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.938 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.557 HG13 HD11 ' A' ' 111' ' ' LEU . 45.6 t -89.2 128.94 40.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.091 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -115.07 151.21 34.68 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.917 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -136.35 106.71 6.43 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.069 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 55.92 34.67 24.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.856 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 80.71 31.36 36.53 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.506 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 12.3 mm100 -138.32 123.78 19.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.844 0.354 . . . . 0.0 110.938 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 39.6 t-80 -55.46 101.43 0.05 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.874 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.403 HD22 HD21 ' A' ' 111' ' ' LEU . 11.6 tp -69.85 -69.62 0.34 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.952 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.452 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 6.7 p90 -165.13 169.84 15.67 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -111.22 159.93 17.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.895 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.645 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -130.52 104.39 7.2 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.897 -179.883 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.507 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -62.5 134.96 57.14 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.108 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' HIS . . . . . 0.605 ' CD2' ' O ' ' A' ' 118' ' ' ASP . 20.1 m-70 -58.72 104.62 0.24 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.875 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.425 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 8.8 mtt-85 -83.92 -53.65 5.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.867 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.7 tp -91.85 107.77 19.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.956 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 12.7 t -45.74 -36.14 4.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.893 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.416 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.72 29.97 0.44 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.09 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.524 ' O ' HD12 ' A' ' 37' ' ' LEU . 21.7 p90 -48.49 -45.82 37.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.886 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' GLN . . . . . 0.466 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 8.3 pt20 -47.8 -41.34 23.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.908 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.538 ' O ' HG13 ' A' ' 62' ' ' VAL . 30.7 mtp180 -54.21 -41.64 68.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.851 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.655 HG21 ' CB ' ' A' ' 69' ' ' ALA . 97.2 t -49.23 102.92 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.177 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -124.74 28.34 6.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.865 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' THR . . . . . 0.419 ' HA ' ' HA ' ' A' ' 32' ' ' ARG . 0.6 OUTLIER -135.29 125.44 26.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.138 -179.927 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.779 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.2 tp -123.97 106.79 10.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.922 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -110.37 153.44 24.94 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.911 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 17.2 mt -138.47 115.28 11.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.104 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -125.52 174.92 7.89 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.917 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.04 -143.78 15.84 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.502 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -114.81 92.39 3.93 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.888 0.375 . . . . 0.0 110.86 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.3 p -151.31 145.74 16.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.171 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 21.5 m -105.37 93.8 4.87 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.126 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.465 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 95.0 mt -75.76 131.43 39.81 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.869 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 7.5 m -113.62 -41.6 3.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.86 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . 0.413 ' CD1' ' C ' ' A' ' 155' ' ' TYR . 8.4 t80 -145.06 132.98 21.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.919 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 94.4 t -140.69 116.96 7.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.112 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 9.7 tt0 -134.18 125.13 27.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.941 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' ILE . . . . . 0.455 HD13 HD23 ' A' ' 33' ' ' LEU . 24.0 mt . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.139 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.494 HG22 ' H ' ' A' ' 156' ' ' VAL . 10.8 t . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.816 0.341 . . . . 0.0 111.151 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 7.8 m-85 -139.43 115.61 10.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.914 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . 0.489 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 5.3 t-20 66.95 51.63 0.65 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.568 0.699 . . . . 0.0 110.845 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.489 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.75 132.65 23.79 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.679 2.253 . . . . 0.0 112.343 179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -178.43 2.34 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.68 2.253 . . . . 0.0 112.326 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.684 HG13 ' HA ' ' A' ' 28' ' ' PRO . 94.4 t -139.87 137.87 18.98 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.661 0.743 . . . . 0.0 111.146 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.684 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.8 Cg_endo -69.78 144.51 76.89 Favored 'Cis proline' 0 C--N 1.341 0.181 0 C-N-CA 122.731 -1.779 . . . . 0.0 112.292 0.009 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 14.4 t80 -94.87 118.2 31.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.973 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -102.33 100.76 10.95 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.905 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -107.54 109.58 3.01 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.464 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 10.2 mmt85 -75.35 117.65 17.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.85 0.357 . . . . 0.0 110.855 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 3.5 mt -78.17 93.22 4.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.897 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.8 mm-40 -64.83 99.74 0.36 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.899 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.23 -41.55 1.45 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.54 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.592 ' O ' HG23 ' A' ' 38' ' ' THR . . . 95.21 164.59 34.97 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.499 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . 0.41 HD12 ' O ' ' A' ' 139' ' ' PHE . 87.5 mt -58.48 110.68 1.02 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.872 0.368 . . . . 0.0 110.903 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.592 HG23 ' O ' ' A' ' 36' ' ' GLY . 44.4 p -124.12 146.23 48.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.134 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -47.27 -22.69 0.44 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.088 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.02 35.22 3.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.861 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.417 ' NE ' ' O ' ' A' ' 36' ' ' GLY . 20.3 ttm-85 -114.59 138.81 50.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.872 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 88.2 m -136.31 114.55 11.59 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.143 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 4.8 mp -90.78 135.07 27.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.13 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 80.1 mt -130.26 132.61 64.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.127 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 55.8 mt -133.56 107.09 10.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.103 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 10.7 mttm -102.46 108.42 19.73 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.927 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.03 -156.06 6.78 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.454 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -161.98 127.87 3.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.941 0.4 . . . . 0.0 110.867 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 21.9 t -76.05 114.53 38.28 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.675 0.75 . . . . 0.0 111.13 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 158.5 56.7 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.662 2.241 . . . . 0.0 112.317 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -13.65 34.93 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.681 2.254 . . . . 0.0 112.341 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 40.7 p -114.08 19.0 16.8 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.146 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -114.12 116.6 3.89 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.517 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 19.0 mtpp -61.64 -57.5 11.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.801 0.334 . . . . 0.0 110.895 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 16.6 p -174.88 160.7 2.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.857 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 17.6 p90 -115.44 -174.41 2.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.85 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.944 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -156.5 130.3 8.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.113 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.7 HG22 ' CE1' ' A' ' 60' ' ' PHE . 5.3 mp -114.55 103.56 15.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.11 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.4 m-80 -101.44 146.22 27.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.865 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.7 ' CE1' HG22 ' A' ' 58' ' ' ILE . 3.4 m-85 -118.38 99.72 7.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.887 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.454 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 32.8 ttmt -97.47 169.23 9.88 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.884 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.631 HG22 ' HA ' ' A' ' 142' ' ' VAL . 39.8 t -101.23 120.4 50.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.133 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -56.54 -39.61 85.23 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.523 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 35.1 m -62.26 -72.33 0.13 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.875 0.369 . . . . 0.0 110.859 -179.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 40.6 p -80.17 -70.21 0.54 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.87 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 127.26 44.25 0.23 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.491 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.404 ' OD1' ' OD1' ' A' ' 88' ' ' ASN . 0.6 OUTLIER -117.37 142.63 46.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.834 0.349 . . . . 0.0 110.87 179.977 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.567 HD12 ' HB3' ' A' ' 86' ' ' LEU . 41.0 mt -86.11 111.2 20.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.128 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.624 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -82.23 -31.25 30.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.075 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.688 HD21 HD11 ' A' ' 72' ' ' ILE . 32.4 tp -142.37 132.46 24.59 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.93 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.441 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.8 OUTLIER -134.78 98.79 4.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.88 179.838 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.688 HD11 HD21 ' A' ' 70' ' ' LEU . 17.9 mt -101.74 133.57 44.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.102 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.944 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -141.08 106.82 6.2 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.658 0.742 . . . . 0.0 110.878 179.918 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.2 Cg_endo -69.76 155.32 66.26 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.718 2.278 . . . . 0.0 112.332 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 38.4 mtp180 -132.37 96.56 3.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.875 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . 0.422 ' HE2' ' HB3' ' A' ' 103' ' ' PHE . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.862 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.3 p . . . . . 0 N--CA 1.457 -0.112 0 CA-C-O 120.828 0.346 . . . . 0.0 111.139 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.48 HG22 ' HA ' ' A' ' 74' ' ' PRO . 21.7 t -100.93 112.85 35.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.128 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.648 HG22 ' HD3' ' A' ' 96' ' ' LYS . 30.2 t -82.3 144.85 9.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.137 179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -129.46 126.59 39.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.89 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.441 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.6 OUTLIER -137.07 -177.09 4.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.908 -179.943 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 40.1 t -158.65 105.32 1.82 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.855 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.897 HD13 ' CE2' ' A' ' 91' ' ' TRP . 35.9 tp -76.83 115.86 16.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.902 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.519 ' N ' ' O ' ' A' ' 90' ' ' SER . 83.2 mt -93.72 162.45 13.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.946 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.454 ' ND2' ' H ' ' A' ' 88' ' ' ASN . 8.2 m-80 -41.26 102.17 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.907 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.37 -0.49 3.74 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.51 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.81 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -126.45 171.16 11.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.919 0.39 . . . . 0.0 110.826 -179.713 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.897 ' CE2' HD13 ' A' ' 86' ' ' LEU . 26.6 m95 -128.25 160.72 31.24 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.899 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.85 -109.76 1.89 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.496 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . 0.434 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 47.5 m -155.5 174.52 15.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.791 0.329 . . . . 0.0 110.905 -179.749 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -100.01 125.17 46.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.884 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -120.17 121.22 38.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.854 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.648 ' HD3' HG22 ' A' ' 82' ' ' VAL . 6.4 mtmp? -127.57 118.56 24.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.932 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 20.9 tttt -170.85 107.49 0.29 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.937 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.87 HD11 ' O ' ' A' ' 100' ' ' HIS . 2.3 tt -145.53 153.38 13.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.147 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.434 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 8.9 t -97.52 -36.2 10.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.128 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . 0.87 ' O ' HD11 ' A' ' 98' ' ' ILE . 2.3 p-80 -148.88 128.16 12.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.848 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -102.87 96.66 8.07 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.619 0.723 . . . . 0.0 110.874 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.406 ' O ' ' C ' ' A' ' 103' ' ' PHE . 54.2 Cg_endo -69.74 -42.98 2.95 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.693 2.262 . . . . 0.0 112.374 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.463 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 8.6 m-85 -37.84 105.13 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.868 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -133.21 139.22 10.75 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.481 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 104.21 1.29 Allowed 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.63 2.22 . . . . 0.0 112.352 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 124.41 -7.88 8.45 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.529 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.485 ' NE2' ' O ' ' A' ' 108' ' ' PHE . 2.1 pp0? -131.37 168.7 17.13 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.83 0.348 . . . . 0.0 110.922 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' PHE . . . . . 0.485 ' O ' ' NE2' ' A' ' 107' ' ' GLN . 1.4 p90 -90.89 172.56 8.52 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.856 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 31.9 p90 -158.36 129.2 6.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.881 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -98.86 102.18 13.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.888 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.836 HD13 ' N ' ' A' ' 112' ' ' SER . 0.9 OUTLIER -99.85 137.51 38.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.876 -179.918 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.836 ' N ' HD13 ' A' ' 111' ' ' LEU . 2.4 m -145.14 111.71 5.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.9 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.529 HG23 HG22 ' A' ' 122' ' ' VAL . 3.9 mp -94.71 121.04 44.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.162 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . 0.59 ' HD3' ' CD1' ' A' ' 123' ' ' TYR . 0.2 OUTLIER -99.54 123.92 44.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.864 179.984 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . 0.583 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 7.9 t -90.11 126.66 35.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.907 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -123.35 -150.32 8.0 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.489 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 9.2 mt -111.8 -39.72 4.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.863 0.363 . . . . 0.0 110.946 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . 0.423 ' C ' ' CD2' ' A' ' 134' ' ' HIS . 29.0 t0 -88.78 -34.66 17.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.831 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.5 ptt180 -172.73 167.87 5.22 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.888 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.583 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.4 m-30 -93.18 158.68 15.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.865 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.43 ' HB3' ' CE1' ' A' ' 123' ' ' TYR . 17.9 mtpp -130.62 104.72 7.37 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.897 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.7 HG13 HD11 ' A' ' 111' ' ' LEU . 92.5 t -93.4 108.47 20.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.116 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' TYR . . . . . 0.59 ' CD1' ' HD3' ' A' ' 114' ' ' ARG . 32.9 m-85 -96.43 147.86 23.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.904 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.593 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -127.5 102.14 6.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.074 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 57.19 37.62 28.48 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.875 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.38 33.39 28.59 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.504 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -142.89 120.67 11.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.85 0.357 . . . . 0.0 110.895 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . 0.488 ' CE1' ' OD2' ' A' ' 131' ' ' ASP . 33.6 t-80 -53.22 99.86 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.884 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.593 HD13 ' CB ' ' A' ' 124' ' ' ALA . 10.5 tp -70.01 -67.41 0.49 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.883 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.524 ' HZ ' HD13 ' A' ' 72' ' ' ILE . 8.2 p90 -162.41 175.48 11.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.886 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.488 ' OD2' ' CE1' ' A' ' 128' ' ' HIS . 15.7 m-20 -120.21 150.17 41.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.864 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.597 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -115.86 107.81 15.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.848 -179.886 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.558 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -63.22 131.87 49.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.11 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' HIS . . . . . 0.423 ' CD2' ' C ' ' A' ' 118' ' ' ASP . 44.0 m-70 -62.35 102.39 0.31 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.893 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.434 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 68.9 mtt-85 -89.34 -45.98 9.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.872 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 4.5 tp -99.7 108.16 20.44 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.907 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 58.2 p -50.88 -33.17 22.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.853 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.468 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.23 31.17 0.39 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.095 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.41 ' O ' HD12 ' A' ' 37' ' ' LEU . 40.0 p90 -52.37 -42.31 63.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.883 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 8.2 pt20 -48.68 -42.31 34.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.916 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.468 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 72.2 mtp180 -54.36 -40.96 68.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.895 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.631 ' HA ' HG22 ' A' ' 62' ' ' VAL . 69.8 t -44.99 105.43 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.148 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -129.92 34.32 4.28 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.898 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 11.6 m -143.04 116.68 9.21 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.126 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.59 HD13 ' CE2' ' A' ' 60' ' ' PHE . 7.1 tp -116.45 107.8 15.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.959 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' GLU . . . . . 0.418 ' C ' HG13 ' A' ' 147' ' ' ILE . 8.0 pt-20 -111.79 153.02 27.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.852 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.622 HG23 HG13 ' A' ' 58' ' ' ILE . 16.8 mt -139.95 109.8 3.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.172 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -118.54 173.64 6.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.911 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.46 -145.45 16.09 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.503 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -112.18 93.05 4.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.868 0.366 . . . . 0.0 110.879 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 5.6 p -151.12 149.13 14.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.138 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 40.0 m -110.23 95.06 5.34 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.132 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.473 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 84.6 mt -76.53 136.09 39.3 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.901 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 6.0 m -120.08 -36.54 3.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.897 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 53.5 t80 -150.64 130.94 13.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.909 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.494 ' H ' HG22 ' A' ' 22' ' ' THR . 44.8 t -139.72 105.0 2.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.123 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 12.2 tt0 -120.37 135.42 55.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.879 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 16.9 mt . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.135 179.964 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.473 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.9 m . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.785 0.326 . . . . 0.0 111.131 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.473 ' CD1' ' O ' ' A' ' 22' ' ' THR . 6.7 m-85 -147.37 124.59 11.5 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.891 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . 0.575 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 4.6 t-20 58.93 46.23 1.48 Allowed Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.621 0.724 . . . . 0.0 110.883 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.575 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.77 134.47 28.04 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.679 2.252 . . . . 0.0 112.337 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -177.77 2.03 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.714 2.276 . . . . 0.0 112.301 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.707 HG13 ' HA ' ' A' ' 28' ' ' PRO . 96.0 t -142.25 138.72 16.9 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-O 121.634 0.731 . . . . 0.0 111.14 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.707 ' HA ' HG13 ' A' ' 27' ' ' VAL . 54.2 Cg_endo -69.72 144.39 76.44 Favored 'Cis proline' 0 C--N 1.341 0.17 0 C-N-CA 122.685 -1.798 . . . . 0.0 112.381 -0.11 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -98.37 115.68 28.98 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.925 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.489 ' CD2' ' HB3' ' A' ' 146' ' ' GLU . 63.7 m-85 -103.27 102.65 12.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.851 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -115.75 103.97 1.25 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.479 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.486 ' NH1' ' NE2' ' A' ' 34' ' ' GLN . 0.0 OUTLIER -72.34 132.03 43.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.836 0.35 . . . . 0.0 110.862 -179.848 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 143' ' ' ASP . 9.5 mt -76.87 142.57 40.13 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.942 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . 0.486 ' NE2' ' NH1' ' A' ' 32' ' ' ARG . 23.0 mm-40 -100.39 91.49 4.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.926 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 133.23 -50.02 0.89 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.53 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.968 ' O ' HG23 ' A' ' 38' ' ' THR . . . 108.56 161.56 20.34 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.504 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . 0.64 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 99.4 mt -50.31 105.32 0.09 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.881 0.372 . . . . 0.0 110.933 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.968 HG23 ' O ' ' A' ' 36' ' ' GLY . 12.1 p -123.12 146.27 47.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.11 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.431 ' HB2' HD21 ' A' ' 117' ' ' LEU . . . -44.59 -31.98 1.31 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.173 179.856 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -103.45 41.05 1.31 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.895 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.413 ' NH2' ' O ' ' A' ' 34' ' ' GLN . 45.5 ttm-85 -124.31 136.03 53.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.861 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 39.3 m -135.91 126.33 26.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.14 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 mp -98.94 132.48 44.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.101 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 95.3 mt -123.58 134.68 65.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.137 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 59.5 mt -135.95 107.88 7.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.144 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.4 mtmm -110.34 111.07 22.12 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.925 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.66 -143.45 4.31 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.51 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 1.6 t80 -170.16 126.78 0.82 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.851 0.357 . . . . 0.0 110.944 -179.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 11.2 t -77.36 116.13 55.11 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.616 0.722 . . . . 0.0 111.124 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 158.68 56.15 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.699 2.266 . . . . 0.0 112.331 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -19.36 36.38 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.733 2.288 . . . . 0.0 112.327 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 69.2 p -109.7 21.27 17.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.142 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -115.02 120.04 4.84 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.486 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 20.6 mtpp -61.27 -60.19 4.13 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.797 0.332 . . . . 0.0 110.897 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.7 p -175.29 157.59 2.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.886 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.508 ' O ' ' ND2' ' A' ' 73' ' ' ASN . 4.0 p90 -108.47 -172.5 2.07 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.857 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.55 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -154.82 141.41 18.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.082 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.429 HD12 ' N ' ' A' ' 58' ' ' ILE . 2.6 mp -123.0 98.7 5.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.166 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.0 m-80 -101.07 144.84 29.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.908 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.546 ' CE2' HD13 ' A' ' 145' ' ' LEU . 29.6 m-85 -117.24 101.45 8.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.912 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.427 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 32.8 ttmt -95.83 168.39 10.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.863 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.591 HG22 ' HA ' ' A' ' 142' ' ' VAL . 61.4 t -100.41 122.27 52.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.171 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -57.08 -41.13 92.42 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.515 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 44.2 t -65.15 -73.04 0.13 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.888 0.375 . . . . 0.0 110.856 -179.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 39.0 t -77.99 -75.94 0.2 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.918 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 132.42 40.28 0.21 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.485 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.458 ' O ' HG23 ' A' ' 62' ' ' VAL . 0.7 OUTLIER -111.88 142.01 44.81 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.761 0.315 . . . . 0.0 110.892 -179.971 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.623 HD12 ' HB3' ' A' ' 86' ' ' LEU . 50.0 mt -86.41 120.11 35.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.152 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.527 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -92.24 -33.55 14.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.08 179.829 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.613 HD13 ' CD1' ' A' ' 132' ' ' PHE . 59.8 tp -138.85 130.61 27.65 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.907 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.492 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.5 OUTLIER -134.96 92.63 2.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.913 179.843 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.573 HD11 HD21 ' A' ' 70' ' ' LEU . 30.5 mt -94.99 128.37 46.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.117 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.55 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -134.58 105.4 10.89 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.611 0.719 . . . . 0.0 110.897 179.929 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.501 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.2 Cg_endo -69.71 154.51 67.85 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.701 2.267 . . . . 0.0 112.354 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 36.1 mtp180 -130.32 96.94 4.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.876 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.845 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 34.8 p . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.838 0.352 . . . . 0.0 111.17 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.474 HG21 ' HE2' ' A' ' 103' ' ' PHE . 13.1 t -89.29 108.73 19.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.097 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.559 HG22 ' HD3' ' A' ' 96' ' ' LYS . 91.6 t -80.93 145.97 8.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.088 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -127.34 124.81 39.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.892 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.492 ' O ' ' N ' ' A' ' 71' ' ' HIS . 2.7 m120 -135.22 179.3 6.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.901 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 46.1 t -160.78 105.63 1.4 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.861 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.929 HD12 ' O ' ' A' ' 90' ' ' SER . 27.0 tp -77.96 119.34 21.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.92 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.503 ' N ' ' O ' ' A' ' 90' ' ' SER . 87.0 mt -97.08 161.35 13.86 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.919 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.547 HD22 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.23 101.61 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.931 179.898 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.45 -6.41 0.82 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.501 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.929 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -118.96 172.06 7.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.834 0.349 . . . . 0.0 110.844 -179.725 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.837 ' NE1' HD13 ' A' ' 86' ' ' LEU . 22.0 m95 -129.43 161.07 31.21 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.929 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.09 -106.01 1.55 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.476 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 2.9 m -165.76 174.92 9.2 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.812 0.339 . . . . 0.0 110.835 -179.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.419 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 7.6 mt-10 -104.66 117.62 34.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.88 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -123.05 108.78 13.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.876 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.559 ' HD3' HG22 ' A' ' 82' ' ' VAL . 35.8 mtmt -105.57 131.32 53.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.864 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.479 ' HE3' ' N ' ' A' ' 98' ' ' ILE . 0.0 OUTLIER -174.31 105.23 0.11 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.903 179.889 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.933 HD11 ' O ' ' A' ' 100' ' ' HIS . 5.1 tt -148.09 154.25 10.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.12 179.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.488 HG23 ' N ' ' A' ' 100' ' ' HIS . 9.0 t -95.29 -44.62 7.51 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.143 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . 0.933 ' O ' HD11 ' A' ' 98' ' ' ILE . 4.9 p-80 -139.1 133.3 31.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.856 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . 0.402 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 44.2 t-20 -110.92 95.99 27.07 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.628 0.728 . . . . 0.0 110.892 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.434 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.4 Cg_endo -69.78 -42.6 3.24 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.646 2.231 . . . . 0.0 112.34 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.527 ' CZ ' HD21 ' A' ' 129' ' ' LEU . 5.2 m-85 -35.88 104.84 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.861 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -135.88 138.44 9.92 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.455 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 99.95 0.78 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.722 2.281 . . . . 0.0 112.319 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 130.45 -9.59 5.87 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.461 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.1 pt20 -131.49 159.22 38.76 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.806 0.336 . . . . 0.0 110.941 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -76.45 174.09 10.7 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.849 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.468 ' O ' ' CD2' ' A' ' 109' ' ' PHE . 23.4 p90 -161.55 117.87 2.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.887 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -94.76 102.08 13.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.878 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.739 HD13 ' N ' ' A' ' 112' ' ' SER . 0.9 OUTLIER -101.23 137.33 39.73 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.921 -179.943 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.739 ' N ' HD13 ' A' ' 111' ' ' LEU . 5.2 m -144.2 114.16 7.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.859 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.475 HD11 HD12 ' A' ' 111' ' ' LEU . 5.1 mp -96.47 140.71 16.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.147 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 24.6 mtt180 -115.57 124.93 52.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.879 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . 0.563 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 6.5 t -92.89 118.45 31.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.85 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.99 -144.82 8.51 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.434 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.431 HD21 ' HB2' ' A' ' 39' ' ' ALA . 13.6 mt -116.85 -36.95 3.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.838 0.351 . . . . 0.0 110.933 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -92.23 -34.69 14.17 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.833 179.861 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 17.8 ptp180 -171.77 172.83 4.75 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.885 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.64 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 3.6 m-30 -96.28 158.17 15.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.845 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 27.4 mtpt -129.82 100.34 5.44 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.917 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.459 HG13 HD11 ' A' ' 111' ' ' LEU . 88.0 t -86.18 137.07 21.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.133 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -126.54 152.72 46.16 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.884 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -140.83 111.17 6.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.069 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 56.78 29.71 16.45 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.9 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 83.37 32.12 26.11 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.503 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 8.5 mm100 -139.01 125.77 20.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.872 0.368 . . . . 0.0 110.875 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . 0.445 ' CE1' ' OD1' ' A' ' 131' ' ' ASP . 31.3 t-80 -56.6 109.22 0.58 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.839 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.527 HD21 ' CZ ' ' A' ' 103' ' ' PHE . 10.7 tp -77.8 -68.38 0.63 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.939 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.437 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 7.6 p90 -165.18 171.48 13.66 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.883 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.445 ' OD1' ' CE1' ' A' ' 128' ' ' HIS . 1.4 m-20 -113.97 151.64 32.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.865 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.613 ' CD1' HD13 ' A' ' 70' ' ' LEU . 0.3 OUTLIER -116.8 108.58 16.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.929 -179.933 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.513 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -63.49 134.42 55.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.065 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 15.8 m-70 -62.82 103.0 0.4 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.849 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 47.2 mtt-85 -87.1 -52.82 5.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.906 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 9.5 tp -91.54 108.34 19.83 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.934 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 99.2 p -50.5 -32.48 18.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.867 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.499 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.93 25.54 0.67 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.06 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.492 ' O ' HD12 ' A' ' 37' ' ' LEU . 12.5 p90 -45.44 -42.81 10.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.869 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' GLN . . . . . 0.436 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 10.7 pt20 -48.93 -40.06 28.65 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.894 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.499 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 41.0 mtp85 -55.9 -39.71 71.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.9 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.591 ' HA ' HG22 ' A' ' 62' ' ' VAL . 53.1 t -51.7 103.24 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.511 ' O ' ' N ' ' A' ' 33' ' ' LEU . 3.1 p30 -125.47 25.94 6.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.849 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 2.2 m -132.99 140.19 47.65 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.137 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.546 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.7 tp -134.64 108.32 7.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.947 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' GLU . . . . . 0.489 ' HB3' ' CD2' ' A' ' 30' ' ' PHE . 5.8 pt-20 -111.51 148.85 32.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.896 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.409 HG13 ' C ' ' A' ' 146' ' ' GLU . 9.9 mt -136.65 111.46 10.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.11 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 1.1 pm0 -124.26 176.68 6.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.956 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 109.97 -139.48 15.41 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.495 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -120.47 90.82 3.4 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.848 0.356 . . . . 0.0 110.898 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.441 HG22 ' N ' ' A' ' 152' ' ' THR . 2.8 p -151.15 155.33 7.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.13 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . 0.441 ' N ' HG22 ' A' ' 151' ' ' VAL . 38.0 m -113.32 93.7 4.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.156 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.478 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 68.2 mt -77.27 137.33 38.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.939 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 6.9 t -121.42 -39.55 2.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.888 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 19.3 t80 -143.49 129.17 19.26 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.929 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 76.3 t -141.05 105.42 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.128 179.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 14.6 tt0 -118.39 134.39 55.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.927 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 21.3 mt . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.158 179.947 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.538 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.6 m . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.867 0.365 . . . . 0.0 111.118 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.538 ' CD1' ' O ' ' A' ' 22' ' ' THR . 8.3 m-85 -150.84 127.4 10.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.887 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . 0.59 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 3.4 m120 54.48 45.46 2.27 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.607 0.718 . . . . 0.0 110.893 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.59 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.6 Cg_endo -69.76 132.56 23.59 Favored 'Trans proline' 0 C--O 1.231 0.175 0 C-N-CA 122.655 2.236 . . . . 0.0 112.299 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.81 -175.11 1.06 Allowed 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.669 2.246 . . . . 0.0 112.394 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.658 HG13 ' HA ' ' A' ' 28' ' ' PRO . 86.9 t -143.17 137.63 14.95 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.616 0.722 . . . . 0.0 111.14 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.658 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.6 Cg_endo -69.79 144.63 77.27 Favored 'Cis proline' 0 C--N 1.341 0.184 0 C-N-CA 122.702 -1.791 . . . . 0.0 112.319 -0.017 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 6.4 t80 -98.31 121.99 40.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.938 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -102.17 101.95 12.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.842 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -100.82 108.77 3.52 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.455 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 6.8 mmt85 -73.28 123.29 23.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.856 0.36 . . . . 0.0 110.902 -179.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.406 HD22 ' CZ ' ' A' ' 41' ' ' ARG . 7.8 mt -87.05 113.73 23.05 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.929 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 5.7 mm100 -84.62 80.53 9.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.888 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 143.54 -36.83 1.51 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.501 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.469 ' CA ' ' OD1' ' A' ' 143' ' ' ASP . . . 93.72 -177.93 37.59 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.48 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . 0.791 HD23 ' HE ' ' A' ' 41' ' ' ARG . 89.0 mt -68.47 98.05 0.82 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.899 0.38 . . . . 0.0 110.885 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 34.6 p -107.77 161.85 14.52 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.1 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.437 ' HB2' HD21 ' A' ' 117' ' ' LEU . . . -62.18 -27.47 68.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.112 179.845 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 8.8 mpt_? -105.61 33.06 3.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.918 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.791 ' HE ' HD23 ' A' ' 37' ' ' LEU . 4.5 ttt85 -109.74 137.98 46.77 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 87.4 m -138.96 120.82 15.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.136 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.487 HD11 ' CZ ' ' A' ' 41' ' ' ARG . 5.4 mp -93.74 137.78 21.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.159 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 76.2 mt -128.96 118.65 47.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.084 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 71.9 mt -118.1 107.37 21.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.104 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 21.9 mtmt -113.69 109.49 18.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.928 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -143.2 -143.61 4.15 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.528 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -168.03 128.6 1.35 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.941 0.4 . . . . 0.0 110.944 -179.845 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 15.4 t -79.11 119.6 77.75 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.646 0.736 . . . . 0.0 111.17 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 158.91 55.29 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.683 2.255 . . . . 0.0 112.313 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -17.96 37.03 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.712 2.274 . . . . 0.0 112.304 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 30.2 p -109.52 18.77 20.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.126 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -115.74 121.18 5.17 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.477 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 20.2 mtpp -63.91 -58.78 5.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.78 0.324 . . . . 0.0 110.906 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.0 m -173.12 167.77 4.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.833 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.531 ' CE2' HD11 ' A' ' 58' ' ' ILE . 1.9 p90 -119.07 -172.2 2.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.86 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.952 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -154.67 133.82 12.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.106 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.531 HD11 ' CE2' ' A' ' 56' ' ' PHE . 3.6 mp -115.77 98.18 6.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.151 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . 0.415 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 6.0 m-80 -100.25 143.33 30.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.939 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.559 ' CE2' HD13 ' A' ' 145' ' ' LEU . 28.5 m-85 -115.32 98.38 6.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.904 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.431 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 33.7 ttmt -95.68 168.31 10.75 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.934 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.756 HG22 ' HA ' ' A' ' 142' ' ' VAL . 53.4 t -100.24 125.08 54.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.147 179.85 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -60.44 -36.88 92.25 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.509 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 69.7 m -65.95 -73.34 0.13 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.871 0.367 . . . . 0.0 110.897 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 58.0 m -81.18 -73.36 0.38 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.853 -179.874 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 133.62 39.8 0.19 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.491 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.468 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.2 m-20 -108.92 142.88 38.9 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.789 0.328 . . . . 0.0 110.886 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.525 HD12 ' HB3' ' A' ' 86' ' ' LEU . 35.8 mt -92.35 114.01 28.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.127 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -83.63 -31.49 26.19 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.112 179.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.74 HD21 HD11 ' A' ' 72' ' ' ILE . 56.0 tp -141.28 130.91 24.04 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.889 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.476 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.2 t60 -134.49 92.94 2.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.845 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.74 HD11 HD21 ' A' ' 70' ' ' LEU . 18.2 mt -97.31 132.97 40.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.112 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.952 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -140.27 106.49 6.65 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.63 0.728 . . . . 0.0 110.899 179.941 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.618 ' HB3' ' CD2' ' A' ' 103' ' ' PHE . 54.0 Cg_endo -69.74 154.98 67.16 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.652 2.235 . . . . 0.0 112.335 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 57.8 mtp180 -131.49 100.57 5.19 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.887 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . 0.422 ' SD ' ' HB2' ' A' ' 103' ' ' PHE . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.891 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.2 p . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.797 0.332 . . . . 0.0 111.167 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.408 HG22 ' HA ' ' A' ' 74' ' ' PRO . 15.2 t -102.54 114.26 41.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.13 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.572 HG22 ' HD3' ' A' ' 96' ' ' LYS . 37.1 t -84.53 143.34 11.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.127 179.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -125.4 124.88 42.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.853 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.476 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.7 OUTLIER -136.23 176.29 8.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.906 -179.975 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 47.7 t -156.15 105.07 2.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.891 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.893 HD13 ' NE1' ' A' ' 91' ' ' TRP . 39.0 tp -77.18 114.33 15.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.904 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.518 ' N ' ' O ' ' A' ' 90' ' ' SER . 79.7 mt -92.44 161.93 14.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.929 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.435 ' ND2' ' OD2' ' A' ' 67' ' ' ASP . 13.5 m-80 -41.17 101.83 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.938 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.15 -1.55 3.61 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.485 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.829 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -125.31 170.59 11.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.828 0.347 . . . . 0.0 110.898 -179.815 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.893 ' NE1' HD13 ' A' ' 86' ' ' LEU . 23.1 m95 -128.12 160.57 31.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.903 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -91.97 -102.04 1.38 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.461 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 9.9 m -167.82 174.41 7.56 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.868 0.366 . . . . 0.0 110.823 -179.752 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -96.71 123.64 40.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.881 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 17.8 mm-40 -121.37 116.12 24.2 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.9 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.572 ' HD3' HG22 ' A' ' 82' ' ' VAL . 6.7 mtmp? -120.72 122.16 39.82 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.888 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -175.17 105.54 0.09 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.855 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.881 HD11 ' O ' ' A' ' 100' ' ' HIS . 6.4 tt -147.64 146.58 18.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.137 179.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.485 HG23 ' N ' ' A' ' 100' ' ' HIS . 10.2 t -81.34 -44.79 17.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . 0.881 ' O ' HD11 ' A' ' 98' ' ' ILE . 5.1 p-80 -148.5 141.26 24.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.9 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . 0.443 ' C ' ' OD1' ' A' ' 101' ' ' ASN . 4.9 t-20 -101.63 102.13 20.97 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.605 0.717 . . . . 0.0 110.899 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.476 ' CD ' HD11 ' A' ' 129' ' ' LEU . 53.8 Cg_endo -69.78 -29.6 23.53 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.691 2.26 . . . . 0.0 112.33 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.618 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 19.6 m-85 -58.6 115.02 2.77 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.866 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -140.06 139.83 10.18 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.516 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 111.0 2.7 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.716 2.277 . . . . 0.0 112.305 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 107.18 0.9 35.64 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.487 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -137.85 142.09 40.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.849 0.356 . . . . 0.0 110.903 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.4 p90 -68.57 174.51 4.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.844 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 29.1 p90 -161.25 132.21 5.32 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.922 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -103.34 106.38 16.88 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.859 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.794 HD13 ' N ' ' A' ' 112' ' ' SER . 0.4 OUTLIER -109.16 138.39 45.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.912 -179.955 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.794 ' N ' HD13 ' A' ' 111' ' ' LEU . 2.6 m -145.44 113.67 6.59 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.867 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.552 HG23 HG22 ' A' ' 122' ' ' VAL . 4.0 mp -93.55 136.82 24.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.108 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 50.1 mtt-85 -110.22 120.9 43.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.851 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . 0.431 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 26.3 t -92.06 122.21 34.35 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.918 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -123.62 -149.44 7.77 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.484 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.437 HD21 ' HB2' ' A' ' 39' ' ' ALA . 36.3 mt -109.37 -40.88 4.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.86 0.362 . . . . 0.0 110.904 -179.871 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -80.72 -39.54 26.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.83 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -174.11 179.91 1.8 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.898 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.542 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 18.9 m-85 -97.95 155.04 17.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.877 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 15.5 mtpp -130.48 100.55 5.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.921 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.781 ' CG1' HD11 ' A' ' 111' ' ' LEU . 21.3 t -88.16 128.61 40.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.116 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -120.59 149.79 41.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.909 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.45 ' CB ' ' HG3' ' A' ' 102' ' ' PRO . . . -134.17 110.1 9.34 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.093 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 58.13 31.58 20.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.911 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.31 38.2 15.64 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.484 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 8.7 mm100 -143.77 128.88 18.66 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.868 0.366 . . . . 0.0 110.914 -179.854 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 35.6 t-80 -59.21 107.19 0.52 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.845 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.476 HD11 ' CD ' ' A' ' 102' ' ' PRO . 8.5 tp -78.41 -66.12 0.89 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.899 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.472 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 5.3 p90 -166.42 169.53 13.86 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.861 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -115.21 149.71 37.28 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.917 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.657 ' CG ' HD13 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -117.73 108.02 14.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.899 -179.92 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.579 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -63.33 134.97 56.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.066 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 42.3 m-70 -63.34 107.3 1.06 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.884 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 67.6 mtt-85 -89.71 -48.85 7.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.849 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . 0.422 HD13 HD22 ' A' ' 87' ' ' LEU . 12.2 tp -93.51 109.33 20.93 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.943 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 12.1 t -50.64 -33.37 22.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.868 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.518 ' HB1' ' HD2' ' A' ' 141' ' ' ARG . . . -87.19 33.55 0.68 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.107 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.647 ' O ' HD12 ' A' ' 37' ' ' LEU . 8.2 p90 -50.74 -31.61 17.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.868 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 6.1 pt20 -56.14 -46.46 79.22 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.885 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.518 ' HD2' ' HB1' ' A' ' 138' ' ' ALA . 27.6 mtt-85 -47.5 -44.22 25.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.866 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.756 ' HA ' HG22 ' A' ' 62' ' ' VAL . 92.3 t -43.3 103.45 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.153 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.469 ' OD1' ' CA ' ' A' ' 36' ' ' GLY . 17.1 m-20 -128.19 31.48 5.05 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.841 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 18.1 m -142.44 123.19 14.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.122 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.559 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.6 tp -120.15 107.69 13.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.933 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -110.75 152.31 26.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.919 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 25.1 mt -139.58 112.77 6.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.177 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -123.57 171.29 9.64 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.928 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 113.03 -148.07 18.54 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.522 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 28.8 m-20 -111.56 89.1 2.96 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.859 0.361 . . . . 0.0 110.881 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.448 HG22 ' N ' ' A' ' 152' ' ' THR . 7.2 p -148.85 155.33 8.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.129 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . 0.448 ' N ' HG22 ' A' ' 151' ' ' VAL . 16.9 m -116.21 94.51 4.68 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.16 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.476 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 78.6 mt -75.92 139.95 41.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.886 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 68.6 m -127.8 -35.57 2.09 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.858 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 39.6 t80 -146.93 125.08 12.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.942 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 79.4 t -138.97 106.33 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.118 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 13.9 tt0 -119.69 141.16 49.63 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.931 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' ILE . . . . . 0.638 HG23 ' NH1' ' A' ' 41' ' ' ARG . 15.6 mt . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.121 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 1.2 t . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.828 0.347 . . . . 0.0 111.129 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -138.92 127.83 23.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.92 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . 0.567 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 8.8 m-80 61.55 47.0 1.08 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.578 0.704 . . . . 0.0 110.901 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.567 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 54.0 Cg_endo -69.75 136.03 31.99 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.65 2.234 . . . . 0.0 112.312 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 -177.72 2.02 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.68 2.253 . . . . 0.0 112.331 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.686 HG13 ' HA ' ' A' ' 28' ' ' PRO . 97.0 t -141.72 138.09 16.87 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.685 0.755 . . . . 0.0 111.107 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.686 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.3 Cg_endo -69.77 144.33 76.38 Favored 'Cis proline' 0 C--N 1.342 0.198 0 C-N-CA 122.65 -1.812 . . . . 0.0 112.325 -0.027 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 8.2 t80 -97.47 117.15 31.09 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.933 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -100.66 102.3 13.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.884 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -97.77 109.4 3.81 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.456 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 9.7 mmt180 -72.91 102.99 3.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.854 0.359 . . . . 0.0 110.876 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.487 HD13 ' NH2' ' A' ' 41' ' ' ARG . 5.6 mt -71.1 114.7 9.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.939 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 5.6 mm-40 -86.32 94.49 9.36 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.911 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 131.33 -32.75 2.9 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.453 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.714 ' O ' HG23 ' A' ' 38' ' ' THR . . . 88.69 173.45 46.87 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.51 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . 0.676 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 88.0 mt -57.18 104.97 0.19 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.854 0.359 . . . . 0.0 110.938 -179.9 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.714 HG23 ' O ' ' A' ' 36' ' ' GLY . 29.0 p -117.07 149.94 39.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.116 -180.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -59.71 -21.27 60.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.122 179.83 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 25.5 mmm-85 -104.42 26.46 8.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.884 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.675 ' CZ ' HD23 ' A' ' 37' ' ' LEU . 23.4 ttt180 -116.97 142.86 46.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.863 -179.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 91.2 m -137.16 121.21 17.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.123 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 mp -90.86 132.46 35.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.156 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.459 ' CG2' ' HE2' ' A' ' 46' ' ' LYS . 70.1 mt -128.57 117.24 44.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.154 179.792 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 34.9 mt -116.15 107.59 22.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.168 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.459 ' HE2' ' CG2' ' A' ' 44' ' ' ILE . 22.3 mtmt -111.65 111.18 21.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.904 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -143.67 -143.62 4.12 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.484 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . 0.405 ' O ' ' CD1' ' A' ' 48' ' ' TYR . 1.1 t80 -167.59 118.27 0.85 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.944 0.402 . . . . 0.0 110.896 -179.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 15.1 t -69.96 115.45 34.0 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.638 0.732 . . . . 0.0 111.135 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 159.02 54.96 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.714 2.276 . . . . 0.0 112.359 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -25.16 29.01 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.683 2.256 . . . . 0.0 112.328 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 67.1 p -100.74 15.41 28.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.134 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -109.89 119.4 5.4 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.489 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.418 ' O ' ' SD ' ' A' ' 76' ' ' MET . 24.8 mtpt -62.47 -58.91 5.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.816 0.341 . . . . 0.0 110.89 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 37.0 p -175.58 162.37 2.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.827 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 3.5 p90 -116.14 -174.98 2.65 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.87 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.98 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -156.91 137.38 13.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.119 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.429 HD12 ' N ' ' A' ' 58' ' ' ILE . 4.6 mp -118.14 100.78 10.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.152 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -99.85 144.04 29.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.911 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.62 ' CE2' HD13 ' A' ' 145' ' ' LEU . 50.1 m-85 -115.04 97.69 6.37 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.881 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.47 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 35.5 ttmt -96.13 167.68 11.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.899 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.615 HG22 ' HA ' ' A' ' 142' ' ' VAL . 43.6 t -100.61 122.52 52.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.102 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -58.58 -40.21 94.28 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.515 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.0 t -64.43 -70.74 0.21 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.941 0.4 . . . . 0.0 110.902 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 48.5 t -79.75 -75.06 0.27 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.875 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 131.43 41.37 0.21 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.487 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.433 ' O ' HG23 ' A' ' 62' ' ' VAL . 0.8 OUTLIER -114.71 141.47 47.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.833 0.349 . . . . 0.0 110.879 179.995 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.479 HD12 ' HB3' ' A' ' 86' ' ' LEU . 43.0 mt -88.05 119.55 35.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.111 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -90.25 -33.57 16.1 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.059 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.712 HD21 HD11 ' A' ' 72' ' ' ILE . 62.7 tp -138.44 131.2 29.43 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.898 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.497 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.3 OUTLIER -135.01 93.91 3.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.866 179.877 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.712 HD11 HD21 ' A' ' 70' ' ' LEU . 17.1 mt -98.09 133.16 41.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.096 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.98 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.2 OUTLIER -140.8 106.87 6.36 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.597 0.713 . . . . 0.0 110.871 179.937 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.611 ' HB3' ' CD2' ' A' ' 103' ' ' PHE . 53.8 Cg_endo -69.75 154.63 67.56 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.702 2.268 . . . . 0.0 112.383 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 46.0 mtp85 -132.96 94.58 3.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.892 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . 0.418 ' SD ' ' O ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.885 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 28.8 p . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.85 0.357 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.2 t -99.35 110.46 26.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.149 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.525 HG22 ' HD3' ' A' ' 96' ' ' LYS . 67.6 t -82.71 145.45 8.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.113 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -125.84 124.15 40.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.895 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.497 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.4 m120 -135.49 177.12 8.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.889 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 87.1 p -160.67 105.13 1.4 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.826 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.934 HD12 ' O ' ' A' ' 90' ' ' SER . 22.9 tp -77.74 119.34 21.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.943 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 90' ' ' SER . 93.0 mt -96.71 161.48 13.86 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.915 179.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.554 HD22 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -37.91 101.67 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.864 179.895 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.51 -7.05 0.68 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.477 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.934 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -117.54 170.03 9.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.856 0.36 . . . . 0.0 110.871 -179.748 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.841 ' NE1' HD13 ' A' ' 86' ' ' LEU . 20.7 m95 -128.58 161.1 30.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.927 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -93.14 -110.26 1.98 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.465 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 72.0 m -159.91 178.12 10.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.855 0.359 . . . . 0.0 110.87 -179.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.435 ' C ' ' OE2' ' A' ' 95' ' ' GLU . 30.2 mt-10 -103.07 123.62 47.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.887 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . 0.435 ' OE2' ' C ' ' A' ' 94' ' ' GLU . 3.5 mp0 -122.88 116.96 24.5 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.89 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.525 ' HD3' HG22 ' A' ' 82' ' ' VAL . 9.4 mtmp? -118.79 120.55 37.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.891 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -171.84 108.0 0.23 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.966 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.788 HD11 ' O ' ' A' ' 100' ' ' HIS . 4.1 tt -147.66 152.3 12.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.119 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.523 HG23 ' N ' ' A' ' 100' ' ' HIS . 8.9 t -85.42 -47.18 10.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.162 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . 0.788 ' O ' HD11 ' A' ' 98' ' ' ILE . 1.7 p-80 -147.06 133.49 19.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.87 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . 0.41 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 7.4 t30 -103.67 98.17 12.34 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.674 0.749 . . . . 0.0 110.856 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.5 Cg_endo -69.75 -42.5 3.36 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.687 2.258 . . . . 0.0 112.331 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.611 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 11.7 m-85 -34.01 110.58 0.09 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.858 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -133.09 136.66 8.84 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.515 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 97.78 0.65 Allowed 'Trans proline' 0 N--CA 1.465 -0.151 0 C-N-CA 122.715 2.277 . . . . 0.0 112.371 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 119.97 1.92 12.8 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.473 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 9.4 pt20 -134.59 149.09 50.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.846 0.355 . . . . 0.0 110.911 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -66.52 168.39 9.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.901 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.41 ' O ' ' CG ' ' A' ' 109' ' ' PHE . 14.9 p90 -160.71 125.51 3.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.906 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -101.75 108.28 19.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.883 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.735 HD13 ' N ' ' A' ' 112' ' ' SER . 0.7 OUTLIER -111.81 139.01 47.65 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.932 -179.96 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.735 ' N ' HD13 ' A' ' 111' ' ' LEU . 1.5 m -144.9 115.51 7.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.834 -179.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.504 HG22 ' HD2' ' A' ' 120' ' ' PHE . 4.9 mp -97.28 132.03 42.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.135 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . 0.535 ' O ' ' CD2' ' A' ' 120' ' ' PHE . 6.1 mtp-105 -104.53 133.39 49.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.879 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . 0.559 ' HA ' ' CE2' ' A' ' 120' ' ' PHE . 5.7 t -98.08 121.72 40.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.895 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -122.97 -163.04 11.69 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.521 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 7.6 mt -104.82 -28.75 10.96 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.784 0.326 . . . . 0.0 110.892 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . 0.4 ' C ' ' OD1' ' A' ' 118' ' ' ASP . 7.2 t0 -97.43 -39.91 8.94 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.886 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 29.4 ptt-85 -170.34 163.89 8.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.676 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 14.8 m-85 -88.23 154.78 20.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.86 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 13.6 mtpp -126.94 100.17 6.04 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.908 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.524 HG13 HD11 ' A' ' 111' ' ' LEU . 39.3 t -87.44 132.28 33.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.128 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -123.79 146.59 48.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.919 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -134.74 111.89 10.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.111 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 55.64 35.18 24.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.865 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.57 39.57 21.25 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.492 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 9.8 mt-30 -145.99 129.11 16.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.837 0.351 . . . . 0.0 110.937 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 33.0 t-80 -60.76 99.29 0.08 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.889 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.538 HD22 HD21 ' A' ' 111' ' ' LEU . 9.8 tp -66.71 -69.62 0.3 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.93 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.482 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 4.9 p90 -163.29 171.38 16.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.913 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -116.49 148.09 41.12 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.86 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.673 ' CG ' HD13 ' A' ' 70' ' ' LEU . 0.3 OUTLIER -116.99 107.66 14.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.859 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.463 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -64.89 133.27 51.49 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.092 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 34.3 m-70 -60.68 109.09 0.95 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.846 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 32.0 mtt-85 -91.54 -51.38 5.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.891 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.0 tp -93.18 109.3 20.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.913 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 81.6 p -49.72 -35.22 21.26 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.83 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -82.22 39.44 0.58 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.115 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.485 ' O ' HD12 ' A' ' 37' ' ' LEU . 7.5 p90 -60.68 -37.62 82.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.942 -179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -55.5 -32.68 63.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.915 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.509 ' O ' HG13 ' A' ' 62' ' ' VAL . 34.6 mtp85 -62.2 -37.72 86.39 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.879 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.615 ' HA ' HG22 ' A' ' 62' ' ' VAL . 93.5 t -49.08 104.12 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.087 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.405 ' OD1' ' CA ' ' A' ' 36' ' ' GLY . 0.9 OUTLIER -127.56 34.55 4.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.905 179.892 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 18.7 m -146.89 112.93 5.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.144 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.62 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.3 tp -112.18 107.14 15.93 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.902 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' GLU . . . . . 0.41 ' C ' HG13 ' A' ' 147' ' ' ILE . 2.0 pm0 -109.21 153.97 23.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.903 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.41 HG13 ' C ' ' A' ' 146' ' ' GLU . 20.2 mt -140.03 107.23 2.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.146 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -115.69 171.5 7.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.932 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 110.64 -146.72 17.5 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.502 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -114.6 93.44 4.33 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.801 0.334 . . . . 0.0 110.896 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 4.0 p -151.2 142.09 16.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.144 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 9.9 m -101.94 94.78 5.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.161 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.458 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 83.8 mt -77.33 138.1 39.15 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.89 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 16.6 m -122.35 -39.75 2.54 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.87 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 23.8 t80 -146.0 129.01 16.5 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.914 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 70.1 t -140.3 106.33 2.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.138 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 8.9 tt0 -120.8 132.89 55.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.928 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 14.1 mt . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.165 179.945 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.437 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.4 m . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.851 0.358 . . . . 0.0 111.129 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -137.48 125.54 22.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . 0.501 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.2 t-20 52.15 50.69 8.59 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.583 0.706 . . . . 0.0 110.862 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.501 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.77 140.36 42.46 Favored 'Trans proline' 0 N--CA 1.465 -0.176 0 C-N-CA 122.678 2.252 . . . . 0.0 112.379 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 -178.4 2.3 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.709 2.273 . . . . 0.0 112.371 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.666 HG13 ' HA ' ' A' ' 28' ' ' PRO . 97.8 t -140.35 137.58 17.95 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.658 0.742 . . . . 0.0 111.085 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.666 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.8 Cg_endo -69.72 144.68 77.24 Favored 'Cis proline' 0 C--N 1.342 0.187 0 C-N-CA 122.658 -1.809 . . . . 0.0 112.338 -0.067 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 6.2 t80 -97.88 120.72 38.78 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.925 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -103.07 101.02 10.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.887 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -106.62 109.69 3.15 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.477 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.427 ' NH1' ' HA3' ' A' ' 63' ' ' GLY . 8.3 mmt180 -74.04 109.34 7.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.841 0.353 . . . . 0.0 110.876 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.639 HD23 HG12 ' A' ' 158' ' ' ILE . 6.9 mt -67.54 101.08 0.94 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.88 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 24.3 mt-30 -73.36 100.35 3.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.867 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 132.81 -40.18 1.64 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.498 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.785 ' O ' HG23 ' A' ' 38' ' ' THR . . . 89.84 161.45 37.48 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.466 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . 0.661 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 91.3 mt -55.42 99.07 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.891 0.376 . . . . 0.0 110.893 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.785 HG23 ' O ' ' A' ' 36' ' ' GLY . 26.9 p -117.94 145.95 44.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.167 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -41.7 -33.76 0.53 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.113 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 19.0 mmt180 -101.9 41.63 1.2 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.885 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.491 ' NE ' ' O ' ' A' ' 36' ' ' GLY . 29.7 ttm-85 -122.66 138.6 54.55 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 52.7 m -139.54 120.34 14.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.15 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.43 ' N ' HD12 ' A' ' 43' ' ' ILE . 4.8 mp -93.32 136.47 25.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.099 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 96.6 mt -128.46 137.0 58.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.125 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 55.0 mt -136.97 107.49 5.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.202 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 24.2 mtmt -110.64 108.69 18.69 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.877 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -139.84 -139.69 3.8 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.498 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -171.39 136.72 1.03 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.948 0.404 . . . . 0.0 110.913 -179.853 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.402 HG23 ' CD1' ' A' ' 109' ' ' PHE . 21.5 t -86.73 116.34 65.61 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.64 0.733 . . . . 0.0 111.121 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 158.97 55.13 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.687 2.258 . . . . 0.0 112.324 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 -14.88 36.6 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.642 2.228 . . . . 0.0 112.368 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 38.0 p -113.91 20.13 16.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.154 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -113.03 113.45 3.18 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.501 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 25.1 mtpt -58.89 -58.91 6.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.809 0.337 . . . . 0.0 110.89 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 40.5 p -174.22 162.45 3.68 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.862 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.604 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 6.0 p90 -119.37 -173.57 2.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.874 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.45 137.37 13.49 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.147 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.543 HG22 ' CE1' ' A' ' 60' ' ' PHE . 3.9 mp -114.24 104.26 16.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.11 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . 0.497 ' ND2' ' ND1' ' A' ' 71' ' ' HIS . 22.0 m120 -98.48 141.4 31.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.875 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.567 ' CE2' HD13 ' A' ' 145' ' ' LEU . 5.6 m-85 -115.88 97.16 5.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.881 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.443 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 35.2 ttmt -96.02 168.37 10.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.874 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.671 HG22 ' HA ' ' A' ' 142' ' ' VAL . 49.0 t -99.78 124.33 53.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.086 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.427 ' HA3' ' NH1' ' A' ' 32' ' ' ARG . . . -62.25 -30.46 76.03 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.467 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.483 ' H ' HG12 ' A' ' 62' ' ' VAL . 9.7 t -71.24 -71.63 0.25 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.846 0.355 . . . . 0.0 110.821 -179.703 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 22.8 t -83.87 -70.98 0.53 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 132.14 42.82 0.17 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.501 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.517 ' O ' HG23 ' A' ' 62' ' ' VAL . 0.8 OUTLIER -114.02 141.74 47.05 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.808 0.337 . . . . 0.0 110.88 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.448 HD12 ' HB3' ' A' ' 86' ' ' LEU . 80.7 mt -86.6 120.2 35.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.14 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.541 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -90.09 -37.57 14.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.076 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.775 HD21 HD11 ' A' ' 72' ' ' ILE . 21.8 tp -139.26 133.48 31.33 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.902 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.518 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.2 OUTLIER -134.46 92.78 2.96 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.856 179.878 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.775 HD11 HD21 ' A' ' 70' ' ' LEU . 20.4 mt -93.52 135.66 27.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.126 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.5 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 1.1 t-20 -140.91 107.13 6.31 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.626 0.727 . . . . 0.0 110.881 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.604 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.8 Cg_endo -69.77 154.73 67.33 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.669 2.246 . . . . 0.0 112.373 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 45.4 mtp85 -131.67 98.46 4.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.919 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.883 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 16.9 p . . . . . 0 N--CA 1.457 -0.113 0 CA-C-O 120.807 0.337 . . . . 0.0 111.194 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.579 HG22 ' HA ' ' A' ' 74' ' ' PRO . 20.3 t -84.07 109.03 17.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.116 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.706 HG22 ' HD3' ' A' ' 96' ' ' LYS . 57.5 t -78.1 146.09 8.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.117 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -129.81 129.66 44.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.834 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.518 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.8 m120 -141.62 178.45 7.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.847 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 93.1 p -160.83 105.02 1.37 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.873 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.914 HD13 ' NE1' ' A' ' 91' ' ' TRP . 25.1 tp -77.77 118.79 20.46 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.899 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.521 ' N ' ' O ' ' A' ' 90' ' ' SER . 92.7 mt -95.88 162.22 13.67 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.905 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.447 ' ND2' ' H ' ' A' ' 88' ' ' ASN . 8.8 m-80 -40.76 101.87 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.878 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.03 -3.94 2.8 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.477 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.845 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -123.73 172.65 8.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.828 0.347 . . . . 0.0 110.885 -179.739 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.914 ' NE1' HD13 ' A' ' 86' ' ' LEU . 18.8 m95 -129.04 160.93 31.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.917 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -91.46 -106.65 1.47 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.52 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . 0.441 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 3.5 m -163.06 174.83 11.75 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.787 0.327 . . . . 0.0 110.902 -179.759 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.468 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 24.7 mt-10 -99.53 121.74 41.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.844 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 25.0 mm-40 -120.97 109.55 15.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.895 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.706 ' HD3' HG22 ' A' ' 82' ' ' VAL . 39.6 mtmt -115.51 117.65 30.95 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.933 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 2.8 tppp? -168.59 107.1 0.47 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.887 179.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.79 HD11 ' O ' ' A' ' 100' ' ' HIS . 8.7 tt -144.39 146.1 20.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.139 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.4 t -83.72 -38.34 21.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.109 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . 0.79 ' O ' HD11 ' A' ' 98' ' ' ILE . 5.2 p-80 -153.71 134.27 13.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.847 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . 0.441 ' C ' ' OD1' ' A' ' 101' ' ' ASN . 27.1 t-20 -107.86 96.92 18.67 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.604 0.716 . . . . 0.0 110.879 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 101' ' ' ASN . 53.8 Cg_endo -69.72 -36.08 11.59 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.674 2.249 . . . . 0.0 112.36 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.483 ' CE2' ' HB3' ' A' ' 74' ' ' PRO . 5.7 m-85 -40.29 110.23 0.14 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.823 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -136.63 139.8 10.93 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.52 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 106.39 1.64 Allowed 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.694 2.263 . . . . 0.0 112.362 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 124.86 -11.47 7.82 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.51 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.9 pt20 -130.14 165.22 22.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.803 0.335 . . . . 0.0 110.925 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.3 p90 -87.48 169.26 12.37 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.889 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.48 ' CZ ' ' CZ ' ' A' ' 56' ' ' PHE . 30.0 p90 -153.63 124.75 7.41 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.898 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -94.34 103.38 15.38 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.843 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.859 HD13 ' N ' ' A' ' 112' ' ' SER . 0.5 OUTLIER -101.61 136.77 40.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.946 -179.965 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.859 ' N ' HD13 ' A' ' 111' ' ' LEU . 6.1 m -144.01 111.59 6.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.84 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.411 HG23 HG22 ' A' ' 122' ' ' VAL . 4.2 mp -93.53 141.72 14.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.103 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . 0.427 ' O ' ' CG ' ' A' ' 120' ' ' PHE . 19.6 mtp180 -112.52 142.07 45.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.917 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . 0.585 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 3.1 t -114.0 109.41 18.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.892 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -107.53 -138.76 8.86 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.515 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.5 mt -118.69 -40.56 2.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.811 0.339 . . . . 0.0 110.903 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . 0.427 ' OD1' ' N ' ' A' ' 119' ' ' ARG . 19.8 p-10 -87.73 -34.09 18.49 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.831 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.427 ' N ' ' OD1' ' A' ' 118' ' ' ASP . 10.6 ptp85 -172.57 176.07 3.33 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.922 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.661 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 3.7 m-30 -98.98 166.08 11.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.893 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 26.2 mtpt -137.73 105.92 5.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.916 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.63 HG13 HD11 ' A' ' 111' ' ' LEU . 42.8 t -90.84 132.52 35.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.096 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 53.9 m-85 -122.2 155.97 34.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.916 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.499 ' O ' ' ND2' ' A' ' 125' ' ' ASN . . . -141.15 118.96 11.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.104 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.499 ' ND2' ' O ' ' A' ' 124' ' ' ALA . 10.2 p30 50.87 30.75 5.42 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.894 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 82.88 30.96 30.46 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.475 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 33.3 mm-40 -135.6 139.51 43.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.797 0.332 . . . . 0.0 110.905 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 31.2 t-80 -67.7 112.54 4.86 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.857 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 8.3 tp -84.23 -66.97 0.83 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.894 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.4 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 12.1 p90 -168.63 170.76 9.27 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.906 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -114.01 149.11 35.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.806 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.603 ' CD1' HD13 ' A' ' 70' ' ' LEU . 0.4 OUTLIER -111.6 105.09 13.54 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.906 -179.931 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.487 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -60.45 137.15 58.19 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.105 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 8.2 m-70 -66.35 110.41 3.07 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.861 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.441 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 71.6 mtt-85 -96.72 -46.6 6.22 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.859 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.4 tp -98.54 108.06 20.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.852 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 29.4 t -50.23 -33.64 20.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.858 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.453 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.79 29.28 0.46 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.083 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.416 ' CG ' ' N ' ' A' ' 140' ' ' GLN . 33.8 p90 -49.66 -44.35 47.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.869 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' GLN . . . . . 0.416 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 7.8 pt20 -47.81 -39.13 17.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.913 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.453 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 67.3 mtp180 -56.45 -40.83 75.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.85 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.671 ' HA ' HG22 ' A' ' 62' ' ' VAL . 58.7 t -45.68 101.82 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.11 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.492 ' OD2' ' N ' ' A' ' 36' ' ' GLY . 0.7 OUTLIER -127.04 34.28 4.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.851 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 24.6 m -147.02 115.55 6.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.148 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.567 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.1 tp -114.69 114.55 25.79 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.908 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' GLU . . . . . 0.428 ' C ' HG13 ' A' ' 147' ' ' ILE . 4.1 pt-20 -114.38 158.12 21.94 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.868 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.428 HG13 ' C ' ' A' ' 146' ' ' GLU . 30.7 mt -142.9 123.14 10.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.119 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -132.21 175.65 9.07 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.912 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 102.49 -151.64 18.24 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.475 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -103.66 92.5 4.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.87 0.367 . . . . 0.0 110.85 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.4 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 7.4 p -150.95 150.15 13.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.165 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 26.7 m -113.57 93.7 4.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.131 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.445 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 66.5 mt -75.5 138.27 41.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.925 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 36.7 m -122.43 -34.91 3.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.878 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 17.3 t80 -150.59 130.69 13.5 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.96 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 94.8 t -140.56 111.89 4.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.123 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 11.9 tt0 -134.05 129.21 35.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.944 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' ILE . . . . . 0.639 HG12 HD23 ' A' ' 33' ' ' LEU . 4.6 mp . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.17 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.512 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.6 m . . . . . 0 C--O 1.232 0.149 0 CA-C-O 120.861 0.363 . . . . 0.0 111.158 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.512 ' CD1' ' O ' ' A' ' 22' ' ' THR . 10.2 m-85 -150.06 132.53 15.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.924 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . 0.565 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 22.1 m-80 50.74 46.58 3.83 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.607 0.718 . . . . 0.0 110.835 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.565 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.78 137.04 34.47 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.668 2.245 . . . . 0.0 112.378 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 179.88 3.38 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.674 2.249 . . . . 0.0 112.351 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.686 HG13 ' HA ' ' A' ' 28' ' ' PRO . 95.2 t -140.21 138.18 18.9 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.643 0.735 . . . . 0.0 111.11 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.686 ' HA ' HG13 ' A' ' 27' ' ' VAL . 54.1 Cg_endo -69.72 144.96 78.02 Favored 'Cis proline' 0 C--N 1.341 0.161 0 C-N-CA 122.658 -1.809 . . . . 0.0 112.353 -0.145 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 8.9 t80 -97.45 121.39 39.3 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.891 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 70.6 m-85 -108.02 101.65 10.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.86 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -116.33 104.61 1.27 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.487 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.401 ' HD2' ' C ' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -72.54 130.48 40.73 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.848 0.356 . . . . 0.0 110.9 -179.893 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.44 ' N ' ' O ' ' A' ' 143' ' ' ASP . 5.0 mt -74.2 147.47 42.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.905 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 55.8 mt-30 -107.81 89.59 3.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.903 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.78 -47.43 0.99 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.503 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.636 ' O ' HG22 ' A' ' 38' ' ' THR . . . 104.94 159.03 23.47 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.484 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . 0.506 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 79.3 mt -53.32 110.73 0.58 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.88 0.372 . . . . 0.0 110.934 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.707 HG23 ' HB2' ' A' ' 41' ' ' ARG . 0.0 OUTLIER -133.8 170.37 15.69 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.112 179.967 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.713 ' HB2' HD21 ' A' ' 117' ' ' LEU . . . -59.29 -41.93 90.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.085 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 6.5 mpt_? -94.5 51.07 1.4 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.862 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.722 ' NH1' HG22 ' A' ' 158' ' ' ILE . 20.4 ttm-85 -138.94 136.6 35.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 91.8 m -139.52 125.16 19.38 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.173 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.4 mp -96.31 138.79 20.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.152 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 90.5 mt -131.57 138.38 53.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.143 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 69.7 mt -135.42 107.56 7.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.152 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.409 ' HE3' ' CD1' ' A' ' 155' ' ' TYR . 8.7 mtmm -108.1 111.64 23.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 179.865 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -144.61 -144.92 4.25 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.495 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . 0.58 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 1.3 t80 -170.65 123.87 0.66 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.853 0.359 . . . . 0.0 110.957 -179.82 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 13.1 t -73.58 115.28 40.07 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.584 0.707 . . . . 0.0 111.152 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 155.48 65.86 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.663 2.242 . . . . 0.0 112.337 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.85 -13.58 34.64 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.679 2.253 . . . . 0.0 112.305 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 32.9 p -111.71 14.51 21.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.114 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -111.02 122.07 6.03 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.51 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.4 mtpt -63.71 -59.81 4.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.809 0.338 . . . . 0.0 110.93 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 14.4 p -172.8 158.33 3.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.826 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.588 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 17.9 p90 -113.76 -172.62 2.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.846 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.901 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -155.68 140.98 17.62 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.098 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.441 HG23 HG12 ' A' ' 147' ' ' ILE . 7.2 mt -127.17 101.18 7.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.122 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . 0.415 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 5.4 m-80 -103.14 154.05 19.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.907 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.624 ' CE2' HD13 ' A' ' 145' ' ' LEU . 6.1 m-85 -122.4 102.01 7.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.857 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.401 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 32.8 ttmt -95.68 168.2 10.82 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.864 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.713 HG22 ' HA ' ' A' ' 142' ' ' VAL . 83.2 t -100.06 120.55 49.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.127 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -57.54 -30.25 61.85 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.479 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.484 ' H ' HG12 ' A' ' 62' ' ' VAL . 2.1 m -72.84 -75.3 0.14 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.863 0.363 . . . . 0.0 110.882 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.3 t -79.33 -70.85 0.48 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.867 -179.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 131.18 40.51 0.23 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.486 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.402 ' OD1' ' OD1' ' A' ' 88' ' ' ASN . 0.5 OUTLIER -109.38 147.95 31.91 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.758 0.314 . . . . 0.0 110.854 -179.981 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.427 HD12 ' HB3' ' A' ' 86' ' ' LEU . 53.4 mt -94.35 113.7 29.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.153 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.634 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -86.02 -32.15 21.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.117 179.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.589 HD22 ' CD2' ' A' ' 132' ' ' PHE . 43.3 tp -138.83 131.09 28.4 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.487 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.8 OUTLIER -134.42 95.38 3.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.867 179.855 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.566 HD11 HD21 ' A' ' 70' ' ' LEU . 32.1 mt -100.05 131.53 47.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.133 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.901 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -141.17 107.58 6.21 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.644 0.735 . . . . 0.0 110.874 179.933 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.588 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.9 Cg_endo -69.78 155.23 66.38 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.651 2.234 . . . . 0.0 112.333 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 80.0 mtp180 -132.15 100.01 4.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.87 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . 0.453 ' HE3' ' HB3' ' A' ' 103' ' ' PHE . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.905 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 18.7 p . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.823 0.344 . . . . 0.0 111.135 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.497 HG21 ' HE2' ' A' ' 103' ' ' PHE . 18.4 t -94.39 109.72 22.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.184 179.859 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.593 HG22 ' HD3' ' A' ' 96' ' ' LYS . 41.5 t -81.88 145.25 8.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.137 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -126.45 123.92 38.96 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.888 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.487 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.7 OUTLIER -135.97 178.82 6.75 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.882 -179.935 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 50.7 p -160.07 106.29 1.58 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.855 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.904 HD13 ' NE1' ' A' ' 91' ' ' TRP . 24.4 tp -77.38 115.78 17.43 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.904 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.494 HD22 HD13 ' A' ' 136' ' ' LEU . 24.0 mt -91.55 161.09 15.09 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.886 179.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.402 ' OD1' ' OD1' ' A' ' 67' ' ' ASP . 12.3 m-80 -41.58 101.56 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.913 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 67.43 -3.56 4.53 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.46 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.858 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -124.26 172.25 9.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.836 0.351 . . . . 0.0 110.851 -179.709 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.904 ' NE1' HD13 ' A' ' 86' ' ' LEU . 21.0 m95 -129.43 158.63 38.66 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.908 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -89.22 -106.59 1.12 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.445 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 3.7 m -163.6 176.29 9.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.791 0.329 . . . . 0.0 110.887 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.455 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 16.1 mt-10 -99.04 119.65 38.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.908 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -119.23 116.4 26.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.883 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.593 ' HD3' HG22 ' A' ' 82' ' ' VAL . 39.8 mtmt -121.89 119.28 31.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.902 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 27.7 tttp -167.26 108.03 0.62 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.889 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.554 HD11 ' O ' ' A' ' 100' ' ' HIS . 7.2 tt -149.4 147.21 16.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.165 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.543 HG23 ' N ' ' A' ' 100' ' ' HIS . 12.6 t -89.32 -47.47 8.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.134 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . 0.554 ' O ' HD11 ' A' ' 98' ' ' ILE . 4.2 p-80 -138.41 125.24 21.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.845 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -103.3 95.91 7.62 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.613 0.72 . . . . 0.0 110.898 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.82 -34.38 14.49 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.672 2.248 . . . . 0.0 112.303 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.497 ' HE2' HG21 ' A' ' 81' ' ' VAL . 19.0 m-85 -39.33 99.6 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.857 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -129.81 136.3 8.86 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.498 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 99.84 0.78 Allowed 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.658 2.239 . . . . 0.0 112.348 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 130.33 -8.38 5.95 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.48 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 -131.37 162.11 30.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.882 0.372 . . . . 0.0 110.896 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' PHE . . . . . 0.58 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 17.2 m-85 -80.27 172.1 14.2 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.858 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.483 ' O ' ' CD1' ' A' ' 109' ' ' PHE . 19.8 p90 -161.17 119.62 2.45 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.9 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -93.86 101.74 13.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.843 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.875 HD13 ' N ' ' A' ' 112' ' ' SER . 0.5 OUTLIER -101.2 136.75 40.53 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.909 -179.942 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.875 ' N ' HD13 ' A' ' 111' ' ' LEU . 10.4 m -141.6 112.88 7.5 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.882 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.608 HG22 ' HD2' ' A' ' 120' ' ' PHE . 4.1 mp -96.91 115.91 37.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.171 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 21.2 mtp85 -89.75 141.32 28.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.896 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . 0.573 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 13.6 t -113.41 115.25 27.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -111.76 -141.83 8.59 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.473 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.713 HD21 ' HB2' ' A' ' 39' ' ' ALA . 7.4 mt -115.2 -33.38 5.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.804 0.335 . . . . 0.0 110.922 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . 0.582 ' O ' ' CD2' ' A' ' 134' ' ' HIS . 6.3 m-20 -89.53 -42.27 11.54 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.904 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -166.22 -176.34 3.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.893 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.608 ' HD2' HG22 ' A' ' 113' ' ' ILE . 12.0 m-85 -102.44 156.2 17.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.897 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 23.2 mtpt -130.1 105.92 8.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.865 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.715 HG13 HD11 ' A' ' 111' ' ' LEU . 46.8 t -91.3 131.73 37.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.109 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 79.5 m-85 -122.26 149.98 42.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.933 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.442 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -134.59 108.28 7.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.094 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 56.93 35.27 26.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.871 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.09 38.31 15.79 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.483 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 7.3 mt-30 -146.18 126.63 14.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.81 0.338 . . . . 0.0 110.924 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 -60.27 102.25 0.16 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.874 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.442 HD13 ' CB ' ' A' ' 124' ' ' ALA . 7.2 tp -70.19 -66.5 0.59 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.932 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.44 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 7.0 p90 -162.16 172.13 16.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.864 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 21.0 p-10 -118.1 145.79 44.6 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.847 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.589 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -112.92 107.02 15.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.833 -179.893 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.587 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -62.97 134.31 55.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.087 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' HIS . . . . . 0.582 ' CD2' ' O ' ' A' ' 118' ' ' ASP . 10.0 m-70 -60.54 101.68 0.15 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.883 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 12.3 mtt-85 -88.11 -45.97 9.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.875 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . 0.494 HD13 HD22 ' A' ' 87' ' ' LEU . 10.0 tp -98.4 108.08 20.69 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.937 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 28.6 p -51.8 -31.23 26.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.858 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.651 ' HB1' ' HG3' ' A' ' 141' ' ' ARG . . . -82.71 29.08 0.46 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.08 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -49.59 -35.19 19.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.899 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' GLN . . . . . 0.443 ' HG2' ' N ' ' A' ' 141' ' ' ARG . 18.4 pm0 -60.17 -28.92 68.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.964 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.651 ' HG3' ' HB1' ' A' ' 138' ' ' ALA . 52.9 mtp85 -65.27 -38.86 91.57 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.887 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.713 ' HA ' HG22 ' A' ' 62' ' ' VAL . 52.4 t -55.15 108.97 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.113 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.44 ' O ' ' N ' ' A' ' 33' ' ' LEU . 3.4 p30 -129.52 27.91 5.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.839 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -135.82 135.57 39.95 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.174 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.624 HD13 ' CE2' ' A' ' 60' ' ' PHE . 7.5 tp -131.13 103.9 6.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.9 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' GLU . . . . . 0.428 ' C ' HG13 ' A' ' 147' ' ' ILE . 2.6 pt-20 -106.51 151.22 25.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.874 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.441 HG12 HG23 ' A' ' 58' ' ' ILE . 15.7 mt -140.17 109.57 3.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.116 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -120.41 170.93 8.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.916 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 109.85 -150.68 17.42 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.517 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -107.5 91.36 3.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.886 0.374 . . . . 0.0 110.902 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.447 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 3.3 p -150.91 137.62 12.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.123 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 24.7 m -96.96 93.65 6.74 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.119 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.481 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 61.3 mt -77.98 132.76 37.98 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.898 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 53.5 m -119.13 -40.86 2.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.894 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . 0.409 ' CD1' ' HE3' ' A' ' 46' ' ' LYS . 36.4 t80 -141.74 129.53 21.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.948 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 75.3 t -140.77 105.65 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.159 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 19.3 tt0 -120.26 132.03 55.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.92 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' ILE . . . . . 0.722 HG22 ' NH1' ' A' ' 41' ' ' ARG . 12.8 mt . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.161 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.55 ' CG2' ' N ' ' A' ' 23' ' ' PHE . 1.8 m . . . . . 0 N--CA 1.457 -0.11 0 CA-C-O 120.804 0.335 . . . . 0.0 111.126 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.55 ' N ' ' CG2' ' A' ' 22' ' ' THR . 14.3 m-85 -154.52 136.18 14.37 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . 0.514 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 10.4 m-20 41.21 49.76 3.74 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.61 0.719 . . . . 0.0 110.858 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.514 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.8 Cg_endo -69.74 140.9 43.87 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.678 2.252 . . . . 0.0 112.341 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 178.4 4.61 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.663 2.242 . . . . 0.0 112.375 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.67 HG13 ' HA ' ' A' ' 28' ' ' PRO . 89.5 t -140.18 137.82 18.49 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.657 0.741 . . . . 0.0 111.123 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.67 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.4 Cg_endo -69.74 144.34 76.35 Favored 'Cis proline' 0 C--O 1.231 0.173 0 C-N-CA 122.7 -1.792 . . . . 0.0 112.345 -0.055 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 9.2 t80 -96.75 118.9 34.21 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.931 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 65.3 m-85 -104.8 101.12 10.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.888 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -112.83 102.05 1.26 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.456 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.419 ' O ' ' HG3' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -72.63 121.6 20.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.852 0.358 . . . . 0.0 110.923 -179.897 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.482 ' N ' ' O ' ' A' ' 143' ' ' ASP . 13.9 mt -65.71 149.62 49.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.914 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . 0.401 HE21 ' NH1' ' A' ' 32' ' ' ARG . 10.4 mm-40 -110.68 82.06 1.53 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.919 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.447 ' C ' ' OD2' ' A' ' 143' ' ' ASP . . . 140.49 -46.87 0.9 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.504 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.754 ' O ' HG23 ' A' ' 38' ' ' THR . . . 109.54 166.55 20.14 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.505 -179.882 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . 0.501 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 49.8 mt -57.3 105.16 0.21 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.96 0.41 . . . . 0.0 110.891 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.754 HG23 ' O ' ' A' ' 36' ' ' GLY . 2.1 p -116.76 151.81 35.67 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.148 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -58.07 -18.21 23.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.117 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 7.3 mpt_? -109.93 27.53 9.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.899 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.718 ' NH2' HD11 ' A' ' 43' ' ' ILE . 20.8 ttp85 -113.66 141.5 47.15 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.857 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 97.9 m -139.56 121.35 15.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.111 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.718 HD11 ' NH2' ' A' ' 41' ' ' ARG . 5.0 mp -90.95 143.64 10.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.125 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 89.3 mt -136.22 129.21 46.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.149 179.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 60.6 mt -130.05 107.74 15.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.152 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.506 ' HE3' ' CD1' ' A' ' 155' ' ' TYR . 18.5 mtmt -110.36 111.8 23.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.904 179.856 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -147.14 -145.54 4.21 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.505 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -166.81 126.14 1.47 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.884 0.374 . . . . 0.0 110.913 -179.815 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 24.6 t -74.82 117.02 59.3 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.643 0.735 . . . . 0.0 111.114 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 156.23 63.82 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.698 2.266 . . . . 0.0 112.331 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -15.44 37.1 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.657 2.238 . . . . 0.0 112.359 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 26.4 p -110.36 14.64 22.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.154 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -109.25 120.44 5.81 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.493 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 30.1 mtpt -61.65 -60.97 2.88 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.775 0.321 . . . . 0.0 110.914 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 9.2 p -174.19 156.51 2.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.823 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.616 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 11.1 p90 -111.0 -174.46 2.48 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.83 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.961 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -155.42 141.15 18.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.096 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.508 HD11 ' CE2' ' A' ' 56' ' ' PHE . 3.6 mp -121.24 100.08 8.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.136 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -102.56 148.08 25.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.887 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.924 ' CE2' HD13 ' A' ' 145' ' ' LEU . 34.7 m-85 -119.99 102.9 8.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.894 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.404 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 33.6 ttmt -95.62 166.95 11.59 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.91 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.741 HG22 ' HA ' ' A' ' 142' ' ' VAL . 91.4 t -98.2 125.54 51.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.166 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -61.26 -35.7 91.31 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.511 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.9 m -67.68 -73.27 0.14 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.896 0.379 . . . . 0.0 110.817 -179.708 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 32.3 t -80.37 -71.49 0.46 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.867 -179.794 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 130.7 41.69 0.22 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.464 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -112.58 146.37 38.69 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.782 0.325 . . . . 0.0 110.848 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.514 HD12 ' HB3' ' A' ' 86' ' ' LEU . 50.7 mt -91.65 121.23 41.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.135 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.505 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -91.3 -36.97 13.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.114 179.828 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.637 HD21 HD11 ' A' ' 72' ' ' ILE . 32.1 tp -134.87 130.4 35.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.919 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.487 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.3 OUTLIER -134.76 92.97 2.96 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.84 179.855 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.637 HD11 HD21 ' A' ' 70' ' ' LEU . 20.6 mt -96.69 134.08 35.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.17 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.961 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -140.93 107.42 6.32 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.591 0.71 . . . . 0.0 110.885 179.969 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.616 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.6 Cg_endo -69.76 155.05 66.93 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.679 2.253 . . . . 0.0 112.337 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 66.4 mtp85 -129.24 99.31 5.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.876 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.893 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 32.9 p . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.799 0.333 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.447 ' CG1' ' CG2' ' A' ' 72' ' ' ILE . 20.6 t -106.42 106.03 19.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.126 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.619 HG22 ' HD3' ' A' ' 96' ' ' LYS . 39.2 t -76.38 134.29 29.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.133 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . 0.415 ' NH1' ' O ' ' A' ' 95' ' ' GLU . 0.0 OUTLIER -120.57 123.52 43.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.881 -179.955 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.487 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.2 OUTLIER -134.25 -179.11 5.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.898 -179.934 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 93.5 p -160.57 105.54 1.44 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.839 -179.871 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.942 HD12 ' O ' ' A' ' 90' ' ' SER . 26.1 tp -77.26 117.04 18.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.921 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.503 HD22 HD13 ' A' ' 136' ' ' LEU . 68.5 mt -93.97 160.9 14.52 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.887 179.897 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.543 HD22 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.72 101.35 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.87 179.913 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.93 -6.97 1.27 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.492 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.942 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -119.14 172.22 7.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.877 0.37 . . . . 0.0 110.832 -179.726 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.833 ' NE1' HD13 ' A' ' 86' ' ' LEU . 24.1 m95 -129.05 160.89 31.34 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.908 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -90.84 -93.94 1.26 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.513 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . 0.408 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 2.4 m -174.49 169.46 3.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.841 0.353 . . . . 0.0 110.883 -179.727 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.411 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 27.3 mt-10 -100.84 118.4 36.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.895 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . 0.415 ' O ' ' NH1' ' A' ' 83' ' ' ARG . 5.3 mm-40 -123.19 134.81 54.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.881 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.619 ' HD3' HG22 ' A' ' 82' ' ' VAL . 40.9 mtmt -132.19 116.95 17.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.905 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 17.9 ttpp -164.48 110.4 1.01 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.934 179.862 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.688 HD11 ' O ' ' A' ' 100' ' ' HIS . 4.4 tt -148.72 153.04 11.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.134 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.554 HG23 ' N ' ' A' ' 100' ' ' HIS . 9.0 t -89.64 -48.52 7.23 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.118 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . 0.688 ' O ' HD11 ' A' ' 98' ' ' ILE . 6.1 p-80 -141.24 125.41 17.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.858 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -104.46 96.83 10.79 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.633 0.73 . . . . 0.0 110.882 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 -30.46 22.07 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.725 2.283 . . . . 0.0 112.303 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.444 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 21.8 m-85 -43.94 104.64 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.887 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -132.65 135.86 8.38 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.489 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 97.79 0.66 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.69 2.26 . . . . 0.0 112.322 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 129.94 -3.67 6.03 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.524 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.2 pm0 -135.9 155.92 49.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.839 0.352 . . . . 0.0 110.908 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -77.85 171.16 15.4 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.887 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 29.8 p90 -160.03 133.21 6.81 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.897 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -103.1 103.79 13.89 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.874 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.886 HD13 ' N ' ' A' ' 112' ' ' SER . 0.6 OUTLIER -104.3 137.7 41.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.887 -179.919 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.886 ' N ' HD13 ' A' ' 111' ' ' LEU . 3.6 m -145.16 111.87 5.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.842 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.589 HG23 HG22 ' A' ' 122' ' ' VAL . 4.0 mp -92.99 140.38 16.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.165 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 18.9 mtp180 -113.24 137.67 51.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.86 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . 0.568 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 3.4 t -108.87 117.29 33.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -119.35 -140.97 6.35 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.464 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.5 mt -118.66 -36.09 3.56 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.844 0.354 . . . . 0.0 110.916 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 17.4 m-20 -87.2 -38.39 16.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.862 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 16.2 ptp180 -175.31 169.28 3.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.838 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.568 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.6 m-30 -92.02 147.71 22.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 24.9 mtpp -120.75 102.19 8.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.921 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.616 HG13 HD11 ' A' ' 111' ' ' LEU . 55.7 t -88.82 132.22 34.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.106 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 62.3 m-85 -118.9 156.66 29.13 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.947 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.416 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -142.21 109.45 5.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.097 179.834 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 56.3 28.78 13.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.888 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 85.67 30.52 23.8 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.466 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . 0.422 ' HB2' ' CE1' ' A' ' 100' ' ' HIS . 56.1 mm-40 -137.91 121.51 17.36 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.791 0.329 . . . . 0.0 110.949 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 29.1 t-80 -50.69 105.14 0.09 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.849 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.439 HD22 ' CD2' ' A' ' 111' ' ' LEU . 10.8 tp -72.84 -69.1 0.43 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.547 ' HZ ' HD13 ' A' ' 72' ' ' ILE . 4.2 p90 -165.62 170.76 13.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.874 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 61.9 m-20 -114.96 148.76 38.32 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.876 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.574 ' CE1' ' O ' ' A' ' 133' ' ' ALA . 0.1 OUTLIER -115.01 107.88 15.95 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.88 -179.868 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.574 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -64.0 131.1 46.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.117 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 46.2 m-70 -56.62 100.58 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.847 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.408 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 17.6 mtt-85 -83.9 -51.45 7.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.865 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . 0.503 HD13 HD22 ' A' ' 87' ' ' LEU . 14.2 tp -93.27 108.01 19.72 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.908 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 4.3 p -51.4 -30.26 18.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.829 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.579 ' HB1' ' HG3' ' A' ' 141' ' ' ARG . . . -87.28 24.23 1.66 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.114 179.9 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.5 ' O ' HD12 ' A' ' 37' ' ' LEU . 26.8 p90 -43.58 -44.67 6.31 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.911 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' GLN . . . . . 0.426 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 5.3 pt20 -44.7 -42.23 7.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.905 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.579 ' HG3' ' HB1' ' A' ' 138' ' ' ALA . 21.5 mtt180 -52.07 -42.4 63.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.895 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.741 ' HA ' HG22 ' A' ' 62' ' ' VAL . 99.4 t -46.96 108.89 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.12 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.482 ' O ' ' N ' ' A' ' 33' ' ' LEU . 1.0 OUTLIER -129.8 20.43 5.52 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.902 179.903 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 2.1 m -133.06 138.1 46.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.141 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.924 HD13 ' CE2' ' A' ' 60' ' ' PHE . 7.2 tp -132.41 116.08 16.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.949 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -118.59 151.8 37.23 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.838 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.457 HG12 HG23 ' A' ' 58' ' ' ILE . 24.8 mt -138.66 110.34 5.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.08 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 1.1 pm0 -120.17 171.99 8.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.888 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 111.28 -147.51 17.86 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.544 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -112.96 92.72 4.11 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.851 0.357 . . . . 0.0 110.858 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 4.3 p -151.02 141.9 16.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.145 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 17.1 m -101.31 92.91 5.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.175 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.459 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 80.5 mt -76.03 139.85 41.66 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.913 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 58.1 m -125.01 -33.76 2.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.836 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . 0.506 ' CD1' ' HE3' ' A' ' 46' ' ' LYS . 36.3 t80 -150.46 130.97 13.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.917 -179.855 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 56.0 t -138.92 105.41 2.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.149 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . 0.412 ' HB2' ' CE1' ' A' ' 155' ' ' TYR . 13.2 tt0 -114.17 120.67 41.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.92 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' ILE . . . . . 0.547 HG23 ' NH1' ' A' ' 41' ' ' ARG . 83.1 mt . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.159 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.485 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.5 m . . . . . 0 C--O 1.232 0.151 0 CA-C-O 120.778 0.323 . . . . 0.0 111.174 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.485 ' CD1' ' O ' ' A' ' 22' ' ' THR . 9.3 m-85 -149.83 135.68 18.6 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.896 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . 0.558 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 4.1 t-20 46.1 47.25 3.95 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.625 0.726 . . . . 0.0 110.886 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.558 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.5 Cg_endo -69.78 138.69 38.35 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.669 2.246 . . . . 0.0 112.332 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -174.65 0.95 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.664 2.243 . . . . 0.0 112.344 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.684 HG13 ' HA ' ' A' ' 28' ' ' PRO . 93.5 t -142.45 138.25 16.24 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.62 0.724 . . . . 0.0 111.102 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.684 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.79 144.76 77.63 Favored 'Cis proline' 0 C--N 1.342 0.197 0 C-N-CA 122.642 -1.816 . . . . 0.0 112.354 -0.078 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -97.55 120.69 38.38 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.918 -179.886 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 86.3 m-85 -102.42 104.94 15.44 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.901 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -104.24 107.52 2.97 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.463 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 6.6 mmt180 -73.71 115.86 13.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.833 0.349 . . . . 0.0 110.903 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.485 HD22 ' NH1' ' A' ' 41' ' ' ARG . 5.0 mt -82.0 111.51 18.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.902 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 37.6 mt-30 -78.71 97.14 5.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.88 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 131.1 -51.22 0.86 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.515 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.529 ' O ' HG23 ' A' ' 38' ' ' THR . . . 107.96 168.39 21.51 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.496 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . 0.596 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 68.4 mt -55.1 110.88 0.74 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.886 0.374 . . . . 0.0 110.902 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.529 HG23 ' O ' ' A' ' 36' ' ' GLY . 81.6 p -128.69 146.37 50.9 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.181 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -51.67 -18.33 1.16 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.085 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 2.8 mpt_? -107.73 30.53 6.23 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.868 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.486 ' HE ' HD23 ' A' ' 37' ' ' LEU . 6.9 ttp85 -115.85 142.2 47.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.904 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 29.5 m -138.64 120.72 15.66 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.151 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.456 HD11 ' NH2' ' A' ' 41' ' ' ARG . 5.3 mp -94.39 134.21 32.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.135 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 76.7 mt -129.8 119.59 47.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.098 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 31.6 mt -119.11 107.36 21.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.159 179.822 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.43 ' HE3' ' CD1' ' A' ' 155' ' ' TYR . 16.5 mtmt -108.89 110.18 21.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.9 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -144.86 -147.94 4.74 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.473 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . 0.571 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.7 OUTLIER -163.57 127.88 2.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.934 0.397 . . . . 0.0 110.955 -179.789 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.411 HG23 ' CD2' ' A' ' 109' ' ' PHE . 13.4 t -77.6 117.38 65.21 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 121.585 0.707 . . . . 0.0 111.14 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 154.91 67.1 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.7 2.266 . . . . 0.0 112.348 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -13.92 35.36 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.648 2.232 . . . . 0.0 112.353 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 70.6 p -112.64 16.78 19.58 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.163 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -110.09 123.24 6.63 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.497 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.402 ' O ' ' SD ' ' A' ' 76' ' ' MET . 19.2 mtpt -64.75 -61.72 2.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.801 0.334 . . . . 0.0 110.896 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 14.8 p -172.97 156.57 3.35 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.849 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.599 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 20.4 p90 -111.05 -174.57 2.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.874 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.582 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -156.82 135.37 11.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.126 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.484 HG22 ' CE1' ' A' ' 60' ' ' PHE . 5.3 mp -117.59 98.16 6.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.114 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -96.85 143.72 27.48 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.894 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.711 ' CE2' HD13 ' A' ' 145' ' ' LEU . 47.0 m-85 -115.24 97.62 6.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.906 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.433 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 31.3 ttmt -96.08 168.94 10.31 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.894 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.6 HG22 ' HA ' ' A' ' 142' ' ' VAL . 23.4 t -100.27 123.7 53.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.094 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -59.64 -29.17 66.46 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.506 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.52 ' H ' HG12 ' A' ' 62' ' ' VAL . 11.5 t -75.18 -73.71 0.24 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.849 0.357 . . . . 0.0 110.854 -179.729 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 5.3 t -77.53 -71.47 0.41 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.811 -179.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 128.65 39.7 0.32 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.492 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.44 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.1 m-20 -112.81 139.15 48.67 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.801 0.334 . . . . 0.0 110.879 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.613 HD12 ' HB3' ' A' ' 86' ' ' LEU . 60.3 mt -84.7 120.65 35.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.145 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.451 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -90.16 -30.66 17.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.129 179.795 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.698 HD22 ' CD2' ' A' ' 132' ' ' PHE . 41.3 tp -143.11 132.34 23.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.921 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.494 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.7 OUTLIER -134.93 92.61 2.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.919 179.838 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.524 HD11 HD21 ' A' ' 70' ' ' LEU . 53.2 mt -94.85 132.7 38.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.107 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.582 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -139.12 105.66 7.29 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.661 0.743 . . . . 0.0 110.908 179.929 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.599 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.7 Cg_endo -69.74 154.84 67.34 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.72 2.28 . . . . 0.0 112.372 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 73.9 mtp85 -129.27 94.26 3.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.865 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . 0.402 ' SD ' ' O ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.887 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 21.1 p . . . . . 0 N--CA 1.456 -0.132 0 CA-C-O 120.845 0.355 . . . . 0.0 111.161 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.418 HG22 ' HA ' ' A' ' 74' ' ' PRO . 21.4 t -102.79 107.29 21.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.128 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.542 HG22 ' HD3' ' A' ' 96' ' ' LYS . 99.9 t -76.15 144.36 11.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.087 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -126.19 124.65 40.94 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.887 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.494 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.8 OUTLIER -135.71 178.56 6.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.951 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 19.1 t -160.38 105.05 1.46 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 -179.837 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.916 HD12 ' O ' ' A' ' 90' ' ' SER . 25.4 tp -76.97 118.01 19.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.935 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.513 ' N ' ' O ' ' A' ' 90' ' ' SER . 69.9 mt -95.62 161.6 13.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.884 179.92 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.548 HD22 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.34 101.42 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.907 179.849 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.79 -6.58 0.87 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.441 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.916 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -118.42 170.57 8.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.874 0.369 . . . . 0.0 110.832 -179.727 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.857 ' NE1' HD13 ' A' ' 86' ' ' LEU . 23.7 m95 -128.82 161.05 30.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.929 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.31 -106.45 1.61 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.471 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 67.5 m -164.09 176.05 9.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.809 0.338 . . . . 0.0 110.915 -179.754 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -98.63 123.11 42.63 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.909 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 7.6 mm-40 -122.54 118.11 27.48 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.854 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.542 ' HD3' HG22 ' A' ' 82' ' ' VAL . 9.5 mtmp? -121.23 123.05 41.28 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.903 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 15.0 tptm -172.76 105.04 0.15 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.889 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.665 HD11 ' O ' ' A' ' 100' ' ' HIS . 7.5 tt -147.66 151.32 13.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.152 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.585 HG23 ' N ' ' A' ' 100' ' ' HIS . 8.8 t -86.49 -50.54 6.79 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.149 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . 0.665 ' O ' HD11 ' A' ' 98' ' ' ILE . 5.3 p-80 -141.75 135.67 29.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.843 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . 0.407 ' OD1' ' C ' ' A' ' 101' ' ' ASN . 6.9 t-20 -104.73 95.97 9.72 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.647 0.737 . . . . 0.0 110.918 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.464 ' HG3' ' HB1' ' A' ' 124' ' ' ALA . 53.8 Cg_endo -69.74 -31.18 21.12 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.692 2.261 . . . . 0.0 112.39 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.515 ' CZ ' HD21 ' A' ' 129' ' ' LEU . 6.7 m-85 -47.12 113.93 0.76 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.874 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -140.59 138.11 8.75 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.489 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.73 102.69 1.05 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.653 2.235 . . . . 0.0 112.336 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 122.86 -6.49 9.56 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.488 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -130.67 147.11 52.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.857 0.361 . . . . 0.0 110.855 -179.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' PHE . . . . . 0.571 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 54.5 m-85 -66.5 172.03 4.46 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.888 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.411 ' CD2' HG23 ' A' ' 49' ' ' VAL . 22.5 p90 -160.65 128.38 4.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.856 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -103.45 105.39 15.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.813 HD13 ' N ' ' A' ' 112' ' ' SER . 0.9 OUTLIER -107.32 137.97 44.38 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.946 -179.962 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.813 ' N ' HD13 ' A' ' 111' ' ' LEU . 2.9 m -145.09 112.93 6.35 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.87 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.2 mp -94.29 134.64 31.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.113 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 57.1 mtt180 -109.14 123.19 48.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.853 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . 0.577 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 33.8 t -90.53 123.22 34.02 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -124.72 -153.76 8.65 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.501 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 7.8 mt -109.81 -37.96 5.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.804 0.335 . . . . 0.0 110.913 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -86.1 -37.73 18.52 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.853 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 22.8 ptt180 -174.75 168.56 3.64 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.894 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.596 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 2.9 m-30 -91.81 153.28 19.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.913 -179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 18.9 mtmt -127.29 106.41 9.21 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.897 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.668 HG13 HD11 ' A' ' 111' ' ' LEU . 45.9 t -90.41 137.69 21.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.166 179.844 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' TYR . . . . . 0.421 ' O ' HD22 ' A' ' 111' ' ' LEU . 40.4 m-85 -121.37 147.28 45.91 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.913 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.545 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -137.68 105.52 5.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.126 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 62.09 34.08 16.63 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.84 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.403 ' C ' ' HG2' ' A' ' 127' ' ' GLN . . . 79.62 38.94 19.23 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.467 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . 0.403 ' HG2' ' C ' ' A' ' 126' ' ' GLY . 15.4 mm-40 -148.32 132.25 17.14 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.807 0.337 . . . . 0.0 110.892 -179.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 26.9 t-80 -61.58 101.05 0.16 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.828 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.545 HD13 ' CB ' ' A' ' 124' ' ' ALA . 9.8 tp -66.31 -69.85 0.28 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.877 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.434 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 7.3 p90 -161.87 174.66 12.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.874 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -114.96 150.73 35.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.868 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.698 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -117.53 104.62 11.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.896 -179.912 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.581 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -59.91 134.68 57.27 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.106 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 63.1 m-70 -61.99 112.89 2.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.889 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 83.1 mtt-85 -96.36 -52.48 3.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.834 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 9.4 tp -93.57 108.22 19.96 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.921 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 94.3 p -50.69 -32.25 18.81 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.896 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.465 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -83.79 23.56 0.98 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.135 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.525 ' O ' HD12 ' A' ' 37' ' ' LEU . 14.2 p90 -47.06 -38.99 12.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.883 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 10.0 pt20 -53.52 -34.01 56.62 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.938 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.465 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 51.9 mtp85 -63.47 -37.69 88.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.849 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.6 ' HA ' HG22 ' A' ' 62' ' ' VAL . 92.7 t -46.9 109.36 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.156 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -132.3 31.39 4.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.86 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 8.6 m -141.45 111.98 7.02 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.118 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.711 HD13 ' CE2' ' A' ' 60' ' ' PHE . 3.9 tp -110.51 109.79 20.27 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.945 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' GLU . . . . . 0.428 ' C ' HG13 ' A' ' 147' ' ' ILE . 3.3 pt-20 -112.8 153.81 27.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.843 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.428 HG13 ' C ' ' A' ' 146' ' ' GLU . 20.2 mt -140.72 110.63 3.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.096 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -119.6 174.37 6.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.943 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.17 -142.87 16.03 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.533 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -116.54 94.0 4.44 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.837 0.351 . . . . 0.0 110.913 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.6 p -151.08 151.15 12.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.173 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 10.4 m -110.98 94.5 5.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.13 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.47 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 37.6 mt -77.7 137.84 38.72 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.888 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 3.3 t -122.2 -37.43 2.82 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.869 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . 0.43 ' CD1' ' HE3' ' A' ' 46' ' ' LYS . 19.4 t80 -149.75 130.6 14.21 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.921 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 98.8 t -140.61 105.18 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.096 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 10.9 tt0 -112.13 145.3 40.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.89 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' ILE . . . . . 0.418 HG23 ' NH1' ' A' ' 41' ' ' ARG . 30.1 mt . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.109 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.418 HG22 ' H ' ' A' ' 156' ' ' VAL . 7.6 t . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.803 0.335 . . . . 0.0 111.187 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.4 ' CD1' ' O ' ' A' ' 22' ' ' THR . 7.0 m-85 -142.07 117.28 10.1 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.908 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . 0.516 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 9.0 m120 66.92 49.97 0.56 Allowed Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.633 0.73 . . . . 0.0 110.927 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.516 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.7 Cg_endo -69.73 131.35 21.09 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.662 2.241 . . . . 0.0 112.335 179.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 -174.03 0.84 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.643 2.229 . . . . 0.0 112.319 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.696 HG13 ' HA ' ' A' ' 28' ' ' PRO . 97.5 t -144.03 138.33 14.91 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.593 0.711 . . . . 0.0 111.129 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.696 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.78 144.72 77.48 Favored 'Cis proline' 0 C--O 1.232 0.177 0 C-N-CA 122.73 -1.779 . . . . 0.0 112.321 -0.025 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.6 t80 -98.04 119.12 36.11 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.942 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 75.7 m-85 -105.66 108.26 19.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.844 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -119.89 103.39 0.95 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.454 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.4 ' HG3' ' O ' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -73.45 128.28 35.05 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.813 0.34 . . . . 0.0 110.899 -179.886 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.551 HD23 HD13 ' A' ' 158' ' ' ILE . 6.1 mt -73.07 151.83 41.51 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.902 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 20.0 mt-30 -88.29 -63.36 1.31 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.934 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.527 ' O ' HG23 ' A' ' 38' ' ' THR . . . -96.94 43.56 2.02 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.54 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.483 ' N ' ' OD2' ' A' ' 143' ' ' ASP . . . 34.39 -152.68 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.499 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . 0.505 HD12 ' O ' ' A' ' 139' ' ' PHE . 52.4 mt -87.64 113.16 23.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.854 0.359 . . . . 0.0 110.934 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.527 HG23 ' O ' ' A' ' 35' ' ' GLY . 24.7 p -121.01 153.16 37.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.113 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -59.75 -25.77 65.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.12 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 13.2 mmt180 -105.43 35.62 2.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.869 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.445 ' HB2' ' NH1' ' A' ' 41' ' ' ARG . 9.4 ttm105 -125.02 140.78 52.6 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.915 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 90.7 m -139.68 121.7 15.67 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.14 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 mp -90.99 134.25 30.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.128 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 77.6 mt -123.45 133.41 69.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.139 179.817 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 75.0 mt -131.41 107.8 13.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.153 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.1 mtmt -109.31 107.74 18.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.9 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.26 -146.25 4.79 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.536 179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . 0.57 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.7 OUTLIER -167.91 129.29 1.44 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.904 0.383 . . . . 0.0 110.934 -179.798 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 11.8 t -77.88 116.74 60.96 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.6 0.714 . . . . 0.0 111.14 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 158.52 56.63 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.627 2.218 . . . . 0.0 112.346 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -14.54 36.26 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.654 2.236 . . . . 0.0 112.394 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 66.7 p -113.16 19.22 17.33 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.151 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -113.37 118.34 4.49 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.419 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 15.7 mtpp -62.96 -58.85 5.95 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.755 0.312 . . . . 0.0 110.877 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 25.3 p -173.04 159.73 4.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.877 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.598 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 10.9 p90 -114.84 -173.19 2.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.873 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.954 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -156.65 141.79 17.28 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.067 179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.431 HG22 ' CE1' ' A' ' 60' ' ' PHE . 9.1 mt -127.59 98.38 4.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.12 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . 0.471 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 2.2 m-80 -100.47 150.48 22.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.917 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.504 ' CE2' HD13 ' A' ' 145' ' ' LEU . 4.3 m-85 -118.1 101.17 8.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.912 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.415 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 28.3 ttmt -95.58 169.85 9.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.901 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.704 HG22 ' HA ' ' A' ' 142' ' ' VAL . 67.8 t -101.17 124.14 54.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.105 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -59.08 -39.87 94.89 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.507 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 15.0 m -66.19 -73.5 0.13 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.837 0.351 . . . . 0.0 110.858 -179.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 68.5 m -76.72 -75.38 0.2 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.833 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 133.31 35.13 0.3 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.475 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.42 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.4 m-20 -106.61 143.94 34.0 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.823 0.344 . . . . 0.0 110.861 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.56 HD12 ' HB3' ' A' ' 86' ' ' LEU . 58.7 mt -88.24 122.56 39.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.154 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.72 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -92.8 -33.33 14.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.114 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.575 HD21 HD11 ' A' ' 72' ' ' ILE . 42.4 tp -139.15 131.61 28.62 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.913 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.5 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.0 OUTLIER -134.66 92.95 2.97 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.838 179.863 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.575 HD11 HD21 ' A' ' 70' ' ' LEU . 40.3 mt -98.64 130.96 46.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.152 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.954 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.2 OUTLIER -140.67 107.74 6.5 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.64 0.733 . . . . 0.0 110.914 179.934 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.598 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.4 Cg_endo -69.74 155.13 66.82 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.704 2.269 . . . . 0.0 112.349 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 71.3 mtp180 -130.61 96.36 4.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.858 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . 0.483 ' HE3' ' HB3' ' A' ' 103' ' ' PHE . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.901 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 7.6 p . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.788 0.327 . . . . 0.0 111.128 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.9 t -100.61 112.83 34.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.153 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.703 HG22 ' HD3' ' A' ' 96' ' ' LYS . 61.5 t -80.67 142.31 14.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.172 179.922 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -122.4 124.09 42.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.862 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.5 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.1 m120 -138.49 176.56 8.59 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.839 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 45.2 t -160.35 105.08 1.47 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.866 -179.854 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.915 HD12 ' O ' ' A' ' 90' ' ' SER . 24.8 tp -77.55 119.02 20.54 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.951 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.513 ' N ' ' O ' ' A' ' 90' ' ' SER . 76.0 mt -95.88 161.35 14.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.916 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.517 HD22 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.89 101.43 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.902 179.933 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.98 -5.83 1.14 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.493 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.915 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -120.0 171.36 8.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.827 0.346 . . . . 0.0 110.866 -179.763 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.866 ' NE1' HD13 ' A' ' 86' ' ' LEU . 23.8 m95 -129.12 159.82 34.81 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.925 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -93.31 -114.71 2.36 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.53 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . 0.449 ' HB2' ' CZ ' ' A' ' 135' ' ' ARG . 3.6 m -151.96 169.36 22.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.825 0.345 . . . . 0.0 110.878 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.421 ' HG2' ' ND2' ' A' ' 84' ' ' ASN . 7.0 mt-10 -97.7 121.75 39.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.937 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -117.33 116.26 26.87 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.845 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.703 ' HD3' HG22 ' A' ' 82' ' ' VAL . 38.2 mtmt -122.32 117.21 25.54 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.896 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -169.37 108.96 0.44 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.896 179.843 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.784 HD11 ' O ' ' A' ' 100' ' ' HIS . 3.5 tt -145.4 153.79 13.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.073 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.431 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 8.7 t -97.44 -38.74 9.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.169 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . 0.784 ' O ' HD11 ' A' ' 98' ' ' ILE . 3.3 p-80 -146.67 125.07 12.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.862 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . 0.403 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 31.0 t-20 -102.56 96.82 7.93 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.633 0.73 . . . . 0.0 110.864 -179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.436 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.7 Cg_endo -69.83 -40.55 5.09 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.631 2.22 . . . . 0.0 112.357 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.483 ' HB3' ' HE3' ' A' ' 76' ' ' MET . 32.0 m-85 -35.7 106.74 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.883 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -134.53 136.66 8.72 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.506 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 100.11 0.8 Allowed 'Trans proline' 0 C--N 1.34 0.124 0 C-N-CA 122.672 2.248 . . . . 0.0 112.299 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 124.9 -6.58 8.31 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.466 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 9.2 pt20 -131.01 147.29 52.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.852 0.358 . . . . 0.0 110.886 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' PHE . . . . . 0.57 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 66.0 m-85 -64.24 172.16 2.63 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.889 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.461 ' CG ' ' O ' ' A' ' 109' ' ' PHE . 21.8 p90 -160.73 117.97 2.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.882 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -93.64 106.8 18.74 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.848 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.842 HD13 ' N ' ' A' ' 112' ' ' SER . 0.5 OUTLIER -108.64 138.68 44.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.921 -179.961 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.842 ' N ' HD13 ' A' ' 111' ' ' LEU . 5.4 m -145.36 113.42 6.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.829 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.541 HG22 ' HD2' ' A' ' 120' ' ' PHE . 4.5 mp -93.66 137.5 22.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.125 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . 0.596 ' O ' ' CD2' ' A' ' 120' ' ' PHE . 16.9 mtp180 -109.88 135.05 51.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.87 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . 0.543 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 20.7 t -103.74 116.19 31.87 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.903 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -115.34 -149.2 9.54 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.504 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.414 ' O ' ' CD2' ' A' ' 134' ' ' HIS . 8.6 mt -111.83 -39.04 4.67 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.794 0.331 . . . . 0.0 110.899 -179.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . 0.553 ' C ' ' CD2' ' A' ' 134' ' ' HIS . 8.1 m-20 -89.41 -35.45 16.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.86 179.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 13.4 ptt180 -171.3 175.04 4.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 -179.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.596 ' CD2' ' O ' ' A' ' 114' ' ' ARG . 9.2 m-85 -98.9 162.51 13.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.887 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 36.6 mtpt -133.37 104.46 6.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.911 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.679 HG13 HD11 ' A' ' 111' ' ' LEU . 41.5 t -91.04 125.02 43.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.105 179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 48.6 m-85 -115.52 146.32 41.82 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.885 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.505 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -131.57 108.62 9.67 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.061 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 58.62 35.54 24.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.835 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.46 40.61 22.79 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.487 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 13.9 mt-30 -146.39 130.22 17.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.83 0.348 . . . . 0.0 110.922 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 33.2 t-80 -60.08 99.47 0.07 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.849 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.505 HD13 ' CB ' ' A' ' 124' ' ' ALA . 8.7 tp -70.17 -69.64 0.34 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.946 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.539 ' HZ ' HD13 ' A' ' 72' ' ' ILE . 5.4 p90 -163.44 169.63 18.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.879 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -113.66 151.08 32.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.872 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.55 ' CG ' HD13 ' A' ' 70' ' ' LEU . 0.2 OUTLIER -115.7 105.83 13.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.89 -179.942 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.533 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -61.71 134.01 56.25 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.132 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' HIS . . . . . 0.553 ' CD2' ' C ' ' A' ' 118' ' ' ASP . 14.3 m-70 -62.64 94.53 0.06 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.827 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.449 ' CZ ' ' HB2' ' A' ' 93' ' ' SER . 61.3 mtt-85 -78.78 -41.48 30.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.87 -179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 12.3 tp -100.55 108.32 20.22 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.884 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 59.8 p -51.86 -30.78 25.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.887 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.535 ' HB1' ' HD2' ' A' ' 141' ' ' ARG . . . -89.72 30.61 1.02 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.078 179.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.587 ' CE1' ' HG3' ' A' ' 140' ' ' GLN . 2.9 p90 -41.39 -40.14 1.64 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.91 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' GLN . . . . . 0.587 ' HG3' ' CE1' ' A' ' 139' ' ' PHE . 0.0 OUTLIER -48.05 -52.52 19.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.943 -179.952 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.659 ' O ' HG13 ' A' ' 62' ' ' VAL . 47.9 mtt180 -42.4 -39.41 2.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.89 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.72 HG21 ' CB ' ' A' ' 69' ' ' ALA . 66.6 t -52.7 105.12 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.17 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.483 ' OD2' ' N ' ' A' ' 36' ' ' GLY . 0.9 OUTLIER -130.27 31.08 4.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.877 179.93 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -140.43 129.84 23.94 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.149 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.504 HD13 ' CE2' ' A' ' 60' ' ' PHE . 6.0 tp -125.59 108.91 12.04 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.869 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' GLU . . . . . 0.424 ' C ' HG13 ' A' ' 147' ' ' ILE . 3.0 pt-20 -111.12 148.85 31.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.907 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.424 HG13 ' C ' ' A' ' 146' ' ' GLU . 8.8 mt -138.69 105.32 2.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.138 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -117.87 176.69 5.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.907 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.96 -145.94 16.57 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.477 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -114.6 91.63 3.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.868 0.366 . . . . 0.0 110.896 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 4.7 p -150.76 151.21 12.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.109 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 28.7 m -109.67 93.17 4.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.134 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.485 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 66.8 mt -76.52 138.34 40.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.957 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 74.0 m -122.82 -37.97 2.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.85 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 26.9 t80 -145.96 129.42 16.9 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.922 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.418 ' H ' HG22 ' A' ' 22' ' ' THR . 55.0 t -140.71 105.37 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.093 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 13.0 tt0 -121.58 120.4 34.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.907 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' ILE . . . . . 0.551 HD13 HD23 ' A' ' 33' ' ' LEU . 27.1 mt . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.123 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.45 HG22 ' H ' ' A' ' 156' ' ' VAL . 6.5 t . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.793 0.33 . . . . 0.0 111.171 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.406 ' CD1' ' O ' ' A' ' 22' ' ' THR . 7.4 m-85 -142.68 116.86 9.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.92 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . 0.474 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 11.8 m120 61.68 52.23 2.25 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.671 0.748 . . . . 0.0 110.914 -179.889 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.487 ' HG2' ' CB ' ' A' ' 153' ' ' LEU . 54.2 Cg_endo -69.76 133.41 25.5 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.665 2.243 . . . . 0.0 112.387 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 -174.22 0.86 Allowed 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.707 2.272 . . . . 0.0 112.33 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.708 HG13 ' HA ' ' A' ' 28' ' ' PRO . 84.7 t -144.04 138.77 15.28 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.621 0.724 . . . . 0.0 111.113 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.708 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.79 145.27 79.01 Favored 'Cis proline' 0 C--N 1.342 0.186 0 C-N-CA 122.659 -1.809 . . . . 0.0 112.303 -0.048 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.0 t80 -100.96 117.1 34.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.931 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.513 ' CD2' ' HB3' ' A' ' 146' ' ' GLU . 58.2 m-85 -104.61 105.98 16.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.896 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -116.34 103.44 1.15 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.496 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.513 ' O ' ' CD ' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -72.61 114.08 10.36 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.799 0.333 . . . . 0.0 110.856 -179.873 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.425 HD12 ' N ' ' A' ' 144' ' ' THR . 3.9 mt -59.1 151.32 22.78 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.932 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 3.0 mp0 -104.26 101.22 10.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.906 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.64 -58.62 0.52 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.493 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.711 ' O ' HG23 ' A' ' 38' ' ' THR . . . 123.73 171.83 13.62 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.48 -179.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . 0.721 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 93.7 mt -58.74 103.74 0.18 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.879 0.371 . . . . 0.0 110.949 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.711 HG23 ' O ' ' A' ' 36' ' ' GLY . 22.0 p -118.98 150.16 40.4 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.098 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -54.83 -28.16 47.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.107 179.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 3.9 tpt180 -102.97 37.47 1.95 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.899 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 11.7 ttm180 -129.16 139.51 51.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.871 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 91.8 m -137.4 124.75 21.9 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.128 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.414 ' N ' HD12 ' A' ' 43' ' ' ILE . 4.9 mp -92.67 134.05 31.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.161 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 89.7 mt -122.93 135.89 61.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.087 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 56.1 mt -133.98 107.92 10.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.132 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.3 mtmt -113.82 113.78 25.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.836 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.416 ' CA ' ' O ' ' A' ' 152' ' ' THR . . . -146.56 -140.6 3.47 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.519 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -170.55 137.45 1.38 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.916 0.389 . . . . 0.0 110.927 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 14.2 t -86.62 114.87 60.07 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.604 0.716 . . . . 0.0 111.124 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.83 155.71 65.0 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.685 2.256 . . . . 0.0 112.358 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 -13.9 35.46 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.701 2.267 . . . . 0.0 112.356 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 57.8 p -112.28 16.19 20.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.112 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -112.72 120.23 5.18 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.468 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 12.1 mtpt -61.62 -60.46 3.64 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.767 0.318 . . . . 0.0 110.857 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 25.8 p -173.16 158.4 3.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.85 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.596 ' CE2' HD11 ' A' ' 58' ' ' ILE . 8.2 p90 -112.01 -172.8 2.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.88 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.48 141.8 18.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.12 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.596 HD11 ' CE2' ' A' ' 56' ' ' PHE . 2.9 mp -123.01 102.23 11.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.105 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.5 m-80 -103.22 146.09 28.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.846 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.6 ' CE2' HD13 ' A' ' 145' ' ' LEU . 40.7 m-85 -117.63 101.16 8.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.905 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.427 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 33.1 ttmt -96.33 168.57 10.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.854 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.589 HG22 ' HA ' ' A' ' 142' ' ' VAL . 38.4 t -99.57 122.83 51.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.137 179.846 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.424 ' N ' ' OG1' ' A' ' 144' ' ' THR . . . -59.55 -28.69 65.46 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.482 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.541 ' H ' HG12 ' A' ' 62' ' ' VAL . 1.4 t -77.53 -71.09 0.43 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.839 0.352 . . . . 0.0 110.856 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.6 t -79.33 -75.51 0.24 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.818 -179.786 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 132.18 41.31 0.2 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.467 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.437 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.4 m-20 -115.45 139.62 49.87 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.763 0.316 . . . . 0.0 110.855 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.507 HD12 ' HB3' ' A' ' 86' ' ' LEU . 37.6 mt -86.43 114.8 26.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.079 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.22 -34.69 21.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.092 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.651 HD22 ' CD2' ' A' ' 132' ' ' PHE . 32.1 tp -138.01 131.75 31.2 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.939 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.467 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.1 t60 -134.95 98.38 4.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.848 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.554 HD11 HD21 ' A' ' 70' ' ' LEU . 22.4 mt -96.42 129.27 46.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.129 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.503 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.2 OUTLIER -134.36 104.15 11.3 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.588 0.708 . . . . 0.0 110.927 179.966 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.585 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.6 Cg_endo -69.77 155.48 65.78 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.688 2.259 . . . . 0.0 112.341 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 81.6 mtt-85 -133.25 97.99 4.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.892 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.914 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 13.8 p . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.845 0.355 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.441 HG21 ' HE2' ' A' ' 103' ' ' PHE . 16.2 t -99.46 109.65 24.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.132 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.593 HG22 ' HD3' ' A' ' 96' ' ' LYS . 82.5 t -79.24 140.19 17.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.123 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . 0.647 ' NH1' ' CD2' ' A' ' 130' ' ' PHE . 1.4 mpp_? -121.37 115.02 22.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.875 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.467 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.4 t-20 -125.98 179.75 5.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.896 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 94.7 p -160.95 110.07 1.64 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.869 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.95 HD12 ' O ' ' A' ' 90' ' ' SER . 24.5 tp -82.73 118.99 23.76 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.909 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.495 ' N ' ' O ' ' A' ' 90' ' ' SER . 96.8 mt -96.12 161.07 14.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.931 179.85 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.519 HD22 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.5 101.64 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.85 179.932 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.62 -7.0 1.11 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.481 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.95 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -118.85 172.11 7.76 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.879 0.371 . . . . 0.0 110.85 -179.752 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.836 ' NE1' HD13 ' A' ' 86' ' ' LEU . 23.8 m95 -129.12 160.66 32.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.924 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.59 -114.7 2.19 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.454 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . 0.439 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 4.5 m -152.78 167.56 28.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.806 0.336 . . . . 0.0 110.88 -179.728 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -97.66 120.46 38.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 20.8 mm-40 -119.63 128.22 53.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.875 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.593 ' HD3' HG22 ' A' ' 82' ' ' VAL . 47.4 mtmt -130.11 117.68 20.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.922 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 25.0 tptt -171.73 105.7 0.21 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.922 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.932 HD11 ' O ' ' A' ' 100' ' ' HIS . 2.1 tt -145.23 151.09 15.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.101 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.594 HG23 ' N ' ' A' ' 100' ' ' HIS . 9.7 t -85.83 -50.35 7.19 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.168 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . 0.932 ' O ' HD11 ' A' ' 98' ' ' ILE . 9.7 p-80 -137.33 132.55 33.77 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.847 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . 0.435 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 43.2 t-20 -112.82 99.62 48.61 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.608 0.718 . . . . 0.0 110.907 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.456 ' HG3' ' HB1' ' A' ' 124' ' ' ALA . 53.6 Cg_endo -69.8 -41.1 4.51 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.705 2.27 . . . . 0.0 112.35 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.442 ' C ' ' O ' ' A' ' 102' ' ' PRO . 7.5 m-85 -35.32 101.91 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.866 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -131.5 136.5 8.83 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.522 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 97.9 0.66 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.675 2.25 . . . . 0.0 112.318 -179.87 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 133.56 -10.45 4.95 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.48 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -133.3 161.77 33.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.837 0.351 . . . . 0.0 110.879 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -82.23 175.08 10.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.864 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 23.0 p90 -161.81 127.26 3.54 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.866 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -98.39 104.49 16.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.85 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.895 HD13 ' N ' ' A' ' 112' ' ' SER . 0.6 OUTLIER -104.85 139.47 39.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.92 -179.945 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.895 ' N ' HD13 ' A' ' 111' ' ' LEU . 4.7 m -144.8 113.41 6.69 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.854 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.7 mp -93.36 136.16 25.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.175 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 42.7 mtt180 -111.68 120.22 41.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.901 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . 0.576 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 2.3 t -90.42 116.7 28.56 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.913 -179.929 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -113.03 -148.85 10.39 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.467 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 19.1 mt -112.76 -35.24 5.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.826 0.346 . . . . 0.0 110.903 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 52.4 m-20 -91.2 -33.14 15.51 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.893 179.812 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.2 ptp180 -174.77 176.2 2.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.867 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.721 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 3.9 m-30 -99.22 158.15 15.89 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 -179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.9 mtpt -130.75 100.82 5.42 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.9 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.847 HG13 HD11 ' A' ' 111' ' ' LEU . 25.1 t -87.83 126.67 41.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.136 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' TYR . . . . . 0.411 ' O ' HD22 ' A' ' 111' ' ' LEU . 85.2 m-85 -118.37 150.49 39.43 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.946 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.456 ' HB1' ' HG3' ' A' ' 102' ' ' PRO . . . -134.86 110.14 8.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.097 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.403 ' ND2' ' C ' ' A' ' 124' ' ' ALA . 0.6 OUTLIER 60.68 39.24 17.82 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.907 -179.889 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 72.92 41.59 48.32 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.495 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 20.3 mm-40 -148.41 136.84 21.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.79 0.329 . . . . 0.0 110.917 -179.851 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 46.5 t-80 -63.1 107.39 1.02 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.856 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.498 HD22 HD21 ' A' ' 111' ' ' LEU . 11.8 tp -78.35 -64.24 1.21 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.914 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.647 ' CD2' ' NH1' ' A' ' 83' ' ' ARG . 24.7 p90 -166.84 -178.68 4.38 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.889 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -125.37 144.86 50.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.861 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.651 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.4 OUTLIER -113.06 106.42 14.65 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.905 -179.915 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.491 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -61.74 137.98 58.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.106 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 17.8 m-70 -66.31 100.74 0.66 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.8 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.439 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 60.5 mtt-85 -83.97 -55.1 4.41 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.855 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 4.9 tp -88.67 107.91 19.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.913 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 19.9 p -48.79 -34.4 12.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.858 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.516 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.67 28.99 0.46 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.107 179.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.535 ' O ' HD12 ' A' ' 37' ' ' LEU . 27.0 p90 -50.94 -42.54 59.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.899 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' GLN . . . . . 0.416 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 7.3 pt20 -48.83 -37.25 18.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.907 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.516 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 45.4 mtp85 -58.17 -40.91 82.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.861 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.589 ' HA ' HG22 ' A' ' 62' ' ' VAL . 60.0 t -48.17 102.3 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.133 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.492 ' OD1' ' N ' ' A' ' 36' ' ' GLY . 22.6 t0 -124.26 24.91 7.93 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.869 179.868 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' THR . . . . . 0.425 ' N ' HD12 ' A' ' 33' ' ' LEU . 1.5 m -132.59 140.63 48.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.127 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.6 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.5 tp -135.91 113.81 11.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.875 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' GLU . . . . . 0.513 ' HB3' ' CD2' ' A' ' 30' ' ' PHE . 5.9 pt-20 -117.82 151.85 36.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.932 179.903 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.528 HG12 HG23 ' A' ' 58' ' ' ILE . 18.0 mt -139.19 118.35 13.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.117 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 1.1 pm0 -128.19 177.9 6.61 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.868 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 106.32 -137.5 13.88 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.474 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -122.54 92.48 3.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.816 0.341 . . . . 0.0 110.905 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.406 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 2.1 p -151.17 150.6 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.103 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . 0.416 ' O ' ' CA ' ' A' ' 47' ' ' GLY . 23.7 m -107.48 93.52 4.59 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.114 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.487 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 67.8 mt -77.24 128.97 35.29 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.938 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 3.8 m -111.96 -41.66 3.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.901 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 35.2 t80 -143.87 130.62 20.26 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.942 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.45 ' H ' HG22 ' A' ' 22' ' ' THR . 72.9 t -140.7 105.29 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.122 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -120.66 129.62 53.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.879 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 16.6 mt . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.103 179.979 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.416 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.4 m . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.844 0.354 . . . . 0.0 111.149 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.404 ' CD1' ' O ' ' A' ' 22' ' ' THR . 7.2 m-85 -142.52 134.47 27.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.854 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . 0.51 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.5 t-20 42.68 49.9 4.95 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.554 0.692 . . . . 0.0 110.878 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.51 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.8 Cg_endo -69.8 143.87 52.04 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.634 2.223 . . . . 0.0 112.378 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -178.74 2.49 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.701 2.267 . . . . 0.0 112.315 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.675 HG13 ' HA ' ' A' ' 28' ' ' PRO . 98.8 t -143.71 137.93 14.81 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.636 0.731 . . . . 0.0 111.106 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.675 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.77 144.65 77.25 Favored 'Cis proline' 0 C--O 1.231 0.171 0 C-N-CA 122.698 -1.792 . . . . 0.0 112.357 -0.066 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -98.8 118.12 34.83 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.954 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.438 ' CD1' ' HB3' ' A' ' 146' ' ' GLU . 63.8 m-85 -104.7 103.01 12.57 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.872 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -113.77 104.32 1.46 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.503 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.449 ' O ' ' HG3' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -73.44 121.89 21.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.876 0.37 . . . . 0.0 110.874 -179.868 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.419 HD12 ' N ' ' A' ' 144' ' ' THR . 5.4 mt -68.77 147.12 52.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.922 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 29.1 mt-30 -106.0 83.63 1.94 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.917 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 138.13 -49.0 0.86 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.49 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.561 ' O ' HG23 ' A' ' 38' ' ' THR . . . 109.35 166.98 20.33 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.454 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . 0.451 HD13 ' CZ ' ' A' ' 120' ' ' PHE . 87.5 mt -55.0 110.27 0.64 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.895 0.378 . . . . 0.0 110.901 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.561 HG23 ' O ' ' A' ' 36' ' ' GLY . 61.7 p -129.93 145.4 51.62 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.178 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -47.37 -31.1 3.7 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.098 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 8.9 tpt180 -97.32 31.66 2.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.881 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 12.3 ttm180 -124.13 141.56 51.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.879 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 94.0 m -138.33 124.85 20.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.147 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.1 mp -96.85 130.15 45.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.112 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 86.5 mt -123.49 134.04 67.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.132 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 72.1 mt -133.32 107.39 11.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.156 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 25.9 mtmt -112.01 109.93 19.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.898 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.501 ' CA ' ' O ' ' A' ' 152' ' ' THR . . . -138.09 -139.89 3.93 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.492 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -173.63 119.4 0.29 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.947 0.404 . . . . 0.0 110.884 -179.777 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 21.9 t -70.77 113.52 19.37 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.615 0.721 . . . . 0.0 111.124 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 156.88 62.35 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.671 2.248 . . . . 0.0 112.344 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -14.48 36.18 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.669 2.246 . . . . 0.0 112.366 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 72.6 p -111.7 18.46 18.96 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.181 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -116.12 123.47 5.89 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.509 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 33.8 mtpt -65.39 -59.43 4.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.823 0.344 . . . . 0.0 110.891 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 34.9 p -174.03 160.74 3.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.833 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.608 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 3.4 p90 -114.19 -174.37 2.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.869 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.862 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -156.37 128.19 7.31 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.076 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.534 HG13 HG23 ' A' ' 147' ' ' ILE . 5.3 mp -112.22 102.28 13.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.155 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.3 m-80 -100.84 149.69 23.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.938 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.698 ' CE2' HD13 ' A' ' 145' ' ' LEU . 56.6 m-85 -118.65 101.08 7.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.872 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.425 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 34.9 ttmt -95.69 168.92 10.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.904 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.672 HG22 ' HA ' ' A' ' 142' ' ' VAL . 55.2 t -100.48 124.83 54.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.124 179.856 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -60.48 -33.76 82.76 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.506 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.442 ' H ' HG12 ' A' ' 62' ' ' VAL . 70.1 m -70.84 -71.05 0.27 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.837 0.351 . . . . 0.0 110.864 -179.738 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 82.6 p -82.07 -75.1 0.31 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.875 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 133.37 44.31 0.13 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.46 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.411 ' OD1' ' OD1' ' A' ' 88' ' ' ASN . 1.2 m-20 -113.65 144.83 42.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.798 0.332 . . . . 0.0 110.889 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.431 HD12 ' HB3' ' A' ' 86' ' ' LEU . 40.9 mt -90.22 113.85 26.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.124 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.571 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -87.17 -32.3 19.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.126 179.799 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.738 HD22 ' CD2' ' A' ' 132' ' ' PHE . 41.4 tp -136.83 129.73 30.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.9 -179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.482 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.0 OUTLIER -134.61 94.42 3.19 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.869 179.836 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.541 HD13 ' HZ ' ' A' ' 130' ' ' PHE . 44.7 mt -99.59 134.74 37.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.148 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.862 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -141.38 106.9 6.07 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.594 0.711 . . . . 0.0 110.859 179.955 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.608 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.0 Cg_endo -69.81 155.14 66.54 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.708 2.272 . . . . 0.0 112.362 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 34.6 mtt85 -128.97 97.49 4.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.877 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . 0.522 ' HE3' ' HB3' ' A' ' 103' ' ' PHE . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 24.7 p . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.777 0.322 . . . . 0.0 111.164 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.508 HG22 ' HA ' ' A' ' 74' ' ' PRO . 13.8 t -97.79 113.58 32.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.131 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.499 HG22 ' HD3' ' A' ' 96' ' ' LYS . 58.2 t -83.12 144.81 9.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.111 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -123.89 125.46 44.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.873 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.482 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.7 OUTLIER -139.29 177.96 7.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.935 -179.955 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 92.4 p -160.67 107.68 1.53 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.868 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.897 HD13 ' NE1' ' A' ' 91' ' ' TRP . 24.6 tp -76.98 117.41 18.54 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.935 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.486 ' N ' ' O ' ' A' ' 90' ' ' SER . 25.9 mt -93.44 161.19 14.48 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.908 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.415 ' ND2' ' H ' ' A' ' 88' ' ' ASN . 10.6 m-80 -41.31 101.48 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.866 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.94 -3.25 4.11 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.471 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.851 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.4 OUTLIER -124.5 173.41 8.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.87 0.367 . . . . 0.0 110.831 -179.716 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.897 ' NE1' HD13 ' A' ' 86' ' ' LEU . 23.8 m95 -130.21 159.58 36.44 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.948 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -90.8 -109.3 1.47 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.478 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 3.4 m -159.92 176.03 12.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.839 0.352 . . . . 0.0 110.832 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.424 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 4.6 mt-10 -104.05 122.96 46.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.866 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -121.75 113.25 19.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.892 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.499 ' HD3' HG22 ' A' ' 82' ' ' VAL . 40.4 mtmt -114.34 118.41 33.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.868 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 12.1 tptm -172.13 105.27 0.18 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.879 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.793 HD11 ' O ' ' A' ' 100' ' ' HIS . 2.4 tt -144.23 143.58 23.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.155 179.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.606 HG23 ' N ' ' A' ' 100' ' ' HIS . 10.3 t -77.25 -51.58 10.67 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.154 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . 0.793 ' O ' HD11 ' A' ' 98' ' ' ILE . 21.3 p80 -140.55 134.21 30.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.85 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . 0.404 ' C ' ' OD1' ' A' ' 101' ' ' ASN . 4.9 t-20 -101.65 99.13 10.88 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.608 0.718 . . . . 0.0 110.931 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.403 ' HD2' HD11 ' A' ' 129' ' ' LEU . 53.6 Cg_endo -69.76 -40.81 4.89 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.693 2.262 . . . . 0.0 112.328 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.522 ' HB3' ' HE3' ' A' ' 76' ' ' MET . 6.7 m-85 -41.02 111.86 0.25 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.885 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -134.08 133.85 7.1 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.511 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 96.5 0.6 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.632 2.222 . . . . 0.0 112.333 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 127.25 0.23 6.92 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.49 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -138.78 154.48 48.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.85 0.357 . . . . 0.0 110.952 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 -71.9 171.96 10.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.87 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 27.4 p90 -160.52 136.33 8.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.909 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.67 105.8 14.82 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.854 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.827 HD13 ' N ' ' A' ' 112' ' ' SER . 0.6 OUTLIER -107.14 139.72 41.11 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.9 -179.931 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.827 ' N ' HD13 ' A' ' 111' ' ' LEU . 3.6 m -144.88 114.88 7.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.839 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.422 HG22 ' HD2' ' A' ' 120' ' ' PHE . 4.6 mp -98.23 127.42 50.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.142 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 9.9 mtp180 -100.25 133.48 44.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.875 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 14.1 t -98.49 100.41 11.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.894 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -91.04 -140.51 8.87 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.469 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.3 mt -122.8 -38.55 2.62 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.845 0.355 . . . . 0.0 110.933 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.4 t0 -94.39 -21.43 18.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.867 179.848 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.402 ' CD ' ' C ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -175.18 -175.12 0.81 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.834 -179.902 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.451 ' CZ ' HD13 ' A' ' 37' ' ' LEU . 20.4 m-85 -108.42 148.91 29.46 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.871 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 2.1 mmmm -120.17 101.95 8.18 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.866 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.6 HG13 HD11 ' A' ' 111' ' ' LEU . 65.8 t -89.31 129.74 39.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.141 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 54.6 m-85 -116.16 160.7 20.01 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.925 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.473 ' HB2' HD13 ' A' ' 129' ' ' LEU . . . -139.92 114.34 9.21 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.111 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 41.41 38.68 0.88 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.852 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 83.71 27.63 37.9 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.458 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . 0.421 ' N ' ' O ' ' A' ' 124' ' ' ALA . 9.4 mm100 -138.88 115.88 10.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.855 0.359 . . . . 0.0 110.897 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 34.4 t-80 -47.93 103.19 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.876 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.619 HD22 HD21 ' A' ' 111' ' ' LEU . 13.5 tp -69.65 -68.48 0.41 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.894 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.541 ' HZ ' HD13 ' A' ' 72' ' ' ILE . 9.4 p90 -164.2 175.8 9.81 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.912 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.48 ' OD1' ' N ' ' A' ' 132' ' ' PHE . 0.4 OUTLIER -117.06 156.73 27.05 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 179.967 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.738 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -128.31 106.12 8.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.889 -179.864 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.605 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -63.35 136.66 57.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.137 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' HIS . . . . . 0.404 ' HE1' ' CE1' ' A' ' 120' ' ' PHE . 15.8 m-70 -61.37 115.65 4.02 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.883 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 8.1 mtt-85 -95.9 -47.65 6.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.861 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 9.9 tp -96.56 108.19 20.74 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.905 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 78.9 p -47.73 -34.22 8.07 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.847 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.668 ' HB1' ' HG3' ' A' ' 141' ' ' ARG . . . -83.62 31.09 0.47 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.084 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -50.36 -34.89 25.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.871 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' GLN . . . . . 0.456 ' HG2' ' N ' ' A' ' 141' ' ' ARG . 18.1 pm0 -59.7 -29.41 68.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.923 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.668 ' HG3' ' HB1' ' A' ' 138' ' ' ALA . 36.3 mtp85 -65.29 -39.64 92.81 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.672 ' HA ' HG22 ' A' ' 62' ' ' VAL . 84.3 t -50.62 103.94 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.151 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 9.3 p-10 -125.27 31.85 5.49 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.886 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' THR . . . . . 0.419 ' N ' HD12 ' A' ' 33' ' ' LEU . 1.7 m -140.72 135.04 31.18 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.14 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.698 HD13 ' CE2' ' A' ' 60' ' ' PHE . 6.4 tp -129.88 115.88 17.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.932 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' GLU . . . . . 0.438 ' HB3' ' CD1' ' A' ' 30' ' ' PHE . 5.1 pt-20 -120.0 150.95 39.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.885 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.534 HG23 HG13 ' A' ' 58' ' ' ILE . 15.0 mt -139.36 112.85 6.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.152 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -122.58 175.59 6.4 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.902 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 105.11 -146.36 16.06 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.498 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -111.69 92.51 4.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.886 0.374 . . . . 0.0 110.865 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.483 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 4.7 p -151.22 140.59 15.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.107 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . 0.501 ' O ' ' CA ' ' A' ' 47' ' ' GLY . 14.1 m -100.52 94.15 5.99 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.16 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.463 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 80.4 mt -78.59 132.99 37.34 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.92 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 64.9 m -118.29 -34.38 4.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.889 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 13.8 t80 -149.98 130.36 13.79 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.941 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 86.3 t -140.77 106.14 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.152 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 16.0 tt0 -114.57 135.85 53.68 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.919 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' ILE . . . . . 0.412 ' O ' HG22 ' A' ' 158' ' ' ILE . 42.1 mt . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.166 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.51 ' CG2' ' N ' ' A' ' 23' ' ' PHE . 1.3 m . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.853 0.358 . . . . 0.0 111.115 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.51 ' N ' ' CG2' ' A' ' 22' ' ' THR . 8.4 m-85 -147.73 141.65 25.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.873 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . 0.485 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 15.8 m120 35.12 51.95 1.37 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.63 0.729 . . . . 0.0 110.88 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.491 ' HG2' ' CB ' ' A' ' 153' ' ' LEU . 53.6 Cg_endo -69.82 145.78 57.85 Favored 'Trans proline' 0 C--O 1.232 0.192 0 C-N-CA 122.693 2.262 . . . . 0.0 112.309 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.79 -178.25 2.27 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.663 2.242 . . . . 0.0 112.32 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.681 HG13 ' HA ' ' A' ' 28' ' ' PRO . 95.2 t -142.85 138.0 15.58 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.688 0.756 . . . . 0.0 111.081 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.681 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.9 Cg_endo -69.77 144.54 76.95 Favored 'Cis proline' 0 C--N 1.342 0.195 0 C-N-CA 122.656 -1.81 . . . . 0.0 112.347 -0.028 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 1.9 t80 -96.22 117.64 31.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.95 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -100.53 104.09 15.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.888 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -109.03 109.19 2.74 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.48 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 6.8 mmt85 -72.97 116.55 13.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.829 0.347 . . . . 0.0 110.887 -179.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.482 HD23 HG12 ' A' ' 158' ' ' ILE . 6.1 mt -75.69 94.61 3.27 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.913 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 22.2 mm-40 -67.22 92.55 0.27 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.886 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 138.21 -37.63 1.79 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.476 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.816 ' O ' HG23 ' A' ' 38' ' ' THR . . . 88.92 157.48 32.85 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.493 -179.884 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . 0.423 HD12 ' O ' ' A' ' 139' ' ' PHE . 66.4 mt -51.08 95.77 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.914 0.388 . . . . 0.0 110.907 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.816 HG23 ' O ' ' A' ' 36' ' ' GLY . 44.4 p -116.24 148.59 40.3 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.092 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -50.6 -21.27 1.48 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.106 179.813 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.455 ' HA ' ' NE ' ' A' ' 40' ' ' ARG . 3.8 mmp_? -106.88 34.28 3.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.859 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 14.7 ttt85 -125.9 140.06 52.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.904 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 99.9 m -139.36 119.81 13.95 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.168 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 4.9 mp -90.59 142.19 13.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.15 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 82.4 mt -133.76 115.66 22.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.111 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 54.3 mt -114.92 107.59 23.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.123 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.0 mtmm -110.18 109.3 19.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.885 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.59 -147.53 4.98 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.507 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . 0.587 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.5 OUTLIER -168.14 127.13 1.22 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.892 0.377 . . . . 0.0 110.97 -179.806 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 11.3 t -75.97 115.38 46.06 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.627 0.727 . . . . 0.0 111.141 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 155.42 66.15 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.661 2.241 . . . . 0.0 112.423 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -14.83 36.61 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.657 2.238 . . . . 0.0 112.326 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 49.7 p -111.62 17.94 19.49 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.162 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -113.36 124.14 6.44 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.48 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 14.8 mttp -64.89 -62.6 1.46 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.802 0.334 . . . . 0.0 110.897 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 17.5 p -171.76 157.51 4.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.875 -179.869 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.6 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 9.1 p90 -113.1 -172.27 2.03 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.931 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.629 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -155.19 139.12 16.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.081 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.575 HD11 ' CE2' ' A' ' 56' ' ' PHE . 2.7 mp -118.95 99.03 7.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.139 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . 0.512 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 33.0 m-80 -101.22 141.67 33.77 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.897 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.678 ' CE2' HD13 ' A' ' 145' ' ' LEU . 26.8 m-85 -115.49 97.92 6.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.861 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.404 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 32.9 ttmt -95.59 169.91 9.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.94 179.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.595 HG13 ' O ' ' A' ' 141' ' ' ARG . 16.7 t -99.33 123.35 51.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.131 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -61.08 -22.87 61.05 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.497 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.584 ' H ' HG12 ' A' ' 62' ' ' VAL . 30.7 t -81.73 -72.78 0.42 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.928 0.394 . . . . 0.0 110.855 -179.72 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 36.0 t -80.61 -72.79 0.4 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.839 -179.82 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 133.69 40.65 0.18 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.487 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.555 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.1 m-20 -110.29 137.54 47.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.796 0.331 . . . . 0.0 110.847 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.538 HD12 ' HB3' ' A' ' 86' ' ' LEU . 57.0 mt -85.84 112.46 22.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.155 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.587 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -80.7 -34.66 34.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.114 179.829 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.713 HD21 HD11 ' A' ' 72' ' ' ILE . 53.4 tp -140.69 132.16 26.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.951 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.512 ' CG ' ' OD1' ' A' ' 59' ' ' ASN . 3.3 t60 -134.92 92.3 2.86 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.857 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.713 HD11 HD21 ' A' ' 70' ' ' LEU . 20.3 mt -96.17 134.78 32.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.163 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.629 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -140.06 105.88 6.75 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.643 0.735 . . . . 0.0 110.904 179.968 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.6 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.2 Cg_endo -69.75 155.01 67.1 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.67 2.247 . . . . 0.0 112.364 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 36.7 mtp180 -131.85 94.72 3.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.854 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . 0.431 ' HE3' ' HB3' ' A' ' 103' ' ' PHE . 0.3 OUTLIER . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.877 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 13.7 p . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.807 0.337 . . . . 0.0 111.187 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.53 HG22 ' HA ' ' A' ' 74' ' ' PRO . 29.4 t -104.43 109.47 27.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.119 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.741 HG22 ' CE ' ' A' ' 96' ' ' LYS . 58.2 t -80.01 135.53 25.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.107 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . 0.483 ' HD3' ' N ' ' A' ' 83' ' ' ARG . 0.7 OUTLIER -121.06 115.18 22.63 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.884 -179.989 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.434 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.2 t-20 -124.81 -176.82 3.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.911 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.431 ' CB ' ' HD2' ' A' ' 135' ' ' ARG . 47.5 t -161.17 106.45 1.36 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.883 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.904 HD13 ' NE1' ' A' ' 91' ' ' TRP . 28.9 tp -78.9 115.35 18.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.923 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.519 ' N ' ' O ' ' A' ' 90' ' ' SER . 73.2 mt -92.96 162.18 14.16 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.882 179.901 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.488 ' ND2' ' OD2' ' A' ' 67' ' ' ASP . 10.6 m-80 -40.66 101.64 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.891 179.902 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.77 -3.59 2.79 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.466 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.854 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -123.15 170.97 9.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.901 0.382 . . . . 0.0 110.833 -179.73 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.904 ' NE1' HD13 ' A' ' 86' ' ' LEU . 24.7 m95 -128.41 160.62 31.69 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.926 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -91.24 -108.26 1.5 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.483 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 2.9 m -163.07 169.5 19.38 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.851 0.358 . . . . 0.0 110.873 -179.73 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 71.6 mt-10 -93.58 119.19 32.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.901 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 -122.87 124.95 44.42 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.92 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.741 ' CE ' HG22 ' A' ' 82' ' ' VAL . 17.4 mttp -126.52 122.74 36.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.896 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.413 ' HB3' ' NH2' ' A' ' 83' ' ' ARG . 4.6 ttpm? -169.5 105.81 0.37 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.91 179.827 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.737 HD11 ' O ' ' A' ' 100' ' ' HIS . 1.3 tt -147.75 150.2 14.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.144 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.48 HG23 ' N ' ' A' ' 100' ' ' HIS . 11.5 t -86.52 -43.48 12.7 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.145 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . 0.737 ' O ' HD11 ' A' ' 98' ' ' ILE . 2.9 p-80 -149.64 127.2 11.58 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.898 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . 0.43 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 51.7 t-20 -99.51 101.01 11.91 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.604 0.716 . . . . 0.0 110.867 -179.89 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.456 ' HD2' HD11 ' A' ' 129' ' ' LEU . 53.8 Cg_endo -69.78 -31.81 19.72 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.738 2.292 . . . . 0.0 112.341 179.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.593 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 17.9 m-85 -44.2 102.48 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.837 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -132.06 135.18 8.02 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.482 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 98.26 0.67 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.672 2.248 . . . . 0.0 112.351 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 130.75 -5.87 5.82 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.44 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 -135.47 159.83 40.37 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.849 0.356 . . . . 0.0 110.91 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' PHE . . . . . 0.587 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 16.2 m-85 -77.64 174.56 10.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.876 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.544 ' O ' ' CD1' ' A' ' 109' ' ' PHE . 33.5 p90 -161.49 118.08 2.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.881 -179.872 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -92.5 106.93 18.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.892 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.817 HD13 ' N ' ' A' ' 112' ' ' SER . 0.3 OUTLIER -106.75 138.38 43.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.91 -179.948 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.817 ' N ' HD13 ' A' ' 111' ' ' LEU . 7.4 m -145.37 112.04 5.87 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.841 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.8 mp -94.55 134.12 33.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.116 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 70.7 mtt180 -111.79 123.35 50.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.844 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . 0.576 ' HA ' ' CD1' ' A' ' 120' ' ' PHE . 3.5 t -93.91 100.87 12.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.89 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -93.11 -126.96 4.34 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.476 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.4 mt -132.74 -43.19 0.91 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.842 0.353 . . . . 0.0 110.885 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -86.04 -29.34 23.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.9 179.82 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 10.6 ptp85 -175.16 162.37 2.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.838 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.576 ' CD1' ' HA ' ' A' ' 115' ' ' CYS . 3.0 m-30 -85.45 141.43 29.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.902 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 12.0 mmmt -113.67 105.01 12.8 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.941 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.591 HG13 HD11 ' A' ' 111' ' ' LEU . 48.8 t -95.18 133.2 36.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.12 179.898 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 11.0 m-85 -120.16 159.24 25.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.874 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.53 ' HB2' HD13 ' A' ' 129' ' ' LEU . . . -141.4 116.25 9.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.059 179.872 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 45.07 35.94 1.82 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.896 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 84.33 29.36 30.67 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.458 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 10.5 mm100 -140.96 116.11 9.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.789 0.328 . . . . 0.0 110.911 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 42.1 t-80 -51.27 105.02 0.09 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.831 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.53 HD13 ' HB2' ' A' ' 124' ' ' ALA . 6.4 tp -72.13 -67.52 0.53 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.941 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.629 ' HZ ' HD13 ' A' ' 72' ' ' ILE . 6.7 p90 -166.35 179.82 5.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.898 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -126.27 158.9 34.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.845 -179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.638 ' CD1' HD13 ' A' ' 70' ' ' LEU . 0.2 OUTLIER -115.4 110.24 19.05 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.89 -179.914 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.595 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -54.52 138.69 40.0 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.071 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 18.4 m-70 -78.15 69.22 4.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.83 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.431 ' HD2' ' CB ' ' A' ' 85' ' ' SER . 0.0 OUTLIER -66.33 -37.89 86.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.872 -179.948 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.8 tp -98.23 107.89 20.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.916 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 78.8 p -58.1 -25.12 60.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.859 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.67 ' HB1' ' HD2' ' A' ' 141' ' ' ARG . . . -91.06 39.71 1.0 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.114 179.894 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.423 ' O ' HD12 ' A' ' 37' ' ' LEU . 28.9 p90 -65.47 -30.88 71.71 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.909 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 4.9 pt20 -59.32 -31.16 68.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.889 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.67 ' HD2' ' HB1' ' A' ' 138' ' ' ALA . 27.4 mtt180 -64.26 -40.16 95.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.889 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.587 HG21 ' CB ' ' A' ' 69' ' ' ALA . 92.0 t -48.91 106.01 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.139 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.505 ' OD2' ' N ' ' A' ' 36' ' ' GLY . 0.7 OUTLIER -130.84 33.41 4.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.892 179.922 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 9.1 m -143.74 113.5 7.12 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.175 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.678 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.7 tp -111.19 106.99 16.17 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.905 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' GLU . . . . . 0.417 ' C ' HG13 ' A' ' 147' ' ' ILE . 3.1 pt-20 -108.59 153.91 22.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.901 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.417 HG13 ' C ' ' A' ' 146' ' ' GLU . 21.3 mt -140.78 116.49 7.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.081 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -126.19 171.76 10.62 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.926 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 104.74 -157.07 16.84 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.459 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 64.6 m-20 -98.6 94.32 6.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.868 0.366 . . . . 0.0 110.844 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 10.4 p -151.07 141.5 16.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.142 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 33.7 m -105.5 92.71 4.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.176 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.491 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 94.6 mt -71.75 133.65 45.71 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.895 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 3.6 m -114.61 -35.66 4.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.886 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . 0.462 ' C ' ' CD1' ' A' ' 155' ' ' TYR . 4.2 t80 -157.16 132.43 9.06 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.941 -179.885 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 85.0 t -140.47 133.79 33.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.113 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 8.0 tt0 -156.57 138.45 14.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.891 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' ILE . . . . . 0.482 HG12 HD23 ' A' ' 33' ' ' LEU . 4.7 mp . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.141 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 3.7 t . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.839 0.352 . . . . 0.0 111.127 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -129.05 122.67 30.47 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.875 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . 0.555 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 6.3 t-20 74.11 47.76 0.21 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.589 0.709 . . . . 0.0 110.899 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.555 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.78 123.29 9.95 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.646 2.231 . . . . 0.0 112.375 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.78 -179.28 2.81 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.674 2.25 . . . . 0.0 112.363 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.704 HG13 ' HA ' ' A' ' 28' ' ' PRO . 90.8 t -140.97 138.5 18.11 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.592 0.711 . . . . 0.0 111.096 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.704 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.6 Cg_endo -69.76 144.22 76.05 Favored 'Cis proline' 0 C--O 1.231 0.174 0 C-N-CA 122.69 -1.796 . . . . 0.0 112.311 -0.056 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.6 t80 -97.29 114.32 26.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.942 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.432 ' CD1' ' HB3' ' A' ' 146' ' ' GLU . 66.6 m-85 -99.55 107.25 19.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.875 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -115.29 100.44 0.97 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.513 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.483 ' O ' ' CG ' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -72.78 117.11 14.08 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.84 0.353 . . . . 0.0 110.895 -179.848 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.4 ' O ' ' HD3' ' A' ' 32' ' ' ARG . 11.6 mt -63.45 150.11 44.47 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.937 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . 0.455 ' OE1' ' NH1' ' A' ' 32' ' ' ARG . 7.3 mm100 -98.01 -46.44 5.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.943 179.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.557 ' O ' HG23 ' A' ' 38' ' ' THR . . . -103.47 33.22 6.76 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.486 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.41 ' O ' ' O ' ' A' ' 35' ' ' GLY . . . 37.21 -157.5 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.443 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 51.3 mt -88.43 106.7 18.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.832 0.348 . . . . 0.0 110.92 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.557 HG23 ' O ' ' A' ' 35' ' ' GLY . 34.4 p -122.12 170.57 9.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.109 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.495 ' HB2' ' HG ' ' A' ' 117' ' ' LEU . . . -79.13 -11.81 59.99 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.074 179.884 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 12.2 mmm180 -110.64 22.39 15.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.841 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.817 ' CZ ' HD11 ' A' ' 43' ' ' ILE . 27.8 ttt-85 -117.94 143.22 46.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.873 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 51.9 m -138.14 129.1 27.07 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.129 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.817 HD11 ' CZ ' ' A' ' 41' ' ' ARG . 4.8 mp -94.64 145.73 7.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.133 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 76.6 mt -142.73 114.33 3.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.125 179.852 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 48.3 mt -115.93 107.71 23.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.143 179.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.5 mtmm -109.89 112.92 25.24 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.919 179.827 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.411 ' CA ' ' O ' ' A' ' 152' ' ' THR . . . -146.85 -142.89 3.78 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.534 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -167.58 130.64 1.67 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.874 0.368 . . . . 0.0 110.92 -179.827 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 16.0 t -78.98 115.74 54.69 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.661 0.743 . . . . 0.0 111.099 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 155.42 65.81 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.676 2.251 . . . . 0.0 112.326 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 -19.27 36.47 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.723 2.282 . . . . 0.0 112.319 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 69.5 p -106.15 16.84 24.39 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.167 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -114.66 125.91 7.01 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.489 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 15.7 mttp -66.25 -61.84 1.8 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.785 0.326 . . . . 0.0 110.895 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.0 p -172.56 158.2 4.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.883 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.596 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 8.1 p90 -108.88 -173.85 2.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.845 -179.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.654 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -156.32 140.79 16.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.092 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.56 HG23 HG12 ' A' ' 147' ' ' ILE . 3.1 mp -122.38 107.84 20.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.098 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -111.74 143.52 42.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.852 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.687 ' CE2' HD13 ' A' ' 145' ' ' LEU . 13.6 m-85 -113.67 102.04 9.88 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.91 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.411 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 31.9 ttmt -95.1 168.07 10.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.888 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.78 HG13 ' O ' ' A' ' 141' ' ' ARG . 25.5 t -98.94 122.37 50.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.106 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -60.22 -26.62 64.05 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.479 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.564 ' H ' HG12 ' A' ' 62' ' ' VAL . 66.4 m -75.47 -70.88 0.4 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.869 0.366 . . . . 0.0 110.855 -179.76 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.8 m -85.23 -73.54 0.43 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.825 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 137.58 35.87 0.17 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.447 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.534 ' O ' HG23 ' A' ' 62' ' ' VAL . 0.3 OUTLIER -104.11 146.87 28.11 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.766 0.317 . . . . 0.0 110.879 -179.972 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 60.4 mt -94.79 115.89 34.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.203 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.7 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -83.19 -39.11 21.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.075 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.687 HD13 ' CG ' ' A' ' 132' ' ' PHE . 38.8 tp -135.06 133.01 38.89 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.952 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.474 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.9 OUTLIER -134.34 93.09 3.01 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.827 179.885 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.543 HD11 HD21 ' A' ' 70' ' ' LEU . 59.3 mt -97.21 130.84 45.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.094 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.654 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -136.11 106.5 9.53 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.629 0.728 . . . . 0.0 110.942 179.87 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.643 ' HA ' HG22 ' A' ' 81' ' ' VAL . 54.1 Cg_endo -69.75 155.12 66.78 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.664 2.243 . . . . 0.0 112.399 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 25.9 mtp180 -132.35 101.48 5.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.822 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.855 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 25.1 p . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.823 0.344 . . . . 0.0 111.123 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.643 HG22 ' HA ' ' A' ' 74' ' ' PRO . 17.3 t -87.84 104.64 14.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.126 179.888 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.712 HG22 ' HD3' ' A' ' 96' ' ' LYS . 58.7 t -76.25 145.52 10.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.125 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -125.78 131.28 52.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.861 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.474 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.2 m120 -143.81 179.52 7.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.892 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.405 ' CB ' ' O ' ' A' ' 69' ' ' ALA . 96.6 p -160.7 107.29 1.49 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.816 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.888 HD13 ' NE1' ' A' ' 91' ' ' TRP . 28.5 tp -77.38 116.92 18.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.935 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.534 HD22 HD13 ' A' ' 136' ' ' LEU . 66.7 mt -93.33 161.58 14.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.933 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.455 ' ND2' ' OD2' ' A' ' 67' ' ' ASP . 14.0 m-80 -41.63 101.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.869 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.86 -3.38 3.94 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.516 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.843 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -124.83 171.58 10.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.838 0.351 . . . . 0.0 110.868 -179.72 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.888 ' NE1' HD13 ' A' ' 86' ' ' LEU . 23.0 m95 -128.08 159.85 33.8 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.968 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -89.37 -105.82 1.12 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.478 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . 0.424 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 25.2 m -165.91 166.15 17.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.86 0.362 . . . . 0.0 110.82 -179.76 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.412 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 5.6 mt-10 -88.32 119.99 29.26 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.867 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -120.03 116.44 25.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.85 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.712 ' HD3' HG22 ' A' ' 82' ' ' VAL . 46.5 mtmt -122.25 124.79 44.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.873 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 26.9 ttpt -172.53 107.95 0.19 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.919 179.882 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.825 HD11 ' O ' ' A' ' 100' ' ' HIS . 7.1 tt -147.35 159.58 8.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.125 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.482 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 9.8 t -102.75 -34.23 9.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.13 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . 0.825 ' O ' HD11 ' A' ' 98' ' ' ILE . 1.7 p-80 -155.66 130.25 9.06 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.847 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . 0.632 ' ND2' HD13 ' A' ' 98' ' ' ILE . 11.6 m120 -101.71 97.72 8.41 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.61 0.719 . . . . 0.0 110.937 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.403 ' HD3' ' O ' ' A' ' 100' ' ' HIS . 53.7 Cg_endo -69.7 -31.06 21.54 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.698 2.265 . . . . 0.0 112.339 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.543 ' CZ ' HD21 ' A' ' 129' ' ' LEU . 5.8 m-85 -52.77 107.97 0.27 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.86 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -133.52 139.66 11.11 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.507 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 105.21 1.43 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.727 2.285 . . . . 0.0 112.38 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 122.97 -8.04 9.24 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.497 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.3 pt20 -132.97 153.85 51.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.83 0.348 . . . . 0.0 110.887 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -77.15 172.94 12.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.865 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 32.4 p90 -160.16 139.89 11.25 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.899 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -109.55 104.91 14.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.898 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.694 HD13 ' N ' ' A' ' 112' ' ' SER . 1.0 OUTLIER -105.51 138.17 42.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.919 -179.955 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.694 ' N ' HD13 ' A' ' 111' ' ' LEU . 2.6 m -144.64 113.98 7.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.857 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.464 HD11 HD12 ' A' ' 111' ' ' LEU . 4.9 mp -95.32 131.62 41.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.116 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 15.7 mtp180 -106.38 128.01 53.71 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.842 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . 0.481 ' HA ' ' CD1' ' A' ' 120' ' ' PHE . 35.6 t -98.99 121.37 40.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.908 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -116.38 -138.13 6.22 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.477 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.495 ' HG ' ' HB2' ' A' ' 39' ' ' ALA . 9.7 mt -123.03 -31.38 3.63 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.806 0.336 . . . . 0.0 110.932 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . 0.423 ' C ' ' CD2' ' A' ' 134' ' ' HIS . 0.9 OUTLIER -96.66 -34.21 11.47 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.871 179.891 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 20.8 ptt-85 -172.91 171.48 4.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.481 ' CD1' ' HA ' ' A' ' 115' ' ' CYS . 4.1 m-30 -94.8 157.62 15.85 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.887 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 19.8 mtpp -130.49 99.77 5.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.891 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.486 HG13 HD11 ' A' ' 111' ' ' LEU . 42.2 t -84.46 133.97 28.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.131 179.867 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' TYR . . . . . 0.449 ' O ' HD22 ' A' ' 111' ' ' LEU . 81.5 m-85 -122.46 153.84 38.59 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.886 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.435 ' O ' ' CG ' ' A' ' 125' ' ' ASN . . . -139.72 121.34 15.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.123 179.815 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.435 ' CG ' ' O ' ' A' ' 124' ' ' ALA . 10.7 p30 48.49 33.66 4.2 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.895 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.78 26.5 49.75 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.438 179.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 37.0 mm-40 -129.76 168.02 17.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.842 0.353 . . . . 0.0 110.909 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 33.9 t-80 -91.16 116.09 28.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.829 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.543 HD21 ' CZ ' ' A' ' 103' ' ' PHE . 9.0 tp -87.93 -68.32 0.77 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.957 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.49 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 3.9 p90 -168.68 172.21 8.15 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.862 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -115.43 156.73 25.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.853 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.687 ' CG ' HD13 ' A' ' 70' ' ' LEU . 0.2 OUTLIER -122.49 104.4 9.35 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.893 -179.94 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.514 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -60.08 134.13 56.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.13 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' HIS . . . . . 0.423 ' CD2' ' C ' ' A' ' 118' ' ' ASP . 25.7 m-70 -61.77 99.56 0.12 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.836 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.424 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 11.7 mtt-85 -82.12 -46.36 13.95 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . 0.534 HD13 HD22 ' A' ' 87' ' ' LEU . 13.9 tp -97.55 113.67 25.42 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.906 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 90.8 p -56.05 -32.78 64.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.843 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.647 ' HB1' ' HG3' ' A' ' 141' ' ' ARG . . . -85.69 37.88 0.72 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.061 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 4.7 p90 -56.13 -27.93 55.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.867 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' GLN . . . . . 0.464 ' HG2' ' N ' ' A' ' 141' ' ' ARG . 17.9 pm0 -63.48 -30.41 71.54 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.942 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.78 ' O ' HG13 ' A' ' 62' ' ' VAL . 22.5 mtt180 -65.38 -36.11 82.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.824 -179.866 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.7 HG21 ' CB ' ' A' ' 69' ' ' ALA . 90.5 t -56.55 105.0 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.119 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -126.01 35.7 4.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.879 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 32' ' ' ARG . 0.6 OUTLIER -144.58 137.98 27.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.138 -179.874 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.687 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.0 tp -134.7 106.43 6.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.904 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' GLU . . . . . 0.432 ' HB3' ' CD1' ' A' ' 30' ' ' PHE . 4.9 pt-20 -109.22 149.16 29.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.934 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.56 HG12 HG23 ' A' ' 58' ' ' ILE . 12.7 mt -137.49 106.82 4.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.154 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -118.58 174.5 6.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.908 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 110.02 -140.81 15.99 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.482 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -117.86 91.92 3.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.811 0.338 . . . . 0.0 110.839 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.426 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 2.9 p -151.37 135.68 9.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.116 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . 0.411 ' O ' ' CA ' ' A' ' 47' ' ' GLY . 17.7 m -95.93 92.82 6.68 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.171 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.494 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 93.3 mt -76.31 136.38 39.59 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.965 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 19.5 m -123.1 -39.27 2.5 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.858 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 37.3 t80 -141.81 127.07 18.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.905 -179.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 75.9 t -140.43 105.24 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.096 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -121.34 119.82 33.29 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.916 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 56.1 mt . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.107 -179.993 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.439 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.5 m . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.835 0.35 . . . . 0.0 111.127 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -137.35 120.18 16.35 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.907 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . 0.53 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 8.8 m120 60.27 49.03 1.94 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.57 0.7 . . . . 0.0 110.899 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.53 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.2 Cg_endo -69.82 141.75 45.8 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.646 2.23 . . . . 0.0 112.296 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -178.02 2.14 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.63 2.22 . . . . 0.0 112.387 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.684 HG13 ' HA ' ' A' ' 28' ' ' PRO . 96.6 t -142.35 137.89 16.01 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.651 0.739 . . . . 0.0 111.088 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.684 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.8 Cg_endo -69.78 145.23 78.87 Favored 'Cis proline' 0 C--O 1.232 0.192 0 C-N-CA 122.65 -1.812 . . . . 0.0 112.394 -0.057 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -97.52 123.03 41.24 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.885 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -107.74 102.79 11.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.853 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -108.5 110.66 3.12 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.508 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.413 ' NH1' ' HA3' ' A' ' 63' ' ' GLY . 9.0 mmt180 -73.14 113.36 10.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.87 0.366 . . . . 0.0 110.887 -179.859 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 5.9 mt -73.25 97.9 2.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.909 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 20.6 mt-30 -66.79 94.76 0.32 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.885 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 135.69 -42.94 1.29 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.481 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.592 ' O ' HG23 ' A' ' 38' ' ' THR . . . 96.23 170.13 34.85 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.423 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . 0.768 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 96.1 mt -60.26 105.09 0.38 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.914 0.388 . . . . 0.0 110.913 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.592 HG23 ' O ' ' A' ' 36' ' ' GLY . 38.2 p -117.31 158.76 23.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.119 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -64.32 -16.12 61.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.106 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -114.96 23.92 12.16 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.821 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.504 ' NH1' ' CG2' ' A' ' 158' ' ' ILE . 44.4 ttm-85 -112.6 135.35 53.42 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.869 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 92.3 m -133.16 126.1 30.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.166 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.466 ' N ' HD12 ' A' ' 43' ' ' ILE . 4.6 mp -95.44 138.86 20.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.166 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 88.7 mt -128.91 126.67 65.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.13 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 58.5 mt -126.08 107.59 17.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.117 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 23.2 mtmt -112.05 112.43 24.06 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.883 179.849 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -143.69 -141.91 3.87 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.436 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . 0.586 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.6 OUTLIER -169.28 124.03 0.84 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.931 0.396 . . . . 0.0 110.928 -179.775 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.543 HG23 ' CD2' ' A' ' 109' ' ' PHE . 14.1 t -75.35 116.39 54.17 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.651 0.738 . . . . 0.0 111.113 179.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 158.94 55.28 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.671 2.247 . . . . 0.0 112.355 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 -21.93 32.93 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.711 2.274 . . . . 0.0 112.393 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 24.4 p -105.88 18.88 21.44 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.142 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -110.2 117.71 4.81 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.44 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 29.2 mtpt -61.58 -60.04 4.3 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.797 0.332 . . . . 0.0 110.891 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 10.5 p -174.59 154.87 2.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.882 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.585 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 5.2 p90 -109.54 -173.48 2.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.881 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.704 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -155.24 143.9 20.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.123 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.465 HG22 ' CE1' ' A' ' 60' ' ' PHE . 2.8 mp -123.91 99.0 5.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.142 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.7 m-80 -99.0 143.71 28.98 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.934 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.551 ' HB3' HG11 ' A' ' 142' ' ' VAL . 15.8 m-85 -118.24 97.26 5.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.864 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.437 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 31.5 ttmt -96.66 169.77 9.65 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.906 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.623 HG22 ' HA ' ' A' ' 142' ' ' VAL . 28.4 t -101.42 124.75 55.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.097 179.871 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.413 ' HA3' ' NH1' ' A' ' 32' ' ' ARG . . . -59.72 -36.21 88.95 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.51 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 23.1 t -67.21 -73.57 0.13 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.86 0.362 . . . . 0.0 110.857 -179.75 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 10.6 t -78.17 -72.48 0.37 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 -179.795 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 129.51 42.33 0.23 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.459 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.431 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.1 m-20 -115.12 140.89 48.69 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.817 0.341 . . . . 0.0 110.84 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.615 HD12 ' HB3' ' A' ' 86' ' ' LEU . 55.2 mt -86.08 122.17 38.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.113 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.517 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -92.93 -31.8 14.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.087 179.831 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.655 HD22 ' CD2' ' A' ' 132' ' ' PHE . 40.0 tp -140.44 131.1 25.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.903 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.488 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.5 OUTLIER -134.1 92.31 2.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.863 179.862 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.515 HD11 HD21 ' A' ' 70' ' ' LEU . 55.7 mt -95.84 130.53 44.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.142 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.704 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -137.79 106.0 8.23 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.632 0.729 . . . . 0.0 110.905 179.924 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.585 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.3 Cg_endo -69.71 155.45 66.06 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.698 2.265 . . . . 0.0 112.394 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 39.3 mtp180 -130.67 96.11 4.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.868 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . 0.4 ' HE3' ' HB3' ' A' ' 103' ' ' PHE . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.85 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.9 p . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.83 0.348 . . . . 0.0 111.112 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.455 HG21 ' HE2' ' A' ' 103' ' ' PHE . 20.6 t -99.67 108.38 22.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.169 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.641 HG22 ' HD3' ' A' ' 96' ' ' LYS . 47.3 t -76.95 143.1 13.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.133 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . 0.437 ' NH1' ' CD2' ' A' ' 130' ' ' PHE . 0.2 OUTLIER -126.93 129.87 49.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.873 -179.977 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.488 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.4 OUTLIER -140.6 179.65 6.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.905 -179.922 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 28.8 t -160.06 105.01 1.52 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.891 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.904 HD12 ' O ' ' A' ' 90' ' ' SER . 24.9 tp -76.92 118.29 19.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.93 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.51 ' N ' ' O ' ' A' ' 90' ' ' SER . 86.5 mt -95.8 161.63 13.94 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.901 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.462 ' C ' ' H ' ' A' ' 90' ' ' SER . 0.2 OUTLIER -38.64 101.81 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.911 179.931 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.33 -6.09 0.86 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.493 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.904 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -118.47 169.24 9.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.879 0.371 . . . . 0.0 110.84 -179.705 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.862 ' NE1' HD13 ' A' ' 86' ' ' LEU . 20.5 m95 -128.39 161.29 29.81 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.939 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -93.96 -111.71 2.26 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.467 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . 0.433 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 39.3 m -158.0 170.97 21.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.839 0.352 . . . . 0.0 110.844 -179.717 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -94.87 123.32 38.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.913 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -120.99 120.52 35.65 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.888 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.641 ' HD3' HG22 ' A' ' 82' ' ' VAL . 9.4 mtmp? -123.41 120.02 31.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.913 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -170.75 109.67 0.34 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.903 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.843 HD11 ' O ' ' A' ' 100' ' ' HIS . 2.8 tt -148.84 154.2 10.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.127 179.86 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.445 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 9.0 t -93.95 -40.91 9.87 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.176 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . 0.843 ' O ' HD11 ' A' ' 98' ' ' ILE . 2.4 p-80 -147.18 128.44 14.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.865 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -103.32 95.62 7.23 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.652 0.739 . . . . 0.0 110.865 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.45 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.7 Cg_endo -69.79 -40.24 5.51 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.715 2.277 . . . . 0.0 112.324 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.477 ' CE2' ' HB3' ' A' ' 74' ' ' PRO . 8.1 m-85 -34.46 112.01 0.13 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.811 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -138.34 134.67 6.99 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.494 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 98.05 0.66 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.685 2.256 . . . . 0.0 112.337 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 126.01 -3.59 7.9 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.493 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.3 pt20 -132.46 149.39 52.34 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.806 0.336 . . . . 0.0 110.926 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' PHE . . . . . 0.586 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 79.8 m-85 -67.04 169.91 7.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.883 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.543 ' CD2' HG23 ' A' ' 49' ' ' VAL . 19.6 p90 -161.1 120.02 2.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.847 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -96.6 107.13 19.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.895 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.786 HD13 ' N ' ' A' ' 112' ' ' SER . 0.6 OUTLIER -108.95 138.56 45.1 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.926 -179.921 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.786 ' N ' HD13 ' A' ' 111' ' ' LEU . 3.7 m -145.27 115.4 7.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.854 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.509 HG23 HG22 ' A' ' 122' ' ' VAL . 4.1 mp -95.12 138.89 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.105 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 45.6 mtt-85 -113.19 123.74 50.92 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.874 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . 0.578 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 11.2 t -92.75 117.53 30.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.872 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.87 -142.41 7.83 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.468 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 17.4 mt -121.43 -35.99 3.16 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.788 0.328 . . . . 0.0 110.884 -179.9 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -92.32 -33.36 14.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.856 179.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -174.07 164.62 4.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.871 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.768 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 2.8 m-30 -90.52 156.8 17.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.921 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 23.2 mtpp -128.9 103.23 6.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.927 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.737 HG13 HD11 ' A' ' 111' ' ' LEU . 46.3 t -92.7 127.95 44.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.121 179.92 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 14.7 m-85 -117.9 153.05 34.23 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.878 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -135.89 110.4 8.55 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.128 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 57.38 33.43 23.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.857 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 82.35 29.52 36.52 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.498 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 37.2 mm-40 -138.27 121.52 16.97 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.845 0.355 . . . . 0.0 110.907 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 26.4 t-80 -54.41 110.71 0.66 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.86 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.446 HD21 ' CZ ' ' A' ' 103' ' ' PHE . 8.6 tp -76.81 -66.45 0.82 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.906 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.437 ' CD2' ' NH1' ' A' ' 83' ' ' ARG . 5.3 p90 -166.24 171.26 12.38 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.882 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -111.4 147.07 36.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.887 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.655 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -113.01 107.46 15.99 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.872 -179.872 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.557 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -64.0 130.95 46.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.132 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 33.7 m-70 -58.5 111.81 1.37 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.838 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.433 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 44.9 mtt-85 -96.08 -44.18 7.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.915 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 4.4 tp -100.96 109.35 21.26 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 97.4 p -49.37 -34.39 15.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.512 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -83.27 31.53 0.45 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.086 179.893 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.533 ' O ' HD12 ' A' ' 37' ' ' LEU . 3.9 p90 -50.44 -40.09 49.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.846 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 10.4 pt20 -52.87 -43.21 65.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.904 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.512 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 56.9 mtp85 -50.95 -42.76 60.04 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.874 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.623 ' HA ' HG22 ' A' ' 62' ' ' VAL . 97.1 t -44.35 106.12 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.121 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -130.43 29.44 4.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.838 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 25.4 m -139.92 112.65 7.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.124 -179.89 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.537 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.0 tp -110.54 108.03 17.86 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.929 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' GLU . . . . . 0.406 ' C ' HG13 ' A' ' 147' ' ' ILE . 1.2 pm0 -111.67 153.59 26.18 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.858 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.406 HG13 ' C ' ' A' ' 146' ' ' GLU . 16.9 mt -139.39 112.05 5.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.135 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -121.14 172.35 8.04 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.928 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 110.6 -142.47 16.71 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.452 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -117.49 93.57 4.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.88 0.371 . . . . 0.0 110.847 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.4 p -151.23 152.24 11.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.182 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 27.8 m -113.55 93.59 4.46 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.141 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.477 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 79.2 mt -73.03 141.4 47.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.94 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 50.1 m -125.83 -28.54 3.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.857 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 31.3 t80 -157.56 129.97 7.3 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 90.2 t -140.53 105.52 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.108 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 18.8 tt0 -121.13 140.56 51.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.855 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 158' ' ' ILE . . . . . 0.504 ' CG2' ' NH1' ' A' ' 41' ' ' ARG . 14.9 mt . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.092 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.429 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.9 m . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.83 0.347 . . . . 0.0 111.15 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -143.18 137.32 28.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.824 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . 0.549 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 9.0 m120 45.44 47.94 4.51 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.61 0.719 . . . . 0.0 110.93 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.549 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 54.1 Cg_endo -69.71 139.26 39.96 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.641 2.227 . . . . 0.0 112.375 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -177.62 1.95 Allowed 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.693 2.262 . . . . 0.0 112.304 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.633 HG13 ' HA ' ' A' ' 28' ' ' PRO . 84.2 t -143.7 136.73 13.82 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.592 0.711 . . . . 0.0 111.124 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.633 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.4 Cg_endo -69.71 145.37 79.12 Favored 'Cis proline' 0 C--N 1.341 0.153 0 C-N-CA 122.681 -1.799 . . . . 0.0 112.373 -0.091 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 4.9 t80 -98.34 115.26 28.07 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.937 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -99.44 103.1 14.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.901 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -118.09 102.16 0.95 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.488 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.4 ' HA ' ' HA ' ' A' ' 144' ' ' THR . 0.0 OUTLIER -73.45 128.47 35.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.843 0.354 . . . . 0.0 110.867 -179.886 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.455 ' N ' ' O ' ' A' ' 143' ' ' ASP . 3.3 mt -74.0 150.25 40.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.885 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 10.6 mm100 -105.24 99.67 9.27 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.913 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 124.46 -55.92 0.7 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.488 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.538 ' O ' HG23 ' A' ' 38' ' ' THR . . . 119.47 169.65 14.3 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.515 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . 0.516 HD12 ' O ' ' A' ' 139' ' ' PHE . 87.5 mt -61.04 97.91 0.07 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.87 0.367 . . . . 0.0 110.953 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.538 HG23 ' O ' ' A' ' 36' ' ' GLY . 48.4 p -109.5 160.73 15.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.159 179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -58.1 -28.6 64.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.084 179.892 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 3.1 mpt_? -105.96 39.1 1.85 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.863 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 29.5 ttm-85 -117.76 137.62 52.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.872 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 93.6 m -138.41 120.84 16.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.155 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.46 ' N ' HD12 ' A' ' 43' ' ' ILE . 4.7 mp -94.35 134.99 29.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.148 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 93.3 mt -125.24 138.41 54.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.116 179.839 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 42.9 mt -138.92 107.65 3.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.103 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 8.6 mtmm -110.04 111.32 22.62 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.924 179.823 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -142.23 -143.14 4.16 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.478 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . 0.57 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 1.1 t80 -170.0 128.66 0.91 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.949 0.404 . . . . 0.0 110.91 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 4.4 t -80.41 115.96 58.55 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.624 0.726 . . . . 0.0 111.143 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.74 155.81 65.04 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.672 2.248 . . . . 0.0 112.369 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 -14.07 35.44 Favored 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.689 2.259 . . . . 0.0 112.33 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 46.8 p -112.24 15.91 20.25 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.107 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -112.06 118.88 4.85 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.491 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 14.1 mtpp -58.09 -62.78 1.57 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.77 0.319 . . . . 0.0 110.859 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 70.1 p -173.71 164.45 4.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.872 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.604 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 5.2 p90 -119.02 -173.27 2.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.879 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.56 138.73 15.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.105 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.598 HD11 ' CE2' ' A' ' 56' ' ' PHE . 3.7 mp -117.61 104.61 16.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.121 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 2.8 m-80 -105.24 147.94 27.51 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.883 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.571 ' CE1' HG22 ' A' ' 58' ' ' ILE . 2.4 m-85 -120.89 101.22 7.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.885 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.43 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 34.5 ttmt -95.78 167.26 11.37 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.901 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.774 HG22 ' HA ' ' A' ' 142' ' ' VAL . 94.2 t -100.27 121.09 50.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.097 179.889 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -57.0 -41.2 92.27 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.481 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 10.8 t -62.18 -72.2 0.13 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.885 0.374 . . . . 0.0 110.89 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.4 t -80.56 -71.04 0.48 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.878 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 128.26 42.48 0.25 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.507 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.406 ' OD1' ' OD1' ' A' ' 88' ' ' ASN . 1.5 m-20 -115.02 144.14 44.08 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.824 0.345 . . . . 0.0 110.856 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.609 HD12 ' HB3' ' A' ' 86' ' ' LEU . 42.8 mt -88.74 122.59 40.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.145 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.536 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -92.82 -34.77 13.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.134 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.708 HD21 HD11 ' A' ' 72' ' ' ILE . 30.3 tp -139.17 130.4 26.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.928 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.473 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.2 OUTLIER -134.81 92.14 2.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.83 179.914 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.708 HD11 HD21 ' A' ' 70' ' ' LEU . 16.0 mt -94.25 137.61 22.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.111 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.5 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 1.0 OUTLIER -141.86 106.17 5.81 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.619 0.723 . . . . 0.0 110.923 179.949 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.604 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.8 Cg_endo -69.75 154.87 67.26 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.677 2.251 . . . . 0.0 112.302 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 63.7 mtt-85 -129.78 100.76 5.6 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.854 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.92 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 20.7 p . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.803 0.335 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.429 ' CG1' ' CG2' ' A' ' 72' ' ' ILE . 18.5 t -86.59 111.01 20.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.121 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.519 HG22 ' HD3' ' A' ' 96' ' ' LYS . 61.4 t -82.84 139.81 17.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.097 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -126.94 124.46 39.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.865 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.473 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.5 OUTLIER -135.11 -178.15 4.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.885 -179.909 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 47.5 t -160.16 105.02 1.5 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.867 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.9 HD13 ' NE1' ' A' ' 91' ' ' TRP . 38.1 tp -77.09 116.71 17.98 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.932 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.518 ' N ' ' O ' ' A' ' 90' ' ' SER . 86.4 mt -94.84 162.07 13.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.9 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.433 ' ND2' ' H ' ' A' ' 88' ' ' ASN . 9.7 m-80 -40.88 102.0 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.86 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.49 -1.39 3.11 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.516 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.84 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -125.62 171.59 10.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.886 0.374 . . . . 0.0 110.841 -179.74 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.9 ' NE1' HD13 ' A' ' 86' ' ' LEU . 22.1 m95 -128.74 158.64 38.06 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.877 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -88.75 -96.3 1.02 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.427 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 2.0 m -174.68 164.76 3.66 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.894 0.378 . . . . 0.0 110.841 -179.711 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.404 ' HG3' ' ND2' ' A' ' 84' ' ' ASN . 14.2 mp0 -88.63 118.5 28.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.878 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 72.4 mm-40 -116.09 121.03 40.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.897 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.519 ' HD3' HG22 ' A' ' 82' ' ' VAL . 7.0 mtmp? -125.58 118.67 26.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.86 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -169.66 108.16 0.4 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.873 179.835 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.583 HD11 ' O ' ' A' ' 100' ' ' HIS . 10.5 tt -147.89 151.19 13.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.132 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.476 HG23 ' N ' ' A' ' 100' ' ' HIS . 8.9 t -91.64 -43.92 9.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.168 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . 0.583 ' O ' HD11 ' A' ' 98' ' ' ILE . 2.0 p-80 -145.0 127.58 16.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.896 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . 0.414 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 38.6 t-20 -104.74 98.49 15.21 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.633 0.73 . . . . 0.0 110.835 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.414 ' HD2' ' HA ' ' A' ' 101' ' ' ASN . 53.8 Cg_endo -69.81 -37.14 9.45 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.674 2.25 . . . . 0.0 112.331 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.547 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 20.9 m-85 -37.96 112.83 0.24 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.892 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -137.92 137.98 9.26 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.468 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 100.21 0.81 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.69 2.26 . . . . 0.0 112.303 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 120.85 0.9 11.84 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.457 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -135.22 148.6 49.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.815 0.34 . . . . 0.0 110.93 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' PHE . . . . . 0.57 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 76.8 m-85 -68.23 171.08 7.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.822 -179.892 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 28.1 p90 -161.26 124.79 3.29 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.903 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -99.45 104.5 16.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.871 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.78 HD13 ' N ' ' A' ' 112' ' ' SER . 0.6 OUTLIER -104.68 136.83 43.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.903 -179.945 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.78 ' N ' HD13 ' A' ' 111' ' ' LEU . 3.6 m -145.03 113.64 6.72 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.828 -179.864 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.5 HG22 ' HD2' ' A' ' 120' ' ' PHE . 4.4 mp -96.56 137.22 24.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.111 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . 0.497 ' O ' ' CD2' ' A' ' 120' ' ' PHE . 18.2 mtp180 -110.11 138.12 46.92 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.852 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . 0.465 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 17.7 t -105.13 120.11 40.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.917 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -115.02 -140.55 7.23 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.447 -179.867 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.5 mt -117.53 -38.08 3.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.785 0.326 . . . . 0.0 110.895 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . 0.58 ' O ' ' CD2' ' A' ' 134' ' ' HIS . 20.3 t70 -89.79 -45.69 9.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.895 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.444 ' HG3' ' C ' ' A' ' 118' ' ' ASP . 32.3 mtp180 -157.56 -177.07 6.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.879 -179.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.5 ' HD2' HG22 ' A' ' 113' ' ' ILE . 12.4 m-85 -103.32 162.09 13.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.876 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 21.4 mtpp -134.26 105.15 6.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.906 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.577 HG13 HD11 ' A' ' 111' ' ' LEU . 57.8 t -90.44 136.48 23.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.1 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -124.85 143.57 50.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.955 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.405 ' HB1' ' HG3' ' A' ' 102' ' ' PRO . . . -131.13 106.93 8.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.039 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 59.1 35.83 23.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.918 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.69 40.55 17.76 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.448 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 18.9 mt-30 -146.84 135.64 22.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.868 0.366 . . . . 0.0 110.919 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 40.8 t-80 -66.77 100.75 0.73 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.89 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 10.2 tp -69.1 -68.58 0.39 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.875 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.482 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 4.4 p90 -164.02 171.3 15.4 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.845 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 24.1 p-10 -110.65 158.79 18.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.906 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.589 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -129.86 104.49 7.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.85 -179.883 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.555 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -62.99 135.71 57.44 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.04 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' HIS . . . . . 0.58 ' CD2' ' O ' ' A' ' 118' ' ' ASP . 29.9 m-70 -62.82 108.22 1.14 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.859 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 4.9 mtp-105 -88.37 -48.71 7.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.891 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 8.5 tp -94.06 108.1 19.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.913 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 14.7 t -47.31 -36.0 8.71 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.494 ' HB1' ' HG3' ' A' ' 141' ' ' ARG . . . -83.47 33.32 0.46 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.101 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.516 ' O ' HD12 ' A' ' 37' ' ' LEU . 28.5 p90 -50.05 -36.12 27.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.872 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 6.1 pt20 -53.45 -46.4 69.86 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.904 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.494 ' HG3' ' HB1' ' A' ' 138' ' ' ALA . 31.5 mtt180 -49.7 -41.78 44.22 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.859 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.774 ' HA ' HG22 ' A' ' 62' ' ' VAL . 61.9 t -48.71 100.3 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.138 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.455 ' O ' ' N ' ' A' ' 33' ' ' LEU . 3.9 p30 -124.95 26.24 7.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.906 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 32' ' ' ARG . 0.8 OUTLIER -132.1 131.72 42.62 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.142 -179.848 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.477 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.8 tp -128.82 104.85 7.86 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.922 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -108.88 151.57 26.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.904 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 15.5 mt -136.82 118.23 18.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.127 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -128.65 173.43 10.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.891 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.41 -151.34 16.91 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.519 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -107.23 92.75 4.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.855 0.36 . . . . 0.0 110.845 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.435 HG22 ' N ' ' A' ' 152' ' ' THR . 7.7 p -151.19 154.88 7.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.094 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . 0.435 ' N ' HG22 ' A' ' 151' ' ' VAL . 23.3 m -114.83 93.91 4.53 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.151 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.406 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 50.1 mt -79.25 132.83 36.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.911 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 14.7 m -117.42 -40.88 3.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.851 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 59.7 t80 -140.37 130.13 24.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.947 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 89.8 t -140.53 105.15 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.092 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 13.8 tt0 -120.81 121.93 39.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.958 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 14.9 mt . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.169 179.957 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.558 ' CG2' ' N ' ' A' ' 23' ' ' PHE . 1.9 m . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.786 0.327 . . . . 0.0 111.163 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.558 ' N ' ' CG2' ' A' ' 22' ' ' THR . 11.9 m-85 -156.01 135.95 12.75 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.908 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ASN . . . . . 0.544 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 72.3 m-20 42.9 48.42 3.7 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.645 0.736 . . . . 0.0 110.927 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.544 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.6 Cg_endo -69.74 137.96 36.75 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.709 2.273 . . . . 0.0 112.301 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -176.11 1.38 Allowed 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.646 2.231 . . . . 0.0 112.334 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.675 HG13 ' HA ' ' A' ' 28' ' ' PRO . 98.4 t -142.97 137.87 15.33 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.668 0.747 . . . . 0.0 111.109 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.675 ' HA ' HG13 ' A' ' 27' ' ' VAL . 54.0 Cg_endo -69.75 145.58 79.8 Favored 'Cis proline' 0 C--O 1.232 0.179 0 C-N-CA 122.71 -1.787 . . . . 0.0 112.342 -0.02 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 13.3 t80 -96.87 121.17 38.44 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.946 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -101.79 101.46 11.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.865 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -98.96 109.94 3.89 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.526 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 4.1 mmm180 -72.87 99.51 2.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.866 0.365 . . . . 0.0 110.877 -179.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 27.6 mt -66.94 93.05 0.25 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.905 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 18.7 mp0 -67.99 93.69 0.44 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.938 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.75 -37.77 1.9 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.501 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 91.19 175.07 43.71 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.454 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . 0.498 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 78.4 mt -65.4 93.43 0.15 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.859 0.361 . . . . 0.0 110.911 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 44.0 p -105.33 154.56 20.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.136 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -49.84 -30.61 10.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.061 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 2.6 mpt_? -105.13 34.93 2.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.875 -179.873 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 5.0 tpm_? -108.03 135.15 49.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 -179.878 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 85.3 m -136.87 116.35 12.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.193 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.0 mp -91.69 135.81 26.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.176 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 96.8 mt -127.38 132.95 68.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.116 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 50.7 mt -134.9 107.57 8.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.092 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 16.0 mtmt -111.2 111.4 22.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.864 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -142.88 -140.7 3.75 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.544 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . 0.568 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.4 OUTLIER -172.08 119.95 0.43 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.937 0.399 . . . . 0.0 110.941 -179.8 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 40.5 t -69.16 117.09 48.7 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.638 0.732 . . . . 0.0 111.15 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 154.98 67.25 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.69 2.26 . . . . 0.0 112.333 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.72 -16.11 37.55 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.693 2.262 . . . . 0.0 112.358 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 70.6 p -110.41 18.6 19.66 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.122 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -113.54 123.23 6.06 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.465 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.403 ' O ' ' SD ' ' A' ' 76' ' ' MET . 22.2 mttt -63.03 -61.67 2.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.778 0.323 . . . . 0.0 110.859 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.8 p -174.03 157.9 3.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.886 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.599 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 12.3 p90 -111.16 -174.64 2.51 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.864 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.863 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -157.05 130.5 8.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.12 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.558 HG22 ' CE1' ' A' ' 60' ' ' PHE . 5.3 mp -112.91 101.78 12.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.11 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -101.2 143.59 31.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.913 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.558 ' CE1' HG22 ' A' ' 58' ' ' ILE . 16.0 m-85 -115.26 97.99 6.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.869 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.459 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 35.8 ttmt -96.79 167.88 10.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.886 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.781 HG22 ' HA ' ' A' ' 142' ' ' VAL . 59.1 t -100.94 123.88 54.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.089 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -59.79 -39.74 95.75 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.455 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 7.6 t -62.93 -70.67 0.19 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.868 0.366 . . . . 0.0 110.867 -179.728 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 60.0 m -82.33 -71.43 0.49 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.863 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 128.32 42.68 0.24 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.451 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . 0.425 ' OD2' ' ND2' ' A' ' 88' ' ' ASN . 3.9 m-20 -112.78 143.7 43.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.81 0.338 . . . . 0.0 110.847 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 66.6 mt -89.1 113.35 25.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.135 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.47 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -81.75 -39.3 24.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.105 179.836 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.738 HD21 HD11 ' A' ' 72' ' ' ILE . 48.1 tp -136.82 134.53 37.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.964 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.495 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.4 OUTLIER -134.89 97.03 3.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.894 179.877 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.738 HD11 HD21 ' A' ' 70' ' ' LEU . 27.0 mt -101.26 133.56 44.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.134 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.863 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -140.53 106.51 6.5 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.674 0.749 . . . . 0.0 110.905 179.961 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.599 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.0 Cg_endo -69.67 154.7 67.76 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.713 2.275 . . . . 0.0 112.347 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 36.7 mtp180 -130.6 94.99 3.76 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.932 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' MET . . . . . 0.403 ' SD ' ' O ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.846 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 49.2 p . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.828 0.347 . . . . 0.0 111.142 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.514 HG22 ' HA ' ' A' ' 74' ' ' PRO . 14.1 t -99.8 110.45 26.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.132 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.558 HG22 ' HD3' ' A' ' 96' ' ' LYS . 32.7 t -82.52 144.78 9.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.13 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.86 124.17 38.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.864 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.495 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.3 m120 -136.32 178.59 6.94 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.914 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.433 ' CB ' ' O ' ' A' ' 69' ' ' ALA . 78.1 p -158.69 105.55 1.83 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.864 -179.84 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.921 HD13 ' NE1' ' A' ' 91' ' ' TRP . 28.3 tp -78.06 117.34 19.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.917 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.532 ' N ' ' O ' ' A' ' 90' ' ' SER . 86.0 mt -95.38 162.54 13.62 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.936 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.425 ' ND2' ' OD2' ' A' ' 67' ' ' ASP . 11.0 m-80 -40.97 102.14 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.878 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.35 -2.47 3.14 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.492 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.813 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -124.63 170.54 10.85 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.81 0.338 . . . . 0.0 110.85 -179.72 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.921 ' NE1' HD13 ' A' ' 86' ' ' LEU . 21.8 m95 -128.1 160.73 31.08 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.936 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -89.53 -100.31 1.06 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.487 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 16.4 m -172.4 167.97 5.57 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.819 0.343 . . . . 0.0 110.849 -179.753 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -89.99 121.85 32.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.904 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -122.22 115.33 22.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.88 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.558 ' HD3' HG22 ' A' ' 82' ' ' VAL . 9.9 mtmp? -119.68 119.79 34.73 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.904 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' LYS . . . . . 0.478 ' HE3' ' N ' ' A' ' 98' ' ' ILE . 0.0 OUTLIER -173.9 105.11 0.12 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.866 179.846 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.912 HD11 ' O ' ' A' ' 100' ' ' HIS . 1.9 tt -141.76 149.86 19.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.172 179.862 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.461 HG23 ' CD2' ' A' ' 100' ' ' HIS . 4.7 t -84.45 -41.06 16.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.084 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . 0.912 ' O ' HD11 ' A' ' 98' ' ' ILE . 28.9 p80 -153.09 133.62 13.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.835 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' ASN . . . . . 0.407 ' C ' ' OD1' ' A' ' 101' ' ' ASN . 7.2 t-20 -103.47 95.84 7.74 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.597 0.713 . . . . 0.0 110.888 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.447 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.7 Cg_endo -69.77 -41.3 4.38 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.675 2.25 . . . . 0.0 112.368 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.564 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 10.2 m-85 -34.17 104.66 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.881 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -127.85 137.16 9.61 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.695 -0.765 . . . . 0.0 112.451 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 97.25 0.62 Allowed 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.715 2.277 . . . . 0.0 112.325 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 118.39 3.53 14.58 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.513 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 17.5 pt20 -133.73 137.82 45.44 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.819 0.343 . . . . 0.0 110.906 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' PHE . . . . . 0.568 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 79.7 m-85 -61.34 166.35 3.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.882 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 17.9 p90 -158.45 130.58 6.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.886 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -103.68 104.62 14.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.877 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' LEU . . . . . 0.775 HD13 ' N ' ' A' ' 112' ' ' SER . 0.7 OUTLIER -105.09 136.5 44.46 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.948 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . 0.775 ' N ' HD13 ' A' ' 111' ' ' LEU . 3.8 m -145.15 113.49 6.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.864 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.601 HG23 HG22 ' A' ' 122' ' ' VAL . 4.0 mp -95.47 140.05 17.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.142 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 15.6 mtp85 -112.78 137.63 50.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.899 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . 0.582 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 2.9 t -110.03 114.47 28.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.874 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -113.77 -136.03 6.29 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.496 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 12.2 mt -121.52 -39.06 2.69 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.829 0.347 . . . . 0.0 110.924 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 23.2 p-10 -85.63 -37.26 19.69 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.88 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.8 ptp180 -173.66 172.62 3.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.875 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.582 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.7 m-30 -93.32 155.06 17.63 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.887 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 26.6 mtpt -128.99 102.12 6.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.898 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.601 HG22 HG23 ' A' ' 113' ' ' ILE . 51.5 t -89.27 136.77 22.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.105 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 57.9 m-85 -120.29 152.95 37.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.958 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' ALA . . . . . 0.604 ' HB2' HD13 ' A' ' 129' ' ' LEU . . . -136.55 107.12 6.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.097 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 53.56 35.61 21.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.929 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 84.09 29.26 31.67 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.477 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 20.0 mm-40 -140.77 119.53 12.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.819 0.342 . . . . 0.0 110.931 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 35.5 t-80 -52.06 103.85 0.07 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.846 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.604 HD13 ' HB2' ' A' ' 124' ' ' ALA . 10.6 tp -67.12 -67.71 0.43 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.923 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.499 ' HZ ' HD13 ' A' ' 72' ' ' ILE . 6.0 p90 -163.67 177.02 9.06 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.86 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 41.1 p30 -118.02 149.92 40.16 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.851 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.677 ' CD1' HD13 ' A' ' 70' ' ' LEU . 0.2 OUTLIER -117.17 107.02 13.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.872 -179.937 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.525 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -62.41 133.56 55.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.099 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 29.7 m-70 -60.03 110.84 1.29 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.811 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.4 ' CD ' ' OG ' ' A' ' 85' ' ' SER . 10.0 mtt-85 -93.93 -51.5 4.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.878 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 6.8 tp -96.06 108.39 20.8 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.906 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 27.1 t -49.44 -33.33 13.87 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.862 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.468 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.45 25.76 0.6 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.073 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.406 ' CG ' ' N ' ' A' ' 140' ' ' GLN . 19.3 p90 -45.49 -41.78 9.96 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.895 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' GLN . . . . . 0.406 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 5.7 pt20 -49.75 -41.0 42.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.885 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.468 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 57.0 mtp180 -55.48 -39.74 70.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.874 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.781 ' HA ' HG22 ' A' ' 62' ' ' VAL . 85.6 t -48.11 106.8 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.14 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -131.81 34.08 3.91 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.867 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 16.2 m -141.38 115.32 9.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.167 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.52 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.2 tp -113.66 107.96 16.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.91 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 -113.0 150.7 31.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.896 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.423 HG23 HG13 ' A' ' 58' ' ' ILE . 17.0 mt -138.29 106.94 3.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.115 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -115.42 173.33 6.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.915 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.57 -146.37 16.22 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.469 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 46.7 m-20 -112.27 92.56 4.07 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.852 0.358 . . . . 0.0 110.843 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 5.8 p -151.28 138.06 12.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.124 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 33.7 m -99.62 93.92 6.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.134 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.462 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 68.8 mt -74.88 137.85 42.06 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.903 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 20.5 m -119.76 -39.28 2.86 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.878 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . 0.494 ' CE1' ' HB2' ' A' ' 157' ' ' GLN . 43.6 t80 -148.07 135.45 20.55 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.938 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 70.8 t -140.18 109.42 3.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.141 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . 0.494 ' HB2' ' CE1' ' A' ' 155' ' ' TYR . 14.7 tt0 -121.47 136.57 54.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.902 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 18.6 mt . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.065 -179.955 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 112.471 -0.252 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.2 m -158.13 138.23 12.42 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.85 0.357 . . . . 0.0 110.883 -179.74 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 39.2 m -129.96 161.94 29.79 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.855 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 91.76 140.09 9.02 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.48 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.3 m -160.43 137.53 9.22 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.832 0.349 . . . . 0.0 110.865 -179.708 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 44.2 t -66.24 -52.56 46.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.84 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 47.84 95.55 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.518 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 34.1 p-80 -132.49 101.13 5.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.763 0.316 . . . . 0.0 110.88 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -49.44 -41.05 38.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.89 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 27.1 mt-30 -150.83 122.21 7.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.957 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.616 ' H ' HD12 ' A' ' 11' ' ' LEU . 5.2 mp -50.67 124.54 11.12 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.928 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.8 m120 -144.8 176.13 9.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.926 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 60.9 p -108.67 143.7 37.41 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.876 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.428 ' O ' HD12 ' A' ' 14' ' ' LEU . 3.4 pp -59.76 154.68 45.6 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.615 0.721 . . . . 0.0 110.9 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.72 -176.57 1.52 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.686 2.257 . . . . 0.0 112.337 179.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.483 HG23 ' H ' ' A' ' 18' ' ' GLU . 7.0 t -63.87 159.95 18.59 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.132 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . 0.456 ' HE2' ' O ' ' A' ' 32' ' ' ARG . 17.7 mtm -98.76 43.53 1.06 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.872 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.483 ' H ' HG23 ' A' ' 16' ' ' THR . 7.1 mm-40 -79.91 -179.06 6.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.913 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 84.84 -156.78 31.71 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.474 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 169.49 18.82 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.653 2.235 . . . . 0.0 112.363 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.491 ' HB2' ' CE2' ' A' ' 155' ' ' TYR . 54.0 Cg_endo -69.8 160.68 48.81 Favored 'Trans proline' 0 C--O 1.232 0.213 0 C-N-CA 122.68 2.253 . . . . 0.0 112.334 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 2.3 t -78.77 148.29 33.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.147 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -129.61 120.78 25.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . 0.48 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 12.4 m120 61.78 52.18 2.19 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.616 0.722 . . . . 0.0 110.907 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.48 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.2 Cg_endo -69.81 138.67 38.23 Favored 'Trans proline' 0 N--CA 1.466 -0.13 0 C-N-CA 122.705 2.27 . . . . 0.0 112.328 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 178.7 4.3 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.633 2.222 . . . . 0.0 112.357 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.694 HG13 ' HA ' ' A' ' 28' ' ' PRO . 95.4 t -138.09 138.24 22.83 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.658 0.742 . . . . 0.0 111.115 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.694 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.7 Cg_endo -69.7 143.61 74.22 Favored 'Cis proline' 0 C--N 1.342 0.193 0 C-N-CA 122.741 -1.774 . . . . 0.0 112.345 -0.083 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.473 ' CE1' HG11 ' A' ' 156' ' ' VAL . 2.2 t80 -95.82 116.68 29.27 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.886 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 72.3 m-85 -100.15 105.31 16.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.844 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -118.21 103.33 1.03 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.507 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.456 ' O ' ' HE2' ' A' ' 17' ' ' MET . 0.0 OUTLIER -72.44 135.4 45.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.84 0.352 . . . . 0.0 110.876 -179.837 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.894 HD23 HG12 ' A' ' 158' ' ' ILE . 4.9 mt -82.73 119.12 23.92 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.928 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 25.2 mt-30 -74.09 94.97 2.48 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.887 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 124.31 -55.81 0.7 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.483 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.443 ' O ' HG23 ' A' ' 38' ' ' THR . . . 120.37 176.3 15.69 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.51 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . 0.744 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 82.5 mt -62.6 101.37 0.24 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.936 0.398 . . . . 0.0 110.896 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.502 ' O ' ' N ' ' A' ' 41' ' ' ARG . 44.9 p -120.77 137.89 54.29 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.202 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.551 ' HB2' ' HG ' ' A' ' 117' ' ' LEU . . . -41.97 -23.39 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.119 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.444 ' N ' ' O ' ' A' ' 38' ' ' THR . 20.9 mmt180 -104.62 34.13 3.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.866 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.502 ' N ' ' O ' ' A' ' 38' ' ' THR . 4.6 ttt85 -121.05 139.86 52.74 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.931 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 85.9 m -137.66 117.55 13.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.154 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.1 mp -90.68 133.98 30.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.146 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 94.7 mt -127.55 134.33 65.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.123 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 48.5 mt -135.57 107.63 7.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.142 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.5 mtmt -109.35 108.19 18.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.917 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.52 -145.72 4.68 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.49 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . 0.564 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.7 OUTLIER -167.55 129.13 1.53 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.9 0.381 . . . . 0.0 110.912 -179.803 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 13.7 t -77.34 115.5 49.72 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.619 0.723 . . . . 0.0 111.116 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 155.54 65.7 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.681 2.254 . . . . 0.0 112.354 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -15.69 37.11 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.683 2.255 . . . . 0.0 112.344 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 52.8 p -109.65 14.2 23.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.13 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -111.22 122.82 6.25 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.523 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 17.5 mtpt -63.96 -60.21 3.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.798 0.332 . . . . 0.0 110.867 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.5 p -174.21 158.75 3.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.89 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.565 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 2.4 p90 -112.57 -173.72 2.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.851 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.924 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -155.56 135.57 12.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.157 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.454 HG22 ' CE1' ' A' ' 60' ' ' PHE . 3.6 mp -115.85 103.7 15.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.132 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.3 m-80 -104.41 143.13 33.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.904 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.726 ' CE2' HD13 ' A' ' 145' ' ' LEU . 6.7 m-85 -115.66 101.36 8.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.875 -179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.421 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 30.3 ttmt -95.33 169.08 10.32 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.89 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.61 HG22 ' HA ' ' A' ' 142' ' ' VAL . 35.0 t -100.24 123.73 53.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.136 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -60.59 -34.25 85.27 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.498 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.9 t -68.5 -71.54 0.21 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.926 0.393 . . . . 0.0 110.87 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 3.3 t -83.7 -71.34 0.51 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.856 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 131.6 40.82 0.22 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.5 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.598 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.9 m-20 -110.87 143.11 41.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.776 0.322 . . . . 0.0 110.853 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.629 HD12 ' HB3' ' A' ' 86' ' ' LEU . 39.2 mt -88.9 119.2 35.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.113 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.66 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -91.57 -33.12 15.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.109 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.616 HD22 ' CD2' ' A' ' 132' ' ' PHE . 52.5 tp -138.46 130.0 27.66 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.939 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.489 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.2 OUTLIER -134.82 92.71 2.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.844 179.891 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.579 HD11 HD21 ' A' ' 70' ' ' LEU . 29.0 mt -96.25 134.98 31.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.146 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.924 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -140.33 107.76 6.7 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.596 0.712 . . . . 0.0 110.863 179.946 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.767 ' HA ' HG22 ' A' ' 81' ' ' VAL . 53.8 Cg_endo -69.79 154.87 67.1 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.665 2.243 . . . . 0.0 112.338 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 45.3 mtp85 -130.4 98.0 4.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.909 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -61.28 -39.99 92.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.878 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -60.63 -91.27 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.493 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 56.6 t30 -50.28 -56.41 11.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.933 0.397 . . . . 0.0 110.896 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 112.53 37.79 1.4 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.53 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 32.4 p -137.64 122.23 18.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.802 0.334 . . . . 0.0 111.122 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.767 HG22 ' HA ' ' A' ' 74' ' ' PRO . 36.0 t -91.44 108.54 20.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.136 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.566 HG22 ' HD3' ' A' ' 96' ' ' LYS . 48.7 t -79.93 146.69 7.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.11 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -128.87 130.21 46.57 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.845 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.489 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.9 OUTLIER -142.45 179.62 6.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.928 -179.971 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 89.5 p -157.99 107.25 2.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.901 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.892 HD13 ' NE1' ' A' ' 91' ' ' TRP . 27.6 tp -76.98 117.86 18.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.926 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.505 ' N ' ' O ' ' A' ' 90' ' ' SER . 82.7 mt -95.1 162.3 13.77 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.927 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.412 ' OD1' ' OD1' ' A' ' 67' ' ' ASP . 11.7 m-80 -41.1 102.14 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.855 179.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.89 -1.49 3.37 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.51 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.828 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -125.63 172.49 9.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.839 0.352 . . . . 0.0 110.84 -179.722 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.892 ' NE1' HD13 ' A' ' 86' ' ' LEU . 25.0 m95 -129.4 160.67 32.37 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.932 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -90.34 -104.18 1.21 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.507 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 39.2 m -165.56 171.92 12.6 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.834 0.35 . . . . 0.0 110.852 -179.755 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -95.54 120.8 36.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.92 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 60.3 mt-10 -120.07 122.21 40.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.845 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.566 ' HD3' HG22 ' A' ' 82' ' ' VAL . 7.6 mtmp? -126.29 122.23 34.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.873 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 10.4 tptp -171.89 105.87 0.2 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.895 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.903 HD11 ' O ' ' A' ' 100' ' ' HIS . 2.0 tt -146.59 149.9 15.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.129 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.427 HG23 ' N ' ' A' ' 100' ' ' HIS . 9.2 t -91.65 -41.39 10.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.149 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . 0.903 ' O ' HD11 ' A' ' 98' ' ' ILE . 2.6 p-80 -144.06 131.64 21.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.834 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . 0.411 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 24.7 t30 -109.21 96.52 21.89 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.632 0.73 . . . . 0.0 110.881 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.44 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.8 Cg_endo -69.78 -41.27 4.39 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.648 2.232 . . . . 0.0 112.305 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.569 ' CZ ' HD21 ' A' ' 129' ' ' LEU . 6.2 m-85 -35.33 108.65 0.07 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.898 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -137.14 138.77 10.02 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.48 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 103.12 1.11 Allowed 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.689 2.26 . . . . 0.0 112.38 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 119.95 -2.32 13.24 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.541 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.3 pt20 -134.03 147.62 50.97 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.857 0.361 . . . . 0.0 110.902 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' PHE . . . . . 0.564 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 29.6 m-85 -67.21 172.82 4.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.877 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.422 ' O ' ' CG ' ' A' ' 109' ' ' PHE . 14.4 p90 -161.33 124.25 3.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.867 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -99.08 105.09 17.16 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.837 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.757 HD13 ' N ' ' A' ' 112' ' ' SER . 0.7 OUTLIER -105.18 136.89 43.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.92 -179.98 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.757 ' N ' HD13 ' A' ' 111' ' ' LEU . 3.4 m -144.8 113.63 6.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.847 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.445 ' CD1' HD12 ' A' ' 111' ' ' LEU . 4.7 mp -96.68 135.43 30.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.147 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 40.0 mtt180 -108.51 126.26 52.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.886 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . 0.534 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 11.7 t -93.06 120.42 33.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.902 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -122.31 -159.8 10.73 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.511 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.551 ' HG ' ' HB2' ' A' ' 39' ' ' ALA . 7.8 mt -101.83 -42.3 6.2 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.838 0.351 . . . . 0.0 110.943 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -82.19 -37.1 26.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.883 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.1 ptt180 -173.5 -178.2 1.61 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.889 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.744 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 3.2 m-30 -102.48 158.52 16.16 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.892 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 24.2 mtpt -132.13 104.86 7.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.921 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.486 HG13 HD11 ' A' ' 111' ' ' LEU . 60.6 t -90.98 133.58 32.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.125 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 74.7 m-85 -121.69 146.96 46.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.938 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.526 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -133.27 107.98 8.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.133 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 55.04 39.5 31.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.885 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.12 36.73 34.43 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.451 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 22.6 mt-30 -143.93 123.65 13.36 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.848 0.356 . . . . 0.0 110.898 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 32.6 t-80 -57.79 95.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.863 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.569 HD21 ' CZ ' ' A' ' 103' ' ' PHE . 9.4 tp -60.88 -68.75 0.28 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.929 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.473 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 4.5 p90 -164.96 175.87 9.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.903 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -116.32 155.74 27.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.894 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.616 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.2 OUTLIER -122.38 104.58 9.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.847 -179.874 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.531 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -60.6 134.8 57.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.077 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' HIS . . . . . 0.437 ' CD2' ' O ' ' A' ' 117' ' ' LEU . 18.4 m-70 -62.4 98.8 0.12 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.894 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 17.6 mtt-85 -81.47 -47.59 12.97 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.842 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . 0.453 HD13 HD22 ' A' ' 87' ' ' LEU . 7.8 tp -98.72 107.8 20.33 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.924 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 15.0 m -49.35 -33.19 12.9 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.839 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.495 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -83.3 27.67 0.57 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.122 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.468 ' O ' HD12 ' A' ' 37' ' ' LEU . 17.6 p90 -47.21 -44.29 22.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.892 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' GLN . . . . . 0.44 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 9.2 pt20 -46.24 -40.63 11.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.931 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.577 ' O ' HG13 ' A' ' 62' ' ' VAL . 16.1 mtp180 -54.33 -41.71 69.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.875 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.66 HG21 ' CB ' ' A' ' 69' ' ' ALA . 88.7 t -50.3 104.72 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.167 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -127.38 28.83 5.64 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.877 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.3 m -137.67 131.96 32.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.168 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.726 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.4 tp -128.47 109.09 11.09 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.944 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 -112.3 152.31 28.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.901 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 19.8 mt -137.47 113.54 11.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.135 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -123.06 174.19 7.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.954 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.4 -144.5 15.99 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.512 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -114.71 92.1 3.84 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.871 0.367 . . . . 0.0 110.845 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.448 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 5.1 p -151.04 142.77 16.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.134 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 25.8 m -102.37 93.25 5.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.163 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.464 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 95.9 mt -74.31 136.73 42.58 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.899 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 5.1 m -117.18 -39.36 3.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.871 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . 0.491 ' CE2' ' HB2' ' A' ' 21' ' ' PRO . 7.4 t80 -147.35 130.93 16.81 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.917 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.473 HG11 ' CE1' ' A' ' 29' ' ' TYR . 65.8 t -140.77 124.48 17.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.138 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 12.8 tt0 -148.85 132.95 17.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.908 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' ILE . . . . . 0.894 HG12 HD23 ' A' ' 33' ' ' LEU . 5.1 mp -92.82 88.61 2.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.152 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 20.2 m -55.66 131.04 45.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.81 -179.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -129.03 -157.57 9.3 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.449 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -1.38 8.38 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.694 2.263 . . . . 0.0 112.328 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 29.9 t -44.73 -63.74 0.85 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.844 -179.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 28.8 t -59.77 115.76 3.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.871 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.487 -179.992 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 63.2 p -153.94 156.16 36.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.874 0.368 . . . . 0.0 110.845 -179.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.7 t -109.72 125.71 52.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.875 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -157.8 173.83 35.13 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.49 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.1 t -157.22 155.1 30.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.907 0.384 . . . . 0.0 110.86 -179.764 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 30.9 t -137.95 148.42 45.23 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.813 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -84.61 -140.53 4.86 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.461 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 30.3 m170 -115.13 145.21 42.58 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.762 0.315 . . . . 0.0 110.868 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 50.8 mt-30 -146.52 143.87 29.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.917 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -54.25 155.08 3.95 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.916 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.562 ' C ' HD12 ' A' ' 11' ' ' LEU . 1.0 OUTLIER -101.94 -37.05 8.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.92 -179.978 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -56.87 -45.58 82.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.882 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 42.2 p -164.63 128.09 2.44 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.848 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.503 ' O ' HD12 ' A' ' 14' ' ' LEU . 4.2 pp -68.62 153.42 95.83 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.568 0.699 . . . . 0.0 110.93 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -164.91 0.14 Allowed 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.657 2.238 . . . . 0.0 112.338 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.502 HG23 ' HG3' ' A' ' 34' ' ' GLN . 1.3 m -88.57 151.54 22.43 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.16 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 25.4 mtp -85.25 89.9 7.77 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.916 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -125.73 160.51 29.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.886 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.411 ' HA3' ' HD2' ' A' ' 20' ' ' PRO . . . 95.22 -136.45 12.92 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.468 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.411 ' HD2' ' HA3' ' A' ' 19' ' ' GLY . 54.5 Cg_endo -69.71 168.64 20.92 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.689 2.26 . . . . 0.0 112.361 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.74 -175.37 1.13 Allowed 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.695 2.263 . . . . 0.0 112.354 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.468 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.6 m -95.53 151.41 19.34 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.119 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.468 ' CD1' ' O ' ' A' ' 22' ' ' THR . 9.8 m-85 -150.71 137.15 18.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.887 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . 0.601 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 52.8 m-80 51.37 44.48 2.16 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.663 0.744 . . . . 0.0 110.919 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.601 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.78 133.82 26.45 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.632 2.221 . . . . 0.0 112.316 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.85 179.36 3.8 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.673 2.249 . . . . 0.0 112.361 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.677 HG13 ' HA ' ' A' ' 28' ' ' PRO . 86.6 t -138.79 137.68 20.27 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.606 0.717 . . . . 0.0 111.134 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.677 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.2 Cg_endo -69.77 144.21 76.03 Favored 'Cis proline' 0 C--O 1.231 0.161 0 C-N-CA 122.668 -1.805 . . . . 0.0 112.338 -0.074 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 2.9 t80 -94.13 120.15 33.98 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.927 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -105.12 102.14 11.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.899 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -109.7 109.43 2.71 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.471 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 6.4 mmt85 -73.38 108.93 6.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.875 0.369 . . . . 0.0 110.873 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.429 ' HB3' ' NH1' ' A' ' 41' ' ' ARG . 5.3 mt -70.58 92.76 0.86 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.918 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.502 ' HG3' HG23 ' A' ' 16' ' ' THR . 14.9 mm-40 -64.73 105.36 0.97 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.896 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 130.59 -46.89 1.05 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.477 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.661 ' O ' HG23 ' A' ' 38' ' ' THR . . . 98.67 161.36 29.98 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.51 -179.909 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . 0.646 HD12 ' O ' ' A' ' 139' ' ' PHE . 95.9 mt -54.81 107.14 0.26 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.903 0.383 . . . . 0.0 110.872 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.661 HG23 ' O ' ' A' ' 36' ' ' GLY . 73.0 p -118.71 149.04 42.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.128 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -49.8 -23.62 1.95 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.085 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.412 ' HB3' ' NH1' ' A' ' 40' ' ' ARG . 0.0 OUTLIER -108.81 34.19 3.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.882 -179.921 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.429 ' NH1' ' HB3' ' A' ' 33' ' ' LEU . 13.1 ttm180 -113.81 139.28 49.27 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.859 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 74.2 m -137.52 119.83 15.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.134 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 mp -91.92 136.27 24.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.109 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 97.0 mt -131.25 133.55 62.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.107 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 34.5 mt -136.53 111.52 10.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.143 179.861 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 16.1 mtmt -112.68 109.0 18.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.923 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -138.1 -142.95 4.42 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.44 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . 0.435 ' O ' ' CD1' ' A' ' 48' ' ' TYR . 0.5 OUTLIER -170.2 117.04 0.54 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.914 0.388 . . . . 0.0 110.939 -179.769 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 15.2 t -70.19 115.8 38.05 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.644 0.735 . . . . 0.0 111.139 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 157.52 60.12 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.678 2.252 . . . . 0.0 112.356 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -15.42 37.17 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.664 2.243 . . . . 0.0 112.34 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 21.5 p -109.71 17.11 21.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.18 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -110.69 118.99 5.13 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.511 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.3 mtpt -61.31 -60.63 3.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.778 0.323 . . . . 0.0 110.912 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 13.2 p -173.64 158.44 3.35 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.869 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.607 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 6.1 p90 -115.88 -174.68 2.58 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.864 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.937 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -154.81 145.3 22.17 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.126 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.526 HG22 ' CE1' ' A' ' 60' ' ' PHE . 3.2 mp -123.52 98.77 5.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.115 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.7 m-80 -98.86 141.98 30.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.914 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.526 ' CE1' HG22 ' A' ' 58' ' ' ILE . 10.5 m-85 -117.16 99.03 6.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.893 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.441 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 31.3 ttmt -96.62 169.24 10.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.878 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.658 HG22 ' HA ' ' A' ' 142' ' ' VAL . 38.7 t -101.44 119.59 49.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.129 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -55.22 -36.79 62.82 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.502 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.5 m -66.47 -72.86 0.15 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.889 0.376 . . . . 0.0 110.904 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 19.7 m -79.34 -74.68 0.28 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.868 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 132.92 38.58 0.23 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.523 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.414 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.5 m-20 -111.36 143.61 41.89 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.795 0.331 . . . . 0.0 110.846 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.572 HD12 ' HB3' ' A' ' 86' ' ' LEU . 47.4 mt -89.77 117.71 33.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.123 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.41 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -89.25 -31.07 18.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.122 179.783 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.663 HD22 ' CD2' ' A' ' 132' ' ' PHE . 53.2 tp -140.84 130.25 23.83 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.927 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.452 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.3 OUTLIER -134.91 92.55 2.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.884 179.82 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.599 HD11 HD21 ' A' ' 70' ' ' LEU . 26.3 mt -96.36 133.81 36.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.149 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.937 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -141.24 106.78 6.13 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.619 0.723 . . . . 0.0 110.853 179.978 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.607 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.8 Cg_endo -69.78 155.28 66.3 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.647 2.231 . . . . 0.0 112.364 179.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 68.3 mtp180 -130.55 99.35 4.95 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -57.49 148.64 23.11 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.899 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 87.16 -89.89 1.65 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.495 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 15.1 t30 -42.78 -56.0 3.39 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.908 0.385 . . . . 0.0 110.873 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 98.57 54.59 1.14 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.467 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 16.9 p -147.7 118.19 7.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.795 0.331 . . . . 0.0 111.133 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.402 HG22 ' HA ' ' A' ' 74' ' ' PRO . 21.3 t -99.67 111.72 30.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.123 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.545 HG22 ' HD3' ' A' ' 96' ' ' LYS . 92.5 t -79.36 142.06 14.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.176 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . 0.557 ' NH1' ' CD2' ' A' ' 130' ' ' PHE . 0.3 OUTLIER -126.19 125.52 42.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.885 -179.948 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.452 ' O ' ' N ' ' A' ' 71' ' ' HIS . 2.3 m120 -137.39 177.82 7.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.883 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 28.9 t -158.92 105.08 1.76 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.814 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.938 HD12 ' O ' ' A' ' 90' ' ' SER . 25.6 tp -77.36 119.58 21.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.918 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.513 ' N ' ' O ' ' A' ' 90' ' ' SER . 77.7 mt -96.98 161.47 13.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.893 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.545 HD22 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.28 101.67 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.868 179.938 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.76 -7.12 0.73 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.488 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.938 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -118.13 170.74 8.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.885 0.374 . . . . 0.0 110.855 -179.719 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.828 ' NE1' HD13 ' A' ' 86' ' ' LEU . 21.4 m95 -128.31 160.89 30.75 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.959 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -94.16 -116.85 2.78 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.454 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 33.8 m -152.14 178.61 9.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.79 0.329 . . . . 0.0 110.898 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.424 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 11.9 mt-10 -103.73 126.05 50.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.891 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -123.36 105.37 9.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.893 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.545 ' HD3' HG22 ' A' ' 82' ' ' VAL . 18.2 mtmm -111.69 122.46 47.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.919 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -171.54 105.95 0.22 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.905 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.801 HD11 ' O ' ' A' ' 100' ' ' HIS . 3.0 tt -145.13 152.85 14.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.125 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.44 HG23 ' N ' ' A' ' 100' ' ' HIS . 9.5 t -96.39 -41.9 8.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.141 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . 0.801 ' O ' HD11 ' A' ' 98' ' ' ILE . 4.4 p-80 -142.89 128.57 19.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.852 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 -103.29 95.55 7.09 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.652 0.739 . . . . 0.0 110.882 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.444 ' HD2' HD11 ' A' ' 129' ' ' LEU . 53.2 Cg_endo -69.75 -40.41 5.38 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.702 2.268 . . . . 0.0 112.318 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -41.01 108.41 0.09 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.867 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -131.49 139.64 11.11 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.491 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 100.62 0.84 Allowed 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.714 2.276 . . . . 0.0 112.328 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 117.89 6.63 12.45 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.472 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 4.7 pt20 -137.17 143.92 42.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.78 0.324 . . . . 0.0 110.926 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -66.14 168.76 7.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.915 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 30.1 p90 -161.28 144.74 12.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.85 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -118.31 101.73 8.41 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.87 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.659 HD13 ' N ' ' A' ' 112' ' ' SER . 1.1 tm? -99.24 137.18 38.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.923 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.659 ' N ' HD13 ' A' ' 111' ' ' LEU . 6.2 m -144.98 111.27 5.61 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.864 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.64 HD11 HD12 ' A' ' 111' ' ' LEU . 4.8 mp -94.73 135.57 28.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.081 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -109.61 130.59 55.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.846 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . 0.581 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 11.9 t -101.19 116.02 31.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.876 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -115.26 -143.9 8.17 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.517 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.7 mt -116.02 -37.47 3.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.829 0.347 . . . . 0.0 110.88 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -87.66 -37.5 16.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.873 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.9 ptt180 -173.85 170.38 3.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.874 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.581 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.1 m-30 -90.71 158.23 17.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.85 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 30.5 mtpt -132.33 99.39 4.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.886 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 97.6 t -86.73 139.18 17.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.095 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 84.3 m-85 -129.4 148.96 51.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.947 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -137.12 109.77 7.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.096 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 57.97 34.66 24.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.849 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.9 40.5 21.23 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.494 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -144.84 134.86 23.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.81 0.338 . . . . 0.0 110.875 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 32.2 t-80 -68.06 101.31 1.12 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.865 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.444 HD11 ' HD2' ' A' ' 102' ' ' PRO . 8.0 tp -71.7 -67.39 0.53 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.898 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.557 ' CD2' ' NH1' ' A' ' 83' ' ' ARG . 5.1 p90 -166.89 173.44 9.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.886 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -116.12 155.69 27.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.663 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -120.15 104.47 10.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.896 -179.883 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.574 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -59.62 136.64 58.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.101 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 55.4 m-70 -63.52 106.16 0.89 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.879 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 23.6 mtt-85 -91.73 -50.2 5.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.861 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 6.1 tp -95.43 109.02 21.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.923 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 41.3 t -51.67 -33.4 33.7 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.812 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.501 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.67 23.83 0.77 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.097 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.646 ' O ' HD12 ' A' ' 37' ' ' LEU . 32.0 p90 -45.57 -37.87 5.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.854 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -52.73 -46.97 67.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.918 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.501 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 70.6 mtp85 -48.63 -43.38 36.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.87 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.658 ' HA ' HG22 ' A' ' 62' ' ' VAL . 85.5 t -41.24 106.93 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.171 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -131.86 31.68 4.18 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.861 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 18.9 m -142.03 114.94 8.66 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.134 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.517 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.9 tp -111.89 108.46 17.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.917 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' GLU . . . . . 0.433 ' C ' HG13 ' A' ' 147' ' ' ILE . 3.6 pt-20 -111.77 155.29 23.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.91 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.442 HG12 HG23 ' A' ' 58' ' ' ILE . 35.2 mt -143.45 116.4 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.105 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -124.79 170.27 11.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.94 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.79 -153.47 16.8 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.496 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -104.17 93.28 4.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.808 0.337 . . . . 0.0 110.879 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 8.8 p -151.3 143.59 16.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.126 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 12.0 m -105.19 94.39 5.21 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.107 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 58.0 mt -78.51 134.4 37.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.88 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 58.6 m -119.25 -39.85 2.87 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.851 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 39.7 t80 -144.6 131.14 19.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.92 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 93.4 t -140.54 106.57 2.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.132 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 15.2 tt0 -118.42 138.97 52.1 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.922 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 18.4 mt -106.73 93.51 2.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.113 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 46.1 t -61.7 149.12 40.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.882 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 135.45 -166.15 24.56 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.479 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 100.67 0.83 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.682 2.255 . . . . 0.0 112.361 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 31.2 t -81.54 153.92 26.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.858 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 87.5 p -104.27 152.72 21.87 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.868 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.544 179.983 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.27 0 N-CA-C 112.498 -0.241 . . . . 0.0 112.498 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.1 m -85.58 105.34 16.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.912 0.387 . . . . 0.0 110.838 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 4.0 t -174.16 107.08 0.12 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.868 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 166.62 107.12 0.2 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.527 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 5.2 m -147.68 155.65 41.97 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.812 0.339 . . . . 0.0 110.859 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.1 m -68.76 174.94 3.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.874 -179.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.442 ' O ' ' N ' ' A' ' 9' ' ' GLN . . . -139.36 -38.59 0.1 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.528 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 39.7 m80 -59.51 81.55 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.698 0.285 . . . . 0.0 110.825 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.442 ' N ' ' O ' ' A' ' 7' ' ' GLY . 38.9 mt-30 -136.82 157.56 46.48 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.919 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 10.2 pt20 -96.92 65.72 2.12 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.93 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 18.4 mt -145.04 176.93 9.14 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.937 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 20.2 m-80 -105.75 140.59 38.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.858 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 59.6 p -151.6 157.48 42.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.866 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.537 HD11 ' HB2' ' A' ' 32' ' ' ARG . 2.1 pp -121.97 156.22 59.85 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.682 0.753 . . . . 0.0 110.886 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 157.28 60.96 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.726 2.284 . . . . 0.0 112.339 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 8.8 t -48.86 146.35 3.3 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.166 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 45.7 mtm -96.86 31.05 2.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.832 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -59.65 163.52 4.24 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.887 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 101.15 -149.4 18.37 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.474 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 168.59 21.1 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.67 2.247 . . . . 0.0 112.383 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.82 174.74 9.12 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.654 2.236 . . . . 0.0 112.293 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.457 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.5 m -84.68 144.99 28.2 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.145 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.435 ' C ' ' HD3' ' A' ' 25' ' ' PRO . 5.6 m-85 -142.95 133.63 25.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.893 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . 0.585 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.6 m120 48.42 45.6 2.94 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.591 0.71 . . . . 0.0 110.867 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.585 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.3 Cg_endo -69.79 137.33 35.11 Favored 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 122.702 2.268 . . . . 0.0 112.34 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 -176.93 1.63 Allowed 'Trans proline' 0 N--CA 1.465 -0.164 0 C-N-CA 122.732 2.288 . . . . 0.0 112.357 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.669 HG13 ' HA ' ' A' ' 28' ' ' PRO . 88.1 t -142.28 137.64 15.84 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.616 0.722 . . . . 0.0 111.125 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.669 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.3 Cg_endo -69.81 143.88 75.21 Favored 'Cis proline' 0 C--N 1.341 0.179 0 C-N-CA 122.671 -1.804 . . . . 0.0 112.318 0.005 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.9 t80 -95.61 120.72 36.35 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.904 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -102.94 104.01 14.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.866 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -115.92 109.55 2.04 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.524 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.537 ' HB2' HD11 ' A' ' 14' ' ' LEU . 3.2 mmt85 -74.08 118.47 17.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.856 0.36 . . . . 0.0 110.84 -179.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.544 HD23 HD13 ' A' ' 158' ' ' ILE . 8.0 mt -76.8 92.13 3.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.935 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 23.0 mm-40 -65.4 102.86 0.73 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.961 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.23 -37.96 1.89 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.453 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.86 ' O ' HG23 ' A' ' 38' ' ' THR . . . 88.28 156.19 30.44 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.469 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . 0.621 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 86.8 mt -52.43 100.0 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.905 0.383 . . . . 0.0 110.895 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.86 HG23 ' O ' ' A' ' 36' ' ' GLY . 29.7 p -116.73 153.84 31.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.176 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.462 ' HB2' ' CD2' ' A' ' 117' ' ' LEU . . . -51.34 -31.51 22.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.127 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.43 ' HA ' ' NE ' ' A' ' 40' ' ' ARG . 10.8 mmp_? -100.14 33.7 2.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.852 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 28.2 ttm-85 -118.73 137.99 52.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.867 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 96.6 m -139.37 118.22 12.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.135 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.479 ' N ' HD12 ' A' ' 43' ' ' ILE . 4.6 mp -91.58 136.28 24.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.099 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 89.0 mt -128.87 133.8 65.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.138 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.8 mt -134.26 107.61 9.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.113 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.3 mtmt -108.24 103.9 13.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -134.21 -148.35 5.78 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.517 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -169.17 127.56 1.0 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.98 0.419 . . . . 0.0 110.894 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 16.0 t -75.91 117.65 65.37 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.635 0.731 . . . . 0.0 111.158 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 154.01 68.35 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.687 2.258 . . . . 0.0 112.359 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -20.71 34.37 Favored 'Trans proline' 0 C--O 1.231 0.175 0 C-N-CA 122.674 2.249 . . . . 0.0 112.343 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 41.1 p -99.63 9.41 43.18 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.153 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -99.08 -172.16 31.28 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.491 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 4.1 mmmm -133.75 -64.56 0.7 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.787 0.327 . . . . 0.0 110.895 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 2.6 p -165.75 147.07 7.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.816 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.597 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 13.0 p90 -110.53 -175.35 2.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.898 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.702 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -154.98 143.58 20.59 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.123 179.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.566 HG22 ' CE1' ' A' ' 60' ' ' PHE . 3.2 mp -121.85 102.14 11.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.107 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.2 m-80 -102.06 143.57 31.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.888 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.566 ' CE1' HG22 ' A' ' 58' ' ' ILE . 5.4 m-85 -118.76 98.56 6.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.937 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.447 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 32.8 ttmt -96.93 169.25 9.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.892 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.624 HG23 ' O ' ' A' ' 67' ' ' ASP . 19.4 t -100.64 122.4 52.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.131 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -60.04 -34.24 82.75 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.509 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 10.1 t -67.15 -71.81 0.19 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.872 0.368 . . . . 0.0 110.89 -179.76 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.4 t -81.86 -69.19 0.63 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.836 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 128.97 36.53 0.43 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.519 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.624 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.6 m-20 -110.22 140.99 43.78 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.853 0.359 . . . . 0.0 110.856 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.615 HD12 ' HB3' ' A' ' 86' ' ' LEU . 58.9 mt -85.86 122.0 37.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.133 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.631 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -93.13 -30.01 15.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.098 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.73 HD22 ' CD2' ' A' ' 132' ' ' PHE . 46.3 tp -144.2 130.1 19.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.946 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.472 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.3 OUTLIER -134.93 92.58 2.9 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.862 179.899 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.488 HD11 HD21 ' A' ' 70' ' ' LEU . 41.4 mt -94.55 134.69 31.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.173 179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.702 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -139.02 106.24 7.36 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.612 0.72 . . . . 0.0 110.879 179.959 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.597 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.7 Cg_endo -69.73 155.25 66.52 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.683 2.255 . . . . 0.0 112.329 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 42.1 mtp180 -131.56 99.41 4.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.865 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -59.34 148.4 32.47 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.858 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 88.83 -81.98 1.51 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.464 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 28.9 t-20 -49.62 -67.57 0.25 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.877 0.37 . . . . 0.0 110.869 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.425 ' HA2' ' CG ' ' A' ' 101' ' ' ASN . . . 113.58 41.86 0.92 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.508 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 16.9 p -137.29 117.92 13.94 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.887 0.375 . . . . 0.0 111.108 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.575 HG22 ' HA ' ' A' ' 74' ' ' PRO . 39.5 t -101.76 107.24 21.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.125 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.673 HG22 ' HD3' ' A' ' 96' ' ' LYS . 24.6 t -78.29 138.52 20.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.171 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . 0.628 HH12 ' N ' ' A' ' 97' ' ' LYS . 2.8 mpp_? -126.94 125.72 42.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.885 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.472 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.3 m120 -132.86 -176.23 4.04 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.854 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 30.3 t -159.31 105.18 1.68 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.864 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.93 HD12 ' O ' ' A' ' 90' ' ' SER . 25.8 tp -77.06 117.43 18.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.861 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 90' ' ' SER . 80.7 mt -95.28 161.63 14.01 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.913 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.555 HD22 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.42 101.59 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.863 179.98 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.83 -6.49 0.91 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.504 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.93 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -119.21 172.47 7.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.913 0.387 . . . . 0.0 110.833 -179.773 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.865 ' NE1' HD13 ' A' ' 86' ' ' LEU . 22.4 m95 -129.49 160.69 32.39 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.908 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -89.59 -92.5 1.17 Allowed Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.457 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 2.3 m -174.74 173.78 2.74 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.905 0.383 . . . . 0.0 110.838 -179.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.449 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 3.8 mt-10 -104.97 117.64 34.53 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.89 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 50.7 mm-40 -122.49 133.88 54.58 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.895 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.673 ' HD3' HG22 ' A' ' 82' ' ' VAL . 43.8 mtmt -131.1 128.13 39.54 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.91 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.628 ' N ' HH12 ' A' ' 83' ' ' ARG . 12.7 tmtt? -175.79 108.37 0.09 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.946 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.922 HD11 ' O ' ' A' ' 100' ' ' HIS . 4.1 tt -147.67 144.04 19.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.109 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.6 t -79.19 -39.58 32.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.141 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . 0.922 ' O ' HD11 ' A' ' 98' ' ' ILE . 3.1 p-80 -154.35 136.91 15.1 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.883 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . 0.617 ' CG ' HD13 ' A' ' 98' ' ' ILE . 8.1 m120 -105.11 95.78 9.98 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.573 0.702 . . . . 0.0 110.893 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.72 -35.04 13.49 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.674 2.249 . . . . 0.0 112.397 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.425 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 11.9 m-85 -45.84 113.69 0.65 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.898 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -144.91 142.19 10.64 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.484 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.75 109.56 2.34 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.723 2.282 . . . . 0.0 112.334 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 118.88 -8.55 12.73 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.5 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -133.29 150.63 51.89 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.851 0.358 . . . . 0.0 110.883 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 2.3 p90 -77.86 160.02 28.57 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.919 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.511 ' O ' ' CD1' ' A' ' 109' ' ' PHE . 29.6 p90 -145.3 122.36 11.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.874 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -92.89 101.94 14.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.911 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.718 HD13 ' N ' ' A' ' 112' ' ' SER . 1.0 OUTLIER -101.84 138.37 38.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.875 -179.911 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.718 ' N ' HD13 ' A' ' 111' ' ' LEU . 4.3 m -144.67 114.41 7.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.871 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.605 HD11 HD12 ' A' ' 111' ' ' LEU . 4.3 mp -99.16 122.22 50.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.157 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 7.7 mtp180 -97.16 132.72 42.66 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.842 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . 0.438 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 7.0 t -98.61 123.07 42.58 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.867 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.93 -141.23 7.46 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.494 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.462 ' CD2' ' HB2' ' A' ' 39' ' ' ALA . 7.9 mt -118.57 -33.4 4.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.792 0.329 . . . . 0.0 110.931 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.598 ' O ' ' CD2' ' A' ' 134' ' ' HIS . 16.1 m-20 -97.6 -45.26 6.46 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.908 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.428 ' HG3' ' C ' ' A' ' 118' ' ' ASP . 47.7 mtt180 -152.36 -175.85 5.44 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.91 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.621 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 12.1 m-85 -107.66 158.59 17.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.905 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 19.1 mtpt -130.83 105.23 7.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.903 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.445 HG13 HD11 ' A' ' 111' ' ' LEU . 47.7 t -94.37 134.83 30.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.121 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -123.32 147.82 46.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.91 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.504 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -132.65 107.5 8.45 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.104 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 59.34 34.17 22.75 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.86 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.55 28.99 41.25 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.468 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 13.0 mm100 -136.38 119.61 16.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.8 0.333 . . . . 0.0 110.921 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 26.5 t-80 -51.58 101.53 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.831 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.504 HD13 ' CB ' ' A' ' 124' ' ' ALA . 10.5 tp -65.57 -69.16 0.31 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.933 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.462 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 4.5 p90 -164.66 175.54 9.66 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.884 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 41.0 m-20 -113.75 157.42 22.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.893 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.73 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -130.81 106.29 8.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.942 -179.911 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.545 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -64.54 131.77 47.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.075 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' HIS . . . . . 0.598 ' CD2' ' O ' ' A' ' 118' ' ' ASP . 16.7 m-70 -56.65 117.49 3.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.85 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 71.9 mtt-85 -97.61 -49.48 4.85 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.84 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . 0.439 HD23 ' HB2' ' A' ' 69' ' ' ALA . 12.2 tp -95.37 109.08 21.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.941 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 79.3 p -48.74 -33.17 9.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.836 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.578 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -83.36 28.24 0.55 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.096 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -51.47 -34.56 35.99 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.838 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' GLN . . . . . 0.42 ' HG2' ' N ' ' A' ' 141' ' ' ARG . 19.7 pm0 -60.58 -27.19 67.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.945 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.578 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 33.1 mtp180 -69.27 -37.58 77.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.908 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.631 HG21 ' HB3' ' A' ' 69' ' ' ALA . 89.4 t -46.52 104.35 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.096 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -127.84 29.24 5.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.875 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 10.5 m -139.2 110.94 7.16 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.085 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.56 HD13 ' CE2' ' A' ' 60' ' ' PHE . 6.2 tp -109.55 105.71 15.13 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.952 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -110.11 152.49 25.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.856 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.406 HG12 HG23 ' A' ' 58' ' ' ILE . 29.4 mt -139.92 118.67 11.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.131 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -126.77 171.43 11.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.927 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 109.36 -152.28 17.12 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.518 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -106.52 92.04 3.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.802 0.334 . . . . 0.0 110.89 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 8.7 p -150.37 149.27 14.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.114 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 29.7 m -109.71 94.9 5.27 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.114 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.437 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 77.6 mt -76.93 132.22 38.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.917 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 3.0 m -117.37 -33.7 4.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.879 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 19.5 t80 -153.1 131.9 12.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.93 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 60.8 t -139.53 112.2 5.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.171 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 17.9 tt0 -124.92 136.56 53.88 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' ILE . . . . . 0.544 HD13 HD23 ' A' ' 33' ' ' LEU . 15.3 mt -107.17 90.69 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.129 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 23.3 t -43.03 135.51 3.11 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.89 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 172.64 156.38 12.56 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.498 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 138.87 38.88 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.685 2.257 . . . . 0.0 112.306 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 58.2 m -81.67 164.33 21.88 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.829 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 6.9 m 58.98 41.81 20.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.871 -179.852 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.362 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.512 -179.927 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 N-CA-C 112.506 -0.238 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 16.1 m 53.83 42.11 31.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.912 0.387 . . . . 0.0 110.893 -179.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 42.6 t -148.19 155.62 41.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.865 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 171.03 100.11 0.13 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.454 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 68.2 m -156.08 135.09 12.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.88 0.371 . . . . 0.0 110.871 -179.749 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 98.4 p -123.05 109.35 13.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.9 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 179.63 73.35 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.47 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 29.1 m-70 -116.85 81.81 1.7 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.722 0.296 . . . . 0.0 110.825 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 61.6 tt0 -47.82 -48.12 30.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.963 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 64.8 mm-40 -138.1 131.0 29.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.922 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 11.7 mt -102.93 120.27 40.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.95 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.7 p-10 -108.59 -64.28 1.25 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.845 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 32.5 p -161.27 152.43 18.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.836 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 2.4 pp -56.53 154.82 15.62 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.59 0.709 . . . . 0.0 110.92 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -163.67 0.11 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.7 2.267 . . . . 0.0 112.323 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.4 m -85.6 149.02 25.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.154 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 42.8 mtm -89.03 88.26 7.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.883 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -112.86 167.09 10.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.884 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 87.57 -143.89 18.72 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.469 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 169.72 18.22 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.69 2.26 . . . . 0.0 112.353 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 -179.62 3.06 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.67 2.247 . . . . 0.0 112.336 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.525 ' CG2' ' N ' ' A' ' 23' ' ' PHE . 1.6 m -90.81 158.74 16.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.132 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.525 ' N ' ' CG2' ' A' ' 22' ' ' THR . 8.6 m-85 -154.32 137.72 15.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.88 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . 0.549 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 12.5 m120 44.27 47.99 4.03 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.648 0.737 . . . . 0.0 110.909 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.549 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.6 Cg_endo -69.79 140.09 41.73 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.688 2.259 . . . . 0.0 112.327 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 178.61 4.38 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.718 2.279 . . . . 0.0 112.357 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.703 HG13 ' HA ' ' A' ' 28' ' ' PRO . 96.4 t -139.36 138.31 20.36 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.605 0.717 . . . . 0.0 111.136 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.703 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.74 144.3 76.2 Favored 'Cis proline' 0 C--O 1.231 0.158 0 C-N-CA 122.72 -1.783 . . . . 0.0 112.334 -0.082 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -95.37 114.07 25.8 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.923 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -97.65 105.34 17.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.896 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -119.34 106.32 1.24 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.487 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.482 ' O ' ' NE2' ' A' ' 34' ' ' GLN . 0.0 OUTLIER -77.98 128.19 33.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.904 0.383 . . . . 0.0 110.848 -179.855 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.455 HD23 HD13 ' A' ' 158' ' ' ILE . 5.5 mt -71.8 122.02 19.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.89 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.482 ' NE2' ' O ' ' A' ' 32' ' ' ARG . 24.5 mp0 -77.15 79.6 3.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.899 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 139.01 -47.51 0.91 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.525 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.963 ' O ' HG23 ' A' ' 38' ' ' THR . . . 108.47 164.98 20.98 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.467 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . 0.524 HD12 ' O ' ' A' ' 139' ' ' PHE . 68.7 mt -50.85 106.48 0.13 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.92 0.39 . . . . 0.0 110.898 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.963 HG23 ' O ' ' A' ' 36' ' ' GLY . 10.2 p -124.61 141.19 52.28 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.146 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -42.86 -27.78 0.21 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.15 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 14.4 mmt85 -105.03 43.61 1.09 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.919 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.407 ' NH2' ' O ' ' A' ' 34' ' ' GLN . 6.6 ttt85 -130.43 139.93 50.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.838 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 98.0 m -139.73 121.6 15.52 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.09 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.47 ' N ' HD12 ' A' ' 43' ' ' ILE . 4.7 mp -91.39 132.76 35.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.137 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.436 ' CG2' ' HE2' ' A' ' 46' ' ' LYS . 83.8 mt -125.16 117.01 48.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.113 179.893 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 46.6 mt -118.12 107.63 22.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.092 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.436 ' HE2' ' CG2' ' A' ' 44' ' ' ILE . 25.1 mtmt -111.06 112.12 23.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.907 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -145.04 -143.43 3.99 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.487 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -168.99 126.42 0.97 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.924 0.392 . . . . 0.0 110.957 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 21.6 t -75.99 116.89 59.75 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.642 0.734 . . . . 0.0 111.138 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.82 157.52 60.0 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.631 2.221 . . . . 0.0 112.302 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -16.88 37.63 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.685 2.257 . . . . 0.0 112.307 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 76.8 p -110.91 19.73 18.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.138 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -111.68 116.53 4.2 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.506 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 21.7 mtpp -59.24 -60.66 3.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.761 0.315 . . . . 0.0 110.904 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 21.7 p -174.06 157.43 2.89 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.888 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.595 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 5.7 p90 -112.52 -173.18 2.19 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.9 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.472 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -155.18 145.49 21.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.095 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 2.7 mp -125.52 100.01 6.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.087 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . 0.443 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 19.4 m-80 -101.9 144.76 30.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.882 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.779 ' CE2' HD13 ' A' ' 145' ' ' LEU . 32.7 m-85 -117.93 99.95 7.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.873 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.425 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 34.5 ttmt -95.65 168.16 10.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.945 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.645 HG22 ' HA ' ' A' ' 142' ' ' VAL . 22.6 t -99.72 122.86 52.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.147 179.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -58.23 -34.23 73.14 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.481 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.407 ' H ' HG12 ' A' ' 62' ' ' VAL . 26.1 m -70.22 -75.26 0.12 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.865 0.364 . . . . 0.0 110.813 -179.695 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 26.9 t -77.64 -71.93 0.39 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.866 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 129.3 43.4 0.21 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.469 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.505 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.1 m-20 -113.69 142.1 46.43 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.784 0.326 . . . . 0.0 110.866 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.6 HD12 ' HB3' ' A' ' 86' ' ' LEU . 44.9 mt -87.05 118.78 33.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.119 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.655 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -91.95 -30.09 16.29 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.089 179.835 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.645 HD22 ' CD2' ' A' ' 132' ' ' PHE . 58.2 tp -142.18 129.62 21.26 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.899 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.496 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.2 t60 -134.81 92.8 2.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.842 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.555 HD11 HD21 ' A' ' 70' ' ' LEU . 28.3 mt -94.78 130.88 42.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.102 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.499 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.1 OUTLIER -136.04 104.79 9.62 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.643 0.735 . . . . 0.0 110.902 179.9 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.595 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.4 Cg_endo -69.78 155.66 65.3 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.644 2.229 . . . . 0.0 112.309 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 28.6 mtt-85 -130.77 101.92 5.87 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.859 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -59.68 150.04 28.84 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.879 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 87.49 -87.88 1.55 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.497 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 12.7 t30 -47.34 -54.31 11.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.907 0.384 . . . . 0.0 110.9 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 97.87 52.85 1.35 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.498 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 7.0 p -143.15 118.01 9.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.827 0.346 . . . . 0.0 111.123 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.585 HG22 ' HA ' ' A' ' 74' ' ' PRO . 41.8 t -101.46 114.65 41.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.166 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.711 HG22 ' HD3' ' A' ' 96' ' ' LYS . 57.4 t -83.54 144.18 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.135 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -126.26 124.91 41.43 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.845 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.496 ' O ' ' N ' ' A' ' 71' ' ' HIS . 2.6 m120 -135.17 176.3 8.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.867 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 40.4 t -157.72 105.01 1.99 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.892 -179.883 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.893 HD13 ' NE1' ' A' ' 91' ' ' TRP . 34.5 tp -77.14 117.73 18.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.919 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 90' ' ' SER . 85.0 mt -95.48 162.36 13.68 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.951 179.893 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.423 ' ND2' ' H ' ' A' ' 88' ' ' ASN . 10.6 m-80 -41.08 102.23 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.866 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.19 -1.15 3.0 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.49 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.826 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -125.71 171.64 10.46 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.849 0.357 . . . . 0.0 110.853 -179.715 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.893 ' NE1' HD13 ' A' ' 86' ' ' LEU . 22.2 m95 -128.93 160.63 32.08 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.921 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.57 -115.21 2.23 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.491 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . 0.425 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 58.3 m -151.42 173.67 14.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.82 0.343 . . . . 0.0 110.852 -179.768 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.412 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 14.4 mt-10 -102.59 123.95 47.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.875 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -123.08 125.86 45.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.904 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.711 ' HD3' HG22 ' A' ' 82' ' ' VAL . 45.6 mtmt -129.52 118.99 22.96 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.886 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 1.3 tppp? -170.58 106.52 0.29 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.851 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.544 HD11 ' O ' ' A' ' 100' ' ' HIS . 7.4 tt -144.22 150.53 16.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.114 179.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.507 HG23 ' N ' ' A' ' 100' ' ' HIS . 8.8 t -87.26 -46.12 10.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.154 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . 0.544 ' O ' HD11 ' A' ' 98' ' ' ILE . 4.6 p-80 -147.37 125.78 12.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.886 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . 0.44 ' C ' ' OD1' ' A' ' 101' ' ' ASN . 27.1 t-20 -99.41 100.73 11.13 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.628 0.727 . . . . 0.0 110.906 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.425 ' HD2' ' HA ' ' A' ' 101' ' ' ASN . 54.1 Cg_endo -69.72 -36.44 10.89 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.751 2.301 . . . . 0.0 112.335 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -41.51 109.72 0.13 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.872 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -137.96 138.56 9.68 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.481 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 103.06 1.11 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.646 2.231 . . . . 0.0 112.363 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 121.44 -2.12 11.31 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.485 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -137.05 146.04 44.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.871 0.367 . . . . 0.0 110.874 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 2.3 p90 -70.93 172.76 8.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.861 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 30.0 p90 -160.25 137.5 9.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.884 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.59 107.8 18.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.863 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.699 HD13 ' N ' ' A' ' 112' ' ' SER . 0.7 OUTLIER -109.12 136.99 47.71 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.926 -179.938 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.699 ' N ' HD13 ' A' ' 111' ' ' LEU . 6.0 m -145.08 113.56 6.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.809 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.443 HG22 ' HD2' ' A' ' 120' ' ' PHE . 4.3 mp -93.92 137.42 22.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.129 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.462 ' O ' ' CD2' ' A' ' 120' ' ' PHE . 14.5 mtp180 -109.56 133.93 52.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.855 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 9.0 t -101.45 115.29 30.18 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.86 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -110.94 -141.66 8.8 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.487 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 5.5 mt -118.58 -34.81 3.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.827 0.346 . . . . 0.0 110.948 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.605 ' O ' ' CD2' ' A' ' 134' ' ' HIS . 2.0 m-20 -95.05 -45.83 7.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.856 179.858 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.447 ' HG3' ' C ' ' A' ' 118' ' ' ASP . 25.5 mtt180 -154.98 -179.72 8.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.462 ' CD2' ' O ' ' A' ' 114' ' ' ARG . 20.5 m-85 -103.41 157.59 16.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.919 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 32.9 mtpt -129.52 100.08 5.41 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.938 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.557 HG13 HD11 ' A' ' 111' ' ' LEU . 45.6 t -89.2 128.94 40.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.091 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -115.07 151.21 34.68 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.917 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -136.35 106.71 6.43 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.069 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 55.92 34.67 24.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.856 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 80.71 31.36 36.53 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.506 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 12.3 mm100 -138.32 123.78 19.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.844 0.354 . . . . 0.0 110.938 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 39.6 t-80 -55.46 101.43 0.05 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.874 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.403 HD22 HD21 ' A' ' 111' ' ' LEU . 11.6 tp -69.85 -69.62 0.34 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.952 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.452 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 6.7 p90 -165.13 169.84 15.67 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -111.22 159.93 17.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.895 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.645 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -130.52 104.39 7.2 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.897 -179.883 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.507 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -62.5 134.96 57.14 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.108 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' HIS . . . . . 0.605 ' CD2' ' O ' ' A' ' 118' ' ' ASP . 20.1 m-70 -58.72 104.62 0.24 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.875 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.425 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 8.8 mtt-85 -83.92 -53.65 5.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.867 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.7 tp -91.85 107.77 19.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.956 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 12.7 t -45.74 -36.14 4.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.893 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.416 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.72 29.97 0.44 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.09 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.524 ' O ' HD12 ' A' ' 37' ' ' LEU . 21.7 p90 -48.49 -45.82 37.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.886 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' GLN . . . . . 0.466 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 8.3 pt20 -47.8 -41.34 23.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.908 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.538 ' O ' HG13 ' A' ' 62' ' ' VAL . 30.7 mtp180 -54.21 -41.64 68.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.851 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.655 HG21 ' CB ' ' A' ' 69' ' ' ALA . 97.2 t -49.23 102.92 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.177 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -124.74 28.34 6.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.865 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . 0.419 ' HA ' ' HA ' ' A' ' 32' ' ' ARG . 0.6 OUTLIER -135.29 125.44 26.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.138 -179.927 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.779 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.2 tp -123.97 106.79 10.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.922 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -110.37 153.44 24.94 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.911 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 17.2 mt -138.47 115.28 11.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.104 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -125.52 174.92 7.89 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.917 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.04 -143.78 15.84 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.502 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -114.81 92.39 3.93 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.888 0.375 . . . . 0.0 110.86 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.3 p -151.31 145.74 16.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.171 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 21.5 m -105.37 93.8 4.87 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.126 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.465 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 95.0 mt -75.76 131.43 39.81 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.869 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 7.5 m -113.62 -41.6 3.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.86 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . 0.413 ' CD1' ' C ' ' A' ' 155' ' ' TYR . 8.4 t80 -145.06 132.98 21.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.919 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 94.4 t -140.69 116.96 7.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.112 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 9.7 tt0 -134.18 125.13 27.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.941 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' ILE . . . . . 0.455 HD13 HD23 ' A' ' 33' ' ' LEU . 24.0 mt -96.95 88.92 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.139 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 53.3 p -69.65 136.65 51.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.821 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -139.08 -173.63 13.11 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.504 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 126.93 13.91 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.698 2.265 . . . . 0.0 112.359 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 3.8 m -154.56 120.84 5.33 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.855 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 22.6 t -110.25 133.87 52.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.865 -179.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.276 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.457 -179.999 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.484 -0.246 . . . . 0.0 112.484 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.8 t 59.53 42.16 17.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.912 0.387 . . . . 0.0 110.855 -179.743 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 36.4 m -88.92 119.51 29.5 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.837 -179.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 116.47 77.31 0.65 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.496 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.0 t -100.93 166.01 11.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.949 0.404 . . . . 0.0 110.814 -179.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.0 m -159.86 158.72 31.45 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.852 -179.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 85.18 -168.75 43.06 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.443 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 13.9 t-80 46.88 43.03 12.97 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.75 0.309 . . . . 0.0 110.858 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 42.7 tt0 -88.21 139.83 30.09 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.929 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 48.4 mt-30 -146.39 149.98 34.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.885 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.666 ' H ' HD23 ' A' ' 11' ' ' LEU . 0.1 OUTLIER -70.27 105.25 2.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.88 -179.985 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 5.0 m120 -130.57 168.62 16.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.904 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 6.0 m -70.89 158.18 36.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.879 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.418 ' O ' HD12 ' A' ' 14' ' ' LEU . 1.7 pp -38.54 155.95 0.12 Allowed Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.611 0.72 . . . . 0.0 110.926 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -170.7 0.41 Allowed 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.701 2.267 . . . . 0.0 112.334 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.2 m -86.64 150.47 24.18 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.128 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . 0.461 ' HE3' HD12 ' A' ' 158' ' ' ILE . 5.9 ptt? -99.91 79.61 2.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.835 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -104.17 148.09 26.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.819 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.417 ' HA3' ' HD2' ' A' ' 20' ' ' PRO . . . 115.86 -137.03 13.43 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.442 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.417 ' HD2' ' HA3' ' A' ' 19' ' ' GLY . 53.8 Cg_endo -69.73 169.94 17.72 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.673 2.249 . . . . 0.0 112.365 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.578 ' HB2' ' CE2' ' A' ' 155' ' ' TYR . 53.5 Cg_endo -69.72 176.86 6.18 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.709 2.272 . . . . 0.0 112.324 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.494 HG22 ' H ' ' A' ' 156' ' ' VAL . 10.8 t -93.74 157.32 16.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.151 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 7.8 m-85 -139.43 115.61 10.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.914 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . 0.489 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 5.3 t-20 66.95 51.63 0.65 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.568 0.699 . . . . 0.0 110.845 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.489 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.75 132.65 23.79 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.679 2.253 . . . . 0.0 112.343 179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -178.43 2.34 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.68 2.253 . . . . 0.0 112.326 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.684 HG13 ' HA ' ' A' ' 28' ' ' PRO . 94.4 t -139.87 137.87 18.98 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.661 0.743 . . . . 0.0 111.146 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.684 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.8 Cg_endo -69.78 144.51 76.89 Favored 'Cis proline' 0 C--N 1.341 0.181 0 C-N-CA 122.731 -1.779 . . . . 0.0 112.292 0.009 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 14.4 t80 -94.87 118.2 31.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.973 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -102.33 100.76 10.95 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.905 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -107.54 109.58 3.01 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.464 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 10.2 mmt85 -75.35 117.65 17.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.85 0.357 . . . . 0.0 110.855 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 3.5 mt -78.17 93.22 4.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.897 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.8 mm-40 -64.83 99.74 0.36 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.899 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.23 -41.55 1.45 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.54 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.592 ' O ' HG23 ' A' ' 38' ' ' THR . . . 95.21 164.59 34.97 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.499 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . 0.41 HD12 ' O ' ' A' ' 139' ' ' PHE . 87.5 mt -58.48 110.68 1.02 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.872 0.368 . . . . 0.0 110.903 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.592 HG23 ' O ' ' A' ' 36' ' ' GLY . 44.4 p -124.12 146.23 48.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.134 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -47.27 -22.69 0.44 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.088 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.02 35.22 3.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.861 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.417 ' NE ' ' O ' ' A' ' 36' ' ' GLY . 20.3 ttm-85 -114.59 138.81 50.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.872 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 88.2 m -136.31 114.55 11.59 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.143 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 4.8 mp -90.78 135.07 27.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.13 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 80.1 mt -130.26 132.61 64.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.127 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 55.8 mt -133.56 107.09 10.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.103 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 10.7 mttm -102.46 108.42 19.73 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.927 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.03 -156.06 6.78 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.454 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -161.98 127.87 3.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.941 0.4 . . . . 0.0 110.867 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 21.9 t -76.05 114.53 38.28 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.675 0.75 . . . . 0.0 111.13 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 158.5 56.7 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.662 2.241 . . . . 0.0 112.317 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -13.65 34.93 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.681 2.254 . . . . 0.0 112.341 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 40.7 p -114.08 19.0 16.8 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.146 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -114.12 116.6 3.89 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.517 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 19.0 mtpp -61.64 -57.5 11.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.801 0.334 . . . . 0.0 110.895 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 16.6 p -174.88 160.7 2.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.857 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 17.6 p90 -115.44 -174.41 2.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.85 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.944 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -156.5 130.3 8.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.113 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.7 HG22 ' CE1' ' A' ' 60' ' ' PHE . 5.3 mp -114.55 103.56 15.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.11 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 11.4 m-80 -101.44 146.22 27.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.865 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.7 ' CE1' HG22 ' A' ' 58' ' ' ILE . 3.4 m-85 -118.38 99.72 7.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.887 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.454 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 32.8 ttmt -97.47 169.23 9.88 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.884 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.631 HG22 ' HA ' ' A' ' 142' ' ' VAL . 39.8 t -101.23 120.4 50.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.133 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -56.54 -39.61 85.23 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.523 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 35.1 m -62.26 -72.33 0.13 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.875 0.369 . . . . 0.0 110.859 -179.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 40.6 p -80.17 -70.21 0.54 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.87 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 127.26 44.25 0.23 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.491 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.404 ' OD1' ' OD1' ' A' ' 88' ' ' ASN . 0.6 OUTLIER -117.37 142.63 46.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.834 0.349 . . . . 0.0 110.87 179.977 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.567 HD12 ' HB3' ' A' ' 86' ' ' LEU . 41.0 mt -86.11 111.2 20.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.128 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.624 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -82.23 -31.25 30.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.075 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.688 HD21 HD11 ' A' ' 72' ' ' ILE . 32.4 tp -142.37 132.46 24.59 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.93 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.441 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.8 OUTLIER -134.78 98.79 4.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.88 179.838 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.688 HD11 HD21 ' A' ' 70' ' ' LEU . 17.9 mt -101.74 133.57 44.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.102 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.944 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -141.08 106.82 6.2 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.658 0.742 . . . . 0.0 110.878 179.918 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.2 Cg_endo -69.76 155.32 66.26 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.718 2.278 . . . . 0.0 112.332 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 38.4 mtp180 -132.37 96.56 3.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.875 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . 0.422 ' HE2' ' HB3' ' A' ' 103' ' ' PHE . 0.2 OUTLIER -55.4 168.08 0.41 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.862 179.93 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 70.86 -73.29 0.66 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.507 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 35.1 t30 -58.85 -63.54 1.26 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.833 0.349 . . . . 0.0 110.86 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 106.76 39.85 1.96 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.533 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.3 p -134.76 118.18 16.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.828 0.346 . . . . 0.0 111.139 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.48 HG22 ' HA ' ' A' ' 74' ' ' PRO . 21.7 t -100.93 112.85 35.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.128 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.648 HG22 ' HD3' ' A' ' 96' ' ' LYS . 30.2 t -82.3 144.85 9.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.137 179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -129.46 126.59 39.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.89 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.441 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.6 OUTLIER -137.07 -177.09 4.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.908 -179.943 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 40.1 t -158.65 105.32 1.82 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.855 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.897 HD13 ' CE2' ' A' ' 91' ' ' TRP . 35.9 tp -76.83 115.86 16.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.902 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.519 ' N ' ' O ' ' A' ' 90' ' ' SER . 83.2 mt -93.72 162.45 13.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.946 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.454 ' ND2' ' H ' ' A' ' 88' ' ' ASN . 8.2 m-80 -41.26 102.17 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.907 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.37 -0.49 3.74 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.51 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.81 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -126.45 171.16 11.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.919 0.39 . . . . 0.0 110.826 -179.713 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.897 ' CE2' HD13 ' A' ' 86' ' ' LEU . 26.6 m95 -128.25 160.72 31.24 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.899 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.85 -109.76 1.89 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.496 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . 0.434 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 47.5 m -155.5 174.52 15.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.791 0.329 . . . . 0.0 110.905 -179.749 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -100.01 125.17 46.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.884 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -120.17 121.22 38.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.854 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.648 ' HD3' HG22 ' A' ' 82' ' ' VAL . 6.4 mtmp? -127.57 118.56 24.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.932 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 20.9 tttt -170.85 107.49 0.29 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.937 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.87 HD11 ' O ' ' A' ' 100' ' ' HIS . 2.3 tt -145.53 153.38 13.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.147 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.434 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 8.9 t -97.52 -36.2 10.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.128 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . 0.87 ' O ' HD11 ' A' ' 98' ' ' ILE . 2.3 p-80 -148.88 128.16 12.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.848 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -102.87 96.66 8.07 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.619 0.723 . . . . 0.0 110.874 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.406 ' O ' ' C ' ' A' ' 103' ' ' PHE . 54.2 Cg_endo -69.74 -42.98 2.95 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.693 2.262 . . . . 0.0 112.374 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.463 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 8.6 m-85 -37.84 105.13 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.868 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -133.21 139.22 10.75 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.481 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 104.21 1.29 Allowed 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.63 2.22 . . . . 0.0 112.352 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 124.41 -7.88 8.45 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.529 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.485 ' NE2' ' O ' ' A' ' 108' ' ' PHE . 2.1 pp0? -131.37 168.7 17.13 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.83 0.348 . . . . 0.0 110.922 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' PHE . . . . . 0.485 ' O ' ' NE2' ' A' ' 107' ' ' GLN . 1.4 p90 -90.89 172.56 8.52 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.856 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 31.9 p90 -158.36 129.2 6.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.881 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -98.86 102.18 13.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.888 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.836 HD13 ' N ' ' A' ' 112' ' ' SER . 0.9 OUTLIER -99.85 137.51 38.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.876 -179.918 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.836 ' N ' HD13 ' A' ' 111' ' ' LEU . 2.4 m -145.14 111.71 5.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.9 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.529 HG23 HG22 ' A' ' 122' ' ' VAL . 3.9 mp -94.71 121.04 44.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.162 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.59 ' HD3' ' CD1' ' A' ' 123' ' ' TYR . 0.2 OUTLIER -99.54 123.92 44.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.864 179.984 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . 0.583 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 7.9 t -90.11 126.66 35.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.907 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -123.35 -150.32 8.0 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.489 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 9.2 mt -111.8 -39.72 4.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.863 0.363 . . . . 0.0 110.946 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.423 ' C ' ' CD2' ' A' ' 134' ' ' HIS . 29.0 t0 -88.78 -34.66 17.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.831 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.5 ptt180 -172.73 167.87 5.22 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.888 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.583 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.4 m-30 -93.18 158.68 15.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.865 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.43 ' HB3' ' CE1' ' A' ' 123' ' ' TYR . 17.9 mtpp -130.62 104.72 7.37 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.897 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.7 HG13 HD11 ' A' ' 111' ' ' LEU . 92.5 t -93.4 108.47 20.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.116 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' TYR . . . . . 0.59 ' CD1' ' HD3' ' A' ' 114' ' ' ARG . 32.9 m-85 -96.43 147.86 23.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.904 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.593 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -127.5 102.14 6.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.074 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 57.19 37.62 28.48 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.875 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.38 33.39 28.59 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.504 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -142.89 120.67 11.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.85 0.357 . . . . 0.0 110.895 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . 0.488 ' CE1' ' OD2' ' A' ' 131' ' ' ASP . 33.6 t-80 -53.22 99.86 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.884 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.593 HD13 ' CB ' ' A' ' 124' ' ' ALA . 10.5 tp -70.01 -67.41 0.49 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.883 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.524 ' HZ ' HD13 ' A' ' 72' ' ' ILE . 8.2 p90 -162.41 175.48 11.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.886 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.488 ' OD2' ' CE1' ' A' ' 128' ' ' HIS . 15.7 m-20 -120.21 150.17 41.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.864 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.597 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -115.86 107.81 15.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.848 -179.886 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.558 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -63.22 131.87 49.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.11 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' HIS . . . . . 0.423 ' CD2' ' C ' ' A' ' 118' ' ' ASP . 44.0 m-70 -62.35 102.39 0.31 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.893 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.434 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 68.9 mtt-85 -89.34 -45.98 9.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.872 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 4.5 tp -99.7 108.16 20.44 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.907 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 58.2 p -50.88 -33.17 22.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.853 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.468 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.23 31.17 0.39 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.095 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.41 ' O ' HD12 ' A' ' 37' ' ' LEU . 40.0 p90 -52.37 -42.31 63.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.883 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 8.2 pt20 -48.68 -42.31 34.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.916 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.468 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 72.2 mtp180 -54.36 -40.96 68.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.895 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.631 ' HA ' HG22 ' A' ' 62' ' ' VAL . 69.8 t -44.99 105.43 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.148 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -129.92 34.32 4.28 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.898 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 11.6 m -143.04 116.68 9.21 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.126 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.59 HD13 ' CE2' ' A' ' 60' ' ' PHE . 7.1 tp -116.45 107.8 15.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.959 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' GLU . . . . . 0.418 ' C ' HG13 ' A' ' 147' ' ' ILE . 8.0 pt-20 -111.79 153.02 27.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.852 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.622 HG23 HG13 ' A' ' 58' ' ' ILE . 16.8 mt -139.95 109.8 3.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.172 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -118.54 173.64 6.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.911 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.46 -145.45 16.09 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.503 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -112.18 93.05 4.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.868 0.366 . . . . 0.0 110.879 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 5.6 p -151.12 149.13 14.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.138 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 40.0 m -110.23 95.06 5.34 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.132 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.473 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 84.6 mt -76.53 136.09 39.3 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.901 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 6.0 m -120.08 -36.54 3.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.897 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . 0.578 ' CE2' ' HB2' ' A' ' 21' ' ' PRO . 53.5 t80 -150.64 130.94 13.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.909 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.494 ' H ' HG22 ' A' ' 22' ' ' THR . 44.8 t -139.72 105.0 2.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.123 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 12.2 tt0 -120.37 135.42 55.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.879 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' ILE . . . . . 0.461 HD12 ' HE3' ' A' ' 17' ' ' MET . 16.9 mt -104.38 94.36 3.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.135 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 36.9 t -56.99 152.06 13.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.882 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 171.36 -174.4 44.96 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.523 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 152.42 69.22 Favored 'Trans proline' 0 C--O 1.231 0.139 0 C-N-CA 122.671 2.247 . . . . 0.0 112.334 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 19.9 m -61.47 -48.84 79.28 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.875 -179.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 38.6 m -125.8 177.4 6.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.849 -179.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.3 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.505 -179.975 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.517 -0.233 . . . . 0.0 112.517 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.3 t 47.93 42.84 16.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.918 0.389 . . . . 0.0 110.871 -179.758 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 97.8 p -117.85 135.29 54.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.865 -179.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.15 169.77 28.12 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.515 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 71.0 m -106.08 123.1 47.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.862 0.363 . . . . 0.0 110.878 -179.736 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 28.7 t -89.63 98.73 11.93 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.875 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 162.29 137.86 2.29 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.489 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 22.2 p80 -160.51 163.08 33.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.766 0.317 . . . . 0.0 110.89 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 21.1 mm-40 -110.53 130.37 55.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.88 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -85.77 15.46 4.78 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.884 -179.909 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 8.2 mp -88.59 162.37 16.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.96 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . 0.444 ' O ' ' C ' ' A' ' 13' ' ' SER . 8.5 m-80 -40.68 -47.38 2.78 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.848 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.444 ' C ' ' O ' ' A' ' 12' ' ' ASN . 34.3 m -34.49 147.46 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.856 -179.838 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.579 HD11 ' HG2' ' A' ' 32' ' ' ARG . 4.6 pp -99.99 153.81 37.57 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.62 0.724 . . . . 0.0 110.901 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.548 ' O ' HD12 ' A' ' 14' ' ' LEU . 53.8 Cg_endo -69.75 -165.64 0.16 Allowed 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.649 2.233 . . . . 0.0 112.391 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.432 ' CG2' ' N ' ' A' ' 17' ' ' MET . 1.5 m -82.9 152.67 25.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.162 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . 0.432 ' N ' ' CG2' ' A' ' 16' ' ' THR . 20.1 mtm -106.72 74.84 1.02 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.841 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -109.22 -176.84 3.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.878 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.4 ' HA3' ' HD2' ' A' ' 20' ' ' PRO . . . 87.49 -144.46 19.08 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.53 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.4 ' HD2' ' HA3' ' A' ' 19' ' ' GLY . 53.5 Cg_endo -69.79 165.47 30.88 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.664 2.243 . . . . 0.0 112.33 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 174.91 8.82 Favored 'Trans proline' 0 C--O 1.232 0.213 0 C-N-CA 122.683 2.255 . . . . 0.0 112.398 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.473 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.9 m -84.95 147.02 26.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.131 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.473 ' CD1' ' O ' ' A' ' 22' ' ' THR . 6.7 m-85 -147.37 124.59 11.5 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.891 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . 0.575 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 4.6 t-20 58.93 46.23 1.48 Allowed Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.621 0.724 . . . . 0.0 110.883 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.575 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.77 134.47 28.04 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.679 2.252 . . . . 0.0 112.337 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -177.77 2.03 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.714 2.276 . . . . 0.0 112.301 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.707 HG13 ' HA ' ' A' ' 28' ' ' PRO . 96.0 t -142.25 138.72 16.9 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-O 121.634 0.731 . . . . 0.0 111.14 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.707 ' HA ' HG13 ' A' ' 27' ' ' VAL . 54.2 Cg_endo -69.72 144.39 76.44 Favored 'Cis proline' 0 C--N 1.341 0.17 0 C-N-CA 122.685 -1.798 . . . . 0.0 112.381 -0.11 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -98.37 115.68 28.98 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.925 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.489 ' CD2' ' HB3' ' A' ' 146' ' ' GLU . 63.7 m-85 -103.27 102.65 12.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.851 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -115.75 103.97 1.25 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.479 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.579 ' HG2' HD11 ' A' ' 14' ' ' LEU . 0.0 OUTLIER -72.34 132.03 43.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.836 0.35 . . . . 0.0 110.862 -179.848 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 143' ' ' ASP . 9.5 mt -76.87 142.57 40.13 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.942 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.486 ' NE2' ' NH1' ' A' ' 32' ' ' ARG . 23.0 mm-40 -100.39 91.49 4.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.926 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 133.23 -50.02 0.89 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.53 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.968 ' O ' HG23 ' A' ' 38' ' ' THR . . . 108.56 161.56 20.34 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.504 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . 0.64 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 99.4 mt -50.31 105.32 0.09 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.881 0.372 . . . . 0.0 110.933 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.968 HG23 ' O ' ' A' ' 36' ' ' GLY . 12.1 p -123.12 146.27 47.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.11 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.431 ' HB2' HD21 ' A' ' 117' ' ' LEU . . . -44.59 -31.98 1.31 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.173 179.856 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -103.45 41.05 1.31 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.895 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.413 ' NH2' ' O ' ' A' ' 34' ' ' GLN . 45.5 ttm-85 -124.31 136.03 53.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.861 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 39.3 m -135.91 126.33 26.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.14 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 mp -98.94 132.48 44.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.101 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 95.3 mt -123.58 134.68 65.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.137 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 59.5 mt -135.95 107.88 7.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.144 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.4 mtmm -110.34 111.07 22.12 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.925 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.66 -143.45 4.31 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.51 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 1.6 t80 -170.16 126.78 0.82 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.851 0.357 . . . . 0.0 110.944 -179.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 11.2 t -77.36 116.13 55.11 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.616 0.722 . . . . 0.0 111.124 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 158.68 56.15 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.699 2.266 . . . . 0.0 112.331 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -19.36 36.38 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.733 2.288 . . . . 0.0 112.327 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 69.2 p -109.7 21.27 17.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.142 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -115.02 120.04 4.84 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.486 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 20.6 mtpp -61.27 -60.19 4.13 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.797 0.332 . . . . 0.0 110.897 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.7 p -175.29 157.59 2.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.886 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.508 ' O ' ' ND2' ' A' ' 73' ' ' ASN . 4.0 p90 -108.47 -172.5 2.07 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.857 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.55 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -154.82 141.41 18.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.082 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.429 HD12 ' N ' ' A' ' 58' ' ' ILE . 2.6 mp -123.0 98.7 5.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.166 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.0 m-80 -101.07 144.84 29.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.908 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.546 ' CE2' HD13 ' A' ' 145' ' ' LEU . 29.6 m-85 -117.24 101.45 8.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.912 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.427 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 32.8 ttmt -95.83 168.39 10.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.863 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.591 HG22 ' HA ' ' A' ' 142' ' ' VAL . 61.4 t -100.41 122.27 52.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.171 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -57.08 -41.13 92.42 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.515 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 44.2 t -65.15 -73.04 0.13 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.888 0.375 . . . . 0.0 110.856 -179.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 39.0 t -77.99 -75.94 0.2 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.918 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 132.42 40.28 0.21 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.485 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.458 ' O ' HG23 ' A' ' 62' ' ' VAL . 0.7 OUTLIER -111.88 142.01 44.81 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.761 0.315 . . . . 0.0 110.892 -179.971 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.623 HD12 ' HB3' ' A' ' 86' ' ' LEU . 50.0 mt -86.41 120.11 35.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.152 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.527 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -92.24 -33.55 14.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.08 179.829 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.613 HD13 ' CD1' ' A' ' 132' ' ' PHE . 59.8 tp -138.85 130.61 27.65 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.907 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.492 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.5 OUTLIER -134.96 92.63 2.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.913 179.843 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.573 HD11 HD21 ' A' ' 70' ' ' LEU . 30.5 mt -94.99 128.37 46.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.117 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.55 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -134.58 105.4 10.89 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.611 0.719 . . . . 0.0 110.897 179.929 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.501 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.2 Cg_endo -69.71 154.51 67.85 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.701 2.267 . . . . 0.0 112.354 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 36.1 mtp180 -130.32 96.94 4.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.876 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -61.42 -43.14 99.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.845 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -55.2 -86.42 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.461 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 30.3 t30 -55.1 -60.09 3.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.884 0.374 . . . . 0.0 110.92 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 116.38 50.44 0.42 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.447 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 34.8 p -151.21 122.92 8.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.838 0.352 . . . . 0.0 111.17 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.474 HG21 ' HE2' ' A' ' 103' ' ' PHE . 13.1 t -89.29 108.73 19.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.097 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.559 HG22 ' HD3' ' A' ' 96' ' ' LYS . 91.6 t -80.93 145.97 8.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.088 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -127.34 124.81 39.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.892 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.492 ' O ' ' N ' ' A' ' 71' ' ' HIS . 2.7 m120 -135.22 179.3 6.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.901 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 46.1 t -160.78 105.63 1.4 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.861 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.929 HD12 ' O ' ' A' ' 90' ' ' SER . 27.0 tp -77.96 119.34 21.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.92 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.503 ' N ' ' O ' ' A' ' 90' ' ' SER . 87.0 mt -97.08 161.35 13.86 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.919 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.547 HD22 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.23 101.61 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.931 179.898 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.45 -6.41 0.82 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.501 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.929 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -118.96 172.06 7.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.834 0.349 . . . . 0.0 110.844 -179.725 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.837 ' NE1' HD13 ' A' ' 86' ' ' LEU . 22.0 m95 -129.43 161.07 31.21 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.929 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.09 -106.01 1.55 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.476 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 2.9 m -165.76 174.92 9.2 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.812 0.339 . . . . 0.0 110.835 -179.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.419 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 7.6 mt-10 -104.66 117.62 34.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.88 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -123.05 108.78 13.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.876 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.559 ' HD3' HG22 ' A' ' 82' ' ' VAL . 35.8 mtmt -105.57 131.32 53.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.864 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.479 ' HE3' ' N ' ' A' ' 98' ' ' ILE . 0.0 OUTLIER -174.31 105.23 0.11 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.903 179.889 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.933 HD11 ' O ' ' A' ' 100' ' ' HIS . 5.1 tt -148.09 154.25 10.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.12 179.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.488 HG23 ' N ' ' A' ' 100' ' ' HIS . 9.0 t -95.29 -44.62 7.51 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.143 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . 0.933 ' O ' HD11 ' A' ' 98' ' ' ILE . 4.9 p-80 -139.1 133.3 31.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.856 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . 0.402 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 44.2 t-20 -110.92 95.99 27.07 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.628 0.728 . . . . 0.0 110.892 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.434 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.4 Cg_endo -69.78 -42.6 3.24 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.646 2.231 . . . . 0.0 112.34 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.527 ' CZ ' HD21 ' A' ' 129' ' ' LEU . 5.2 m-85 -35.88 104.84 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.861 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -135.88 138.44 9.92 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.455 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 99.95 0.78 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.722 2.281 . . . . 0.0 112.319 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 130.45 -9.59 5.87 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.461 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.1 pt20 -131.49 159.22 38.76 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.806 0.336 . . . . 0.0 110.941 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -76.45 174.09 10.7 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.849 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.468 ' O ' ' CD2' ' A' ' 109' ' ' PHE . 23.4 p90 -161.55 117.87 2.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.887 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -94.76 102.08 13.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.878 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.739 HD13 ' N ' ' A' ' 112' ' ' SER . 0.9 OUTLIER -101.23 137.33 39.73 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.921 -179.943 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.739 ' N ' HD13 ' A' ' 111' ' ' LEU . 5.2 m -144.2 114.16 7.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.859 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.475 HD11 HD12 ' A' ' 111' ' ' LEU . 5.1 mp -96.47 140.71 16.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.147 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 24.6 mtt180 -115.57 124.93 52.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.879 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . 0.563 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 6.5 t -92.89 118.45 31.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.85 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.99 -144.82 8.51 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.434 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.431 HD21 ' HB2' ' A' ' 39' ' ' ALA . 13.6 mt -116.85 -36.95 3.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.838 0.351 . . . . 0.0 110.933 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -92.23 -34.69 14.17 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.833 179.861 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 17.8 ptp180 -171.77 172.83 4.75 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.885 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.64 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 3.6 m-30 -96.28 158.17 15.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.845 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 27.4 mtpt -129.82 100.34 5.44 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.917 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.459 HG13 HD11 ' A' ' 111' ' ' LEU . 88.0 t -86.18 137.07 21.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.133 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -126.54 152.72 46.16 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.884 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -140.83 111.17 6.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.069 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 56.78 29.71 16.45 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.9 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 83.37 32.12 26.11 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.503 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 8.5 mm100 -139.01 125.77 20.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.872 0.368 . . . . 0.0 110.875 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . 0.445 ' CE1' ' OD1' ' A' ' 131' ' ' ASP . 31.3 t-80 -56.6 109.22 0.58 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.839 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.527 HD21 ' CZ ' ' A' ' 103' ' ' PHE . 10.7 tp -77.8 -68.38 0.63 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.939 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.437 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 7.6 p90 -165.18 171.48 13.66 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.883 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.445 ' OD1' ' CE1' ' A' ' 128' ' ' HIS . 1.4 m-20 -113.97 151.64 32.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.865 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.613 ' CD1' HD13 ' A' ' 70' ' ' LEU . 0.3 OUTLIER -116.8 108.58 16.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.929 -179.933 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.513 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -63.49 134.42 55.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.065 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 15.8 m-70 -62.82 103.0 0.4 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.849 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 47.2 mtt-85 -87.1 -52.82 5.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.906 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 9.5 tp -91.54 108.34 19.83 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.934 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 99.2 p -50.5 -32.48 18.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.867 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.499 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.93 25.54 0.67 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.06 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.492 ' O ' HD12 ' A' ' 37' ' ' LEU . 12.5 p90 -45.44 -42.81 10.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.869 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' GLN . . . . . 0.436 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 10.7 pt20 -48.93 -40.06 28.65 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.894 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.499 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 41.0 mtp85 -55.9 -39.71 71.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.9 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.591 ' HA ' HG22 ' A' ' 62' ' ' VAL . 53.1 t -51.7 103.24 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.511 ' O ' ' N ' ' A' ' 33' ' ' LEU . 3.1 p30 -125.47 25.94 6.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.849 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 2.2 m -132.99 140.19 47.65 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.137 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.546 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.7 tp -134.64 108.32 7.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.947 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' GLU . . . . . 0.489 ' HB3' ' CD2' ' A' ' 30' ' ' PHE . 5.8 pt-20 -111.51 148.85 32.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.896 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.409 HG13 ' C ' ' A' ' 146' ' ' GLU . 9.9 mt -136.65 111.46 10.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.11 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 1.1 pm0 -124.26 176.68 6.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.956 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 109.97 -139.48 15.41 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.495 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -120.47 90.82 3.4 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.848 0.356 . . . . 0.0 110.898 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.441 HG22 ' N ' ' A' ' 152' ' ' THR . 2.8 p -151.15 155.33 7.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.13 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . 0.441 ' N ' HG22 ' A' ' 151' ' ' VAL . 38.0 m -113.32 93.7 4.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.156 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.478 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 68.2 mt -77.27 137.33 38.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.939 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 6.9 t -121.42 -39.55 2.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.888 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 19.3 t80 -143.49 129.17 19.26 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.929 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 76.3 t -141.05 105.42 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.128 179.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 14.6 tt0 -118.39 134.39 55.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.927 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 21.3 mt -105.22 90.44 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.158 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 27.4 p -60.39 176.14 0.38 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.872 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 151.36 -156.74 26.84 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.503 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 178.68 4.32 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.701 2.267 . . . . 0.0 112.335 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 4.3 t -110.94 113.01 25.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.898 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 97.0 p -101.68 41.4 1.21 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.836 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.275 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.5 -179.997 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.305 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 25.4 t -129.25 81.05 2.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.877 0.37 . . . . 0.0 110.882 -179.751 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 23.2 t -43.76 102.12 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.839 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -142.03 90.37 0.18 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.492 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.8 m -109.02 86.23 2.24 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.919 0.39 . . . . 0.0 110.873 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.2 t -93.56 129.48 39.78 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.887 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -125.86 157.46 19.86 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.468 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 25.3 p80 -38.83 152.24 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.74 0.305 . . . . 0.0 110.894 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -84.66 163.84 18.99 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.89 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 50.9 mt-30 -72.58 105.17 4.12 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.963 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.576 ' H ' HD23 ' A' ' 11' ' ' LEU . 0.1 OUTLIER -65.53 -28.77 69.41 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.92 -179.993 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 4.6 m120 -113.75 119.41 37.29 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.902 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 17.5 m -125.06 171.81 9.96 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.838 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 2.8 pp -119.56 155.23 54.55 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.653 0.739 . . . . 0.0 110.917 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.71 175.73 7.67 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.685 2.257 . . . . 0.0 112.366 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 9.2 t -70.24 148.37 48.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.108 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 4.0 ptt? -99.08 40.3 1.22 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.89 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -77.54 -176.64 4.36 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.841 -179.898 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.65 -131.08 10.52 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.476 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 166.52 27.26 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.701 2.267 . . . . 0.0 112.332 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -175.5 1.18 Allowed 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.684 2.256 . . . . 0.0 112.354 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.538 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.6 m -96.09 151.95 18.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.118 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.538 ' CD1' ' O ' ' A' ' 22' ' ' THR . 8.3 m-85 -150.84 127.4 10.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.887 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . 0.59 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 3.4 m120 54.48 45.46 2.27 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.607 0.718 . . . . 0.0 110.893 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.59 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.6 Cg_endo -69.76 132.56 23.59 Favored 'Trans proline' 0 C--O 1.231 0.175 0 C-N-CA 122.655 2.236 . . . . 0.0 112.299 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.81 -175.11 1.06 Allowed 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.669 2.246 . . . . 0.0 112.394 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.658 HG13 ' HA ' ' A' ' 28' ' ' PRO . 86.9 t -143.17 137.63 14.95 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.616 0.722 . . . . 0.0 111.14 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.658 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.6 Cg_endo -69.79 144.63 77.27 Favored 'Cis proline' 0 C--N 1.341 0.184 0 C-N-CA 122.702 -1.791 . . . . 0.0 112.319 -0.017 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 6.4 t80 -98.31 121.99 40.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.938 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -102.17 101.95 12.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.842 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -100.82 108.77 3.52 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.455 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 6.8 mmt85 -73.28 123.29 23.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.856 0.36 . . . . 0.0 110.902 -179.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.406 HD22 ' CZ ' ' A' ' 41' ' ' ARG . 7.8 mt -87.05 113.73 23.05 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.929 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 5.7 mm100 -84.62 80.53 9.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.888 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 143.54 -36.83 1.51 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.501 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.469 ' CA ' ' OD1' ' A' ' 143' ' ' ASP . . . 93.72 -177.93 37.59 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.48 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . 0.791 HD23 ' HE ' ' A' ' 41' ' ' ARG . 89.0 mt -68.47 98.05 0.82 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.899 0.38 . . . . 0.0 110.885 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 34.6 p -107.77 161.85 14.52 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.1 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.437 ' HB2' HD21 ' A' ' 117' ' ' LEU . . . -62.18 -27.47 68.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.112 179.845 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 8.8 mpt_? -105.61 33.06 3.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.918 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.791 ' HE ' HD23 ' A' ' 37' ' ' LEU . 4.5 ttt85 -109.74 137.98 46.77 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 87.4 m -138.96 120.82 15.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.136 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.487 HD11 ' CZ ' ' A' ' 41' ' ' ARG . 5.4 mp -93.74 137.78 21.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.159 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 76.2 mt -128.96 118.65 47.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.084 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 71.9 mt -118.1 107.37 21.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.104 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 21.9 mtmt -113.69 109.49 18.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.928 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -143.2 -143.61 4.15 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.528 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -168.03 128.6 1.35 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.941 0.4 . . . . 0.0 110.944 -179.845 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 15.4 t -79.11 119.6 77.75 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.646 0.736 . . . . 0.0 111.17 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 158.91 55.29 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.683 2.255 . . . . 0.0 112.313 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -17.96 37.03 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.712 2.274 . . . . 0.0 112.304 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 30.2 p -109.52 18.77 20.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.126 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -115.74 121.18 5.17 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.477 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 20.2 mtpp -63.91 -58.78 5.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.78 0.324 . . . . 0.0 110.906 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.0 m -173.12 167.77 4.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.833 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.531 ' CE2' HD11 ' A' ' 58' ' ' ILE . 1.9 p90 -119.07 -172.2 2.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.86 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.952 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -154.67 133.82 12.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.106 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.531 HD11 ' CE2' ' A' ' 56' ' ' PHE . 3.6 mp -115.77 98.18 6.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.151 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . 0.415 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 6.0 m-80 -100.25 143.33 30.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.939 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.559 ' CE2' HD13 ' A' ' 145' ' ' LEU . 28.5 m-85 -115.32 98.38 6.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.904 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.431 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 33.7 ttmt -95.68 168.31 10.75 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.934 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.756 HG22 ' HA ' ' A' ' 142' ' ' VAL . 53.4 t -100.24 125.08 54.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.147 179.85 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -60.44 -36.88 92.25 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.509 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 69.7 m -65.95 -73.34 0.13 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.871 0.367 . . . . 0.0 110.897 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 58.0 m -81.18 -73.36 0.38 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.853 -179.874 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 133.62 39.8 0.19 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.491 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.468 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.2 m-20 -108.92 142.88 38.9 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.789 0.328 . . . . 0.0 110.886 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.525 HD12 ' HB3' ' A' ' 86' ' ' LEU . 35.8 mt -92.35 114.01 28.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.127 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -83.63 -31.49 26.19 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.112 179.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.74 HD21 HD11 ' A' ' 72' ' ' ILE . 56.0 tp -141.28 130.91 24.04 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.889 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.476 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.2 t60 -134.49 92.94 2.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.845 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.74 HD11 HD21 ' A' ' 70' ' ' LEU . 18.2 mt -97.31 132.97 40.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.112 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.952 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -140.27 106.49 6.65 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.63 0.728 . . . . 0.0 110.899 179.941 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.618 ' HB3' ' CD2' ' A' ' 103' ' ' PHE . 54.0 Cg_endo -69.74 154.98 67.16 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.652 2.235 . . . . 0.0 112.335 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 57.8 mtp180 -131.49 100.57 5.19 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.887 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . 0.422 ' SD ' ' HB2' ' A' ' 103' ' ' PHE . 0.0 OUTLIER -63.63 161.62 14.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.891 179.952 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 85.28 -67.8 3.57 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.457 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -75.43 -57.83 3.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.848 0.356 . . . . 0.0 110.887 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 105.73 48.89 0.99 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.513 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.2 p -136.95 118.15 14.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.797 0.332 . . . . 0.0 111.167 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.408 HG22 ' HA ' ' A' ' 74' ' ' PRO . 15.2 t -102.54 114.26 41.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.13 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.572 HG22 ' HD3' ' A' ' 96' ' ' LYS . 37.1 t -84.53 143.34 11.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.127 179.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -125.4 124.88 42.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.853 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.476 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.7 OUTLIER -136.23 176.29 8.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.906 -179.975 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 47.7 t -156.15 105.07 2.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.891 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.893 HD13 ' NE1' ' A' ' 91' ' ' TRP . 39.0 tp -77.18 114.33 15.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.904 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.518 ' N ' ' O ' ' A' ' 90' ' ' SER . 79.7 mt -92.44 161.93 14.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.929 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.435 ' ND2' ' OD2' ' A' ' 67' ' ' ASP . 13.5 m-80 -41.17 101.83 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.938 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.15 -1.55 3.61 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.485 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.829 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -125.31 170.59 11.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.828 0.347 . . . . 0.0 110.898 -179.815 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.893 ' NE1' HD13 ' A' ' 86' ' ' LEU . 23.1 m95 -128.12 160.57 31.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.903 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -91.97 -102.04 1.38 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.461 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 9.9 m -167.82 174.41 7.56 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.868 0.366 . . . . 0.0 110.823 -179.752 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -96.71 123.64 40.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.881 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 17.8 mm-40 -121.37 116.12 24.2 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.9 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.572 ' HD3' HG22 ' A' ' 82' ' ' VAL . 6.7 mtmp? -120.72 122.16 39.82 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.888 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -175.17 105.54 0.09 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.855 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.881 HD11 ' O ' ' A' ' 100' ' ' HIS . 6.4 tt -147.64 146.58 18.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.137 179.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.485 HG23 ' N ' ' A' ' 100' ' ' HIS . 10.2 t -81.34 -44.79 17.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . 0.881 ' O ' HD11 ' A' ' 98' ' ' ILE . 5.1 p-80 -148.5 141.26 24.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.9 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . 0.443 ' C ' ' OD1' ' A' ' 101' ' ' ASN . 4.9 t-20 -101.63 102.13 20.97 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.605 0.717 . . . . 0.0 110.899 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.476 ' CD ' HD11 ' A' ' 129' ' ' LEU . 53.8 Cg_endo -69.78 -29.6 23.53 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.691 2.26 . . . . 0.0 112.33 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.618 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 19.6 m-85 -58.6 115.02 2.77 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.866 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -140.06 139.83 10.18 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.516 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 111.0 2.7 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.716 2.277 . . . . 0.0 112.305 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 107.18 0.9 35.64 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.487 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -137.85 142.09 40.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.849 0.356 . . . . 0.0 110.903 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.4 p90 -68.57 174.51 4.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.844 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 29.1 p90 -161.25 132.21 5.32 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.922 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -103.34 106.38 16.88 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.859 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.794 HD13 ' N ' ' A' ' 112' ' ' SER . 0.4 OUTLIER -109.16 138.39 45.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.912 -179.955 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.794 ' N ' HD13 ' A' ' 111' ' ' LEU . 2.6 m -145.44 113.67 6.59 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.867 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.552 HG23 HG22 ' A' ' 122' ' ' VAL . 4.0 mp -93.55 136.82 24.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.108 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 50.1 mtt-85 -110.22 120.9 43.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.851 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . 0.431 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 26.3 t -92.06 122.21 34.35 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.918 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -123.62 -149.44 7.77 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.484 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.437 HD21 ' HB2' ' A' ' 39' ' ' ALA . 36.3 mt -109.37 -40.88 4.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.86 0.362 . . . . 0.0 110.904 -179.871 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -80.72 -39.54 26.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.83 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -174.11 179.91 1.8 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.898 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.542 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 18.9 m-85 -97.95 155.04 17.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.877 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 15.5 mtpp -130.48 100.55 5.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.921 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.781 ' CG1' HD11 ' A' ' 111' ' ' LEU . 21.3 t -88.16 128.61 40.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.116 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -120.59 149.79 41.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.909 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.45 ' CB ' ' HG3' ' A' ' 102' ' ' PRO . . . -134.17 110.1 9.34 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.093 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 58.13 31.58 20.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.911 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.31 38.2 15.64 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.484 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 8.7 mm100 -143.77 128.88 18.66 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.868 0.366 . . . . 0.0 110.914 -179.854 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 35.6 t-80 -59.21 107.19 0.52 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.845 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.476 HD11 ' CD ' ' A' ' 102' ' ' PRO . 8.5 tp -78.41 -66.12 0.89 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.899 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.472 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 5.3 p90 -166.42 169.53 13.86 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.861 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -115.21 149.71 37.28 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.917 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.657 ' CG ' HD13 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -117.73 108.02 14.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.899 -179.92 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.579 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -63.33 134.97 56.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.066 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 42.3 m-70 -63.34 107.3 1.06 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.884 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 67.6 mtt-85 -89.71 -48.85 7.0 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.849 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . 0.422 HD13 HD22 ' A' ' 87' ' ' LEU . 12.2 tp -93.51 109.33 20.93 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.943 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 12.1 t -50.64 -33.37 22.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.868 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.518 ' HB1' ' HD2' ' A' ' 141' ' ' ARG . . . -87.19 33.55 0.68 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.107 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.647 ' O ' HD12 ' A' ' 37' ' ' LEU . 8.2 p90 -50.74 -31.61 17.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.868 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 6.1 pt20 -56.14 -46.46 79.22 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.885 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.518 ' HD2' ' HB1' ' A' ' 138' ' ' ALA . 27.6 mtt-85 -47.5 -44.22 25.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.866 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.756 ' HA ' HG22 ' A' ' 62' ' ' VAL . 92.3 t -43.3 103.45 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.153 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.469 ' OD1' ' CA ' ' A' ' 36' ' ' GLY . 17.1 m-20 -128.19 31.48 5.05 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.841 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 18.1 m -142.44 123.19 14.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.122 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.559 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.6 tp -120.15 107.69 13.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.933 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -110.75 152.31 26.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.919 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 25.1 mt -139.58 112.77 6.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.177 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -123.57 171.29 9.64 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.928 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 113.03 -148.07 18.54 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.522 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 28.8 m-20 -111.56 89.1 2.96 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.859 0.361 . . . . 0.0 110.881 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.448 HG22 ' N ' ' A' ' 152' ' ' THR . 7.2 p -148.85 155.33 8.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.129 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . 0.448 ' N ' HG22 ' A' ' 151' ' ' VAL . 16.9 m -116.21 94.51 4.68 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.16 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.476 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 78.6 mt -75.92 139.95 41.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.886 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 68.6 m -127.8 -35.57 2.09 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.858 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 39.6 t80 -146.93 125.08 12.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.942 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 79.4 t -138.97 106.33 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.118 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 13.9 tt0 -119.69 141.16 49.63 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.931 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' ILE . . . . . 0.638 HG23 ' NH1' ' A' ' 41' ' ' ARG . 15.6 mt -110.1 97.27 5.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.121 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 42.4 t -45.85 141.9 2.82 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.856 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -90.74 177.82 42.13 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.507 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -17.58 37.42 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.738 2.292 . . . . 0.0 112.309 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 23.8 m -132.26 133.24 43.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.839 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 25.8 t -133.0 132.48 41.94 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.876 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.493 -179.988 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 N-CA-C 112.534 -0.226 . . . . 0.0 112.534 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 69.0 m -114.88 -54.65 2.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.888 0.375 . . . . 0.0 110.897 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 59.6 p -130.76 153.31 49.17 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.869 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 153.29 95.25 0.11 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.466 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.0 m -124.12 157.45 34.61 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.881 0.372 . . . . 0.0 110.852 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 12.5 t -97.34 -48.67 5.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.906 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 111.84 117.94 3.66 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.476 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 28.2 p-80 -83.2 130.06 35.06 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.776 0.322 . . . . 0.0 110.822 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 91.3 mm-40 -78.53 88.67 4.47 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.883 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 41.4 tt0 -118.6 82.91 1.93 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.935 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 56.5 mt -117.44 44.06 2.21 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.911 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 74.3 m-80 -58.2 -39.77 79.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.897 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 29.5 p -105.56 158.06 16.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.836 -179.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 97.1 mt -51.68 151.29 6.09 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-O 121.586 0.708 . . . . 0.0 110.916 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.7 -163.9 0.12 Allowed 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.665 2.243 . . . . 0.0 112.399 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.5 m -88.78 149.46 23.42 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.136 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . 0.507 ' HE3' ' CA ' ' A' ' 31' ' ' GLY . 3.2 mpp? -95.99 102.03 13.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.833 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.4 163.25 14.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.863 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.41 ' HA3' ' HD2' ' A' ' 20' ' ' PRO . . . 77.89 -132.25 11.72 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.518 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.41 ' HD2' ' HA3' ' A' ' 19' ' ' GLY . 53.9 Cg_endo -69.71 168.71 20.7 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.708 2.272 . . . . 0.0 112.366 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.69 -179.09 2.64 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.679 2.253 . . . . 0.0 112.344 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 1.2 t -97.8 148.86 22.96 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.129 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -138.92 127.83 23.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.92 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . 0.567 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 8.8 m-80 61.55 47.0 1.08 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.578 0.704 . . . . 0.0 110.901 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.567 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 54.0 Cg_endo -69.75 136.03 31.99 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.65 2.234 . . . . 0.0 112.312 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 -177.72 2.02 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.68 2.253 . . . . 0.0 112.331 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.686 HG13 ' HA ' ' A' ' 28' ' ' PRO . 97.0 t -141.72 138.09 16.87 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.685 0.755 . . . . 0.0 111.107 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.686 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.3 Cg_endo -69.77 144.33 76.38 Favored 'Cis proline' 0 C--N 1.342 0.198 0 C-N-CA 122.65 -1.812 . . . . 0.0 112.325 -0.027 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 8.2 t80 -97.47 117.15 31.09 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.933 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -100.66 102.3 13.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.884 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.507 ' CA ' ' HE3' ' A' ' 17' ' ' MET . . . -97.77 109.4 3.81 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.456 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 9.7 mmt180 -72.91 102.99 3.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.854 0.359 . . . . 0.0 110.876 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.487 HD13 ' NH2' ' A' ' 41' ' ' ARG . 5.6 mt -71.1 114.7 9.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.939 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 5.6 mm-40 -86.32 94.49 9.36 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.911 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 131.33 -32.75 2.9 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.453 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.714 ' O ' HG23 ' A' ' 38' ' ' THR . . . 88.69 173.45 46.87 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.51 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . 0.676 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 88.0 mt -57.18 104.97 0.19 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.854 0.359 . . . . 0.0 110.938 -179.9 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.714 HG23 ' O ' ' A' ' 36' ' ' GLY . 29.0 p -117.07 149.94 39.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.116 -180.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -59.71 -21.27 60.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.122 179.83 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 25.5 mmm-85 -104.42 26.46 8.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.884 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.675 ' CZ ' HD23 ' A' ' 37' ' ' LEU . 23.4 ttt180 -116.97 142.86 46.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.863 -179.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 91.2 m -137.16 121.21 17.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.123 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 mp -90.86 132.46 35.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.156 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.459 ' CG2' ' HE2' ' A' ' 46' ' ' LYS . 70.1 mt -128.57 117.24 44.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.154 179.792 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 34.9 mt -116.15 107.59 22.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.168 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.459 ' HE2' ' CG2' ' A' ' 44' ' ' ILE . 22.3 mtmt -111.65 111.18 21.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.904 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -143.67 -143.62 4.12 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.484 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . 0.405 ' O ' ' CD1' ' A' ' 48' ' ' TYR . 1.1 t80 -167.59 118.27 0.85 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.944 0.402 . . . . 0.0 110.896 -179.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 15.1 t -69.96 115.45 34.0 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.638 0.732 . . . . 0.0 111.135 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 159.02 54.96 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.714 2.276 . . . . 0.0 112.359 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -25.16 29.01 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.683 2.256 . . . . 0.0 112.328 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 67.1 p -100.74 15.41 28.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.134 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -109.89 119.4 5.4 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.489 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.418 ' O ' ' SD ' ' A' ' 76' ' ' MET . 24.8 mtpt -62.47 -58.91 5.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.816 0.341 . . . . 0.0 110.89 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 37.0 p -175.58 162.37 2.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.827 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 3.5 p90 -116.14 -174.98 2.65 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.87 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.98 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -156.91 137.38 13.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.119 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.429 HD12 ' N ' ' A' ' 58' ' ' ILE . 4.6 mp -118.14 100.78 10.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.152 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -99.85 144.04 29.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.911 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.62 ' CE2' HD13 ' A' ' 145' ' ' LEU . 50.1 m-85 -115.04 97.69 6.37 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.881 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.47 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 35.5 ttmt -96.13 167.68 11.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.899 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.615 HG22 ' HA ' ' A' ' 142' ' ' VAL . 43.6 t -100.61 122.52 52.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.102 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -58.58 -40.21 94.28 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.515 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.0 t -64.43 -70.74 0.21 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.941 0.4 . . . . 0.0 110.902 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 48.5 t -79.75 -75.06 0.27 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.875 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 131.43 41.37 0.21 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.487 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.433 ' O ' HG23 ' A' ' 62' ' ' VAL . 0.8 OUTLIER -114.71 141.47 47.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.833 0.349 . . . . 0.0 110.879 179.995 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.479 HD12 ' HB3' ' A' ' 86' ' ' LEU . 43.0 mt -88.05 119.55 35.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.111 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -90.25 -33.57 16.1 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.059 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.712 HD21 HD11 ' A' ' 72' ' ' ILE . 62.7 tp -138.44 131.2 29.43 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.898 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.497 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.3 OUTLIER -135.01 93.91 3.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.866 179.877 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.712 HD11 HD21 ' A' ' 70' ' ' LEU . 17.1 mt -98.09 133.16 41.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.096 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.98 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.2 OUTLIER -140.8 106.87 6.36 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.597 0.713 . . . . 0.0 110.871 179.937 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.611 ' HB3' ' CD2' ' A' ' 103' ' ' PHE . 53.8 Cg_endo -69.75 154.63 67.56 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.702 2.268 . . . . 0.0 112.383 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 46.0 mtp85 -132.96 94.58 3.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.892 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . 0.418 ' SD ' ' O ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -47.52 -26.1 1.31 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.885 179.983 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -52.25 -94.83 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.466 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -89.54 19.75 4.37 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.852 0.358 . . . . 0.0 110.895 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.462 ' HA2' ' ND2' ' A' ' 101' ' ' ASN . . . 53.92 39.82 63.55 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.496 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 28.8 p -108.94 117.86 35.31 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.85 0.357 . . . . 0.0 111.114 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.2 t -99.35 110.46 26.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.149 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.525 HG22 ' HD3' ' A' ' 96' ' ' LYS . 67.6 t -82.71 145.45 8.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.113 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -125.84 124.15 40.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.895 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.497 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.4 m120 -135.49 177.12 8.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.889 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 87.1 p -160.67 105.13 1.4 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.826 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.934 HD12 ' O ' ' A' ' 90' ' ' SER . 22.9 tp -77.74 119.34 21.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.943 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.511 ' N ' ' O ' ' A' ' 90' ' ' SER . 93.0 mt -96.71 161.48 13.86 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.915 179.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.554 HD22 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -37.91 101.67 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.864 179.895 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.51 -7.05 0.68 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.477 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.934 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -117.54 170.03 9.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.856 0.36 . . . . 0.0 110.871 -179.748 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.841 ' NE1' HD13 ' A' ' 86' ' ' LEU . 20.7 m95 -128.58 161.1 30.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.927 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -93.14 -110.26 1.98 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.465 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 72.0 m -159.91 178.12 10.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.855 0.359 . . . . 0.0 110.87 -179.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.435 ' C ' ' OE2' ' A' ' 95' ' ' GLU . 30.2 mt-10 -103.07 123.62 47.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.887 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . 0.435 ' OE2' ' C ' ' A' ' 94' ' ' GLU . 3.5 mp0 -122.88 116.96 24.5 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.89 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.525 ' HD3' HG22 ' A' ' 82' ' ' VAL . 9.4 mtmp? -118.79 120.55 37.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.891 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -171.84 108.0 0.23 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.966 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.788 HD11 ' O ' ' A' ' 100' ' ' HIS . 4.1 tt -147.66 152.3 12.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.119 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.523 HG23 ' N ' ' A' ' 100' ' ' HIS . 8.9 t -85.42 -47.18 10.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.162 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . 0.788 ' O ' HD11 ' A' ' 98' ' ' ILE . 1.7 p-80 -147.06 133.49 19.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.87 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . 0.462 ' ND2' ' HA2' ' A' ' 79' ' ' GLY . 7.4 t30 -103.67 98.17 12.34 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.674 0.749 . . . . 0.0 110.856 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.5 Cg_endo -69.75 -42.5 3.36 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.687 2.258 . . . . 0.0 112.331 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.611 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 11.7 m-85 -34.01 110.58 0.09 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.858 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -133.09 136.66 8.84 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.515 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 97.78 0.65 Allowed 'Trans proline' 0 N--CA 1.465 -0.151 0 C-N-CA 122.715 2.277 . . . . 0.0 112.371 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 119.97 1.92 12.8 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.473 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 9.4 pt20 -134.59 149.09 50.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.846 0.355 . . . . 0.0 110.911 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -66.52 168.39 9.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.901 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.41 ' O ' ' CG ' ' A' ' 109' ' ' PHE . 14.9 p90 -160.71 125.51 3.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.906 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -101.75 108.28 19.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.883 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.735 HD13 ' N ' ' A' ' 112' ' ' SER . 0.7 OUTLIER -111.81 139.01 47.65 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.932 -179.96 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.735 ' N ' HD13 ' A' ' 111' ' ' LEU . 1.5 m -144.9 115.51 7.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.834 -179.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.504 HG22 ' HD2' ' A' ' 120' ' ' PHE . 4.9 mp -97.28 132.03 42.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.135 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.535 ' O ' ' CD2' ' A' ' 120' ' ' PHE . 6.1 mtp-105 -104.53 133.39 49.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.879 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . 0.559 ' HA ' ' CE2' ' A' ' 120' ' ' PHE . 5.7 t -98.08 121.72 40.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.895 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -122.97 -163.04 11.69 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.521 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 7.6 mt -104.82 -28.75 10.96 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.784 0.326 . . . . 0.0 110.892 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.4 ' C ' ' OD1' ' A' ' 118' ' ' ASP . 7.2 t0 -97.43 -39.91 8.94 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.886 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 29.4 ptt-85 -170.34 163.89 8.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.676 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 14.8 m-85 -88.23 154.78 20.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.86 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 13.6 mtpp -126.94 100.17 6.04 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.908 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.524 HG13 HD11 ' A' ' 111' ' ' LEU . 39.3 t -87.44 132.28 33.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.128 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -123.79 146.59 48.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.919 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -134.74 111.89 10.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.111 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 55.64 35.18 24.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.865 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.57 39.57 21.25 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.492 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 9.8 mt-30 -145.99 129.11 16.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.837 0.351 . . . . 0.0 110.937 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 33.0 t-80 -60.76 99.29 0.08 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.889 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.538 HD22 HD21 ' A' ' 111' ' ' LEU . 9.8 tp -66.71 -69.62 0.3 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.93 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.482 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 4.9 p90 -163.29 171.38 16.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.913 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -116.49 148.09 41.12 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.86 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.673 ' CG ' HD13 ' A' ' 70' ' ' LEU . 0.3 OUTLIER -116.99 107.66 14.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.859 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.463 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -64.89 133.27 51.49 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.092 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 34.3 m-70 -60.68 109.09 0.95 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.846 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 32.0 mtt-85 -91.54 -51.38 5.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.891 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.0 tp -93.18 109.3 20.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.913 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 81.6 p -49.72 -35.22 21.26 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.83 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -82.22 39.44 0.58 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.115 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.485 ' O ' HD12 ' A' ' 37' ' ' LEU . 7.5 p90 -60.68 -37.62 82.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.942 -179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -55.5 -32.68 63.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.915 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.509 ' O ' HG13 ' A' ' 62' ' ' VAL . 34.6 mtp85 -62.2 -37.72 86.39 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.879 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.615 ' HA ' HG22 ' A' ' 62' ' ' VAL . 93.5 t -49.08 104.12 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.087 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.405 ' OD1' ' CA ' ' A' ' 36' ' ' GLY . 0.9 OUTLIER -127.56 34.55 4.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.905 179.892 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 18.7 m -146.89 112.93 5.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.144 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.62 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.3 tp -112.18 107.14 15.93 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.902 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' GLU . . . . . 0.41 ' C ' HG13 ' A' ' 147' ' ' ILE . 2.0 pm0 -109.21 153.97 23.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.903 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.41 HG13 ' C ' ' A' ' 146' ' ' GLU . 20.2 mt -140.03 107.23 2.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.146 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -115.69 171.5 7.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.932 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 110.64 -146.72 17.5 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.502 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -114.6 93.44 4.33 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.801 0.334 . . . . 0.0 110.896 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 4.0 p -151.2 142.09 16.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.144 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 9.9 m -101.94 94.78 5.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.161 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.458 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 83.8 mt -77.33 138.1 39.15 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.89 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 16.6 m -122.35 -39.75 2.54 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.87 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 23.8 t80 -146.0 129.01 16.5 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.914 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 70.1 t -140.3 106.33 2.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.138 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 8.9 tt0 -120.8 132.89 55.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.928 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 14.1 mt -99.01 88.52 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.165 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 16.9 m -56.12 119.22 5.56 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.865 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -134.36 164.17 24.58 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.524 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -3.83 12.79 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.674 2.249 . . . . 0.0 112.336 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 9.0 t -113.26 172.21 7.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.889 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 80.5 p -163.83 110.53 1.11 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.865 -179.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.273 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.518 -179.991 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 N-CA-C 112.508 -0.237 . . . . 0.0 112.508 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.6 m -46.42 -59.85 2.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.914 0.388 . . . . 0.0 110.849 -179.738 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.9 t -144.06 146.74 33.04 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.851 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.68 43.8 2.84 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.44 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 7.8 t -46.49 112.46 0.5 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.913 0.387 . . . . 0.0 110.891 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 72.8 m -50.99 -43.95 60.75 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.873 -179.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 49.99 53.23 23.5 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.485 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 5.2 p-80 -87.53 137.34 32.42 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.756 0.312 . . . . 0.0 110.856 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 21.1 mm-40 -109.22 105.39 14.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.926 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 8.2 pt20 -44.73 99.74 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.866 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 51.4 mt -144.22 156.01 44.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.2 p30 -86.48 -45.16 11.38 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 3.8 m -54.54 -174.47 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.84 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.551 HD11 ' HG2' ' A' ' 32' ' ' ARG . 0.4 OUTLIER -117.17 157.33 47.17 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.567 0.698 . . . . 0.0 110.966 179.977 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.442 ' HD2' ' HB2' ' A' ' 14' ' ' LEU . 53.6 Cg_endo -69.75 174.57 9.3 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.737 2.291 . . . . 0.0 112.305 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 6.1 t -92.66 -7.1 47.82 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.159 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 40.2 mtm 64.1 43.06 5.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.86 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -80.57 161.91 24.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.886 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.36 -136.63 13.42 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.477 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 170.0 17.63 Favored 'Trans proline' 0 C--O 1.231 0.13 0 C-N-CA 122.694 2.263 . . . . 0.0 112.3 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 -173.51 0.72 Allowed 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.687 2.258 . . . . 0.0 112.398 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.437 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.4 m -98.2 140.69 32.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.129 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -137.48 125.54 22.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . 0.501 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.2 t-20 52.15 50.69 8.59 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.583 0.706 . . . . 0.0 110.862 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.501 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.77 140.36 42.46 Favored 'Trans proline' 0 N--CA 1.465 -0.176 0 C-N-CA 122.678 2.252 . . . . 0.0 112.379 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 -178.4 2.3 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.709 2.273 . . . . 0.0 112.371 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.666 HG13 ' HA ' ' A' ' 28' ' ' PRO . 97.8 t -140.35 137.58 17.95 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.658 0.742 . . . . 0.0 111.085 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.666 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.8 Cg_endo -69.72 144.68 77.24 Favored 'Cis proline' 0 C--N 1.342 0.187 0 C-N-CA 122.658 -1.809 . . . . 0.0 112.338 -0.067 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 6.2 t80 -97.88 120.72 38.78 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.925 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -103.07 101.02 10.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.887 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -106.62 109.69 3.15 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.477 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.551 ' HG2' HD11 ' A' ' 14' ' ' LEU . 8.3 mmt180 -74.04 109.34 7.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.841 0.353 . . . . 0.0 110.876 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.639 HD23 HG12 ' A' ' 158' ' ' ILE . 6.9 mt -67.54 101.08 0.94 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.88 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 24.3 mt-30 -73.36 100.35 3.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.867 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 132.81 -40.18 1.64 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.498 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.785 ' O ' HG23 ' A' ' 38' ' ' THR . . . 89.84 161.45 37.48 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.466 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . 0.661 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 91.3 mt -55.42 99.07 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.891 0.376 . . . . 0.0 110.893 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.785 HG23 ' O ' ' A' ' 36' ' ' GLY . 26.9 p -117.94 145.95 44.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.167 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -41.7 -33.76 0.53 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.113 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 19.0 mmt180 -101.9 41.63 1.2 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.885 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.491 ' NE ' ' O ' ' A' ' 36' ' ' GLY . 29.7 ttm-85 -122.66 138.6 54.55 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 52.7 m -139.54 120.34 14.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.15 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.43 ' N ' HD12 ' A' ' 43' ' ' ILE . 4.8 mp -93.32 136.47 25.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.099 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 96.6 mt -128.46 137.0 58.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.125 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 55.0 mt -136.97 107.49 5.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.202 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 24.2 mtmt -110.64 108.69 18.69 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.877 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -139.84 -139.69 3.8 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.498 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -171.39 136.72 1.03 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.948 0.404 . . . . 0.0 110.913 -179.853 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.402 HG23 ' CD1' ' A' ' 109' ' ' PHE . 21.5 t -86.73 116.34 65.61 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.64 0.733 . . . . 0.0 111.121 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 158.97 55.13 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.687 2.258 . . . . 0.0 112.324 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 -14.88 36.6 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.642 2.228 . . . . 0.0 112.368 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 38.0 p -113.91 20.13 16.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.154 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -113.03 113.45 3.18 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.501 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 25.1 mtpt -58.89 -58.91 6.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.809 0.337 . . . . 0.0 110.89 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 40.5 p -174.22 162.45 3.68 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.862 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.604 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 6.0 p90 -119.37 -173.57 2.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.874 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -156.45 137.37 13.49 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.147 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.543 HG22 ' CE1' ' A' ' 60' ' ' PHE . 3.9 mp -114.24 104.26 16.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.11 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . 0.497 ' ND2' ' ND1' ' A' ' 71' ' ' HIS . 22.0 m120 -98.48 141.4 31.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.875 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.567 ' CE2' HD13 ' A' ' 145' ' ' LEU . 5.6 m-85 -115.88 97.16 5.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.881 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.443 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 35.2 ttmt -96.02 168.37 10.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.874 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.671 HG22 ' HA ' ' A' ' 142' ' ' VAL . 49.0 t -99.78 124.33 53.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.086 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.427 ' HA3' ' NH1' ' A' ' 32' ' ' ARG . . . -62.25 -30.46 76.03 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.467 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.483 ' H ' HG12 ' A' ' 62' ' ' VAL . 9.7 t -71.24 -71.63 0.25 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.846 0.355 . . . . 0.0 110.821 -179.703 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 22.8 t -83.87 -70.98 0.53 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 132.14 42.82 0.17 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.501 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.517 ' O ' HG23 ' A' ' 62' ' ' VAL . 0.8 OUTLIER -114.02 141.74 47.05 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.808 0.337 . . . . 0.0 110.88 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.448 HD12 ' HB3' ' A' ' 86' ' ' LEU . 80.7 mt -86.6 120.2 35.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.14 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.541 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -90.09 -37.57 14.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.076 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.775 HD21 HD11 ' A' ' 72' ' ' ILE . 21.8 tp -139.26 133.48 31.33 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.902 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.518 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.2 OUTLIER -134.46 92.78 2.96 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.856 179.878 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.775 HD11 HD21 ' A' ' 70' ' ' LEU . 20.4 mt -93.52 135.66 27.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.126 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.5 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 1.1 t-20 -140.91 107.13 6.31 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.626 0.727 . . . . 0.0 110.881 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.604 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.8 Cg_endo -69.77 154.73 67.33 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.669 2.246 . . . . 0.0 112.373 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 45.4 mtp85 -131.67 98.46 4.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.919 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -58.74 -44.73 90.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.883 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -63.72 -92.56 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.492 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -43.35 -47.58 6.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.885 0.374 . . . . 0.0 110.88 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 96.63 38.06 4.56 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.483 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 16.9 p -138.11 117.92 13.22 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.807 0.337 . . . . 0.0 111.194 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.579 HG22 ' HA ' ' A' ' 74' ' ' PRO . 20.3 t -84.07 109.03 17.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.116 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.706 HG22 ' HD3' ' A' ' 96' ' ' LYS . 57.5 t -78.1 146.09 8.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.117 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -129.81 129.66 44.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.834 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.518 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.8 m120 -141.62 178.45 7.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.847 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 93.1 p -160.83 105.02 1.37 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.873 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.914 HD13 ' NE1' ' A' ' 91' ' ' TRP . 25.1 tp -77.77 118.79 20.46 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.899 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.521 ' N ' ' O ' ' A' ' 90' ' ' SER . 92.7 mt -95.88 162.22 13.67 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.905 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.447 ' ND2' ' H ' ' A' ' 88' ' ' ASN . 8.8 m-80 -40.76 101.87 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.878 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.03 -3.94 2.8 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.477 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.845 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -123.73 172.65 8.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.828 0.347 . . . . 0.0 110.885 -179.739 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.914 ' NE1' HD13 ' A' ' 86' ' ' LEU . 18.8 m95 -129.04 160.93 31.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.917 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -91.46 -106.65 1.47 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.52 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . 0.441 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 3.5 m -163.06 174.83 11.75 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.787 0.327 . . . . 0.0 110.902 -179.759 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.468 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 24.7 mt-10 -99.53 121.74 41.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.844 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 25.0 mm-40 -120.97 109.55 15.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.895 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.706 ' HD3' HG22 ' A' ' 82' ' ' VAL . 39.6 mtmt -115.51 117.65 30.95 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.933 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 2.8 tppp? -168.59 107.1 0.47 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.887 179.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.79 HD11 ' O ' ' A' ' 100' ' ' HIS . 8.7 tt -144.39 146.1 20.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.139 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.4 t -83.72 -38.34 21.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.109 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . 0.79 ' O ' HD11 ' A' ' 98' ' ' ILE . 5.2 p-80 -153.71 134.27 13.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.847 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . 0.441 ' C ' ' OD1' ' A' ' 101' ' ' ASN . 27.1 t-20 -107.86 96.92 18.67 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.604 0.716 . . . . 0.0 110.879 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 101' ' ' ASN . 53.8 Cg_endo -69.72 -36.08 11.59 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.674 2.249 . . . . 0.0 112.36 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.483 ' CE2' ' HB3' ' A' ' 74' ' ' PRO . 5.7 m-85 -40.29 110.23 0.14 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.823 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -136.63 139.8 10.93 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.52 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 106.39 1.64 Allowed 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.694 2.263 . . . . 0.0 112.362 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 124.86 -11.47 7.82 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.51 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.9 pt20 -130.14 165.22 22.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.803 0.335 . . . . 0.0 110.925 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.3 p90 -87.48 169.26 12.37 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.889 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.48 ' CZ ' ' CZ ' ' A' ' 56' ' ' PHE . 30.0 p90 -153.63 124.75 7.41 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.898 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -94.34 103.38 15.38 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.843 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.859 HD13 ' N ' ' A' ' 112' ' ' SER . 0.5 OUTLIER -101.61 136.77 40.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.946 -179.965 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.859 ' N ' HD13 ' A' ' 111' ' ' LEU . 6.1 m -144.01 111.59 6.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.84 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.411 HG23 HG22 ' A' ' 122' ' ' VAL . 4.2 mp -93.53 141.72 14.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.103 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.427 ' O ' ' CG ' ' A' ' 120' ' ' PHE . 19.6 mtp180 -112.52 142.07 45.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.917 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . 0.585 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 3.1 t -114.0 109.41 18.42 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.892 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -107.53 -138.76 8.86 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.515 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.5 mt -118.69 -40.56 2.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.811 0.339 . . . . 0.0 110.903 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.427 ' OD1' ' N ' ' A' ' 119' ' ' ARG . 19.8 p-10 -87.73 -34.09 18.49 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.831 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.427 ' N ' ' OD1' ' A' ' 118' ' ' ASP . 10.6 ptp85 -172.57 176.07 3.33 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.922 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.661 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 3.7 m-30 -98.98 166.08 11.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.893 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 26.2 mtpt -137.73 105.92 5.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.916 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.63 HG13 HD11 ' A' ' 111' ' ' LEU . 42.8 t -90.84 132.52 35.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.096 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 53.9 m-85 -122.2 155.97 34.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.916 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.499 ' O ' ' ND2' ' A' ' 125' ' ' ASN . . . -141.15 118.96 11.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.104 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.499 ' ND2' ' O ' ' A' ' 124' ' ' ALA . 10.2 p30 50.87 30.75 5.42 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.894 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 82.88 30.96 30.46 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.475 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 33.3 mm-40 -135.6 139.51 43.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.797 0.332 . . . . 0.0 110.905 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 31.2 t-80 -67.7 112.54 4.86 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.857 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 8.3 tp -84.23 -66.97 0.83 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.894 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.4 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 12.1 p90 -168.63 170.76 9.27 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.906 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -114.01 149.11 35.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.806 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.603 ' CD1' HD13 ' A' ' 70' ' ' LEU . 0.4 OUTLIER -111.6 105.09 13.54 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.906 -179.931 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.487 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -60.45 137.15 58.19 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.105 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 8.2 m-70 -66.35 110.41 3.07 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.861 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.441 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 71.6 mtt-85 -96.72 -46.6 6.22 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.859 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.4 tp -98.54 108.06 20.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.852 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 29.4 t -50.23 -33.64 20.28 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.858 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.453 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.79 29.28 0.46 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.083 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.416 ' CG ' ' N ' ' A' ' 140' ' ' GLN . 33.8 p90 -49.66 -44.35 47.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.869 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' GLN . . . . . 0.416 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 7.8 pt20 -47.81 -39.13 17.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.913 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.453 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 67.3 mtp180 -56.45 -40.83 75.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.85 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.671 ' HA ' HG22 ' A' ' 62' ' ' VAL . 58.7 t -45.68 101.82 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.11 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.492 ' OD2' ' N ' ' A' ' 36' ' ' GLY . 0.7 OUTLIER -127.04 34.28 4.78 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.851 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 24.6 m -147.02 115.55 6.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.148 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.567 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.1 tp -114.69 114.55 25.79 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.908 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' GLU . . . . . 0.428 ' C ' HG13 ' A' ' 147' ' ' ILE . 4.1 pt-20 -114.38 158.12 21.94 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.868 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.428 HG13 ' C ' ' A' ' 146' ' ' GLU . 30.7 mt -142.9 123.14 10.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.119 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -132.21 175.65 9.07 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.912 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 102.49 -151.64 18.24 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.475 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -103.66 92.5 4.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.87 0.367 . . . . 0.0 110.85 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.4 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 7.4 p -150.95 150.15 13.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.165 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 26.7 m -113.57 93.7 4.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.131 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.445 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 66.5 mt -75.5 138.27 41.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.925 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 36.7 m -122.43 -34.91 3.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.878 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 17.3 t80 -150.59 130.69 13.5 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.96 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 94.8 t -140.56 111.89 4.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.123 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 11.9 tt0 -134.05 129.21 35.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.944 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' ILE . . . . . 0.639 HG12 HD23 ' A' ' 33' ' ' LEU . 4.6 mp -90.23 90.58 3.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.17 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 2.8 m -44.7 138.54 3.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.884 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -178.84 -175.3 45.78 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.493 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 134.08 27.12 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.732 2.288 . . . . 0.0 112.306 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 18.0 m -92.84 -45.17 8.12 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.875 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 33.1 t -127.87 110.3 12.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.837 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.317 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.482 179.983 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.531 -0.228 . . . . 0.0 112.531 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 17.3 t -162.06 134.58 5.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.928 0.395 . . . . 0.0 110.866 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.6 t -167.6 135.65 2.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.862 -179.801 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 107.79 115.78 3.97 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.476 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.0 m -145.97 135.57 23.21 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.845 0.355 . . . . 0.0 110.877 -179.75 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 19.3 m -121.64 109.99 15.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.881 -179.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 156.75 133.1 1.58 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.482 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 91.1 m-70 -141.14 160.87 39.18 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.814 0.34 . . . . 0.0 110.862 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 59.1 mm-40 -98.79 151.38 20.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.921 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 7.8 mp0 -108.47 102.55 11.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.918 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.7 mt -141.76 157.47 44.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.893 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 15.1 p-10 -84.61 45.56 1.15 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.903 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 2.8 m -88.55 157.61 18.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.87 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 15.4 mt -42.64 151.59 0.38 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.619 0.723 . . . . 0.0 110.955 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.75 159.44 53.41 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.711 2.274 . . . . 0.0 112.346 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 9.6 t -82.83 139.55 33.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.132 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . 0.493 ' CE ' HD12 ' A' ' 158' ' ' ILE . 23.9 ptt? -91.96 42.67 1.11 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.853 179.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -63.98 157.81 24.06 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.851 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.412 ' HA3' ' HD2' ' A' ' 20' ' ' PRO . . . 111.08 -135.34 12.78 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.509 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.412 ' HD2' ' HA3' ' A' ' 19' ' ' GLY . 54.3 Cg_endo -69.73 166.97 25.77 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.742 2.294 . . . . 0.0 112.339 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 179.11 3.92 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.647 2.232 . . . . 0.0 112.351 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.512 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.6 m -93.18 152.1 19.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.158 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.512 ' CD1' ' O ' ' A' ' 22' ' ' THR . 10.2 m-85 -150.06 132.53 15.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.924 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . 0.565 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 22.1 m-80 50.74 46.58 3.83 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.607 0.718 . . . . 0.0 110.835 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.565 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.78 137.04 34.47 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.668 2.245 . . . . 0.0 112.378 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 179.88 3.38 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.674 2.249 . . . . 0.0 112.351 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.686 HG13 ' HA ' ' A' ' 28' ' ' PRO . 95.2 t -140.21 138.18 18.9 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.643 0.735 . . . . 0.0 111.11 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.686 ' HA ' HG13 ' A' ' 27' ' ' VAL . 54.1 Cg_endo -69.72 144.96 78.02 Favored 'Cis proline' 0 C--N 1.341 0.161 0 C-N-CA 122.658 -1.809 . . . . 0.0 112.353 -0.145 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 8.9 t80 -97.45 121.39 39.3 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.891 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 70.6 m-85 -108.02 101.65 10.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.86 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -116.33 104.61 1.27 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.487 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.401 ' HD2' ' C ' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -72.54 130.48 40.73 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.848 0.356 . . . . 0.0 110.9 -179.893 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.44 ' N ' ' O ' ' A' ' 143' ' ' ASP . 5.0 mt -74.2 147.47 42.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.905 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 55.8 mt-30 -107.81 89.59 3.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.903 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.78 -47.43 0.99 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.503 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.636 ' O ' HG22 ' A' ' 38' ' ' THR . . . 104.94 159.03 23.47 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.484 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . 0.506 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 79.3 mt -53.32 110.73 0.58 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.88 0.372 . . . . 0.0 110.934 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.707 HG23 ' HB2' ' A' ' 41' ' ' ARG . 0.0 OUTLIER -133.8 170.37 15.69 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.112 179.967 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.713 ' HB2' HD21 ' A' ' 117' ' ' LEU . . . -59.29 -41.93 90.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.085 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 6.5 mpt_? -94.5 51.07 1.4 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.862 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.722 ' NH1' HG22 ' A' ' 158' ' ' ILE . 20.4 ttm-85 -138.94 136.6 35.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 91.8 m -139.52 125.16 19.38 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.173 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.4 mp -96.31 138.79 20.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.152 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 90.5 mt -131.57 138.38 53.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.143 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 69.7 mt -135.42 107.56 7.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.152 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.409 ' HE3' ' CD1' ' A' ' 155' ' ' TYR . 8.7 mtmm -108.1 111.64 23.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 179.865 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -144.61 -144.92 4.25 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.495 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . 0.58 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 1.3 t80 -170.65 123.87 0.66 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.853 0.359 . . . . 0.0 110.957 -179.82 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 13.1 t -73.58 115.28 40.07 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.584 0.707 . . . . 0.0 111.152 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 155.48 65.86 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.663 2.242 . . . . 0.0 112.337 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.85 -13.58 34.64 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.679 2.253 . . . . 0.0 112.305 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 32.9 p -111.71 14.51 21.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.114 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -111.02 122.07 6.03 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.51 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.4 mtpt -63.71 -59.81 4.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.809 0.338 . . . . 0.0 110.93 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 14.4 p -172.8 158.33 3.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.826 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.588 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 17.9 p90 -113.76 -172.62 2.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.846 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.901 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -155.68 140.98 17.62 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.098 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.441 HG23 HG12 ' A' ' 147' ' ' ILE . 7.2 mt -127.17 101.18 7.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.122 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . 0.415 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 5.4 m-80 -103.14 154.05 19.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.907 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.624 ' CE2' HD13 ' A' ' 145' ' ' LEU . 6.1 m-85 -122.4 102.01 7.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.857 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.401 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 32.8 ttmt -95.68 168.2 10.82 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.864 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.713 HG22 ' HA ' ' A' ' 142' ' ' VAL . 83.2 t -100.06 120.55 49.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.127 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -57.54 -30.25 61.85 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.479 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.484 ' H ' HG12 ' A' ' 62' ' ' VAL . 2.1 m -72.84 -75.3 0.14 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.863 0.363 . . . . 0.0 110.882 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.3 t -79.33 -70.85 0.48 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.867 -179.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 131.18 40.51 0.23 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.486 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.402 ' OD1' ' OD1' ' A' ' 88' ' ' ASN . 0.5 OUTLIER -109.38 147.95 31.91 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.758 0.314 . . . . 0.0 110.854 -179.981 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.427 HD12 ' HB3' ' A' ' 86' ' ' LEU . 53.4 mt -94.35 113.7 29.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.153 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.634 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -86.02 -32.15 21.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.117 179.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.589 HD22 ' CD2' ' A' ' 132' ' ' PHE . 43.3 tp -138.83 131.09 28.4 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.487 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.8 OUTLIER -134.42 95.38 3.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.867 179.855 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.566 HD11 HD21 ' A' ' 70' ' ' LEU . 32.1 mt -100.05 131.53 47.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.133 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.901 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -141.17 107.58 6.21 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.644 0.735 . . . . 0.0 110.874 179.933 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.588 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.9 Cg_endo -69.78 155.23 66.38 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.651 2.234 . . . . 0.0 112.333 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 80.0 mtp180 -132.15 100.01 4.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.87 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . 0.453 ' HE3' ' HB3' ' A' ' 103' ' ' PHE . 0.1 OUTLIER -68.38 -40.36 81.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.905 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -45.33 -66.09 1.66 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.498 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.2 t30 -89.3 -54.09 4.26 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.905 0.383 . . . . 0.0 110.903 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 118.77 47.23 0.41 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.47 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 18.7 p -141.45 124.48 16.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.823 0.344 . . . . 0.0 111.135 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.497 HG21 ' HE2' ' A' ' 103' ' ' PHE . 18.4 t -94.39 109.72 22.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.184 179.859 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.593 HG22 ' HD3' ' A' ' 96' ' ' LYS . 41.5 t -81.88 145.25 8.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.137 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -126.45 123.92 38.96 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.888 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.487 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.7 OUTLIER -135.97 178.82 6.75 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.882 -179.935 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 50.7 p -160.07 106.29 1.58 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.855 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.904 HD13 ' NE1' ' A' ' 91' ' ' TRP . 24.4 tp -77.38 115.78 17.43 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.904 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.494 HD22 HD13 ' A' ' 136' ' ' LEU . 24.0 mt -91.55 161.09 15.09 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.886 179.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.402 ' OD1' ' OD1' ' A' ' 67' ' ' ASP . 12.3 m-80 -41.58 101.56 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.913 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 67.43 -3.56 4.53 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.46 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.858 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -124.26 172.25 9.23 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.836 0.351 . . . . 0.0 110.851 -179.709 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.904 ' NE1' HD13 ' A' ' 86' ' ' LEU . 21.0 m95 -129.43 158.63 38.66 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.908 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -89.22 -106.59 1.12 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.445 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 3.7 m -163.6 176.29 9.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.791 0.329 . . . . 0.0 110.887 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.455 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 16.1 mt-10 -99.04 119.65 38.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.908 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -119.23 116.4 26.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.883 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.593 ' HD3' HG22 ' A' ' 82' ' ' VAL . 39.8 mtmt -121.89 119.28 31.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.902 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 27.7 tttp -167.26 108.03 0.62 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.889 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.554 HD11 ' O ' ' A' ' 100' ' ' HIS . 7.2 tt -149.4 147.21 16.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.165 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.543 HG23 ' N ' ' A' ' 100' ' ' HIS . 12.6 t -89.32 -47.47 8.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.134 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . 0.554 ' O ' HD11 ' A' ' 98' ' ' ILE . 4.2 p-80 -138.41 125.24 21.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.845 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -103.3 95.91 7.62 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.613 0.72 . . . . 0.0 110.898 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.82 -34.38 14.49 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.672 2.248 . . . . 0.0 112.303 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.497 ' HE2' HG21 ' A' ' 81' ' ' VAL . 19.0 m-85 -39.33 99.6 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.857 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -129.81 136.3 8.86 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.498 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 99.84 0.78 Allowed 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.658 2.239 . . . . 0.0 112.348 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 130.33 -8.38 5.95 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.48 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 -131.37 162.11 30.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.882 0.372 . . . . 0.0 110.896 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' PHE . . . . . 0.58 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 17.2 m-85 -80.27 172.1 14.2 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.858 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.483 ' O ' ' CD1' ' A' ' 109' ' ' PHE . 19.8 p90 -161.17 119.62 2.45 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.9 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -93.86 101.74 13.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.843 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.875 HD13 ' N ' ' A' ' 112' ' ' SER . 0.5 OUTLIER -101.2 136.75 40.53 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.909 -179.942 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.875 ' N ' HD13 ' A' ' 111' ' ' LEU . 10.4 m -141.6 112.88 7.5 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.882 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.608 HG22 ' HD2' ' A' ' 120' ' ' PHE . 4.1 mp -96.91 115.91 37.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.171 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 21.2 mtp85 -89.75 141.32 28.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.896 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . 0.573 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 13.6 t -113.41 115.25 27.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -111.76 -141.83 8.59 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.473 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.713 HD21 ' HB2' ' A' ' 39' ' ' ALA . 7.4 mt -115.2 -33.38 5.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.804 0.335 . . . . 0.0 110.922 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.582 ' O ' ' CD2' ' A' ' 134' ' ' HIS . 6.3 m-20 -89.53 -42.27 11.54 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.904 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -166.22 -176.34 3.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.893 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.608 ' HD2' HG22 ' A' ' 113' ' ' ILE . 12.0 m-85 -102.44 156.2 17.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.897 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 23.2 mtpt -130.1 105.92 8.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.865 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.715 HG13 HD11 ' A' ' 111' ' ' LEU . 46.8 t -91.3 131.73 37.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.109 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 79.5 m-85 -122.26 149.98 42.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.933 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.442 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -134.59 108.28 7.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.094 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 56.93 35.27 26.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.871 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.09 38.31 15.79 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.483 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 7.3 mt-30 -146.18 126.63 14.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.81 0.338 . . . . 0.0 110.924 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 -60.27 102.25 0.16 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.874 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.442 HD13 ' CB ' ' A' ' 124' ' ' ALA . 7.2 tp -70.19 -66.5 0.59 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.932 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.44 ' CD1' ' C ' ' A' ' 130' ' ' PHE . 7.0 p90 -162.16 172.13 16.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.864 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 21.0 p-10 -118.1 145.79 44.6 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.847 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.589 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -112.92 107.02 15.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.833 -179.893 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.587 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -62.97 134.31 55.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.087 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' HIS . . . . . 0.582 ' CD2' ' O ' ' A' ' 118' ' ' ASP . 10.0 m-70 -60.54 101.68 0.15 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.883 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 12.3 mtt-85 -88.11 -45.97 9.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.875 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . 0.494 HD13 HD22 ' A' ' 87' ' ' LEU . 10.0 tp -98.4 108.08 20.69 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.937 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 28.6 p -51.8 -31.23 26.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.858 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.651 ' HB1' ' HG3' ' A' ' 141' ' ' ARG . . . -82.71 29.08 0.46 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.08 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -49.59 -35.19 19.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.899 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' GLN . . . . . 0.443 ' HG2' ' N ' ' A' ' 141' ' ' ARG . 18.4 pm0 -60.17 -28.92 68.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.964 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.651 ' HG3' ' HB1' ' A' ' 138' ' ' ALA . 52.9 mtp85 -65.27 -38.86 91.57 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.887 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.713 ' HA ' HG22 ' A' ' 62' ' ' VAL . 52.4 t -55.15 108.97 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.113 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.44 ' O ' ' N ' ' A' ' 33' ' ' LEU . 3.4 p30 -129.52 27.91 5.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.839 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -135.82 135.57 39.95 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.174 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.624 HD13 ' CE2' ' A' ' 60' ' ' PHE . 7.5 tp -131.13 103.9 6.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.9 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' GLU . . . . . 0.428 ' C ' HG13 ' A' ' 147' ' ' ILE . 2.6 pt-20 -106.51 151.22 25.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.874 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.441 HG12 HG23 ' A' ' 58' ' ' ILE . 15.7 mt -140.17 109.57 3.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.116 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -120.41 170.93 8.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.916 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 109.85 -150.68 17.42 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.517 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -107.5 91.36 3.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.886 0.374 . . . . 0.0 110.902 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.447 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 3.3 p -150.91 137.62 12.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.123 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 24.7 m -96.96 93.65 6.74 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.119 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.481 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 61.3 mt -77.98 132.76 37.98 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.898 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 53.5 m -119.13 -40.86 2.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.894 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . 0.409 ' CD1' ' HE3' ' A' ' 46' ' ' LYS . 36.4 t80 -141.74 129.53 21.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.948 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 75.3 t -140.77 105.65 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.159 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 19.3 tt0 -120.26 132.03 55.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.92 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' ILE . . . . . 0.722 HG22 ' NH1' ' A' ' 41' ' ' ARG . 12.8 mt -102.9 88.23 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.161 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . 0.407 ' O ' ' NH1' ' A' ' 41' ' ' ARG . 28.8 t -52.19 147.21 7.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.873 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -178.29 -177.98 47.39 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.513 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 143.15 49.91 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.682 2.255 . . . . 0.0 112.387 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 1.2 t -68.85 117.78 10.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.878 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 39.8 m -90.69 132.34 35.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.874 -179.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.46 179.989 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 N-CA-C 112.478 -0.249 . . . . 0.0 112.478 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 32.3 p -130.58 84.35 2.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.871 0.367 . . . . 0.0 110.909 -179.77 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 89.5 p -140.42 134.89 31.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.867 -179.804 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 137.13 131.86 3.0 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.491 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 33.2 t -165.03 131.52 2.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.923 0.392 . . . . 0.0 110.821 -179.731 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 21.5 m -43.8 -47.28 8.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.839 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -118.15 92.42 0.54 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.53 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 9.2 t60 -71.65 130.26 40.73 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.78 0.324 . . . . 0.0 110.871 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 75.3 mt-30 -146.11 111.96 5.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.883 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 17.7 tm0? -68.74 82.88 0.29 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.878 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 86.3 mt -129.37 80.68 1.98 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.897 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -162.78 121.62 2.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.88 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 64.2 m -124.55 155.34 39.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.884 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 20.0 mt -44.83 149.93 0.77 Allowed Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.577 0.703 . . . . 0.0 110.904 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 -178.58 2.41 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.701 2.268 . . . . 0.0 112.331 179.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 11.7 t -83.71 146.39 28.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.099 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . 0.549 ' CE ' HD12 ' A' ' 158' ' ' ILE . 4.4 ptp -95.55 30.87 2.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.895 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -49.98 -178.54 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.907 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.416 ' HA3' ' HD2' ' A' ' 20' ' ' PRO . . . 81.49 -145.32 25.09 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.513 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.416 ' HD2' ' HA3' ' A' ' 19' ' ' GLY . 54.0 Cg_endo -69.73 168.82 20.43 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.693 2.262 . . . . 0.0 112.336 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 -166.36 0.18 Allowed 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.678 2.252 . . . . 0.0 112.348 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.55 ' CG2' ' N ' ' A' ' 23' ' ' PHE . 1.8 m -100.95 160.84 14.03 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.126 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.55 ' N ' ' CG2' ' A' ' 22' ' ' THR . 14.3 m-85 -154.52 136.18 14.37 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . 0.514 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 10.4 m-20 41.21 49.76 3.74 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.61 0.719 . . . . 0.0 110.858 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.514 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.8 Cg_endo -69.74 140.9 43.87 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.678 2.252 . . . . 0.0 112.341 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 178.4 4.61 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.663 2.242 . . . . 0.0 112.375 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.67 HG13 ' HA ' ' A' ' 28' ' ' PRO . 89.5 t -140.18 137.82 18.49 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.657 0.741 . . . . 0.0 111.123 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.67 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.4 Cg_endo -69.74 144.34 76.35 Favored 'Cis proline' 0 C--O 1.231 0.173 0 C-N-CA 122.7 -1.792 . . . . 0.0 112.345 -0.055 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 9.2 t80 -96.75 118.9 34.21 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.931 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 65.3 m-85 -104.8 101.12 10.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.888 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -112.83 102.05 1.26 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.456 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.419 ' O ' ' HG3' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -72.63 121.6 20.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.852 0.358 . . . . 0.0 110.923 -179.897 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.482 ' N ' ' O ' ' A' ' 143' ' ' ASP . 13.9 mt -65.71 149.62 49.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.914 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.401 HE21 ' NH1' ' A' ' 32' ' ' ARG . 10.4 mm-40 -110.68 82.06 1.53 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.919 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.447 ' C ' ' OD2' ' A' ' 143' ' ' ASP . . . 140.49 -46.87 0.9 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.504 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.754 ' O ' HG23 ' A' ' 38' ' ' THR . . . 109.54 166.55 20.14 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.505 -179.882 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . 0.501 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 49.8 mt -57.3 105.16 0.21 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.96 0.41 . . . . 0.0 110.891 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.754 HG23 ' O ' ' A' ' 36' ' ' GLY . 2.1 p -116.76 151.81 35.67 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.148 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -58.07 -18.21 23.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.117 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 7.3 mpt_? -109.93 27.53 9.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.899 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.718 ' NH2' HD11 ' A' ' 43' ' ' ILE . 20.8 ttp85 -113.66 141.5 47.15 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.857 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 97.9 m -139.56 121.35 15.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.111 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.718 HD11 ' NH2' ' A' ' 41' ' ' ARG . 5.0 mp -90.95 143.64 10.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.125 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 89.3 mt -136.22 129.21 46.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.149 179.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 60.6 mt -130.05 107.74 15.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.152 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.506 ' HE3' ' CD1' ' A' ' 155' ' ' TYR . 18.5 mtmt -110.36 111.8 23.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.904 179.856 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -147.14 -145.54 4.21 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.505 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -166.81 126.14 1.47 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.884 0.374 . . . . 0.0 110.913 -179.815 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 24.6 t -74.82 117.02 59.3 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.643 0.735 . . . . 0.0 111.114 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 156.23 63.82 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.698 2.266 . . . . 0.0 112.331 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -15.44 37.1 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.657 2.238 . . . . 0.0 112.359 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 26.4 p -110.36 14.64 22.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.154 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -109.25 120.44 5.81 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.493 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 30.1 mtpt -61.65 -60.97 2.88 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.775 0.321 . . . . 0.0 110.914 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 9.2 p -174.19 156.51 2.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.823 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.616 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 11.1 p90 -111.0 -174.46 2.48 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.83 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.961 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -155.42 141.15 18.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.096 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.508 HD11 ' CE2' ' A' ' 56' ' ' PHE . 3.6 mp -121.24 100.08 8.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.136 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -102.56 148.08 25.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.887 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.924 ' CE2' HD13 ' A' ' 145' ' ' LEU . 34.7 m-85 -119.99 102.9 8.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.894 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.404 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 33.6 ttmt -95.62 166.95 11.59 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.91 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.741 HG22 ' HA ' ' A' ' 142' ' ' VAL . 91.4 t -98.2 125.54 51.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.166 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -61.26 -35.7 91.31 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.511 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.9 m -67.68 -73.27 0.14 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.896 0.379 . . . . 0.0 110.817 -179.708 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 32.3 t -80.37 -71.49 0.46 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.867 -179.794 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 130.7 41.69 0.22 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.464 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -112.58 146.37 38.69 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.782 0.325 . . . . 0.0 110.848 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.514 HD12 ' HB3' ' A' ' 86' ' ' LEU . 50.7 mt -91.65 121.23 41.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.135 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.505 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -91.3 -36.97 13.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.114 179.828 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.637 HD21 HD11 ' A' ' 72' ' ' ILE . 32.1 tp -134.87 130.4 35.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.919 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.487 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.3 OUTLIER -134.76 92.97 2.96 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.84 179.855 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.637 HD11 HD21 ' A' ' 70' ' ' LEU . 20.6 mt -96.69 134.08 35.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.17 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.961 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -140.93 107.42 6.32 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.591 0.71 . . . . 0.0 110.885 179.969 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.616 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.6 Cg_endo -69.76 155.05 66.93 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.679 2.253 . . . . 0.0 112.337 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 66.4 mtp85 -129.24 99.31 5.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.876 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -55.9 144.16 29.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.893 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 114.49 -88.33 0.47 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.493 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -75.52 -48.45 22.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.883 0.373 . . . . 0.0 110.866 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.482 ' HA2' ' ND2' ' A' ' 101' ' ' ASN . . . 112.14 47.14 0.72 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.495 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 32.9 p -115.92 119.16 35.04 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.799 0.333 . . . . 0.0 111.118 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.447 ' CG1' ' CG2' ' A' ' 72' ' ' ILE . 20.6 t -106.42 106.03 19.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.126 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.619 HG22 ' HD3' ' A' ' 96' ' ' LYS . 39.2 t -76.38 134.29 29.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.133 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . 0.415 ' NH1' ' O ' ' A' ' 95' ' ' GLU . 0.0 OUTLIER -120.57 123.52 43.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.881 -179.955 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.487 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.2 OUTLIER -134.25 -179.11 5.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.898 -179.934 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 93.5 p -160.57 105.54 1.44 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.839 -179.871 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.942 HD12 ' O ' ' A' ' 90' ' ' SER . 26.1 tp -77.26 117.04 18.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.921 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.503 HD22 HD13 ' A' ' 136' ' ' LEU . 68.5 mt -93.97 160.9 14.52 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.887 179.897 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.543 HD22 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.72 101.35 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.87 179.913 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.93 -6.97 1.27 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.492 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.942 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -119.14 172.22 7.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.877 0.37 . . . . 0.0 110.832 -179.726 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.833 ' NE1' HD13 ' A' ' 86' ' ' LEU . 24.1 m95 -129.05 160.89 31.34 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.908 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -90.84 -93.94 1.26 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.513 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . 0.408 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 2.4 m -174.49 169.46 3.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.841 0.353 . . . . 0.0 110.883 -179.727 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.411 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 27.3 mt-10 -100.84 118.4 36.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.895 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . 0.415 ' O ' ' NH1' ' A' ' 83' ' ' ARG . 5.3 mm-40 -123.19 134.81 54.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.881 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.619 ' HD3' HG22 ' A' ' 82' ' ' VAL . 40.9 mtmt -132.19 116.95 17.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.905 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 17.9 ttpp -164.48 110.4 1.01 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.934 179.862 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.688 HD11 ' O ' ' A' ' 100' ' ' HIS . 4.4 tt -148.72 153.04 11.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.134 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.554 HG23 ' N ' ' A' ' 100' ' ' HIS . 9.0 t -89.64 -48.52 7.23 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.118 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . 0.688 ' O ' HD11 ' A' ' 98' ' ' ILE . 6.1 p-80 -141.24 125.41 17.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.858 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . 0.482 ' ND2' ' HA2' ' A' ' 79' ' ' GLY . 17.7 t-20 -104.46 96.83 10.79 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.633 0.73 . . . . 0.0 110.882 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 -30.46 22.07 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.725 2.283 . . . . 0.0 112.303 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.444 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 21.8 m-85 -43.94 104.64 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.887 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -132.65 135.86 8.38 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.489 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 97.79 0.66 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.69 2.26 . . . . 0.0 112.322 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 129.94 -3.67 6.03 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.524 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.2 pm0 -135.9 155.92 49.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.839 0.352 . . . . 0.0 110.908 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -77.85 171.16 15.4 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.887 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 29.8 p90 -160.03 133.21 6.81 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.897 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -103.1 103.79 13.89 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.874 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.886 HD13 ' N ' ' A' ' 112' ' ' SER . 0.6 OUTLIER -104.3 137.7 41.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.887 -179.919 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.886 ' N ' HD13 ' A' ' 111' ' ' LEU . 3.6 m -145.16 111.87 5.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.842 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.589 HG23 HG22 ' A' ' 122' ' ' VAL . 4.0 mp -92.99 140.38 16.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.165 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 18.9 mtp180 -113.24 137.67 51.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.86 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . 0.568 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 3.4 t -108.87 117.29 33.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -119.35 -140.97 6.35 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.464 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.5 mt -118.66 -36.09 3.56 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.844 0.354 . . . . 0.0 110.916 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 17.4 m-20 -87.2 -38.39 16.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.862 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 16.2 ptp180 -175.31 169.28 3.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.838 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.568 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.6 m-30 -92.02 147.71 22.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 24.9 mtpp -120.75 102.19 8.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.921 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.616 HG13 HD11 ' A' ' 111' ' ' LEU . 55.7 t -88.82 132.22 34.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.106 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 62.3 m-85 -118.9 156.66 29.13 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.947 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.416 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -142.21 109.45 5.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.097 179.834 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 56.3 28.78 13.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.888 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 85.67 30.52 23.8 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.466 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . 0.422 ' HB2' ' CE1' ' A' ' 100' ' ' HIS . 56.1 mm-40 -137.91 121.51 17.36 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.791 0.329 . . . . 0.0 110.949 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 29.1 t-80 -50.69 105.14 0.09 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.849 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.439 HD22 ' CD2' ' A' ' 111' ' ' LEU . 10.8 tp -72.84 -69.1 0.43 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.547 ' HZ ' HD13 ' A' ' 72' ' ' ILE . 4.2 p90 -165.62 170.76 13.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.874 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 61.9 m-20 -114.96 148.76 38.32 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.876 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.574 ' CE1' ' O ' ' A' ' 133' ' ' ALA . 0.1 OUTLIER -115.01 107.88 15.95 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.88 -179.868 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.574 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -64.0 131.1 46.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.117 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 46.2 m-70 -56.62 100.58 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.847 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.408 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 17.6 mtt-85 -83.9 -51.45 7.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.865 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . 0.503 HD13 HD22 ' A' ' 87' ' ' LEU . 14.2 tp -93.27 108.01 19.72 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.908 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 4.3 p -51.4 -30.26 18.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.829 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.579 ' HB1' ' HG3' ' A' ' 141' ' ' ARG . . . -87.28 24.23 1.66 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.114 179.9 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.5 ' O ' HD12 ' A' ' 37' ' ' LEU . 26.8 p90 -43.58 -44.67 6.31 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.911 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' GLN . . . . . 0.426 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 5.3 pt20 -44.7 -42.23 7.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.905 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.579 ' HG3' ' HB1' ' A' ' 138' ' ' ALA . 21.5 mtt180 -52.07 -42.4 63.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.895 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.741 ' HA ' HG22 ' A' ' 62' ' ' VAL . 99.4 t -46.96 108.89 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.12 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.482 ' O ' ' N ' ' A' ' 33' ' ' LEU . 1.0 OUTLIER -129.8 20.43 5.52 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.902 179.903 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 2.1 m -133.06 138.1 46.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.141 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.924 HD13 ' CE2' ' A' ' 60' ' ' PHE . 7.2 tp -132.41 116.08 16.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.949 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -118.59 151.8 37.23 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.838 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.457 HG12 HG23 ' A' ' 58' ' ' ILE . 24.8 mt -138.66 110.34 5.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.08 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 1.1 pm0 -120.17 171.99 8.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.888 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 111.28 -147.51 17.86 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.544 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -112.96 92.72 4.11 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.851 0.357 . . . . 0.0 110.858 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 4.3 p -151.02 141.9 16.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.145 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 17.1 m -101.31 92.91 5.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.175 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.459 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 80.5 mt -76.03 139.85 41.66 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.913 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 58.1 m -125.01 -33.76 2.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.836 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . 0.506 ' CD1' ' HE3' ' A' ' 46' ' ' LYS . 36.3 t80 -150.46 130.97 13.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.917 -179.855 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 56.0 t -138.92 105.41 2.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.149 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . 0.412 ' HB2' ' CE1' ' A' ' 155' ' ' TYR . 13.2 tt0 -114.17 120.67 41.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.92 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' ILE . . . . . 0.549 HD12 ' CE ' ' A' ' 17' ' ' MET . 83.1 mt -95.25 89.28 2.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.159 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 28.7 t -71.87 139.29 48.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.843 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 157.76 154.13 6.99 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.484 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 129.92 18.45 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.708 2.272 . . . . 0.0 112.316 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 40.1 p -132.4 103.62 6.29 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.883 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 90.2 p -160.14 175.3 13.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.902 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.502 -179.954 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 112.476 -0.25 . . . . 0.0 112.476 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.6 t -133.12 86.0 2.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.879 0.371 . . . . 0.0 110.842 -179.694 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 60.2 p -136.92 167.92 20.55 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.841 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -105.08 -145.15 13.38 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.498 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 73.1 m -120.85 176.25 5.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.836 0.35 . . . . 0.0 110.86 -179.751 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 36.4 m -133.25 169.32 17.07 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.846 -179.799 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -152.56 72.31 0.28 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.692 -0.765 . . . . 0.0 112.488 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 6.7 p80 -121.77 137.41 54.78 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.72 0.295 . . . . 0.0 110.87 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -87.27 153.76 21.22 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.901 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 9.6 mm100 -116.07 156.59 26.11 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.935 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.7 mt -98.23 146.88 25.18 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.878 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 23.7 t30 -100.09 88.69 3.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.864 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 5.1 m -166.74 168.98 13.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.891 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 65.2 mt -49.8 154.03 1.94 Allowed Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.585 0.707 . . . . 0.0 110.923 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 -166.11 0.17 Allowed 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.712 2.274 . . . . 0.0 112.343 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.405 ' CG2' ' N ' ' A' ' 17' ' ' MET . 1.3 m -88.21 152.0 22.28 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.183 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . 0.482 ' O ' ' NE2' ' A' ' 34' ' ' GLN . 56.7 mtm -96.06 89.49 5.2 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.898 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 17.9 pt-20 -110.05 160.51 16.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.898 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.63 -140.26 14.94 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.465 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 170.22 17.03 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.659 2.24 . . . . 0.0 112.346 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.74 -169.64 0.34 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.681 2.254 . . . . 0.0 112.396 179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.485 ' O ' ' CD1' ' A' ' 23' ' ' PHE . 1.5 m -103.49 153.38 20.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.174 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.485 ' CD1' ' O ' ' A' ' 22' ' ' THR . 9.3 m-85 -149.83 135.68 18.6 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.896 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . 0.558 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 4.1 t-20 46.1 47.25 3.95 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.625 0.726 . . . . 0.0 110.886 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.558 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.5 Cg_endo -69.78 138.69 38.35 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.669 2.246 . . . . 0.0 112.332 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -174.65 0.95 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.664 2.243 . . . . 0.0 112.344 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.684 HG13 ' HA ' ' A' ' 28' ' ' PRO . 93.5 t -142.45 138.25 16.24 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.62 0.724 . . . . 0.0 111.102 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.684 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.79 144.76 77.63 Favored 'Cis proline' 0 C--N 1.342 0.197 0 C-N-CA 122.642 -1.816 . . . . 0.0 112.354 -0.078 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -97.55 120.69 38.38 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.918 -179.886 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 86.3 m-85 -102.42 104.94 15.44 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.901 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -104.24 107.52 2.97 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.463 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 6.6 mmt180 -73.71 115.86 13.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.833 0.349 . . . . 0.0 110.903 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.485 HD22 ' NH1' ' A' ' 41' ' ' ARG . 5.0 mt -82.0 111.51 18.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.902 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.482 ' NE2' ' O ' ' A' ' 17' ' ' MET . 37.6 mt-30 -78.71 97.14 5.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.88 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 131.1 -51.22 0.86 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.515 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.529 ' O ' HG23 ' A' ' 38' ' ' THR . . . 107.96 168.39 21.51 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.496 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . 0.596 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 68.4 mt -55.1 110.88 0.74 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.886 0.374 . . . . 0.0 110.902 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.529 HG23 ' O ' ' A' ' 36' ' ' GLY . 81.6 p -128.69 146.37 50.9 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.181 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -51.67 -18.33 1.16 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.085 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 2.8 mpt_? -107.73 30.53 6.23 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.868 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.486 ' HE ' HD23 ' A' ' 37' ' ' LEU . 6.9 ttp85 -115.85 142.2 47.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.904 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 29.5 m -138.64 120.72 15.66 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.151 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.456 HD11 ' NH2' ' A' ' 41' ' ' ARG . 5.3 mp -94.39 134.21 32.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.135 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 76.7 mt -129.8 119.59 47.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.098 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 31.6 mt -119.11 107.36 21.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.159 179.822 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.43 ' HE3' ' CD1' ' A' ' 155' ' ' TYR . 16.5 mtmt -108.89 110.18 21.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.9 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -144.86 -147.94 4.74 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.473 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . 0.571 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.7 OUTLIER -163.57 127.88 2.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.934 0.397 . . . . 0.0 110.955 -179.789 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.411 HG23 ' CD2' ' A' ' 109' ' ' PHE . 13.4 t -77.6 117.38 65.21 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 121.585 0.707 . . . . 0.0 111.14 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 154.91 67.1 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.7 2.266 . . . . 0.0 112.348 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -13.92 35.36 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.648 2.232 . . . . 0.0 112.353 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 70.6 p -112.64 16.78 19.58 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.163 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -110.09 123.24 6.63 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.497 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.402 ' O ' ' SD ' ' A' ' 76' ' ' MET . 19.2 mtpt -64.75 -61.72 2.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.801 0.334 . . . . 0.0 110.896 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 14.8 p -172.97 156.57 3.35 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.849 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.599 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 20.4 p90 -111.05 -174.57 2.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.874 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.582 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -156.82 135.37 11.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.126 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.484 HG22 ' CE1' ' A' ' 60' ' ' PHE . 5.3 mp -117.59 98.16 6.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.114 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -96.85 143.72 27.48 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.894 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.711 ' CE2' HD13 ' A' ' 145' ' ' LEU . 47.0 m-85 -115.24 97.62 6.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.906 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.433 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 31.3 ttmt -96.08 168.94 10.31 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.894 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.6 HG22 ' HA ' ' A' ' 142' ' ' VAL . 23.4 t -100.27 123.7 53.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.094 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -59.64 -29.17 66.46 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.506 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.52 ' H ' HG12 ' A' ' 62' ' ' VAL . 11.5 t -75.18 -73.71 0.24 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.849 0.357 . . . . 0.0 110.854 -179.729 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 5.3 t -77.53 -71.47 0.41 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.811 -179.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 128.65 39.7 0.32 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.492 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.44 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.1 m-20 -112.81 139.15 48.67 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.801 0.334 . . . . 0.0 110.879 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.613 HD12 ' HB3' ' A' ' 86' ' ' LEU . 60.3 mt -84.7 120.65 35.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.145 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.451 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -90.16 -30.66 17.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.129 179.795 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.698 HD22 ' CD2' ' A' ' 132' ' ' PHE . 41.3 tp -143.11 132.34 23.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.921 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.494 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.7 OUTLIER -134.93 92.61 2.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.919 179.838 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.524 HD11 HD21 ' A' ' 70' ' ' LEU . 53.2 mt -94.85 132.7 38.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.107 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.582 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -139.12 105.66 7.29 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.661 0.743 . . . . 0.0 110.908 179.929 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.599 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.7 Cg_endo -69.74 154.84 67.34 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.72 2.28 . . . . 0.0 112.372 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 73.9 mtp85 -129.27 94.26 3.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.865 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . 0.402 ' SD ' ' O ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -53.92 153.51 4.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.887 179.991 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 88.85 -87.46 1.49 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.476 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 57.1 t30 -52.9 -65.66 0.52 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.853 0.359 . . . . 0.0 110.908 -179.869 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 114.76 50.32 0.48 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.511 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 21.1 p -137.18 118.01 14.14 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.845 0.355 . . . . 0.0 111.161 -179.842 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.418 HG22 ' HA ' ' A' ' 74' ' ' PRO . 21.4 t -102.79 107.29 21.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.128 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.542 HG22 ' HD3' ' A' ' 96' ' ' LYS . 99.9 t -76.15 144.36 11.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.087 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -126.19 124.65 40.94 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.887 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.494 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.8 OUTLIER -135.71 178.56 6.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.951 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 19.1 t -160.38 105.05 1.46 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 -179.837 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.916 HD12 ' O ' ' A' ' 90' ' ' SER . 25.4 tp -76.97 118.01 19.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.935 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.513 ' N ' ' O ' ' A' ' 90' ' ' SER . 69.9 mt -95.62 161.6 13.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.884 179.92 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.548 HD22 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.34 101.42 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.907 179.849 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.79 -6.58 0.87 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.441 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.916 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -118.42 170.57 8.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.874 0.369 . . . . 0.0 110.832 -179.727 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.857 ' NE1' HD13 ' A' ' 86' ' ' LEU . 23.7 m95 -128.82 161.05 30.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.929 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.31 -106.45 1.61 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.471 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 67.5 m -164.09 176.05 9.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.809 0.338 . . . . 0.0 110.915 -179.754 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -98.63 123.11 42.63 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.909 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 7.6 mm-40 -122.54 118.11 27.48 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.854 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.542 ' HD3' HG22 ' A' ' 82' ' ' VAL . 9.5 mtmp? -121.23 123.05 41.28 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.903 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 15.0 tptm -172.76 105.04 0.15 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.889 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.665 HD11 ' O ' ' A' ' 100' ' ' HIS . 7.5 tt -147.66 151.32 13.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.152 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.585 HG23 ' N ' ' A' ' 100' ' ' HIS . 8.8 t -86.49 -50.54 6.79 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.149 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . 0.665 ' O ' HD11 ' A' ' 98' ' ' ILE . 5.3 p-80 -141.75 135.67 29.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.843 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . 0.407 ' OD1' ' C ' ' A' ' 101' ' ' ASN . 6.9 t-20 -104.73 95.97 9.72 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.647 0.737 . . . . 0.0 110.918 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.464 ' HG3' ' HB1' ' A' ' 124' ' ' ALA . 53.8 Cg_endo -69.74 -31.18 21.12 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.692 2.261 . . . . 0.0 112.39 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.515 ' CZ ' HD21 ' A' ' 129' ' ' LEU . 6.7 m-85 -47.12 113.93 0.76 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.874 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -140.59 138.11 8.75 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.489 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.73 102.69 1.05 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.653 2.235 . . . . 0.0 112.336 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 122.86 -6.49 9.56 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.488 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -130.67 147.11 52.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.857 0.361 . . . . 0.0 110.855 -179.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' PHE . . . . . 0.571 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 54.5 m-85 -66.5 172.03 4.46 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.888 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.411 ' CD2' HG23 ' A' ' 49' ' ' VAL . 22.5 p90 -160.65 128.38 4.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.856 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -103.45 105.39 15.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.813 HD13 ' N ' ' A' ' 112' ' ' SER . 0.9 OUTLIER -107.32 137.97 44.38 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.946 -179.962 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.813 ' N ' HD13 ' A' ' 111' ' ' LEU . 2.9 m -145.09 112.93 6.35 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.87 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.2 mp -94.29 134.64 31.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.113 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 57.1 mtt180 -109.14 123.19 48.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.853 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . 0.577 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 33.8 t -90.53 123.22 34.02 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -124.72 -153.76 8.65 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.501 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 7.8 mt -109.81 -37.96 5.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.804 0.335 . . . . 0.0 110.913 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -86.1 -37.73 18.52 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.853 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 22.8 ptt180 -174.75 168.56 3.64 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.894 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.596 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 2.9 m-30 -91.81 153.28 19.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.913 -179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 18.9 mtmt -127.29 106.41 9.21 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.897 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.668 HG13 HD11 ' A' ' 111' ' ' LEU . 45.9 t -90.41 137.69 21.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.166 179.844 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' TYR . . . . . 0.421 ' O ' HD22 ' A' ' 111' ' ' LEU . 40.4 m-85 -121.37 147.28 45.91 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.913 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.545 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -137.68 105.52 5.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.126 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 62.09 34.08 16.63 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.84 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.403 ' C ' ' HG2' ' A' ' 127' ' ' GLN . . . 79.62 38.94 19.23 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.467 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . 0.403 ' HG2' ' C ' ' A' ' 126' ' ' GLY . 15.4 mm-40 -148.32 132.25 17.14 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.807 0.337 . . . . 0.0 110.892 -179.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 26.9 t-80 -61.58 101.05 0.16 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.828 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.545 HD13 ' CB ' ' A' ' 124' ' ' ALA . 9.8 tp -66.31 -69.85 0.28 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.877 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.434 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 7.3 p90 -161.87 174.66 12.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.874 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -114.96 150.73 35.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.868 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.698 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -117.53 104.62 11.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.896 -179.912 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.581 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -59.91 134.68 57.27 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.106 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 63.1 m-70 -61.99 112.89 2.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.889 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 83.1 mtt-85 -96.36 -52.48 3.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.834 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 9.4 tp -93.57 108.22 19.96 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.921 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 94.3 p -50.69 -32.25 18.81 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.896 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.465 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -83.79 23.56 0.98 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.135 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.525 ' O ' HD12 ' A' ' 37' ' ' LEU . 14.2 p90 -47.06 -38.99 12.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.883 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 10.0 pt20 -53.52 -34.01 56.62 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.938 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.465 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 51.9 mtp85 -63.47 -37.69 88.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.849 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.6 ' HA ' HG22 ' A' ' 62' ' ' VAL . 92.7 t -46.9 109.36 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.156 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -132.3 31.39 4.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.86 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 8.6 m -141.45 111.98 7.02 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.118 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.711 HD13 ' CE2' ' A' ' 60' ' ' PHE . 3.9 tp -110.51 109.79 20.27 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.945 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' GLU . . . . . 0.428 ' C ' HG13 ' A' ' 147' ' ' ILE . 3.3 pt-20 -112.8 153.81 27.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.843 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.428 HG13 ' C ' ' A' ' 146' ' ' GLU . 20.2 mt -140.72 110.63 3.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.096 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -119.6 174.37 6.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.943 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.17 -142.87 16.03 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.533 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -116.54 94.0 4.44 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.837 0.351 . . . . 0.0 110.913 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.6 p -151.08 151.15 12.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.173 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 10.4 m -110.98 94.5 5.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.13 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.47 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 37.6 mt -77.7 137.84 38.72 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.888 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 3.3 t -122.2 -37.43 2.82 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.869 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . 0.43 ' CD1' ' HE3' ' A' ' 46' ' ' LYS . 19.4 t80 -149.75 130.6 14.21 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.921 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 98.8 t -140.61 105.18 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.096 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 10.9 tt0 -112.13 145.3 40.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.89 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' ILE . . . . . 0.418 HG23 ' NH1' ' A' ' 41' ' ' ARG . 30.1 mt -109.43 90.47 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.109 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 39.6 t -50.4 140.04 14.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -116.37 175.01 15.54 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.5 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 93.72 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.649 2.233 . . . . 0.0 112.367 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 4.5 t -164.33 150.35 10.78 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.835 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 93.1 p -97.04 149.51 21.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.851 -179.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.294 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.521 -179.971 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 N-CA-C 112.456 -0.258 . . . . 0.0 112.456 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.8 m -156.84 169.37 24.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.887 0.375 . . . . 0.0 110.875 -179.769 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 24.4 m -138.06 143.14 40.35 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.851 -179.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.84 -166.21 35.04 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.471 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 26.7 m -73.92 104.3 4.73 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.877 0.37 . . . . 0.0 110.868 -179.723 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 32.4 t -125.44 91.28 3.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.834 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -168.52 84.17 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.475 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 54.1 m80 -151.62 150.68 30.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.744 0.307 . . . . 0.0 110.862 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 84.8 mt-30 -71.04 173.78 7.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.907 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -111.93 111.05 21.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.893 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 96.6 mt -79.38 -49.26 12.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.949 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 56.7 m-20 -138.97 169.45 17.77 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.913 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 4.2 t -63.31 160.25 16.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.84 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 2.6 pp -42.95 155.55 0.27 Allowed Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.671 0.748 . . . . 0.0 110.868 -180.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -169.49 0.33 Allowed 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.684 2.256 . . . . 0.0 112.344 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.607 HG23 ' HG2' ' A' ' 18' ' ' GLU . 14.7 t -66.57 159.54 27.21 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.124 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . 0.46 ' SD ' ' N ' ' A' ' 32' ' ' ARG . 36.6 mtp -100.28 44.94 1.0 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.894 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.607 ' HG2' HG23 ' A' ' 16' ' ' THR . 3.4 pt-20 -78.86 156.31 28.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.834 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 111.11 -156.33 15.61 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.494 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 170.01 17.58 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.645 2.23 . . . . 0.0 112.331 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 175.62 7.91 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.7 2.267 . . . . 0.0 112.341 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.418 HG22 ' H ' ' A' ' 156' ' ' VAL . 7.6 t -91.41 158.76 16.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.187 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.4 ' CD1' ' O ' ' A' ' 22' ' ' THR . 7.0 m-85 -142.07 117.28 10.1 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.908 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . 0.516 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 9.0 m120 66.92 49.97 0.56 Allowed Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.633 0.73 . . . . 0.0 110.927 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.516 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.7 Cg_endo -69.73 131.35 21.09 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.662 2.241 . . . . 0.0 112.335 179.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 -174.03 0.84 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.643 2.229 . . . . 0.0 112.319 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.696 HG13 ' HA ' ' A' ' 28' ' ' PRO . 97.5 t -144.03 138.33 14.91 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.593 0.711 . . . . 0.0 111.129 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.696 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.78 144.72 77.48 Favored 'Cis proline' 0 C--O 1.232 0.177 0 C-N-CA 122.73 -1.779 . . . . 0.0 112.321 -0.025 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.6 t80 -98.04 119.12 36.11 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.942 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 75.7 m-85 -105.66 108.26 19.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.844 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -119.89 103.39 0.95 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.454 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.46 ' N ' ' SD ' ' A' ' 17' ' ' MET . 0.0 OUTLIER -73.45 128.28 35.05 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.813 0.34 . . . . 0.0 110.899 -179.886 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.551 HD23 HD13 ' A' ' 158' ' ' ILE . 6.1 mt -73.07 151.83 41.51 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.902 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 20.0 mt-30 -88.29 -63.36 1.31 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.934 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.527 ' O ' HG23 ' A' ' 38' ' ' THR . . . -96.94 43.56 2.02 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.54 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.483 ' N ' ' OD2' ' A' ' 143' ' ' ASP . . . 34.39 -152.68 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.499 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . 0.505 HD12 ' O ' ' A' ' 139' ' ' PHE . 52.4 mt -87.64 113.16 23.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.854 0.359 . . . . 0.0 110.934 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.527 HG23 ' O ' ' A' ' 35' ' ' GLY . 24.7 p -121.01 153.16 37.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.113 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -59.75 -25.77 65.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.12 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 13.2 mmt180 -105.43 35.62 2.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.869 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.445 ' HB2' ' NH1' ' A' ' 41' ' ' ARG . 9.4 ttm105 -125.02 140.78 52.6 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.915 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 90.7 m -139.68 121.7 15.67 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.14 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 mp -90.99 134.25 30.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.128 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 77.6 mt -123.45 133.41 69.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.139 179.817 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 75.0 mt -131.41 107.8 13.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.153 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.1 mtmt -109.31 107.74 18.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.9 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.26 -146.25 4.79 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.536 179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . 0.57 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.7 OUTLIER -167.91 129.29 1.44 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.904 0.383 . . . . 0.0 110.934 -179.798 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 11.8 t -77.88 116.74 60.96 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.6 0.714 . . . . 0.0 111.14 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 158.52 56.63 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.627 2.218 . . . . 0.0 112.346 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -14.54 36.26 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.654 2.236 . . . . 0.0 112.394 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 66.7 p -113.16 19.22 17.33 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.151 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -113.37 118.34 4.49 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.419 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 15.7 mtpp -62.96 -58.85 5.95 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.755 0.312 . . . . 0.0 110.877 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 25.3 p -173.04 159.73 4.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.877 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.598 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 10.9 p90 -114.84 -173.19 2.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.873 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.954 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -156.65 141.79 17.28 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.067 179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.431 HG22 ' CE1' ' A' ' 60' ' ' PHE . 9.1 mt -127.59 98.38 4.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.12 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . 0.471 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 2.2 m-80 -100.47 150.48 22.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.917 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.504 ' CE2' HD13 ' A' ' 145' ' ' LEU . 4.3 m-85 -118.1 101.17 8.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.912 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.415 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 28.3 ttmt -95.58 169.85 9.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.901 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.704 HG22 ' HA ' ' A' ' 142' ' ' VAL . 67.8 t -101.17 124.14 54.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.105 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -59.08 -39.87 94.89 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.507 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 15.0 m -66.19 -73.5 0.13 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.837 0.351 . . . . 0.0 110.858 -179.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 68.5 m -76.72 -75.38 0.2 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.833 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 133.31 35.13 0.3 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.475 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.42 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.4 m-20 -106.61 143.94 34.0 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.823 0.344 . . . . 0.0 110.861 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.56 HD12 ' HB3' ' A' ' 86' ' ' LEU . 58.7 mt -88.24 122.56 39.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.154 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.72 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -92.8 -33.33 14.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.114 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.575 HD21 HD11 ' A' ' 72' ' ' ILE . 42.4 tp -139.15 131.61 28.62 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.913 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.5 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.0 OUTLIER -134.66 92.95 2.97 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.838 179.863 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.575 HD11 HD21 ' A' ' 70' ' ' LEU . 40.3 mt -98.64 130.96 46.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.152 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.954 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.2 OUTLIER -140.67 107.74 6.5 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.64 0.733 . . . . 0.0 110.914 179.934 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.598 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.4 Cg_endo -69.74 155.13 66.82 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.704 2.269 . . . . 0.0 112.349 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 71.3 mtp180 -130.61 96.36 4.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.858 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . 0.483 ' HE3' ' HB3' ' A' ' 103' ' ' PHE . 0.0 OUTLIER -60.96 168.85 2.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.901 179.947 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 76.13 -54.94 3.13 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.49 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 7.7 t30 -86.17 -57.44 3.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.858 0.361 . . . . 0.0 110.889 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 103.38 53.57 0.87 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.472 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 7.6 p -145.03 118.71 9.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.788 0.327 . . . . 0.0 111.128 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.9 t -100.61 112.83 34.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.153 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.703 HG22 ' HD3' ' A' ' 96' ' ' LYS . 61.5 t -80.67 142.31 14.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.172 179.922 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -122.4 124.09 42.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.862 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.5 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.1 m120 -138.49 176.56 8.59 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.839 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 45.2 t -160.35 105.08 1.47 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.866 -179.854 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.915 HD12 ' O ' ' A' ' 90' ' ' SER . 24.8 tp -77.55 119.02 20.54 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.951 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.513 ' N ' ' O ' ' A' ' 90' ' ' SER . 76.0 mt -95.88 161.35 14.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.916 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.517 HD22 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.89 101.43 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.902 179.933 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.98 -5.83 1.14 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.493 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.915 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -120.0 171.36 8.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.827 0.346 . . . . 0.0 110.866 -179.763 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.866 ' NE1' HD13 ' A' ' 86' ' ' LEU . 23.8 m95 -129.12 159.82 34.81 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.925 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -93.31 -114.71 2.36 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.53 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . 0.449 ' HB2' ' CZ ' ' A' ' 135' ' ' ARG . 3.6 m -151.96 169.36 22.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.825 0.345 . . . . 0.0 110.878 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.421 ' HG2' ' ND2' ' A' ' 84' ' ' ASN . 7.0 mt-10 -97.7 121.75 39.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.937 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -117.33 116.26 26.87 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.845 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.703 ' HD3' HG22 ' A' ' 82' ' ' VAL . 38.2 mtmt -122.32 117.21 25.54 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.896 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -169.37 108.96 0.44 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.896 179.843 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.784 HD11 ' O ' ' A' ' 100' ' ' HIS . 3.5 tt -145.4 153.79 13.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.073 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.431 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 8.7 t -97.44 -38.74 9.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.169 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . 0.784 ' O ' HD11 ' A' ' 98' ' ' ILE . 3.3 p-80 -146.67 125.07 12.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.862 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . 0.403 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 31.0 t-20 -102.56 96.82 7.93 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.633 0.73 . . . . 0.0 110.864 -179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.436 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.7 Cg_endo -69.83 -40.55 5.09 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.631 2.22 . . . . 0.0 112.357 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.483 ' HB3' ' HE3' ' A' ' 76' ' ' MET . 32.0 m-85 -35.7 106.74 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.883 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -134.53 136.66 8.72 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.506 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 100.11 0.8 Allowed 'Trans proline' 0 C--N 1.34 0.124 0 C-N-CA 122.672 2.248 . . . . 0.0 112.299 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 124.9 -6.58 8.31 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.466 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 9.2 pt20 -131.01 147.29 52.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.852 0.358 . . . . 0.0 110.886 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' PHE . . . . . 0.57 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 66.0 m-85 -64.24 172.16 2.63 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.889 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.461 ' CG ' ' O ' ' A' ' 109' ' ' PHE . 21.8 p90 -160.73 117.97 2.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.882 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -93.64 106.8 18.74 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.848 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.842 HD13 ' N ' ' A' ' 112' ' ' SER . 0.5 OUTLIER -108.64 138.68 44.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.921 -179.961 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.842 ' N ' HD13 ' A' ' 111' ' ' LEU . 5.4 m -145.36 113.42 6.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.829 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.541 HG22 ' HD2' ' A' ' 120' ' ' PHE . 4.5 mp -93.66 137.5 22.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.125 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.596 ' O ' ' CD2' ' A' ' 120' ' ' PHE . 16.9 mtp180 -109.88 135.05 51.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.87 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . 0.543 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 20.7 t -103.74 116.19 31.87 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.903 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -115.34 -149.2 9.54 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.504 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.414 ' O ' ' CD2' ' A' ' 134' ' ' HIS . 8.6 mt -111.83 -39.04 4.67 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.794 0.331 . . . . 0.0 110.899 -179.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.553 ' C ' ' CD2' ' A' ' 134' ' ' HIS . 8.1 m-20 -89.41 -35.45 16.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.86 179.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 13.4 ptt180 -171.3 175.04 4.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 -179.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.596 ' CD2' ' O ' ' A' ' 114' ' ' ARG . 9.2 m-85 -98.9 162.51 13.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.887 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 36.6 mtpt -133.37 104.46 6.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.911 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.679 HG13 HD11 ' A' ' 111' ' ' LEU . 41.5 t -91.04 125.02 43.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.105 179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 48.6 m-85 -115.52 146.32 41.82 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.885 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.505 ' CB ' HD13 ' A' ' 129' ' ' LEU . . . -131.57 108.62 9.67 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.061 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 58.62 35.54 24.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.835 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.46 40.61 22.79 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.487 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 13.9 mt-30 -146.39 130.22 17.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.83 0.348 . . . . 0.0 110.922 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 33.2 t-80 -60.08 99.47 0.07 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.849 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.505 HD13 ' CB ' ' A' ' 124' ' ' ALA . 8.7 tp -70.17 -69.64 0.34 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.946 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.539 ' HZ ' HD13 ' A' ' 72' ' ' ILE . 5.4 p90 -163.44 169.63 18.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.879 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -113.66 151.08 32.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.872 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.55 ' CG ' HD13 ' A' ' 70' ' ' LEU . 0.2 OUTLIER -115.7 105.83 13.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.89 -179.942 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.533 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -61.71 134.01 56.25 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.132 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' HIS . . . . . 0.553 ' CD2' ' C ' ' A' ' 118' ' ' ASP . 14.3 m-70 -62.64 94.53 0.06 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.827 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.449 ' CZ ' ' HB2' ' A' ' 93' ' ' SER . 61.3 mtt-85 -78.78 -41.48 30.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.87 -179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 12.3 tp -100.55 108.32 20.22 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.884 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 59.8 p -51.86 -30.78 25.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.887 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.535 ' HB1' ' HD2' ' A' ' 141' ' ' ARG . . . -89.72 30.61 1.02 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.078 179.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.587 ' CE1' ' HG3' ' A' ' 140' ' ' GLN . 2.9 p90 -41.39 -40.14 1.64 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.91 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' GLN . . . . . 0.587 ' HG3' ' CE1' ' A' ' 139' ' ' PHE . 0.0 OUTLIER -48.05 -52.52 19.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.943 -179.952 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.659 ' O ' HG13 ' A' ' 62' ' ' VAL . 47.9 mtt180 -42.4 -39.41 2.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.89 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.72 HG21 ' CB ' ' A' ' 69' ' ' ALA . 66.6 t -52.7 105.12 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.17 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.483 ' OD2' ' N ' ' A' ' 36' ' ' GLY . 0.9 OUTLIER -130.27 31.08 4.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.877 179.93 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -140.43 129.84 23.94 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.149 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.504 HD13 ' CE2' ' A' ' 60' ' ' PHE . 6.0 tp -125.59 108.91 12.04 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.869 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' GLU . . . . . 0.424 ' C ' HG13 ' A' ' 147' ' ' ILE . 3.0 pt-20 -111.12 148.85 31.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.907 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.424 HG13 ' C ' ' A' ' 146' ' ' GLU . 8.8 mt -138.69 105.32 2.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.138 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -117.87 176.69 5.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.907 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 108.96 -145.94 16.57 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.477 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -114.6 91.63 3.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.868 0.366 . . . . 0.0 110.896 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 4.7 p -150.76 151.21 12.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.109 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 28.7 m -109.67 93.17 4.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.134 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.485 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 66.8 mt -76.52 138.34 40.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.957 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 74.0 m -122.82 -37.97 2.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.85 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 26.9 t80 -145.96 129.42 16.9 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.922 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.418 ' H ' HG22 ' A' ' 22' ' ' THR . 55.0 t -140.71 105.37 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.093 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 13.0 tt0 -121.58 120.4 34.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.907 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' ILE . . . . . 0.551 HD13 HD23 ' A' ' 33' ' ' LEU . 27.1 mt -89.84 89.48 3.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.123 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . 0.457 ' C ' ' O ' ' A' ' 158' ' ' ILE . 28.2 t -33.96 138.03 0.09 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.878 -179.903 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 175.37 169.21 36.87 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.449 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 98.24 0.68 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.653 2.235 . . . . 0.0 112.339 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 3.1 m -86.68 139.78 30.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.894 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 2.3 t -78.41 155.01 30.2 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.832 -179.796 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.503 179.965 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 74.0 m -155.42 135.01 12.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.873 0.368 . . . . 0.0 110.873 -179.718 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.446 ' O ' ' C ' ' A' ' 4' ' ' GLY . 28.2 m -62.03 -51.17 69.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.873 -179.857 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.446 ' C ' ' O ' ' A' ' 3' ' ' SER . . . 34.53 -103.51 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.475 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 5.8 m -55.22 169.23 0.28 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.867 0.365 . . . . 0.0 110.893 -179.765 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.43 ' O ' ' C ' ' A' ' 7' ' ' GLY . 12.1 t -49.46 118.27 2.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.914 -179.815 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.43 ' C ' ' O ' ' A' ' 6' ' ' SER . . . -36.01 -57.31 1.06 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.496 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 42.6 p-80 -85.49 134.0 34.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.728 0.299 . . . . 0.0 110.881 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -110.11 139.33 45.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.869 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 1.8 pm0 -86.53 24.74 1.35 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.93 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.6 mt -138.36 157.5 46.11 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.945 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 -108.53 47.79 0.89 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.881 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 20.1 m -115.98 178.55 4.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.905 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 32.2 mt -74.09 153.19 88.59 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.592 0.71 . . . . 0.0 110.905 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 -165.96 0.17 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.684 2.256 . . . . 0.0 112.321 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.467 HG23 ' CG ' ' A' ' 34' ' ' GLN . 1.5 m -86.79 -13.48 45.02 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.089 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 3.4 ptt? 41.14 54.58 3.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.856 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.419 ' CD ' ' H ' ' A' ' 18' ' ' GLU . 1.3 pm0 -88.91 174.24 8.05 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.87 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 101.28 -138.16 13.7 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.469 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 170.13 17.35 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.632 2.222 . . . . 0.0 112.341 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 170.93 15.43 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.67 2.247 . . . . 0.0 112.343 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.45 HG22 ' H ' ' A' ' 156' ' ' VAL . 6.5 t -87.34 162.07 17.57 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.171 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.406 ' CD1' ' O ' ' A' ' 22' ' ' THR . 7.4 m-85 -142.68 116.86 9.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.92 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . 0.474 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 11.8 m120 61.68 52.23 2.25 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.671 0.748 . . . . 0.0 110.914 -179.889 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.487 ' HG2' ' CB ' ' A' ' 153' ' ' LEU . 54.2 Cg_endo -69.76 133.41 25.5 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.665 2.243 . . . . 0.0 112.387 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 -174.22 0.86 Allowed 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.707 2.272 . . . . 0.0 112.33 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.708 HG13 ' HA ' ' A' ' 28' ' ' PRO . 84.7 t -144.04 138.77 15.28 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.621 0.724 . . . . 0.0 111.113 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.708 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.79 145.27 79.01 Favored 'Cis proline' 0 C--N 1.342 0.186 0 C-N-CA 122.659 -1.809 . . . . 0.0 112.303 -0.048 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.0 t80 -100.96 117.1 34.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.931 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.513 ' CD2' ' HB3' ' A' ' 146' ' ' GLU . 58.2 m-85 -104.61 105.98 16.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.896 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -116.34 103.44 1.15 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.496 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.513 ' O ' ' CD ' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -72.61 114.08 10.36 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.799 0.333 . . . . 0.0 110.856 -179.873 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.425 HD12 ' N ' ' A' ' 144' ' ' THR . 3.9 mt -59.1 151.32 22.78 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.932 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.467 ' CG ' HG23 ' A' ' 16' ' ' THR . 3.0 mp0 -104.26 101.22 10.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.906 179.936 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.64 -58.62 0.52 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.493 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.711 ' O ' HG23 ' A' ' 38' ' ' THR . . . 123.73 171.83 13.62 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.48 -179.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . 0.721 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 93.7 mt -58.74 103.74 0.18 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.879 0.371 . . . . 0.0 110.949 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.711 HG23 ' O ' ' A' ' 36' ' ' GLY . 22.0 p -118.98 150.16 40.4 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.098 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -54.83 -28.16 47.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.107 179.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 3.9 tpt180 -102.97 37.47 1.95 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.899 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 11.7 ttm180 -129.16 139.51 51.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.871 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 91.8 m -137.4 124.75 21.9 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.128 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.414 ' N ' HD12 ' A' ' 43' ' ' ILE . 4.9 mp -92.67 134.05 31.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.161 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 89.7 mt -122.93 135.89 61.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.087 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 56.1 mt -133.98 107.92 10.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.132 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.3 mtmt -113.82 113.78 25.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.836 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.416 ' CA ' ' O ' ' A' ' 152' ' ' THR . . . -146.56 -140.6 3.47 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.519 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -170.55 137.45 1.38 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.916 0.389 . . . . 0.0 110.927 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 14.2 t -86.62 114.87 60.07 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.604 0.716 . . . . 0.0 111.124 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.83 155.71 65.0 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.685 2.256 . . . . 0.0 112.358 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 -13.9 35.46 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.701 2.267 . . . . 0.0 112.356 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 57.8 p -112.28 16.19 20.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.112 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -112.72 120.23 5.18 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.468 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 12.1 mtpt -61.62 -60.46 3.64 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.767 0.318 . . . . 0.0 110.857 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 25.8 p -173.16 158.4 3.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.85 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.596 ' CE2' HD11 ' A' ' 58' ' ' ILE . 8.2 p90 -112.01 -172.8 2.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.88 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.48 141.8 18.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.12 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.596 HD11 ' CE2' ' A' ' 56' ' ' PHE . 2.9 mp -123.01 102.23 11.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.105 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.5 m-80 -103.22 146.09 28.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.846 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.6 ' CE2' HD13 ' A' ' 145' ' ' LEU . 40.7 m-85 -117.63 101.16 8.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.905 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.427 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 33.1 ttmt -96.33 168.57 10.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.854 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.589 HG22 ' HA ' ' A' ' 142' ' ' VAL . 38.4 t -99.57 122.83 51.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.137 179.846 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.424 ' N ' ' OG1' ' A' ' 144' ' ' THR . . . -59.55 -28.69 65.46 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.482 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.541 ' H ' HG12 ' A' ' 62' ' ' VAL . 1.4 t -77.53 -71.09 0.43 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.839 0.352 . . . . 0.0 110.856 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.6 t -79.33 -75.51 0.24 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.818 -179.786 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 132.18 41.31 0.2 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.467 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.437 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.4 m-20 -115.45 139.62 49.87 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.763 0.316 . . . . 0.0 110.855 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.507 HD12 ' HB3' ' A' ' 86' ' ' LEU . 37.6 mt -86.43 114.8 26.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.079 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -85.22 -34.69 21.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.092 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.651 HD22 ' CD2' ' A' ' 132' ' ' PHE . 32.1 tp -138.01 131.75 31.2 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.939 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.467 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.1 t60 -134.95 98.38 4.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.848 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.554 HD11 HD21 ' A' ' 70' ' ' LEU . 22.4 mt -96.42 129.27 46.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.129 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.503 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 0.2 OUTLIER -134.36 104.15 11.3 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.588 0.708 . . . . 0.0 110.927 179.966 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.585 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.6 Cg_endo -69.77 155.48 65.78 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.688 2.259 . . . . 0.0 112.341 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 81.6 mtt-85 -133.25 97.99 4.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.892 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . 0.463 ' O ' ' N ' ' A' ' 78' ' ' ASN . 0.1 OUTLIER -54.41 177.25 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.914 179.931 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 60.81 -76.04 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.522 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.463 ' N ' ' O ' ' A' ' 76' ' ' MET . 45.1 t30 -56.99 -65.76 0.56 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.851 0.358 . . . . 0.0 110.884 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 107.28 51.78 0.75 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.46 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 13.8 p -141.84 117.83 10.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.845 0.355 . . . . 0.0 111.118 -179.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.441 HG21 ' HE2' ' A' ' 103' ' ' PHE . 16.2 t -99.46 109.65 24.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.132 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.593 HG22 ' HD3' ' A' ' 96' ' ' LYS . 82.5 t -79.24 140.19 17.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.123 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . 0.647 ' NH1' ' CD2' ' A' ' 130' ' ' PHE . 1.4 mpp_? -121.37 115.02 22.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.875 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.467 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.4 t-20 -125.98 179.75 5.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.896 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 94.7 p -160.95 110.07 1.64 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.869 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.95 HD12 ' O ' ' A' ' 90' ' ' SER . 24.5 tp -82.73 118.99 23.76 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.909 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.495 ' N ' ' O ' ' A' ' 90' ' ' SER . 96.8 mt -96.12 161.07 14.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.931 179.85 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.519 HD22 ' N ' ' A' ' 88' ' ' ASN . 0.0 OUTLIER -38.5 101.64 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.85 179.932 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.62 -7.0 1.11 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.481 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.95 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -118.85 172.11 7.76 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.879 0.371 . . . . 0.0 110.85 -179.752 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.836 ' NE1' HD13 ' A' ' 86' ' ' LEU . 23.8 m95 -129.12 160.66 32.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.924 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -92.59 -114.7 2.19 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.454 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . 0.439 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 4.5 m -152.78 167.56 28.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.806 0.336 . . . . 0.0 110.88 -179.728 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -97.66 120.46 38.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 20.8 mm-40 -119.63 128.22 53.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.875 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.593 ' HD3' HG22 ' A' ' 82' ' ' VAL . 47.4 mtmt -130.11 117.68 20.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.922 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 25.0 tptt -171.73 105.7 0.21 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.922 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.932 HD11 ' O ' ' A' ' 100' ' ' HIS . 2.1 tt -145.23 151.09 15.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.101 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.594 HG23 ' N ' ' A' ' 100' ' ' HIS . 9.7 t -85.83 -50.35 7.19 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.168 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . 0.932 ' O ' HD11 ' A' ' 98' ' ' ILE . 9.7 p-80 -137.33 132.55 33.77 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.847 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . 0.435 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 43.2 t-20 -112.82 99.62 48.61 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.608 0.718 . . . . 0.0 110.907 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.456 ' HG3' ' HB1' ' A' ' 124' ' ' ALA . 53.6 Cg_endo -69.8 -41.1 4.51 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.705 2.27 . . . . 0.0 112.35 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.442 ' C ' ' O ' ' A' ' 102' ' ' PRO . 7.5 m-85 -35.32 101.91 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.866 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -131.5 136.5 8.83 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.522 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 97.9 0.66 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.675 2.25 . . . . 0.0 112.318 -179.87 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 133.56 -10.45 4.95 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.48 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -133.3 161.77 33.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.837 0.351 . . . . 0.0 110.879 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -82.23 175.08 10.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.864 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 23.0 p90 -161.81 127.26 3.54 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.866 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -98.39 104.49 16.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.85 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.895 HD13 ' N ' ' A' ' 112' ' ' SER . 0.6 OUTLIER -104.85 139.47 39.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.92 -179.945 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.895 ' N ' HD13 ' A' ' 111' ' ' LEU . 4.7 m -144.8 113.41 6.69 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.854 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.7 mp -93.36 136.16 25.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.175 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 42.7 mtt180 -111.68 120.22 41.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.901 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . 0.576 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 2.3 t -90.42 116.7 28.56 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.913 -179.929 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -113.03 -148.85 10.39 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.467 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 19.1 mt -112.76 -35.24 5.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.826 0.346 . . . . 0.0 110.903 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 52.4 m-20 -91.2 -33.14 15.51 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.893 179.812 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.2 ptp180 -174.77 176.2 2.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.867 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.721 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 3.9 m-30 -99.22 158.15 15.89 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 -179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.9 mtpt -130.75 100.82 5.42 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.9 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.847 HG13 HD11 ' A' ' 111' ' ' LEU . 25.1 t -87.83 126.67 41.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.136 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' TYR . . . . . 0.411 ' O ' HD22 ' A' ' 111' ' ' LEU . 85.2 m-85 -118.37 150.49 39.43 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.946 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.456 ' HB1' ' HG3' ' A' ' 102' ' ' PRO . . . -134.86 110.14 8.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.097 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.403 ' ND2' ' C ' ' A' ' 124' ' ' ALA . 0.6 OUTLIER 60.68 39.24 17.82 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.907 -179.889 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 72.92 41.59 48.32 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.495 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 20.3 mm-40 -148.41 136.84 21.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.79 0.329 . . . . 0.0 110.917 -179.851 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 46.5 t-80 -63.1 107.39 1.02 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.856 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.498 HD22 HD21 ' A' ' 111' ' ' LEU . 11.8 tp -78.35 -64.24 1.21 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.914 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.647 ' CD2' ' NH1' ' A' ' 83' ' ' ARG . 24.7 p90 -166.84 -178.68 4.38 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.889 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -125.37 144.86 50.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.861 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.651 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.4 OUTLIER -113.06 106.42 14.65 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.905 -179.915 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.491 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -61.74 137.98 58.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.106 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 17.8 m-70 -66.31 100.74 0.66 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.8 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.439 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 60.5 mtt-85 -83.97 -55.1 4.41 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.855 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 4.9 tp -88.67 107.91 19.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.913 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 19.9 p -48.79 -34.4 12.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.858 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.516 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.67 28.99 0.46 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.107 179.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.535 ' O ' HD12 ' A' ' 37' ' ' LEU . 27.0 p90 -50.94 -42.54 59.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.899 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' GLN . . . . . 0.416 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 7.3 pt20 -48.83 -37.25 18.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.907 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.516 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 45.4 mtp85 -58.17 -40.91 82.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.861 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.589 ' HA ' HG22 ' A' ' 62' ' ' VAL . 60.0 t -48.17 102.3 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.133 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.492 ' OD1' ' N ' ' A' ' 36' ' ' GLY . 22.6 t0 -124.26 24.91 7.93 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.869 179.868 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . 0.425 ' N ' HD12 ' A' ' 33' ' ' LEU . 1.5 m -132.59 140.63 48.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.127 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.6 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.5 tp -135.91 113.81 11.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.875 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' GLU . . . . . 0.513 ' HB3' ' CD2' ' A' ' 30' ' ' PHE . 5.9 pt-20 -117.82 151.85 36.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.932 179.903 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.528 HG12 HG23 ' A' ' 58' ' ' ILE . 18.0 mt -139.19 118.35 13.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.117 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 1.1 pm0 -128.19 177.9 6.61 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.868 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 106.32 -137.5 13.88 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.474 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -122.54 92.48 3.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.816 0.341 . . . . 0.0 110.905 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.406 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 2.1 p -151.17 150.6 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.103 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . 0.416 ' O ' ' CA ' ' A' ' 47' ' ' GLY . 23.7 m -107.48 93.52 4.59 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.114 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.487 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 67.8 mt -77.24 128.97 35.29 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.938 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 3.8 m -111.96 -41.66 3.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.901 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 35.2 t80 -143.87 130.62 20.26 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.942 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.45 ' H ' HG22 ' A' ' 22' ' ' THR . 72.9 t -140.7 105.29 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.122 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -120.66 129.62 53.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.879 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 16.6 mt -95.31 94.13 4.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.103 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 17.8 t -53.03 147.35 9.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.854 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -145.53 154.81 26.17 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.478 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -1.31 8.22 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.658 2.239 . . . . 0.0 112.358 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 14.8 m -54.85 91.03 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.861 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 32.6 p -39.48 134.4 1.26 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.877 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.471 -179.988 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.3 0 N-CA-C 112.473 -0.251 . . . . 0.0 112.473 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.3 m -140.19 125.49 18.83 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.851 0.358 . . . . 0.0 110.89 -179.762 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 28.7 m -102.84 142.73 33.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.869 -179.808 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.25 -174.57 13.89 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.526 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 93.1 p -136.85 136.15 38.5 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.894 0.378 . . . . 0.0 110.847 -179.717 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 14.8 m -88.95 140.89 28.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.858 -179.848 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -109.77 139.07 15.2 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.475 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.448 ' CD2' ' HG2' ' A' ' 10' ' ' GLN . 27.0 t60 -101.53 103.1 13.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.73 0.3 . . . . 0.0 110.833 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -86.51 86.24 7.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.924 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.448 ' HG2' ' CD2' ' A' ' 8' ' ' HIS . 7.3 mm100 -76.12 84.14 2.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.942 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 51.6 mt -146.32 147.83 31.76 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.942 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 5.4 m120 -75.19 138.73 42.17 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.886 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 3.6 m -162.43 130.83 4.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.87 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.742 ' O ' HD12 ' A' ' 14' ' ' LEU . 0.9 OUTLIER -58.59 152.89 43.41 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.577 0.704 . . . . 0.0 110.96 179.989 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -172.47 0.58 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.634 2.222 . . . . 0.0 112.349 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.3 m -79.18 150.43 31.69 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.129 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 3.4 ptt? -110.58 69.71 0.7 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.842 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -83.53 160.13 21.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.897 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 117.05 -142.69 17.62 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.517 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 170.05 17.4 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.697 2.265 . . . . 0.0 112.378 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 176.57 6.61 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.696 2.264 . . . . 0.0 112.299 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.416 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.4 m -92.2 148.38 22.2 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.149 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.404 ' CD1' ' O ' ' A' ' 22' ' ' THR . 7.2 m-85 -142.52 134.47 27.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.854 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . 0.51 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.5 t-20 42.68 49.9 4.95 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.554 0.692 . . . . 0.0 110.878 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.51 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.8 Cg_endo -69.8 143.87 52.04 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.634 2.223 . . . . 0.0 112.378 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -178.74 2.49 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.701 2.267 . . . . 0.0 112.315 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.675 HG13 ' HA ' ' A' ' 28' ' ' PRO . 98.8 t -143.71 137.93 14.81 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.636 0.731 . . . . 0.0 111.106 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.675 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.5 Cg_endo -69.77 144.65 77.25 Favored 'Cis proline' 0 C--O 1.231 0.171 0 C-N-CA 122.698 -1.792 . . . . 0.0 112.357 -0.066 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -98.8 118.12 34.83 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.954 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.438 ' CD1' ' HB3' ' A' ' 146' ' ' GLU . 63.8 m-85 -104.7 103.01 12.57 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.872 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -113.77 104.32 1.46 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.503 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.449 ' O ' ' HG3' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -73.44 121.89 21.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.876 0.37 . . . . 0.0 110.874 -179.868 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.419 HD12 ' N ' ' A' ' 144' ' ' THR . 5.4 mt -68.77 147.12 52.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.922 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 29.1 mt-30 -106.0 83.63 1.94 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.917 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 138.13 -49.0 0.86 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.49 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.561 ' O ' HG23 ' A' ' 38' ' ' THR . . . 109.35 166.98 20.33 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.454 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . 0.451 HD13 ' CZ ' ' A' ' 120' ' ' PHE . 87.5 mt -55.0 110.27 0.64 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.895 0.378 . . . . 0.0 110.901 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.561 HG23 ' O ' ' A' ' 36' ' ' GLY . 61.7 p -129.93 145.4 51.62 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.178 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -47.37 -31.1 3.7 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.098 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 8.9 tpt180 -97.32 31.66 2.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.881 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 12.3 ttm180 -124.13 141.56 51.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.879 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 94.0 m -138.33 124.85 20.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.147 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.1 mp -96.85 130.15 45.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.112 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 86.5 mt -123.49 134.04 67.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.132 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 72.1 mt -133.32 107.39 11.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.156 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 25.9 mtmt -112.01 109.93 19.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.898 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.501 ' CA ' ' O ' ' A' ' 152' ' ' THR . . . -138.09 -139.89 3.93 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.492 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -173.63 119.4 0.29 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.947 0.404 . . . . 0.0 110.884 -179.777 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 21.9 t -70.77 113.52 19.37 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.615 0.721 . . . . 0.0 111.124 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 156.88 62.35 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.671 2.248 . . . . 0.0 112.344 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -14.48 36.18 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.669 2.246 . . . . 0.0 112.366 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 72.6 p -111.7 18.46 18.96 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.181 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -116.12 123.47 5.89 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.509 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 33.8 mtpt -65.39 -59.43 4.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.823 0.344 . . . . 0.0 110.891 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 34.9 p -174.03 160.74 3.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.833 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.608 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 3.4 p90 -114.19 -174.37 2.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.869 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.862 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -156.37 128.19 7.31 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.076 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.534 HG13 HG23 ' A' ' 147' ' ' ILE . 5.3 mp -112.22 102.28 13.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.155 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.3 m-80 -100.84 149.69 23.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.938 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.698 ' CE2' HD13 ' A' ' 145' ' ' LEU . 56.6 m-85 -118.65 101.08 7.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.872 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.425 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 34.9 ttmt -95.69 168.92 10.38 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.904 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.672 HG22 ' HA ' ' A' ' 142' ' ' VAL . 55.2 t -100.48 124.83 54.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.124 179.856 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -60.48 -33.76 82.76 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.506 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.442 ' H ' HG12 ' A' ' 62' ' ' VAL . 70.1 m -70.84 -71.05 0.27 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.837 0.351 . . . . 0.0 110.864 -179.738 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 82.6 p -82.07 -75.1 0.31 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.875 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 133.37 44.31 0.13 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.46 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.411 ' OD1' ' OD1' ' A' ' 88' ' ' ASN . 1.2 m-20 -113.65 144.83 42.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.798 0.332 . . . . 0.0 110.889 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.431 HD12 ' HB3' ' A' ' 86' ' ' LEU . 40.9 mt -90.22 113.85 26.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.124 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.571 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -87.17 -32.3 19.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.126 179.799 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.738 HD22 ' CD2' ' A' ' 132' ' ' PHE . 41.4 tp -136.83 129.73 30.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.9 -179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.482 ' N ' ' O ' ' A' ' 84' ' ' ASN . 1.0 OUTLIER -134.61 94.42 3.19 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.869 179.836 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.541 HD13 ' HZ ' ' A' ' 130' ' ' PHE . 44.7 mt -99.59 134.74 37.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.148 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.862 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -141.38 106.9 6.07 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.594 0.711 . . . . 0.0 110.859 179.955 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.608 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.0 Cg_endo -69.81 155.14 66.54 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.708 2.272 . . . . 0.0 112.362 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 34.6 mtt85 -128.97 97.49 4.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.877 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . 0.522 ' HE3' ' HB3' ' A' ' 103' ' ' PHE . 0.0 OUTLIER -55.37 -32.33 62.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 179.945 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -43.0 -88.01 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.505 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -88.4 -41.62 12.7 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.821 0.343 . . . . 0.0 110.873 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.456 ' HA2' ' ND2' ' A' ' 101' ' ' ASN . . . 121.09 32.66 1.04 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.494 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 24.7 p -109.61 118.08 35.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.777 0.322 . . . . 0.0 111.164 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.508 HG22 ' HA ' ' A' ' 74' ' ' PRO . 13.8 t -97.79 113.58 32.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.131 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.499 HG22 ' HD3' ' A' ' 96' ' ' LYS . 58.2 t -83.12 144.81 9.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.111 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -123.89 125.46 44.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.873 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.482 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.7 OUTLIER -139.29 177.96 7.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.935 -179.955 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 92.4 p -160.67 107.68 1.53 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.868 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.897 HD13 ' NE1' ' A' ' 91' ' ' TRP . 24.6 tp -76.98 117.41 18.54 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.935 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.486 ' N ' ' O ' ' A' ' 90' ' ' SER . 25.9 mt -93.44 161.19 14.48 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.908 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.415 ' ND2' ' H ' ' A' ' 88' ' ' ASN . 10.6 m-80 -41.31 101.48 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.866 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.94 -3.25 4.11 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.471 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.851 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.4 OUTLIER -124.5 173.41 8.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.87 0.367 . . . . 0.0 110.831 -179.716 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.897 ' NE1' HD13 ' A' ' 86' ' ' LEU . 23.8 m95 -130.21 159.58 36.44 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.948 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -90.8 -109.3 1.47 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.478 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 3.4 m -159.92 176.03 12.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.839 0.352 . . . . 0.0 110.832 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.424 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 4.6 mt-10 -104.05 122.96 46.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.866 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -121.75 113.25 19.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.892 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.499 ' HD3' HG22 ' A' ' 82' ' ' VAL . 40.4 mtmt -114.34 118.41 33.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.868 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 12.1 tptm -172.13 105.27 0.18 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.879 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.793 HD11 ' O ' ' A' ' 100' ' ' HIS . 2.4 tt -144.23 143.58 23.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.155 179.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.606 HG23 ' N ' ' A' ' 100' ' ' HIS . 10.3 t -77.25 -51.58 10.67 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.154 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . 0.793 ' O ' HD11 ' A' ' 98' ' ' ILE . 21.3 p80 -140.55 134.21 30.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.85 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . 0.456 ' ND2' ' HA2' ' A' ' 79' ' ' GLY . 4.9 t-20 -101.65 99.13 10.88 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.608 0.718 . . . . 0.0 110.931 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.403 ' HD2' HD11 ' A' ' 129' ' ' LEU . 53.6 Cg_endo -69.76 -40.81 4.89 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.693 2.262 . . . . 0.0 112.328 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.522 ' HB3' ' HE3' ' A' ' 76' ' ' MET . 6.7 m-85 -41.02 111.86 0.25 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.885 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -134.08 133.85 7.1 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.511 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 96.5 0.6 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.632 2.222 . . . . 0.0 112.333 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 127.25 0.23 6.92 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.49 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -138.78 154.48 48.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.85 0.357 . . . . 0.0 110.952 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 -71.9 171.96 10.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.87 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 27.4 p90 -160.52 136.33 8.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.909 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.67 105.8 14.82 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.854 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.827 HD13 ' N ' ' A' ' 112' ' ' SER . 0.6 OUTLIER -107.14 139.72 41.11 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.9 -179.931 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.827 ' N ' HD13 ' A' ' 111' ' ' LEU . 3.6 m -144.88 114.88 7.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.839 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.422 HG22 ' HD2' ' A' ' 120' ' ' PHE . 4.6 mp -98.23 127.42 50.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.142 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 9.9 mtp180 -100.25 133.48 44.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.875 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 14.1 t -98.49 100.41 11.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.894 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -91.04 -140.51 8.87 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.469 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 10.3 mt -122.8 -38.55 2.62 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.845 0.355 . . . . 0.0 110.933 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.4 t0 -94.39 -21.43 18.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.867 179.848 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.402 ' CD ' ' C ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -175.18 -175.12 0.81 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.834 -179.902 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.451 ' CZ ' HD13 ' A' ' 37' ' ' LEU . 20.4 m-85 -108.42 148.91 29.46 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.871 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 2.1 mmmm -120.17 101.95 8.18 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.866 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.6 HG13 HD11 ' A' ' 111' ' ' LEU . 65.8 t -89.31 129.74 39.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.141 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 54.6 m-85 -116.16 160.7 20.01 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.925 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.473 ' HB2' HD13 ' A' ' 129' ' ' LEU . . . -139.92 114.34 9.21 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.111 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 41.41 38.68 0.88 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.852 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 83.71 27.63 37.9 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.458 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . 0.421 ' N ' ' O ' ' A' ' 124' ' ' ALA . 9.4 mm100 -138.88 115.88 10.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.855 0.359 . . . . 0.0 110.897 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 34.4 t-80 -47.93 103.19 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.876 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.619 HD22 HD21 ' A' ' 111' ' ' LEU . 13.5 tp -69.65 -68.48 0.41 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.894 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.541 ' HZ ' HD13 ' A' ' 72' ' ' ILE . 9.4 p90 -164.2 175.8 9.81 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.912 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.48 ' OD1' ' N ' ' A' ' 132' ' ' PHE . 0.4 OUTLIER -117.06 156.73 27.05 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 179.967 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.738 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -128.31 106.12 8.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.889 -179.864 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.605 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -63.35 136.66 57.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.137 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' HIS . . . . . 0.404 ' HE1' ' CE1' ' A' ' 120' ' ' PHE . 15.8 m-70 -61.37 115.65 4.02 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.883 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 8.1 mtt-85 -95.9 -47.65 6.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.861 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 9.9 tp -96.56 108.19 20.74 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.905 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 78.9 p -47.73 -34.22 8.07 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.847 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.668 ' HB1' ' HG3' ' A' ' 141' ' ' ARG . . . -83.62 31.09 0.47 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.084 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -50.36 -34.89 25.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.871 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' GLN . . . . . 0.456 ' HG2' ' N ' ' A' ' 141' ' ' ARG . 18.1 pm0 -59.7 -29.41 68.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.923 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.668 ' HG3' ' HB1' ' A' ' 138' ' ' ALA . 36.3 mtp85 -65.29 -39.64 92.81 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.871 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.672 ' HA ' HG22 ' A' ' 62' ' ' VAL . 84.3 t -50.62 103.94 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.151 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 9.3 p-10 -125.27 31.85 5.49 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.886 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . 0.419 ' N ' HD12 ' A' ' 33' ' ' LEU . 1.7 m -140.72 135.04 31.18 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.14 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.698 HD13 ' CE2' ' A' ' 60' ' ' PHE . 6.4 tp -129.88 115.88 17.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.932 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' GLU . . . . . 0.438 ' HB3' ' CD1' ' A' ' 30' ' ' PHE . 5.1 pt-20 -120.0 150.95 39.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.885 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.534 HG23 HG13 ' A' ' 58' ' ' ILE . 15.0 mt -139.36 112.85 6.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.152 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -122.58 175.59 6.4 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.902 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 105.11 -146.36 16.06 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.498 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -111.69 92.51 4.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.886 0.374 . . . . 0.0 110.865 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.483 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 4.7 p -151.22 140.59 15.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.107 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . 0.501 ' O ' ' CA ' ' A' ' 47' ' ' GLY . 14.1 m -100.52 94.15 5.99 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.16 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.463 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 80.4 mt -78.59 132.99 37.34 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.92 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 64.9 m -118.29 -34.38 4.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.889 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 13.8 t80 -149.98 130.36 13.79 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.941 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 86.3 t -140.77 106.14 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.152 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 16.0 tt0 -114.57 135.85 53.68 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.919 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' ILE . . . . . 0.412 ' O ' HG22 ' A' ' 158' ' ' ILE . 42.1 mt -104.11 88.46 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.166 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 16.4 m -62.32 136.2 57.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.876 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -162.41 178.09 38.32 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.46 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 125.76 12.53 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.662 2.241 . . . . 0.0 112.347 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 35.7 m -90.76 103.12 15.86 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.804 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 7.7 t 46.57 42.46 11.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.847 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.528 180.0 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 N-CA-C 112.501 -0.24 . . . . 0.0 112.501 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 15.7 m -96.21 90.91 5.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.845 0.355 . . . . 0.0 110.854 -179.762 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 23.6 t -70.91 147.61 48.59 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.858 -179.837 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 118.98 152.68 9.23 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.49 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 79.0 p -63.84 106.31 0.98 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.836 0.351 . . . . 0.0 110.814 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 93.0 p -156.61 149.65 24.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.865 -179.829 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 123.67 -130.67 7.76 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.49 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 55.2 m-70 -144.59 153.07 41.42 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.735 0.303 . . . . 0.0 110.868 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.7 tt0 -105.94 41.84 1.34 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.871 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 87.9 mt-30 -80.82 43.42 0.68 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.909 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 26.1 mt -151.44 161.72 42.21 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.856 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 20.2 t30 -121.31 130.43 53.64 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.841 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 19.8 m -158.94 156.0 28.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.808 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.603 HD11 ' HB2' ' A' ' 32' ' ' ARG . 4.3 pp -83.31 153.8 66.01 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.583 0.706 . . . . 0.0 110.951 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 175.75 7.65 Favored 'Trans proline' 0 C--O 1.232 0.21 0 C-N-CA 122.665 2.244 . . . . 0.0 112.378 179.865 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.403 ' CG2' ' HG2' ' A' ' 18' ' ' GLU . 9.6 t -50.96 178.98 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.157 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . 0.403 ' O ' ' O ' ' A' ' 18' ' ' GLU . 23.8 mmm -118.17 7.37 12.12 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.894 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.403 ' HG2' ' CG2' ' A' ' 16' ' ' THR . 22.1 pt-20 -50.96 -176.08 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.923 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 76.85 -155.81 45.18 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.475 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 166.32 27.94 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.677 2.251 . . . . 0.0 112.34 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 178.35 4.66 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.667 2.245 . . . . 0.0 112.373 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.51 ' CG2' ' N ' ' A' ' 23' ' ' PHE . 1.3 m -92.14 157.26 16.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.115 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.51 ' N ' ' CG2' ' A' ' 22' ' ' THR . 8.4 m-85 -147.73 141.65 25.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.873 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . 0.485 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 15.8 m120 35.12 51.95 1.37 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.63 0.729 . . . . 0.0 110.88 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.491 ' HG2' ' CB ' ' A' ' 153' ' ' LEU . 53.6 Cg_endo -69.82 145.78 57.85 Favored 'Trans proline' 0 C--O 1.232 0.192 0 C-N-CA 122.693 2.262 . . . . 0.0 112.309 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.79 -178.25 2.27 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.663 2.242 . . . . 0.0 112.32 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.681 HG13 ' HA ' ' A' ' 28' ' ' PRO . 95.2 t -142.85 138.0 15.58 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.688 0.756 . . . . 0.0 111.081 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.681 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.9 Cg_endo -69.77 144.54 76.95 Favored 'Cis proline' 0 C--N 1.342 0.195 0 C-N-CA 122.656 -1.81 . . . . 0.0 112.347 -0.028 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 1.9 t80 -96.22 117.64 31.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.95 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -100.53 104.09 15.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.888 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -109.03 109.19 2.74 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.48 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.603 ' HB2' HD11 ' A' ' 14' ' ' LEU . 6.8 mmt85 -72.97 116.55 13.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.829 0.347 . . . . 0.0 110.887 -179.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.482 HD23 HG12 ' A' ' 158' ' ' ILE . 6.1 mt -75.69 94.61 3.27 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.913 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 22.2 mm-40 -67.22 92.55 0.27 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.886 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 138.21 -37.63 1.79 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.476 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.816 ' O ' HG23 ' A' ' 38' ' ' THR . . . 88.92 157.48 32.85 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.493 -179.884 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . 0.423 HD12 ' O ' ' A' ' 139' ' ' PHE . 66.4 mt -51.08 95.77 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.914 0.388 . . . . 0.0 110.907 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.816 HG23 ' O ' ' A' ' 36' ' ' GLY . 44.4 p -116.24 148.59 40.3 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.092 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -50.6 -21.27 1.48 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.106 179.813 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.455 ' HA ' ' NE ' ' A' ' 40' ' ' ARG . 3.8 mmp_? -106.88 34.28 3.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.859 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 14.7 ttt85 -125.9 140.06 52.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.904 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 99.9 m -139.36 119.81 13.95 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.168 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 4.9 mp -90.59 142.19 13.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.15 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 82.4 mt -133.76 115.66 22.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.111 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 54.3 mt -114.92 107.59 23.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.123 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.0 mtmm -110.18 109.3 19.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.885 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.59 -147.53 4.98 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.507 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . 0.587 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.5 OUTLIER -168.14 127.13 1.22 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.892 0.377 . . . . 0.0 110.97 -179.806 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 11.3 t -75.97 115.38 46.06 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.627 0.727 . . . . 0.0 111.141 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 155.42 66.15 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.661 2.241 . . . . 0.0 112.423 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -14.83 36.61 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.657 2.238 . . . . 0.0 112.326 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 49.7 p -111.62 17.94 19.49 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.162 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -113.36 124.14 6.44 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.48 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 14.8 mttp -64.89 -62.6 1.46 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.802 0.334 . . . . 0.0 110.897 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 17.5 p -171.76 157.51 4.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.875 -179.869 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.6 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 9.1 p90 -113.1 -172.27 2.03 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.931 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.629 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -155.19 139.12 16.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.081 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.575 HD11 ' CE2' ' A' ' 56' ' ' PHE . 2.7 mp -118.95 99.03 7.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.139 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . 0.512 ' OD1' ' CG ' ' A' ' 71' ' ' HIS . 33.0 m-80 -101.22 141.67 33.77 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.897 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.678 ' CE2' HD13 ' A' ' 145' ' ' LEU . 26.8 m-85 -115.49 97.92 6.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.861 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.404 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 32.9 ttmt -95.59 169.91 9.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.94 179.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.595 HG13 ' O ' ' A' ' 141' ' ' ARG . 16.7 t -99.33 123.35 51.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.131 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -61.08 -22.87 61.05 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.497 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.584 ' H ' HG12 ' A' ' 62' ' ' VAL . 30.7 t -81.73 -72.78 0.42 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.928 0.394 . . . . 0.0 110.855 -179.72 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 36.0 t -80.61 -72.79 0.4 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.839 -179.82 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 133.69 40.65 0.18 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.487 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.555 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.1 m-20 -110.29 137.54 47.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.796 0.331 . . . . 0.0 110.847 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.538 HD12 ' HB3' ' A' ' 86' ' ' LEU . 57.0 mt -85.84 112.46 22.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.155 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.587 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -80.7 -34.66 34.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.114 179.829 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.713 HD21 HD11 ' A' ' 72' ' ' ILE . 53.4 tp -140.69 132.16 26.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.951 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.512 ' CG ' ' OD1' ' A' ' 59' ' ' ASN . 3.3 t60 -134.92 92.3 2.86 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.857 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.713 HD11 HD21 ' A' ' 70' ' ' LEU . 20.3 mt -96.17 134.78 32.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.163 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.629 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -140.06 105.88 6.75 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.643 0.735 . . . . 0.0 110.904 179.968 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.6 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.2 Cg_endo -69.75 155.01 67.1 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.67 2.247 . . . . 0.0 112.364 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 36.7 mtp180 -131.85 94.72 3.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.854 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . 0.431 ' HE3' ' HB3' ' A' ' 103' ' ' PHE . 0.3 OUTLIER -61.57 148.93 40.63 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.877 179.95 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 99.98 -68.0 0.54 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.471 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 11.3 t-20 -78.84 -51.34 9.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.822 0.344 . . . . 0.0 110.89 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 102.36 56.96 0.81 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.467 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 13.7 p -144.04 117.85 9.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.807 0.337 . . . . 0.0 111.187 -179.883 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.53 HG22 ' HA ' ' A' ' 74' ' ' PRO . 29.4 t -104.43 109.47 27.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.119 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.741 HG22 ' CE ' ' A' ' 96' ' ' LYS . 58.2 t -80.01 135.53 25.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.107 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . 0.483 ' HD3' ' N ' ' A' ' 83' ' ' ARG . 0.7 OUTLIER -121.06 115.18 22.63 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.884 -179.989 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.434 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.2 t-20 -124.81 -176.82 3.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.911 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.431 ' CB ' ' HD2' ' A' ' 135' ' ' ARG . 47.5 t -161.17 106.45 1.36 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.883 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.904 HD13 ' NE1' ' A' ' 91' ' ' TRP . 28.9 tp -78.9 115.35 18.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.923 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.519 ' N ' ' O ' ' A' ' 90' ' ' SER . 73.2 mt -92.96 162.18 14.16 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.882 179.901 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.488 ' ND2' ' OD2' ' A' ' 67' ' ' ASP . 10.6 m-80 -40.66 101.64 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.891 179.902 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.77 -3.59 2.79 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.466 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.854 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -123.15 170.97 9.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.901 0.382 . . . . 0.0 110.833 -179.73 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.904 ' NE1' HD13 ' A' ' 86' ' ' LEU . 24.7 m95 -128.41 160.62 31.69 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.926 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -91.24 -108.26 1.5 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.483 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 2.9 m -163.07 169.5 19.38 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.851 0.358 . . . . 0.0 110.873 -179.73 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 71.6 mt-10 -93.58 119.19 32.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.901 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 -122.87 124.95 44.42 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.92 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.741 ' CE ' HG22 ' A' ' 82' ' ' VAL . 17.4 mttp -126.52 122.74 36.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.896 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.413 ' HB3' ' NH2' ' A' ' 83' ' ' ARG . 4.6 ttpm? -169.5 105.81 0.37 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.91 179.827 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.737 HD11 ' O ' ' A' ' 100' ' ' HIS . 1.3 tt -147.75 150.2 14.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.144 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.48 HG23 ' N ' ' A' ' 100' ' ' HIS . 11.5 t -86.52 -43.48 12.7 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.145 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . 0.737 ' O ' HD11 ' A' ' 98' ' ' ILE . 2.9 p-80 -149.64 127.2 11.58 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.898 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . 0.43 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 51.7 t-20 -99.51 101.01 11.91 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.604 0.716 . . . . 0.0 110.867 -179.89 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.456 ' HD2' HD11 ' A' ' 129' ' ' LEU . 53.8 Cg_endo -69.78 -31.81 19.72 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.738 2.292 . . . . 0.0 112.341 179.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.593 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 17.9 m-85 -44.2 102.48 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.837 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -132.06 135.18 8.02 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.482 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 98.26 0.67 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.672 2.248 . . . . 0.0 112.351 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 130.75 -5.87 5.82 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.44 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 -135.47 159.83 40.37 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.849 0.356 . . . . 0.0 110.91 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' PHE . . . . . 0.587 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 16.2 m-85 -77.64 174.56 10.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.876 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.544 ' O ' ' CD1' ' A' ' 109' ' ' PHE . 33.5 p90 -161.49 118.08 2.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.881 -179.872 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -92.5 106.93 18.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.892 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.817 HD13 ' N ' ' A' ' 112' ' ' SER . 0.3 OUTLIER -106.75 138.38 43.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.91 -179.948 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.817 ' N ' HD13 ' A' ' 111' ' ' LEU . 7.4 m -145.37 112.04 5.87 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.841 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.8 mp -94.55 134.12 33.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.116 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 70.7 mtt180 -111.79 123.35 50.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.844 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . 0.576 ' HA ' ' CD1' ' A' ' 120' ' ' PHE . 3.5 t -93.91 100.87 12.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.89 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -93.11 -126.96 4.34 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.476 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.4 mt -132.74 -43.19 0.91 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.842 0.353 . . . . 0.0 110.885 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -86.04 -29.34 23.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.9 179.82 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 10.6 ptp85 -175.16 162.37 2.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.838 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.576 ' CD1' ' HA ' ' A' ' 115' ' ' CYS . 3.0 m-30 -85.45 141.43 29.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.902 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 12.0 mmmt -113.67 105.01 12.8 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.941 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.591 HG13 HD11 ' A' ' 111' ' ' LEU . 48.8 t -95.18 133.2 36.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.12 179.898 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 11.0 m-85 -120.16 159.24 25.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.874 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.53 ' HB2' HD13 ' A' ' 129' ' ' LEU . . . -141.4 116.25 9.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.059 179.872 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 45.07 35.94 1.82 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.896 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 84.33 29.36 30.67 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.458 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 10.5 mm100 -140.96 116.11 9.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.789 0.328 . . . . 0.0 110.911 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 42.1 t-80 -51.27 105.02 0.09 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.831 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.53 HD13 ' HB2' ' A' ' 124' ' ' ALA . 6.4 tp -72.13 -67.52 0.53 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.941 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.629 ' HZ ' HD13 ' A' ' 72' ' ' ILE . 6.7 p90 -166.35 179.82 5.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.898 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -126.27 158.9 34.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.845 -179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.638 ' CD1' HD13 ' A' ' 70' ' ' LEU . 0.2 OUTLIER -115.4 110.24 19.05 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.89 -179.914 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.595 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -54.52 138.69 40.0 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.071 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 18.4 m-70 -78.15 69.22 4.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.83 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.431 ' HD2' ' CB ' ' A' ' 85' ' ' SER . 0.0 OUTLIER -66.33 -37.89 86.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.872 -179.948 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.8 tp -98.23 107.89 20.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.916 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 78.8 p -58.1 -25.12 60.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.859 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.67 ' HB1' ' HD2' ' A' ' 141' ' ' ARG . . . -91.06 39.71 1.0 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.114 179.894 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.423 ' O ' HD12 ' A' ' 37' ' ' LEU . 28.9 p90 -65.47 -30.88 71.71 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.909 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 4.9 pt20 -59.32 -31.16 68.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.889 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.67 ' HD2' ' HB1' ' A' ' 138' ' ' ALA . 27.4 mtt180 -64.26 -40.16 95.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.889 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.587 HG21 ' CB ' ' A' ' 69' ' ' ALA . 92.0 t -48.91 106.01 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.139 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.505 ' OD2' ' N ' ' A' ' 36' ' ' GLY . 0.7 OUTLIER -130.84 33.41 4.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.892 179.922 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 9.1 m -143.74 113.5 7.12 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.175 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.678 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.7 tp -111.19 106.99 16.17 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.905 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' GLU . . . . . 0.417 ' C ' HG13 ' A' ' 147' ' ' ILE . 3.1 pt-20 -108.59 153.91 22.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.901 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.417 HG13 ' C ' ' A' ' 146' ' ' GLU . 21.3 mt -140.78 116.49 7.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.081 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -126.19 171.76 10.62 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.926 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 104.74 -157.07 16.84 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.459 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 64.6 m-20 -98.6 94.32 6.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.868 0.366 . . . . 0.0 110.844 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 10.4 p -151.07 141.5 16.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.142 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 33.7 m -105.5 92.71 4.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.176 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.491 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 94.6 mt -71.75 133.65 45.71 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.895 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 3.6 m -114.61 -35.66 4.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.886 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . 0.462 ' C ' ' CD1' ' A' ' 155' ' ' TYR . 4.2 t80 -157.16 132.43 9.06 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.941 -179.885 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 85.0 t -140.47 133.79 33.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.113 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 8.0 tt0 -156.57 138.45 14.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.891 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' ILE . . . . . 0.482 HG12 HD23 ' A' ' 33' ' ' LEU . 4.7 mp -97.29 96.82 5.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.141 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . 0.455 ' C ' ' O ' ' A' ' 158' ' ' ILE . 74.9 m -33.63 -45.82 0.18 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.842 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . 0.442 ' C ' ' O ' ' A' ' 159' ' ' SER . . . -34.39 142.49 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.476 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 154.86 67.37 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.718 2.279 . . . . 0.0 112.363 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 83.1 p -69.5 109.88 4.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.904 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 3.5 t -96.68 104.13 16.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.873 -179.783 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.263 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.491 -179.979 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.9 t -78.47 112.54 15.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.907 0.384 . . . . 0.0 110.826 -179.744 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 93.9 p -41.27 104.49 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.881 -179.844 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 107.81 178.55 22.24 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.532 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.2 t -134.85 -49.59 0.76 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.853 0.359 . . . . 0.0 110.831 -179.714 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.2 m 45.94 41.82 8.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.846 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 89.93 -133.57 11.88 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.482 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 38.74 42.62 0.63 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.741 0.305 . . . . 0.0 110.874 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 8.9 mm100 -90.76 -60.33 1.94 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.939 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.6 tp60 -124.57 102.85 7.83 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.584 HD23 ' N ' ' A' ' 11' ' ' LEU . 0.3 OUTLIER -126.84 41.83 3.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.91 -179.998 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.6 m120 64.45 42.51 5.04 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.924 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 1.1 t -110.51 -176.46 2.98 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.839 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 10.7 mt -143.54 152.17 55.94 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.632 0.729 . . . . 0.0 110.931 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 159.83 51.95 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.683 2.255 . . . . 0.0 112.383 179.853 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 9.8 t -85.41 137.4 32.95 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.146 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . 0.4 ' HE3' ' CA ' ' A' ' 31' ' ' GLY . 0.0 OUTLIER -98.36 37.98 1.39 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.889 179.933 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 -71.09 -176.29 1.37 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.885 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 73.77 -122.81 7.82 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.546 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.83 146.4 59.63 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.689 2.26 . . . . 0.0 112.301 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.432 ' HB2' ' CE2' ' A' ' 155' ' ' TYR . 53.7 Cg_endo -69.72 161.88 44.22 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.64 2.226 . . . . 0.0 112.336 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 3.7 t -79.26 141.71 36.84 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.127 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -129.05 122.67 30.47 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.875 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . 0.555 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 6.3 t-20 74.11 47.76 0.21 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.589 0.709 . . . . 0.0 110.899 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.555 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.9 Cg_endo -69.78 123.29 9.95 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.646 2.231 . . . . 0.0 112.375 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.78 -179.28 2.81 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.674 2.25 . . . . 0.0 112.363 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.704 HG13 ' HA ' ' A' ' 28' ' ' PRO . 90.8 t -140.97 138.5 18.11 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.592 0.711 . . . . 0.0 111.096 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.704 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.6 Cg_endo -69.76 144.22 76.05 Favored 'Cis proline' 0 C--O 1.231 0.174 0 C-N-CA 122.69 -1.796 . . . . 0.0 112.311 -0.056 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 5.6 t80 -97.29 114.32 26.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.942 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.432 ' CD1' ' HB3' ' A' ' 146' ' ' GLU . 66.6 m-85 -99.55 107.25 19.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.875 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.4 ' CA ' ' HE3' ' A' ' 17' ' ' MET . . . -115.29 100.44 0.97 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.513 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.483 ' O ' ' CG ' ' A' ' 32' ' ' ARG . 0.0 OUTLIER -72.78 117.11 14.08 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.84 0.353 . . . . 0.0 110.895 -179.848 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.4 ' O ' ' HD3' ' A' ' 32' ' ' ARG . 11.6 mt -63.45 150.11 44.47 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.937 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.455 ' OE1' ' NH1' ' A' ' 32' ' ' ARG . 7.3 mm100 -98.01 -46.44 5.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.943 179.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.557 ' O ' HG23 ' A' ' 38' ' ' THR . . . -103.47 33.22 6.76 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.486 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.41 ' O ' ' O ' ' A' ' 35' ' ' GLY . . . 37.21 -157.5 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.443 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 51.3 mt -88.43 106.7 18.43 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.832 0.348 . . . . 0.0 110.92 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.557 HG23 ' O ' ' A' ' 35' ' ' GLY . 34.4 p -122.12 170.57 9.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.109 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.495 ' HB2' ' HG ' ' A' ' 117' ' ' LEU . . . -79.13 -11.81 59.99 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.074 179.884 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 12.2 mmm180 -110.64 22.39 15.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.841 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.817 ' CZ ' HD11 ' A' ' 43' ' ' ILE . 27.8 ttt-85 -117.94 143.22 46.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.873 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 51.9 m -138.14 129.1 27.07 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.129 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.817 HD11 ' CZ ' ' A' ' 41' ' ' ARG . 4.8 mp -94.64 145.73 7.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.133 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 76.6 mt -142.73 114.33 3.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.125 179.852 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 48.3 mt -115.93 107.71 23.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.143 179.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.5 mtmm -109.89 112.92 25.24 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.919 179.827 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.411 ' CA ' ' O ' ' A' ' 152' ' ' THR . . . -146.85 -142.89 3.78 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.534 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -167.58 130.64 1.67 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.874 0.368 . . . . 0.0 110.92 -179.827 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 16.0 t -78.98 115.74 54.69 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.661 0.743 . . . . 0.0 111.099 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 155.42 65.81 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.676 2.251 . . . . 0.0 112.326 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 -19.27 36.47 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.723 2.282 . . . . 0.0 112.319 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 69.5 p -106.15 16.84 24.39 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.167 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -114.66 125.91 7.01 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.489 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 15.7 mttp -66.25 -61.84 1.8 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.785 0.326 . . . . 0.0 110.895 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.0 p -172.56 158.2 4.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.883 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.596 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 8.1 p90 -108.88 -173.85 2.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.845 -179.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.654 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -156.32 140.79 16.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.092 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.56 HG23 HG12 ' A' ' 147' ' ' ILE . 3.1 mp -122.38 107.84 20.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.098 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -111.74 143.52 42.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.852 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.687 ' CE2' HD13 ' A' ' 145' ' ' LEU . 13.6 m-85 -113.67 102.04 9.88 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.91 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.411 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 31.9 ttmt -95.1 168.07 10.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.888 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.78 HG13 ' O ' ' A' ' 141' ' ' ARG . 25.5 t -98.94 122.37 50.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.106 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -60.22 -26.62 64.05 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.479 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.564 ' H ' HG12 ' A' ' 62' ' ' VAL . 66.4 m -75.47 -70.88 0.4 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.869 0.366 . . . . 0.0 110.855 -179.76 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 29.8 m -85.23 -73.54 0.43 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.825 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 137.58 35.87 0.17 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.447 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.534 ' O ' HG23 ' A' ' 62' ' ' VAL . 0.3 OUTLIER -104.11 146.87 28.11 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.766 0.317 . . . . 0.0 110.879 -179.972 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 60.4 mt -94.79 115.89 34.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.203 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.7 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -83.19 -39.11 21.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.075 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.687 HD13 ' CG ' ' A' ' 132' ' ' PHE . 38.8 tp -135.06 133.01 38.89 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.952 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.474 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.9 OUTLIER -134.34 93.09 3.01 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.827 179.885 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.543 HD11 HD21 ' A' ' 70' ' ' LEU . 59.3 mt -97.21 130.84 45.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.094 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.654 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -136.11 106.5 9.53 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.629 0.728 . . . . 0.0 110.942 179.87 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.643 ' HA ' HG22 ' A' ' 81' ' ' VAL . 54.1 Cg_endo -69.75 155.12 66.78 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.664 2.243 . . . . 0.0 112.399 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 25.9 mtp180 -132.35 101.48 5.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.822 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -58.61 -52.08 67.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.855 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.418 ' O ' ' C ' ' A' ' 78' ' ' ASN . . . -63.36 -91.64 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.49 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.418 ' C ' ' O ' ' A' ' 77' ' ' GLY . 19.9 t-20 -35.95 -49.07 0.61 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.889 0.376 . . . . 0.0 110.914 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 92.43 40.75 4.99 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.491 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 25.1 p -144.8 118.26 9.08 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.823 0.344 . . . . 0.0 111.123 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.643 HG22 ' HA ' ' A' ' 74' ' ' PRO . 17.3 t -87.84 104.64 14.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.126 179.888 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.712 HG22 ' HD3' ' A' ' 96' ' ' LYS . 58.7 t -76.25 145.52 10.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.125 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -125.78 131.28 52.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.861 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.474 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.2 m120 -143.81 179.52 7.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.892 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.405 ' CB ' ' O ' ' A' ' 69' ' ' ALA . 96.6 p -160.7 107.29 1.49 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.816 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.888 HD13 ' NE1' ' A' ' 91' ' ' TRP . 28.5 tp -77.38 116.92 18.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.935 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.534 HD22 HD13 ' A' ' 136' ' ' LEU . 66.7 mt -93.33 161.58 14.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.933 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.455 ' ND2' ' OD2' ' A' ' 67' ' ' ASP . 14.0 m-80 -41.63 101.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.869 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.86 -3.38 3.94 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.516 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.843 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -124.83 171.58 10.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.838 0.351 . . . . 0.0 110.868 -179.72 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.888 ' NE1' HD13 ' A' ' 86' ' ' LEU . 23.0 m95 -128.08 159.85 33.8 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.968 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -89.37 -105.82 1.12 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.478 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . 0.424 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 25.2 m -165.91 166.15 17.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.86 0.362 . . . . 0.0 110.82 -179.76 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.412 ' HA ' ' ND2' ' A' ' 84' ' ' ASN . 5.6 mt-10 -88.32 119.99 29.26 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.867 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -120.03 116.44 25.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.85 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.712 ' HD3' HG22 ' A' ' 82' ' ' VAL . 46.5 mtmt -122.25 124.79 44.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.873 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 26.9 ttpt -172.53 107.95 0.19 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.919 179.882 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.825 HD11 ' O ' ' A' ' 100' ' ' HIS . 7.1 tt -147.35 159.58 8.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.125 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.482 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 9.8 t -102.75 -34.23 9.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.13 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . 0.825 ' O ' HD11 ' A' ' 98' ' ' ILE . 1.7 p-80 -155.66 130.25 9.06 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.847 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . 0.632 ' ND2' HD13 ' A' ' 98' ' ' ILE . 11.6 m120 -101.71 97.72 8.41 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.61 0.719 . . . . 0.0 110.937 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.403 ' HD3' ' O ' ' A' ' 100' ' ' HIS . 53.7 Cg_endo -69.7 -31.06 21.54 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.698 2.265 . . . . 0.0 112.339 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.543 ' CZ ' HD21 ' A' ' 129' ' ' LEU . 5.8 m-85 -52.77 107.97 0.27 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.86 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -133.52 139.66 11.11 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.507 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 105.21 1.43 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.727 2.285 . . . . 0.0 112.38 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 122.97 -8.04 9.24 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.497 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 7.3 pt20 -132.97 153.85 51.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.83 0.348 . . . . 0.0 110.887 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -77.15 172.94 12.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.865 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 32.4 p90 -160.16 139.89 11.25 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.899 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -109.55 104.91 14.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.898 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.694 HD13 ' N ' ' A' ' 112' ' ' SER . 1.0 OUTLIER -105.51 138.17 42.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.919 -179.955 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.694 ' N ' HD13 ' A' ' 111' ' ' LEU . 2.6 m -144.64 113.98 7.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.857 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.464 HD11 HD12 ' A' ' 111' ' ' LEU . 4.9 mp -95.32 131.62 41.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.116 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 15.7 mtp180 -106.38 128.01 53.71 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.842 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . 0.481 ' HA ' ' CD1' ' A' ' 120' ' ' PHE . 35.6 t -98.99 121.37 40.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.908 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -116.38 -138.13 6.22 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.477 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.495 ' HG ' ' HB2' ' A' ' 39' ' ' ALA . 9.7 mt -123.03 -31.38 3.63 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.806 0.336 . . . . 0.0 110.932 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.423 ' C ' ' CD2' ' A' ' 134' ' ' HIS . 0.9 OUTLIER -96.66 -34.21 11.47 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.871 179.891 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 20.8 ptt-85 -172.91 171.48 4.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.481 ' CD1' ' HA ' ' A' ' 115' ' ' CYS . 4.1 m-30 -94.8 157.62 15.85 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.887 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 19.8 mtpp -130.49 99.77 5.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.891 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.486 HG13 HD11 ' A' ' 111' ' ' LEU . 42.2 t -84.46 133.97 28.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.131 179.867 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' TYR . . . . . 0.449 ' O ' HD22 ' A' ' 111' ' ' LEU . 81.5 m-85 -122.46 153.84 38.59 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.886 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.435 ' O ' ' CG ' ' A' ' 125' ' ' ASN . . . -139.72 121.34 15.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.123 179.815 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.435 ' CG ' ' O ' ' A' ' 124' ' ' ALA . 10.7 p30 48.49 33.66 4.2 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.895 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 81.78 26.5 49.75 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.438 179.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 37.0 mm-40 -129.76 168.02 17.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.842 0.353 . . . . 0.0 110.909 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 33.9 t-80 -91.16 116.09 28.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.829 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.543 HD21 ' CZ ' ' A' ' 103' ' ' PHE . 9.0 tp -87.93 -68.32 0.77 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.957 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.49 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 3.9 p90 -168.68 172.21 8.15 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.862 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -115.43 156.73 25.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.853 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.687 ' CG ' HD13 ' A' ' 70' ' ' LEU . 0.2 OUTLIER -122.49 104.4 9.35 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.893 -179.94 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.514 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -60.08 134.13 56.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.13 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' HIS . . . . . 0.423 ' CD2' ' C ' ' A' ' 118' ' ' ASP . 25.7 m-70 -61.77 99.56 0.12 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.836 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.424 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 11.7 mtt-85 -82.12 -46.36 13.95 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . 0.534 HD13 HD22 ' A' ' 87' ' ' LEU . 13.9 tp -97.55 113.67 25.42 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.906 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 90.8 p -56.05 -32.78 64.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.843 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.647 ' HB1' ' HG3' ' A' ' 141' ' ' ARG . . . -85.69 37.88 0.72 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.061 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 4.7 p90 -56.13 -27.93 55.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.867 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' GLN . . . . . 0.464 ' HG2' ' N ' ' A' ' 141' ' ' ARG . 17.9 pm0 -63.48 -30.41 71.54 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.942 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.78 ' O ' HG13 ' A' ' 62' ' ' VAL . 22.5 mtt180 -65.38 -36.11 82.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.824 -179.866 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.7 HG21 ' CB ' ' A' ' 69' ' ' ALA . 90.5 t -56.55 105.0 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.119 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -126.01 35.7 4.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.879 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 32' ' ' ARG . 0.6 OUTLIER -144.58 137.98 27.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.138 -179.874 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.687 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.0 tp -134.7 106.43 6.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.904 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' GLU . . . . . 0.432 ' HB3' ' CD1' ' A' ' 30' ' ' PHE . 4.9 pt-20 -109.22 149.16 29.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.934 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.56 HG12 HG23 ' A' ' 58' ' ' ILE . 12.7 mt -137.49 106.82 4.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.154 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -118.58 174.5 6.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.908 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 110.02 -140.81 15.99 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.482 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -117.86 91.92 3.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.811 0.338 . . . . 0.0 110.839 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.426 ' HB ' ' CG ' ' A' ' 56' ' ' PHE . 2.9 p -151.37 135.68 9.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.116 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . 0.411 ' O ' ' CA ' ' A' ' 47' ' ' GLY . 17.7 m -95.93 92.82 6.68 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.171 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.494 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 93.3 mt -76.31 136.38 39.59 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.965 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 19.5 m -123.1 -39.27 2.5 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.858 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . 0.432 ' CE2' ' HB2' ' A' ' 21' ' ' PRO . 37.3 t80 -141.81 127.07 18.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.905 -179.828 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 75.9 t -140.43 105.24 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.096 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -121.34 119.82 33.29 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.916 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 56.1 mt -91.87 88.77 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.107 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 24.9 p -72.49 132.34 43.72 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.878 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -176.06 -157.63 17.73 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.451 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.84 107.5 1.89 Allowed 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.662 2.241 . . . . 0.0 112.3 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 56.6 p -72.98 86.62 1.31 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.81 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 1.4 t -69.45 167.81 15.85 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.836 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.472 -179.994 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.29 0 N-CA-C 112.465 -0.254 . . . . 0.0 112.465 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 40.1 t 47.46 42.1 13.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.846 0.355 . . . . 0.0 110.856 -179.723 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 25.6 t -93.7 154.88 17.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.853 -179.795 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -116.86 -94.66 1.82 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.465 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 32.5 m -109.98 172.52 6.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.877 0.37 . . . . 0.0 110.842 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 37.1 p -120.91 160.12 24.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.854 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -66.45 -116.37 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.493 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 74.6 t60 -84.11 146.38 27.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.704 0.287 . . . . 0.0 110.883 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 15.5 tt0 -154.74 125.85 7.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.917 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 12.1 pt20 -105.46 127.81 53.2 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.9 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 8.4 mt -132.33 99.05 4.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.94 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.6 m-20 -69.32 -40.67 77.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.865 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 69.0 m -56.81 -178.39 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.81 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.452 ' HB2' ' HD2' ' A' ' 15' ' ' PRO . 0.5 OUTLIER -108.61 157.35 36.87 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.574 0.702 . . . . 0.0 110.927 -179.997 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.452 ' HD2' ' HB2' ' A' ' 14' ' ' LEU . 53.8 Cg_endo -69.78 -169.76 0.35 Allowed 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.664 2.242 . . . . 0.0 112.376 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.435 ' CG2' ' N ' ' A' ' 17' ' ' MET . 1.3 m -79.9 153.24 29.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.144 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . 0.435 ' N ' ' CG2' ' A' ' 16' ' ' THR . 1.4 ptt? -83.97 68.54 10.05 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.859 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 18.2 mp0 -73.73 157.71 36.0 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.901 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.28 -135.07 12.31 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.51 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 170.08 17.34 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.727 2.285 . . . . 0.0 112.32 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.78 -173.66 0.76 Allowed 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.664 2.242 . . . . 0.0 112.349 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.439 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.5 m -96.29 137.33 35.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.127 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -137.35 120.18 16.35 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.907 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . 0.53 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 8.8 m120 60.27 49.03 1.94 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.57 0.7 . . . . 0.0 110.899 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.53 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.2 Cg_endo -69.82 141.75 45.8 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.646 2.23 . . . . 0.0 112.296 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -178.02 2.14 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.63 2.22 . . . . 0.0 112.387 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.684 HG13 ' HA ' ' A' ' 28' ' ' PRO . 96.6 t -142.35 137.89 16.01 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.651 0.739 . . . . 0.0 111.088 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.684 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.8 Cg_endo -69.78 145.23 78.87 Favored 'Cis proline' 0 C--O 1.232 0.192 0 C-N-CA 122.65 -1.812 . . . . 0.0 112.394 -0.057 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -97.52 123.03 41.24 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.885 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -107.74 102.79 11.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.853 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -108.5 110.66 3.12 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.508 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.413 ' NH1' ' HA3' ' A' ' 63' ' ' GLY . 9.0 mmt180 -73.14 113.36 10.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.87 0.366 . . . . 0.0 110.887 -179.859 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 5.9 mt -73.25 97.9 2.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.909 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.402 ' CD ' HG21 ' A' ' 16' ' ' THR . 20.6 mt-30 -66.79 94.76 0.32 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.885 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 135.69 -42.94 1.29 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.481 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.592 ' O ' HG23 ' A' ' 38' ' ' THR . . . 96.23 170.13 34.85 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.423 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . 0.768 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 96.1 mt -60.26 105.09 0.38 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.914 0.388 . . . . 0.0 110.913 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.592 HG23 ' O ' ' A' ' 36' ' ' GLY . 38.2 p -117.31 158.76 23.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.119 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -64.32 -16.12 61.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.106 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -114.96 23.92 12.16 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.821 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.504 ' NH1' ' CG2' ' A' ' 158' ' ' ILE . 44.4 ttm-85 -112.6 135.35 53.42 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.869 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 92.3 m -133.16 126.1 30.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.166 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.466 ' N ' HD12 ' A' ' 43' ' ' ILE . 4.6 mp -95.44 138.86 20.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.166 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 88.7 mt -128.91 126.67 65.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.13 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 58.5 mt -126.08 107.59 17.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.117 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 23.2 mtmt -112.05 112.43 24.06 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.883 179.849 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -143.69 -141.91 3.87 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.436 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . 0.586 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.6 OUTLIER -169.28 124.03 0.84 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.931 0.396 . . . . 0.0 110.928 -179.775 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.543 HG23 ' CD2' ' A' ' 109' ' ' PHE . 14.1 t -75.35 116.39 54.17 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.651 0.738 . . . . 0.0 111.113 179.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 158.94 55.28 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.671 2.247 . . . . 0.0 112.355 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 -21.93 32.93 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.711 2.274 . . . . 0.0 112.393 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 24.4 p -105.88 18.88 21.44 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.142 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -110.2 117.71 4.81 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.44 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 29.2 mtpt -61.58 -60.04 4.3 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.797 0.332 . . . . 0.0 110.891 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 10.5 p -174.59 154.87 2.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.882 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.585 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 5.2 p90 -109.54 -173.48 2.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.881 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.704 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -155.24 143.9 20.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.123 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.465 HG22 ' CE1' ' A' ' 60' ' ' PHE . 2.8 mp -123.91 99.0 5.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.142 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.7 m-80 -99.0 143.71 28.98 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.934 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.551 ' HB3' HG11 ' A' ' 142' ' ' VAL . 15.8 m-85 -118.24 97.26 5.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.864 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.437 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 31.5 ttmt -96.66 169.77 9.65 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.906 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.623 HG22 ' HA ' ' A' ' 142' ' ' VAL . 28.4 t -101.42 124.75 55.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.097 179.871 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.413 ' HA3' ' NH1' ' A' ' 32' ' ' ARG . . . -59.72 -36.21 88.95 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.51 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 23.1 t -67.21 -73.57 0.13 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.86 0.362 . . . . 0.0 110.857 -179.75 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 10.6 t -78.17 -72.48 0.37 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 -179.795 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 129.51 42.33 0.23 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.459 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.431 ' O ' HG23 ' A' ' 62' ' ' VAL . 1.1 m-20 -115.12 140.89 48.69 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.817 0.341 . . . . 0.0 110.84 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.615 HD12 ' HB3' ' A' ' 86' ' ' LEU . 55.2 mt -86.08 122.17 38.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.113 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.517 ' HB3' HG21 ' A' ' 142' ' ' VAL . . . -92.93 -31.8 14.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.087 179.831 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.655 HD22 ' CD2' ' A' ' 132' ' ' PHE . 40.0 tp -140.44 131.1 25.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.903 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.488 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.5 OUTLIER -134.1 92.31 2.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.863 179.862 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.515 HD11 HD21 ' A' ' 70' ' ' LEU . 55.7 mt -95.84 130.53 44.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.142 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.704 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -137.79 106.0 8.23 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.632 0.729 . . . . 0.0 110.905 179.924 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.585 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.3 Cg_endo -69.71 155.45 66.06 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.698 2.265 . . . . 0.0 112.394 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 39.3 mtp180 -130.67 96.11 4.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.868 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . 0.4 ' HE3' ' HB3' ' A' ' 103' ' ' PHE . 0.0 OUTLIER -55.5 156.73 4.36 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.85 179.995 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 83.2 -79.93 1.87 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.5 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 7.5 t30 -55.05 -66.64 0.37 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.852 0.358 . . . . 0.0 110.916 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 113.25 43.55 0.84 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.503 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.9 p -135.97 117.62 14.96 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.83 0.348 . . . . 0.0 111.112 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.455 HG21 ' HE2' ' A' ' 103' ' ' PHE . 20.6 t -99.67 108.38 22.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.169 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.641 HG22 ' HD3' ' A' ' 96' ' ' LYS . 47.3 t -76.95 143.1 13.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.133 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . 0.437 ' NH1' ' CD2' ' A' ' 130' ' ' PHE . 0.2 OUTLIER -126.93 129.87 49.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.873 -179.977 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.488 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.4 OUTLIER -140.6 179.65 6.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.905 -179.922 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 28.8 t -160.06 105.01 1.52 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.891 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.904 HD12 ' O ' ' A' ' 90' ' ' SER . 24.9 tp -76.92 118.29 19.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.93 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.51 ' N ' ' O ' ' A' ' 90' ' ' SER . 86.5 mt -95.8 161.63 13.94 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.901 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.462 ' C ' ' H ' ' A' ' 90' ' ' SER . 0.2 OUTLIER -38.64 101.81 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.911 179.931 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.33 -6.09 0.86 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.493 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.904 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -118.47 169.24 9.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.879 0.371 . . . . 0.0 110.84 -179.705 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.862 ' NE1' HD13 ' A' ' 86' ' ' LEU . 20.5 m95 -128.39 161.29 29.81 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.939 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -93.96 -111.71 2.26 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.467 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . 0.433 ' HB2' ' NH2' ' A' ' 135' ' ' ARG . 39.3 m -158.0 170.97 21.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.839 0.352 . . . . 0.0 110.844 -179.717 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -94.87 123.32 38.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.913 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -120.99 120.52 35.65 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.888 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.641 ' HD3' HG22 ' A' ' 82' ' ' VAL . 9.4 mtmp? -123.41 120.02 31.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.913 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -170.75 109.67 0.34 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.903 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.843 HD11 ' O ' ' A' ' 100' ' ' HIS . 2.8 tt -148.84 154.2 10.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.127 179.86 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.445 ' N ' ' CG1' ' A' ' 98' ' ' ILE . 9.0 t -93.95 -40.91 9.87 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.176 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . 0.843 ' O ' HD11 ' A' ' 98' ' ' ILE . 2.4 p-80 -147.18 128.44 14.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.865 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -103.32 95.62 7.23 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.652 0.739 . . . . 0.0 110.865 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.45 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.7 Cg_endo -69.79 -40.24 5.51 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.715 2.277 . . . . 0.0 112.324 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.477 ' CE2' ' HB3' ' A' ' 74' ' ' PRO . 8.1 m-85 -34.46 112.01 0.13 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.811 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -138.34 134.67 6.99 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.494 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 98.05 0.66 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.685 2.256 . . . . 0.0 112.337 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 126.01 -3.59 7.9 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.493 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.3 pt20 -132.46 149.39 52.34 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.806 0.336 . . . . 0.0 110.926 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' PHE . . . . . 0.586 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 79.8 m-85 -67.04 169.91 7.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.883 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.543 ' CD2' HG23 ' A' ' 49' ' ' VAL . 19.6 p90 -161.1 120.02 2.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.847 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -96.6 107.13 19.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.895 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.786 HD13 ' N ' ' A' ' 112' ' ' SER . 0.6 OUTLIER -108.95 138.56 45.1 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.926 -179.921 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.786 ' N ' HD13 ' A' ' 111' ' ' LEU . 3.7 m -145.27 115.4 7.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.854 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.509 HG23 HG22 ' A' ' 122' ' ' VAL . 4.1 mp -95.12 138.89 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.105 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 45.6 mtt-85 -113.19 123.74 50.92 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.874 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . 0.578 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 11.2 t -92.75 117.53 30.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.872 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -114.87 -142.41 7.83 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.468 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 17.4 mt -121.43 -35.99 3.16 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.788 0.328 . . . . 0.0 110.884 -179.9 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -92.32 -33.36 14.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.856 179.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -174.07 164.62 4.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.871 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.768 ' HZ ' HD22 ' A' ' 37' ' ' LEU . 2.8 m-30 -90.52 156.8 17.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.921 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 23.2 mtpp -128.9 103.23 6.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.927 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.737 HG13 HD11 ' A' ' 111' ' ' LEU . 46.3 t -92.7 127.95 44.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.121 179.92 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 14.7 m-85 -117.9 153.05 34.23 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.878 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . . . . . . . . . . . -135.89 110.4 8.55 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.128 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 57.38 33.43 23.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.857 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 82.35 29.52 36.52 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.498 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 37.2 mm-40 -138.27 121.52 16.97 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.845 0.355 . . . . 0.0 110.907 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 26.4 t-80 -54.41 110.71 0.66 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.86 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.446 HD21 ' CZ ' ' A' ' 103' ' ' PHE . 8.6 tp -76.81 -66.45 0.82 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.906 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.437 ' CD2' ' NH1' ' A' ' 83' ' ' ARG . 5.3 p90 -166.24 171.26 12.38 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.882 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -111.4 147.07 36.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.887 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.655 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -113.01 107.46 15.99 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.872 -179.872 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.557 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -64.0 130.95 46.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.132 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 33.7 m-70 -58.5 111.81 1.37 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.838 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.433 ' NH2' ' HB2' ' A' ' 93' ' ' SER . 44.9 mtt-85 -96.08 -44.18 7.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.915 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 4.4 tp -100.96 109.35 21.26 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 97.4 p -49.37 -34.39 15.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.512 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -83.27 31.53 0.45 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.086 179.893 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.533 ' O ' HD12 ' A' ' 37' ' ' LEU . 3.9 p90 -50.44 -40.09 49.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.846 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 10.4 pt20 -52.87 -43.21 65.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.904 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.512 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 56.9 mtp85 -50.95 -42.76 60.04 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.874 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.623 ' HA ' HG22 ' A' ' 62' ' ' VAL . 97.1 t -44.35 106.12 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.121 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -130.43 29.44 4.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.838 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 25.4 m -139.92 112.65 7.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.124 -179.89 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.537 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.0 tp -110.54 108.03 17.86 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.929 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' GLU . . . . . 0.406 ' C ' HG13 ' A' ' 147' ' ' ILE . 1.2 pm0 -111.67 153.59 26.18 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.858 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.406 HG13 ' C ' ' A' ' 146' ' ' GLU . 16.9 mt -139.39 112.05 5.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.135 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -121.14 172.35 8.04 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.928 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 110.6 -142.47 16.71 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.452 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -117.49 93.57 4.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.88 0.371 . . . . 0.0 110.847 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.4 p -151.23 152.24 11.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.182 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 27.8 m -113.55 93.59 4.46 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.141 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.477 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 79.2 mt -73.03 141.4 47.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.94 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 50.1 m -125.83 -28.54 3.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.857 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 31.3 t80 -157.56 129.97 7.3 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 90.2 t -140.53 105.52 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.108 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 18.8 tt0 -121.13 140.56 51.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.855 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' ILE . . . . . 0.504 ' CG2' ' NH1' ' A' ' 41' ' ' ARG . 14.9 mt -111.0 94.59 3.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.092 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 5.7 p -59.43 125.61 24.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.844 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 150.9 -167.65 30.55 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.481 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 154.9 67.25 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.705 2.27 . . . . 0.0 112.325 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 18.3 m -119.15 -56.98 2.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.874 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 4.0 t -88.65 96.19 10.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.84 -179.82 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.483 -179.979 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.523 -0.231 . . . . 0.0 112.523 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 37.8 p 43.71 41.75 3.83 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.877 0.37 . . . . 0.0 110.874 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.7 m -63.72 114.47 4.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.836 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -165.67 172.35 41.13 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.496 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 57.6 m -151.66 143.87 23.99 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.836 0.351 . . . . 0.0 110.884 -179.74 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 67.1 p -49.8 -65.96 0.47 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.823 -179.814 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 80.12 114.7 0.28 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.503 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 7.4 p80 37.33 47.36 0.7 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.743 0.306 . . . . 0.0 110.829 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -106.59 -53.8 2.57 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.939 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 44.8 mm-40 -112.44 108.98 18.31 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.885 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 8.5 mt -40.14 141.87 0.43 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.873 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 74.9 m-20 -122.48 -44.96 2.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.905 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 36.8 p -119.26 -174.42 2.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.862 -179.851 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.434 ' HB2' ' HD2' ' A' ' 15' ' ' PRO . 0.5 OUTLIER -116.0 157.14 45.71 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.645 0.736 . . . . 0.0 110.918 179.952 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.434 ' HD2' ' HB2' ' A' ' 14' ' ' LEU . 53.9 Cg_endo -69.72 171.4 14.48 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.74 2.293 . . . . 0.0 112.327 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.538 HG23 ' HG2' ' A' ' 18' ' ' GLU . 11.3 t -77.23 150.92 35.36 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.162 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 72.9 mtm -88.82 35.57 0.79 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.891 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.538 ' HG2' HG23 ' A' ' 16' ' ' THR . 11.3 pt-20 -60.24 169.08 1.73 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.899 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.409 ' HA3' ' HD2' ' A' ' 20' ' ' PRO . . . 94.15 -147.03 18.43 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.504 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.409 ' HD2' ' HA3' ' A' ' 19' ' ' GLY . 53.7 Cg_endo -69.75 168.38 21.72 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.729 2.286 . . . . 0.0 112.324 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 177.98 5.04 Favored 'Trans proline' 0 C--O 1.233 0.23 0 C-N-CA 122.685 2.257 . . . . 0.0 112.359 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.429 ' CG2' ' HB3' ' A' ' 25' ' ' PRO . 1.9 m -89.75 145.08 25.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.15 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -143.18 137.32 28.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.824 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . 0.549 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 9.0 m120 45.44 47.94 4.51 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.61 0.719 . . . . 0.0 110.93 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.549 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 54.1 Cg_endo -69.71 139.26 39.96 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.641 2.227 . . . . 0.0 112.375 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -177.62 1.95 Allowed 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.693 2.262 . . . . 0.0 112.304 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.633 HG13 ' HA ' ' A' ' 28' ' ' PRO . 84.2 t -143.7 136.73 13.82 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.592 0.711 . . . . 0.0 111.124 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.633 ' HA ' HG13 ' A' ' 27' ' ' VAL . 53.4 Cg_endo -69.71 145.37 79.12 Favored 'Cis proline' 0 C--N 1.341 0.153 0 C-N-CA 122.681 -1.799 . . . . 0.0 112.373 -0.091 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 4.9 t80 -98.34 115.26 28.07 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.937 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -99.44 103.1 14.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.901 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -118.09 102.16 0.95 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.488 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.4 ' HA ' ' HA ' ' A' ' 144' ' ' THR . 0.0 OUTLIER -73.45 128.47 35.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.843 0.354 . . . . 0.0 110.867 -179.886 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.455 ' N ' ' O ' ' A' ' 143' ' ' ASP . 3.3 mt -74.0 150.25 40.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.885 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 10.6 mm100 -105.24 99.67 9.27 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.913 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 124.46 -55.92 0.7 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.488 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.538 ' O ' HG23 ' A' ' 38' ' ' THR . . . 119.47 169.65 14.3 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.515 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . 0.516 HD12 ' O ' ' A' ' 139' ' ' PHE . 87.5 mt -61.04 97.91 0.07 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.87 0.367 . . . . 0.0 110.953 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.538 HG23 ' O ' ' A' ' 36' ' ' GLY . 48.4 p -109.5 160.73 15.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.159 179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -58.1 -28.6 64.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.084 179.892 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 3.1 mpt_? -105.96 39.1 1.85 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.863 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 29.5 ttm-85 -117.76 137.62 52.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.872 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 93.6 m -138.41 120.84 16.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.155 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.46 ' N ' HD12 ' A' ' 43' ' ' ILE . 4.7 mp -94.35 134.99 29.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.148 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 93.3 mt -125.24 138.41 54.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.116 179.839 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 42.9 mt -138.92 107.65 3.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.103 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 8.6 mtmm -110.04 111.32 22.62 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.924 179.823 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -142.23 -143.14 4.16 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.478 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . 0.57 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 1.1 t80 -170.0 128.66 0.91 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.949 0.404 . . . . 0.0 110.91 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 4.4 t -80.41 115.96 58.55 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.624 0.726 . . . . 0.0 111.143 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.74 155.81 65.04 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.672 2.248 . . . . 0.0 112.369 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 -14.07 35.44 Favored 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.689 2.259 . . . . 0.0 112.33 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 46.8 p -112.24 15.91 20.25 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.107 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -112.06 118.88 4.85 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.491 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 14.1 mtpp -58.09 -62.78 1.57 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.77 0.319 . . . . 0.0 110.859 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 70.1 p -173.71 164.45 4.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.872 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.604 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 5.2 p90 -119.02 -173.27 2.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.879 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -155.56 138.73 15.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.105 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.598 HD11 ' CE2' ' A' ' 56' ' ' PHE . 3.7 mp -117.61 104.61 16.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.121 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 2.8 m-80 -105.24 147.94 27.51 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.883 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.571 ' CE1' HG22 ' A' ' 58' ' ' ILE . 2.4 m-85 -120.89 101.22 7.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.885 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.43 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 34.5 ttmt -95.78 167.26 11.37 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.901 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.774 HG22 ' HA ' ' A' ' 142' ' ' VAL . 94.2 t -100.27 121.09 50.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.097 179.889 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -57.0 -41.2 92.27 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.481 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 10.8 t -62.18 -72.2 0.13 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.885 0.374 . . . . 0.0 110.89 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.4 t -80.56 -71.04 0.48 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.878 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 128.26 42.48 0.25 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.507 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.406 ' OD1' ' OD1' ' A' ' 88' ' ' ASN . 1.5 m-20 -115.02 144.14 44.08 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.824 0.345 . . . . 0.0 110.856 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.609 HD12 ' HB3' ' A' ' 86' ' ' LEU . 42.8 mt -88.74 122.59 40.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.145 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.536 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -92.82 -34.77 13.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.134 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.708 HD21 HD11 ' A' ' 72' ' ' ILE . 30.3 tp -139.17 130.4 26.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.928 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.473 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.2 OUTLIER -134.81 92.14 2.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.83 179.914 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.708 HD11 HD21 ' A' ' 70' ' ' LEU . 16.0 mt -94.25 137.61 22.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.111 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.5 ' ND2' ' O ' ' A' ' 56' ' ' PHE . 1.0 OUTLIER -141.86 106.17 5.81 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.619 0.723 . . . . 0.0 110.923 179.949 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.604 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 53.8 Cg_endo -69.75 154.87 67.26 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.677 2.251 . . . . 0.0 112.302 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 63.7 mtt-85 -129.78 100.76 5.6 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.854 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -62.25 -43.39 98.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.92 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -66.36 -83.97 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.462 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 4.7 t30 -48.09 -57.09 6.3 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.825 0.345 . . . . 0.0 110.874 -179.881 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 106.57 40.59 1.87 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.542 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 20.7 p -143.94 121.79 11.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.803 0.335 . . . . 0.0 111.176 -179.891 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.429 ' CG1' ' CG2' ' A' ' 72' ' ' ILE . 18.5 t -86.59 111.01 20.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.121 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.519 HG22 ' HD3' ' A' ' 96' ' ' LYS . 61.4 t -82.84 139.81 17.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.097 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -126.94 124.46 39.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.865 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.473 ' O ' ' N ' ' A' ' 71' ' ' HIS . 0.5 OUTLIER -135.11 -178.15 4.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.885 -179.909 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 47.5 t -160.16 105.02 1.5 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.867 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.9 HD13 ' NE1' ' A' ' 91' ' ' TRP . 38.1 tp -77.09 116.71 17.98 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.932 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.518 ' N ' ' O ' ' A' ' 90' ' ' SER . 86.4 mt -94.84 162.07 13.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.9 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.433 ' ND2' ' H ' ' A' ' 88' ' ' ASN . 9.7 m-80 -40.88 102.0 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.86 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 64.49 -1.39 3.11 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.516 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.84 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -125.62 171.59 10.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.886 0.374 . . . . 0.0 110.841 -179.74 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.9 ' NE1' HD13 ' A' ' 86' ' ' LEU . 22.1 m95 -128.74 158.64 38.06 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.877 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -88.75 -96.3 1.02 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.427 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 2.0 m -174.68 164.76 3.66 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.894 0.378 . . . . 0.0 110.841 -179.711 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.404 ' HG3' ' ND2' ' A' ' 84' ' ' ASN . 14.2 mp0 -88.63 118.5 28.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.878 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 72.4 mm-40 -116.09 121.03 40.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.897 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.519 ' HD3' HG22 ' A' ' 82' ' ' VAL . 7.0 mtmp? -125.58 118.67 26.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.86 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -169.66 108.16 0.4 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.873 179.835 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.583 HD11 ' O ' ' A' ' 100' ' ' HIS . 10.5 tt -147.89 151.19 13.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.132 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.476 HG23 ' N ' ' A' ' 100' ' ' HIS . 8.9 t -91.64 -43.92 9.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.168 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . 0.583 ' O ' HD11 ' A' ' 98' ' ' ILE . 2.0 p-80 -145.0 127.58 16.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.896 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . 0.414 ' HA ' ' HD2' ' A' ' 102' ' ' PRO . 38.6 t-20 -104.74 98.49 15.21 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.633 0.73 . . . . 0.0 110.835 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.414 ' HD2' ' HA ' ' A' ' 101' ' ' ASN . 53.8 Cg_endo -69.81 -37.14 9.45 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.674 2.25 . . . . 0.0 112.331 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.547 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 20.9 m-85 -37.96 112.83 0.24 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.892 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -137.92 137.98 9.26 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.468 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 100.21 0.81 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.69 2.26 . . . . 0.0 112.303 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 120.85 0.9 11.84 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.457 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -135.22 148.6 49.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.815 0.34 . . . . 0.0 110.93 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' PHE . . . . . 0.57 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 76.8 m-85 -68.23 171.08 7.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.822 -179.892 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 28.1 p90 -161.26 124.79 3.29 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.903 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -99.45 104.5 16.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.871 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.78 HD13 ' N ' ' A' ' 112' ' ' SER . 0.6 OUTLIER -104.68 136.83 43.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.903 -179.945 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.78 ' N ' HD13 ' A' ' 111' ' ' LEU . 3.6 m -145.03 113.64 6.72 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.828 -179.864 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.5 HG22 ' HD2' ' A' ' 120' ' ' PHE . 4.4 mp -96.56 137.22 24.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.111 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.497 ' O ' ' CD2' ' A' ' 120' ' ' PHE . 18.2 mtp180 -110.11 138.12 46.92 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.852 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . 0.465 ' HB2' ' CE2' ' A' ' 120' ' ' PHE . 17.7 t -105.13 120.11 40.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.917 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -115.02 -140.55 7.23 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.447 -179.867 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.5 mt -117.53 -38.08 3.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.785 0.326 . . . . 0.0 110.895 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.58 ' O ' ' CD2' ' A' ' 134' ' ' HIS . 20.3 t70 -89.79 -45.69 9.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.895 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.444 ' HG3' ' C ' ' A' ' 118' ' ' ASP . 32.3 mtp180 -157.56 -177.07 6.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.879 -179.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.5 ' HD2' HG22 ' A' ' 113' ' ' ILE . 12.4 m-85 -103.32 162.09 13.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.876 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 21.4 mtpp -134.26 105.15 6.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.906 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.577 HG13 HD11 ' A' ' 111' ' ' LEU . 57.8 t -90.44 136.48 23.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.1 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -124.85 143.57 50.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.955 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.405 ' HB1' ' HG3' ' A' ' 102' ' ' PRO . . . -131.13 106.93 8.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.039 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 59.1 35.83 23.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.918 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.69 40.55 17.76 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.448 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 18.9 mt-30 -146.84 135.64 22.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.868 0.366 . . . . 0.0 110.919 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 40.8 t-80 -66.77 100.75 0.73 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.89 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 10.2 tp -69.1 -68.58 0.39 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.875 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.482 ' C ' ' CD1' ' A' ' 130' ' ' PHE . 4.4 p90 -164.02 171.3 15.4 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.845 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 24.1 p-10 -110.65 158.79 18.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.906 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.589 ' CD2' HD22 ' A' ' 70' ' ' LEU . 0.1 OUTLIER -129.86 104.49 7.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.85 -179.883 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.555 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -62.99 135.71 57.44 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.04 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' HIS . . . . . 0.58 ' CD2' ' O ' ' A' ' 118' ' ' ASP . 29.9 m-70 -62.82 108.22 1.14 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.859 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . . . . . . . . . 4.9 mtp-105 -88.37 -48.71 7.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.891 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 8.5 tp -94.06 108.1 19.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.913 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 14.7 t -47.31 -36.0 8.71 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.494 ' HB1' ' HG3' ' A' ' 141' ' ' ARG . . . -83.47 33.32 0.46 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.101 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.516 ' O ' HD12 ' A' ' 37' ' ' LEU . 28.5 p90 -50.05 -36.12 27.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.872 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' GLN . . . . . . . . . . . . . 6.1 pt20 -53.45 -46.4 69.86 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.904 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.494 ' HG3' ' HB1' ' A' ' 138' ' ' ALA . 31.5 mtt180 -49.7 -41.78 44.22 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.859 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.774 ' HA ' HG22 ' A' ' 62' ' ' VAL . 61.9 t -48.71 100.3 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.138 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.455 ' O ' ' N ' ' A' ' 33' ' ' LEU . 3.9 p30 -124.95 26.24 7.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.906 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 32' ' ' ARG . 0.8 OUTLIER -132.1 131.72 42.62 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.142 -179.848 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.477 HD13 ' CE2' ' A' ' 60' ' ' PHE . 4.8 tp -128.82 104.85 7.86 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.922 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -108.88 151.57 26.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.904 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 15.5 mt -136.82 118.23 18.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.127 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -128.65 173.43 10.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.891 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.41 -151.34 16.91 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.519 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -107.23 92.75 4.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.855 0.36 . . . . 0.0 110.845 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.435 HG22 ' N ' ' A' ' 152' ' ' THR . 7.7 p -151.19 154.88 7.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.094 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . 0.435 ' N ' HG22 ' A' ' 151' ' ' VAL . 23.3 m -114.83 93.91 4.53 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.151 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.406 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 50.1 mt -79.25 132.83 36.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.911 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 14.7 m -117.42 -40.88 3.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.851 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 59.7 t80 -140.37 130.13 24.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.947 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 89.8 t -140.53 105.15 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.092 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 13.8 tt0 -120.81 121.93 39.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.958 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 14.9 mt -88.96 93.32 4.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.169 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 28.0 t -65.89 142.49 57.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.889 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 171.41 170.58 35.65 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.499 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 137.96 36.66 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.706 2.27 . . . . 0.0 112.314 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 3.7 t -121.59 125.73 47.44 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.858 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 51.8 p 50.22 41.93 24.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.894 -179.801 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.297 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.451 179.987 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.262 0 N-CA-C 112.461 -0.256 . . . . 0.0 112.461 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 57.6 m -121.51 138.13 54.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.889 0.376 . . . . 0.0 110.85 -179.741 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 97.9 p -105.64 42.17 1.28 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.829 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -122.03 177.91 16.42 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.481 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 18.3 m -122.7 149.27 44.28 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.818 0.342 . . . . 0.0 110.896 -179.766 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 42.3 m -62.87 -44.15 96.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.841 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -100.92 112.95 4.54 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.45 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 35.0 m-70 -73.19 83.44 1.34 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.746 0.308 . . . . 0.0 110.804 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 60.5 mm-40 38.64 46.82 1.05 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.87 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -145.83 129.15 16.78 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.946 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.2 mt -113.26 -60.76 1.84 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.94 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 14.7 t30 -81.32 88.6 6.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.912 179.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 6.5 p -96.62 -174.71 3.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.873 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.43 ' HB2' ' HD2' ' A' ' 15' ' ' PRO . 0.5 OUTLIER -109.55 157.25 37.96 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.632 0.73 . . . . 0.0 110.898 -179.964 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.43 ' HD2' ' HB2' ' A' ' 14' ' ' LEU . 53.3 Cg_endo -69.73 162.86 40.42 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.702 2.268 . . . . 0.0 112.349 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 9.3 t -73.46 163.4 28.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.162 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . 0.527 ' H ' ' NE2' ' A' ' 34' ' ' GLN . 36.6 mtm -96.46 34.87 1.56 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.892 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 15.6 mm-40 -69.74 -175.61 0.91 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.868 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 74.82 -138.5 23.88 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.49 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 162.78 40.76 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.642 2.228 . . . . 0.0 112.368 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -171.06 0.44 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.697 2.265 . . . . 0.0 112.335 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.558 ' CG2' ' N ' ' A' ' 23' ' ' PHE . 1.9 m -93.69 161.17 14.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.163 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.558 ' N ' ' CG2' ' A' ' 22' ' ' THR . 11.9 m-85 -156.01 135.95 12.75 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.908 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ASN . . . . . 0.544 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 72.3 m-20 42.9 48.42 3.7 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.645 0.736 . . . . 0.0 110.927 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.544 ' CD ' ' N ' ' A' ' 24' ' ' ASN . 53.6 Cg_endo -69.74 137.96 36.75 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.709 2.273 . . . . 0.0 112.301 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -176.11 1.38 Allowed 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.646 2.231 . . . . 0.0 112.334 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.675 HG13 ' HA ' ' A' ' 28' ' ' PRO . 98.4 t -142.97 137.87 15.33 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.668 0.747 . . . . 0.0 111.109 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.675 ' HA ' HG13 ' A' ' 27' ' ' VAL . 54.0 Cg_endo -69.75 145.58 79.8 Favored 'Cis proline' 0 C--O 1.232 0.179 0 C-N-CA 122.71 -1.787 . . . . 0.0 112.342 -0.02 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 13.3 t80 -96.87 121.17 38.44 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.946 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -101.79 101.46 11.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.865 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -98.96 109.94 3.89 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.526 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 4.1 mmm180 -72.87 99.51 2.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.866 0.365 . . . . 0.0 110.877 -179.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 27.6 mt -66.94 93.05 0.25 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.905 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.527 ' NE2' ' H ' ' A' ' 17' ' ' MET . 18.7 mp0 -67.99 93.69 0.44 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.938 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 134.75 -37.77 1.9 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.501 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 91.19 175.07 43.71 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.454 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . 0.498 HD22 ' HZ ' ' A' ' 120' ' ' PHE . 78.4 mt -65.4 93.43 0.15 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.859 0.361 . . . . 0.0 110.911 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 44.0 p -105.33 154.56 20.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.136 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -49.84 -30.61 10.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.061 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 2.6 mpt_? -105.13 34.93 2.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.875 -179.873 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 5.0 tpm_? -108.03 135.15 49.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 -179.878 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 85.3 m -136.87 116.35 12.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.193 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 5.0 mp -91.69 135.81 26.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.176 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 96.8 mt -127.38 132.95 68.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.116 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 50.7 mt -134.9 107.57 8.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.092 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 16.0 mtmt -111.2 111.4 22.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.864 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -142.88 -140.7 3.75 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.544 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . 0.568 ' HB2' ' CD2' ' A' ' 108' ' ' PHE . 0.4 OUTLIER -172.08 119.95 0.43 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.937 0.399 . . . . 0.0 110.941 -179.8 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 40.5 t -69.16 117.09 48.7 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.638 0.732 . . . . 0.0 111.15 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 154.98 67.25 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.69 2.26 . . . . 0.0 112.333 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.72 -16.11 37.55 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.693 2.262 . . . . 0.0 112.358 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 70.6 p -110.41 18.6 19.66 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.122 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -113.54 123.23 6.06 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.465 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.403 ' O ' ' SD ' ' A' ' 76' ' ' MET . 22.2 mttt -63.03 -61.67 2.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.778 0.323 . . . . 0.0 110.859 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.8 p -174.03 157.9 3.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.886 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.599 ' CZ ' ' HG3' ' A' ' 74' ' ' PRO . 12.3 p90 -111.16 -174.64 2.51 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.864 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.863 ' HB2' ' OD1' ' A' ' 73' ' ' ASN . . . -157.05 130.5 8.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.12 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.558 HG22 ' CE1' ' A' ' 60' ' ' PHE . 5.3 mp -112.91 101.78 12.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.11 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -101.2 143.59 31.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.913 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.558 ' CE1' HG22 ' A' ' 58' ' ' ILE . 16.0 m-85 -115.26 97.99 6.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.869 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.459 ' HG2' ' N ' ' A' ' 62' ' ' VAL . 35.8 ttmt -96.79 167.88 10.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.886 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.781 HG22 ' HA ' ' A' ' 142' ' ' VAL . 59.1 t -100.94 123.88 54.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.089 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -59.79 -39.74 95.75 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.455 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 7.6 t -62.93 -70.67 0.19 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.868 0.366 . . . . 0.0 110.867 -179.728 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 60.0 m -82.33 -71.43 0.49 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.863 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 128.32 42.68 0.24 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.451 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.425 ' OD2' ' ND2' ' A' ' 88' ' ' ASN . 3.9 m-20 -112.78 143.7 43.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.81 0.338 . . . . 0.0 110.847 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 66.6 mt -89.1 113.35 25.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.135 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.47 ' CB ' HG21 ' A' ' 142' ' ' VAL . . . -81.75 -39.3 24.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.105 179.836 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.738 HD21 HD11 ' A' ' 72' ' ' ILE . 48.1 tp -136.82 134.53 37.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.964 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.495 ' N ' ' O ' ' A' ' 84' ' ' ASN . 0.4 OUTLIER -134.89 97.03 3.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.894 179.877 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.738 HD11 HD21 ' A' ' 70' ' ' LEU . 27.0 mt -101.26 133.56 44.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.134 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.863 ' OD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -140.53 106.51 6.5 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.674 0.749 . . . . 0.0 110.905 179.961 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.599 ' HG3' ' CZ ' ' A' ' 56' ' ' PHE . 54.0 Cg_endo -69.67 154.7 67.76 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.713 2.275 . . . . 0.0 112.347 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 36.7 mtp180 -130.6 94.99 3.76 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.932 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' MET . . . . . 0.403 ' SD ' ' O ' ' A' ' 54' ' ' LYS . 0.0 OUTLIER -53.07 -34.34 56.13 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.846 -179.991 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -39.51 -90.93 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.507 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -87.22 -40.89 14.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.88 0.371 . . . . 0.0 110.912 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 120.39 43.8 0.45 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.492 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 49.2 p -119.25 118.14 30.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.828 0.347 . . . . 0.0 111.142 -179.857 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.514 HG22 ' HA ' ' A' ' 74' ' ' PRO . 14.1 t -99.8 110.45 26.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.132 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.558 HG22 ' HD3' ' A' ' 96' ' ' LYS . 32.7 t -82.52 144.78 9.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.13 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.86 124.17 38.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.864 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.495 ' O ' ' N ' ' A' ' 71' ' ' HIS . 1.3 m120 -136.32 178.59 6.94 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.914 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.433 ' CB ' ' O ' ' A' ' 69' ' ' ALA . 78.1 p -158.69 105.55 1.83 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.864 -179.84 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.921 HD13 ' NE1' ' A' ' 91' ' ' TRP . 28.3 tp -78.06 117.34 19.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.917 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.532 ' N ' ' O ' ' A' ' 90' ' ' SER . 86.0 mt -95.38 162.54 13.62 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.936 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.425 ' ND2' ' OD2' ' A' ' 67' ' ' ASP . 11.0 m-80 -40.97 102.14 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.878 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.35 -2.47 3.14 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.492 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.813 ' O ' HD12 ' A' ' 86' ' ' LEU . 0.3 OUTLIER -124.63 170.54 10.85 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.81 0.338 . . . . 0.0 110.85 -179.72 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.921 ' NE1' HD13 ' A' ' 86' ' ' LEU . 21.8 m95 -128.1 160.73 31.08 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.936 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -89.53 -100.31 1.06 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.487 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 16.4 m -172.4 167.97 5.57 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.819 0.343 . . . . 0.0 110.849 -179.753 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -89.99 121.85 32.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.904 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -122.22 115.33 22.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.88 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.558 ' HD3' HG22 ' A' ' 82' ' ' VAL . 9.9 mtmp? -119.68 119.79 34.73 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.904 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . 0.478 ' HE3' ' N ' ' A' ' 98' ' ' ILE . 0.0 OUTLIER -173.9 105.11 0.12 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.866 179.846 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.912 HD11 ' O ' ' A' ' 100' ' ' HIS . 1.9 tt -141.76 149.86 19.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.172 179.862 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.461 HG23 ' CD2' ' A' ' 100' ' ' HIS . 4.7 t -84.45 -41.06 16.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.084 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . 0.912 ' O ' HD11 ' A' ' 98' ' ' ILE . 28.9 p80 -153.09 133.62 13.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.835 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' ASN . . . . . 0.407 ' C ' ' OD1' ' A' ' 101' ' ' ASN . 7.2 t-20 -103.47 95.84 7.74 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.597 0.713 . . . . 0.0 110.888 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.447 ' O ' ' C ' ' A' ' 103' ' ' PHE . 53.7 Cg_endo -69.77 -41.3 4.38 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.675 2.25 . . . . 0.0 112.368 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.564 ' CD2' ' HB3' ' A' ' 74' ' ' PRO . 10.2 m-85 -34.17 104.66 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.881 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -127.85 137.16 9.61 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.695 -0.765 . . . . 0.0 112.451 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 97.25 0.62 Allowed 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.715 2.277 . . . . 0.0 112.325 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 118.39 3.53 14.58 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.513 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 17.5 pt20 -133.73 137.82 45.44 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.819 0.343 . . . . 0.0 110.906 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' PHE . . . . . 0.568 ' CD2' ' HB2' ' A' ' 48' ' ' TYR . 79.7 m-85 -61.34 166.35 3.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.882 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 17.9 p90 -158.45 130.58 6.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.886 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -103.68 104.62 14.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.877 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' LEU . . . . . 0.775 HD13 ' N ' ' A' ' 112' ' ' SER . 0.7 OUTLIER -105.09 136.5 44.46 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.948 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . 0.775 ' N ' HD13 ' A' ' 111' ' ' LEU . 3.8 m -145.15 113.49 6.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.864 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.601 HG23 HG22 ' A' ' 122' ' ' VAL . 4.0 mp -95.47 140.05 17.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.142 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 15.6 mtp85 -112.78 137.63 50.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.899 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . 0.582 ' HA ' ' CE1' ' A' ' 120' ' ' PHE . 2.9 t -110.03 114.47 28.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.874 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -113.77 -136.03 6.29 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.496 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 12.2 mt -121.52 -39.06 2.69 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.829 0.347 . . . . 0.0 110.924 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 23.2 p-10 -85.63 -37.26 19.69 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.88 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.8 ptp180 -173.66 172.62 3.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.875 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.582 ' CE1' ' HA ' ' A' ' 115' ' ' CYS . 3.7 m-30 -93.32 155.06 17.63 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.887 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 26.6 mtpt -128.99 102.12 6.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.898 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.601 HG22 HG23 ' A' ' 113' ' ' ILE . 51.5 t -89.27 136.77 22.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.105 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' TYR . . . . . . . . . . . . . 57.9 m-85 -120.29 152.95 37.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.958 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' ALA . . . . . 0.604 ' HB2' HD13 ' A' ' 129' ' ' LEU . . . -136.55 107.12 6.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.097 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 53.56 35.61 21.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.929 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 84.09 29.26 31.67 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.477 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 20.0 mm-40 -140.77 119.53 12.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.819 0.342 . . . . 0.0 110.931 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 35.5 t-80 -52.06 103.85 0.07 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.846 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.604 HD13 ' HB2' ' A' ' 124' ' ' ALA . 10.6 tp -67.12 -67.71 0.43 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.923 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.499 ' HZ ' HD13 ' A' ' 72' ' ' ILE . 6.0 p90 -163.67 177.02 9.06 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.86 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 41.1 p30 -118.02 149.92 40.16 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.851 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.677 ' CD1' HD13 ' A' ' 70' ' ' LEU . 0.2 OUTLIER -117.17 107.02 13.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.872 -179.937 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.525 ' O ' ' CE1' ' A' ' 132' ' ' PHE . . . -62.41 133.56 55.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.099 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' HIS . . . . . . . . . . . . . 29.7 m-70 -60.03 110.84 1.29 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.811 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.4 ' CD ' ' OG ' ' A' ' 85' ' ' SER . 10.0 mtt-85 -93.93 -51.5 4.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.878 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 6.8 tp -96.06 108.39 20.8 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.906 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 27.1 t -49.44 -33.33 13.87 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.862 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.468 ' HB1' ' CD ' ' A' ' 141' ' ' ARG . . . -82.45 25.76 0.6 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.073 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.406 ' CG ' ' N ' ' A' ' 140' ' ' GLN . 19.3 p90 -45.49 -41.78 9.96 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.895 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' GLN . . . . . 0.406 ' N ' ' CG ' ' A' ' 139' ' ' PHE . 5.7 pt20 -49.75 -41.0 42.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.885 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.468 ' CD ' ' HB1' ' A' ' 138' ' ' ALA . 57.0 mtp180 -55.48 -39.74 70.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.874 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.781 ' HA ' HG22 ' A' ' 62' ' ' VAL . 85.6 t -48.11 106.8 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.14 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -131.81 34.08 3.91 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.867 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 16.2 m -141.38 115.32 9.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.167 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.52 HD13 ' CE2' ' A' ' 60' ' ' PHE . 5.2 tp -113.66 107.96 16.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.91 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 -113.0 150.7 31.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.896 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.423 HG23 HG13 ' A' ' 58' ' ' ILE . 17.0 mt -138.29 106.94 3.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.115 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -115.42 173.33 6.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.915 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . 107.57 -146.37 16.22 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.469 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 46.7 m-20 -112.27 92.56 4.07 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.852 0.358 . . . . 0.0 110.843 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 5.8 p -151.28 138.06 12.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.124 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 33.7 m -99.62 93.92 6.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.134 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.462 ' CB ' ' HG2' ' A' ' 25' ' ' PRO . 68.8 mt -74.88 137.85 42.06 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.903 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 20.5 m -119.76 -39.28 2.86 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.878 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . 0.494 ' CE1' ' HB2' ' A' ' 157' ' ' GLN . 43.6 t80 -148.07 135.45 20.55 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.938 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 70.8 t -140.18 109.42 3.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.141 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . 0.494 ' HB2' ' CE1' ' A' ' 155' ' ' TYR . 14.7 tt0 -121.47 136.57 54.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.902 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' ILE . . . . . . . . . . . . . 18.6 mt -103.69 91.45 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.065 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 65.6 m -72.56 150.89 42.75 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.88 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 170.77 -156.95 27.66 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.526 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.81 160.22 50.49 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.674 2.249 . . . . 0.0 112.361 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 162' ' ' SER . . . . . . . . . . . . . 35.0 t -116.85 84.25 2.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.87 -179.819 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 2.5 t -75.28 126.89 31.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.869 -179.8 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.481 -179.952 . . . . . . . . 0 0 . 1 stop_ save_